
<html lang="en"     class="pb-page"  data-request-id="e5355bf0-ebd1-4351-be9e-18af618499da"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2019.62.issue-2;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.8b00760"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds" /></meta><meta name="dc.Creator" content="Ewgenij  Proschak" /></meta><meta name="dc.Creator" content="Holger  Stark" /></meta><meta name="dc.Creator" content="Daniel  Merk" /></meta><meta name="dc.Description" content="Multitargeting compounds comprising activity on more than a single biological target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as ca..." /></meta><meta name="Description" content="Multitargeting compounds comprising activity on more than a single biological target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as ca..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 23, 2018" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00760" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00760" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00760" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00760" /></link>
        
    
    

<title>Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00760" /></meta><meta property="og:title" content="Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0011.jpeg" /></meta><meta property="og:description" content="Multitargeting compounds comprising activity on more than a single biological target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome. Polypharmacological drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin. While their identification has long been the result of serendipity, medicinal chemistry now tends to design polypharmacology. Modern in vitro pharmacological methods and chemical probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallography, or fragment-based design equip multitarget compound development with valuable tools. In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacology. We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacology holds enormous potential to secure future therapeutic innovation." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00760"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00760">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00760&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00760&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00760&amp;href=/doi/10.1021/acs.jmedchem.8b00760" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 2</span><span class="cit-fg-pageRange">, 420-444</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/2" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00714" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.8b01945" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Ewgenij Proschak</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ewgenij Proschak</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Max-von-Laue-Strasse 9, D-60438 Frankfurt, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ewgenij++Proschak">Ewgenij Proschak</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1961-1859" title="Orcid link">http://orcid.org/0000-0003-1961-1859</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Holger Stark</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Holger Stark</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Universitaetsstrasse 1, D-40225, Duesseldorf, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Holger++Stark">Holger Stark</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Daniel Merk</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel Merk</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Max-von-Laue-Strasse 9, D-60438 Frankfurt, Germany</div><div class="loa-info-affiliations-info">Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH) Zürich, Vladimir-Prelog-Weg 4, CH-8093 Zürich, Switzerland</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +41 44 6337439, +49 69 79829327. E-mail: <a href="/cdn-cgi/l/email-protection#e185808f88848dcf8c84938aa1918980938c80cf8495899bcf8289"><span class="__cf_email__" data-cfemail="91f5f0fff8f4fdbffcf4e3fad1e1f9f0e3fcf0bff4e5f9ebbff2f9">[email protected]</span></a>, <a href="/cdn-cgi/l/email-protection#94f9f1e6ffd4e4fcf5e6f9f7fcf1f9bae1fafdb9f2e6f5fafff2e1e6e0baf0f1"><span class="__cf_email__" data-cfemail="deb3bbacb59eaeb6bfacb3bdb6bbb3f0abb0b7f3b8acbfb0b5b8abacaaf0babb">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++Merk">Daniel Merk</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5359-8128" title="Orcid link">http://orcid.org/0000-0002-5359-8128</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00760&amp;href=/doi/10.1021%2Facs.jmedchem.8b00760" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 2</span><span class="cit-pageRange">, 420–444</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 23, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>11 May 2018</li><li><span class="item_label"><b>Published</b> online</span>23 July 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 January 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00760" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00760</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D420%26pageCount%3D25%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DEwgenij%2BProschak%252C%2BHolger%2BStark%252C%2BDaniel%2BMerk%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D2%26contentID%3Dacs.jmedchem.8b00760%26title%3DPolypharmacology%2Bby%2BDesign%253A%2BA%2BMedicinal%2BChemist%25E2%2580%2599s%2BPerspective%2Bon%2BMultitargeting%2BCompounds%26numPages%3D25%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D444%26publicationDate%3DJanuary%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00760"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">8081</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">132</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00760" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Ewgenij&quot;,&quot;last_name&quot;:&quot;Proschak&quot;},{&quot;first_name&quot;:&quot;Holger&quot;,&quot;last_name&quot;:&quot;Stark&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;Merk&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;23&quot;,&quot;issue&quot;:&quot;2&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;420-444&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00760&quot;},&quot;abstract&quot;:&quot;Multitargeting compounds comprising activity on more than a single biological target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome. Polypharmacological drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin. While their identification has long been the result of serendipity, medicinal chemistry now tends to design polypharmacology. Modern in vitro pharmacological methods and chemical probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallography, or fragment-based design equip multitarget compound development with valuable tools. In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacology. We conclude that despite some char&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00760&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00760" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00760&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00760" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00760&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00760" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00760&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00760&amp;href=/doi/10.1021/acs.jmedchem.8b00760" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00760" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00760" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00760%26sid%3Dliteratum%253Aachs%26pmid%3D30035545%26genre%3Darticle%26aulast%3DProschak%26date%3D2019%26atitle%3DPolypharmacology%2Bby%2BDesign%253A%2BA%2BMedicinal%2BChemist%25E2%2580%2599s%2BPerspective%2Bon%2BMultitargeting%2BCompounds%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D2%26spage%3D420%26epage%3D444%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290677" title="Toxicological synergy">Toxicological synergy</a>,</li><li><a href="/action/doSearch?ConceptID=290663" title="Pharmacophores">Pharmacophores</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=292202" title="Drug discovery">Drug discovery</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/2" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/jmcmar.2019.62.issue-2/20190124/jmcmar.2019.62.issue-2.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/medium/jm-2018-00760f_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Multitargeting compounds comprising activity on more than a single biological target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome. Polypharmacological drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin. While their identification has long been the result of serendipity, medicinal chemistry now tends to design polypharmacology. Modern in vitro pharmacological methods and chemical probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallography, or fragment-based design equip multitarget compound development with valuable tools. In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacology. We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacology holds enormous potential to secure future therapeutic innovation.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04102" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04102" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3">1.1.  History of Multitarget Drug Discovery: From “Dirty Drugs” To Designed Multiple-Targeting Ligands</h3><div class="NLM_p">The high therapeutic efficacy of some of our oldest drugs is ascribed to their pleiotropic activities on multiple targets. Long known small molecules such as acetyl salicylic acid, paracetamol, and metformin interact with a variety of proteins, leading to activity profiles that cause synergistic modulatory effects in complementary signaling pathways or enzymatic cascades.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5">(1−5)</a> The sum of numerous pharmacodynamic effects forms their often superior clinical activity profile. The same holds true for newer drugs such as statins, which, e.g., exhibit anti-inflammatory effects that support their clinical efficacy profile but appear not to be mediated by their main target of action.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> Though never designed, such multiple activities often account for the desirable overall efficacy of a drug. While beneficial multitarget activity profiles that produce additive or even synergistic efficacy were generated serendipitously for a long time (for many drugs not even all known activities can be linked to a biological target), modern drug discovery has started to intentionally design small molecule drugs with defined multitarget activity.</div><div class="NLM_p">Starting in 2004, Morphy and Rankovic and others systematically classified multitarget agents, and reviewed strategies to multiple ligand development with several foundation papers.<a onclick="showRef(event, 'ref8 ref9 ref10 ref11 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10 ref11 ref12 ref13 ref14">(8−14)</a> Since then, multitarget drugs have experienced steadily growing interest owing to their various advantages. The progress of multitarget compounds as well as strategies and technologies for their development were repeatedly reviewed.<a onclick="showRef(event, 'ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24">(15−24)</a> Currently, neurodegenerative<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> and psychiatric disorders,<a onclick="showRef(event, 'ref27 ref28 ref29 ref30 ref31 ref32 ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29 ref30 ref31 ref32 ref33 ref34 ref35">(27−35)</a> infectious diseases,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> cancer,<a onclick="showRef(event, 'ref37 ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39 ref40">(37−40)</a> and metabolic/cardiovascular diseases<a onclick="showRef(event, 'ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref41 ref42 ref43">(41−43)</a> are in the focus of multitarget drug discovery due to their multifactorial nature or because of therapeutic resistance development. The treatment of these diseases may strongly benefit from multiple additive or synergistic pharmacodynamic activities in terms of higher therapeutic efficacy or delayed resistance development. Moreover, targeted delivery<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> exploiting the affinity of a small molecule homing ligand to a biological target which allows tissue or even cell selective deployment of potent agents linked to the homing ligand is increasingly gaining relevance.</div><div class="NLM_p last">This article intends to evaluate the significance of multitarget design in current medicinal chemistry and give a view of what is possible in the field of designing multitarget small molecules. It analyzes strategies and technologies to access multiple ligands from rational and computational perspectives as toolbox for multitarget drug discovery and discusses where the field is heading in the future.</div></div><div id="sec1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">1.2.  Advantages of Multitarget Drugs</h3><div class="NLM_p">Many diseases, e.g., metabolic dysbalance culminating in the metabolic syndrome, psychiatric or degenerative CNS disorders, or cancer, have a multifactorial nature that can hardly be “cured” by the specific modulation of a single target. The multifactorial processes leading to neurodegeneration, to cancer development, proliferation, and metastasis, or to manifestation of diabetes and other metabolic diseases involve multiple signaling pathways and dysregulation of multiple physiological processes.<a onclick="showRef(event, 'ref42 ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref42 ref46 ref47">(42,46,47)</a> Treatment of these diseases hence requires modulation of multiple biological targets to restore the physiological balance and generate sufficient therapeutic efficacy. This is either achieved by combination therapies consisting of several target specific drugs, termed polypharmacy, or by using multitarget drugs that address several biological targets and produce additive or synergistic effects, termed polypharmacology.<a onclick="showRef(event, 'ref48 ref49 ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref48 ref49 ref50 ref51">(48−51)</a> Repetitive failures of highly potent and target-specific drugs in clinical development and limited therapeutic efficacy of single-target drugs are continuously promoting multitarget compound design in rational drug discovery.<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52,53)</a></div><div class="NLM_p last">As obvious from these considerations, multitarget drugs offer a variety of advantages. Well-designed and optimally balanced multiple ligands may replace a series of drugs in a combination therapy and thereby markedly reduce polypharmacy.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> With the resulting reduction in treatment complexity, drug side effects, pharmacokinetic complexity, and drug–drug interactions can be diminished and compliance improved. Moreover, modulation of multiple biological targets may increase therapeutic efficacy through synergies.<a onclick="showRef(event, 'ref48 ref54'); return false;" href="javascript:void(0);" class="ref ref48 ref54">(48,54)</a> Suitable target combinations may allow application of lower drug doses to produce adequate therapeutic effects because partial modulation of synergistically acting targets may be sufficient to reach full therapeutic efficacy.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> This in turn can reduce side effects mediated by full engagement on the individual targets without losing therapeutic efficacy and can widen therapeutic windows. And finally, multitarget drug discovery also offers economic advantages because the clinical development of a single multitarget drug requires less clinical trials than multiple specific drugs.</div></div><div id="sec1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">1.3.  Areas of Applicability</h3><div class="NLM_p">The central idea of multitarget compounds is modulation of multiple targets that promise additive or synergistic effects, of course. With this characteristic, multiple ligands affect many disciplines and research fields in medicinal chemistry. They hold enormous therapeutic potential, for example, by synergistic antibacterial<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> or anticancer<a onclick="showRef(event, 'ref39 ref55'); return false;" href="javascript:void(0);" class="ref ref39 ref55">(39,55)</a> target combinations that could help avoiding development of antibiotic or chemotherapy resistance as global challenges of current drug discovery. In addition, multifactorial diseases involving dysregulation of several physiological functions such as neurological disorders or the metabolic syndrome may remarkably benefit from multitarget compounds that combine several suitable modes of action.</div><div class="NLM_p">However, multiple ligands can also be designed to address multiple binding sites on a single target and thereby simultaneously exhibit allosteric and orthosteric modulation. This kind of compounds with multiple biological binding sites, e.g., has relevance in targeting G protein coupled receptors (GPCR) where bitopic ligands constitute a promising strategy to achieve subtype or signaling selectivity despite highly conserved orthosteric binding sites and might offer a way to specifically modulate GPCR function.<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56,57)</a></div><div class="NLM_p">Another field related to multiple ligand development is targeted delivery where drug conjugates are designed to contain a targeting molecule linked to a potent active agent that is delivered to the intended site of action with the help of the targeted ligand (cf. <a class="ref internalNav" href="#sec3_2" aria-label="section 3.2">section 3.2</a>). Such targeted drug conjugates are often composed of a monoclonal antibody and a potent cytotoxic agent to be used in cancer therapy but also small molecules are increasingly employed as targeting ligands. Drug conjugates must be clearly distinguished from designed multiple ligands because their pharmacophores are not joined in a common motif (cf. <a class="ref internalNav" href="#sec3" aria-label="section 3">section 3</a>, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><div class="NLM_p">In the context of the central idea behind multitarget ligands to exhibit pharmacodynamic effects on multiple biological targets, virtually every combination of targets is thinkable. The more different the targets of interest respectively the chemotype of their ligands are the more difficult is the development of compounds addressing the target combination. Therefore, the majority of designed multitarget compounds either addresses target combinations within a protein family such as multiple kinases or GPCRs, or modulates targets within enzymatic pathways such as the arachidonic acid cascade where the different enzymes accommodate structurally similar substrates. Still, examples<a onclick="showRef(event, 'ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref58 ref59">(58,59)</a> of multiple ligands for markedly different biological targets demonstrate that also much more complex target combinations in terms of multitarget compound design are feasible.</div><div class="NLM_p last">A key to successful multitarget compound design is discrete selection of target combinations that produce additive effects or even synergies. Additionally, the targets must be compatible in terms of ligand accommodation and cellular/tissue localization to allow the development of efficacious and drug-like multiple-targeting ligands. It should be stressed that distinct target localization in different cell or tissue compartments opens another level of complexity in pharmacodynamic, pharmacokinetic and also toxicological aspects in the already complex situation in drug development.</div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">2.  Identifying Suitable Target Combinations for Multiple-Targeting Ligands</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22362" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22362" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As stated above, a central issue in target selection for multitargeting drug discovery is the chemical feasibility of a multitarget ligand. It is intuitional that designing a dual-target ligand is easier for highly related targets as exemplified by designed multitarget ligands of aminergic receptors<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> or kinases.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> The more challenging scenario is the design of multiple ligands addressing unrelated targets. In such case, successful development of a multiple ligand depends on the ability of these unrelated targets to accommodate chemically related compounds, e.g., for cyclooxygenase-2 (COX-2) inhibition and thromboxane receptor antagonism,<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> multiple ligand design was achieved. Although the two targets are strongly different, their ligands arachidonic acid and thromboxane A2 are structurally related, suggesting that the binding sites possess a certain degree of similarity and might accommodate a shared ligand. An even greater challenge are multitarget ligands for unrelated targets that accommodate structurally unrelated ligands. Still, there are several examples demonstrating that design of such ligands is possible, as well. Ciceri et al. for example have described dual ATP-competitive kinase/bromodomain 4 inhibitors, the latter of which recognizes acetylated lysins.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Moreover, the angiotensin II receptor 1 (AT1R) antagonist telmisartan (a peptide mimetic) also binds to peroxisome proliferator receptor gamma (PPARγ),<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> which acts as a receptor for fatty acids and respective mimetics, thereby enabling the discovery of dual AT1R antagonists/PPARγ modulators<a onclick="showRef(event, 'ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref65 ref66">(65,66)</a> with remarkable activity in vivo.</div><div class="NLM_p">Although the theoretical feasibility determinants of target combinations for multiple ligand development have not been systematically studied, yet many suitable methods for this task are available. Most of them rely on the chemical similarity principle postulated by Johnson and Maggiora.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Although this principle is not general by far,<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> a multitude of studies demonstrated its applicability to predict polypharmacology and to define relationships between distinct targets based on the chemical similarity of their corresponding ligands.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Oppositely, these methods can also be employed to prioritize promising target combinations that share similar ligands for multitarget design.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">2.1.  Rational Target Selection Based on Clinical Observations</h3><div class="NLM_p">Unsatisfying efficacies of available therapeutic options in many diseases promoted the use of drug combinations that addressed distinct targets. In many cases, medical needs led to drug cocktails as an initial therapeutic approach instead of synergistic target combinations realized in a single molecule. However, differences in pharmacokinetic properties such as half-life and distribution and drug–drug interactions make drug combination formulations problematic for many patients and, therefore, their applicability is often limited. Still, the knowledge of enhanced therapeutic efficacy of such drug combinations despite their obvious drawbacks has promoted the rational development of multitarget agents for target combinations that were previously validated by drug cocktails. Increasing knowledge on biomarkers and their analytical accessibility open further avenues to clinically verify multitargeting approaches<a onclick="showRef(event, 'ref70 ref71 ref72'); return false;" href="javascript:void(0);" class="ref ref70 ref71 ref72">(70−72)</a> with suitable drug cocktails, even for orphan diseases.<a onclick="showRef(event, 'ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref73 ref74">(73,74)</a></div><div class="NLM_p">A prime example of multitarget drug discovery relying on clinical observations are antipsychotics. The initial therapeutic approach of inhibiting dopamine D<sub>2</sub>-like receptors as a primary target (derived from early first-generation histamine H<sub>1</sub> receptor antagonists) was associated with considerable side effects such as extrapyramidal motor symptoms. Subsequent inclusion of antiserotonergic 5-HT<sub>2A</sub> activity significantly improved the therapeutic efficacy and reduced adverse effects.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Later, the modulation of efficacies on different biological targets involving partial agonism on one and inverse agonism on another receptor enabled functional selectivity on multiple receptors.<a onclick="showRef(event, 'ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref76 ref77">(76,77)</a> This rational, clinical observation-driven multitarget design reduced side effects and enhanced patient response rates as exemplified with successful atypical antipsychotic drugs such as aripiprazole or cariprazine (RGH-188).<a onclick="showRef(event, 'ref78 ref79 ref80'); return false;" href="javascript:void(0);" class="ref ref78 ref79 ref80">(78−80)</a></div><div class="NLM_p">In addition to multiple ligand design guided by clinical efficacy and safety observations, clinical observations of polypharmacological drug effects have led to their repurposing or repositioning<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> in different therapeutic indications<a onclick="showRef(event, 'ref82 ref83'); return false;" href="javascript:void(0);" class="ref ref82 ref83">(82,83)</a> (cf. <a class="ref internalNav" href="#sec3_3_1_4" aria-label="section 3.3.1.4">section 3.3.1.4</a>). Moreover, unexpected or superior efficacy of drugs comprising polypharmacological profiles can serve as hint to favorable multitarget profiles and allow rational target selection for combination. This is further supported by increasing clinical knowledge on underlying causes of a disease combined with understanding of the dysregulated signaling pathways. The discovery of suitable molecular targets by clinical observation of therapeutic efficacy allows a rational design of favorable polypharmacological profiles. With the help of fragment-based (cf. <a class="ref internalNav" href="#sec3_4" aria-label="section 3.4">section 3.4</a>) and pharmacophore-based (cf. <a class="ref internalNav" href="#sec3_3_1_3" aria-label="section 3.3.1.3">section 3.3.1.3</a>) approaches, drugs (or other bioactive small molecules) with suitable structural similarity can then be identified as leads for combination and optimization toward the desired multitarget profiles on clinically validated target combinations.<a onclick="showRef(event, 'ref33 ref84 ref85 ref86'); return false;" href="javascript:void(0);" class="ref ref33 ref84 ref85 ref86">(33,84−86)</a></div><div class="NLM_p last">Related targets comprising similar binding sites such as different aminergic class A GPCRs, kinases, or cognate nuclear receptors are well accessible for such multitarget approaches but may also be source of off-target cross-reactivity leading to adverse effects. In such cases, targeted promiscuity by design or cross-reactivity by serendipity cannot be fully separated. Designed combination of different targets like membrane GPCRs, transmembrane transporters, and intracellular enzymes at different parts of cell architecture or nuclear targets is a more challenging endeavor. Still, several examples<a onclick="showRef(event, 'ref58 ref87 ref88 ref89'); return false;" href="javascript:void(0);" class="ref ref58 ref87 ref88 ref89">(58,87−89)</a> highlight the possibility of designing multiple ligands for rationally defined target combinations in psychiatric and CNS disorders and metabolic and inflammatory diseases but also for oncologic or antimicrobial drugs where resistances raise urgent need for multifactorial interventions.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> For example, activity on three clinically validated cognitive targets, namely the presynaptic histamine H<sub>3</sub> autoreceptor, <i>N</i><sup>τ</sup>-methyltransferase, and acetyl- and butyrylcholinesterase, could be united in single multitarget agents despite pharmacokinetic issues and limited brain penetration.<a onclick="showRef(event, 'ref90 ref91'); return false;" href="javascript:void(0);" class="ref ref90 ref91">(90,91)</a></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">2.2.  Phenotypic Screening of Drug Combinations</h3><div class="NLM_p">Chemical probes, well-characterized ligands with high selectivity against related targets,<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> are unique tools to identify target combinations that produce synergistic effects. However, it is most inconvenient to screen for synergistic effects of two or even more targets in complex animal disease models. High numbers of necessary animals due to high numbers of putative compound/target combinations that exponentially grow with the number of employed probes is ethically intolerable. Even with a small number of chemical probes, different dose combinations might be required, equally leading to a high number of necessary animal experiments. Genetic knockout or knockdown of one (possibly prevalidated) target combined with the use of chemical probes is a valuable approach to reduce the number of necessary animals in screenings for synergistic target combinations.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> An exemplary study employed the COX inhibitor diclofenac in inflammatory models performed in FAAH(−/−) mice in order to validate the synergy between the targets COX and FAAH.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Still, chemical probes are often poorly characterized in vivo and inappropriate pharmacokinetics can cause false negative results. Therefore, cellular, tissue, or nonmammalian animal models appear more suitable to study large numbers of compound combinations to identify synergistic targets. Such assay systems usually rely on functional read-outs like apoptosis (especially in cancer cells), viral entry (in viral diseases), or bacterial death (in infectious diseases). Especially in the field of anticancer drug discovery, where powerful combination therapies are required, drug combination screenings helped identify several target combination synergies. A recent example screened compound cocktails for efficacy in myeloid- and lymphoid-derived hematologic malignancies.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> The 122 primary patient samples with various hematologic malignancies were profiled against a panel of 48 drug combinations ex vivo which uncovered synergistic activity of the B-cell lymphoma (BCL2) inhibitor venetoclax and the mitogen-activated protein kinase kinase (MEK) inhibitor cobimetinib, the mouse double minute 2 homologue (MDM2) inhibitor idasanutlin, or the bromo- and extra-terminal domain (BET) inhibitor ABBV-075. Such hints for suitable drug combinations can subsequently be validated, e.g., using CRISPR/Cas9 gene silencing<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> and in vivo experiments to provide ideal and validated starting points for a multitarget drug discovery campaign.</div><div class="NLM_p">Biological assays that rely on complex multidimensional read-outs are often referred to as high-content screening or phenotypic screening when entire organisms are used. Such high-content and phenotypic screening systems are an inevitable tool in drug discovery<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> and have particularly high value for multitarget design. BioMAP are well-established high-content screening systems.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> The BioMAP cultures are low-passage primary human cells providing physiological responses upon exposure to pharmacological agents. The disease and tissue relevance of the BioMAP cell cultures is very broad, and various high-content read-outs are available for each cell type.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Another powerful high content screening system are induced pluripotent stem cells (IPSC)<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> which can be converted into various cell types suitable for high content screening of chemical probes and their combinations to discover synergies.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a></div><div class="NLM_p last">More sophisticated screening systems employ entire organisms such as fruit fly <i>Drosophila melanogaster</i> or zebrafish <i>Danio rerio</i>. Assays relying on these organisms allow complex read-outs including even behavioral changes which can be employed to screen for synergistic target combinations in CNS-related disorders.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> For example, Sonoshita et al. used a <i>Drosophila</i> medullary thyroid carcinoma (MTC) model to tune the multikinase inhibitor sorafenib toward an improved efficacy and safety profile.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">2.3.  In Silico Approaches to Target Combinations: Systems Biology/Pharmacology</h3><div class="NLM_p">Identification of suitable target combinations is also feasible with in silico techniques. Especially the network pharmacology approach relying on the analysis of biological target networks has been successfully employed to identify promising target combinations.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> A broad panel of in silico methods<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> to suggest synergistic drug combinations according to this strategy is available such as the widely used analysis of signaling networks by machine learning.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Notably, such computational approaches only provide hypotheses which subsequently need validation in vitro or in vivo to confirm predicted target combinations as suitable and favorable. <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> gives an overview of computational techniques that were proposed for the prediction of promising target and drug combinations. Of note, many of these approaches have not been experimentally validated for multitarget design but still appear as interesting tools.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Available in Silico Techniques to Identify Synergistic Target Combinations<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">approach</th><th class="colsep0 rowsep0" align="center">application</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left"><b>Statistical Approaches</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Bliss and Loewe interaction analysis</td><td class="colsep0 rowsep0" align="left">statistical analysis of additivity and independence combined with tailored nonparametric statistical analysis</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">significance analysis of mutant/drug combinations</td><td class="colsep0 rowsep0" align="left">analysis of chemical-genetic data set of resistant bacteria</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">snalysis of substructure profiles</td><td class="colsep0 rowsep0" align="left">prediction of antibiotic combination efficacy</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">probabilistic concordance index and resampled Spearman correlation</td><td class="colsep0 rowsep0" align="left">mining of NCI-DREAM Drug Synergy Prediction Challenge data set</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left"><b>Machine Learning Approaches</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">deep learning</td><td class="colsep0 rowsep0" align="left">analysis of drug combination screening on different cell lines</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">random forest</td><td class="colsep0 rowsep0" align="left">learning physicochemical features and network features to predict synergistic drug combinations</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">random forest</td><td class="colsep0 rowsep0" align="left">learning synergy of anticancer drugs in mutant BRAF melanoma</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">semisupervised learning</td><td class="colsep0 rowsep0" align="left">network-based Laplacian regularized least square synergistic drug combination prediction of antifungal drug combinations</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left"><b>Pathway/Network Analysis</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">statistical pair analysis</td><td class="colsep0 rowsep0" align="left">mining clinically relevant synthetic lethality interactions</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Monte Carlo cross-validation</td><td class="colsep0 rowsep0" align="left">analysis of pathway cross-talk inhibition</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">quantitative chemical–genetic interaction map</td><td class="colsep0 rowsep0" align="left">impact of knockdown of cancer-related genes on response to classes of chemotherapy</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ordinary differential equation model</td><td class="colsep0 rowsep0" align="left">prediction of drug combinations efficacy within EGFR-ERK signaling pathway</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">network simulation</td><td class="colsep0 rowsep0" align="left">synergistic drug combinations for breast cancer</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left"><b>Combination of Different Techniques</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pathway analysis, machine learning, statistical analysis</td><td class="colsep0 rowsep0" align="left">quantitative systems pharmacology identification of cell protective pathways and drug combinations</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left"><b>Combined in Silico/in Vitro Approaches</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RNAi screen, statistical analysis</td><td class="colsep0 rowsep0" align="left">synergistic combinations of targeted therapeutic agents with essential target genes in colorectal cancer cell lines</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup><sup>a</sup></sup><p class="last">For further information and details refer to reviews <a onclick="showRef(event, 'ref104 ref108'); return false;" href="javascript:void(0);" class="ref ref104 ref108">(104,108)</a>.</p></div></div></div><div class="NLM_p">Successful studies to identify synergistic target combinations have widely relied on a combination of experimental and computational techniques, e.g., the combination of a phenotypic assay on primary CNS neurons with machine learning algorithms for deconvolution of compound-mediated effects led to identification of target combinations promoting axon growth.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Moreover, a combinatorial drug screen in dedifferentiated liposarcoma (DDL)-derived cells with subsequent computational modeling of the underlying signaling networks uncovered cyclin-dependent kinase 4 (CDK4) and insulin-like growth factor 1 receptor (IGF1R) as synergistic drug targets for DDL.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Thus, employing combinations of in vitro and in silico techniques appears as most reliable and economic way to discover synergies in multitarget modulation. The high performance of such translational approaches might result from the possibility to minimize uncertainties in the computational methods by in vitro screening data. Computational approaches mostly rely on very heterogeneous data that can be improved with the help of focused in vitro experiments. Moreover, in silico deconvolution of the targeting pathways helps to reduce the influence of potential off-target activities of the screened chemical probes. Therefore, multidisciplinary approaches can provide reliable data on target synergy as inevitable starting point for multitarget drug discovery.</div><div class="NLM_p last">Beyond computationally predicting synergistic target combinations, in silico quantitative flux modeling techniques can be employed to calculate the extent to which each target must be modulated for producing the desired therapeutic effect with minimal side effects. The concept of targeting multiple pathways with low drug doses postulates that maximum therapeutic efficacy can be achieved without full target engagement on a single target but rather by partial modulation of target combinations.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> In this context, the arachidonic acid cascade, which has been in the focus of multitarget drug discovery for several decades, was extensively investigated, e.g., Yang et al. performed a time-resolved flux analysis of the individual branches (cyclooxygenase and lipoxygenase) of the arachidonic acid metabolic network in human polymorphous leukocytes and thereby predicted the most promising target combinations for synergistic effects.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> Subsequently, these computational predictions were confirmed by time-resolved LC-MS/MS profiling of pro- and anti-inflammatory arachidonic acid metabolites.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Progressive developments in the field of quantitative in silico modeling of metabolic pathways may provide many further insights to promote multitarget drug discovery.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">3.  Multiple-Targeting Ligand Identification and Optimization</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24162" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24162" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Multitarget compounds can be classified according to their molecular and pharmacophore architecture in three general types<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). The simplest manner of combining multiple activities is the conjugation of pharmacophores with a linking group. Such linked pharmacophores (cf. <a class="ref internalNav" href="#sec3_2" aria-label="section 3.2">section 3.2</a>) tend to possess large molecular weights coupled with several disadvantages but increasingly gain relevance in targeted delivery. Conjugation of two (or more) individual pharmacophores without a linking group produces fused multiple ligands that are also prone of having undesirable characteristics such as high molecular weight and extensive lipophilicity. The most demanding but also most fruitful type of small molecule multitarget agents are merged multiple ligands (cf. <a class="ref internalNav" href="#sec3_3" aria-label="section 3.3">section 3.3</a>) whose pharmacophores are amalgamated as far as their biological targets allow. Between fused and merged multiple ligands various intermediate forms are possible, of course. Merged multiple ligands can be designed to possess low molecular weight and to fulfill Lipinski’s Rule of Five<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> and thus be considered drug-like. However, the design of a merged pharmacophore satisfying the biological targets of interest and its optimization to a potent multitarget compound are very challenging tasks.</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/medium/jm-2018-00760f_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Multitarget Agents Can Arise from Linking Pharmacophores with Stable or Biodegradable Linkers, Fusing of Pharmacophores, or Merging of Pharmacophores for the Biological Targets of Interest</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">3.1.  Serendipity</h3><div class="NLM_p">From the stories that were told, it is difficult to report on the percentage of multiple-targeting drugs developed by rational design or found by serendipity. Concerning the early histamine H<sub>1</sub> receptor antagonists, anesthetic, and antipsychotic properties were observed and then further optimized based on enhanced tissue- and animal models,<a onclick="showRef(event, 'ref127 ref128'); return false;" href="javascript:void(0);" class="ref ref127 ref128">(127,128)</a> thus involving serendipity and rational optimization efforts. In optimal scenarios, serendipity meets genius, excellent knowledge, and hard work.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> In many cases, the complexity of a compound’s profile is detected at later stages in biological screenings. Selection of compounds for further development is then made not only based on binding to the original target but on the biological efficacy. This superior efficacy profile is then traced down to identify the multiple involved targets. A thus defined target profile subsequently enables more specific selection criteria and more clearly guided optimization processes of new lead structures.</div><div class="NLM_p">In the field of natural compounds as a rich and heterogeneous source of novel lead structures,<a onclick="showRef(event, 'ref129 ref130'); return false;" href="javascript:void(0);" class="ref ref129 ref130">(129,130)</a> (multitarget) biological activity is often detected by trial and error approaches. Prominent examples of oncologic and antibiotic agents, including Vinca alkaloids and taxoles,<a onclick="showRef(event, 'ref55 ref131 ref132'); return false;" href="javascript:void(0);" class="ref ref55 ref131 ref132">(55,131,132)</a> penicillin, macrolides, and peptide antibiotics,<a onclick="showRef(event, 'ref133 ref134'); return false;" href="javascript:void(0);" class="ref ref133 ref134">(133,134)</a> were originally claimed as monotargeted but later found to address multiple targets or optimized for multiple targeting.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> The need for multitargeted agents is steadily increasing due to resistance development. Natural compound derived leads have become important starting points for partial or full synthesis, as well, to optimize a beneficial designed-in profile for more potent multitargeting compounds.<a onclick="showRef(event, 'ref131 ref135 ref136 ref137 ref138 ref139 ref140'); return false;" href="javascript:void(0);" class="ref ref131 ref135 ref136 ref137 ref138 ref139 ref140">(131,135−140)</a></div><div class="NLM_p">Also in the field of multikinase inhibitors many initial findings of multitarget activity were based on serendipity. By increasing knowledge through elaborate structure–activity relationship (SAR) studies and the availability of broad structural data, multikinase inhibitors could then be rationally designed.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> The discovery of dual p38 mitogen-activated protein kinase (p38α/MAPK) and phosphodiesterase 4 (PDE-4) inhibitor CBS-3595 (<b>1</b>, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) exemplifies such serendipitous discovery followed by rational optimization of the multitarget compound.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> During lead profiling of a series of p38α/MAPK inhibitors in experimental endotoxemia, one candidate displayed significantly more pronounced in vivo efficacy than could be expected from its in vitro potency. PDE-4 was then identified as a secondary target and exploration of the SAR landscape led to identification of <b>1</b>, an almost equipotent dual p38α/MAPK/PDE-4 inhibitor. Its dual inhibition of p38α/MAPK and PDE-4 synergistically attenuates the TNFα release in vitro an in vivo, rendering <b>1</b> a promising candidate for treatment of chronic inflammatory diseases.</div><figure id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/medium/jm-2018-00760f_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Dual p38α/MAPK/PDE-4 Inhibitor CBS-3595 (<b>1</b>), Which Is the Product of a Serendipitously Discovered Multitarget Profile and Subsequent Optimization of the Dual Activity</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">3.2.  Linked Pharmacophores</h3><div class="NLM_p">The simplest way to rationally combine pharmacophores of two (or more) distinct targets is their connection with a stable or biodegradable linker.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> A resultant multitarget compound still exploits the advantages of addressing multiple targets with a single molecule. Additionally, this strategy offers a way of combining two potent agents addressing distinct targets without the need of excessive structural optimization.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> However, linkage of two pharmacophores usually results in rather large molecules<a onclick="showRef(event, 'ref8 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref10">(8,10)</a> that may fail to provide favorable bioavailability or reach intracellular compartments and the presence of a linker can significantly hinder the interaction with target proteins rendering the kind and attachment point of linkers a crucial optimization topic.</div><div class="NLM_p">Linked pharmacophores are currently of great interest in antibody drug conjugates<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> where the linkage often aims the exploit one pharmacophore (e.g., the antibody) as targeting agent that delivers the second pharmacophore (a small molecule) to its desired site of action. Thereby, highly potent agents can be applied in cancer treatment which exhibit too strong cytotoxicity to be used in monotherapy. The concepts of antibody drug conjugates are increasingly transferred to small molecule drug conjugates, and some lessons from this field of drug discovery can also be learned for small molecule pharmacophore linkage.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div><div id="sec3_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16">3.2.1.  Linked Pharmacophore Examples</h4><div class="NLM_p">The targeted delivery strategy that is explored with the linkage of antibodies and cytotoxic payloads has also been successfully established by linking two small molecules. One of the first example of two linked pharmacophores for targeted delivery to cancer cells was reported as early as 1992,<a onclick="showRef(event, 'ref143 ref144'); return false;" href="javascript:void(0);" class="ref ref143 ref144">(143,144)</a> when cytotoxic drugs were linked to cholic acid derivatives as targeting pharmacophore which helped the compounds to be specifically taken up into targeted cells via bile acid transporters. Since then, various transport systems and cell surface receptors were used to deliver linked multitarget compounds to specific cell populations by addressing, e.g., estrogen receptors, folate receptors, sigma-2 receptor, prostate-specific membrane antigen, the polyamine transport system, and even glucose transporters. Moreover, exploiting the affinity of a ligand to a transport system or cell surface receptor can also serve imaging purposes, modulate pharmacokinetic properties, or allow passage of physiological barriers such as the blood–brain barrier.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div><div class="NLM_p">Currently, targeted delivery of antibiotics into bacteria by exploiting bacterial uptake mechanisms catches remarkable attention. Because of their need of iron acquisition from the surroundings, bacteria produce and excrete iron-chelating compounds, so-called siderophores. Specific active uptake mechanisms then internalize the chelator–iron complexes to satisfy the bacterial need for iron. This active transport system is now successfully targeted to furnish active uptake of antibacterials by conjugation of an antibiotic agent and a siderophore with a (biodegradable) linker. There are also natural sideromycins such as albomycin and salmycin produced by streptomycetes,<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> and several promising synthetic examples of such drug conjugates (<b>2a</b>–<b>c</b>) have been reported recently showing remarkable potency even against multiresistant strains.<a onclick="showRef(event, 'ref146 ref147 ref148 ref149'); return false;" href="javascript:void(0);" class="ref ref146 ref147 ref148 ref149">(146−149)</a> Some sideromycins are cleaved after uptake by bacterial enzymes to release the antibiotic pharmacophore. Cefiderocol (<b>2c</b>), the most advanced example of designed sideromycins, has entered clinical trials and holds promise for efficacy versus multidrug-resistant Gram-negative pathogens<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/medium/jm-2018-00760f_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0005.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Sideromycins (<b>2a</b>–<b>c</b>, Examples),<a onclick="showRef(event, 'ref146 ref147 ref150'); return false;" href="javascript:void(0);" class="ref ref146 ref147 ref150">(146,147,150)</a> Conjugates Composed of a Siderphore and a Potent Antibiotic, Exploit Bacterial Iron Uptake Mechanisms to Furnish Active Transport of the Conjugates into Bacteria Where the Conjugate Is Cleaved to Release the Antibiotic; Cefiderocol (<b>2c</b>) Has Already Entered Clinical Development</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Linkage of therapeutic pharmacophores that are not intended to facilitate uptake but to exhibit pharmacodynamic effects on both their targets for potential synergistic activity has also caught attention in the field of antimicrobial agents.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> Although this field is rather new, linked multitarget antibiotics might increasingly gain significance in times of limited availability of antimicrobial agents.</div></div><div id="sec3_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18">3.2.2.  Linker Chemistry</h4><div class="NLM_p">All pharmacophore linkage approaches have in common that their linker chemistry<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> is crucial to achieve the desired characteristics and effects because their behavior strongly depends on the linking group. It may significantly affect activity on the targets but also governs pharmacokinetics and defines whether and where the linked molecules can be released from each other by cleavage.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Regiochemistry is of particular importance to retain affinity of the linked pharmacophores to their targets, and information on the SAR of the linked pharmacophores must be available to identify suitable positions for linker attachment. Suitable linkers can improve polarity and solubility,<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> reduce unspecific uptake of the conjugate into cells by passive diffusion,<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> and define site and kinetics of linker cleavage, e.g., by pH dependence or liability to a certain enzyme. For noncleavable linkers, attachment points to the pharmacophores as well as linker length and geometry require special attention.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a></div><div class="NLM_p">For conjugate agents with a cleavable linker, the intended site of cleavage and release of the linked pharmacophores is a central consideration to select the most suitable linker. Cleavable linkers<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>) include linking groups that are labile to acid (hydrazones, oximes, thiomaleimides<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a>) or reducing agents (disulfides) as well as linkers that can be degraded by enzymes (peptide-based: valine-citrulline<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> is cleaved by cathepsin B, imide groups are cleaved by endopeptidases;<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> β-glucuronic acid<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> is cleaved by β-glucuronidase). After cleavage of the labile group in the linker, modern linkers may undergo intramolecular reactions that ultimately lead to total release of the linker group and its spacers from the linked pharmacophores (self-immolative spacers,<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a><a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).</div><figure id="sch4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/medium/jm-2018-00760f_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Typical Cleavable Linkers (Examples) Are Either Labile to Acidic Conditions or Reducing Agents, or Designed to Be Specifically Cleaved by Certain Enzymes</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/medium/jm-2018-00760f_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0007.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Self-Immolative Spacers (Examples)<a onclick="showRef(event, 'ref155 ref156'); return false;" href="javascript:void(0);" class="ref ref155 ref156">(155,156)</a> Undergo Intramolecular Reactions to Entirely Release the Linked Drugs from the Conjugate</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21">3.2.3.  Fused Multiple-Targeting Ligands</h4><div class="NLM_p">In addition to conjugating two individual pharmacophores with a linker, two bioactive small molecules addressing two targets can also be fused directly without a linker connecting them.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Depending on the nature of the bond linking the two compounds, the characteristics of such fused multiple ligands can vary between cleavable and noncleavable like in linked conjugates. For example, fused multiple ligands that are connected via an ester moiety, an imine, or a hydrazone may be cleaved in vivo.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> Similar to linked conjugates where the site of linker attachment is a crucial optimization task, also the site and manner of compound fusion needs to be carefully evaluated and optimized. Especially noncleavable fused multiple ligands may fail to exhibit their desired activities when fusion of pharmacophores hinders their binding to the targets. In some cases, this may be an insuperable obstacle, e.g., when the ligand binding site of a target is buried within the protein such as in nuclear receptors.</div><div class="NLM_p last">Simple fusion of two pharmacophores will produce quite large molecules and may seem hardly attractive on first glance.<a onclick="showRef(event, 'ref8 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref10">(8,10)</a> However, for some target combinations which too strongly differ in the chemotypes of ligands they can accommodate, fusion of pharmacophores may be an <i>ultima ratio</i> to generate a multiple ligand with the desired pharmacological profile.</div></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">3.3.  Merged Multiple-Targeting Ligands</h3><div class="NLM_p">The most elegant way of designing small molecules that modulate more than one target is merging their pharmacophores.<a onclick="showRef(event, 'ref8 ref12 ref161'); return false;" href="javascript:void(0);" class="ref ref8 ref12 ref161">(8,12,161)</a> Explicitly, in such merged multiple ligands, the key pharmacophore features required to interact with the targets of interest are combined in one united pharmacophore. To allow such pharmacophore merging, a certain overlap in the pharmacophores of the individual targets is required.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> Moreover, the binding sites of both targets of interest must be capable of binding the same chemotypes of molecules in terms of geometry and charge distribution. Key pharmacophore elements such as acidic functions which are, e.g., present in fatty acid mimetics<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> or metal binding motifs must be compatible with the second biological target. On the other hand, the danger of general promiscuity of identified dual binders/modulators must be considered and excluded.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a></div><div id="sec3_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23">3.3.1.  Lead Identification Strategies for Merged Ligands</h4><div id="sec3_3_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24">3.3.1.1.  Rational Approaches</h5><div class="NLM_p">A key step in developing merged multiple ligands is the lead compound identification. Several strategies to discover suitable starting points for multitarget compound development and further optimization have been employed and validated. With the availability of actives on the individual targets of interest, common structural and pharmacophore features of similar ligands can be systematically merged in minimal common lead pharmacophores. X-ray structural information can be very valuable in this step to identify key pharmacophore features that are crucial for activity. Several projects have successfully generated merged multiple ligands by rationally and systematically combining common scaffolds and substructures contained in selective ligands of the targets of interest (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>). Woo et al.<a onclick="showRef(event, 'ref163 ref164 ref165 ref166'); return false;" href="javascript:void(0);" class="ref ref163 ref164 ref165 ref166">(163−166)</a> (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>A) have combined the pharmacophores for aromatase inhibition (<b>3a</b>) and steroid sulfatase inhibition (<b>3b</b>), leading to several dual inhibitors of both enzymes. Initial merging of the pharmacophores was achieved by incorporating a phenol sulfamate moiety crucial for irreversible steroid sulfatase inhibition in a known aromatase inhibitor scaffold. The pharmacophore merging strategy relied on structural information from co-crystals and molecular docking studies and resulted in dual inhibitors such as <b>3c</b> with balanced intermediate nanomolar potency. Extensive SAR studies and scaffold hopping yielded various chemotypes of dual aromatase/steroid sulfatase inhibitors such as <b>3d</b>, with potencies ranging down to picomolar values.</div><figure id="sch6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/medium/jm-2018-00760f_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0008.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Examples for Rational Design of Merged Lead Pharmacophores in Multiple Ligand Development<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(A) Introduction of the steroid sulfatase inhibition pharmacophore phenolsulfamate from <b>3b</b> into aromatase inhibitor <b>3a</b> was sufficient to design merged dual aromatase/steroid sulfatase inhibitor <b>3c</b>. Subsequent SAR studies and scaffold hopping yielded several series of potent dual inhibitors such as <b>3d</b>. (B) Minimal pharmacophores for farnesoid X receptor (FXR) activation (<b>4a</b>) and soluble epoxide hydrolase (sEH) inhibition (<b>4b</b>) were compatible for merging in dual lead pharmacophore <b>4c</b> exhibiting moderate dual potency. <b>4c</b> was systematically optimized towards both targets resulting in dual modulator <b>4d</b> with low nanomolar dual activity. (C) The atypical antipsychotic ziprasidone (<b>5a</b>) was discovered by merging pharmacophores for serotonin 5-HT<sub>2</sub> receptor antagonism (<b>5b</b>) and dopamine (<b>5c</b>) receptor antagonism producing the dual antagonist <b>5d</b> which was systematically optimized to <b>5a</b>. (D) Design of the triple lead pharmacophore <b>6c</b> incorporating pharmacophore elements for choline esterase (ChE) inhibition (adopted from <b>6b</b>), monoamine oxidase (MAO) inhibition (<b>6b</b>) and histamine H<sub>3</sub> receptor antagonism (<b>6a</b>) depicts that even activity on three individual targets can be rationally designed in a single small molecule. Minor structural changes were then sufficient to optimize <b>6c</b> to the potent triple modulator <b>6d</b>.</p></p></figure><div class="NLM_p">Schmidt et al.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>B) have merged pharmacophores for farnesoid X receptor (FXR) activation (<b>4a</b>) and soluble epoxide hydrolase (sEH) inhibition (<b>4b</b>) to generate a minimized merged lead pharmacophore. Key pharmacophore elements, an amide moiety to mimic the transition state of sEH substrate hydrolysis and a carboxylic acid moiety for neutralizing interactions with the FXR ligand binding site, were compatible with a common substructure in a pair of known selective actives of FXR and sEH. One out of three merged candidate lead pharmacophores (<b>4c</b>) possessed moderate dual potency and was extensively optimized to a series of dual FXR/sEH modulators (<b>4d</b>) with low nanomolar potency as potential drug for the treatment of nonalcoholic steatohepatitis and related metabolic diseases.</div><div class="NLM_p">The atypical antipsychotic ziprasidone (<b>5a</b>) was rationally designed from two pharmacophores to target serotonin 5-HT<sub>2</sub> receptors and dopamine receptors (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>C). The naphthylpiperazine 5-HT<sub>2</sub> pharmacophore (<b>5b</b>)<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> was merged with an indolone moiety as dopamine (<b>5c</b>) antagonistic pharmacophore<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> resulting in dual antagonist <b>5d</b>. Subsequent systematic structural optimization enabled the development of <b>5a</b>.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a></div><div class="NLM_p last">Bautista-Aguilera et al.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>D) successfully designed triple ligands of choline esterase (ChE), monoamine oxidase (MAO) and histamine H<sub>3</sub> receptor for the use in neurodegenerative diseases by rationally merging pharmacophores for each target in a single molecule. Incorporation of a general H<sub>3</sub> antagonism pharmacophore derived from <b>6a</b> in the compatible dual ChE/MAO inhibitor <b>6b</b> generated lead <b>6c</b> with intermediate triple potency. Minor structural changes (<b>6d</b>) were then sufficient to optimize the triple activity to balanced nanomolar values.</div></div><div id="sec3_3_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26">3.3.1.2.  Descriptor-Based Computational Approaches</h5><div class="NLM_p">Complementary to rational merging of known common pharmacophore elements, several computational approaches are available as potent alternatives. Large publicly available data sets of structure–bioactivity relationships such as ChEMBL<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> or PubChem<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> can be used to build drug-target interaction networks and to discover scaffolds suitable for merged multiple ligand development. For such approaches, molecular descriptors are required to capture characteristics of the bioactive compounds and various molecular fingerprints have been successfully applied to this problem.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> Suitable fingerprints include simple substructure fingerprints<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> and circular fingerprints<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> but also ligand interaction fingerprints<a onclick="showRef(event, 'ref175 ref176 ref177'); return false;" href="javascript:void(0);" class="ref ref175 ref176 ref177">(175−177)</a> and pharmacophore feature descriptors.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> With such molecular descriptors, the similarity of actives for a pair (or set) of targets of interest can be computed to identify similar ligands.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> Thus, discovered candidates for dual activity can then be characterized in vitro on the respective other target(s) of interest for which no bioactivity data are available and actives can serve as leads for merged multiple ligand development.</div><div class="NLM_p">As an alternative to systematic lead structure searches based on compound similarity, large structure–bioactivity data sets can also be used to generate quantitative structure–activity relationship (QSAR) models for prediction of bioactivity on the targets of interest. Such models can be built using neural networks or support vector machines or random forest models/decision trees.<a onclick="showRef(event, 'ref161 ref180 ref181'); return false;" href="javascript:void(0);" class="ref ref161 ref180 ref181">(161,180,181)</a> QSAR models require a considerably large data set of actives and inactives on the targets of interest for their training but then can be used to score unknown compounds for their probability to be active. Successful examples have used QSAR models to identify dual modulators for defined target pairs with high retrieval and low false positive rates.<a onclick="showRef(event, 'ref182 ref183'); return false;" href="javascript:void(0);" class="ref ref182 ref183">(182,183)</a></div><div class="NLM_p last">Furthermore, generative artificial intelligence is continuously gaining relevance in early drug discovery and might also hold enormous potential in multitarget compound design. Recently, a generative artificial intelligence model trained to capture the constitution of ChEMBL annotated compounds represented as SMILES strings and fine-tuned on a set of ligands for two specific target families was successfully employed to discover novel dual ligands.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> The advantage of this method is that it required far less training data than most other approaches for the targets of interest and invents novel chemical entities that were not annotated in the training data.</div></div><div id="sec3_3_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27">3.3.1.3.  Pharmacophore Models</h5><div class="NLM_p">In addition to aforementioned descriptor-based approaches to multiple ligand identification, pharmacophore models provide a complementary computational approach. Pharmacophore models describing the “ensemble of steric and electronic features of a compound that is necessary for the interaction with a biological target” can be computationally deduced from either a set of known ligands of the target (ligand-based) or from co-crystal structures (structure-based). They represent a three-dimensional arrangement of features such as hydrogen bond donors/acceptors, charged residues, aromatic interactions, or lipophilic contacts. Moreover, excluded volumes may be defined in these three-dimensional models to avoid clashes with the biological target, leading to inactive compounds even though positive pharmacophore features are matched.<a onclick="showRef(event, 'ref185 ref186 ref187'); return false;" href="javascript:void(0);" class="ref ref185 ref186 ref187">(185−187)</a></div><div class="NLM_p">Ligand-based pharmacophores are generated from sets of known actives for a target of interest. For this, the known actives are aligned in order to identify common pharmacophore features to be included in the pharmacophore model. Because the bioactive conformations of these ligands are not known without structural information, a number of preferred energy-minimized conformations have to be included for every ligand which may lead to considerable computation efforts. However, modern algorithms in pharmacophore modeling software are competent to cover the three-dimensional conformational space of small molecules. In addition to sampling preferred conformations of the ligands, their alignment is an elaborate computational task. For example, small molecules can be aligned by superimposing single atoms, atom ensembles (fragments), or chemical/pharmacophore features with least-squares fitting, but also descriptor-based methods are available and modern alignment techniques use, e.g., pattern recognition. This large number of factors influencing the pharmacophore model generation in addition to the selection of training ligands can lead to remarkable variation in the final models and, therefore, ligand-based pharmacophore modeling is a challenging task even for a single target.<a onclick="showRef(event, 'ref185 ref188 ref189 ref190'); return false;" href="javascript:void(0);" class="ref ref185 ref188 ref189 ref190">(185,188−190)</a></div><div class="NLM_p">Structure-based generation of pharmacophore models provides the strong advantage that an optimal three-dimensional conformation of the ligand can be extracted from the co-crystal structure.<a onclick="showRef(event, 'ref185 ref191 ref192 ref193 ref194'); return false;" href="javascript:void(0);" class="ref ref185 ref191 ref192 ref193 ref194">(185,191−194)</a> Moreover, pharmacophore features can be defined from the interactions of the ligand with a biological target and excluded volumes result from the binding site surface. However, structure-based pharmacophore models derived from a single co-crystal structure cannot cover the full chemical space of small molecules that might be interacting with the target of interest. A co-crystal structure represents only one possible “frozen” conformation of the protein and, thus, conformational adaption to a ligand is not reflected by a structure-based pharmacophore model.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a></div><div class="NLM_p">Both, ligand- and structure-based pharmacophore models have their limitations and often suffer from high rates of false-positives in screening approaches, leading to few retrieved actives. Obstacles in pharmacophore-based screening among others include poor data quality, limited number of known inactives, erroneous crystal structures, and restricted computational implementation of some interaction types such as halogen bonding.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> To optimize the output to a maximum hit rate of true actives, pharmacophore models should be carefully adjusted and cross-validated if sufficient data is available.<a onclick="showRef(event, 'ref190 ref195'); return false;" href="javascript:void(0);" class="ref ref190 ref195">(190,195)</a> Although pharmacophore models are often outperformed by descriptor-based approaches for individual targets, they represent a valuable approach to multiple ligand identification.</div><div class="NLM_p">Strategies to obtain multiple ligands from pharmacophore models involve virtual screening of compound libraries to identify potential binders or de novo design of small molecules matching the pharmacophore model(s). For multiple ligand discovery by pharmacophore-based virtual screening, two individual screenings are required using pharmacophore models of both targets of interest. In an optimal scenario, the screened compound libraries contain a set of preferred energy-minimized conformations of each structure to identify conformations matching the pharmacophore model although this may significantly increase computation time. A suitable tolerance radius must be defined for the individual pharmacophore features to be matched by the screening compounds and some features should possibly be defined as optional.<a onclick="showRef(event, 'ref185 ref190'); return false;" href="javascript:void(0);" class="ref ref185 ref190">(185,190)</a> Candidate compounds matching the pharmacophores of both targets of interest should then be analyzed in more detail using for example molecular docking to further validate them in silico before selected compounds are tested experimentally. Successful workflows<a onclick="showRef(event, 'ref196 ref197'); return false;" href="javascript:void(0);" class="ref ref196 ref197">(196,197)</a> following this strategy individually generated pharmacophore models for the ligand binding sites of both targets of interest and then screened compound libraries for candidates matching both pharmacophore models. These molecules were then docked into the binding sites of both targets and top-scoring hits were experimentally validated with good dual hit rates.</div><div class="NLM_p">Alternatively, pharmacophore models can also be developed to cover the common pharmacophore features of both targets of interest.<a onclick="showRef(event, 'ref198 ref199 ref200'); return false;" href="javascript:void(0);" class="ref ref198 ref199 ref200">(198−200)</a> Such consensus models can originate from structural information derived from co-crystals of each target from known dual ligands of both targets or from a combination of both. An exemplary consensus dual pharmacophore model was built by docking known dual ligands into the structures of both targets to identify common pharmacophore elements, which were then used to define the common motifs for the model.<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a></div><div class="NLM_p">A purely ligand-based dual pharmacophore approach<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> individually generated pharmacophore models for sets of inhibitors of soluble epoxide hydrolase (sEH) and 5-lipoxygenase (5-LO). Subsequently, the models were aligned pairwise in a graph-based manner to yield dual pharmacophore models. Importantly, the alignment allowed varying distances between individual pharmacophore features according to the assumption that targets may share ligands due to shared pharmacophore elements even if these elements have distinct spatial distances. Pharmacophore-based virtual screening followed by scaffold analysis and shape/electrostatics-based refinement successfully uncovered a novel dual inhibitor (<b>7</b>) of sEH and 5-LO with fragment-like size and intermediate dual potency (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/medium/jm-2018-00760f_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0001.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. A ligand-based dual pharmacophore approach<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> individually generated pharmacophore models for soluble epoxide hydrolase inhibitors and 5-lipoexigenase inhibitors. Subsequent graph-based alignment of the resulting models produced a dual consensus pharmacophore that was used in virtual screening which yielded a novel dual inhibitor (<b>7</b>) of both enzymes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Pharmacophore-based de novo design as an alternative strategy to obtain active small molecules from pharmacophore models holds the great advantage that new chemical entities are developed instead of identifying ligands from libraries of known compounds. Numerous techniques have been developed to computationally “invent” such novel compounds including reaction-driven approaches<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> that fuse building blocks, fusion of fragment structures,<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> and applications of generative artificial intelligence.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> Independently from their source, de novo designs are then ranked or scored using pharmacophore models for the targets of interest or a consensus pharmacophore model to select candidate compounds for synthesis and biological evaluation. The drawback of this approach may be the challenging synthesis of de novo designs generated by some techniques.<a onclick="showRef(event, 'ref203 ref204'); return false;" href="javascript:void(0);" class="ref ref203 ref204">(203,204)</a></div></div><div id="sec3_3_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28">3.3.1.4.  Identification of Multiple-Targeting Ligands from Clinical Observations</h5><div class="NLM_p">In addition to ligand-/drug- and structure-based approaches to identify multiple ligand leads, disease-based approaches are at least similarly promising. Network analysis<a onclick="showRef(event, 'ref205 ref206'); return false;" href="javascript:void(0);" class="ref ref205 ref206">(205,206)</a> of biological target patterns can not only reveal synergistic target combinations (cf. <a class="ref internalNav" href="#sec2_3" aria-label="section 2.3">section 2.3</a>), but together with observations on drug effects in clinical development or practice may uncover unanticipated activities and targets for known bioactive compounds that potentially display superior efficacy. Such side activities of known drugs can be optimized to new selective agents in a classical selective optimization of side activities (SOSA)<a onclick="showRef(event, 'ref207 ref208'); return false;" href="javascript:void(0);" class="ref ref207 ref208">(207,208)</a> campaign or developed to new multiple ligands. Translational research involving expertise from various professions is a prerequisite to identify multiple ligand lead compounds among drugs from clinical observations, but such starting points may be of extraordinary value for multiple ligand discovery as they already constitute extensively optimized bioactive compounds and are drug-like by definition.</div><div class="NLM_p">The discovery of PPARγ modulating activity of the AT1R antagonist telmisartan (<b>8a</b>) is a prime example of lead identification for multitarget drug discovery from clinical observations. Initially, <b>8a</b> was found to reduce free plasma glucose and free plasma insulin<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a> when compared to the competitor AT1R antagonist losartan. This activity was traced down to a partial activation of PPARγ at pharmacologically relevant concentrations.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> A recent meta-analysis of 21 randomized clinical trials revealed that telmisartan improves insulin resistance in terms of fasting blood glucose and insulin levels.<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a> Structure–activity relationship studies of <b>8a</b> derivatives as partial PPARγ agonists revealed crucial structural features required for PPARγ binding and activation.<a onclick="showRef(event, 'ref211 ref212'); return false;" href="javascript:void(0);" class="ref ref211 ref212">(211,212)</a> Both AT1R and PPARγ displayed similar pharmacophore requirements, leading to the identification of potent dual AT1R antagonists/partial PPARγ agonists such as <b>8b</b> with in vivo efficacy by minor structural modifications of the original drug (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>).<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div><figure id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/medium/jm-2018-00760f_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0009.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Clinical Observations of Improved Insulin Sensitivity under Telmisartan (<b>8a</b>) Treatment Led to Identification of Its PPARγ Activating Potential Which Was Then Optimized by Minor Structural Changes (<b>8b</b>) while Conserving the Original AT1R Antagonistic Activity</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30">3.3.2.  Optimization Strategies for Merged Multiple Ligands</h4><div class="NLM_p">After a multiple ligand lead compound has been identified by whichever technique, a challenging structural optimization process will follow with the objective to generate high potency on two molecular targets and to provide a balanced activity profile on these targets of interest. The challenge of complying with the structural requirements of two targets to achieve high affinity often results in high lipophilicity and compound size and poor pharmacokinetics. Merged lead pharmacophores should, therefore, comprise low molecular weight to provide a sufficient margin for structural variation and enlargement. Moreover, a key focus in the multitarget optimization must lie on conserving low lipophilicity and avoiding extensive structural enlargement.<a onclick="showRef(event, 'ref8 ref10 ref161'); return false;" href="javascript:void(0);" class="ref ref8 ref10 ref161">(8,10,161)</a></div><div class="NLM_p">The multitarget lead optimization must also optimize the potency ratio of the multiple ligand on its targets. In the best case, the optimal ratio also considers exposure of relevant tissues to the multitarget agent in vivo and often animal disease models will be necessary to find the optimal balance in potency on the targets of interest.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p">Besnard et al.<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a> have employed a fully automated multiple ligand development approach to the discovery of compounds addressing various neurotransmitter receptors (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). Using Bayesian probabilistic activity models built on ChEMBL data, e.g., multitarget activity of the ChE inhibitor donepezil (<b>9a</b>) on dopamine receptors was discovered. Continuously relying on Bayesian models, derivatives of donepezil were stepwise optimized toward potent selective as well as multitarget ligands (e.g., <b>9b</b>) by selecting compounds for synthesis based on the computational predictions. Besides activity predictions for serotonin, dopamine and adrenergic receptors, the employed models also covered compound characteristics such as blood–brain barrier penetration.</div><figure id="fig2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/medium/jm-2018-00760f_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0002.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Successful structural optimization of multiple ligands has been achieved by various strategies. (A) A fully automated optimization approach of donepezil (<b>9a</b>) to multiple ligands of serotonin and dopamine receptors employing Bayesian probability models resulted in several highly potent multiple ligands such as <b>9b</b> as well as selective ligands of neurotransmitter receptors. (B) Systematic exploration of substituent vectors allowing dual optimization on multiple ligands scaffold <b>4c</b> allowed stepwise optimization of dual FXR/sEH modulation. Final combination of all SAR knowledge yielded the highly potent dual modulator <b>4d</b>. (C) Relying on molecular docking results, zafirlukast (<b>10a</b>) was optimized to a potent triple ligand (<b>10b</b>) of peroxisome proliferator-activated receptor γ (PPARγ), soluble epoxide hydrolase (sEH), and cysteinylleukotriene receptor 1 (CysLT<sub>1</sub>R) by very minor structural changes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A rational optimization strategy for multiple ligands that does not rely on structural data or computational models is systematic exploration of the SAR on each individual target. Starting from the multiple lead pharmacophore <b>4c</b>, methyl groups and chlorine atoms were systematically introduced in every possible position of the scaffold. Thereby, substituent vectors that are tolerated by both targets of interest were identified. Additionally, the preferred electronic environment can be evaluated for each position by comparing electron-releasing methyl groups with electron-withdrawing chlorine atoms. Preferred substitution vectors that positively affect activity on both targets of interest (or are at least tolerated) can then be analyzed more deeply with various substituents. In such a manner, every position can be systematically optimized. The SAR on multiple targets will, of course, not be congruent for every position and it may become necessary to combine structural elements that individually improve potency on a single target. In such cases, the dual SAR can be visualized by plotting the compounds’ pEC<sub>50</sub>/pIC<sub>50</sub> values for the two targets and select extreme examples for combination if their structures are compatible (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). By this strategy, a highly potent dual FXR/sEH modulator (<b>4d</b>) was developed.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div><div class="NLM_p last">Multiple ligand optimization can also successfully rely on structural information or molecular docking. Zafirlukast (<b>10a</b>) was identified as a triple modulator comprising antagonism on cysteinyl leukotriene 1 receptor (CysLT<sub>1</sub>R), PPARγ agonism and sEH inhibition in vitro but no balanced activity profile. This profile was optimized purely based on molecular docking results. By close inspection of the compound’s proposed binding modes to PPARγ and sEH, very minor structural changes were identified that proved sufficient for increasing PPARγ and sEH potency and thereby balancing the triple modulator’s (<b>10b</b>) activity profile (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C).<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a></div></div><div id="sec3_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31">3.3.3.  Design-In Approach</h4><div class="NLM_p">Complementary to the search for a merged lead pharmacophore that already satisfies the structural requirements for modulation of both targets of interest, also a pair of potent compounds that selectively modulate the two targets can serve as starting point for multiple ligand development. In such an approach, the pharmacophore (and activity on target) of one compound is designed into the other in a design-in strategy.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> By stepwise adaption of one structure toward the other and introduction of structural elements required for activity on the complementary target, dual potency is generated. Of note, the design-in approach and the rational generation of merged consensus pharmacophores (cf. <a class="ref internalNav" href="#sec3_3_1_1" aria-label="section 3.3.1.1">section 3.3.1.1</a>) cannot always be clearly separated but describe a common strategy of uniting two selective compounds in terms of molecular architecture, substituent vectors, and functional groups that are crucial for interaction with the biological targets of interest.</div><div class="NLM_p">The challenge of such a strategy lies in increasing potency for the complementary target while conserving potency on the original target for which the molecular architecture of both selective lead compounds needs to provide sufficient similarity. In the optimal scenario, the two selective leads share a common central scaffold and differ merely in the decoration of this moiety with substituents. Then, systematic evaluation of suitable substitution patterns for dual/multiple potencies can lead to success in multiple-targeting ligand development and optimization.</div><div class="NLM_p last">The design-in approach is a challenging task and may face insuperable obstacles when the two selective compounds used as leads are not sufficiently compatible. On the other hand, designing one existing pharmacophore into another one also offers advantages. When two optimized selective modulators are chosen to be combined, considerable knowledge on their SAR is usually available which can be used for the optimization process toward a multiple ligand. Such SAR data can provide hints in which positions further or alternative substituents are tolerated and whether scaffold hopping toward a more compatible molecular architecture might be feasible.</div></div><div id="sec3_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32">3.3.4.  Design-Out Approach</h4><div class="NLM_p last">The design-out strategy toward multiple ligands with designed target modulation profile follows the opposite direction as the design-in approach.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Instead of using selective compounds and merge their pharmacophores by stepwise structural adaption, the design-out strategy starts from an unselective ligand that modulates multiple biological targets including the targets of interest. By reducing the potency on the undesired targets through directed structural changes, the design-out approach generates designed multiple ligands by increasing their selectivity toward the desired target combination. This strategy can profit from X-ray structural data even more than design-in or pharmacophore merging approaches because it relies on a single lead compound that already interacts with all targets of interest with high affinity. Therefore, co-crystal structures may provide insights where the binding mode of the lead to an undesired target significantly differs from the interaction with the desired targets and where, e.g., clashes with the protein could be generated that disrupt potency on the “off”-target(s). Design-out approaches are less common because suitable lead compounds that possess multiple potent activities, but constitute no promiscuous binders are rare. The design-out approach may still be attractive when target combinations involving more than two individual proteins shall be addressed which with every additional target increases the difficulties and obstacles of the design-in strategy or pharmacophore merging.</div></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33">3.4.  Fragment-Based Approaches to Multiple-Targeting Ligands</h3><div class="NLM_p">The concept of fragment-based discovery of multitarget drugs was suggested by Morphy and Rankovic<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> based on reports by Hann et al.,<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a> which retrospectively show that selectivity tends to increase with molecular complexity. Moreover, Hopkins et al.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> demonstrated an inverse correlation between molecular weight and number of targets to which a compound binds. Taken together, these observations suggest that fragment-based screening for multiple targets to identify multitarget fragment leads may offer higher chances than screening approaches with larger compounds.</div><div class="NLM_p">Although fragment-based discovery of multiple ligands appears as a highly promising approach,<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> the number of successful prospective studies is limited. Most of these rely on in silico preselection of fragments. Achenbach et al.<a onclick="showRef(event, 'ref216'); return false;" href="javascript:void(0);" class="ref ref216">(216)</a> performed a fragment-based screening to identify dual inhibitors of sEH and 5-LO. A commercially available fragment library was virtually screened using an adapted self-organizing map (SOM) algorithm. It involved two self-organizing maps that were trained on molecular fragments derived from known active compounds on the two desired targets. As a background distribution, fragments from FDA approved drugs were used for both SOMs. After training, the SOMs were aligned by minimizing the distance between the background (FDA approved compounds). Thereby, regions populated with sEH fragments or 5-LO fragments were identified. Both regions shared an overlapping space whose visual inspection yielded 24 fragments with predicted activity toward both targets for experimental validation in STD-NMR and activity-based assays. Five out of 24 fragments showed inhibitory activity toward both enzymes in activity assays, while two structures displayed binding to both targets in the STD-NMR setup. One selected fragment was expanded to a potent dual inhibitor with high affinity (nanomolar concentration range) to both targets.</div><div class="NLM_p">A structure-based virtual screening to multitarget fragment identification has successfully yielded dual inhibitors of β-secretase 1 (BACE-1) and glycogen synthase kinase 3β (GSK-3β).<a onclick="showRef(event, 'ref217'); return false;" href="javascript:void(0);" class="ref ref217">(217)</a> Bottegoni et al. based this approach on the hypothesis of common H-bonds required for targeting both enzymes and selected fragments by visual inspection after an unbiased docking procedure. In a subsequent screening step, the selected fragments were enriched by structurally similar compounds and the procedure was repeated to yield 27 fragments for experimental evaluation. NMR-based functional screening of the selected fragments confirmed <b>11</b> as inhibitor of both enzymes (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>).</div><figure id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/medium/jm-2018-00760f_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0010.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Multitarget Fragment Examples<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>The dual inhibitor of β-secretase 1 (BACE-1) and glycogen synthase kinase 3β (GSK-3β) <b>11</b> was computationally identified based on a common H-bond hypothesis and confirmed as inhibitor of both enzymes by NMR-based functional screening. Triazinone <b>12</b> was rationally designed as dual inhibitor of BACE-1 and GSK-3β by combining structural motifs required for interaction with the two enzymes. The approved drug indeglitazar (<b>13</b>) activating the nuclear receptors PPARα, PPARγ, and PPARδ was developed from fragment <b>13a</b> which had been identified as active on the three receptors in a fragment library screening. The structural optimization was guided by co-crystal structure data for <b>13a</b> with all three PPARs.</p></p></figure><div class="NLM_p">Rational generation of a common pharmacophore hypothesis currently appears as best-established technique to identify multitarget fragments. Prati et al. applied such an approach to dual BACE-1/GSK-3β inhibitors.<a onclick="showRef(event, 'ref218'); return false;" href="javascript:void(0);" class="ref ref218">(218)</a> The authors postulated that a cyclic amide is crucial for GSK-3β inhibition, while a guanidine is required to inhibit BACE-1. This rationale led to the combination of both structural motifs in triazinone fragment <b>12</b> with dual inhibitory activity. However, exploration of the starting fragment’s SAR failed to significantly improve inhibitory potency. Shang et al.<a onclick="showRef(event, 'ref219'); return false;" href="javascript:void(0);" class="ref ref219">(219)</a> rationally designed fragments for dual targeting of COX-2 and leukotriene A4 hydrolase (LTA4H) by analyzing selective ligands for both targets and claimed that 9 out of 21 fragments exhibited dual inhibitory activity at 1 μM concentration. Structure-based fragment growing then enabled potency optimization of one fragment in a micromolar range.</div><div class="NLM_p">The authors of the studies described above claim that fragment-based discovery of multitarget drugs is a promising approach, but the results merely depict that its practical implementation is still rather immature. Fragment-based design for single targets is very well established, but this is not the case for multitarget drug design as only few studies have reported a full screening of fragment-based libraries toward a rationally selected target combination.</div><div class="NLM_p">Artis et al. described the fragment-based discovery of the pan-PPAR agonist indeglitazar <b>13</b><a onclick="showRef(event, 'ref220'); return false;" href="javascript:void(0);" class="ref ref220">(220)</a> starting from the multitarget fragment 5-methoxyindole-3-propionic acid <b>13a</b>, which was identified in an in vitro fragment library screen using proximity-based coactivator recruitment assays. X-ray structures of <b>13a</b> with all three PPAR subtypes were then generated to define a rational optimization hypothesis and eventually enable the development of <b>13</b>. Thereby, the successful discovery of <b>13</b> highlights the major drawbacks in present approaches toward fragment-based multitarget approaches: it seems clearly possible to identify fragment hits addressing multiple targets, but structural information will be required for successful fragment growing and fragment-based design.<a onclick="showRef(event, 'ref221'); return false;" href="javascript:void(0);" class="ref ref221">(221)</a> However, few laboratories working in the field have the possibility to generate reliable structural information. Several approaches to fragment-based multitarget design tried to overcome this issue by molecular docking, but most of these attempts failed to achieve significant activity improvement which might be due to the limited predictive power of commonly used scoring functions.<a onclick="showRef(event, 'ref222'); return false;" href="javascript:void(0);" class="ref ref222">(222)</a> Recent advances in high-throughput crystallography<a onclick="showRef(event, 'ref223'); return false;" href="javascript:void(0);" class="ref ref223">(223)</a> may allow a major breakthrough in fragment-based multitarget drug discovery in near future.</div><div class="NLM_p">Another important application of fragment-based design is multikinase inhibitor development. Originally, selectivity rather than designed multitarget activity has been a dominating issue in ATP mimicking orthosetric kinase inhibitor design. However, most approved kinase inhibitors are not selective for a single target but comprise activity on a small subset of the kinome. Despite being designed as selective agents, kinase inhibitors often owe their therapeutic efficacy to these polypharmacological profiles. Recent understanding of cancer resistance toward kinase inhibitors has changed the selectivity paradigm and boosted polypharmacological kinase inhibitor design.<a onclick="showRef(event, 'ref224'); return false;" href="javascript:void(0);" class="ref ref224">(224)</a> Therein, the concept of kinase-privileged fragments facilitates identification of multikinase inhibitor leads.<a onclick="showRef(event, 'ref225'); return false;" href="javascript:void(0);" class="ref ref225">(225)</a> Frett et al. demonstrated the successful application of this approach in the discovery of a dual rearranged during transfection kinase (RET) and vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor.<a onclick="showRef(event, 'ref226'); return false;" href="javascript:void(0);" class="ref ref226">(226)</a> A suitable lead was retrieved by screening a kinase focused fragment collection. Lipophilic interactions with the targets and the PK profile were subsequently optimized to obtain a clinical candidate with the desired polypharmacological profile.</div><div class="NLM_p last">A characteristic challenge in multikinase inhibitor design is balancing potency on desired kinase targets and unwanted kinase off-targets. The combination of a phenotypic <i>Drosophila</i> model of multiple endocrine neoplasia type 2 and kinome-wide activity profiling successfully addressed this issue. The dual screening approach efficiently identified multitarget candidates from a library of kinase-privileged compounds with favorable balance of efficacy and toxicity.<a onclick="showRef(event, 'ref227'); return false;" href="javascript:void(0);" class="ref ref227">(227)</a></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">4.  Test Systems to Characterize Multiple Ligands</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70566" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70566" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Functional characterization of multiple ligands and confirmation of their simultaneous multitarget engagement as well as synergistic pharmacodynamic effects requires sophisticated in vitro assay systems and in vivo disease models. Because multiple ligands are often intended to produce superior synergistic effects, the employed in vitro and in vivo models must be competent to reveal such activity. Although animal models may appear more suitable for such complex requirements, in vitro experiments should preferably be conducted in advance to give first hints on the potential superiority of a multiple ligand over selective compounds before more tedious in vivo experiments are initiated. Both in vitro and in vivo systems suitable for multiple ligand characterization have been developed, but especially the available animal models cannot fully reflect multifactorial human diseases for multiple ligand testing, yet.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36">4.1.  Cellular Assay Systems</h3><div class="NLM_p">The challenge in cellular characterization of multiple ligands lies in demonstrating simultaneous multitarget engagement in a single test system. Techniques to identify multiple targets for the same molecule are widely employed in the field of target identification and have been reviewed extensively.<a onclick="showRef(event, 'ref228'); return false;" href="javascript:void(0);" class="ref ref228">(228)</a> Most of them are only of qualitative nature, however, and/or require modification of the test compound by a tagging system. Still, some label-free, quantitative approaches have been reported as well which can serve to demonstrate simultaneous target engagement in cells or tissues.<a onclick="showRef(event, 'ref229'); return false;" href="javascript:void(0);" class="ref ref229">(229)</a> Drug affinity responsive target stability (DARTS),<a onclick="showRef(event, 'ref230'); return false;" href="javascript:void(0);" class="ref ref230">(230)</a> a method relying on target stabilization against protease degradation upon ligand binding, holds much promise in multitarget compound characterization. Although DARTS is a powerful technique, it still has the drawback that test compounds are added to the cell lysate and neither cell penetration nor compound localization in the cell are taken into account. These drawbacks were overcome by the cellular thermal shift assay (CETSA),<a onclick="showRef(event, 'ref231'); return false;" href="javascript:void(0);" class="ref ref231">(231)</a> where stabilization of a target against thermal denaturation upon ligand binding is analyzed directly in a cellular environment. Of note, the target proteins can be detected in multiple different ways including Western blot analysis, mass spectroscopy, ELISA, or AlphaScreen. Schulz-Fincke et al. reported an application of CETSA to confirm target engagement of a multitarget lysine-specific demethylase 1 (LSD1)/MAO lead compound.<a onclick="showRef(event, 'ref232'); return false;" href="javascript:void(0);" class="ref ref232">(232)</a> Although this study could only demonstrate engagement on LSD1, CETSA has great potential as a method to study simultaneous target engagement for multiple ligands. On the basis of a similar principle, the technique thermal proteome profiling employs multiplexed quantitative mass spectrometry to quantify the amount of nondenatured targets. The method was successfully used to demonstrate target engagement of multitarget pan-HDAC inhibitor panabinostat<a onclick="showRef(event, 'ref233'); return false;" href="javascript:void(0);" class="ref ref233">(233)</a> and to profile interactions of small molecules with transmembrane proteins.<a onclick="showRef(event, 'ref234'); return false;" href="javascript:void(0);" class="ref ref234">(234)</a> In studying target engagement of multikinase inhibitors, both thermal proteome profiling<a onclick="showRef(event, 'ref235'); return false;" href="javascript:void(0);" class="ref ref235">(235)</a> and CETSA<a onclick="showRef(event, 'ref236'); return false;" href="javascript:void(0);" class="ref ref236">(236)</a> proved suitable. In addition, the Kinobeads technique<a onclick="showRef(event, 'ref237'); return false;" href="javascript:void(0);" class="ref ref237">(237)</a> has been successfully applied to demonstrate multiple target engagement of kinase inhibitors. It employs immobilized nonselective kinase inhibitors to bind and separate the kinase subproteome. Subsequent addition of the multitarget kinase inhibitor of interest displaces its targets which can be analyzed by quantitative mass spectrometry.</div><div class="NLM_p">In addition to studying target engagement, in other words confirming an interaction of the multiple ligand with the targets of interest, functional readouts are also essential for in vitro characterization of multitarget compounds, of course. High content screenings (cf. <a class="ref internalNav" href="#sec2_2" aria-label="section 2.2">section 2.2</a>) are very useful for this purpose and can also already give a hint on potential synergy. The detection of a synergistic effect in a cellular context is straightforward if the modulation of two targets results in a single synergistic cellular effect, e.g., apoptosis. When two independent effects are expected, it is markedly more demanding. However, recent advances in metabolomics allow the quantification of a broad spectrum of analytes from complex biological samples. An exemplary study demonstrated whole blood screening of arachidonic acid metabolites for different combinations of anti-inflammatory drugs.<a onclick="showRef(event, 'ref238'); return false;" href="javascript:void(0);" class="ref ref238">(238)</a> In this study, shunting effects that occurred for selective inhibitors were ameliorated by inhibitor combinations, an outcome which would be favored for multitarget inhibitors of the arachidonic acid cascade.<a onclick="showRef(event, 'ref239'); return false;" href="javascript:void(0);" class="ref ref239">(239)</a> Thus, “-omics” techniques are suitable to demonstrate functional properties of multitarget compounds in cells or tissues.</div><div class="NLM_p">Concepts to address target interactions caused by receptor homo- or heterodimerization/oligomerization and other strategies to achieve ligand-specific signaling mechanism are also arising.<a onclick="showRef(event, 'ref240'); return false;" href="javascript:void(0);" class="ref ref240">(240)</a> Here, multiple-targeting may open so-far unseen therapeutic options, but such aspects are out of the scope of this perspective.</div><div class="NLM_p last">An important drawback of cell-based assays for multitarget compound characterization is the missing adoption to the disease state, e.g., inflammatory processes cause overexpression of COX-2 isoenzymes and, therefore, the enzyme concentration may be different from the assay conditions, which may significantly affect the read-out. This may be of particular interest concerning the late formation of anti-inflammatory protectins or resolvins, which are not detected in these assays.<a onclick="showRef(event, 'ref241 ref242'); return false;" href="javascript:void(0);" class="ref ref241 ref242">(241,242)</a> More complex tissue-based test systems or advanced animal disease models provide more appropriate and functional read-outs to study complex biochemical cascades and disease-modifying effects of multiple-targeting ligands.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37">4.2.  Animal Models</h3><div class="NLM_p">With improving in vivo disease models for the screening and characterization of multitarget compounds, one must be aware that the main focus is fighting a disease and not developing a screening system with the highest response to the designed compounds. Read-outs selected for multitargeting approaches should, therefore, be oriented to an optimal disease simulation and not high compound effects. Animal models are supposed to simplify a disease with complex causes and multiple symptoms to simple and measurable effects. Adding further pathological dysregulations, biological targets and read-outs brings additional complexity into erstwhile minimalized models, e.g., the 6-hydroxydopamine (6-OHDA)-induced unilateral movement disorder in rats as a model of Parkinson’s disease only partly resembles the multifactorial disease state in human.<a onclick="showRef(event, 'ref243 ref244'); return false;" href="javascript:void(0);" class="ref ref243 ref244">(243,244)</a> In some instances, phenotypic screenings (cf. <a class="ref internalNav" href="#sec2_2" aria-label="section 2.2">section 2.2</a>) in simple organisms may be a more economic entry into preclinical development and proof-of-concept studies, especially when the primary objective of the animal model is confirmation of dual activity and a resulting synergistic effect.</div><div class="NLM_p">Cross-breeding of animals each reflecting single pathophysiological phenotypes may enable more complex and realistic models of multifactorial diseases that require treatment with multitargeting compounds. One such complex animal model of the metabolic syndrome, the spontaneously hypertensive obese (SHROB) rat,<a onclick="showRef(event, 'ref245'); return false;" href="javascript:void(0);" class="ref ref245">(245)</a> reflects almost all symptoms of the human disease. It allows efficient in vivo characterization of drug combinations (e.g., antihypertensive and antidiabetic drugs) as well as multitarget compounds. Earlier studies of such multitarget agents required multiple models. Casimiro-Garcia et al., e.g., reported the discovery of imidazo[4,5-<i>b</i>]pyridines with dual activity on AT1R and PPARγ but had to demonstrate their in vivo efficacy in two distinct models of hypertension (spontaneously hypertensive rat (SHR)) and insulin resistance (Zucker diabetic fatty (ZDF) rat).<a onclick="showRef(event, 'ref246'); return false;" href="javascript:void(0);" class="ref ref246">(246)</a> More recent studies tested combinations of sEH inhibitors and PPARγ agonists in a SHROB model to reveal synergistic effects and further benefits through more complex read-outs covering the whole range of metabolic parameters.<a onclick="showRef(event, 'ref300 ref301'); return false;" href="javascript:void(0);" class="ref ref300 ref301">(247,248)</a></div><div class="NLM_p last">Still, more complex parameters and models are needed for a realistic animal disease representation useful for multiple targeting<a onclick="showRef(event, 'ref247 ref248 ref249 ref250'); return false;" href="javascript:void(0);" class="ref ref247 ref248 ref249 ref250">(249−252)</a> and in some cases, nonhuman primate screening (marmoset) may be required. As such preclinical trials need many prerequisites, a combination of different animal models with various read-outs are often preferred for the initial in vivo characterization of multiple ligands when no suitable complex model is available.</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">5.  Conclusion and Outlook</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74427" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74427" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Innovative technologies such as systems biology and artificial intelligence coupled with constantly growing knowledge on drug targets, molecular disease determinants, and predictive biomarkers are promoting drug discovery to new heights. Despite this expanding tool box for all aspects of drug discovery, the success of small molecule drugs is not satisfactory in many diseases. For several disorders that arise from complex multifactorial pathologies, this may be ascribed to the need for multiple pharmacological interventions to achieve sufficient therapeutic efficacy. As a result, many severe and complex diseases are treated with drug cocktails instead of single efficacious drugs, but such polypharmacy holds numerous disadvantages. Moreover, chemotherapy resistance development arises as global drug discovery challenge in the fields of anticancer and anti-infectious disease treatment. Multitarget compounds that simultaneously modulate more than a single molecular target hold great potential to overcome both unmet medical needs in enabling therapeutic breakthroughs in severe multifactorial diseases and in preventing development of resistances. Multiple targeting is, therefore, an increasingly productive discipline of medicinal chemistry. It strongly profits from past and recent innovations in computational techniques, in vitro test systems, and animal models that provide the technologies for multitarget compound development.</div><div class="NLM_p">Computational methods and models combined with enormous available data sets are key contributors to the growing success of multitarget compound development and affect virtually every step of this discipline. Signaling network analysis and quantitative flux modeling enable generation of robust hypotheses for potentially synergistic target combinations. Despite often lacking experimental validation, several in silico approaches for this central step in multitarget design have been developed and further examples of their prospective application will provide further evidence which technologies hold most potential. In silico pharmacophore modeling, docking algorithms, and computational de novo design are crucial in silico tools for multitarget lead identification and can be valuable in structural optimization of multiple ligands, as well. And finally, experimental efforts in in vitro and in vivo characterization of multitarget compounds can be reduced with computational support. With growing computational resources and the increasing role of machine learning/artificial intelligence techniques, computational methods will constantly gain even more relevance and improve handling of big data. Especially sound combination of artificial intelligence and focused experiments to reduce model uncertainties has the potential to further improve the quality of computational models and help selecting the “right” experiments.</div><div class="NLM_p">Multitarget design is not only supported by innovations in computational techniques, however. The increasing number of high-quality chemical probes to study the roles of molecular targets and their interplay in pathologies allows robust experimental validation of target synergies and may also reveal unexpected connections between targets in a disease. In addition, several breakthroughs in experimental technologies may strongly promote and accelerate multitarget compound development. High-throughput crystallography might equip multitarget compound discovery with valuable structural information that can improve pharmacophore model generation and significantly support structural optimization when hypotheses for compatible modifications can be retrieved from co-crystal structures. In addition, assay technologies are arising that are competent for revealing simultaneous target engagement and synergistic effects of multitarget modulation. Sophisticated in vitro assays will especially be necessary for multiple ligands that cause effects which cannot be observed in a common convergent read-out (such as apoptosis) but induce parallel activities. Therefore, the predictive value of in vitro assays for complex disease modifications must be carefully (re-)analyzed for complex polypharmacological approaches. Possibly, also innovative technologies such as organs on-a-chip will allow future improvements in functional characterization of multitarget compounds. An unresolved issue of in vitro characterization of multiple ligands remains the lack of test systems that reflect adaptive mechanisms such as overexpression of a target arising from either a disease or as consequence of multitarget modulation.</div><div class="NLM_p">Meaningful in vivo characterization of multitarget compounds often remains a challenge, as well. When multiple ligands are designed to achieve superior therapeutic efficacy in multifactorial diseases through synergistic effects, animal models are required that reflect the multifactorial nature of the human disease and can reveal synergies. Such sophisticated in vivo models are only available for a few diseases, but first examples have been established and cross-breeding of animals reflecting individual aspects of multifactorial pathologies holds promise for future breakthroughs in this field, as well.</div><div class="NLM_p">With the increasing spectrum of available methods and applications, multitarget compound design, optimization and functional characterization involves many disciplines and demands strong expertise in each field. Multidisciplinary collaborative projects involving solid expertise not only in medicinal chemistry but also in computational techniques, in vitro test systems, and in vivo pharmacology and therefore appear necessary for successful development of therapeutically relevant multiple ligands.</div><div class="NLM_p">In summary, improved understanding of pathophysiological conditions that uncovers the multiple factors underlying many diseases highlights the enormous potential of multitarget agents to open new therapeutic avenues. They can overcome polypharmacy and enhance therapeutic efficacy of small molecule drugs. Increasing knowledge on molecular targets, their cross-talk and -regulations combined with the ability to handle big data and the availability of innovative in silico, in vitro, and in vivo technologies equip medicinal chemistry with a versatile toolbox for multitarget design. However, despite the availability of enormous data sets, reliable computational methods involving artificial intelligence and automated steps, e.g., in compound design and optimization, multitarget design and multiple ligand optimization indispensably requires expert knowledge as key decision maker.</div><div class="NLM_p last">Big data analysis and evaluation of drug–target interaction patterns indicate a steadily growing trend toward drugs that address more than one single target.<a onclick="showRef(event, 'ref205 ref206'); return false;" href="javascript:void(0);" class="ref ref205 ref206">(205,206)</a> In addition, increasing disease complexity and improved understanding of pathophysiological correlations promote multitarget compound development and render multiple ligands a key for securing innovation in future drug discovery.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b00760" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44224" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44224" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel Merk</span> - <span class="hlFld-Affiliation affiliation">Institute
of Pharmaceutical Chemistry, Goethe University
Frankfurt, Max-von-Laue-Strasse
9, D-60438 Frankfurt, Germany</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Chemistry and Applied Biosciences, Institute of Pharmaceutical
Sciences, Swiss Federal Institute of Technology
(ETH) Zürich, Vladimir-Prelog-Weg 4, CH-8093 Zürich, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5359-8128" title="Orcid link">http://orcid.org/0000-0002-5359-8128</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f490959a9d9198da9991869fb4849c95869995da91809c8eda979cd49991869fb4849c958699979c9199da819a9dd99286959a9f92818680da9091"><span class="__cf_email__" data-cfemail="0a6e6b64636f6624676f78614a7a626b78676b246f7e6270246962">[email protected]</span> <span class="__cf_email__" data-cfemail="650800170e25150d041708060d00084b100b0c480317040b0e031017114b0100">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ewgenij Proschak</span> - <span class="hlFld-Affiliation affiliation">Institute
of Pharmaceutical Chemistry, Goethe University
Frankfurt, Max-von-Laue-Strasse
9, D-60438 Frankfurt, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1961-1859" title="Orcid link">http://orcid.org/0000-0003-1961-1859</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Holger Stark</span> - <span class="hlFld-Affiliation affiliation">Institute
of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Universitaetsstrasse 1, D-40225, Duesseldorf, Germany</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20187" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20187" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Ewgenij Proschak</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=BIO-d7e1840-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Ewgenij Proschak</b> is Professor for Drug Design at the Institute of Pharmaceutical Chemistry at the Goethe University of Frankfurt. After his doctoral and postdoctoral studies at Goethe University, he became Independent Group Leader at the Lipid Signaling Research Center (LIFF) in Frankfurt. Currently, the German Research Council (DFG) awarded him with a Heisenberg Professorship. He has worked on hit identification and hit-to-lead optimization for fatty acid mimetics including inhibitors of 5-LO, mPGES-1, sEH, and LTA4H and modulators of PPARs and FXR. His current research interests are the design and synthesis of multitarget drugs for the treatment of inflammatory conditions and metabolic syndrome.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Holger Stark</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=BIO-d7e1845-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Holger Stark</b> studied pharmacy in Berlin, Germany. In 2000, he became a full professor at Goethe University in Frankfurt, Germany, and went in 2013 to Heinrich Heine University Düsseldorf, Germany, for his actual position. He founded start-up companies on cancer therapeutics (Warburg Glycomed, PSites Pharma) and has received prizes for successful research as well as for teaching. On more than 350 book contributions, original papers, reviews, and patents, he has focused on neurotransmitter with selectivity or multiple targeting, mainly at histamine and dopamine receptor subtypes as well as on lipid signaling and enzyme research. He is coinventor of pitolisant (Wakix), the first histamine H3 receptor antagonist with market approval. He is editor-in-chief of <i>Archiv der Pharmazie</i> and received an honorary doctorate from University of Nis, Serbia.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Daniel Merk</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=BIO-d7e1853-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Daniel Merk</b> graduated in Pharmacy and Pharmaceutical Sciences at the Ludwig-Maximilians-University Munich and received his Ph.D. in Pharmaceutical/Medicinal Chemistry from Goethe University Frankfurt. Since 2015, he is Junior Group Leader at the Institute of Pharmaceutical Chemistry of Goethe University Frankfurt and since 2017 is an ETH-Fellowship scholar at the Swiss Federal Institute of Technology (ETH) Zurich. His research focuses on the exploration of nuclear receptors as pharmaceutical targets with special emphasis on FXR, PPARs, RXRs, and orphan receptors, the medicinal chemistry of their natural and synthetic modulators, computer-assisted and natural-product-inspired drug discovery, and multitarget compound design.</p></figure></div><div class="ack" id="ACK-d7e1858-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74550" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74550" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We apologize for the numerous excellent works which have not been included in this Perspective. E.P. was supported by the Deutsche Forschungsgemeinschaft (DFG; Sachbeihilfe PR1405/2-2; Heisenberg-Professur PR1405/4-1, SFB1039 Teilprojekt A07). H.S. acknowledges support by the EU COST Action CA15135 MuTaLig. D.M. was supported by an ETH Zurich Fellowship (grant no. 16-2 FEL-07).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">5-HT<sub>2</sub></td><td class="NLM_def"><p class="first last">serotonin receptor 2</p></td></tr><tr><td class="NLM_term">5-HT<sub>2A</sub></td><td class="NLM_def"><p class="first last">serotonin receptor 2A</p></td></tr><tr><td class="NLM_term">5-LO</td><td class="NLM_def"><p class="first last">5-lipoxigenase</p></td></tr><tr><td class="NLM_term">6-OHDA</td><td class="NLM_def"><p class="first last">6-hydroxytryptamine</p></td></tr><tr><td class="NLM_term">AT1R</td><td class="NLM_def"><p class="first last">angiotensin II receptor 1</p></td></tr><tr><td class="NLM_term">BACE-1</td><td class="NLM_def"><p class="first last">β-secretase 1</p></td></tr><tr><td class="NLM_term">BCL</td><td class="NLM_def"><p class="first last">B-cell lymphoma</p></td></tr><tr><td class="NLM_term">BET</td><td class="NLM_def"><p class="first last">bromo- and extra-terminal domain</p></td></tr><tr><td class="NLM_term">CDK4</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase 4</p></td></tr><tr><td class="NLM_term">ChE</td><td class="NLM_def"><p class="first last">choline esterase</p></td></tr><tr><td class="NLM_term">CETSA</td><td class="NLM_def"><p class="first last">cellular thermal shift assay</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">COX</td><td class="NLM_def"><p class="first last">cyclooxygenase</p></td></tr><tr><td class="NLM_term">CRISPR/Cas9</td><td class="NLM_def"><p class="first last">clustered regularly interspaced short palindromic repeats associated endonuclease 9</p></td></tr><tr><td class="NLM_term">CysLT1R</td><td class="NLM_def"><p class="first last">cysteinyl leukotriene 1 receptor</p></td></tr><tr><td class="NLM_term">D<sub>2</sub></td><td class="NLM_def"><p class="first last">dopamine receptor 2</p></td></tr><tr><td class="NLM_term">DARTS</td><td class="NLM_def"><p class="first last">drug affinity responsive target stability</p></td></tr><tr><td class="NLM_term">DDL</td><td class="NLM_def"><p class="first last">dedifferentiated liposarcoma</p></td></tr><tr><td class="NLM_term">FXR</td><td class="NLM_def"><p class="first last">farnesoid X receptor</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein coupled receptor</p></td></tr><tr><td class="NLM_term">GSK-3β</td><td class="NLM_def"><p class="first last">glycogen synthase kinase 3β</p></td></tr><tr><td class="NLM_term">H<sub>1</sub></td><td class="NLM_def"><p class="first last">histamine receptor 1</p></td></tr><tr><td class="NLM_term">H<sub>3</sub></td><td class="NLM_def"><p class="first last">histamine receptor 3</p></td></tr><tr><td class="NLM_term">IGF1R</td><td class="NLM_def"><p class="first last">insulin-like growth factor 1 receptor</p></td></tr><tr><td class="NLM_term">LTA4H</td><td class="NLM_def"><p class="first last">leukotriene A4 hydrolase</p></td></tr><tr><td class="NLM_term">LSD1</td><td class="NLM_def"><p class="first last">lysine-specific demethylase 1</p></td></tr><tr><td class="NLM_term">MAO</td><td class="NLM_def"><p class="first last">monoamine oxidase</p></td></tr><tr><td class="NLM_term">MDM2</td><td class="NLM_def"><p class="first last">mouse double minute 2 homologue</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase kinase</p></td></tr><tr><td class="NLM_term">MTC</td><td class="NLM_def"><p class="first last">medullary thyroid carcinoma</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">p38/MAPK</td><td class="NLM_def"><p class="first last">p38 mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">PDE-4</td><td class="NLM_def"><p class="first last">phosphodiesterase 4</p></td></tr><tr><td class="NLM_term">PEPT1</td><td class="NLM_def"><p class="first last">peptide transporter 1</p></td></tr><tr><td class="NLM_term">PPAR</td><td class="NLM_def"><p class="first last">peroxisome proliferator-activated receptor</p></td></tr><tr><td class="NLM_term">RET</td><td class="NLM_def"><p class="first last">rearranged during transfection kinase</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SHR</td><td class="NLM_def"><p class="first last">spontaneously hypertensive rat</p></td></tr><tr><td class="NLM_term">SHROB rat</td><td class="NLM_def"><p class="first last">spontaneously hypertensive obese rat</p></td></tr><tr><td class="NLM_term">SOM</td><td class="NLM_def"><p class="first last">self-organizing map</p></td></tr><tr><td class="NLM_term">sEH</td><td class="NLM_def"><p class="first last">soluble epoxide hydrolase</p></td></tr><tr><td class="NLM_term">SOSA</td><td class="NLM_def"><p class="first last">selective optimization of side-activities</p></td></tr><tr><td class="NLM_term">STD-NMR</td><td class="NLM_def"><p class="first last">saturation-transfer difference NMR</p></td></tr><tr><td class="NLM_term">QSAR</td><td class="NLM_def"><p class="first last">quantitative structure–activity relationship</p></td></tr><tr><td class="NLM_term">VEGFR2</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor 2</p></td></tr><tr><td class="NLM_term">ZDF rat</td><td class="NLM_def"><p class="first last">Zucker diabetic fatty rat</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24381" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24381" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 252 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amin, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attur, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramson, S. B.</span></span> <span> </span><span class="NLM_article-title">The Pleiotropic Functions of Aspirin: Mechanisms of Action</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">3–4</span>),  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1007/s000180050432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1007%2Fs000180050432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=11212358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADyaK1MXntVGhu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1999&pages=305-312&issue=3%E2%80%934&author=A.+R.+Aminauthor=M.+G.+Atturauthor=M.+Pillingerauthor=S.+B.+Abramson&title=The+Pleiotropic+Functions+of+Aspirin%3A+Mechanisms+of+Action&doi=10.1007%2Fs000180050432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The pleiotropic functions of aspirin. Mechanisms of action</span></div><div class="casAuthors">Amin, A. R.; Attur, M. G.; Pillinger, M.; Abramson, S. B.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3/4</span>),
    <span class="NLM_cas:pages">305-312</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review is given with 62 refs. on the various mechanisms of action of aspirin-like compds. and their relevance to clin. disease and therapy.  Recent studies have suggested that aspirin and aspirin-like compds. have a variety of actions in addn. to their well-studied ability to inhibit cyclooxygenases.  These actions include inhibition of the uncoupling of oxidative phosphorylation, decreases in ATP stores, increases in extracellular adenosine, down regulation of the expression and activity of inducible NO synthetase, inhibition and/or stimulation of various mitogen-activated protein kinase activities and inhibition of nuclear factor binding κB site (NF-κB) activation.  Moreover, aspirin-like compds. have recently been shown to have previously unappreciated clin. and biol. effects, some apparently independent of cyclooxygenase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoebZMQgc7dILVg90H21EOLACvtfcHk0lhaLU3RNs5bQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntVGhu78%253D&md5=ad427051259cc9163246e5fa5828d55f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2Fs000180050432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs000180050432%26sid%3Dliteratum%253Aachs%26aulast%3DAmin%26aufirst%3DA.%2BR.%26aulast%3DAttur%26aufirst%3DM.%2BG.%26aulast%3DPillinger%26aufirst%3DM.%26aulast%3DAbramson%26aufirst%3DS.%2BB.%26atitle%3DThe%2520Pleiotropic%2520Functions%2520of%2520Aspirin%253A%2520Mechanisms%2520of%2520Action%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D1999%26volume%3D56%26issue%3D3%25E2%2580%25934%26spage%3D305%26epage%3D312%26doi%3D10.1007%2Fs000180050432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dzeshka, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shantsila, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lip, G. Y. H.</span></span> <span> </span><span class="NLM_article-title">Effects of Aspirin on Endothelial Function and Hypertension</span>. <i>Curr. Hypertens. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">83</span>, <span class="refDoi"> DOI: 10.1007/s11906-016-0688-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1007%2Fs11906-016-0688-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27787837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC2sngtlektQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=83&issue=11&author=M.+S.+Dzeshkaauthor=A.+Shantsilaauthor=G.+Y.+H.+Lip&title=Effects+of+Aspirin+on+Endothelial+Function+and+Hypertension&doi=10.1007%2Fs11906-016-0688-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Aspirin on Endothelial Function and Hypertension</span></div><div class="casAuthors">Dzeshka Mikhail S; Shantsila Alena; Lip Gregory Y H; Dzeshka Mikhail S; Lip Gregory Y H</div><div class="citationInfo"><span class="NLM_cas:title">Current hypertension reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">83</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  Endothelial dysfunction is intimately related to the development of various cardiovascular diseases, including hypertension, and is often used as a target for pharmacological treatment.  The scope of this review is to assess effects of aspirin on endothelial function and their clinical implication in arterial hypertension.  RECENT FINDINGS:  Emerging data indicate the role of platelets in the development of vascular inflammation due to the release of proinflammatory mediators, for example, triggered largely by thromboxane.  Vascular inflammation further promotes oxidative stress, diminished synthesis of vasodilators, proaggregatory and procoagulant state.  These changes translate into vasoconstriction, impaired circulation and thrombotic complications.  Aspirin inhibits thromboxane synthesis, abolishes platelets activation and acetylates enzymes switching them to the synthesis of anti-inflammatory substances.  Aspirin pleiotropic effects have not been fully elucidated yet.  In secondary prevention studies, the decrease in cardiovascular events with aspirin outweighs bleeding risks, but this is not the case in primary prevention settings.  Ongoing trials will provide more evidence on whether to expand the use of aspirin or stay within current recommendations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQG4GWzhjDUqtj_Vg2vObihfW6udTcc2ea9vsSk25e2-rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sngtlektQ%253D%253D&md5=2c13c77197206bdebed0a365b1ef0e63</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs11906-016-0688-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11906-016-0688-8%26sid%3Dliteratum%253Aachs%26aulast%3DDzeshka%26aufirst%3DM.%2BS.%26aulast%3DShantsila%26aufirst%3DA.%26aulast%3DLip%26aufirst%3DG.%2BY.%2BH.%26atitle%3DEffects%2520of%2520Aspirin%2520on%2520Endothelial%2520Function%2520and%2520Hypertension%26jtitle%3DCurr.%2520Hypertens.%2520Rep.%26date%3D2016%26volume%3D18%26issue%3D11%26spage%3D83%26doi%3D10.1007%2Fs11906-016-0688-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horowitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rayner, C. K.</span></span> <span> </span><span class="NLM_article-title">New Insights into the Anti-Diabetic Actions of Metformin: From the Liver to the Gut</span>. <i>Expert Rev. Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1080/17474124.2017.1273769</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1080%2F17474124.2017.1273769" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27983877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFKltLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=157-166&issue=2&author=T.+Wuauthor=M.+Horowitzauthor=C.+K.+Rayner&title=New+Insights+into+the+Anti-Diabetic+Actions+of+Metformin%3A+From+the+Liver+to+the+Gut&doi=10.1080%2F17474124.2017.1273769"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into the anti-diabetic actions of metformin: from the liver to the gut</span></div><div class="casAuthors">Wu, Tongzhi; Horowitz, Michael; Rayner, Christopher K.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">157-166</span>CODEN:
                <span class="NLM_cas:coden">ERGHBD</span>;
        ISSN:<span class="NLM_cas:issn">1747-4124</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Metformin is established as the first-line therapy for type 2 diabetes (T2DM), but its mode of action remains elusive.  Elucidation of the mechanisms underlying the anti-diabetic action of metformin may have the potential to optimize its glucose-lowering efficacy and lead to the development of agents acting on novel targets for the management of type 2 diabetes.  This review highlights key pharmacokinetic features of metformin, summarises recent insights into its hepatic and gastrointestinal actions relevant to blood glucose homeostasis, and discusses the common gastrointestinal side effects of metformin.  Literature concerning these areas was reviewed on PubMed.  The mechanisms by which metformin improves glycemic control in type 2 diabetes are complex.  Although novel hepatic pathways continue to be reported in preclin. studies, there is a lack of human evidence for most of these.  Considering the fundamental role of the gastrointestinal tract in the regulation of blood glucose homeostasis and pleiotropic actions of metformin on several gastrointestinal targets relevant to glycemic control, the gut is likely to represent at least as important a site of metformin action as the liver in the management of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt4JeELrnJg7Vg90H21EOLACvtfcHk0lgISM-0wGN13Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFKltLzM&md5=5e4e17674beae136f05304354cfe5c0f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1080%2F17474124.2017.1273769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17474124.2017.1273769%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DT.%26aulast%3DHorowitz%26aufirst%3DM.%26aulast%3DRayner%26aufirst%3DC.%2BK.%26atitle%3DNew%2520Insights%2520into%2520the%2520Anti-Diabetic%2520Actions%2520of%2520Metformin%253A%2520From%2520the%2520Liver%2520to%2520the%2520Gut%26jtitle%3DExpert%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2017%26volume%3D11%26issue%3D2%26spage%3D157%26epage%3D166%26doi%3D10.1080%2F17474124.2017.1273769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varjabedian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourafkari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nader, N. D.</span></span> <span> </span><span class="NLM_article-title">Cardioprotection by Metformin: Beneficial Effects Beyond Glucose Reduction</span>. <i>Am. J. Cardiovasc. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1007/s40256-018-0266-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1007%2Fs40256-018-0266-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=181-183&author=L.+Varjabedianauthor=M.+Bourjiauthor=L.+Pourafkariauthor=N.+D.+Nader&title=Cardioprotection+by+Metformin%3A+Beneficial+Effects+Beyond+Glucose+Reduction&doi=10.1007%2Fs40256-018-0266-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2Fs40256-018-0266-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40256-018-0266-3%26sid%3Dliteratum%253Aachs%26aulast%3DVarjabedian%26aufirst%3DL.%26aulast%3DBourji%26aufirst%3DM.%26aulast%3DPourafkari%26aufirst%3DL.%26aulast%3DNader%26aufirst%3DN.%2BD.%26atitle%3DCardioprotection%2520by%2520Metformin%253A%2520Beneficial%2520Effects%2520Beyond%2520Glucose%2520Reduction%26jtitle%3DAm.%2520J.%2520Cardiovasc.%2520Drugs%26date%3D2018%26volume%3D18%26spage%3D181%26epage%3D183%26doi%3D10.1007%2Fs40256-018-0266-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rogliani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Daniele, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauro, D.</span></span> <span> </span><span class="NLM_article-title">Pleiotropic Effects of Hypoglycemic Agents: Implications in Asthma and COPD</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2018.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.coph.2018.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29427967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFGjs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2018&pages=34-38&author=P.+Roglianiauthor=J.+Oraauthor=N.+Di+Danieleauthor=D.+Lauro&title=Pleiotropic+Effects+of+Hypoglycemic+Agents%3A+Implications+in+Asthma+and+COPD&doi=10.1016%2Fj.coph.2018.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Pleiotropic effects of hypoglycemic agents: implications in asthma and COPD</span></div><div class="casAuthors">Rogliani, Paola; Ora, Josuel; Di Daniele, Nicola; Lauro, Davide</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34-38</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Diabetes mellitus (DM) is a complex multifactorial disease due to the interaction between environmental noxae and genetic predisposition.  Furthermore, an increased assocn. between DM, esp. Type 2 diabetes mellitus (T2DM), and the onset of pulmonary function impairment with a bronchial hyperresponsiveness has been documented.  DM is a risk factor for accelerated decline in FEV1 and the development of asthma and COPD.  The increased blood glucose concns. along with higher levels of oxidative stress and inflammation can influence the pulmonary function and, since hypoglycemic drugs can act on these different defects we can hypothesize their direct effect on obstructive pulmonary diseases.  Metformin, a biguanide, is the mol. having several evidences of its action on asthma and COPD in patients with T2DM.  In this population, Metformin can ameliorate pulmonary outcomes reducing high glucose concns., inflammation through the activation of the AMP-activated protein kinase, leading to the decreased prodn. of pro-inflammatory cytokines and blunting allergic eosinophilic airway inflammation.  There are evidences of Pioglitazone role on asthma, since the activation of PPARγ Pioglitazone might inhibit the synthesis and release of pro-inflammatory cytokines.  Indeed, Pioglitazone can improve symptoms assocd. with asthma reducing episodes of exacerbation and oral steroid prescription.  Finally, randomized clin. trials using hypoglycemic agents on patients with asthma and COPD with and without DM should be proposed as well as the implementation of a new formulation of hypoglycemic agents to make it possible to administer it via aerosol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnU_B1xQOwP7Vg90H21EOLACvtfcHk0lgISM-0wGN13Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFGjs7w%253D&md5=f01182738df2f8628d9110ece2dd3c4d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2018.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2018.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DRogliani%26aufirst%3DP.%26aulast%3DOra%26aufirst%3DJ.%26aulast%3DDi%2BDaniele%26aufirst%3DN.%26aulast%3DLauro%26aufirst%3DD.%26atitle%3DPleiotropic%2520Effects%2520of%2520Hypoglycemic%2520Agents%253A%2520Implications%2520in%2520Asthma%2520and%2520COPD%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2018%26volume%3D40%26spage%3D34%26epage%3D38%26doi%3D10.1016%2Fj.coph.2018.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sirtori, C. R.</span></span> <span> </span><span class="NLM_article-title">The Pharmacology of Statins</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2014.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.phrs.2014.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=24657242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlslWmtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2014&pages=3-11&author=C.+R.+Sirtori&title=The+Pharmacology+of+Statins&doi=10.1016%2Fj.phrs.2014.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacology of statins</span></div><div class="casAuthors">Sirtori, Cesare R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3-11</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Statins, inhibitors of the hydroxymethylglutaryl-CoA (HMG-CoA) reductase enzyme, are mols. of fungal origin.  By inhibiting a key step in the sterol biosynthetic pathway statins are powerful cholesterol lowering medications and have provided outstanding contributions to the prevention of cardiovascular disease.  Their detection in mycetes traces back to close to 40 years ago: there were, originally, widely opposing views on their therapeutic potential.  From then on, intensive pharmaceutical development has led to the final availability in the clinic of seven statin mols., characterized by differences in bioavailability, lipo/hydrophilicity, cytochrome P 450 mediated metab. and cellular transport mechanisms.  These differences are reflected in their relative power (mg LDL-cholesterol redn. per mg dose) and possibly in parenchymal or muscular toxicities.  The impact of the antagonism of statins on a crucial step of intermediary metab. leads, in fact, both to a redn. of cholesterol biosynthesis as well as to addnl. pharmacodynamic (so called "pleiotropic") effects.  In the face of an extraordinary clin. success, the emergence of some side effects, e.g. raised incidence of diabetes and cataracts as well as frequent muscular side effects, have led to increasing concern by physicians.  However, also in view of the present relatively low cost of these drugs, their impact on daily therapy of vascular patients is unlikely to change.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKIXZ12_20nrVg90H21EOLACvtfcHk0lgBrtgV_it4RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlslWmtrc%253D&md5=47cb556de48f6a9f546b482088a7a191</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2014.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2014.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DSirtori%26aufirst%3DC.%2BR.%26atitle%3DThe%2520Pharmacology%2520of%2520Statins%26jtitle%3DPharmacol.%2520Res.%26date%3D2014%26volume%3D88%26spage%3D3%26epage%3D11%26doi%3D10.1016%2Fj.phrs.2014.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veillard, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, F.</span></span> <span> </span><span class="NLM_article-title">Statins: The New Aspirin?</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1771</span>– <span class="NLM_lpage">1786</span>, <span class="refDoi"> DOI: 10.1007/PL00012505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1007%2FPL00012505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=12530513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD38Xps1entLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2002&pages=1771-1786&issue=11&author=N.+R.+Veillardauthor=F.+Mach&title=Statins%3A+The+New+Aspirin%3F&doi=10.1007%2FPL00012505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Statins: the new aspirin?</span></div><div class="casAuthors">Veillard, N. R.; Mach, F.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1771-1786</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review.  3-Hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitors, or statins, have been described as the principal and the most effective class of drug to reduce serum cholesterol levels.  Statin therapies have been shown to reduce cardiovascular events, including myocardial infarction, stroke, and death, significantly, by altering vascular atherosclerosis development in patients with or without coronary artery disease symptoms.  Extensive use of statins has led to the increase of some undesirable effects that are heavily counterbalanced by the benefits.  Indeed, pleiotropic effects extend far beyond cholesterol redn. and involve non-lipid-related mechanisms that modify endothelial functions, immunoinflammatory responses, smooth muscle cell activation, proliferation and migration, atherosclerotic plaque stability, and thrombus formation.  In this review, we describe in detail the targets and mechanisms of action of statins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhnFGEBj4m1rVg90H21EOLACvtfcHk0lgBrtgV_it4RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xps1entLc%253D&md5=83a74b6ee6d68eb7b578cc416dafbf56</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2FPL00012505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FPL00012505%26sid%3Dliteratum%253Aachs%26aulast%3DVeillard%26aufirst%3DN.%2BR.%26aulast%3DMach%26aufirst%3DF.%26atitle%3DStatins%253A%2520The%2520New%2520Aspirin%253F%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2002%26volume%3D59%26issue%3D11%26spage%3D1771%26epage%3D1786%26doi%3D10.1007%2FPL00012505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed Multiple Ligands. An Emerging Drug Discovery Paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&issue=21&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+Multiple+Ligands.+An+Emerging+Drug+Discovery+Paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0lgBrtgV_it4RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520Multiple%2520Ligands.%2520An%2520Emerging%2520Drug%2520Discovery%2520Paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D21%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designing Multiple Ligands - Medicinal Chemistry Strategies and Challenges</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.2174/138161209787315594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F138161209787315594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=19199984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVSns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=587-600&issue=6&author=R.+Morphyauthor=Z.+Rankovic&title=Designing+Multiple+Ligands+-+Medicinal+Chemistry+Strategies+and+Challenges&doi=10.2174%2F138161209787315594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Designing multiple ligands - medicinal chemistry strategies and challenges</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">587-600</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  It has been widely recognized over the recent years that parallel modulation of multiple biol. targets can be beneficial for treatment of diseases with complex etiologies such as cancer asthma, and psychiatric disease.  In this article, current strategies for the generation of ligands with a specific multi-target profile (designed multiple ligands or DMLs) are described and a no. of illustrative example are given.  Designing multiple ligands is frequently a challenging endeavor for medicinal chemists, with the need to appropriately balance affinity for 2 or more targets while obtaining physicochem. and pharmacokinetic properties that are consistent with the administration of an oral drug.  Given that the properties of DMLs are influenced to a large extent by the proteomic superfamily to which the targets belong and the lead generation strategy that is pursued, an early assessment of the feasibility of any given DML project is essential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUo6NjoK5D-LVg90H21EOLACvtfcHk0liCp59wEMuSUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVSns70%253D&md5=fa34039be6e9c3b489f530fc74fd0346</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2174%2F138161209787315594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161209787315594%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigning%2520Multiple%2520Ligands%2520-%2520Medicinal%2520Chemistry%2520Strategies%2520and%2520Challenges%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2009%26volume%3D15%26issue%3D6%26spage%3D587%26epage%3D600%26doi%3D10.2174%2F138161209787315594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">The Physicochemical Challenges of Designing Multiple Ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">4961</span>– <span class="NLM_lpage">4970</span>, <span class="refDoi"> DOI: 10.1021/jm0603015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0603015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4961-4970&issue=16&author=R.+Morphyauthor=Z.+Rankovic&title=The+Physicochemical+Challenges+of+Designing+Multiple+Ligands&doi=10.1021%2Fjm0603015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The Physicochemical Challenges of Designing Multiple Ligands</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4961-4970</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compds. designed to bind more than one target can provide a therapeutic benefit relative to highly target-selective ligands.  The physicochem. properties of designed multiple ligands were found to be less druglike than those for preclin. compds. in general.  These properties are controlled by the superfamily to which the targets belong and the lead discovery strategy that was followed.  The properties for peptide G-protein-coupled receptor (GPCR) ligands were the least favorable for oral delivery, whereas transporter, monoamine GPCR, and oxidase ligands were the most druglike.  The lead discovery strategy, framework combination or screening, exerts a profound influence on the property values.  Combining the frameworks from two selective ligands often results in large, complex dual ligands, but druglike ligands can be achieved if the degree of framework overlap is maximized and the size of the selective ligands minimized.  For some target combinations, a screening approach may provide a route to smaller, less complex leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonGHbXyxgv4LVg90H21EOLACvtfcHk0liCp59wEMuSUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D&md5=c7a227848516d0aa58ed037a582943fe</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm0603015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603015%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DThe%2520Physicochemical%2520Challenges%2520of%2520Designing%2520Multiple%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D16%26spage%3D4961%26epage%3D4970%26doi%3D10.1021%2Fjm0603015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Fragments, Network Biology and Designing Multiple Ligands</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">3–4</span>),  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">160</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2006.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.drudis.2006.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=17275736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtleisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=156-160&issue=3%E2%80%934&author=R.+Morphyauthor=Z.+Rankovic&title=Fragments%2C+Network+Biology+and+Designing+Multiple+Ligands&doi=10.1016%2Fj.drudis.2006.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Fragments, network biology and designing multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3&4</span>),
    <span class="NLM_cas:pages">156-160</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Modulating multiple protein targets simultaneously can be beneficial for treating complex diseases.  The redundancy that exists within biol. networks means that modulating single proteins might not be sufficient to produce the desired efficacy while, at the same time, minimizing adverse effects.  Designing multi-target drugs can be challenging for medicinal chemists, with current lead-discovery strategies often producing large, complex mols. with low ligand efficiency and poor oral bioavailability.  Paradoxically, analyses of the relationship between the selectivity of biol. active compds. and their mol. size suggest that promiscuous compds. should typically be smaller than target-selective compds.  A fragment-based approach to multi-target drug discovery could lead to a new generation of compds. with improved physicochem. and pharmacokinetic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXRYwI33BCNLVg90H21EOLACvtfcHk0liCp59wEMuSUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtleisbs%253D&md5=64a3c7e8c3280db166dda799a77d689a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2006.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2006.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFragments%252C%2520Network%2520Biology%2520and%2520Designing%2520Multiple%2520Ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26issue%3D3%25E2%2580%25934%26spage%3D156%26epage%3D160%26doi%3D10.1016%2Fj.drudis.2006.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">From Magic Bullets to Designed Multiple Ligands</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(04)03163-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2FS1359-6446%2804%2903163-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=15279847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=641-651&issue=15&author=R.+Morphyauthor=C.+Kayauthor=Z.+Rankovic&title=From+Magic+Bullets+to+Designed+Multiple+Ligands&doi=10.1016%2FS1359-6446%2804%2903163-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">From magic bullets to designed multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Kay, Corinne; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">641-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major trend in medicinal chem. in the coming years will be the rational design of ligands that are capable of modulating multiple disease-relevant targets in a specific manner.  Increasingly, it is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand.  Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes.  A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile.  An anal. of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsGpfzZok5rVg90H21EOLACvtfcHk0liH0UabgFMTYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D&md5=cd2491baad707043dbee4f59ccad9e1d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903163-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903163-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DC.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFrom%2520Magic%2520Bullets%2520to%2520Designed%2520Multiple%2520Ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26issue%3D15%26spage%3D641%26epage%3D651%26doi%3D10.1016%2FS1359-6446%2804%2903163-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Turning from Monogamy to Strategic Promiscuity</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">736</span>– <span class="NLM_lpage">737</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(04)03208-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2FS1359-6446%2804%2903208-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=15450238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BD2cvot1Krtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=736-737&issue=17&author=H.+Stark&title=Turning+from+Monogamy+to+Strategic+Promiscuity&doi=10.1016%2FS1359-6446%2804%2903208-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Turning from monogamy to strategic promiscuity</span></div><div class="casAuthors">Stark Holger</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">736-7</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQr6xRqqEG95mgRQsDqrjW_fW6udTcc2eYTKmwbxRBWtrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cvot1Krtw%253D%253D&md5=c59c9e1d59c4b22203f842332fb51f4b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903208-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903208-8%26sid%3Dliteratum%253Aachs%26aulast%3DStark%26aufirst%3DH.%26atitle%3DTurning%2520from%2520Monogamy%2520to%2520Strategic%2520Promiscuity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26issue%3D17%26spage%3D736%26epage%3D737%26doi%3D10.1016%2FS1359-6446%2804%2903208-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span> <span> </span><span class="NLM_article-title">Can We Rationally Design Promiscuous Drugs?</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1016/j.sbi.2006.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.sbi.2006.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=16442279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=127-136&issue=1&author=A.+L.+Hopkinsauthor=J.+S.+Masonauthor=J.+P.+Overington&title=Can+We+Rationally+Design+Promiscuous+Drugs%3F&doi=10.1016%2Fj.sbi.2006.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Can we rationally design promiscuous drugs?</span></div><div class="casAuthors">Hopkins, Andrew L.; Mason, Jonathan S.; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-136</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Structure-based drug design is now used widely in modern medicinal chem.  The application of structural biol. to medicinal chem. has heralded the 'rational drug design' vision of discovering exquisitely selective ligands.  However, recent advances in post-genomic biol. are indicating that polypharmacol. may be a necessary trait for the efficacy of many drugs, therefore questioning the 'one drug, one target' assumption of current rational drug design.  By combining advances in chemoinformatics and structural biol., it might be possible to rationally design the next generation of promiscuous drugs with polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQWdh60x9AHrVg90H21EOLACvtfcHk0liH0UabgFMTYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D&md5=8f9e95a41976b8e3ac790f2fff2c406f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2006.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2006.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DCan%2520We%2520Rationally%2520Design%2520Promiscuous%2520Drugs%253F%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2006%26volume%3D16%26issue%3D1%26spage%3D127%26epage%3D136%26doi%3D10.1016%2Fj.sbi.2006.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Handl, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mash, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillies, R. J.</span></span> <span> </span><span class="NLM_article-title">Hitting Multiple Targets with Multimeric Ligands</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">565</span>– <span class="NLM_lpage">586</span>, <span class="refDoi"> DOI: 10.1517/14728222.8.6.565</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1517%2F14728222.8.6.565" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=15584863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmt1eisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2004&pages=565-586&issue=6&author=H.+L.+Handlauthor=J.+Vagnerauthor=H.+Hanauthor=E.+Mashauthor=V.+J.+Hrubyauthor=R.+J.+Gillies&title=Hitting+Multiple+Targets+with+Multimeric+Ligands&doi=10.1517%2F14728222.8.6.565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Hitting multiple targets with multimeric ligands</span></div><div class="casAuthors">Handl, Heather L.; Vagner, Josef; Han, Haiyong; Mash, Eugene; Hruby, Victor J.; Gillies, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">565-586</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Multimeric ligands consist of multiple monomeric ligands attached to a single backbone mol., creating a multimer that can bind to multiple receptors or targets simultaneously.  Numerous examples of multimeric binding exist within nature.  Due to the multiple and simultaneous binding events, multimeric ligands bind with an increased affinity compared to their corresponding monomers.  Multimeric ligands may provide opportunities in the field of drug discovery by providing enhanced selectivity and affinity of binding interactions, thus providing mol.-based targeted therapies.  However, gaps in our knowledge currently exist regarding the quant. measures for important design characteristics, such as flexibility, length and orientation of the inter-ligand linkers, receptor d. and ligand sequence.  In this review, multimeric ligand binding in two sep. phases is examd.  The prerecruitment phase describes the binding of one ligand of a multimer to its corresponding receptor, an event similar to monomeric ligand binding.  This results in transient increases in the local concn. of the other ligands, leading to apparent cooperativity.  The postrecruitment phase only occurs once all receptors have been aligned and bound by their corresponding ligand.  This phase is analogous to DNA-DNA interactions in that the stability of the complex is derived from phys. orientation.  Multiple factors influence the kinetics and thermodn. of multimeric binding, and these are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7NOkX9Q-NcLVg90H21EOLACvtfcHk0liH0UabgFMTYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmt1eisg%253D%253D&md5=8aad8ea5debf2373eb5d59f5bab63dc5</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1517%2F14728222.8.6.565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.8.6.565%26sid%3Dliteratum%253Aachs%26aulast%3DHandl%26aufirst%3DH.%2BL.%26aulast%3DVagner%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DH.%26aulast%3DMash%26aufirst%3DE.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26aulast%3DGillies%26aufirst%3DR.%2BJ.%26atitle%3DHitting%2520Multiple%2520Targets%2520with%2520Multimeric%2520Ligands%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2004%26volume%3D8%26issue%3D6%26spage%3D565%26epage%3D586%26doi%3D10.1517%2F14728222.8.6.565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehár, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, C. T.</span></span> <span> </span><span class="NLM_article-title">Multi-Target Therapeutics: When the Whole Is Greater than the Sum of the Parts</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2006.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.drudis.2006.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=17198971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=34-42&issue=1%E2%80%932&author=G.+R.+Zimmermannauthor=J.+Leh%C3%A1rauthor=C.+T.+Keith&title=Multi-Target+Therapeutics%3A+When+the+Whole+Is+Greater+than+the+Sum+of+the+Parts&doi=10.1016%2Fj.drudis.2006.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target therapeutics: when the whole is greater than the sum of the parts</span></div><div class="casAuthors">Zimmermann Grant R; Lehar Joseph; Keith Curtis T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">34-42</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">Drugs designed to act against individual molecular targets cannot usually combat multigenic diseases such as cancer, or diseases that affect multiple tissues or cell types such as diabetes and immunoinflammatory disorders.  Combination drugs that impact multiple targets simultaneously are better at controlling complex disease systems, are less prone to drug resistance and are the standard of care in many important therapeutic areas.  The combination drugs currently employed are primarily of rational design, but the increased efficacy they provide justifies in vitro discovery efforts for identifying novel multi-target mechanisms.  In this review, we discuss the biological rationale for combination therapeutics, review some existing combination drugs and present a systematic approach to identify interactions between molecular pathways that could be leveraged for therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTI14vYK2Q1LENHe_gFldTbfW6udTcc2eZNoV79D9211bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D&md5=66715499ce21c2855dc6c477aa87f161</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2006.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2006.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DG.%2BR.%26aulast%3DLeh%25C3%25A1r%26aufirst%3DJ.%26aulast%3DKeith%26aufirst%3DC.%2BT.%26atitle%3DMulti-Target%2520Therapeutics%253A%2520When%2520the%2520Whole%2520Is%2520Greater%2520than%2520the%2520Sum%2520of%2520the%2520Parts%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26issue%3D1%25E2%2580%25932%26spage%3D34%26epage%3D42%26doi%3D10.1016%2Fj.drudis.2006.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Costantino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlocco, D.</span></span> <span> </span><span class="NLM_article-title">Designed Multiple Ligands: Basic Research vs Clinical Outcomes</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">3353</span>– <span class="NLM_lpage">3387</span>, <span class="refDoi"> DOI: 10.2174/092986712801215883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F092986712801215883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=22680630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOhtrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=3353-3387&issue=20&author=L.+Costantinoauthor=D.+Barlocco&title=Designed+Multiple+Ligands%3A+Basic+Research+vs+Clinical+Outcomes&doi=10.2174%2F092986712801215883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Designed multiple ligands: basic research vs clinical outcomes</span></div><div class="casAuthors">Costantino, L.; Barlocco, D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3353-3387</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The clin. treatment of multifactorial pathologies (e.g. cancer, Alzheimer's disease, psychiatric disorders), is still a major challenge.  Many researches have been published dealing with the design of multiple ligands, able to act at the same time towards several targets relevant for a given pathol.  In the present review, the clin. results about these compds. have been reported, together with the design strategy adopted, in order to allow a crit. evaluation of the outcomes of these efforts.  What is emerging is that several effective design strategies of multitarget compds. are available, and the choice among these appears to be dependent on the therapeutic area considered.  However, at present, besides multitarget drugs discovered during optimization efforts by means of phenotypic assays, drug coadministrations or fixed dose formulations appear to be more useful therapeutic options than designed multiple ligands; this scenario will change when systems biol. will be able to select crit. targets, i.e. nodal proteins that should be inhibited in order to obtain a therapeutic action; at this point, the design of multiple ligands will allow a renaissance of medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobv_P2UM6L_7Vg90H21EOLACvtfcHk0li6hkwJoPTYYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOhtrrN&md5=82123bbafc10a19c65a0bc0c5be72546</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2174%2F092986712801215883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986712801215883%26sid%3Dliteratum%253Aachs%26aulast%3DCostantino%26aufirst%3DL.%26aulast%3DBarlocco%26aufirst%3DD.%26atitle%3DDesigned%2520Multiple%2520Ligands%253A%2520Basic%2520Research%2520vs%2520Clinical%2520Outcomes%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2012%26volume%3D19%26issue%3D20%26spage%3D3353%26epage%3D3387%26doi%3D10.2174%2F092986712801215883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silakari, O.</span></span> <span> </span><span class="NLM_article-title">Multifunctional Compounds: Smart Molecules for Multifactorial Diseases</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.01.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.ejmech.2014.01.060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=24565571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFyqu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2014&pages=31-42&author=Y.+Bansalauthor=O.+Silakari&title=Multifunctional+Compounds%3A+Smart+Molecules+for+Multifactorial+Diseases&doi=10.1016%2Fj.ejmech.2014.01.060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Multifunctional compounds: Smart molecules for multifactorial diseases</span></div><div class="casAuthors">Bansal, Yogita; Silakari, Om</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31-42</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Multifunctional compds. (MFCs) are designed broadly as hybrid or conjugated drugs or as chimeric drugs from two or more pharmacophores/drugs having specific pharmacol. activities.  These are capable of eliciting multiple pharmacol. actions and have emerged as magic bullets in treatment of multifactorial diseases.  Many research articles disclosing the development of such compds. for treatment of multifactorial diseases are published during last 7 years.  Some successful MFC candidates for multifactorial CNS disorders include ziprasidone, duloxetine, ladostigil and M-30 whereas sunitinib, lapatinib and synthetic oleandane triterpinoids are the successful MFC candidates for various cancers.  Many more compds. derived from berberine, tacrine, artemisnin, quinine, NSAIDs, pralidoxine, donepezil, rivastigmine, curcumin and various antioxidants are under investigations for exploration of their multifunctional potential.  In general, MFCs possess the advantages of reduced molecularity, no drug-drug interactions and improved pharmacokinetics and pharmacodynamics.  A MFC derived from two or more different pharmacophores exerts its activities by interacting with resp. receptors of its constituent pharmacophores.  It may also exhibit addnl. binding interactions with the receptor sites that may be responsible for significantly improved or addnl. activities.  The present review discusses various MFCs developed for specific class of disorders with an aim to provide an insight into the strategies in medicinal chem. for development of such compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr5doWQJHIRbVg90H21EOLACvtfcHk0li6hkwJoPTYYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFyqu7w%253D&md5=53392637dc34c3369831a3e3da359557</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.01.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.01.060%26sid%3Dliteratum%253Aachs%26aulast%3DBansal%26aufirst%3DY.%26aulast%3DSilakari%26aufirst%3DO.%26atitle%3DMultifunctional%2520Compounds%253A%2520Smart%2520Molecules%2520for%2520Multifactorial%2520Diseases%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D76%26spage%3D31%26epage%3D42%26doi%3D10.1016%2Fj.ejmech.2014.01.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span> <span> </span><span class="NLM_article-title">Computational Multitarget Drug Design</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">403</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.6b00491</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.6b00491" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFCntr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=403-412&issue=3&author=W.+Zhangauthor=J.+Peiauthor=L.+Lai&title=Computational+Multitarget+Drug+Design&doi=10.1021%2Facs.jcim.6b00491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Computational Multitarget Drug Design</span></div><div class="casAuthors">Zhang, Weilin; Pei, Jianfeng; Lai, Luhua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">403-412</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Designing drugs that can simultaneously interact with multiple targets is a promising approach for treating complicated diseases.  Compared to using combinations of single target drugs, multitarget drugs have advantages of higher efficacy, improved safety profile, and simpler administration.  Many in silico methods have been developed to approach different aspects of this polypharmacol.-guided drug design, particularly for drug repurposing and multitarget drug design.  In this review, the authors summarize recent progress in computational multitarget drug design and discuss their advantages and limitations.  Perspectives for future drug development will also be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-J4p0tdEUR7Vg90H21EOLACvtfcHk0liNUiVNMfzaJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFCntr8%253D&md5=e00ed6650471d786a04b828a8064f5e9</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.6b00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.6b00491%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DPei%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DComputational%2520Multitarget%2520Drug%2520Design%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2017%26volume%3D57%26issue%3D3%26spage%3D403%26epage%3D412%26doi%3D10.1021%2Facs.jcim.6b00491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Oliveira Pedrosa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte da Cruz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira Viana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olimpio de Moura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishiki, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa Filho, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diniz, M. F. F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scotti, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scotti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezerra
Mendonca, F. J.</span></span> <span> </span><span class="NLM_article-title">Hybrid Compounds as Direct Multitarget Ligands: A Review</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1044</span>– <span class="NLM_lpage">1079</span>, <span class="refDoi"> DOI: 10.2174/1568026616666160927160620</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F1568026616666160927160620" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27697048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC2svmtlOnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=1044-1079&issue=9&author=M.+de%0AOliveira+Pedrosaauthor=R.+M.+Duarte+da+Cruzauthor=J.+de+Oliveira+Vianaauthor=R.+Olimpio+de+Mouraauthor=H.+M.+Ishikiauthor=J.+M.+Barbosa+Filhoauthor=M.+F.+F.+M.+Dinizauthor=M.+T.+Scottiauthor=L.+Scottiauthor=F.+J.+Bezerra%0AMendonca&title=Hybrid+Compounds+as+Direct+Multitarget+Ligands%3A+A+Review&doi=10.2174%2F1568026616666160927160620"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrid Compounds as Direct Multitarget Ligands: A Review</span></div><div class="casAuthors">de Oliveira Pedrosa Michelle; Duarte da Cruz Rayssa Marques; de Oliveira Viana Jessika; de Moura Ricardo Olimpio; Ishiki Hamilton Mitsugu; Barbosa Filho Jose Maria; Diniz Margareth F F M; Scotti Marcus Tullius; Scotti Luciana; Bezerra Mendonca Francisco Jaime</div><div class="citationInfo"><span class="NLM_cas:title">Current topics in medicinal chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1044-1079</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Molecular Hybridization is an approach in rational drug design where new chemical entities are obtained by combining two or more pharmacophoric units from different bioactive compounds into a single molecule.  Through this approach, medicinal chemists hope that the new hybrid derivative presents: better affinity and efficacy when compared to the parent drugs; a modified selectivity profile with improvement over pharmacokinetic and pharmacodynamic restrictions; dual or multiple modes of action; reduction of undesirable side effects; decreases in drug-drug interactions; reduced emergence or spread of drug resistance in microorganisms and protozoans; and lower cost.  The approach has been successfully used by many research groups around the world and has had very promising results with diseases having multifactorial profiles, like Alzheimer's, Parkinson's disease, cancer, inflammation, and hypertension among others.  The purpose of this paper is to conduct an updated review of molecular hybridization and multitarget profiling (a rational drug design approach), and its applications to the design and discovery of novel hybrid compounds with anti-inflammatory, antimicrobial, anticancer and antiprotozoal (leishmaniasis, malaria, and schistosomiasis) activities over the last six years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSlAS_CHdfHQvupmecNw_lfW6udTcc2eZEbz0j7i4vAbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svmtlOnsA%253D%253D&md5=17567b4c0f16fa6af0ad0823532a56bc</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2174%2F1568026616666160927160620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026616666160927160620%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BOliveira%2BPedrosa%26aufirst%3DM.%26aulast%3DDuarte%2Bda%2BCruz%26aufirst%3DR.%2BM.%26aulast%3Dde%2BOliveira%2BViana%26aufirst%3DJ.%26aulast%3DOlimpio%2Bde%2BMoura%26aufirst%3DR.%26aulast%3DIshiki%26aufirst%3DH.%2BM.%26aulast%3DBarbosa%2BFilho%26aufirst%3DJ.%2BM.%26aulast%3DDiniz%26aufirst%3DM.%2BF.%2BF.%2BM.%26aulast%3DScotti%26aufirst%3DM.%2BT.%26aulast%3DScotti%26aufirst%3DL.%26aulast%3DBezerra%2BMendonca%26aufirst%3DF.%2BJ.%26atitle%3DHybrid%2520Compounds%2520as%2520Direct%2520Multitarget%2520Ligands%253A%2520A%2520Review%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2017%26volume%3D17%26issue%3D9%26spage%3D1044%26epage%3D1079%26doi%3D10.2174%2F1568026616666160927160620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korcsmáros, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szalay, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böde, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovács, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csermely, P.</span></span> <span> </span><span class="NLM_article-title">How to Design Multi-Target Drugs</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">799</span>– <span class="NLM_lpage">808</span>, <span class="refDoi"> DOI: 10.1517/17460441.2.6.799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1517%2F17460441.2.6.799" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=799-808&issue=6&author=T.+Korcsm%C3%A1rosauthor=M.+S.+Szalayauthor=C.+B%C3%B6deauthor=I.+A.+Kov%C3%A1csauthor=P.+Csermely&title=How+to+Design+Multi-Target+Drugs&doi=10.1517%2F17460441.2.6.799"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1517%2F17460441.2.6.799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2.6.799%26sid%3Dliteratum%253Aachs%26aulast%3DKorcsm%25C3%25A1ros%26aufirst%3DT.%26aulast%3DSzalay%26aufirst%3DM.%2BS.%26aulast%3DB%25C3%25B6de%26aufirst%3DC.%26aulast%3DKov%25C3%25A1cs%26aufirst%3DI.%2BA.%26aulast%3DCsermely%26aufirst%3DP.%26atitle%3DHow%2520to%2520Design%2520Multi-Target%2520Drugs%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2007%26volume%3D2%26issue%3D6%26spage%3D799%26epage%3D808%26doi%3D10.1517%2F17460441.2.6.799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravikumar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aittokallio, T.</span></span> <span> </span><span class="NLM_article-title">Improving the Efficacy-Safety Balance of Polypharmacology in Multi-Target Drug Discovery</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1080/17460441.2018.1413089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1080%2F17460441.2018.1413089" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=179-192&issue=2&author=B.+Ravikumarauthor=T.+Aittokallio&title=Improving+the+Efficacy-Safety+Balance+of+Polypharmacology+in+Multi-Target+Drug+Discovery&doi=10.1080%2F17460441.2018.1413089"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1080%2F17460441.2018.1413089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2018.1413089%26sid%3Dliteratum%253Aachs%26aulast%3DRavikumar%26aufirst%3DB.%26aulast%3DAittokallio%26aufirst%3DT.%26atitle%3DImproving%2520the%2520Efficacy-Safety%2520Balance%2520of%2520Polypharmacology%2520in%2520Multi-Target%2520Drug%2520Discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2018%26volume%3D13%26issue%3D2%26spage%3D179%26epage%3D192%26doi%3D10.1080%2F17460441.2018.1413089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. U.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology - Foe or Friend?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">8955</span>– <span class="NLM_lpage">8971</span>, <span class="refDoi"> DOI: 10.1021/jm400856t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400856t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8955-8971&issue=22&author=J.+U.+Peters&title=Polypharmacology+-+Foe+or+Friend%3F&doi=10.1021%2Fjm400856t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BU.%26atitle%3DPolypharmacology%2520-%2520Foe%2520or%2520Friend%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D22%26spage%3D8955%26epage%3D8971%26doi%3D10.1021%2Fjm400856t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. U.</span></span> <i>Polypharmacology in Drug Discovery</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J.-U.</span></span>, Ed.; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2F9781118098141" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=J.+U.+Petersauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2F9781118098141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BU.%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteban, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bautista-Aguilera, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inokuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraleda, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iriepa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández Fernández, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricardo-Martínez-Murillo</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unzeta, M.</span></span> <span> </span><span class="NLM_article-title">Donepezil + Propargylamine + 8-Hydroxyquinoline Hybrids as New Multifunctional Metal-Chelators, ChE and MAO Inhibitors for the Potential Treatment of Alzheimer’s Disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">561</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.04.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.ejmech.2014.04.078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=24813882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVensL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2014&pages=543-561&author=L.+Wangauthor=G.+Estebanauthor=M.+Ojimaauthor=O.+M.+Bautista-Aguileraauthor=T.+Inokuchiauthor=I.+Moraledaauthor=I.+Iriepaauthor=A.+Samadiauthor=M.+B.+H.+Youdimauthor=A.+Romeroauthor=E.+Sorianoauthor=R.+Herreroauthor=A.+P.+Fern%C3%A1ndez+Fern%C3%A1ndezauthor=+Ricardo-Mart%C3%ADnez-Murilloauthor=J.+Marco-Contellesauthor=M.+Unzeta&title=Donepezil+%2B+Propargylamine+%2B+8-Hydroxyquinoline+Hybrids+as+New+Multifunctional+Metal-Chelators%2C+ChE+and+MAO+Inhibitors+for+the+Potential+Treatment+of+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.ejmech.2014.04.078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease</span></div><div class="casAuthors">Wang, Li; Esteban, Gerard; Ojima, Masaki; Bautista-Aguilera, Oscar M.; Inokuchi, Tsutomu; Moraleda, Ignacio; Iriepa, Isabel; Samadi, Abdelouahid; Youdim, Moussa B. H.; Romero, Alejandro; Soriano, Elena; Herrero, Raquel; Fernandez Fernandez, Ana Patricia; Ricardo-Martinez-Murillo; Marco-Contelles, Jose; Unzeta, Mercedes</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">543-561</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The synthesis, biochem. evaluation, ADMET, toxicity and mol. modeling of novel multi-target-directed Donepezil + Propargylamine + 8-Hydroxyquinoline (DPH) hybrids for the potential prevention and treatment of Alzheimer's disease is described.  The most interesting deriv. was racemic α-aminotrile4-(1-benzylpiperidin-4-yl)-2-(((8-hydroxyquinolin-5-yl)methyl)(prop-2-yn-1-yl)amino) butanenitrile (DPH6) [MAO A (IC50 = 6.2±0.7 μM); MAO B (IC50 = 10.2±0.9 μM); AChE (IC50 = 1.8±0.1 μM); BuChE (IC50 = 1.6±0.25 μM)], an irreversible MAO A/B inhibitor and mixed-type AChE inhibitor with metal-chelating properties.  According to docking studies, both DPH6 enantiomers interact simultaneously with the catalytic and peripheral site of EeAChE through a linker of appropriate length, supporting the obsd. mixed-type AChE inhibition.  Both enantiomers exhibited a relatively similar position of both hydroxyquinoline and benzyl moieties with the rest of the mol. easily accommodated in the relatively large cavity of MAO A.  For MAO B, the quinoline system was hosted at the cavity entrance, whereas for MAO A this system occupied the substrate cavity.  In this disposition the quinoline moiety interacted directly with the FAD arom. ring.  Very similar binding affinity values were also obsd. for both enantiomers with ChE and MAO enzymes.  DPH derivs. exhibited moderate to good ADMET properties and brain penetration capacity for CNS activity.  DPH6 was less toxic than donepezil at high concns.; while at low concns. both displayed a similar cell viability profile.  Finally, in a passive avoidance task, the antiamnesic effect of DPH6 was tested on mice with exptl. induced amnesia.  DPH6 was capable to significantly decrease scopolamine-induced learning deficits in healthy adult mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphrIxeM4RW2rVg90H21EOLACvtfcHk0liYa2juuse_Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVensL8%253D&md5=2e1f262b4002653cbac7a6dafabe3548</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.04.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.04.078%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DEsteban%26aufirst%3DG.%26aulast%3DOjima%26aufirst%3DM.%26aulast%3DBautista-Aguilera%26aufirst%3DO.%2BM.%26aulast%3DInokuchi%26aufirst%3DT.%26aulast%3DMoraleda%26aufirst%3DI.%26aulast%3DIriepa%26aufirst%3DI.%26aulast%3DSamadi%26aufirst%3DA.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%2BH.%26aulast%3DRomero%26aufirst%3DA.%26aulast%3DSoriano%26aufirst%3DE.%26aulast%3DHerrero%26aufirst%3DR.%26aulast%3DFern%25C3%25A1ndez%2BFern%25C3%25A1ndez%26aufirst%3DA.%2BP.%26aulast%3DRicardo-Mart%25C3%25ADnez-Murillo%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DUnzeta%26aufirst%3DM.%26atitle%3DDonepezil%2520%252B%2520Propargylamine%2520%252B%25208-Hydroxyquinoline%2520Hybrids%2520as%2520New%2520Multifunctional%2520Metal-Chelators%252C%2520ChE%2520and%2520MAO%2520Inhibitors%2520for%2520the%2520Potential%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D80%26spage%3D543%26epage%3D561%26doi%3D10.1016%2Fj.ejmech.2014.04.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Unzeta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteban, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolea, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fogel, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tipton, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span> <span> </span><span class="NLM_article-title">Multi-Target Directed Donepezil-Like Ligands for Alzheimer’s Disease</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">205</span>, <span class="refDoi"> DOI: 10.3389/fnins.2016.00205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.3389%2Ffnins.2016.00205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27252617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FmtV2hsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=205&author=M.+Unzetaauthor=G.+Estebanauthor=I.+Boleaauthor=W.+A.+Fogelauthor=R.+R.+Ramsayauthor=M.+B.+H.+Youdimauthor=K.+F.+Tiptonauthor=J.+Marco-Contelles&title=Multi-Target+Directed+Donepezil-Like+Ligands+for+Alzheimer%E2%80%99s+Disease&doi=10.3389%2Ffnins.2016.00205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease</span></div><div class="casAuthors">Unzeta Mercedes; Bolea Irene; Esteban Gerard; Tipton Keith F; Fogel Wieslawa A; Ramsay Rona R; Youdim Moussa B H; Marco-Contelles Jose</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">205</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">HIGHLIGHTS ASS234 is a MTDL compound containing a moiety from Donepezil and the propargyl group from the PF 9601N, a potent and selective MAO B inhibitor.  This compound is the most advanced anti-Alzheimer agent for preclinical studies identified in our laboratory.Derived from ASS234 both multipotent donepezil-indolyl (MTDL-1) and donepezil-pyridyl hybrids (MTDL-2) were designed and evaluated as inhibitors of AChE/BuChE and both MAO isoforms.  MTDL-2 showed more high affinity toward the four enzymes than MTDL-1.MTDL-3 and MTDL-4, were designed containing the N-benzylpiperidinium moiety from Donepezil, a metal- chelating 8-hydroxyquinoline group and linked to a N-propargyl core and they were pharmacologically evaluated.The presence of the cyano group in MTDL-3, enhanced binding to AChE, BuChE and MAO A.  It showed antioxidant behavior and it was able to strongly complex Cu(II), Zn(II) and Fe(III).MTDL-4 showed higher affinity toward AChE, BuChE.MTDL-3 exhibited good brain penetration capacity (ADMET) and less toxicity than Donepezil.  Memory deficits in scopolamine-lesioned animals were restored by MTDL-3.MTDL-3 particularly emerged as a ligand showing remarkable potential benefits for its use in AD therapy.  Alzheimer's disease (AD), the most common form of adult onset dementia, is an age-related neurodegenerative disorder characterized by progressive memory loss, decline in language skills, and other cognitive impairments.  Although its etiology is not completely known, several factors including deficits of acetylcholine, β-amyloid deposits, τ-protein phosphorylation, oxidative stress, and neuroinflammation are considered to play significant roles in the pathophysiology of this disease.  For a long time, AD patients have been treated with acetylcholinesterase inhibitors such as donepezil (Aricept®) but with limited therapeutic success.  This might be due to the complex multifactorial nature of AD, a fact that has prompted the design of new Multi-Target-Directed Ligands (MTDL) based on the "one molecule, multiple targets" paradigm.  Thus, in this context, different series of novel multifunctional molecules with antioxidant, anti-amyloid, anti-inflammatory, and metal-chelating properties able to interact with multiple enzymes of therapeutic interest in AD pathology including acetylcholinesterase, butyrylcholinesterase, and monoamine oxidases A and B have been designed and assessed biologically.  This review describes the multiple targets, the design rationale and an in-house MTDL library, bearing the N-benzylpiperidine motif present in donepezil, linked to different heterocyclic ring systems (indole, pyridine, or 8-hydroxyquinoline) with special emphasis on compound ASS234, an N-propargylindole derivative.  The description of the in vitro biological properties of the compounds and discussion of the corresponding structure-activity-relationships allows us to highlight new issues for the identification of more efficient MTDL for use in AD therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAKdUtVDXRPgpJitSxOdIlfW6udTcc2eYsxbzRtvgdK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FmtV2hsw%253D%253D&md5=0904cb1e4e1c700e575e192e9d3bebb3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2016.00205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2016.00205%26sid%3Dliteratum%253Aachs%26aulast%3DUnzeta%26aufirst%3DM.%26aulast%3DEsteban%26aufirst%3DG.%26aulast%3DBolea%26aufirst%3DI.%26aulast%3DFogel%26aufirst%3DW.%2BA.%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%2BH.%26aulast%3DTipton%26aufirst%3DK.%2BF.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26atitle%3DMulti-Target%2520Directed%2520Donepezil-Like%2520Ligands%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DFront.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D205%26doi%3D10.3389%2Ffnins.2016.00205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simone
Tranches Dias, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viegas, C.</span></span> <span> </span><span class="NLM_article-title">Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the Treatment of Alzheimer’s Disease</span>. <i>Curr. Neuropharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.2174/1570159X1203140511153200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F1570159X1203140511153200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=24851088" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=239-255&issue=3&author=K.+Simone%0ATranches+Diasauthor=C.+Viegas&title=Multi-Target+Directed+Drugs%3A+A+Modern+Approach+for+Design+of+New+Drugs+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease&doi=10.2174%2F1570159X1203140511153200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2174%2F1570159X1203140511153200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570159X1203140511153200%26sid%3Dliteratum%253Aachs%26aulast%3DSimone%2BTranches%2BDias%26aufirst%3DK.%26aulast%3DViegas%26aufirst%3DC.%26atitle%3DMulti-Target%2520Directed%2520Drugs%253A%2520A%2520Modern%2520Approach%2520for%2520Design%2520of%2520New%2520Drugs%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2014%26volume%3D12%26issue%3D3%26spage%3D239%26epage%3D255%26doi%3D10.2174%2F1570159X1203140511153200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majekova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valoti, M.</span></span> <span> </span><span class="NLM_article-title">Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">375</span>, <span class="refDoi"> DOI: 10.3389/fnins.2016.00375</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.3389%2Ffnins.2016.00375" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27597816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC2sznvFKhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=375&author=R.+R.+Ramsayauthor=M.+Majekovaauthor=M.+Medinaauthor=M.+Valoti&title=Key+Targets+for+Multi-Target+Ligands+Designed+to+Combat+Neurodegeneration&doi=10.3389%2Ffnins.2016.00375"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration</span></div><div class="casAuthors">Ramsay Rona R; Majekova Magdalena; Medina Milagros; Valoti Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">375</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">HIGHLIGHTS Compounds that interact with multiple targets but minimally with the cytochrome P450 system (CYP) address the many factors leading to neurodegeneration.Acetyl- and Butyryl-cholineEsterases (AChE, BChE) and Monoamine Oxidases A/B (MAO A, MAO B) are targets for Multi-Target Designed Ligands (MTDL).ASS234 is an irreversible inhibitor of MAO A >MAO B and has micromolar potency against the cholinesterases.ASS234 is a poor CYP substrate in human liver, yielding the depropargylated metabolite.SMe1EC2, a stobadine derivative, showed high radical scavenging property, in vitro and in vivo giving protection in head trauma and diabetic damage of endothelium.Control of mitochondrial function and morphology by manipulating fission and fusion is emerging as a target area for therapeutic strategies to decrease the pathological outcome of neurodegenerative diseases.  Growing evidence supports the view that neurodegenerative diseases have multiple and common mechanisms in their aetiologies.  These multifactorial aspects have changed the broadly common assumption that selective drugs are superior to "dirty drugs" for use in therapy.  This drives the research in studies of novel compounds that might have multiple action mechanisms.  In neurodegeneration, loss of neuronal signaling is a major cause of the symptoms, so preservation of neurotransmitters by inhibiting the breakdown enzymes is a first approach.  Acetylcholinesterase (AChE) inhibitors are the drugs preferentially used in AD and that one of these, rivastigmine, is licensed also for PD.  Several studies have shown that monoamine oxidase (MAO) B, located mainly in glial cells, increases with age and is elevated in Alzheimer (AD) and Parkinson's Disease's (PD).  Deprenyl, a MAO B inhibitor, significantly delays the initiation of levodopa treatment in PD patients.  These indications underline that AChE and MAO are considered a necessary part of multi-target designed ligands (MTDL).  However, both of these targets are simply symptomatic treatment so if new drugs are to prevent degeneration rather than compensate for loss of neurotransmitters, then oxidative stress and mitochondrial events must also be targeted.  MAO inhibitors can protect neurons from apoptosis by mechanisms unrelated to enzyme inhibition.  Understanding the involvement of MAO and other proteins in the induction and regulation of the apoptosis in mitochondria will aid progress toward strategies to prevent the loss of neurons.  In general, the oxidative stress observed both in PD and AD indicate that antioxidant properties are a desirable part of MTDL molecules.  After two or more properties are incorporated into one molecule, the passage from a lead compound to a therapeutic tool is strictly linked to its pharmacokinetic and toxicity.  In this context the interaction of any new molecules with cytochrome P450 and other xenobiotic metabolic processes is a crucial point.  The present review covers the biochemistry of enzymes targeted in the design of drugs against neurodegeneration and the cytochrome P450-dependent metabolism of MTDLs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQjOr1PdgGetEwlCcfExbvbfW6udTcc2ebbTtjDIAVkh7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sznvFKhsA%253D%253D&md5=d4262692b6fbea1a58815dca979f2c69</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2016.00375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2016.00375%26sid%3Dliteratum%253Aachs%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DMajekova%26aufirst%3DM.%26aulast%3DMedina%26aufirst%3DM.%26aulast%3DValoti%26aufirst%3DM.%26atitle%3DKey%2520Targets%2520for%2520Multi-Target%2520Ligands%2520Designed%2520to%2520Combat%2520Neurodegeneration%26jtitle%3DFront.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D375%26doi%3D10.3389%2Ffnins.2016.00375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer’s Disease</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">466</span>, <span class="refDoi"> DOI: 10.3390/molecules21040466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.3390%2Fmolecules21040466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27070562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWktLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=466&issue=4&author=F.+Pratiauthor=A.+Cavalliauthor=M.+L.+Bolognesi&title=Navigating+the+Chemical+Space+of+Multitarget-Directed+Ligands%3A+From+Hybrids+to+Fragments+in+Alzheimer%E2%80%99s+Disease&doi=10.3390%2Fmolecules21040466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Navigating the chemical space of multitarget-directed ligands: from hybrids to fragments in Alzheimer's disease</span></div><div class="casAuthors">Prati, Federica; Cavalli, Andrea; Bolognesi, Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">466/1-466/12</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Multitarget drug discovery is one of the hottest topics and most active fields in the search for new mols. against Alzheimer's disease (AD).  Over the last 20 years, many promising multitarget-directed ligands (MTDLs) have been identified and developed at a pre-clin. level.  However, how to design them in a rational way remains the most fundamental challenge of medicinal chemists.  This is related to the foundational question of achieving an optimized activity towards multiple targets of interest, while preserving drug-like properties.  In this respect, large hybrid mols. and small fragments are poles apart.  In this review article, our aim is to appraise what we have accomplished in the development of both hybrid- and fragment-like mols. directed to diverse AD targets (i.e., acetylcholinesterase, NMDA receptors, metal chelation, BACE-1 and GSK-3β).  In addn., we attempt to highlight what are the persistent needs that deserve to be improved and cared for, with the ultimate goal of moving an MTDL to AD clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAXsoof4raqbVg90H21EOLACvtfcHk0lgUYNp6FV7I_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWktLjI&md5=3653a0ef6b41711663e8d2f2d4ae74f6</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.3390%2Fmolecules21040466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules21040466%26sid%3Dliteratum%253Aachs%26aulast%3DPrati%26aufirst%3DF.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DNavigating%2520the%2520Chemical%2520Space%2520of%2520Multitarget-Directed%2520Ligands%253A%2520From%2520Hybrids%2520to%2520Fragments%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DMolecules%26date%3D2016%26volume%3D21%26issue%3D4%26spage%3D466%26doi%3D10.3390%2Fmolecules21040466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchiorre, C.</span></span> <span> </span><span class="NLM_article-title">Memoquin: A Multi-Target-Directed Ligand as an Innovative Therapeutic Opportunity for Alzheimer’s Disease</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">152</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1016/j.nurt.2008.10.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.nurt.2008.10.042" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=152-162&issue=1&author=M.+L.+Bolognesiauthor=A.+Cavalliauthor=C.+Melchiorre&title=Memoquin%3A+A+Multi-Target-Directed+Ligand+as+an+Innovative+Therapeutic+Opportunity+for+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.nurt.2008.10.042"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.nurt.2008.10.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nurt.2008.10.042%26sid%3Dliteratum%253Aachs%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DMemoquin%253A%2520A%2520Multi-Target-Directed%2520Ligand%2520as%2520an%2520Innovative%2520Therapeutic%2520Opportunity%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DNeurotherapeutics%26date%3D2009%26volume%3D6%26issue%3D1%26spage%3D152%26epage%3D162%26doi%3D10.1016%2Fj.nurt.2008.10.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geldenhuys, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Schyf, C. J.</span></span> <span> </span><span class="NLM_article-title">Rationally Designed Multi-Targeted Agents against Neurodegenerative Diseases</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1662</span>– <span class="NLM_lpage">1672</span>, <span class="refDoi"> DOI: 10.2174/09298673113209990112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F09298673113209990112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=23410161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotl2jtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1662-1672&issue=13&author=W.+J.+Geldenhuysauthor=C.+J.+Van+der+Schyf&title=Rationally+Designed+Multi-Targeted+Agents+against+Neurodegenerative+Diseases&doi=10.2174%2F09298673113209990112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Rationally designed multi-targeted agents against neurodegenerative diseases</span></div><div class="casAuthors">Geldenhuys, W. J.; Van der Schyf, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1662-1672</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Neurodegenerative diseases are complex disorders with several pathoetiol. pathways leading to cell death.  Rationally designed multi-targeted agents, or "multi-targeted designed drugs" (MTDD) show significant promise in preclin. studies as neuroprotective and disease-modifying agents.  In this review, we highlight the use of chem. scaffolds that lend themselves exquisitely to the development of MTDDs in neurodegeneration.  Notably, synthetic polycyclic cage compds. have served as scaffolds for novel voltage-gated calcium channel blockers, NMDA receptor antagonists, and sigma-receptor ligands - attractive targets in neurodegeneration.  In an entirely different approach, compds. contg. the thiazolidinedione moiety (referred to as glitazones) alter mitochondrial function through the mitochondrial protein mitoNEET, an attractive new drug target for the treatment of neurodegenerative diseases.  The design strategy for yet another agent, ladostigil, employed the amalgamation of active chem. moieties of the AChE inhibitor rivastigmine, and the monoamine oxidase-B (MAO-B) inhibitor rasagiline, leading to a single compd. that targets both enzymes simultaneously.  Natural products have also served as design templates for several MTDD design studies.  In particular, the stilbene scaffold has become popular in particular due to the neuroprotective effects of the non-flavonoid natural product resveratrol.  Recently, stilbene scaffold-based compds. were developed to reduce - through chelation with metal ions that interact with beta-amyloid - both metal-induced beta-amyloid protein aggregation, and ROS generated from this aggregate.  Other subtle modifications of the stilbene motif led to the creation of reversible, non-competitive MAO inhibitors.  Finally, compds. derived from the xanthine scaffold afford neuroprotection in Parkinson's disease through mechanisms that include dual adenosine A2A receptor antagonism and MAO-B inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqZJN4lAGwOrVg90H21EOLACvtfcHk0lgUYNp6FV7I_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotl2jtbw%253D&md5=626f69acb3b3ff995e31b042e48dfba3</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.2174%2F09298673113209990112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F09298673113209990112%26sid%3Dliteratum%253Aachs%26aulast%3DGeldenhuys%26aufirst%3DW.%2BJ.%26aulast%3DVan%2Bder%2BSchyf%26aufirst%3DC.%2BJ.%26atitle%3DRationally%2520Designed%2520Multi-Targeted%2520Agents%2520against%2520Neurodegenerative%2520Diseases%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26issue%3D13%26spage%3D1662%26epage%3D1672%26doi%3D10.2174%2F09298673113209990112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bawa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradeep, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choonara, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillay, V.</span></span> <span> </span><span class="NLM_article-title">Multi-Target Therapeutics for Neuropsychiatric and Neurodegenerative Disorders</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1886</span>– <span class="NLM_lpage">1914</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.drudis.2016.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27506871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlaiu7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=1886-1914&issue=12&author=P.+Bawaauthor=P.+Pradeepauthor=P.+Kumarauthor=Y.+E.+Choonaraauthor=G.+Modiauthor=V.+Pillay&title=Multi-Target+Therapeutics+for+Neuropsychiatric+and+Neurodegenerative+Disorders&doi=10.1016%2Fj.drudis.2016.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders</span></div><div class="casAuthors">Bawa, Priya; Pradeep, Priyamvada; Kumar, Pradeep; Choonara, Yahya E.; Modi, Girish; Pillay, Viness</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1886-1914</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Historically, neuropsychiatric and neurodegenerative disease treatments focused on the 'magic bullet' concept; however multi-targeted strategies are increasingly attractive gauging from the escalating research in this area.  Because these diseases are typically co-morbid, multi-targeted drugs capable of interacting with multiple targets will expand treatment to the co-morbid disease condition.  Despite their theor. efficacy, there are significant impediments to clin. success (e.g., difficulty titrating individual aspects of the drug and inconclusive pathophysiol. mechanisms).  The new and revised diagnostic frameworks along with studies detailing the endophenotypic characteristics of the diseases promise to provide the foundation for the circumvention of these impediments.  This review serves to evaluate the various marketed and nonmarketed multi-targeted drugs with particular emphasis on their design strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaUcziq8vK_bVg90H21EOLACvtfcHk0lgbJZeQYzY6jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlaiu7rL&md5=47734b25b4b55be4f04f3ef936dfa313</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DBawa%26aufirst%3DP.%26aulast%3DPradeep%26aufirst%3DP.%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DChoonara%26aufirst%3DY.%2BE.%26aulast%3DModi%26aufirst%3DG.%26aulast%3DPillay%26aufirst%3DV.%26atitle%3DMulti-Target%2520Therapeutics%2520for%2520Neuropsychiatric%2520and%2520Neurodegenerative%2520Disorders%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26issue%3D12%26spage%3D1886%26epage%3D1914%26doi%3D10.1016%2Fj.drudis.2016.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span> <span> </span><span class="NLM_article-title">One for All? Hitting Multiple Alzheimer’s Disease Targets with One Drug</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">177</span>, <span class="refDoi"> DOI: 10.3389/fnins.2016.00177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.3389%2Ffnins.2016.00177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27199640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FhsV2lug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=177&author=R.+E.+Hughesauthor=K.+Nikolicauthor=R.+R.+Ramsay&title=One+for+All%3F+Hitting+Multiple+Alzheimer%E2%80%99s+Disease+Targets+with+One+Drug&doi=10.3389%2Ffnins.2016.00177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug</span></div><div class="casAuthors">Hughes Rebecca E; Ramsay Rona R; Nikolic Katarina</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">177</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">HIGHLIGHTS Many AD target combinations are being explored for multi-target drug design.New databases and models increase the potential of computational drug designLiraglutide and other antidiabetics are strong candidates for repurposing to AD.Donecopride a dual 5-HT/AChE inhibitor shows promise in pre-clinical studies Alzheimer's Disease is a complex and multifactorial disease for which the mechanism is still not fully understood.  As new insights into disease progression are discovered, new drugs must be designed to target those aspects of the disease that cause neuronal damage rather than just the symptoms currently addressed by single target drugs.  It is becoming possible to target several aspects of the disease pathology at once using multi-target drugs (MTDs).  Intended as an introduction for non-experts, this review describes the key MTD design approaches, namely structure-based, in silico, and data-mining, to evaluate what is preventing compounds progressing through the clinic to the market.  Repurposing current drugs using their off-target effects reduces the cost of development, time to launch, and the uncertainty associated with safety and pharmacokinetics.  The most promising drugs currently being investigated for repurposing to Alzheimer's Disease are rasagiline, originally developed for the treatment of Parkinson's Disease, and liraglutide, an antidiabetic.  Rational drug design can combine pharmacophores of multiple drugs, systematically change functional groups, and rank them by virtual screening.  Hits confirmed experimentally are rationally modified to generate an effective multi-potent lead compound.  Examples from this approach are ASS234 with properties similar to rasagiline, and donecopride, a hybrid of an acetylcholinesterase inhibitor and a 5-HT4 receptor agonist with pro-cognitive effects.  Exploiting these interdisciplinary approaches, public-private collaborative lead factories promise faster delivery of new drugs to the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnTES9o7fNJJHZzFRCXxVKfW6udTcc2ea4b_5rjKSPmLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FhsV2lug%253D%253D&md5=771f4dce4dc9504cc6078715e954a308</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2016.00177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2016.00177%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DR.%2BE.%26aulast%3DNikolic%26aufirst%3DK.%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26atitle%3DOne%2520for%2520All%253F%2520Hitting%2520Multiple%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Targets%2520with%2520One%2520Drug%26jtitle%3DFront.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D177%26doi%3D10.3389%2Ffnins.2016.00177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dekeyne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brocco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loiseau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivet, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Cara, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cremers, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flik, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fone, K. C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, D. J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serres, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cespuglio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavielle, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millan, M. J.</span></span> <span> </span><span class="NLM_article-title">S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/ 2-Adrenoceptor Antagonist and Potential Antidepressant: II. A Behavioral, Neurochemical, and Electrophysiological Characterization</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>340</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">765</span>– <span class="NLM_lpage">780</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.187534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1124%2Fjpet.111.187534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=22178753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtVSksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=2012&pages=765-780&issue=3&author=A.+Dekeyneauthor=M.+Broccoauthor=F.+Loiseauauthor=A.+Gobertauthor=J.-M.+Rivetauthor=B.+Di+Caraauthor=T.+I.+Cremersauthor=G.+Flikauthor=K.+C.+F.+Foneauthor=D.+J.+G.+Watsonauthor=M.+Pappauthor=T.+Sharpauthor=F.+Serresauthor=R.+Cespuglioauthor=B.+Olivierauthor=J.+S.+W.+Chanauthor=G.+Lavielleauthor=M.+J.+Millan&title=S32212%2C+a+Novel+Serotonin+Type+2C+Receptor+Inverse+Agonist%2F+2-Adrenoceptor+Antagonist+and+Potential+Antidepressant%3A+II.+A+Behavioral%2C+Neurochemical%2C+and+Electrophysiological+Characterization&doi=10.1124%2Fjpet.111.187534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization</span></div><div class="casAuthors">Dekeyne, Anne; Brocco, Mauricette; Loiseau, Florence; Gobert, Alain; Rivet, Jean-Michel; Di Cara, Benjamin; Cremers, Thomas I.; Flik, Gunnar; Fone, Kevin C. F.; Watson, David J. G.; Papp, Mariusz; Sharp, Trevor; Serres, Florence; Cespuglio, Raymond; Olivier, Berend; Chan, Johnny S. W.; Lavielle, Gilbert; Millan, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">765-780</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The present studies characterized the functional profile of N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-1,2-dihydro-3H-benzo[e]indole-3-carboxamide) (S32212), a combined serotonin (5-HT)2C receptor inverse agonist and α2-adrenoceptor antagonist that also possesses 5-HT2A antagonist properties.  Upon parenteral and/or oral administration, dose-dependent (0.63-40.0 mg/kg) actions were obsd. in diverse procedures.  Both acute and subchronic administration of S32212 reduced immobility time in a forced-swim test in rats.  Acutely, it also suppressed marble burying and aggressive behavior in mice.  Long-term administration of S32212 was assocd. with rapid (1 wk) and sustained (5 wk) normalization of sucrose intake in rats exposed to chronic mild stress and with elevated levels of mRNA encoding brain-derived neurotrophic factor in hippocampus and amygdala (2 wk).  S32212 accelerated the firing rate of adrenergic perikarya in the locus coeruleus and elevated dialysis levels of noradrenaline in the frontal cortex and hippocampus of freely moving rats.  S32212 also elevated the frontocortical levels of dopamine and acetylcholine, whereas 5-HT, amino acids, and histamine were unaffected.  These neurochem. actions were paralleled by "promnemonic" properties: blockade of scopolamine-induced deficits in radial maze performance and social recognition and reversal of delay-induced impairments in social recognition, social novelty discrimination, and novel object recognition.  It also showed anxiolytic actions in a Vogel conflict procedure.  Furthermore, in an electroencephalog. study of sleep architecture, S32212 enhanced slow-wave and rapid eye movement sleep, while decreasing waking.  Finally, chronic administration of S32212 neither elevated body wt. nor perturbed sexual behavior in male rats.  In conclusion, S32212 displays a functional profile consistent with improved mood and cognitive performance, together with satisfactory tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDWoTa3Y74A7Vg90H21EOLACvtfcHk0lgbJZeQYzY6jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtVSksrc%253D&md5=eb76f053470c98aee181108d01fe2513</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187534%26sid%3Dliteratum%253Aachs%26aulast%3DDekeyne%26aufirst%3DA.%26aulast%3DBrocco%26aufirst%3DM.%26aulast%3DLoiseau%26aufirst%3DF.%26aulast%3DGobert%26aufirst%3DA.%26aulast%3DRivet%26aufirst%3DJ.-M.%26aulast%3DDi%2BCara%26aufirst%3DB.%26aulast%3DCremers%26aufirst%3DT.%2BI.%26aulast%3DFlik%26aufirst%3DG.%26aulast%3DFone%26aufirst%3DK.%2BC.%2BF.%26aulast%3DWatson%26aufirst%3DD.%2BJ.%2BG.%26aulast%3DPapp%26aufirst%3DM.%26aulast%3DSharp%26aufirst%3DT.%26aulast%3DSerres%26aufirst%3DF.%26aulast%3DCespuglio%26aufirst%3DR.%26aulast%3DOlivier%26aufirst%3DB.%26aulast%3DChan%26aufirst%3DJ.%2BS.%2BW.%26aulast%3DLavielle%26aufirst%3DG.%26aulast%3DMillan%26aufirst%3DM.%2BJ.%26atitle%3DS32212%252C%2520a%2520Novel%2520Serotonin%2520Type%25202C%2520Receptor%2520Inverse%2520Agonist%252F%25202-Adrenoceptor%2520Antagonist%2520and%2520Potential%2520Antidepressant%253A%2520II.%2520A%2520Behavioral%252C%2520Neurochemical%252C%2520and%2520Electrophysiological%2520Characterization%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D340%26issue%3D3%26spage%3D765%26epage%3D780%26doi%3D10.1124%2Fjpet.111.187534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Millan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannoury la Cour, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanrion, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupuis, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Cara, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audinot, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cussac, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jockers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bockaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dekeyne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavielle, G.</span></span> <span> </span><span class="NLM_article-title">S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/ 2-Adrenoceptor Antagonist and Potential Antidepressant: I. A Mechanistic Characterization</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>340</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">750</span>– <span class="NLM_lpage">764</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.187468</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1124%2Fjpet.111.187468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=22178752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtVSksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=2012&pages=750-764&issue=3&author=M.+J.+Millanauthor=C.+Mannoury+la+Courauthor=B.+Chanrionauthor=D.+S.+Dupuisauthor=B.+Di+Caraauthor=V.+Audinotauthor=D.+Cussacauthor=A.+Newman-Tancrediauthor=M.+Kamalauthor=J.+A.+Boutinauthor=R.+Jockersauthor=P.+Marinauthor=J.+Bockaertauthor=O.+Mullerauthor=A.+Dekeyneauthor=G.+Lavielle&title=S32212%2C+a+Novel+Serotonin+Type+2C+Receptor+Inverse+Agonist%2F+2-Adrenoceptor+Antagonist+and+Potential+Antidepressant%3A+I.+A+Mechanistic+Characterization&doi=10.1124%2Fjpet.111.187468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">S32212, a novel serotonin type 2C receptor inverse agonist/α2 adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization</span></div><div class="casAuthors">Millan, Mark J.; La Cour, Clotilde Mannoury; Chanrion, Benjamin; Dupuis, Delphine S.; Di Cara, Benjamin; Audinot, Valerie; Cussac, Didier; Newman-Tancredi, Adrian; Kamal, Maud; Boutin, Jean A.; Jockers, Ralf; Marin, Philippe; Bockaert, Joel; Muller, Olivier; Dekeyne, Anne; Lavielle, Gilbert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">750-764</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Although most antidepressants suppress serotonin (5-HT) and/or noradrenaline reuptake, blockade of 5-HT2C receptors and α2-adrenoceptors likewise enhances monoaminergic transmission.  These sites are targeted by the urea deriv. N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-1,2-dihydro-3-H-benzo[e]indole-3-carboxamide (S32212).  S32212 was devoid of affinity for monoamine reuptake sites, yet displayed pronounced affinity (pKi, 8.2) for constitutively active human 5-HT2CINI (h5-HT2CINI) receptors, behaving as an inverse agonist in reducing basal Gαq activation, [3H]inositol-phosphate prodn., and the spontaneous assocn. of h5-HT2CINI-Renilla luciferase receptors with β-arrestin2-yellow fluorescent protein.  Furthermore, upon 18-h pretreatment, S32212 enhanced the plasma membrane expression of h5-HT2CINI receptors as visualized by confocal microscopy and quantified by ELISA.  Its actions were prevented by the neutral antagonist 6-chloro-5-methyl-N-[6-(2-methylpyridin-3-yloxy)pyridin-3-yl]indoline-1-carboxamide (SB242,084), which also impeded the induction by long-term exposure to S32212 of otherwise absent Ca2+ mobilization in mouse cortical neurons.  In vivo, S32212 blunted the inhibitory influence of the 5-HT2C agonist 2-(3-chlorobenzyloxy)-6-(1-piperazinyl)pyrazine (CP809,101) on ventrotegmental dopaminergic neurons.  S32212 also blocked 5-HT-induced Gαq and phospholipase C activation at the h5-HT2A and, less potently, h5-HT2B receptors and suppressed the discriminative stimulus properties of the 5-HT2A agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane in rats.  S32212 manifested marked affinity for human α2A- (pKi 7.2), α2B- (pKi 8.2), and α2C- (pKi 7.4) adrenoceptors, at which it abolished noradrenaline-induced recruitment of Gαi3, Gαo, adenylyl cyclase, and extracellular-regulated kinase1/2.  Moreover, S32212 dose-dependently abolished the discriminative stimulus effects of the α2-adrenoceptor agonist (S)-spiro[(1-oxa-2-amino-3-azacyclopent-2-ene)-4,2'-(1',2',3',4'-tetrahydronaphthalene)] (S18616).  Finally, S32212 displayed negligible affinity for α1A-adrenoceptors, histamine H1 receptors, and muscarinic M1 receptors.  In conclusion, S32212 behaves as an inverse agonist at h5-HT2C receptors and as an antagonist at human α2-adrenoceptors (and h5-HT2A receptors).  Its promising profile in preclin. models potentially relevant to the treatment of depression is described in.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpURy5Z1iERUrVg90H21EOLACvtfcHk0lj1VrBZHl7hiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtVSksrY%253D&md5=9dc9462928ba6309d72a6a36179e71d9</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187468%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DM.%2BJ.%26aulast%3DMannoury%2Bla%2BCour%26aufirst%3DC.%26aulast%3DChanrion%26aufirst%3DB.%26aulast%3DDupuis%26aufirst%3DD.%2BS.%26aulast%3DDi%2BCara%26aufirst%3DB.%26aulast%3DAudinot%26aufirst%3DV.%26aulast%3DCussac%26aufirst%3DD.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26aulast%3DKamal%26aufirst%3DM.%26aulast%3DBoutin%26aufirst%3DJ.%2BA.%26aulast%3DJockers%26aufirst%3DR.%26aulast%3DMarin%26aufirst%3DP.%26aulast%3DBockaert%26aufirst%3DJ.%26aulast%3DMuller%26aufirst%3DO.%26aulast%3DDekeyne%26aufirst%3DA.%26aulast%3DLavielle%26aufirst%3DG.%26atitle%3DS32212%252C%2520a%2520Novel%2520Serotonin%2520Type%25202C%2520Receptor%2520Inverse%2520Agonist%252F%25202-Adrenoceptor%2520Antagonist%2520and%2520Potential%2520Antidepressant%253A%2520I.%2520A%2520Mechanistic%2520Characterization%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D340%26issue%3D3%26spage%3D750%26epage%3D764%26doi%3D10.1124%2Fjpet.111.187468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">East, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, L. L.</span></span> <span> </span><span class="NLM_article-title">Multitarget Ligands in Antibacterial Research: Progress and Opportunities</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1517/17460441.2013.743991</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1517%2F17460441.2013.743991" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=143-156&issue=2&author=S.+P.+Eastauthor=L.+L.+Silver&title=Multitarget+Ligands+in+Antibacterial+Research%3A+Progress+and+Opportunities&doi=10.1517%2F17460441.2013.743991"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1517%2F17460441.2013.743991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2013.743991%26sid%3Dliteratum%253Aachs%26aulast%3DEast%26aufirst%3DS.%2BP.%26aulast%3DSilver%26aufirst%3DL.%2BL.%26atitle%3DMultitarget%2520Ligands%2520in%2520Antibacterial%2520Research%253A%2520Progress%2520and%2520Opportunities%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2013%26volume%3D8%26issue%3D2%26spage%3D143%26epage%3D156%26doi%3D10.1517%2F17460441.2013.743991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, R.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, W.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, D.-F.</span></span> <span> </span><span class="NLM_article-title">Designing Multi-Targeted Agents: An Emerging Anticancer Drug Discovery Paradigm</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.ejmech.2017.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28494256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsV2rtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2017&pages=195-211&author=R.-G.+Fuauthor=Y.+Sunauthor=W.-B.+Shengauthor=D.-F.+Liao&title=Designing+Multi-Targeted+Agents%3A+An+Emerging+Anticancer+Drug+Discovery+Paradigm&doi=10.1016%2Fj.ejmech.2017.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Designing multi-targeted agents: An emerging anticancer drug discovery paradigm</span></div><div class="casAuthors">Fu, Rong-geng; Sun, Yuan; Sheng, Wen-bing; Liao, Duan-fang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">195-211</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is to design ligands with max. selectivity to act on individual drug targets.  With the target-based approach, many new chem. entities have been discovered, developed, and further approved as drugs.  However, there are a large no. of complex diseases such as cancer that cannot be effectively treated or cured only with one medicine to modulate the biol. function of a single target.  As simultaneous intervention of two (or multiple) cancer progression relevant targets has shown improved therapeutic efficacy, the innovation of multi-targeted drugs has become a promising and prevailing research topic and numerous multi-targeted anticancer agents are currently at various developmental stages.  However, most multi-pharmacophore scaffolds are usually discovered by serendipity or screening, while rational design by combining existing pharmacophore scaffolds remains an enormous challenge.  In this review, four types of multi-pharmacophore modes are discussed, and the examples from literature will be used to introduce attractive lead compds. with the capability of simultaneously interfering with different enzyme or signaling pathway of cancer progression, which will reveal the trends and insights to help the design of the next generation multi-targeted anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGjXR-zscrArVg90H21EOLACvtfcHk0lj1VrBZHl7hiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsV2rtL8%253D&md5=511561bd2cd186d5dafa905b7257bf32</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DR.-G.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DW.-B.%26aulast%3DLiao%26aufirst%3DD.-F.%26atitle%3DDesigning%2520Multi-Targeted%2520Agents%253A%2520An%2520Emerging%2520Anticancer%2520Drug%2520Discovery%2520Paradigm%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D136%26spage%3D195%26epage%3D211%26doi%3D10.1016%2Fj.ejmech.2017.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raghavendra, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pingili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadasi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mettu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, S. V. U. M.</span></span> <span> </span><span class="NLM_article-title">Dual or Multi-Targeting Inhibitors: The next Generation Anticancer Agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">1277</span>– <span class="NLM_lpage">1300</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.10.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.ejmech.2017.10.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29126724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslyrt7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=1277-1300&author=N.+M.+Raghavendraauthor=D.+Pingiliauthor=S.+Kadasiauthor=A.+Mettuauthor=S.+V.+U.+M.+Prasad&title=Dual+or+Multi-Targeting+Inhibitors%3A+The+next+Generation+Anticancer+Agents&doi=10.1016%2Fj.ejmech.2017.10.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Dual or multi-targeting inhibitors: The next generation anticancer agents</span></div><div class="casAuthors">Raghavendra, Nulgumnalli Manjunathaiah; Pingili, Divya; Kadasi, Sundeep; Mettu, Akhila; Prasad, S. V. U. M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1277-1300</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Dual-targeting/Multi-targeting of oncoproteins by a single drug mol. represents an efficient, logical and alternative approach to drug combinations.  An increasing interest in this approach is indicated by a steady upsurge in the no. of articles on targeting dual/multi proteins published in the last 5 years.  Combining different inhibitors that destiny specific single target is the std. treatment for cancer.  A new generation of dual or multi-targeting drugs is emerging, where a single chem. entity can act on multiple mol. targets.  Dual/Multi-targeting agents are beneficial for solving limited efficiencies, poor safety and resistant profiles of an individual target.  Designing dual/multi-target inhibitors with predefined biol. profiles present a challenge.  The latest advances in bioinformatic tools and the availability of detailed structural information of target proteins have shown a way of discovering multi-targeting mols.  This neoteric artifice that amalgamates the mol. docking of small mols. with protein-based common pharmacophore to design multi-targeting inhibitors is gaining great importance in anticancer drug discovery.  Current review focus on the discoveries of dual targeting agents in cancer therapy using rational, computational, proteomic, bioinformatics and polypharmacol. approach that enables the discovery and rational design of effective and safe multi-target anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVpBUpxW1okLVg90H21EOLACvtfcHk0lhf-PaRNAXFRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslyrt7jO&md5=a14783194c23f7dc5f200cf6eabf9269</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.10.021%26sid%3Dliteratum%253Aachs%26aulast%3DRaghavendra%26aufirst%3DN.%2BM.%26aulast%3DPingili%26aufirst%3DD.%26aulast%3DKadasi%26aufirst%3DS.%26aulast%3DMettu%26aufirst%3DA.%26aulast%3DPrasad%26aufirst%3DS.%2BV.%2BU.%2BM.%26atitle%3DDual%2520or%2520Multi-Targeting%2520Inhibitors%253A%2520The%2520next%2520Generation%2520Anticancer%2520Agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D1277%26epage%3D1300%26doi%3D10.1016%2Fj.ejmech.2017.10.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petrelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valabrega, G.</span></span> <span> </span><span class="NLM_article-title">Multitarget Drugs: The Present and the Future of Cancer Therapy</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1517/14656560902781907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1517%2F14656560902781907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=19284362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtF2mu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=589-600&issue=4&author=A.+Petrelliauthor=G.+Valabrega&title=Multitarget+Drugs%3A+The+Present+and+the+Future+of+Cancer+Therapy&doi=10.1517%2F14656560902781907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget drugs: the present and the future of cancer therapy</span></div><div class="casAuthors">Petrelli, Annalisa; Valabrega, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">589-600</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Target therapies for the treatment of human cancers have revolutionized the concept of oncol. medicine.  This type of therapeutic approach is directed to the inhibition of mol. targets that play a pivotal role in tumor progression - such as tyrosine kinase receptors (TKIs) controlling cell proliferation and survival - mainly by means of compds. able to block their activity.  In the beginning, the aim of target therapies was specifically to hit a single mol. expressed in neoplastic cells.  Now the prevailing idea is that inhibiting both cancer cells and cells of the stroma supporting the tumor would gain better results in fighting the disease.  Therefore, the single-target therapy is fading in favor of a multitarget approach and the new generation of TKIs is selected on the basis of their ability simultaneously to target different mols.  This review summarizes the mol. basis of multitarget therapies and the most relevant results obtained in different cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSM1xsRJGBX7Vg90H21EOLACvtfcHk0lhf-PaRNAXFRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtF2mu70%253D&md5=c84e048407e6d9354a1f4a595fb4a468</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1517%2F14656560902781907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656560902781907%26sid%3Dliteratum%253Aachs%26aulast%3DPetrelli%26aufirst%3DA.%26aulast%3DValabrega%26aufirst%3DG.%26atitle%3DMultitarget%2520Drugs%253A%2520The%2520Present%2520and%2520the%2520Future%2520of%2520Cancer%2520Therapy%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2009%26volume%3D10%26issue%3D4%26spage%3D589%26epage%3D600%26doi%3D10.1517%2F14656560902781907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Z.</span></span> <span> </span><span class="NLM_article-title">Co-Targeting Cancer Drug Escape Pathways Confers Clinical Advantage for Multi-Target Anticancer Drugs</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2015.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.phrs.2015.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=26438971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1ShtbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2015&pages=123-131&author=L.+Taoauthor=F.+Zhuauthor=F.+Xuauthor=Z.+Chenauthor=Y.+Y.+Jiangauthor=Y.+Z.+Chen&title=Co-Targeting+Cancer+Drug+Escape+Pathways+Confers+Clinical+Advantage+for+Multi-Target+Anticancer+Drugs&doi=10.1016%2Fj.phrs.2015.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs</span></div><div class="casAuthors">Tao, Lin; Zhu, Feng; Xu, Feng; Chen, Zhe; Jiang, Yu Yang; Chen, Yu Zong</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">123-131</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Recent investigations have suggested that anticancer therapeutics may be enhanced by co-targeting the primary anticancer target and the corresponding drug escape pathways.  Whether this strategy confers statistically significant clin. advantage has not been systematically investigated.  This question was probed by the evaluation of the clin. status and the multiple targets of 23 approved and 136 clin. trial multi-target anticancer drugs with particular focus on those co-targeting EGFR, HER2, Abl, VEGFR2, mTOR, PI3K, Alk, MEK, KIT, and DNA topoisomerase, and some of the 14, 7, 13, 20, 6, 5, 7, 2, 4 and 10 cancer drug escape pathways resp.  Most of the approved (73.9%) and phase III (75.0%), the majority of the Phase II (62.8%) and I (53.6%), and the minority of the discontinued (35.3%) multi-target drugs were found to co-target cancer drug escape pathways.  This suggests that co-targeting anticancer targets and drug escape pathways confer significant clin. advantage and such strategy can be more extensively explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZKuYkoBNEebVg90H21EOLACvtfcHk0lhf-PaRNAXFRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1ShtbnM&md5=8596b0d20f94e8e4ec7d74f6cb5c618a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2015.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2015.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DY.%2BY.%26aulast%3DChen%26aufirst%3DY.%2BZ.%26atitle%3DCo-Targeting%2520Cancer%2520Drug%2520Escape%2520Pathways%2520Confers%2520Clinical%2520Advantage%2520for%2520Multi-Target%2520Anticancer%2520Drugs%26jtitle%3DPharmacol.%2520Res.%26date%3D2015%26volume%3D102%26spage%3D123%26epage%3D131%26doi%3D10.1016%2Fj.phrs.2015.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gattrell, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, M.</span></span> <span> </span><span class="NLM_article-title">Designed Multiple Ligands in Metabolic Disease Research: From Concept to Platform</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">15–16</span>),  <span class="NLM_fpage">692</span>– <span class="NLM_lpage">696</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.drudis.2013.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=23454344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVertL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=692-696&issue=15%E2%80%9316&author=W.+Gattrellauthor=C.+Johnstoneauthor=S.+Patelauthor=C.+S.+Smithauthor=A.+Scheelauthor=M.+Schindler&title=Designed+Multiple+Ligands+in+Metabolic+Disease+Research%3A+From+Concept+to+Platform&doi=10.1016%2Fj.drudis.2013.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Designed multiple ligands in metabolic disease research: from concept to platform</span></div><div class="casAuthors">Gattrell, W.; Johnstone, C.; Patel, S.; Smith, C. Sambrook; Scheel, A.; Schindler, M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15-16</span>),
    <span class="NLM_cas:pages">692-696</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Type 2 diabetes mellitus (T2DM) is a multifactorial disease, and drug monotherapy typically results in unsatisfactory treatment outcomes for patients.  Even when used in combination, existing therapies lack efficacy in the long term.  Designed multiple ligands (DMLs) are compds. developed to modulate multiple targets relevant to a disease.  DMLs offer the potential to yield greater efficacy over monotherapies, either by modulating different biol. pathways, or by boosting a single one.  However, examples of DMLs progressing into clin. trials, or onto the market are rare; DML drug discovery is challenging, and perceived by some to be almost impossible.  Nevertheless, with the judicious selection of biol. targets, both from a biol. and chem. perspective, it is possible to develop drug-like DMLs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqsRea2XH7-7Vg90H21EOLACvtfcHk0lhf-PaRNAXFRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVertL8%253D&md5=56204a6c37b64ee11d3f6bd617cad00b</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DGattrell%26aufirst%3DW.%26aulast%3DJohnstone%26aufirst%3DC.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DC.%2BS.%26aulast%3DScheel%26aufirst%3DA.%26aulast%3DSchindler%26aufirst%3DM.%26atitle%3DDesigned%2520Multiple%2520Ligands%2520in%2520Metabolic%2520Disease%2520Research%253A%2520From%2520Concept%2520to%2520Platform%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26issue%3D15%25E2%2580%259316%26spage%3D692%26epage%3D696%26doi%3D10.1016%2Fj.drudis.2013.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gellrich, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Potential of Peroxisome Proliferator-Activated Receptor Modulation in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis</span>. <i>Nucl. Recept. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">101310</span>, <span class="refDoi"> DOI: 10.11131/2017/101310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.11131%2F2017%2F101310" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2017&pages=101310&author=L.+Gellrichauthor=D.+Merk&title=Therapeutic+Potential+of+Peroxisome+Proliferator-Activated+Receptor+Modulation+in+Non-Alcoholic+Fatty+Liver+Disease+and+Non-Alcoholic+Steatohepatitis&doi=10.11131%2F2017%2F101310"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.11131%2F2017%2F101310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.11131%252F2017%252F101310%26sid%3Dliteratum%253Aachs%26aulast%3DGellrich%26aufirst%3DL.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DTherapeutic%2520Potential%2520of%2520Peroxisome%2520Proliferator-Activated%2520Receptor%2520Modulation%2520in%2520Non-Alcoholic%2520Fatty%2520Liver%2520Disease%2520and%2520Non-Alcoholic%2520Steatohepatitis%26jtitle%3DNucl.%2520Recept.%2520Res.%26date%3D2017%26volume%3D4%26spage%3D101310%26doi%3D10.11131%2F2017%2F101310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bisi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobbi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belluti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampa, A.</span></span> <span> </span><span class="NLM_article-title">Design of Multifunctional Compounds for Cardiovascular Disease: From Natural Scaffolds to “Classical” Multitarget Approach</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1759</span>– <span class="NLM_lpage">1782</span>, <span class="refDoi"> DOI: 10.2174/0929867311320130012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F0929867311320130012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=23410171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotl2juro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1759-1782&issue=13&author=A.+Bisiauthor=S.+Gobbiauthor=F.+Bellutiauthor=A.+Rampa&title=Design+of+Multifunctional+Compounds+for+Cardiovascular+Disease%3A+From+Natural+Scaffolds+to+%E2%80%9CClassical%E2%80%9D+Multitarget+Approach&doi=10.2174%2F0929867311320130012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Design of multifunctional compounds for cardiovascular disease: from natural scaffolds to "classical" multitarget approach</span></div><div class="casAuthors">Bisi, A.; Gobbi, S.; Belluti, F.; Rampa, A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1759-1782</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cardiovascular disease represents the main cause of death worldwide.  Novel therapies to reduce elevated blood pressure and treat resistant hypertension, to consequently reduce the assocd. cardiovascular risk factors, are still required.  Among the different strategies commonly used in medicinal chem. to develop new mols., the synthesis of multitarget/hybrid compds. combining two or more pharmacophore groups targeting simultaneously selected factors involved in cardiovascular diseases, has gained increasing interest.  This review will focus on the most recent literature on multifunctional cardiovascular drugs, paying particular attention on hybrid compds. bearing natural scaffolds, considering that compds. derived from medicinal exts. are generally appealing for the medicinal chemist as they often bear the so-called "privileged structures".  Moreover, taking into account many excellent reviews dealing with multitarget cardiovascular drugs published in the last few years, mainly devoted to RAAS inhibition and/or NO donors hybrid drugs, herein the most significant results obtained and the benefits and limitations of these approaches will be highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBZAxoIKJrM7Vg90H21EOLACvtfcHk0lj0RIbDzJHfUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotl2juro%253D&md5=0d6cdd19a2850a461b8b4c576caabd2f</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2174%2F0929867311320130012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320130012%26sid%3Dliteratum%253Aachs%26aulast%3DBisi%26aufirst%3DA.%26aulast%3DGobbi%26aufirst%3DS.%26aulast%3DBelluti%26aufirst%3DF.%26aulast%3DRampa%26aufirst%3DA.%26atitle%3DDesign%2520of%2520Multifunctional%2520Compounds%2520for%2520Cardiovascular%2520Disease%253A%2520From%2520Natural%2520Scaffolds%2520to%2520%25E2%2580%259CClassical%25E2%2580%259D%2520Multitarget%2520Approach%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26issue%3D13%26spage%3D1759%26epage%3D1782%26doi%3D10.2174%2F0929867311320130012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span>; <span class="NLM_string-name">Schubert-Zsilavecz, M.</span></span> <span> </span><span class="NLM_article-title">The Linker Approach: Drug Conjugates</span>. In  <i>Drug Selectivity</i>; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>, <span class="NLM_year">2017</span>; pp  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">245</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2F9783527674381.ch8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=207-245&author=D.+Merk&author=M.+Schubert-Zsilavecz&title=Drug+Selectivity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2F9783527674381.ch8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527674381.ch8%26sid%3Dliteratum%253Aachs%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DThe%2520Linker%2520Approach%253A%2520Drug%2520Conjugates%26btitle%3DDrug%2520Selectivity%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2017%26spage%3D207%26epage%3D245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chittasupho, C.</span></span> <span> </span><span class="NLM_article-title">Multivalent Ligand: Design Principle for Targeted Therapeutic Delivery Approach</span>. <i>Ther. Delivery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1171</span>– <span class="NLM_lpage">1187</span>, <span class="refDoi"> DOI: 10.4155/tde.12.99</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.4155%2Ftde.12.99" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=23116010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFCrurbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1171-1187&issue=10&author=C.+Chittasupho&title=Multivalent+Ligand%3A+Design+Principle+for+Targeted+Therapeutic+Delivery+Approach&doi=10.4155%2Ftde.12.99"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Multivalent ligand: design principle for targeted therapeutic delivery approach</span></div><div class="casAuthors">Chittasupho, Chuda</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Delivery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1171-1187</span>CODEN:
                <span class="NLM_cas:coden">TDHEA7</span>;
        ISSN:<span class="NLM_cas:issn">2041-5990</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Multivalent interactions of biol. mols. play an important role in many biochem. events.  A multivalent ligand comprises of multiple copies of ligands conjugated to scaffolds, allowing the simultaneous binding of multivalent ligands to multiple binding sites or receptors.  Many research groups have successfully designed and synthesized multivalent ligands to increase the binding affinity, avidity and specificity of the ligand to the receptor.  A multimeric ligand is a promising option for the specific treatment of diseases.  In this review, the factors affecting multivalent interactions, including the size and shape of the ligand, geometry and an arrangement of ligands on the scaffold, linker length, thermodn., and kinetics of the interactions are discussed.  Examples of the multivalent ligand applications for therapeutic delivery are also summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWWDU1KszkuLVg90H21EOLACvtfcHk0lj0RIbDzJHfUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFCrurbJ&md5=0b30d1d1675cfb7bbdc38dfbf7168b7e</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.4155%2Ftde.12.99&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ftde.12.99%26sid%3Dliteratum%253Aachs%26aulast%3DChittasupho%26aufirst%3DC.%26atitle%3DMultivalent%2520Ligand%253A%2520Design%2520Principle%2520for%2520Targeted%2520Therapeutic%2520Delivery%2520Approach%26jtitle%3DTher.%2520Delivery%26date%3D2012%26volume%3D3%26issue%3D10%26spage%3D1171%26epage%3D1187%26doi%3D10.4155%2Ftde.12.99" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minarini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumiatti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recanatini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchiorre, C.</span></span> <span> </span><span class="NLM_article-title">Multi-Target-Directed Ligands to Combat Neurodegenerative Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1021/jm7009364</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7009364" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=347-372&issue=3&author=A.+Cavalliauthor=M.+L.+Bolognesiauthor=A.+Minariniauthor=M.+Rosiniauthor=V.+Tumiattiauthor=M.+Recanatiniauthor=C.+Melchiorre&title=Multi-Target-Directed+Ligands+to+Combat+Neurodegenerative+Diseases&doi=10.1021%2Fjm7009364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target-Directed Ligands to Combat Neurodegenerative Diseases</span></div><div class="casAuthors">Cavalli, Andrea; Bolognesi, Maria Laura; Minarini, Anna; Rosini, Michela; Tumiatti, Vincenzo; Recanatini, Maurizio; Melchiorre, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-372</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The authors review the investigations reported in the past decade that illustrate the ability of medicinal chemists to design multi-target-directed ligands (MTDLs) to confront neurodegenerative diseases.  The authors briefly illustrate the multifactorial nature of these diseases before discussing the possible development of MTDLs in light of the known mol. bases of the main neurodegenerative pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYY0I0UHEir7Vg90H21EOLACvtfcHk0lh979HBN3VPSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D&md5=c682235151489316d043cf97f78e56f3</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm7009364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7009364%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DMinarini%26aufirst%3DA.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DTumiatti%26aufirst%3DV.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DMulti-Target-Directed%2520Ligands%2520to%2520Combat%2520Neurodegenerative%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D3%26spage%3D347%26epage%3D372%26doi%3D10.1021%2Fjm7009364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antolin, A.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Lazikani, B.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology in Precision Oncology: Current Applications and Future Prospects</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">46</span>),  <span class="NLM_fpage">6935</span>– <span class="NLM_lpage">6945</span>, <span class="refDoi"> DOI: 10.2174/1381612822666160923115828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F1381612822666160923115828" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=6935-6945&issue=46&author=A.%0AA.+Antolinauthor=P.+Workmanauthor=J.+Mestresauthor=B.+Al-Lazikani&title=Polypharmacology+in+Precision+Oncology%3A+Current+Applications+and+Future+Prospects&doi=10.2174%2F1381612822666160923115828"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.2174%2F1381612822666160923115828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612822666160923115828%26sid%3Dliteratum%253Aachs%26aulast%3DAntolin%26aufirst%3DA.%2BA.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DMestres%26aufirst%3DJ.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26atitle%3DPolypharmacology%2520in%2520Precision%2520Oncology%253A%2520Current%2520Applications%2520and%2520Future%2520Prospects%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2016%26volume%3D22%26issue%3D46%26spage%3D6935%26epage%3D6945%26doi%3D10.2174%2F1381612822666160923115828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anighoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: Challenges and Opportunities in Drug Discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">7874</span>– <span class="NLM_lpage">7887</span>, <span class="refDoi"> DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&issue=19&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+Challenges+and+Opportunities+in+Drug+Discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0lh979HBN3VPSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520Challenges%2520and%2520Opportunities%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D19%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Medina-Franco, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giulianotti, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welmaker, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghten, R. A.</span></span> <span> </span><span class="NLM_article-title">Shifting from the Single to the Multitarget Paradigm in Drug Discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">9–10</span>),  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.drudis.2013.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=23340113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC3szhsV2rsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=495-501&issue=9%E2%80%9310&author=J.+L.+Medina-Francoauthor=M.+A.+Giulianottiauthor=G.+S.+Welmakerauthor=R.+A.+Houghten&title=Shifting+from+the+Single+to+the+Multitarget+Paradigm+in+Drug+Discovery&doi=10.1016%2Fj.drudis.2013.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Shifting from the single to the multitarget paradigm in drug discovery</span></div><div class="casAuthors">Medina-Franco Jose L; Giulianotti Marc A; Welmaker Gregory S; Houghten Richard A</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9-10</span>),
    <span class="NLM_cas:pages">495-501</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Increasing evidence that several drug compounds exert their effects through interactions with multiple targets is boosting the development of research fields that challenge the data reductionism approach.  In this article, we review and discuss the concepts of drug repurposing, polypharmacology, chemogenomics, phenotypic screening and high-throughput in vivo testing of mixture-based libraries in an integrated manner.  These research fields offer alternatives to the current paradigm of drug discovery, from a one target-one drug model to a multiple-target approach.  Furthermore, the goals of lead identification are being expanded accordingly to identify not only 'key' compounds that fit with a single-target 'lock', but also 'master key' compounds that favorably interact with multiple targets (i.e. operate a set of desired locks to gain access to the expected clinical effects).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOFtVP-kWcL7qxQ2mb9Pu8fW6udTcc2eY-0UdfXCYDJbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szhsV2rsQ%253D%253D&md5=b4f8c7d1ebbbf32ed4c6c87500baf66f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DMedina-Franco%26aufirst%3DJ.%2BL.%26aulast%3DGiulianotti%26aufirst%3DM.%2BA.%26aulast%3DWelmaker%26aufirst%3DG.%2BS.%26aulast%3DHoughten%26aufirst%3DR.%2BA.%26atitle%3DShifting%2520from%2520the%2520Single%2520to%2520the%2520Multitarget%2520Paradigm%2520in%2520Drug%2520Discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26issue%3D9%25E2%2580%259310%26spage%3D495%26epage%3D501%26doi%3D10.1016%2Fj.drudis.2013.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aronson, J. K.</span></span> <span> </span><span class="NLM_article-title">In Defence of Polypharmacy</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2004.02067.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1111%2Fj.1365-2125.2004.02067.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=14748809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252FkvVWmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2004&pages=119-120&issue=2&author=J.+K.+Aronson&title=In+Defence+of+Polypharmacy&doi=10.1111%2Fj.1365-2125.2004.02067.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">In defence of polypharmacy</span></div><div class="casAuthors">Aronson J K</div><div class="citationInfo"><span class="NLM_cas:title">British journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-20</span>
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKzbWDkHe77v3jf77P2BG3fW6udTcc2eY-0UdfXCYDJbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252FkvVWmsA%253D%253D&md5=2f5c4c1825dd2de6229a02136b716a8d</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2004.02067.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2004.02067.x%26sid%3Dliteratum%253Aachs%26aulast%3DAronson%26aufirst%3DJ.%2BK.%26atitle%3DIn%2520Defence%2520of%2520Polypharmacy%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2004%26volume%3D57%26issue%3D2%26spage%3D119%26epage%3D120%26doi%3D10.1111%2Fj.1365-2125.2004.02067.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brückmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agbaba, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology of Dopamine Receptor Ligands</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1016/j.pneurobio.2016.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.pneurobio.2016.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27234980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC28XptVCmsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2016&pages=68-103&author=S.+Butiniauthor=K.+Nikolicauthor=S.+Kasselauthor=H.+Br%C3%BCckmannauthor=S.+Filipicauthor=D.+Agbabaauthor=S.+Gemmaauthor=S.+Brogiauthor=M.+Brindisiauthor=G.+Campianiauthor=H.+Stark&title=Polypharmacology+of+Dopamine+Receptor+Ligands&doi=10.1016%2Fj.pneurobio.2016.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology of dopamine receptor ligands</span></div><div class="casAuthors">Butini, S.; Nikolic, K.; Kassel, S.; Bruckmann, H.; Filipic, S.; Agbaba, D.; Gemma, S.; Brogi, S.; Brindisi, M.; Campiani, G.; Stark, H.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">68-103</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Most neurol. diseases have a multifactorial nature and the no. of mol. mechanisms discovered as underpinning these diseases is continuously evolving.  The old concept of developing selective agents for a single target does not fit with the medical need of most neurol. diseases.  The development of designed multiple ligands holds great promises and appears as the next step in drug development for the treatment of these multifactorial diseases.  Dopamine and its five receptor subtypes are intimately involved in numerous neurol. disorders.  Dopamine receptor ligands display a high degree of cross interactions with many other targets including G-protein coupled receptors, transporters, enzymes and ion channels.  For brain disorders like Parkinsons disease, schizophrenia and depression the dopaminergic system, being intertwined with many other signaling systems, plays a key role in pathogenesis and therapy.  The concept of designed multiple ligands and polypharmacol., which perfectly meets the therapeutic needs for these brain disorders, is herein discussed as a general ligand-based concept while focusing on dopaminergic agents and receptor subtypes in particular.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroyjxwUVpuobVg90H21EOLACvtfcHk0li7Iik7W1x_fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptVCmsLk%253D&md5=4e518d55c2b25e20b56a0ac4c5ff117c</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2016.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2016.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DButini%26aufirst%3DS.%26aulast%3DNikolic%26aufirst%3DK.%26aulast%3DKassel%26aufirst%3DS.%26aulast%3DBr%25C3%25BCckmann%26aufirst%3DH.%26aulast%3DFilipic%26aufirst%3DS.%26aulast%3DAgbaba%26aufirst%3DD.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DBrogi%26aufirst%3DS.%26aulast%3DBrindisi%26aufirst%3DM.%26aulast%3DCampiani%26aufirst%3DG.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DPolypharmacology%2520of%2520Dopamine%2520Receptor%2520Ligands%26jtitle%3DProg.%2520Neurobiol.%26date%3D2016%26volume%3D142%26spage%3D68%26epage%3D103%26doi%3D10.1016%2Fj.pneurobio.2016.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cook, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">March, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pangalos, M. N.</span></span> <span> </span><span class="NLM_article-title">Lessons Learned from the Fate of AstraZeneca’s Drug Pipeline: A Five-Dimensional Framework</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1038/nrd4309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnrd4309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=24833294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVyqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=419-431&issue=6&author=D.+Cookauthor=D.+Brownauthor=R.+Alexanderauthor=R.+Marchauthor=P.+Morganauthor=G.+Satterthwaiteauthor=M.+N.+Pangalos&title=Lessons+Learned+from+the+Fate+of+AstraZeneca%E2%80%99s+Drug+Pipeline%3A+A+Five-Dimensional+Framework&doi=10.1038%2Fnrd4309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework</span></div><div class="casAuthors">Cook, David; Brown, Dearg; Alexander, Robert; March, Ruth; Morgan, Paul; Satterthwaite, Gemma; Pangalos, Menelas N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">419-431</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Maintaining research and development (R&D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry.  In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-mol. drug projects from 2005 to 2010.  The anal. allowed us to establish a framework based on the five most important tech. determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right com. potential.  A sixth factor - the right culture - is also crucial in encouraging effective decision-making based on these tech. determinants.  AstraZeneca is currently applying this framework to guide its R&D teams, and although it is too early to demonstrate whether this has improved the company's R&D productivity, we present our data and anal. here in the hope that it may assist the industry overall in addressing this key challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4yhPFZOUNO7Vg90H21EOLACvtfcHk0li7Iik7W1x_fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVyqtrw%253D&md5=746a86c7223f170f7e6c4f9817760e5b</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnrd4309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4309%26sid%3Dliteratum%253Aachs%26aulast%3DCook%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DAlexander%26aufirst%3DR.%26aulast%3DMarch%26aufirst%3DR.%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DSatterthwaite%26aufirst%3DG.%26aulast%3DPangalos%26aufirst%3DM.%2BN.%26atitle%3DLessons%2520Learned%2520from%2520the%2520Fate%2520of%2520AstraZeneca%25E2%2580%2599s%2520Drug%2520Pipeline%253A%2520A%2520Five-Dimensional%2520Framework%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26issue%3D6%26spage%3D419%26epage%3D431%26doi%3D10.1038%2Fnrd4309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miceli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altucci, L.</span></span> <span> </span><span class="NLM_article-title">Targeting Epigenetic Networks with Polypharmacology: A New Avenue to Tackle Cancer</span>. <i>Epigenomics</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">742</span>, <span class="refDoi"> DOI: 10.2217/epi.10.62</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2217%2Fepi.10.62" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=731-742&issue=6&author=G.+Franciauthor=M.+Miceliauthor=L.+Altucci&title=Targeting+Epigenetic+Networks+with+Polypharmacology%3A+A+New+Avenue+to+Tackle+Cancer&doi=10.2217%2Fepi.10.62"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.2217%2Fepi.10.62&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fepi.10.62%26sid%3Dliteratum%253Aachs%26aulast%3DFranci%26aufirst%3DG.%26aulast%3DMiceli%26aufirst%3DM.%26aulast%3DAltucci%26aufirst%3DL.%26atitle%3DTargeting%2520Epigenetic%2520Networks%2520with%2520Polypharmacology%253A%2520A%2520New%2520Avenue%2520to%2520Tackle%2520Cancer%26jtitle%3DEpigenomics%26date%3D2010%26volume%3D2%26issue%3D6%26spage%3D731%26epage%3D742%26doi%3D10.2217%2Fepi.10.62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lötsch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span> <span> </span><span class="NLM_article-title">Low-Dose Drug Combinations along Molecular Pathways Could Maximize Therapeutic Effectiveness While Minimizing Collateral Adverse Effects</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">23–24</span>),  <span class="NLM_fpage">1001</span>– <span class="NLM_lpage">1006</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.drudis.2011.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=22016087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FjtVygtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=1001-1006&issue=23%E2%80%9324&author=J.+L%C3%B6tschauthor=G.+Geisslinger&title=Low-Dose+Drug+Combinations+along+Molecular+Pathways+Could+Maximize+Therapeutic+Effectiveness+While+Minimizing+Collateral+Adverse+Effects&doi=10.1016%2Fj.drudis.2011.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects</span></div><div class="casAuthors">Lotsch Jorn; Geisslinger Gerd</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">23-24</span>),
    <span class="NLM_cas:pages">1001-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Increasing knowledge of molecular signaling processes has enabled the identification of drug targets that synergistically address multifactorial symptoms along several contributing pathways.  The idea behind 'polypills' is that minor doses of pharmacodynamically interacting drugs would selectively achieve intended clinical effects.  Analogously, monofactorial symptoms could be addressed vertically along their main pathway.  Clinical selectivity follows from successive incomplete inhibitions of the pathological pathway at several steps.  Here, we discuss and exemplify of how successive inhibitions in the prostaglandin E2 (PGE(2)) signaling pathway could achieve anti-inflammatory and analgesic effects while preserving physiological PGE(2) signaling in organs of major toxicity.  Intentionally using intelligent low-dose drug combinations might provide an innovative therapeutic concept that directs combined small-drug effects towards a large, selective clinical effect with minor collateral damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRu7M3C_0-j-dfST00W0BcfW6udTcc2ebZ3AUF3QtiP7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FjtVygtg%253D%253D&md5=f88337f88016a3736e13e493dc064089</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6tsch%26aufirst%3DJ.%26aulast%3DGeisslinger%26aufirst%3DG.%26atitle%3DLow-Dose%2520Drug%2520Combinations%2520along%2520Molecular%2520Pathways%2520Could%2520Maximize%2520Therapeutic%2520Effectiveness%2520While%2520Minimizing%2520Collateral%2520Adverse%2520Effects%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26issue%3D23%25E2%2580%259324%26spage%3D1001%26epage%3D1006%26doi%3D10.1016%2Fj.drudis.2011.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span> <span> </span><span class="NLM_article-title">The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">e0165737</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0165737</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1371%2Fjournal.pone.0165737" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0165737&issue=11&author=Y.+H.+Liauthor=P.+P.+Wangauthor=X.+X.+Liauthor=C.+Y.+Yuauthor=H.+Yangauthor=J.+Zhouauthor=W.+W.+Xueauthor=J.+Tanauthor=F.+Zhu&title=The+Human+Kinome+Targeted+by+FDA+Approved+Multi-Target+Drugs+and+Combination+Products%3A+A+Comparative+Study+from+the+Drug-Target+Interaction+Network+Perspective&doi=10.1371%2Fjournal.pone.0165737"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0165737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0165737%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%2BH.%26aulast%3DWang%26aufirst%3DP.%2BP.%26aulast%3DLi%26aufirst%3DX.%2BX.%26aulast%3DYu%26aufirst%3DC.%2BY.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DXue%26aufirst%3DW.%2BW.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DF.%26atitle%3DThe%2520Human%2520Kinome%2520Targeted%2520by%2520FDA%2520Approved%2520Multi-Target%2520Drugs%2520and%2520Combination%2520Products%253A%2520A%2520Comparative%2520Study%2520from%2520the%2520Drug-Target%2520Interaction%2520Network%2520Perspective%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26issue%3D11%26spage%3De0165737%26doi%3D10.1371%2Fjournal.pone.0165737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valant, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">Orthosteric/Allosteric Bitopic Ligands: Going Hybrid at GPCRs</span>. <i>Mol. Interventions</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1124/mi.9.3.6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1124%2Fmi.9.3.6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=125-135&issue=3&author=C.+Valantauthor=P.+M.+Sextonauthor=A.+Christopoulos&title=Orthosteric%2FAllosteric+Bitopic+Ligands%3A+Going+Hybrid+at+GPCRs&doi=10.1124%2Fmi.9.3.6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1124%2Fmi.9.3.6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmi.9.3.6%26sid%3Dliteratum%253Aachs%26aulast%3DValant%26aufirst%3DC.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DOrthosteric%252FAllosteric%2520Bitopic%2520Ligands%253A%2520Going%2520Hybrid%2520at%2520GPCRs%26jtitle%3DMol.%2520Interventions%26date%3D2009%26volume%3D9%26issue%3D3%26spage%3D125%26epage%3D135%26doi%3D10.1124%2Fmi.9.3.6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fronik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaiser, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sejer
Pedersen, D.</span></span> <span> </span><span class="NLM_article-title">Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4126</span>– <span class="NLM_lpage">4134</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01601</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01601" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVyktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4126-4134&issue=10&author=P.+Fronikauthor=B.+I.+Gaiserauthor=D.+Sejer%0APedersen&title=Bitopic+Ligands+and+Metastable+Binding+Sites%3A+Opportunities+for+G+Protein-Coupled+Receptor+%28GPCR%29+Medicinal+Chemistry&doi=10.1021%2Facs.jmedchem.6b01601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry</span></div><div class="casAuthors">Fronik, Philipp; Gaiser, Birgit I.; Sejer Pedersen, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4126-4134</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) belong to a large superfamily of membrane receptors mediating a variety of physiol. functions.  As such they are attractive targets for drug therapy.  However, it remains a challenge to develop subtype selective GPCR ligands, due to the high conservation of orthosteric binding sites.  Bitopic ligands have been employed to address the selectivity problem by combining (linking) an orthosteric ligand with an allosteric modulator, theor. leading to high-affinity subtype selective ligands.  However, it remains a challenge to identify suitable allosteric binding sites.  Computational studies on ligand binding to GPCRs have revealed transient, low-affinity binding sites, termed metastable binding sites.  Metastable binding sites may provide a new source of allosteric binding sites that could be exploited in the design of bitopic ligands.  Unlike the bitopic ligands that have been reported to date this type of bitopic ligands would be composed of two identical pharmacophores.  Herein, the authors outline the concept of bitopic ligands, review metastable binding sites and discuss their potential as a new source of allosteric binding sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpihAXt959S37Vg90H21EOLACvtfcHk0ljenPJKitcg2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVyktbw%253D&md5=a20875145b65a948c772e988ff1217bc</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01601%26sid%3Dliteratum%253Aachs%26aulast%3DFronik%26aufirst%3DP.%26aulast%3DGaiser%26aufirst%3DB.%2BI.%26aulast%3DSejer%2BPedersen%26aufirst%3DD.%26atitle%3DBitopic%2520Ligands%2520and%2520Metastable%2520Binding%2520Sites%253A%2520Opportunities%2520for%2520G%2520Protein-Coupled%2520Receptor%2520%2528GPCR%2529%2520Medicinal%2520Chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D10%26spage%3D4126%26epage%3D4134%26doi%3D10.1021%2Facs.jmedchem.6b01601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goebel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angioni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurglics, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahnt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhilber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase to Counter Nonalcoholic Steatohepatitis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">7703</span>– <span class="NLM_lpage">7724</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00398</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00398" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtl2ls73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7703-7724&issue=18&author=J.+Schmidtauthor=M.+Rotterauthor=T.+Weiserauthor=S.+Wittmannauthor=L.+Weizelauthor=A.+Kaiserauthor=J.+Heeringauthor=T.+Goebelauthor=C.+Angioniauthor=M.+Wurglicsauthor=A.+Paulkeauthor=G.+Geisslingerauthor=A.+Kahntauthor=D.+Steinhilberauthor=E.+Proschakauthor=D.+Merk&title=A+Dual+Modulator+of+Farnesoid+X+Receptor+and+Soluble+Epoxide+Hydrolase+to+Counter+Nonalcoholic+Steatohepatitis&doi=10.1021%2Facs.jmedchem.7b00398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis</span></div><div class="casAuthors">Schmidt, Jurema; Rotter, Marco; Weiser, Tim; Wittmann, Sandra; Weizel, Lilia; Kaiser, Astrid; Heering, Jan; Goebel, Tamara; Angioni, Carlo; Wurglics, Mario; Paulke, Alexander; Geisslinger, Gerd; Kahnt, Astrid; Steinhilber, Dieter; Proschak, Ewgenij; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7703-7724</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonalcoholic steatohepatitis arising from Western diet and lifestyle is characterized by accumulation of fat in liver causing inflammation and fibrosis.  It evolves as serious health burden with alarming incidence, but there is no satisfying pharmacol. therapy to date.  Considering the disease's multifactorial nature, modulation of multiple targets might provide superior therapeutic efficacy.  In particular, farnesoid X receptor (FXR) activation that revealed antisteatotic and antifibrotic effects in clin. trials combined with inhibition of sol. epoxide hydrolase (sEH) as anti-inflammatory strategy promises synergies.  To exploit this dual concept, we developed agents exerting partial FXR agonism and sEH inhibitory activity.  Merging known pharmacophores and systematic exploration of the structure-activity relationship on both targets produced dual modulators with low nanomolar potency.  Extensive in vitro characterization confirmed high dual efficacy in cellular context combined with low toxicity, and pilot in vivo data revealed favorable pharmacokinetics as well as engagement on both targets in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUx3OFEKCgyrVg90H21EOLACvtfcHk0ljenPJKitcg2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtl2ls73J&md5=a35ceea141c78ed9885d7f9a99f4852b</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00398%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DJ.%26aulast%3DRotter%26aufirst%3DM.%26aulast%3DWeiser%26aufirst%3DT.%26aulast%3DWittmann%26aufirst%3DS.%26aulast%3DWeizel%26aufirst%3DL.%26aulast%3DKaiser%26aufirst%3DA.%26aulast%3DHeering%26aufirst%3DJ.%26aulast%3DGoebel%26aufirst%3DT.%26aulast%3DAngioni%26aufirst%3DC.%26aulast%3DWurglics%26aufirst%3DM.%26aulast%3DPaulke%26aufirst%3DA.%26aulast%3DGeisslinger%26aufirst%3DG.%26aulast%3DKahnt%26aufirst%3DA.%26aulast%3DSteinhilber%26aufirst%3DD.%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DA%2520Dual%2520Modulator%2520of%2520Farnesoid%2520X%2520Receptor%2520and%2520Soluble%2520Epoxide%2520Hydrolase%2520to%2520Counter%2520Nonalcoholic%2520Steatohepatitis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D18%26spage%3D7703%26epage%3D7724%26doi%3D10.1021%2Facs.jmedchem.7b00398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunesch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatonnet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohse, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabissi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationships and Computational Investigations into the Development of Potent and Balanced Dual-Acting Butyrylcholinesterase Inhibitors and Human Cannabinoid Receptor 2 Ligands with Pro-Cognitive in Vivo Profiles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1646</span>– <span class="NLM_lpage">1663</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1646-1663&issue=4&author=D.+Dollesauthor=M.+Hoffmannauthor=S.+Guneschauthor=O.+Marinelliauthor=J.+M%C3%B6llerauthor=G.+Santoniauthor=A.+Chatonnetauthor=M.+J.+Lohseauthor=H.+J.+Wittmannauthor=A.+Strasserauthor=M.+Nabissiauthor=T.+Mauriceauthor=M.+Decker&title=Structure-Activity+Relationships+and+Computational+Investigations+into+the+Development+of+Potent+and+Balanced+Dual-Acting+Butyrylcholinesterase+Inhibitors+and+Human+Cannabinoid+Receptor+2+Ligands+with+Pro-Cognitive+in+Vivo+Profiles&doi=10.1021%2Facs.jmedchem.7b01760"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01760%26sid%3Dliteratum%253Aachs%26aulast%3DDolles%26aufirst%3DD.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DGunesch%26aufirst%3DS.%26aulast%3DMarinelli%26aufirst%3DO.%26aulast%3DM%25C3%25B6ller%26aufirst%3DJ.%26aulast%3DSantoni%26aufirst%3DG.%26aulast%3DChatonnet%26aufirst%3DA.%26aulast%3DLohse%26aufirst%3DM.%2BJ.%26aulast%3DWittmann%26aufirst%3DH.%2BJ.%26aulast%3DStrasser%26aufirst%3DA.%26aulast%3DNabissi%26aufirst%3DM.%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DStructure-Activity%2520Relationships%2520and%2520Computational%2520Investigations%2520into%2520the%2520Development%2520of%2520Potent%2520and%2520Balanced%2520Dual-Acting%2520Butyrylcholinesterase%2520Inhibitors%2520and%2520Human%2520Cannabinoid%2520Receptor%25202%2520Ligands%2520with%2520Pro-Cognitive%2520in%2520Vivo%2520Profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D4%26spage%3D1646%26epage%3D1663%26doi%3D10.1021%2Facs.jmedchem.7b01760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Éliás, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovács, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wágner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Némethy, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarcsay, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, I.</span></span> <span> </span><span class="NLM_article-title">Charting the Chemical Space around the (Iso)indoline Scaffold, a Comprehensive Approach towards Multitarget Directed Ligands</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">4211</span>– <span class="NLM_lpage">4215</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.07.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.bmcl.2016.07.055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=4211-4215&issue=17&author=O.+%C3%89li%C3%A1sauthor=Z.+Kov%C3%A1csauthor=G.+W%C3%A1gnerauthor=Z.+N%C3%A9methyauthor=%C3%81.+Tarcsayauthor=I.+Greiner&title=Charting+the+Chemical+Space+around+the+%28Iso%29indoline+Scaffold%2C+a+Comprehensive+Approach+towards+Multitarget+Directed+Ligands&doi=10.1016%2Fj.bmcl.2016.07.055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.07.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.07.055%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2589li%25C3%25A1s%26aufirst%3DO.%26aulast%3DKov%25C3%25A1cs%26aufirst%3DZ.%26aulast%3DW%25C3%25A1gner%26aufirst%3DG.%26aulast%3DN%25C3%25A9methy%26aufirst%3DZ.%26aulast%3DTarcsay%26aufirst%3D%25C3%2581.%26aulast%3DGreiner%26aufirst%3DI.%26atitle%3DCharting%2520the%2520Chemical%2520Space%2520around%2520the%2520%2528Iso%2529indoline%2520Scaffold%252C%2520a%2520Comprehensive%2520Approach%2520towards%2520Multitarget%2520Directed%2520Ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D17%26spage%3D4211%26epage%3D4215%26doi%3D10.1016%2Fj.bmcl.2016.07.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Apsel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nazif, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aizenstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z. A.</span></span> <span> </span><span class="NLM_article-title">Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">691</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.1038/nchembio.117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnchembio.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=18849971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=691-699&issue=11&author=B.+Apselauthor=J.+A.+Blairauthor=B.+Gonzalezauthor=T.+M.+Nazifauthor=M.+E.+Feldmanauthor=B.+Aizensteinauthor=R.+Hoffmanauthor=R.+L.+Williamsauthor=K.+M.+Shokatauthor=Z.+A.+Knight&title=Targeted+Polypharmacology%3A+Discovery+of+Dual+Inhibitors+of+Tyrosine+and+Phosphoinositide+Kinases&doi=10.1038%2Fnchembio.117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases</span></div><div class="casAuthors">Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">691-699</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. success of multitargeted kinase inhibitors has stimulated efforts to identify promiscuous drugs with optimal selectivity profiles.  It remains unclear to what extent such drugs can be rationally designed, particularly for combinations of targets that are structurally divergent.  Here we report the systematic discovery of mols. that potently inhibit both tyrosine kinases and phosphatidylinositol-3-OH kinases, two protein families that are among the most intensely pursued cancer drug targets.  Through iterative chem. synthesis, X-ray crystallog. and kinome-level biochem. profiling, we identified compds. that inhibit a spectrum of new target combinations in these two families.  Crystal structures revealed that the dual selectivity of these mols. is controlled by a hydrophobic pocket conserved in both enzyme classes and accessible through a rotatable bond in the drug skeleton.  We show that compd. I blocks the proliferation of tumor cells by direct inhibition of oncogenic tyrosine kinases and phosphatidylinositol-3-OH kinases.  These mols. demonstrate the feasibility of accessing a chem. space that intersects two families of oncogenes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7xlegha5YF7Vg90H21EOLACvtfcHk0lhz-9D3xA5EnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF&md5=4da10a973f6895f92a644ca82ca5cdcd</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.117%26sid%3Dliteratum%253Aachs%26aulast%3DApsel%26aufirst%3DB.%26aulast%3DBlair%26aufirst%3DJ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%26aulast%3DNazif%26aufirst%3DT.%2BM.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DAizenstein%26aufirst%3DB.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26atitle%3DTargeted%2520Polypharmacology%253A%2520Discovery%2520of%2520Dual%2520Inhibitors%2520of%2520Tyrosine%2520and%2520Phosphoinositide%2520Kinases%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26issue%3D11%26spage%3D691%26epage%3D699%26doi%3D10.1038%2Fnchembio.117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertinaria, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaikh, M. A. A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buccellati, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cena, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolando, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzarato, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruttero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoxha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rovati, G. E.</span></span> <span> </span><span class="NLM_article-title">Designing Multitarget Anti-Inflammatory Agents: Chemical Modulation of the Lumiracoxib Structure toward Dual Thromboxane Antagonists-COX-2 Inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1647</span>– <span class="NLM_lpage">1660</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201200272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fcmdc.201200272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=22865828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFahs7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1647-1660&issue=9&author=M.+Bertinariaauthor=M.+A.+A.+G.+Shaikhauthor=C.+Buccellatiauthor=C.+Cenaauthor=B.+Rolandoauthor=L.+Lazzaratoauthor=R.+Frutteroauthor=A.+Gascoauthor=M.+Hoxhaauthor=V.+Capraauthor=A.+Salaauthor=G.+E.+Rovati&title=Designing+Multitarget+Anti-Inflammatory+Agents%3A+Chemical+Modulation+of+the+Lumiracoxib+Structure+toward+Dual+Thromboxane+Antagonists-COX-2+Inhibitors&doi=10.1002%2Fcmdc.201200272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Designing Multitarget Anti-inflammatory Agents: Chemical Modulation of the Lumiracoxib Structure toward Dual Thromboxane Antagonists-COX-2 Inhibitors</span></div><div class="casAuthors">Bertinaria, Massimo; Shaikh, Mohammed Abrar Abdul Gaffar; Buccellati, Carola; Cena, Clara; Rolando, Barbara; Lazzarato, Loretta; Fruttero, Roberta; Gasco, Alberto; Hoxha, Malvina; Capra, Valerie; Sala, Angelo; Rovati, G. Enrico</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1647-1660</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A series of lumiracoxib derivs. were designed to explore the influence of isosteric substitution on balancing COX-2 inhibition and thromboxane A2 prostanoid (TP) receptor antagonism.  The compds. were synthesized through a copper-catalyzed coupling procedure and characterized for their pKa values.  TP receptor antagonism was assessed on human platelets; COX-2 inhibition was detd. on human isolated monocytes and human whole blood.  TPα receptor binding of the most promising compds. was evaluated through radioligand binding assays.  Some of the isosteric substitutions at the carboxylic acid group afforded compds. with improved TP receptor antagonism; of these, a tetrazole deriv. retained good COX-2 inhibitory activity and selectivity.  The identification of this tetrazole acting as a balanced dual-acting compd. in human whole blood, along with SAR anal. of the synthesized lumiracoxib derivs., might contribute to the rational design of a new class of cardioprotective anti-inflammatory agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWI0l-Gz0GzLVg90H21EOLACvtfcHk0lhz-9D3xA5EnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFahs7bE&md5=64521447d2f44ff168a657299f265ba2</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200272%26sid%3Dliteratum%253Aachs%26aulast%3DBertinaria%26aufirst%3DM.%26aulast%3DShaikh%26aufirst%3DM.%2BA.%2BA.%2BG.%26aulast%3DBuccellati%26aufirst%3DC.%26aulast%3DCena%26aufirst%3DC.%26aulast%3DRolando%26aufirst%3DB.%26aulast%3DLazzarato%26aufirst%3DL.%26aulast%3DFruttero%26aufirst%3DR.%26aulast%3DGasco%26aufirst%3DA.%26aulast%3DHoxha%26aufirst%3DM.%26aulast%3DCapra%26aufirst%3DV.%26aulast%3DSala%26aufirst%3DA.%26aulast%3DRovati%26aufirst%3DG.%2BE.%26atitle%3DDesigning%2520Multitarget%2520Anti-Inflammatory%2520Agents%253A%2520Chemical%2520Modulation%2520of%2520the%2520Lumiracoxib%2520Structure%2520toward%2520Dual%2520Thromboxane%2520Antagonists-COX-2%2520Inhibitors%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26issue%3D9%26spage%3D1647%26epage%3D1660%26doi%3D10.1002%2Fcmdc.201200272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mahony, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippakopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasater, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picaud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Dual Kinase-Bromodomain Inhibitors for Rationally Designed Polypharmacology</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnchembio.1471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=24584101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtl2itro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=305-312&issue=4&author=P.+Ciceriauthor=S.+M%C3%BCllerauthor=A.+O%E2%80%99Mahonyauthor=O.+Fedorovauthor=P.+Filippakopoulosauthor=J.+P.+Huntauthor=E.+A.+Lasaterauthor=G.+Pallaresauthor=S.+Picaudauthor=C.+Wellsauthor=S.+Martinauthor=L.+M.+Wodickaauthor=N.+P.+Shahauthor=D.+K.+Treiberauthor=S.+Knapp&title=Dual+Kinase-Bromodomain+Inhibitors+for+Rationally+Designed+Polypharmacology&doi=10.1038%2Fnchembio.1471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Dual kinase-bromodomain inhibitors for rationally designed polypharmacology</span></div><div class="casAuthors">Ciceri, Pietro; Mueller, Susanne; O'Mahony, Alison; Fedorov, Oleg; Filippakopoulos, Panagis; Hunt, Jeremy P.; Lasater, Elisabeth A.; Pallares, Gabriel; Picaud, Sarah; Wells, Christopher; Martin, Sarah; Wodicka, Lisa M.; Shah, Neil P.; Treiber, Daniel K.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">305-312</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Concomitant inhibition of multiple cancer-driving kinases is an established strategy to improve the durability of clin. responses to targeted therapies.  The difficulty of discovering kinase inhibitors with an appropriate multitarget profile has, however, necessitated the application of combination therapies, which can pose major clin. development challenges.  Epigenetic reader domains of the bromodomain family have recently emerged as new targets for cancer therapy.  Here the authors report that several clin. kinase inhibitors also inhibit bromodomains with therapeutically relevant potencies and are best classified as dual kinase-bromodomain inhibitors.  Nanomolar activity on BRD4 by BI-2536 and TG-101348, which are clin. PLK1 and JAK2-FLT3 kinase inhibitors, resp., is particularly noteworthy as these combinations of activities on independent oncogenic pathways exemplify a new strategy for rational single-agent polypharmacol. targeting.  Furthermore, structure-activity relationships and co-crystal structures identify design features that enable a general platform for the rational design of dual kinase-bromodomain inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotPedDED4FJLVg90H21EOLACvtfcHk0limoRtGf2QhnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtl2itro%253D&md5=a00117db2648ea38dd03750faf3b3cb9</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1471%26sid%3Dliteratum%253Aachs%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLasater%26aufirst%3DE.%2BA.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DWells%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DDual%2520Kinase-Bromodomain%2520Inhibitors%2520for%2520Rationally%2520Designed%2520Polypharmacology%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26issue%3D4%26spage%3D305%26epage%3D312%26doi%3D10.1038%2Fnchembio.1471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benson, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pershadsingh, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chittiboyina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pravenec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, T. W.</span></span> <span> </span><span class="NLM_article-title">Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist with Selective PPARγ-Modulating Activity</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">993</span>– <span class="NLM_lpage">1002</span>, <span class="refDoi"> DOI: 10.1161/01.HYP.0000123072.34629.57</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1161%2F01.HYP.0000123072.34629.57" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=993-1002&issue=5&author=S.+C.+Bensonauthor=H.+A.+Pershadsinghauthor=C.+I.+Hoauthor=A.+Chittiboyinaauthor=P.+Desaiauthor=M.+Pravenecauthor=N.+Qiauthor=J.+Wangauthor=M.+A.+Averyauthor=T.+W.+Kurtz&title=Identification+of+Telmisartan+as+a+Unique+Angiotensin+II+Receptor+Antagonist+with+Selective+PPAR%CE%B3-Modulating+Activity&doi=10.1161%2F01.HYP.0000123072.34629.57"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1161%2F01.HYP.0000123072.34629.57&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.HYP.0000123072.34629.57%26sid%3Dliteratum%253Aachs%26aulast%3DBenson%26aufirst%3DS.%2BC.%26aulast%3DPershadsingh%26aufirst%3DH.%2BA.%26aulast%3DHo%26aufirst%3DC.%2BI.%26aulast%3DChittiboyina%26aufirst%3DA.%26aulast%3DDesai%26aufirst%3DP.%26aulast%3DPravenec%26aufirst%3DM.%26aulast%3DQi%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAvery%26aufirst%3DM.%2BA.%26aulast%3DKurtz%26aufirst%3DT.%2BW.%26atitle%3DIdentification%2520of%2520Telmisartan%2520as%2520a%2520Unique%2520Angiotensin%2520II%2520Receptor%2520Antagonist%2520with%2520Selective%2520PPAR%25CE%25B3-Modulating%2520Activity%26jtitle%3DHypertension%26date%3D2004%26volume%3D43%26issue%3D5%26spage%3D993%26epage%3D1002%26doi%3D10.1161%2F01.HYP.0000123072.34629.57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casimiro-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heemstra, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigge, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciske, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esmaeil, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalaie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohren, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, N. A.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Evaluation of imidazo[4,5-C]pyridin-4-One Derivatives with Dual Activity at Angiotensin II Type 1 Receptor and Peroxisome Proliferator-Activated Receptor-γ</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">767</span>– <span class="NLM_lpage">772</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.11.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.bmcl.2012.11.088" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=767-772&issue=3&author=A.+Casimiro-Garciaauthor=R.+J.+Heemstraauthor=C.+F.+Biggeauthor=J.+Chenauthor=F.+A.+Ciskeauthor=J.+A.+Davisauthor=T.+Ellisauthor=N.+Esmaeilauthor=D.+Flynnauthor=S.+Hanauthor=M.+Jalaieauthor=J.+F.+Ohrenauthor=N.+A.+Powell&title=Design%2C+Synthesis%2C+and+Evaluation+of+imidazo%5B4%2C5-C%5Dpyridin-4-One+Derivatives+with+Dual+Activity+at+Angiotensin+II+Type+1+Receptor+and+Peroxisome+Proliferator-Activated+Receptor-%CE%B3&doi=10.1016%2Fj.bmcl.2012.11.088"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.11.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.11.088%26sid%3Dliteratum%253Aachs%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26aulast%3DHeemstra%26aufirst%3DR.%2BJ.%26aulast%3DBigge%26aufirst%3DC.%2BF.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCiske%26aufirst%3DF.%2BA.%26aulast%3DDavis%26aufirst%3DJ.%2BA.%26aulast%3DEllis%26aufirst%3DT.%26aulast%3DEsmaeil%26aufirst%3DN.%26aulast%3DFlynn%26aufirst%3DD.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DOhren%26aufirst%3DJ.%2BF.%26aulast%3DPowell%26aufirst%3DN.%2BA.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Evaluation%2520of%2520imidazo%255B4%252C5-C%255Dpyridin-4-One%2520Derivatives%2520with%2520Dual%2520Activity%2520at%2520Angiotensin%2520II%2520Type%25201%2520Receptor%2520and%2520Peroxisome%2520Proliferator-Activated%2520Receptor-%25CE%25B3%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D3%26spage%3D767%26epage%3D772%26doi%3D10.1016%2Fj.bmcl.2012.11.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamotte, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faucher, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sançon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pineau, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sautet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouchet, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beneton, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tousaint, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saintillan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ancellin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicodeme, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martres, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Indazole Derivatives as Dual Angiotensin II Antagonists and Partial PPARγ Agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1098</span>– <span class="NLM_lpage">1103</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.bmcl.2014.01.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=1098-1103&issue=4&author=Y.+Lamotteauthor=N.+Faucherauthor=J.+San%C3%A7onauthor=O.+Pineauauthor=S.+Sautetauthor=M.-H.+Fouchetauthor=V.+Benetonauthor=J.-J.+Tousaintauthor=Y.+Saintillanauthor=N.+Ancellinauthor=E.+Nicodemeauthor=D.+Grillotauthor=P.+Martres&title=Discovery+of+Novel+Indazole+Derivatives+as+Dual+Angiotensin+II+Antagonists+and+Partial+PPAR%CE%B3+Agonists&doi=10.1016%2Fj.bmcl.2014.01.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DLamotte%26aufirst%3DY.%26aulast%3DFaucher%26aufirst%3DN.%26aulast%3DSan%25C3%25A7on%26aufirst%3DJ.%26aulast%3DPineau%26aufirst%3DO.%26aulast%3DSautet%26aufirst%3DS.%26aulast%3DFouchet%26aufirst%3DM.-H.%26aulast%3DBeneton%26aufirst%3DV.%26aulast%3DTousaint%26aufirst%3DJ.-J.%26aulast%3DSaintillan%26aufirst%3DY.%26aulast%3DAncellin%26aufirst%3DN.%26aulast%3DNicodeme%26aufirst%3DE.%26aulast%3DGrillot%26aufirst%3DD.%26aulast%3DMartres%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520Novel%2520Indazole%2520Derivatives%2520as%2520Dual%2520Angiotensin%2520II%2520Antagonists%2520and%2520Partial%2520PPAR%25CE%25B3%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D4%26spage%3D1098%26epage%3D1103%26doi%3D10.1016%2Fj.bmcl.2014.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span>; <span class="NLM_string-name">Maggiora, G.</span></span> <i>Concepts and Applications of Molecular Similarity</i>; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">1990</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1990&author=M.+Johnson&author=G.+Maggiora&title=Concepts+and+Applications+of+Molecular+Similarity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DM.%26btitle%3DConcepts%2520and%2520Applications%2520of%2520Molecular%2520Similarity%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, Y.
C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kofron, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traphagen, L. M.</span></span> <span> </span><span class="NLM_article-title">Do Structurally Similar Molecules Have Similar Biological Activity?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">4350</span>– <span class="NLM_lpage">4358</span>, <span class="refDoi"> DOI: 10.1021/jm020155c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020155c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=4350-4358&issue=19&author=Y.%0AC.+Martinauthor=J.+L.+Kofronauthor=L.+M.+Traphagen&title=Do+Structurally+Similar+Molecules+Have+Similar+Biological+Activity%3F&doi=10.1021%2Fjm020155c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjm020155c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020155c%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DY.%2BC.%26aulast%3DKofron%26aufirst%3DJ.%2BL.%26aulast%3DTraphagen%26aufirst%3DL.%2BM.%26atitle%3DDo%2520Structurally%2520Similar%2520Molecules%2520Have%2520Similar%2520Biological%2520Activity%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26issue%3D19%26spage%3D4350%26epage%3D4358%26doi%3D10.1021%2Fjm020155c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lavecchia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerchia, C.</span></span> <span> </span><span class="NLM_article-title">In Silico Methods to Address Polypharmacology: Current Status, Applications and Future Perspectives</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">288</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2015.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.drudis.2015.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=26743596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=288-298&issue=2&author=A.+Lavecchiaauthor=C.+Cerchia&title=In+Silico+Methods+to+Address+Polypharmacology%3A+Current+Status%2C+Applications+and+Future+Perspectives&doi=10.1016%2Fj.drudis.2015.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">In silico methods to address polypharmacology: current status, applications and future perspectives</span></div><div class="casAuthors">Lavecchia, Antonio; Cerchia, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">288-298</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Polypharmacol., a new paradigm in drug discovery that focuses on multi-target drugs (MTDs), has potential application for drug repurposing, the process of finding new uses for existing approved drugs, prediction of off-target toxicities and rational design of MTDs.  In this scenario, computational strategies have demonstrated great potential in predicting polypharmacol. and in facilitating drug repurposing.  Here, we provide a comprehensive overview of various computational approaches that enable the prediction and anal. of in vitro and in vivo drug-response phenotypes and outline their potential for drug discovery.  We give an outlook on the latest advances in rational design of MTDs and discuss possible future directions of algorithm development in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbncXXqTB557Vg90H21EOLACvtfcHk0lgkTFbP5Drukw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCjtQ%253D%253D&md5=55201ecb13f4fee19e73fc4d76ee9f65</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DLavecchia%26aufirst%3DA.%26aulast%3DCerchia%26aufirst%3DC.%26atitle%3DIn%2520Silico%2520Methods%2520to%2520Address%2520Polypharmacology%253A%2520Current%2520Status%252C%2520Applications%2520and%2520Future%2520Perspectives%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26issue%3D2%26spage%3D288%26epage%3D298%26doi%3D10.1016%2Fj.drudis.2015.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span> <span> </span><span class="NLM_article-title">Strategies for Modern Biomarker and Drug Development in Oncology</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">70</span>, <span class="refDoi"> DOI: 10.1186/s13045-014-0070-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1186%2Fs13045-014-0070-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=25277503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsVOrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=70&author=A.+D.+Smithauthor=D.+Rodaauthor=T.+A.+Yap&title=Strategies+for+Modern+Biomarker+and+Drug+Development+in+Oncology&doi=10.1186%2Fs13045-014-0070-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for modern biomarker and drug development in oncology</span></div><div class="casAuthors">Smith, Alan D.; Roda, Desam; Yap, Timothy A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">70/1-70/16</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Technol. advancements in the mol. characterization of cancers have enabled researchers to identify an increasing no. of key mol. drivers of cancer progression.  These discoveries have led to multiple novel anticancer therapeutics, and clin. benefit in selected patient populations.  Despite this, the identification of clin. relevant predictive biomarkers of response continues to lag behind.  In this review, we discuss strategies for the mol. characterization of cancers and the importance of biomarkers for the development of novel antitumor therapeutics.  We also review crit. successes and failures in oncol., and detail the lessons learnt, which may aid in the acceleration of anticancer drug development and biomarker discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWNEkFi4M0pLVg90H21EOLACvtfcHk0lgkTFbP5Drukw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsVOrsQ%253D%253D&md5=735ba9bd2f866b407057dd5cb89e839f</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1186%2Fs13045-014-0070-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-014-0070-8%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%2BD.%26aulast%3DRoda%26aufirst%3DD.%26aulast%3DYap%26aufirst%3DT.%2BA.%26atitle%3DStrategies%2520for%2520Modern%2520Biomarker%2520and%2520Drug%2520Development%2520in%2520Oncology%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2014%26volume%3D7%26spage%3D70%26doi%3D10.1186%2Fs13045-014-0070-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jørgensen, J. T.</span></span> <span> </span><span class="NLM_article-title">The Importance of Predictive Biomarkers in Oncology Drug Development</span>. <i>Expert Rev. Mol. Diagn.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">807</span>– <span class="NLM_lpage">809</span>, <span class="refDoi"> DOI: 10.1080/14737159.2016.1199962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1080%2F14737159.2016.1199962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27282189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FosVChug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=807-809&issue=8&author=J.+T.+J%C3%B8rgensen&title=The+Importance+of+Predictive+Biomarkers+in+Oncology+Drug+Development&doi=10.1080%2F14737159.2016.1199962"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">The importance of predictive biomarkers in oncology drug development</span></div><div class="casAuthors">Jorgensen Jan Trost</div><div class="citationInfo"><span class="NLM_cas:title">Expert review of molecular diagnostics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">807-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpjsop5xOrXENoizSOkG_FfW6udTcc2eacYmdJk0Mr7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FosVChug%253D%253D&md5=a98aabac63825ef0d86e882456e73061</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1080%2F14737159.2016.1199962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737159.2016.1199962%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25B8rgensen%26aufirst%3DJ.%2BT.%26atitle%3DThe%2520Importance%2520of%2520Predictive%2520Biomarkers%2520in%2520Oncology%2520Drug%2520Development%26jtitle%3DExpert%2520Rev.%2520Mol.%2520Diagn.%26date%3D2016%26volume%3D16%26issue%3D8%26spage%3D807%26epage%3D809%26doi%3D10.1080%2F14737159.2016.1199962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poornima, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blunder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efferth, T.</span></span> <span> </span><span class="NLM_article-title">Network Pharmacology of Cancer: From Understanding of Complex Interactomes to the Design of Multi-Target Specific Therapeutics from Nature</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">290</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2016.06.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.phrs.2016.06.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27329331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFShsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=290-302&author=P.+Poornimaauthor=J.+D.+Kumarauthor=Q.+Zhaoauthor=M.+Blunderauthor=T.+Efferth&title=Network+Pharmacology+of+Cancer%3A+From+Understanding+of+Complex+Interactomes+to+the+Design+of+Multi-Target+Specific+Therapeutics+from+Nature&doi=10.1016%2Fj.phrs.2016.06.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature</span></div><div class="casAuthors">Poornima, Paramasivan; Kumar, Jothi Dinesh; Zhao, Qiaoli; Blunder, Martina; Efferth, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">290-302</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Despite massive investments in drug research and development, the significant decline in the no. of new drugs approved or translated to clin. use raises the question, whether single targeted drug discovery is the right approach.  To combat complex systemic diseases that harbor robust biol. networks such as cancer, single target intervention is proved to be ineffective.  In such cases, network pharmacol. approaches are highly useful, because they differ from conventional drug discovery by addressing the ability of drugs to target numerous proteins or networks involved in a disease.  Pleiotropic natural products are one of the promising strategies due to their multi-targeting and due to lower side effects.  In this review, we discuss the application of network pharmacol. for cancer drug discovery.  We provide an overview of the current state of knowledge on network pharmacol., focus on different tech. approaches and implications for cancer therapy (e.g. polypharmacol. and synthetic lethality), and illustrate the therapeutic potential with selected examples green tea polyphenolics, Eleutherococcus senticosus, Rhodiola rosea, and Schisandra chinensis.  Finally, we present future perspectives on their plausible applications for diagnosis and therapy of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwqqjqEH_wtrVg90H21EOLACvtfcHk0lgkTFbP5Drukw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFShsr%252FM&md5=be3757ac287f3b90ebbcb69016a9410c</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.06.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.06.018%26sid%3Dliteratum%253Aachs%26aulast%3DPoornima%26aufirst%3DP.%26aulast%3DKumar%26aufirst%3DJ.%2BD.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DBlunder%26aufirst%3DM.%26aulast%3DEfferth%26aufirst%3DT.%26atitle%3DNetwork%2520Pharmacology%2520of%2520Cancer%253A%2520From%2520Understanding%2520of%2520Complex%2520Interactomes%2520to%2520the%2520Design%2520of%2520Multi-Target%2520Specific%2520Therapeutics%2520from%2520Nature%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D290%26epage%3D302%26doi%3D10.1016%2Fj.phrs.2016.06.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span> <span> </span><span class="NLM_article-title">Drug Discovery and Development for Rare Genetic Disorders</span>. <i>Am. J. Med. Genet., Part A</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>173</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2307</span>– <span class="NLM_lpage">2322</span>, <span class="refDoi"> DOI: 10.1002/ajmg.a.38326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fajmg.a.38326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28731526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC1cjpvFanuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2017&pages=2307-2322&issue=9&author=W.+Sunauthor=W.+Zhengauthor=A.+Simeonov&title=Drug+Discovery+and+Development+for+Rare+Genetic+Disorders&doi=10.1002%2Fajmg.a.38326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery and development for rare genetic disorders</span></div><div class="casAuthors">Sun Wei; Zheng Wei; Simeonov Anton</div><div class="citationInfo"><span class="NLM_cas:title">American journal of medical genetics. Part A</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2307-2322</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Approximately 7,000 rare diseases affect millions of individuals in the United States.  Although rare diseases taken together have an enormous impact, there is a significant gap between basic research and clinical interventions.  Opportunities now exist to accelerate drug development for the treatment of rare diseases.  Disease foundations and research centers worldwide focus on better understanding rare disorders.  Here, the state-of-the-art drug discovery strategies for small molecules and biological approaches for orphan diseases are reviewed.  Rare diseases are usually genetic diseases; hence, employing pharmacogenetics to develop treatments and using whole genome sequencing to identify the etiologies for such diseases are appropriate strategies to exploit.  Beginning with high throughput screening of small molecules, the benefits and challenges of target-based and phenotypic screens are discussed.  Explanations and examples of drug repurposing are given; drug repurposing as an approach to quickly move programs to clinical trials is evaluated.  Consideration is given to the category of biologics which include gene therapy, recombinant proteins, and autologous transplants.  Disease models, including animal models and induced pluripotent stem cells (iPSCs) derived from patients, are surveyed.  Finally, the role of biomarkers in drug discovery and development, as well as clinical trials, is elucidated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJyOLLVY88tAMthz5_Rx5rfW6udTcc2eYvE5BYt1QRx7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjpvFanuw%253D%253D&md5=75fdaeceb8cf3aeb80b609877f4125e2</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1002%2Fajmg.a.38326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajmg.a.38326%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DSimeonov%26aufirst%3DA.%26atitle%3DDrug%2520Discovery%2520and%2520Development%2520for%2520Rare%2520Genetic%2520Disorders%26jtitle%3DAm.%2520J.%2520Med.%2520Genet.%252C%2520Part%2520A%26date%3D2017%26volume%3D173%26issue%3D9%26spage%3D2307%26epage%3D2322%26doi%3D10.1002%2Fajmg.a.38326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bakkar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehringer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowser, R.</span></span> <span> </span><span class="NLM_article-title">Use of Biomarkers in ALS Drug Development and Clinical Trials</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1607</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2014.10.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.brainres.2014.10.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=25452025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVCktL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1607&publication_year=2015&pages=94-107&author=N.+Bakkarauthor=A.+Boehringerauthor=R.+Bowser&title=Use+of+Biomarkers+in+ALS+Drug+Development+and+Clinical+Trials&doi=10.1016%2Fj.brainres.2014.10.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Use of biomarkers in ALS drug development and clinical trials</span></div><div class="casAuthors">Bakkar, Nadine; Boehringer, Ashley; Bowser, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1607</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">94-107</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The past decade has seen a dramatic increase in the discovery of candidate biomarkers for ALS.  These biomarkers typically can either differentiate ALS from control subjects or predict disease course (slow vs. fast progression).  At the same time, late-stage clin. trials for ALS have failed to generate improved drug treatments for ALS patients.  Incorporation of biomarkers into the ALS drug development pipeline and the use of biol. and/or imaging biomarkers in early- and late-stage ALS clin. trials have been absent and only recently pursued in early-phase clin. trials.  Further clin. research studies are needed to validate biomarkers for disease progression and develop biomarkers that can help det. that a drug has reached its target within the central nervous system.  In this review we summarize recent progress in biomarkers across ALS model systems and patient population, and highlight continued research directions for biomarkers that stratify the patient population to enrich for patients that may best respond to a drug candidate, monitor disease progression and track drug responses in clin. trials.  It is crucial that we further develop and validate ALS biomarkers and incorporate these biomarkers into the ALS drug development process.  This article is part of a Special Issue entitled ALS complex pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA9RyxvK5C2rVg90H21EOLACvtfcHk0lhYWV7k-Oj8Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVCktL%252FP&md5=574c7b1ee968a171eb40219c6960381c</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2014.10.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2014.10.031%26sid%3Dliteratum%253Aachs%26aulast%3DBakkar%26aufirst%3DN.%26aulast%3DBoehringer%26aufirst%3DA.%26aulast%3DBowser%26aufirst%3DR.%26atitle%3DUse%2520of%2520Biomarkers%2520in%2520ALS%2520Drug%2520Development%2520and%2520Clinical%2520Trials%26jtitle%3DBrain%2520Res.%26date%3D2015%26volume%3D1607%26spage%3D94%26epage%3D107%26doi%3D10.1016%2Fj.brainres.2014.10.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, E. H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarazi, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahid, M.</span></span> <span> </span><span class="NLM_article-title">The Effectiveness of Multi-Target Agents in Schizophrenia and Mood Disorders: Relevance of Receptor Signature to Clinical Action</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>126</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2010.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.pharmthera.2010.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=20171983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksF2qur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2010&pages=173-185&issue=2&author=E.+H.+F.+Wongauthor=F.+I.+Taraziauthor=M.+Shahid&title=The+Effectiveness+of+Multi-Target+Agents+in+Schizophrenia+and+Mood+Disorders%3A+Relevance+of+Receptor+Signature+to+Clinical+Action&doi=10.1016%2Fj.pharmthera.2010.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">The effectiveness of multi-target agents in schizophrenia and mood disorders: relevance of receptor signature to clinical action</span></div><div class="casAuthors">Wong, Erik H. F.; Tarazi, Frank I.; Shahid, Mohammed</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">173-185</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Schizophrenia, bipolar disorder and unipolar depression are multi-dimensional and severely disabling psychiatric diseases with a strong need for improved pharmacotherapies with better adherence, long-term outcome and patient functionality.  Progress has been achieved with the emergence of tailored multi-target agents (MTAs), such as second-generation antipsychotics for schizophrenia, with expanding clin. utility in bipolar disorder and depression.  Better understanding of how these MTAs exert their beneficial and undesirable clin. effects in terms of receptor interaction remains an area for further elucidation, which may provide insight towards a new generation of individualized, and optimized therapies.  This review explores to what extent the receptor signature of MTAs informs about their clin. action and therapeutic utility.  Compelling clin. validation exists only for a limited no. of mol. targets (e.g. D2 receptor blockade, serotonin transport inhibition), indicating overall high attrition and poor translation of predictive preclin. pharmacol.  Nevertheless, recent advances have identified promising novel approaches for schizophrenia, bipolar disorder and depression that require further clin. validation.  It is hoped that the expanding clin. and mechanistic knowledge garnered from the use of existing MTAs will provide addnl. opportunities for "reverse translation" and towards target validation.  There is considerable scope for further developing and applying the knowledge linking receptor signature to clin. activity to drive stronger target validation, and ultimately support rational development of the next generation of MTAs for the improved treatment of schizophrenia and mood disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprA36orGSrq7Vg90H21EOLACvtfcHk0lhYWV7k-Oj8Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksF2qur8%253D&md5=3ecf4d69c5847b205e004f5379bf3b1a</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2010.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2010.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DE.%2BH.%2BF.%26aulast%3DTarazi%26aufirst%3DF.%2BI.%26aulast%3DShahid%26aufirst%3DM.%26atitle%3DThe%2520Effectiveness%2520of%2520Multi-Target%2520Agents%2520in%2520Schizophrenia%2520and%2520Mood%2520Disorders%253A%2520Relevance%2520of%2520Receptor%2520Signature%2520to%2520Clinical%2520Action%26jtitle%3DPharmacol.%2520Ther.%26date%3D2010%26volume%3D126%26issue%3D2%26spage%3D173%26epage%3D185%26doi%3D10.1016%2Fj.pharmthera.2010.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheffler, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroeze, W. K.</span></span> <span> </span><span class="NLM_article-title">Magic Shotguns versus Magic Bullets: Selectively Non-Selective Drugs for Mood Disorders and Schizophrenia</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">359</span>, <span class="refDoi"> DOI: 10.1038/nrd1346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnrd1346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=15060530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=353-359&issue=4&author=B.+L.+Rothauthor=D.+J.+Shefflerauthor=W.+K.+Kroeze&title=Magic+Shotguns+versus+Magic+Bullets%3A+Selectively+Non-Selective+Drugs+for+Mood+Disorders+and+Schizophrenia&doi=10.1038%2Fnrd1346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span></div><div class="casAuthors">Roth, Bryan L.; Sheffler, Douglas J.; Kroeze, Wesley K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-359</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most common central nervous system disorders - such as depression, bipolar disorder, and schizophrenia - seem to be polygenic in origin, and the most effective medications have exceedingly complex pharmacologies.  Attempts to develop more effective treatments for diseases such as schizophrenia and depression by discovering drugs selective for single mol. targets (i.e., 'magic bullets') have, not surprisingly, been largely unsuccessful.  Here the authors propose that designing selectively non-selective drugs (i.e., 'magic shotguns') that interact with several mol. targets will lead to new and more effective medications for a variety of central nervous system disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnSsuUXzmbirVg90H21EOLACvtfcHk0lgR4hl5rCabGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D&md5=77196583acccca65457fec7a67218463</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fnrd1346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1346%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DSheffler%26aufirst%3DD.%2BJ.%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26atitle%3DMagic%2520Shotguns%2520versus%2520Magic%2520Bullets%253A%2520Selectively%2520Non-Selective%2520Drugs%2520for%2520Mood%2520Disorders%2520and%2520Schizophrenia%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26issue%3D4%26spage%3D353%26epage%3D359%26doi%3D10.1038%2Fnrd1346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeshima, M.</span></span> <span> </span><span class="NLM_article-title">Treating Mixed Mania/hypomania: A Review and Synthesis of the Evidence</span>. <i>CNS Spectr.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1017/S1092852916000845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1017%2FS1092852916000845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28004626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC1c%252FnsVKksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=177-185&issue=2&author=M.+Takeshima&title=Treating+Mixed+Mania%2Fhypomania%3A+A+Review+and+Synthesis+of+the+Evidence&doi=10.1017%2FS1092852916000845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Treating mixed mania/hypomania: a review and synthesis of the evidence</span></div><div class="casAuthors">Takeshima Minoru</div><div class="citationInfo"><span class="NLM_cas:title">CNS spectrums</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">177-185</span>
        ISSN:<span class="NLM_cas:issn">1092-8529</span>.
    </div><div class="casAbstract">The DSM-5 incorporates a broad concept of mixed states and captured ≥3 nonoverlapping symptoms of the opposite polarity using a "with mixed features" specifier to be applied to manic/hypomanic and major depressive episodes.  Pharmacotherapy of mixed states is challenging because of the necessity to treat both manic/hypomanic and depressive symptoms concurrently.  High-potency antipsychotics used to treat manic symptoms and antidepressants can potentially deteriorate symptoms of the opposite polarity.  This review aimed to provide a synthesis of the current evidence for pharmacotherapy of mixed states with an emphasis on mixed mania/hypomania.  A PubMed search was conducted for randomized controlled trials (RCTs) that were at least moderately sized, included a placebo arm, and contained information on acute-phase and maintenance treatments of adult patients with mixed episodes or mania/hypomania with significant depressive symptoms.  Most studies were post-hoc subgroup and pooled analyses of the data from RCTs for acute manic and mixed episodes of bipolar I disorder; only two prospectively examined efficacy for mixed mania/hypomania specifically.  Aripiprazole, asenapine, carbamazepine, olanzapine, and ziprasidone showed the strongest evidence of efficacy in acute-phase treatment.  Quetiapine and divalproex/valproate were also efficacious.  Combination therapies with these atypical antipsychotics and mood stabilizers can be considered in severe cases.  Olanzapine and quetiapine (alone or in combination with lithium/divalproex) showed the strongest evidence of efficacy in maintenance treatment.  Lithium and lamotrigine may be beneficial given their preventive effects on suicide and depressive relapse.  Further prospective studies primarily focusing on mixed states are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5cBz8zkyS2Nj_Vg2vObihfW6udTcc2eZxfrX715zXUbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c%252FnsVKksQ%253D%253D&md5=87a4b1fe530051dc37c3aa50eb1b8e00</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1017%2FS1092852916000845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1092852916000845%26sid%3Dliteratum%253Aachs%26aulast%3DTakeshima%26aufirst%3DM.%26atitle%3DTreating%2520Mixed%2520Mania%252Fhypomania%253A%2520A%2520Review%2520and%2520Synthesis%2520of%2520the%2520Evidence%26jtitle%3DCNS%2520Spectr.%26date%3D2017%26volume%3D22%26issue%3D2%26spage%3D177%26epage%3D185%26doi%3D10.1017%2FS1092852916000845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tuplin, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holahan, M. R.</span></span> <span> </span><span class="NLM_article-title">Aripiprazole, A Drug That Displays Partial Agonism and Functional Selectivity</span>. <i>Curr. Neuropharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1192</span>– <span class="NLM_lpage">1207</span>, <span class="refDoi"> DOI: 10.2174/1570159X15666170413115754</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F1570159X15666170413115754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28412910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFens7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=1192-1207&issue=8&author=E.+W.+Tuplinauthor=M.+R.+Holahan&title=Aripiprazole%2C+A+Drug+That+Displays+Partial+Agonism+and+Functional+Selectivity&doi=10.2174%2F1570159X15666170413115754"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity</span></div><div class="casAuthors">Tuplin, Erin W.; Holahan, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1192-1207</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: The treatment of schizophrenia is challenging due to the wide range of symptoms (pos., neg., cognitive) assocd. with the disease.  Typical antipsychotics that antagonize D2 receptors are effective in treating pos. symptoms, but extrapyramidal side-effects (EPS) are a common occurrence.  Atypical antipsychotics targeting 5-HT2A and D2 receptors are more effective at treating cognitive and neg. symptoms compared to typical antipsychotics, but these drugs also result in side-effects such as metabolic syndromes.  Objective: To identify evidence in the literature that elucidates the pharmacol. profile of aripiprazole.s.  Methods: We searched PubMed for peer reviewed articles on aripiprazole and its clin. efficacy, side-effects, pharmacol., and effects in animal models of schizophrenia symptoms.  Results: Aripiprazole is a newer atypical antipsychotic that displays a unique pharmacol. profile, including partial D2 agonism and functionally selective properties.  Aripiprazole is effective at treating the pos. symptoms of schizophrenia and has the potential to treat neg. and cognitive symptoms at least as well as other atypical antipsychotics.  The drug has a favorable side-effect profile and has a low propensity to result in EPS or metabolic syndromes.  Animal models of schizophrenia have been used to det. the efficacy of aripiprazole in symptom management.  In these instances, aripiprazole resulted in the reversal of deficits in extinction, pre-pulse inhibition, and social withdrawal.  Because aripiprazole requires a greater than 90% occupancy rate at D2 receptors to be clin. active and does not produce EPS, this suggests a functionally selective effect on intracellular signaling pathways.  Conclusion: A combination of factors such as dopamine system stabilization via partial agonism, functional selectivity at D2 receptors, and serotonin-dopamine system interaction may contribute to the ability of aripiprazole to successfully manage schizophrenia symptoms.  This review examines these mechanisms of action to further clarify the pharmacol. actions of aripiprazole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiNaT3zwOCzLVg90H21EOLACvtfcHk0lgR4hl5rCabGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFens7vM&md5=a3e01bec5ee707325ac14bcee420a4d2</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.2174%2F1570159X15666170413115754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570159X15666170413115754%26sid%3Dliteratum%253Aachs%26aulast%3DTuplin%26aufirst%3DE.%2BW.%26aulast%3DHolahan%26aufirst%3DM.%2BR.%26atitle%3DAripiprazole%252C%2520A%2520Drug%2520That%2520Displays%2520Partial%2520Agonism%2520and%2520Functional%2520Selectivity%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2017%26volume%3D15%26issue%3D8%26spage%3D1192%26epage%3D1207%26doi%3D10.2174%2F1570159X15666170413115754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caraci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leggio, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drago, F.</span></span> <span> </span><span class="NLM_article-title">New Drugs in Psychiatry: Focus on New Pharmacological Targets</span>. <i>F1000Research</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">397</span>, <span class="refDoi"> DOI: 10.12688/f1000research.10233.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.12688%2Ff1000research.10233.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28408985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC1cvnslOhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=397&author=F.+Caraciauthor=G.+M.+Leggioauthor=S.+Salomoneauthor=F.+Drago&title=New+Drugs+in+Psychiatry%3A+Focus+on+New+Pharmacological+Targets&doi=10.12688%2Ff1000research.10233.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">New drugs in psychiatry: focus on new pharmacological targets</span></div><div class="casAuthors">Caraci Filippo; Caraci Filippo; Leggio Gian Marco; Salomone Salvatore; Drago Filippo</div><div class="citationInfo"><span class="NLM_cas:title">F1000Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">397</span>
        ISSN:<span class="NLM_cas:issn">2046-1402</span>.
    </div><div class="casAbstract">The approval of psychotropic drugs with novel mechanisms of action has been rare in recent years.  To address this issue, further analysis of the pathophysiology of neuropsychiatric disorders is essential for identifying new pharmacological targets for psychotropic medications.  In this report, we detail drug candidates being examined as treatments for psychiatric disorders.  Particular emphasis is placed on agents with novel mechanisms of action that are being tested as therapies for depression, schizophrenia, or Alzheimer's disease.  All of the compounds considered were recently approved for human use or are in advanced clinical trials.  Drugs included here are new antipsychotic medications endowed with a preferential affinity at dopamine D3 receptor (cariprazine) or at glutamatergic or cannabinoid receptors, as well as vortioxetine, a drug approved for managing the cognitive deficits associated with major depression.  New mechanistic approaches for the treatment of depression include intravenous ketamine or esketamine or intranasal esketamine.  As for Alzheimer's disease, the possible value of passive immunotherapy with agents such as aducanumab is considered to be a potential disease-modifying approach that could slow or halt the progressive decline associated with this devastating disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQm8I_QiD3OJNhSDZx9hyjKfW6udTcc2eYh9GYYdtVXWrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvnslOhsw%253D%253D&md5=a49356e1ef4094435d21d838138a120f</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.12688%2Ff1000research.10233.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12688%252Ff1000research.10233.1%26sid%3Dliteratum%253Aachs%26aulast%3DCaraci%26aufirst%3DF.%26aulast%3DLeggio%26aufirst%3DG.%2BM.%26aulast%3DSalomone%26aufirst%3DS.%26aulast%3DDrago%26aufirst%3DF.%26atitle%3DNew%2520Drugs%2520in%2520Psychiatry%253A%2520Focus%2520on%2520New%2520Pharmacological%2520Targets%26jtitle%3DF1000Research%26date%3D2017%26volume%3D6%26spage%3D397%26doi%3D10.12688%2Ff1000research.10233.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krause, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huhn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider-Thoma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bighelli, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolakopoulou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leucht, S.</span></span> <span> </span><span class="NLM_article-title">Antipsychotic Drugs for Patients with Schizophrenia and Predominant or Prominent Negative Symptoms: A Systematic Review and Meta-Analysis</span>. <i>Eur. Arch. Psychiatry Clin. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1007/s00406-018-0869-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1007%2Fs00406-018-0869-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29332205" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=1-15&author=M.+Krauseauthor=Y.+Zhuauthor=M.+Huhnauthor=J.+Schneider-Thomaauthor=I.+Bighelliauthor=A.+Nikolakopoulouauthor=S.+Leucht&title=Antipsychotic+Drugs+for+Patients+with+Schizophrenia+and+Predominant+or+Prominent+Negative+Symptoms%3A+A+Systematic+Review+and+Meta-Analysis&doi=10.1007%2Fs00406-018-0869-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1007%2Fs00406-018-0869-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00406-018-0869-3%26sid%3Dliteratum%253Aachs%26aulast%3DKrause%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DHuhn%26aufirst%3DM.%26aulast%3DSchneider-Thoma%26aufirst%3DJ.%26aulast%3DBighelli%26aufirst%3DI.%26aulast%3DNikolakopoulou%26aufirst%3DA.%26aulast%3DLeucht%26aufirst%3DS.%26atitle%3DAntipsychotic%2520Drugs%2520for%2520Patients%2520with%2520Schizophrenia%2520and%2520Predominant%2520or%2520Prominent%2520Negative%2520Symptoms%253A%2520A%2520Systematic%2520Review%2520and%2520Meta-Analysis%26jtitle%3DEur.%2520Arch.%2520Psychiatry%2520Clin.%2520Neurosci.%26date%3D2018%26spage%3D1%26epage%3D15%26doi%3D10.1007%2Fs00406-018-0869-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langedijk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantel-Teeuwisse, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slijkerman, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutjens, M.-H. D. B.</span></span> <span> </span><span class="NLM_article-title">Drug Repositioning and Repurposing: Terminology and Definitions in Literature</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1027</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2015.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.drudis.2015.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=25975957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC2MfktVCisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=1027-1034&issue=8&author=J.+Langedijkauthor=A.+K.+Mantel-Teeuwisseauthor=D.+S.+Slijkermanauthor=M.-H.+D.+B.+Schutjens&title=Drug+Repositioning+and+Repurposing%3A+Terminology+and+Definitions+in+Literature&doi=10.1016%2Fj.drudis.2015.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Drug repositioning and repurposing: terminology and definitions in literature</span></div><div class="casAuthors">Langedijk Joris; Mantel-Teeuwisse Aukje K; Slijkerman Diederick S; Schutjens Marie-Helene D B</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1027-34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug repositioning and similar terms have been a trending topic in literature and represent novel drug development strategies.  We analysed in a quantitative and qualitative manner how these terms were used and defined in the literature.  In total, 217 articles referred to 'drug repositioning', 'drug repurposing', 'drug reprofiling', 'drug redirecting' and/or 'drug rediscovery'.  Only 67 included a definition ranging from brief and general to extensive and specific.  No common definition was identified.  Nevertheless, four common features were found: concept, action, use and product.  The different wording used for these features often leads to essential differences in meaning between definitions.  In case a clear definition is needed, for example from a legal or regulatory perspective, the features can provide further guidance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFpzo98DHKlFVwdslNBF-tfW6udTcc2eZigYV-U6oCPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfktVCisg%253D%253D&md5=549b4e5ce337f19a6279764be580bdcd</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DLangedijk%26aufirst%3DJ.%26aulast%3DMantel-Teeuwisse%26aufirst%3DA.%2BK.%26aulast%3DSlijkerman%26aufirst%3DD.%2BS.%26aulast%3DSchutjens%26aufirst%3DM.-H.%2BD.%2BB.%26atitle%3DDrug%2520Repositioning%2520and%2520Repurposing%253A%2520Terminology%2520and%2520Definitions%2520in%2520Literature%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26issue%3D8%26spage%3D1027%26epage%3D1034%26doi%3D10.1016%2Fj.drudis.2015.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aubé, J.</span></span> <span> </span><span class="NLM_article-title">Drug Repurposing and the Medicinal Chemist</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">442</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1021/ml300114c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300114c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=442-444&issue=6&author=J.+Aub%C3%A9&title=Drug+Repurposing+and+the+Medicinal+Chemist&doi=10.1021%2Fml300114c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Fml300114c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300114c%26sid%3Dliteratum%253Aachs%26aulast%3DAub%25C3%25A9%26aufirst%3DJ.%26atitle%3DDrug%2520Repurposing%2520and%2520the%2520Medicinal%2520Chemist%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26issue%3D6%26spage%3D442%26epage%3D444%26doi%3D10.1021%2Fml300114c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasowski, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span> <span> </span><span class="NLM_article-title">In Silico Repositioning of Approved Drugs for Rare and Neglected Diseases</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">7–8</span>),  <span class="NLM_fpage">298</span>– <span class="NLM_lpage">310</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.02.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.drudis.2011.02.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=21376136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC3MvhslKguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=298-310&issue=7%E2%80%938&author=S.+Ekinsauthor=A.+J.+Williamsauthor=M.+D.+Krasowskiauthor=J.+S.+Freundlich&title=In+Silico+Repositioning+of+Approved+Drugs+for+Rare+and+Neglected+Diseases&doi=10.1016%2Fj.drudis.2011.02.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">In silico repositioning of approved drugs for rare and neglected diseases</span></div><div class="casAuthors">Ekins Sean; Williams Antony J; Krasowski Matthew D; Freundlich Joel S</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">298-310</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">One approach to speed up drug discovery is to examine new uses for existing approved drugs, so-called 'drug repositioning' or 'drug repurposing', which has become increasingly popular in recent years.  Analysis of the literature reveals many examples of US Food and Drug Administration-approved drugs that are active against multiple targets (also termed promiscuity) that can also be used to therapeutic advantage for repositioning for other neglected and rare diseases.  Using proof-of-principle examples, we suggest here that with current in silico technologies and databases of the structures and biological activities of chemical compounds (drugs) and related data, as well as close integration with in vitro screening data, improved opportunities for drug repurposing will emerge for neglected or rare/orphan diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT3t5Axd1gtboxhnOQkIHOxfW6udTcc2eZigYV-U6oCPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MvhslKguw%253D%253D&md5=0789fe5c640cb922d93d16e2e759e563</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.02.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.02.016%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DA.%2BJ.%26aulast%3DKrasowski%26aufirst%3DM.%2BD.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26atitle%3DIn%2520Silico%2520Repositioning%2520of%2520Approved%2520Drugs%2520for%2520Rare%2520and%2520Neglected%2520Diseases%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26issue%3D7%25E2%2580%25938%26spage%3D298%26epage%3D310%26doi%3D10.1016%2Fj.drudis.2011.02.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bottegoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favia, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recanatini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span> <span> </span><span class="NLM_article-title">The Role of Fragment-Based and Computational Methods in Polypharmacology</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.drudis.2011.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=21864710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38Xns12gtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=23-34&issue=1%E2%80%932&author=G.+Bottegoniauthor=A.+D.+Faviaauthor=M.+Recanatiniauthor=A.+Cavalli&title=The+Role+of+Fragment-Based+and+Computational+Methods+in+Polypharmacology&doi=10.1016%2Fj.drudis.2011.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">The role of fragment-based and computational methods in polypharmacology</span></div><div class="casAuthors">Bottegoni, Giovanni; Favia, Angelo D.; Recanatini, Maurizio; Cavalli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">23-34</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Polypharmacol.-based strategies are gaining increased attention as a novel approach to obtaining potentially innovative medicines for multifactorial diseases.  However, some within the pharmaceutical community have resisted these strategies because they can be resource-hungry in the early stages of the drug discovery process.  Here, we report on fragment-based and computational methods that might accelerate and optimize the discovery of multitarget drugs.  In particular, we illustrate that fragment-based approaches can be particularly suited for polypharmacol., owing to the inherent promiscuous nature of fragments.  In parallel, we explain how computer-assisted protocols can provide invaluable insights into how to unveil compds. theor. able to bind to more than one protein.  Furthermore, several pragmatic aspects related to the use of these approaches are covered, thus offering the reader practical insights on multitarget-oriented drug discovery projects.  We report on fragment-based and computational approaches as possible ways to accelerate and optimize the discovery of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqX_beZ_hY17Vg90H21EOLACvtfcHk0liIYCaRyP7FEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xns12gtw%253D%253D&md5=c774326a467a2b8fef62c6e1224c2a78</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DBottegoni%26aufirst%3DG.%26aulast%3DFavia%26aufirst%3DA.%2BD.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DThe%2520Role%2520of%2520Fragment-Based%2520and%2520Computational%2520Methods%2520in%2520Polypharmacology%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26issue%3D1%25E2%2580%25932%26spage%3D23%26epage%3D34%26doi%3D10.1016%2Fj.drudis.2011.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovic-Nikolic, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uliassi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">A Perspective on Multi-Target Drug Discovery and Design for Complex Diseases</span>. <i>Clin. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">3</span>, <span class="refDoi"> DOI: 10.1186/s40169-017-0181-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1186%2Fs40169-017-0181-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29340951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC1MvhsVaiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=3&author=R.+R.+Ramsayauthor=M.+R.+Popovic-Nikolicauthor=K.+Nikolicauthor=E.+Uliassiauthor=M.+L.+Bolognesi&title=A+Perspective+on+Multi-Target+Drug+Discovery+and+Design+for+Complex+Diseases&doi=10.1186%2Fs40169-017-0181-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">A perspective on multi-target drug discovery and design for complex diseases</span></div><div class="casAuthors">Ramsay Rona R; Popovic-Nikolic Marija R; Nikolic Katarina; Uliassi Elisa; Bolognesi Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and translational medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3</span>
        ISSN:<span class="NLM_cas:issn">2001-1326</span>.
    </div><div class="casAbstract">Diseases of infection, of neurodegeneration (such as Alzheimer's and Parkinson's diseases), and of malignancy (cancers) have complex and varied causative factors.  Modern drug discovery has the power to identify potential modulators for multiple targets from millions of compounds.  Computational approaches allow the determination of the association of each compound with its target before chemical synthesis and biological testing is done.  These approaches depend on the prior identification of clinically and biologically validated targets.  This Perspective will focus on the molecular and computational approaches that underpin drug design by medicinal chemists to promote understanding and collaboration with clinical scientists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJhSGsWpifCZcXNb62YGmbfW6udTcc2eZUe71ifHqfzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvhsVaiug%253D%253D&md5=5b05a73a3bbc955c77b9b2df93deb946</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1186%2Fs40169-017-0181-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40169-017-0181-2%26sid%3Dliteratum%253Aachs%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DPopovic-Nikolic%26aufirst%3DM.%2BR.%26aulast%3DNikolic%26aufirst%3DK.%26aulast%3DUliassi%26aufirst%3DE.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DA%2520Perspective%2520on%2520Multi-Target%2520Drug%2520Discovery%2520and%2520Design%2520for%2520Complex%2520Diseases%26jtitle%3DClin.%2520Transl.%2520Med.%26date%3D2018%26volume%3D7%26spage%3D3%26doi%3D10.1186%2Fs40169-017-0181-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talevi, A.</span></span> <span> </span><span class="NLM_article-title">Multi-Target Pharmacology: Possibilities and Limitations of The “skeleton Key Approach” from a Medicinal Chemist Perspective</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">205</span>, <span class="refDoi"> DOI: 10.3389/fphar.2015.00205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.3389%2Ffphar.2015.00205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=26441661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1amurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=205&author=A.+Talevi&title=Multi-Target+Pharmacology%3A+Possibilities+and+Limitations+of+The+%E2%80%9Cskeleton+Key+Approach%E2%80%9D+from+a+Medicinal+Chemist+Perspective&doi=10.3389%2Ffphar.2015.00205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective</span></div><div class="casAuthors">Talevi, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">205/1-205/7</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Multi-target drugs have raised considerable interest in the last decade owing to their advantages in the treatment of complex diseases and health conditions linked to drug resistance issues.  Prospective drug repositioning to treat comorbid conditions is an addnl., overlooked application of multi-target ligands.  While medicinal chemists usually rely on some version of the lock and key paradigm to design novel therapeutics, modern pharmacol. recognizes that the mid- and long-term effects of a given drug on a biol. system may depend not only on the specific ligand-target recognition events but also on the influence of the repeated administration of a drug on the cell gene signature.  The design of multi-target agents usually imposes challenging restrictions on the topol. or flexibility of the candidate drugs, which are briefly discussed in the present article.  Finally, computational strategies to approach the identification of novel multi-target agents are overviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSdZokyMjNSLVg90H21EOLACvtfcHk0lh_En_LexWWgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1amurnM&md5=169718a4644d962da33806772a9a33e3</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00205%26sid%3Dliteratum%253Aachs%26aulast%3DTalevi%26aufirst%3DA.%26atitle%3DMulti-Target%2520Pharmacology%253A%2520Possibilities%2520and%2520Limitations%2520of%2520The%2520%25E2%2580%259Cskeleton%2520Key%2520Approach%25E2%2580%259D%2520from%2520a%2520Medicinal%2520Chemist%2520Perspective%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D205%26doi%3D10.3389%2Ffphar.2015.00205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schaller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagenow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alpert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naß, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bermudez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolber, G.</span></span> <span> </span><span class="NLM_article-title">Systematic Data Mining Reveals Synergistic H3R/MCHR1 Ligands</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">648</span>– <span class="NLM_lpage">653</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00118</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00118" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=648-653&issue=6&author=D.+Schallerauthor=S.+Hagenowauthor=G.+Alpertauthor=A.+Na%C3%9Fauthor=R.+Schulzauthor=M.+Bermudezauthor=H.+Starkauthor=G.+Wolber&title=Systematic+Data+Mining+Reveals+Synergistic+H3R%2FMCHR1+Ligands&doi=10.1021%2Facsmedchemlett.7b00118"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00118%26sid%3Dliteratum%253Aachs%26aulast%3DSchaller%26aufirst%3DD.%26aulast%3DHagenow%26aufirst%3DS.%26aulast%3DAlpert%26aufirst%3DG.%26aulast%3DNa%25C3%259F%26aufirst%3DA.%26aulast%3DSchulz%26aufirst%3DR.%26aulast%3DBermudez%26aufirst%3DM.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DWolber%26aufirst%3DG.%26atitle%3DSystematic%2520Data%2520Mining%2520Reveals%2520Synergistic%2520H3R%252FMCHR1%2520Ligands%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D6%26spage%3D648%26epage%3D653%26doi%3D10.1021%2Facsmedchemlett.7b00118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Apelt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligneau, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertz, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrang, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganellin, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schunack, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Development of a New Class of Nonimidazole Histamine H3receptor Ligands with Combined Inhibitory Histamine N-Methyltransferase Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1128</span>– <span class="NLM_lpage">1141</span>, <span class="refDoi"> DOI: 10.1021/jm0110845</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0110845" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=1128-1141&issue=5&author=J.+Apeltauthor=X.+Ligneauauthor=H.+H.+Pertzauthor=J.+M.+Arrangauthor=C.+R.+Ganellinauthor=J.+C.+Schwartzauthor=W.+Schunackauthor=H.+Stark&title=Development+of+a+New+Class+of+Nonimidazole+Histamine+H3receptor+Ligands+with+Combined+Inhibitory+Histamine+N-Methyltransferase+Activity&doi=10.1021%2Fjm0110845"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Fjm0110845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0110845%26sid%3Dliteratum%253Aachs%26aulast%3DApelt%26aufirst%3DJ.%26aulast%3DLigneau%26aufirst%3DX.%26aulast%3DPertz%26aufirst%3DH.%2BH.%26aulast%3DArrang%26aufirst%3DJ.%2BM.%26aulast%3DGanellin%26aufirst%3DC.%2BR.%26aulast%3DSchwartz%26aufirst%3DJ.%2BC.%26aulast%3DSchunack%26aufirst%3DW.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DDevelopment%2520of%2520a%2520New%2520Class%2520of%2520Nonimidazole%2520Histamine%2520H3receptor%2520Ligands%2520with%2520Combined%2520Inhibitory%2520Histamine%2520N-Methyltransferase%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26issue%3D5%26spage%3D1128%26epage%3D1141%26doi%3D10.1021%2Fjm0110845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blöcher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brüggerhoff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boß, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schader, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Göbel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angioni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurglics, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostenis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brüne, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhilber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert-Zsilavecz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahnt, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span> <span> </span><span class="NLM_article-title">N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01239</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01239" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC28vksVWjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=61-81&issue=1&author=R.+Bl%C3%B6cherauthor=C.+Lamersauthor=S.+K.+Wittmannauthor=D.+Merkauthor=M.+Hartmannauthor=L.+Weizelauthor=O.+Diehlauthor=A.+Br%C3%BCggerhoffauthor=M.+Bo%C3%9Fauthor=A.+Kaiserauthor=T.+Schaderauthor=T.+G%C3%B6belauthor=M.+Grundmannauthor=C.+Angioniauthor=J.+Heeringauthor=G.+Geisslingerauthor=M.+Wurglicsauthor=E.+Kostenisauthor=B.+Br%C3%BCneauthor=D.+Steinhilberauthor=M.+Schubert-Zsilaveczauthor=A.+S.+Kahntauthor=E.+Proschak&title=N-Benzylbenzamides%3A+A+Novel+Merged+Scaffold+for+Orally+Available+Dual+Soluble+Epoxide+Hydrolase%2FPeroxisome+Proliferator-Activated+Receptor+%CE%B3+Modulators&doi=10.1021%2Facs.jmedchem.5b01239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators</span></div><div class="casAuthors">Blocher Rene; Lamers Christina; Wittmann Sandra K; Merk Daniel; Hartmann Markus; Weizel Lilia; Diehl Olaf; Bruggerhoff Astrid; Kaiser Astrid; Schader Tim; Gobel Tamara; Wurglics Mario; Steinhilber Dieter; Schubert-Zsilavecz Manfred; Kahnt Astrid S; Proschak Ewgenij; Boss Marcel; Brune Bernhard; Grundmann Manuel; Kostenis Evi; Angioni Carlo; Geisslinger Gerd; Heering Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-81</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Metabolic syndrome (MetS) is a multifactorial disease cluster that consists of dyslipidemia, cardiovascular disease, type 2 diabetes mellitus, and obesity.  MetS patients are strongly exposed to polypharmacy; however, the number of pharmacological compounds required for MetS treatment can be reduced by the application of multitarget compounds.  This study describes the design of dual-target ligands that target soluble epoxide hydrolase (sEH) and the peroxisome proliferator-activated receptor type γ (PPARγ).  Simultaneous modulation of sEH and PPARγ can improve diabetic conditions and hypertension at once.  N-Benzylbenzamide derivatives were determined to fit a merged sEH/PPARγ pharmacophore, and structure-activity relationship studies were performed on both targets, resulting in a submicromolar (sEH IC50 = 0.3 μM/PPARγ EC50 = 0.3 μM) modulator 14c.  In vitro and in vivo evaluations revealed good ADME properties qualifying 14c as a pharmacological tool compound for long-term animal models of MetS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQEKlCRcJ5_1JcXNb62YGmbfW6udTcc2eYKiUnPTsQK8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vksVWjtA%253D%253D&md5=86c5861a77820ae8878382eae893b116</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01239%26sid%3Dliteratum%253Aachs%26aulast%3DBl%25C3%25B6cher%26aufirst%3DR.%26aulast%3DLamers%26aufirst%3DC.%26aulast%3DWittmann%26aufirst%3DS.%2BK.%26aulast%3DMerk%26aufirst%3DD.%26aulast%3DHartmann%26aufirst%3DM.%26aulast%3DWeizel%26aufirst%3DL.%26aulast%3DDiehl%26aufirst%3DO.%26aulast%3DBr%25C3%25BCggerhoff%26aufirst%3DA.%26aulast%3DBo%25C3%259F%26aufirst%3DM.%26aulast%3DKaiser%26aufirst%3DA.%26aulast%3DSchader%26aufirst%3DT.%26aulast%3DG%25C3%25B6bel%26aufirst%3DT.%26aulast%3DGrundmann%26aufirst%3DM.%26aulast%3DAngioni%26aufirst%3DC.%26aulast%3DHeering%26aufirst%3DJ.%26aulast%3DGeisslinger%26aufirst%3DG.%26aulast%3DWurglics%26aufirst%3DM.%26aulast%3DKostenis%26aufirst%3DE.%26aulast%3DBr%25C3%25BCne%26aufirst%3DB.%26aulast%3DSteinhilber%26aufirst%3DD.%26aulast%3DSchubert-Zsilavecz%26aufirst%3DM.%26aulast%3DKahnt%26aufirst%3DA.%2BS.%26aulast%3DProschak%26aufirst%3DE.%26atitle%3DN-Benzylbenzamides%253A%2520A%2520Novel%2520Merged%2520Scaffold%2520for%2520Orally%2520Available%2520Dual%2520Soluble%2520Epoxide%2520Hydrolase%252FPeroxisome%2520Proliferator-Activated%2520Receptor%2520%25CE%25B3%2520Modulators%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D1%26spage%3D61%26epage%3D81%26doi%3D10.1021%2Facs.jmedchem.5b01239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Graßmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apelt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligneau, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertz, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrang, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganellin, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schunack, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Search for Histamine H3 Receptor Ligands with Combined Inhibitory Potency at Histamine N-Methyltransferase: ω- Piperidinoalkanamine Derivatives</span>. <i>Arch. Pharm. (Weinheim, Ger.)</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>337</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1002/ardp.200400897</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fardp.200400897" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=15476285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsFCgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2004&pages=533-545&issue=10&author=S.+Gra%C3%9Fmannauthor=J.+Apeltauthor=X.+Ligneauauthor=H.+H.+Pertzauthor=J.+M.+Arrangauthor=C.+R.+Ganellinauthor=J.+C.+Schwartzauthor=W.+Schunackauthor=H.+Stark&title=Search+for+Histamine+H3+Receptor+Ligands+with+Combined+Inhibitory+Potency+at+Histamine+N-Methyltransferase%3A+%CF%89-+Piperidinoalkanamine+Derivatives&doi=10.1002%2Fardp.200400897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Search for histamine H3 receptor ligands with combined inhibitory potency at histamine N-methyltransferase: ω-piperidinoalkanamine derivatives</span></div><div class="casAuthors">Grassmann, Sven; Apelt, Joachim; Ligneau, Xavier; Pertz, Heinz H.; Arrang, Jean-Michel; Ganellin, C. Robin; Schwartz, Jean-Charles; Schunack, Walter; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">533-545</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">In an effort to design new hybrid compds. with dual properties, i.e. binding affinity at histamine H3 receptors and inhibitory potency at the catabolic enzyme histamine Nτ-methyltransferase (HMT), a novel series of 1-substituted piperidine derivs. was synthesized.  This alicyclic heterocycle is structurally linked via aminoalkyl spacers of variable lengths to addnl. arom. carbo- or heterocycles.  These new hybrid drugs were pharmacol. evaluated regarding their binding affinities at recombinant human H3 receptors, stably expressed in CHO cells, and in a functional assay for their inhibitory potencies at rat kidney HMT.  All compds. investigated proved to be H3 receptor ligands with binding affinities in the micro- to nanomolar concn. range despite significant differences in the type of the arom. moiety introduced.  The most potent compd. in this series was I [n = 5, R1 = Me, R2 = quinolin-4-yl] (Ki = 5.6 nM).  Likewise, all new ligands studied showed impressive HMT inhibitory activities, I [n = 3, 5, R1 = H, R2 = 5-amino-2-pyridinyl; n = 6, R1 = H, R2 = 2-pyrimidinyl; n = 2, 4, 5, R1 = Me, R2 = 4-pyridinyl, 4-quinolinyl] exhibiting submicromolar potencies (IC50 = 0.061-0.56 μM).  I [n = 4, R1 = Me, R2 = 4-quinolinyl] showed almost the same, well balanced nanomolar activities on both targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXgMhlJUXx07Vg90H21EOLACvtfcHk0lg3jiop5zh_uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsFCgsrk%253D&md5=5451de665cf9802ad3c0375397784d76</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1002%2Fardp.200400897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.200400897%26sid%3Dliteratum%253Aachs%26aulast%3DGra%25C3%259Fmann%26aufirst%3DS.%26aulast%3DApelt%26aufirst%3DJ.%26aulast%3DLigneau%26aufirst%3DX.%26aulast%3DPertz%26aufirst%3DH.%2BH.%26aulast%3DArrang%26aufirst%3DJ.%2BM.%26aulast%3DGanellin%26aufirst%3DC.%2BR.%26aulast%3DSchwartz%26aufirst%3DJ.%2BC.%26aulast%3DSchunack%26aufirst%3DW.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DSearch%2520for%2520Histamine%2520H3%2520Receptor%2520Ligands%2520with%2520Combined%2520Inhibitory%2520Potency%2520at%2520Histamine%2520N-Methyltransferase%253A%2520%25CF%2589-%2520Piperidinoalkanamine%2520Derivatives%26jtitle%3DArch.%2520Pharm.%2520%2528Weinheim%252C%2520Ger.%2529%26date%3D2004%26volume%3D337%26issue%3D10%26spage%3D533%26epage%3D545%26doi%3D10.1002%2Fardp.200400897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nurulain, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darras, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadek, B.</span></span> <span> </span><span class="NLM_article-title">The Dual-Acting H3 Receptor Antagonist and AChE Inhibitor UW-MD-71 Dose-Dependently Enhances Memory Retrieval and Reverses Dizocilpine-Induced Memory Impairment in Rats</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>297</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2015.10.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.bbr.2015.10.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=26467607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1yjsb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=297&publication_year=2016&pages=155-164&author=N.+Khanauthor=A.+Saadauthor=S.+M.+Nurulainauthor=F.+H.+Darrasauthor=M.+Deckerauthor=B.+Sadek&title=The+Dual-Acting+H3+Receptor+Antagonist+and+AChE+Inhibitor+UW-MD-71+Dose-Dependently+Enhances+Memory+Retrieval+and+Reverses+Dizocilpine-Induced+Memory+Impairment+in+Rats&doi=10.1016%2Fj.bbr.2015.10.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">The dual-acting H3 receptor antagonist and AChE inhibitor UW-MD-71 dose-dependently enhances memory retrieval and reverses dizocilpine-induced memory impairment in rats</span></div><div class="casAuthors">Khan, Nadia; Saad, Ali; Nurulain, Syed M.; Darras, Fouad H.; Decker, Michael; Sadek, Bassem</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">297</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">155-164</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Both the histamine H3 receptor (H3R) and acetylcholine esterase (AChE) are involved in the regulation of release and metab. of acetylcholine and several other central neurotransmitters.  Therefore, dual-active H3R antagonists and AChE inhibitors (AChEIs) have shown in several studies to hold promise to treat cognitive disorders like Alzheimer's disease (AD).  The novel dual-acting H3R antagonist and AChEI 7-(3-(piperidin-1-yl)propoxy)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline (UW-MD-71) with excellent selectivity profiles over both the three other HRs as well as the AChE's isoenzyme butyrylcholinesterase (BChE) shows high and balanced in vitro affinities at both H3R and AChE with IC50 of 33.9 nM and hH3R antagonism with Ki of 76.2 nM, resp.  In the present study, the effects of UW-MD-71 (1.25-5 mg/kg, i.p.) on acquisition, consolidation, and retrieval in a one-trial inhibitory avoidance task in male rats were investigated applying donepezil (DOZ) and pitolisant (PIT) as ref. drugs.  Furthermore, the effects of UW-MD-71 on memory deficits induced by the non-competitive N-methyl-D-aspartate (NMDA) antagonist dizocilpine (DIZ) were tested.  Our results indicate that administration of UW-MD-71 before the test session dose-dependently increased performance and enhanced procognitive effect on retrieval.  However neither pre- nor post-training acute systemic administration of UW-MD-71 facilitated acquisition or consolidation.  More importantly, UW-MD-71 (2.5 mg/kg, i.p.) ameliorated the DIZ-induced amnesic effects.  Furthermore, the procognitive activity of UW-MD-71 in retrieval was completely reversed and partly abrogated in DIZ-induced amnesia when rats were pretreated with the centrally-acting H2R antagonist zolantidine (ZOL), but not with the CNS penetrant H1R antagonist pyrilamine (PYR).  These results demonstrate the procognitive effects of UW-MD-71 in two in vivo memory models, and are to our knowledge the first demonstration in vivo that a potent dual-acting H3R antagonist and AChEI is effective in improving retrieval processes in the one-trial inhibitory avoidance task and provide evidence to such compds. to treat cognitive disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2h8BAnLwwwrVg90H21EOLACvtfcHk0lg3jiop5zh_uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1yjsb%252FM&md5=e283db0e6872d9cad9c3fb8294a0ab0f</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2015.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2015.10.022%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DN.%26aulast%3DSaad%26aufirst%3DA.%26aulast%3DNurulain%26aufirst%3DS.%2BM.%26aulast%3DDarras%26aufirst%3DF.%2BH.%26aulast%3DDecker%26aufirst%3DM.%26aulast%3DSadek%26aufirst%3DB.%26atitle%3DThe%2520Dual-Acting%2520H3%2520Receptor%2520Antagonist%2520and%2520AChE%2520Inhibitor%2520UW-MD-71%2520Dose-Dependently%2520Enhances%2520Memory%2520Retrieval%2520and%2520Reverses%2520Dizocilpine-Induced%2520Memory%2520Impairment%2520in%2520Rats%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2016%26volume%3D297%26spage%3D155%26epage%3D164%26doi%3D10.1016%2Fj.bbr.2015.10.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bountra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunnage, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buser-Doepner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanak, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederiksen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimshaw, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hepworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K. V. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotz, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mader, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsden, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller-Fahrnow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hagan, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundström, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Superti-Furga, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toledo-Sherman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walpole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span> <span> </span><span class="NLM_article-title">The Promise and Peril of Chemical Probes</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">536</span>– <span class="NLM_lpage">541</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1867</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnchembio.1867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=26196764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Wlu7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=536-541&issue=8&author=C.+H.+Arrowsmithauthor=J.+E.+Audiaauthor=C.+Austinauthor=J.+Baellauthor=J.+Bennettauthor=J.+Blaggauthor=C.+Bountraauthor=P.+E.+Brennanauthor=P.+J.+Brownauthor=M.+E.+Bunnageauthor=C.+Buser-Doepnerauthor=R.+M.+Campbellauthor=A.+J.+Carterauthor=P.+Cohenauthor=R.+A.+Copelandauthor=B.+Cravattauthor=J.+L.+Dahlinauthor=D.+Dhanakauthor=A.+M.+Edwardsauthor=M.+Frederiksenauthor=S.+V.+Fryeauthor=N.+Grayauthor=C.+E.+Grimshawauthor=D.+Hepworthauthor=T.+Howeauthor=K.+V.+M+Huberauthor=J.+Jinauthor=S.+Knappauthor=J.+D.+Kotzauthor=R.+G.+Krugerauthor=D.+Loweauthor=M.+M.+Maderauthor=B.+Marsdenauthor=A.+Mueller-Fahrnowauthor=S.+M%C3%BCllerauthor=R.+C.+O%E2%80%99Haganauthor=J.+P.+Overingtonauthor=D.+R.+Owenauthor=S.+H.+Rosenbergauthor=R.+Rossauthor=B.+Rothauthor=M.+Schapiraauthor=S.+L.+Schreiberauthor=B.+Shoichetauthor=M.+Sundstr%C3%B6mauthor=G.+Superti-Furgaauthor=J.+Tauntonauthor=L.+Toledo-Shermanauthor=C.+Walpoleauthor=M.+A.+Waltersauthor=T.+M.+Willsonauthor=P.+Workmanauthor=R.+N.+Youngauthor=W.+J.+Zuercher&title=The+Promise+and+Peril+of+Chemical+Probes&doi=10.1038%2Fnchembio.1867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">The promise and peril of chemical probes</span></div><div class="casAuthors">Arrowsmith, Cheryl H.; Audia, James E.; Austin, Christopher; Baell, Jonathan; Bennett, Jonathan; Blagg, Julian; Bountra, Chas; Brennan, Paul E.; Brown, Peter J.; Bunnage, Mark E.; Buser-Doepner, Carolyn; Campbell, Robert M.; Carter, Adrian J.; Cohen, Philip; Copeland, Robert A.; Cravatt, Ben; Dahlin, Jayme L.; Dhanak, Dashyant; Edwards, Aled M.; Frye, Stephen V.; Gray, Nathanael; Grimshaw, Charles E.; Hepworth, David; Howe, Trevor; Huber, Kilian V. M.; Jin, Jian; Knapp, Stefan; Kotz, Joanne D.; Kruger, Ryan G.; Lowe, Derek; Mader, Mary M.; Marsden, Brian; Mueller-Fahrnow, Anke; Muller, Susanne; O'Hagan, Ronan C.; Overington, John P.; Owen, Dafydd R.; Rosenberg, Saul H.; Roth, Brian; Ross, Ruth; Schapira, Matthieu; Schreiber, Stuart L.; Shoichet, Brian; Sundstrom, Michael; Superti-Furga, Giulio; Taunton, Jack; Toledo-Sherman, Leticia; Walpole, Chris; Walters, Michael A.; Willson, Timothy M.; Workman, Paul; Young, Robert N.; Zuercher, William J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">536-541</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chem. probes are powerful reagents with increasing impacts on biomedical research.  However, probes of poor quality or that are used incorrectly generate misleading results.  To help address these shortcomings, we will create a community-driven wiki resource to improve quality and convey current best practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-li4dxq487rVg90H21EOLACvtfcHk0lhuqFk9cLFp4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Wlu7zO&md5=d8c7a7af94921ab4cdcc871487cceadd</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1867%26sid%3Dliteratum%253Aachs%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DAustin%26aufirst%3DC.%26aulast%3DBaell%26aufirst%3DJ.%26aulast%3DBennett%26aufirst%3DJ.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DBountra%26aufirst%3DC.%26aulast%3DBrennan%26aufirst%3DP.%2BE.%26aulast%3DBrown%26aufirst%3DP.%2BJ.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DBuser-Doepner%26aufirst%3DC.%26aulast%3DCampbell%26aufirst%3DR.%2BM.%26aulast%3DCarter%26aufirst%3DA.%2BJ.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DCravatt%26aufirst%3DB.%26aulast%3DDahlin%26aufirst%3DJ.%2BL.%26aulast%3DDhanak%26aufirst%3DD.%26aulast%3DEdwards%26aufirst%3DA.%2BM.%26aulast%3DFrederiksen%26aufirst%3DM.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DGrimshaw%26aufirst%3DC.%2BE.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DHowe%26aufirst%3DT.%26aulast%3DHuber%26aufirst%3DK.%2BV.%2BM%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DKotz%26aufirst%3DJ.%2BD.%26aulast%3DKruger%26aufirst%3DR.%2BG.%26aulast%3DLowe%26aufirst%3DD.%26aulast%3DMader%26aufirst%3DM.%2BM.%26aulast%3DMarsden%26aufirst%3DB.%26aulast%3DMueller-Fahrnow%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Hagan%26aufirst%3DR.%2BC.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26aulast%3DOwen%26aufirst%3DD.%2BR.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DRoss%26aufirst%3DR.%26aulast%3DRoth%26aufirst%3DB.%26aulast%3DSchapira%26aufirst%3DM.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DShoichet%26aufirst%3DB.%26aulast%3DSundstr%25C3%25B6m%26aufirst%3DM.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26aulast%3DTaunton%26aufirst%3DJ.%26aulast%3DToledo-Sherman%26aufirst%3DL.%26aulast%3DWalpole%26aufirst%3DC.%26aulast%3DWalters%26aufirst%3DM.%2BA.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DYoung%26aufirst%3DR.%2BN.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26atitle%3DThe%2520Promise%2520and%2520Peril%2520of%2520Chemical%2520Probes%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26issue%3D8%26spage%3D536%26epage%3D541%26doi%3D10.1038%2Fnchembio.1867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naidu, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, A. H.</span></span> <span> </span><span class="NLM_article-title">Synergy between Enzyme Inhibitors of Fatty Acid Amide Hydrolase and Cyclooxygenase in Visceral Nociception</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>329</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1124/jpet.108.143487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1124%2Fjpet.108.143487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=19118134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVKntb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=329&publication_year=2009&pages=48-56&issue=1&author=P.+S.+Naiduauthor=L.+Bookerauthor=B.+F.+Cravattauthor=A.+H.+Lichtman&title=Synergy+between+Enzyme+Inhibitors+of+Fatty+Acid+Amide+Hydrolase+and+Cyclooxygenase+in+Visceral+Nociception&doi=10.1124%2Fjpet.108.143487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception</span></div><div class="casAuthors">Naidu, Pattipati S.; Booker, Lamont; Cravatt, Benjamin F.; Lichtman, Aron H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">329</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-56</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The present study investigated whether inhibition of fatty acid amide hydrolase (FAAH), the enzyme responsible for anandamide catabolism, produces antinociception in the acetic acid-induced abdominal stretching model of visceral nociception.  Genetic deletion or pharmacol. inhibition of FAAH reduced acetic acid-induced abdominal stretching.  Transgenic mice that express FAAH exclusively in the nervous system displayed the antinociceptive phenotype, indicating the involvement of peripheral fatty acid amides.  The cannabinoid receptor 1 (CB1) receptor antagonist, rimonabant, but not the cannabinoid receptor 2 (CB2) receptor antagonist, SR144528, blocked the antinociceptive phenotype of FAAH(-/-) mice and the analgesic effects of URB597 (3'-carbamoyl-biphenyl-3-yl-cyclohexylcarbamate) or OL-135 (1-oxo-1[5-(2-pyridyl)-2-yl]-7-Ph heptane), resp. irreversible and reversible FAAH inhibitors, administered to C57BL/6 mice.  The opioid receptor antagonist, naltrexone, did not block the analgesic effects of either FAAH inhibitor.  URB597, ED50 [95% confidence interval (CI) = 2.1 (1.5-2.9) mg/kg], and the non-selective cyclooxygenase inhibitor, diclofenac sodium [ED50 (95% CI) = 9.8 (8.2-11.7) mg/kg], dose-dependently inhibited acetic acid-induced abdominal stretching.  Combinations of URB597 and diclofenac yielded synergistic analgesic interactions according to isobolog. anal.  It is important that FAAH(-/-) mice and URB597-treated mice displayed significant redns. in the severity of gastric irritation caused by diclofenac.  URB597 lost its gastroprotective effects in CB1(-/-) mice, whereas it maintained its efficacy in CB2(-/-) mice, indicating a CB1 mechanism of action.  Taken together, the results of the present study suggest that FAAH represents a promising target for the treatment of visceral pain, and a combination of FAAH inhibitors and NSAIDs may have great utility to treat visceral pain, with reduced gastric toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg5twrLEI_mbVg90H21EOLACvtfcHk0lhuqFk9cLFp4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVKntb0%253D&md5=8efa156c1a389d8510fb62af14d2cd8b</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.143487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.143487%26sid%3Dliteratum%253Aachs%26aulast%3DNaidu%26aufirst%3DP.%2BS.%26aulast%3DBooker%26aufirst%3DL.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DLichtman%26aufirst%3DA.%2BH.%26atitle%3DSynergy%2520between%2520Enzyme%2520Inhibitors%2520of%2520Fatty%2520Acid%2520Amide%2520Hydrolase%2520and%2520Cyclooxygenase%2520in%2520Visceral%2520Nociception%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D329%26issue%3D1%26spage%3D48%26epage%3D56%26doi%3D10.1124%2Fjpet.108.143487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaempf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanna, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rofelty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">English, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolosky, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swords, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollyea, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medeiros, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tognon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span> <span> </span><span class="NLM_article-title">Molecularly Targeted Drug Combinations Demonstrate Selective Effectiveness for Myeloid- and Lymphoid-Derived Hematologic Malignancies</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">E7554</span>– <span class="NLM_lpage">E7563</span>, <span class="refDoi"> DOI: 10.1073/pnas.1703094114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1073%2Fpnas.1703094114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28784769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1yku7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=E7554-E7563&issue=36&author=S.+E.+Kurtzauthor=C.+A.+Eideauthor=A.+Kaempfauthor=V.+Khannaauthor=S.+L.+Savageauthor=A.+Rofeltyauthor=I.+Englishauthor=H.+Hoauthor=R.+Pandyaauthor=W.+J.+Boloskyauthor=H.+Poonauthor=M.+W.+Deiningerauthor=R.+Collinsauthor=R.+T.+Swordsauthor=J.+Wattsauthor=D.+A.+Pollyeaauthor=B.+C.+Medeirosauthor=E.+Traerauthor=C.+E.+Tognonauthor=M.+Moriauthor=B.+J.+Drukerauthor=J.+W.+Tyner&title=Molecularly+Targeted+Drug+Combinations+Demonstrate+Selective+Effectiveness+for+Myeloid-+and+Lymphoid-Derived+Hematologic+Malignancies&doi=10.1073%2Fpnas.1703094114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies</span></div><div class="casAuthors">Kurtz, Stephen E.; Eide, Christopher A.; Kaempf, Andy; Khanna, Vishesh; Savage, Samantha L.; Rofelty, Angela; English, Isabel; Ho, Hibery; Pandya, Ravi; Bolosky, William J.; Poon, Hoifung; Deininger, Michael W.; Collins, Robert; Swords, Ronan T.; Watts, Justin; Pollyea, Daniel A.; Medeiros, Bruno C.; Traer, Elie; Tognon, Cristina E.; Mori, Motomi; Druker, Brian J.; Tyner, Jeffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">E7554-E7563</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Translating the genetic and epigenetic heterogeneity underlying human cancers into therapeutic strategies is an ongoing challenge.  Large-scale sequencing efforts have uncovered a spectrum of mutations in many hematol. malignancies, including acute myeloid leukemia (AML), suggesting that combinations of agents will be required to treat these diseases effectively.  Combinatorial approaches will also be crit. for combating the emergence of genetically heterogeneous subclones, rescue signals in the microenvironment, and tumor-intrinsic feedback pathways that all contribute to disease relapse.  To identify novel and effective drug combinations, the authors performed ex vivo sensitivity profiling of 122 primary patient samples from a variety of hematol. malignancies against a panel of 48 drug combinations.  The combinations were designed as drug pairs that target nonoverlapping biol. pathways and comprise drugs from different classes, preferably with Food and Drug Administration approval.  A combination ratio (CR) was derived for each drug pair, and CRs were evaluated with respect to diagnostic categories as well as against genetic, cytogenetic, and cellular phenotypes of specimens from the two largest disease categories: AML and chronic lymphocytic leukemia (CLL).  Nearly all tested combinations involving a BCL2 inhibitor showed addnl. benefit in patients with myeloid malignancies, whereas select combinations involving PI3K, CSF1R, or bromodomain inhibitors showed preferential benefit in lymphoid malignancies.  Expanded analyses of patients with AML and CLL revealed specific patterns of ex vivo drug combination efficacy that were assocd. with select genetic, cytogenetic, and phenotypic disease subsets, warranting further evaluation.  These findings highlight the heuristic value of an integrated functional genomic approach to the identification of novel treatment strategies for hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS5BseZMmHHrVg90H21EOLACvtfcHk0lgG5ENaT77New"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1yku7jI&md5=1a8ece4125f7a943cffe2066b4d9b0ed</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1703094114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1703094114%26sid%3Dliteratum%253Aachs%26aulast%3DKurtz%26aufirst%3DS.%2BE.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DKaempf%26aufirst%3DA.%26aulast%3DKhanna%26aufirst%3DV.%26aulast%3DSavage%26aufirst%3DS.%2BL.%26aulast%3DRofelty%26aufirst%3DA.%26aulast%3DEnglish%26aufirst%3DI.%26aulast%3DHo%26aufirst%3DH.%26aulast%3DPandya%26aufirst%3DR.%26aulast%3DBolosky%26aufirst%3DW.%2BJ.%26aulast%3DPoon%26aufirst%3DH.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DSwords%26aufirst%3DR.%2BT.%26aulast%3DWatts%26aufirst%3DJ.%26aulast%3DPollyea%26aufirst%3DD.%2BA.%26aulast%3DMedeiros%26aufirst%3DB.%2BC.%26aulast%3DTraer%26aufirst%3DE.%26aulast%3DTognon%26aufirst%3DC.%2BE.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26atitle%3DMolecularly%2520Targeted%2520Drug%2520Combinations%2520Demonstrate%2520Selective%2520Effectiveness%2520for%2520Myeloid-%2520and%2520Lymphoid-Derived%2520Hematologic%2520Malignancies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26issue%3D36%26spage%3DE7554%26epage%3DE7563%26doi%3D10.1073%2Fpnas.1703094114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doudna, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charpentier, E.</span></span> <span> </span><span class="NLM_article-title">Genome Editing. The New Frontier of Genome Engineering with CRISPR-Cas9</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>346</i></span> (<span class="NLM_issue">6213</span>),  <span class="NLM_fpage">1258096</span>, <span class="refDoi"> DOI: 10.1126/science.1258096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1126%2Fscience.1258096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=25430774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC2MzhsVemtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2014&pages=1258096&issue=6213&author=J.+A.+Doudnaauthor=E.+Charpentier&title=Genome+Editing.+The+New+Frontier+of+Genome+Engineering+with+CRISPR-Cas9&doi=10.1126%2Fscience.1258096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Genome editing. The new frontier of genome engineering with CRISPR-Cas9</span></div><div class="casAuthors">Doudna Jennifer A; Charpentier Emmanuelle</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">6213</span>),
    <span class="NLM_cas:pages">1258096</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The advent of facile genome engineering using the bacterial RNA-guided CRISPR-Cas9 system in animals and plants is transforming biology.  We review the history of CRISPR (clustered regularly interspaced palindromic repeat) biology from its initial discovery through the elucidation of the CRISPR-Cas9 enzyme mechanism, which has set the stage for remarkable developments using this technology to modify, regulate, or mark genomic loci in a wide variety of cells and organisms from all three domains of life.  These results highlight a new era in which genomic manipulation is no longer a bottleneck to experiments, paving the way toward fundamental discoveries in biology, with applications in all branches of biotechnology, as well as strategies for human therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRrbUZVx6ve4TAEfvC7EH1LfW6udTcc2ebUv0gW-vs9O7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MzhsVemtg%253D%253D&md5=ed025d7bc203eb757d935c9bdd671650</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1126%2Fscience.1258096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1258096%26sid%3Dliteratum%253Aachs%26aulast%3DDoudna%26aufirst%3DJ.%2BA.%26aulast%3DCharpentier%26aufirst%3DE.%26atitle%3DGenome%2520Editing.%2520The%2520New%2520Frontier%2520of%2520Genome%2520Engineering%2520with%2520CRISPR-Cas9%26jtitle%3DScience%26date%3D2014%26volume%3D346%26issue%3D6213%26spage%3D1258096%26doi%3D10.1126%2Fscience.1258096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhlik, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moxham, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomandl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sall, D. J.</span></span> <span> </span><span class="NLM_article-title">Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4527</span>– <span class="NLM_lpage">4538</span>, <span class="refDoi"> DOI: 10.1021/jm201649s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201649s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1OitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4527-4538&issue=10&author=J.+A.+Leeauthor=M.+T.+Uhlikauthor=C.+M.+Moxhamauthor=D.+Tomandlauthor=D.+J.+Sall&title=Modern+Phenotypic+Drug+Discovery+Is+a+Viable%2C+Neoclassic+Pharma+Strategy&doi=10.1021%2Fjm201649s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy</span></div><div class="casAuthors">Lee, Jonathan A.; Uhlik, Mark T.; Moxham, Christopher M.; Tomandl, Dirk; Sall, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4527-4538</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pharmaceutical industry (Pharma) is currently facing unprecedented challenges.  In addn. to strategic patent expirations, the rate of drug launches has been essentially const. for 60 years with overall productivity falling since the 1970s.  Similarly, the appearance of novel targets to FDA approved drugs, a measure of industry innovation, has not dramatically improved since the 1980s.  Although Pharma productivity is a multifaceted problem, detailed analyses of comprehensive, industry-wide data indicate that late stage clin. failures are a major contributor that has been attributed to poor target validation (TV) and the lack of predictive biomarkers that translate to the clinic.  In the spirit of "reinventing innovation" Pharma needs to introspectively identify areas for improvement.  This communication considers how choices in drug screening strategies may relate to target validation issues and influence the probability of identifying novel medicines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8CcODiYYNgLVg90H21EOLACvtfcHk0lgG5ENaT77New"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1OitLs%253D&md5=1937641b632e348d7566c016ca4cf51d</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Fjm201649s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201649s%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BA.%26aulast%3DUhlik%26aufirst%3DM.%2BT.%26aulast%3DMoxham%26aufirst%3DC.%2BM.%26aulast%3DTomandl%26aufirst%3DD.%26aulast%3DSall%26aufirst%3DD.%2BJ.%26atitle%3DModern%2520Phenotypic%2520Drug%2520Discovery%2520Is%2520a%2520Viable%252C%2520Neoclassic%2520Pharma%2520Strategy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D10%26spage%3D4527%26epage%3D4538%26doi%3D10.1021%2Fjm201649s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Houck, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judson, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavlock, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, E. L.</span></span> <span> </span><span class="NLM_article-title">Profiling Bioactivity of the ToxCast Chemical Library Using BioMAP Primary Human Cell Systems</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1054</span>– <span class="NLM_lpage">1066</span>, <span class="refDoi"> DOI: 10.1177/1087057109345525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1177%2F1087057109345525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=19773588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVOltr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=1054-1066&issue=9&author=K.+A.+Houckauthor=D.+J.+Dixauthor=R.+S.+Judsonauthor=R.+J.+Kavlockauthor=J.+Yangauthor=E.+L.+Berg&title=Profiling+Bioactivity+of+the+ToxCast+Chemical+Library+Using+BioMAP+Primary+Human+Cell+Systems&doi=10.1177%2F1087057109345525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems</span></div><div class="casAuthors">Houck, Keith A.; Dix, David J.; Judson, Richard S.; Kavlock, Robert J.; Yang, Jian; Berg, Ellen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1054-1066</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The complexity of human biol. has made prediction of health effects as a consequence of exposure to environmental chems. esp. challenging.  Complex cell systems, such as the Biol. Multiplexed Activity Profiling (BioMAP) primary, human, cell-based disease models, leverage cellular regulatory networks to detect and distinguish chems. with a broad range of target mechanisms and biol. processes relevant to human toxicity.  Here the authors use the BioMAP human cell systems to characterize effects relevant to human tissue and inflammatory disease biol. following exposure to the 320 environmental chems. in the Environmental Protection Agency's (EPA's) ToxCast phase I library.  The ToxCast chems. were assayed at 4 concns. in 8 BioMAP cell systems, with a total of 87 assay endpoints resulting in more than 100,000 data points.  Within the context of the BioMAP database, ToxCast compds. could be classified based on their ability to cause overt cytotoxicity in primary human cell types or according to toxicity mechanism class derived from comparisons to activity profiles of BioMAP ref. compds.  ToxCast chems. with similarity to inducers of mitochondrial dysfunction, cAMP elevators, inhibitors of tubulin function, inducers of endoplasmic reticulum stress, or NFκB pathway inhibitors were identified based on this BioMAP anal.  This data set is being combined with addnl. ToxCast data sets for development of predictive toxicity models at the EPA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1Y56HtqVn8LVg90H21EOLACvtfcHk0lijDEBdhoX6mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVOltr3F&md5=473d27ca0d6356c1d646234483b82454</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1177%2F1087057109345525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057109345525%26sid%3Dliteratum%253Aachs%26aulast%3DHouck%26aufirst%3DK.%2BA.%26aulast%3DDix%26aufirst%3DD.%2BJ.%26aulast%3DJudson%26aufirst%3DR.%2BS.%26aulast%3DKavlock%26aufirst%3DR.%2BJ.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DBerg%26aufirst%3DE.%2BL.%26atitle%3DProfiling%2520Bioactivity%2520of%2520the%2520ToxCast%2520Chemical%2520Library%2520Using%2520BioMAP%2520Primary%2520Human%2520Cell%2520Systems%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2009%26volume%3D14%26issue%3D9%26spage%3D1054%26epage%3D1066%26doi%3D10.1177%2F1087057109345525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kleinstreuer, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judson, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polokoff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavlock, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houck, K. A.</span></span> <span> </span><span class="NLM_article-title">Phenotypic Screening of the ToxCast Chemical Library to Classify Toxic and Therapeutic Mechanisms</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">583</span>– <span class="NLM_lpage">591</span>, <span class="refDoi"> DOI: 10.1038/nbt.2914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnbt.2914" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=24837663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotFeqsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=583-591&issue=6&author=N.+C.+Kleinstreuerauthor=J.+Yangauthor=E.+L.+Bergauthor=T.+B.+Knudsenauthor=A.+M.+Richardauthor=M.+T.+Martinauthor=D.+M.+Reifauthor=R.+S.+Judsonauthor=M.+Polokoffauthor=D.+J.+Dixauthor=R.+J.+Kavlockauthor=K.+A.+Houck&title=Phenotypic+Screening+of+the+ToxCast+Chemical+Library+to+Classify+Toxic+and+Therapeutic+Mechanisms&doi=10.1038%2Fnbt.2914"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms</span></div><div class="casAuthors">Kleinstreuer, Nicole C.; Yang, Jian; Berg, Ellen L.; Knudsen, Thomas B.; Richard, Ann M.; Martin, Matthew T.; Reif, David M.; Judson, Richard S.; Polokoff, Mark; Dix, David J.; Kavlock, Robert J.; Houck, Keith A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">583-591</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Addressing the safety aspects of drugs and environmental chems. has historically been undertaken through animal testing.  However, the quantity of chems. in need of assessment and the challenges of species extrapolation require the development of alternative approaches.  Our approach, the US Environmental Protection Agency's ToxCast program, utilizes a large suite of in vitro and model organism assays to interrogate important chem. libraries and computationally analyze bioactivity profiles.  Here we evaluated one component of the ToxCast program, the use of primary human cell systems, by screening for chems. that disrupt physiol. important pathways.  Chem.-response signatures for 87 endpoints covering mol. functions relevant to toxic and therapeutic pathways were generated in eight cell systems for 641 environmental chems. and 135 ref. pharmaceuticals and failed drugs.  Computational clustering of the profiling data provided insights into the polypharmacol. and potential off-target effects for many chems. that have limited or no toxicity information.  The endpoints measured can be closely linked to in vivo outcomes, such as the upregulation of tissue factor in endothelial cell systems by compds. linked to the risk of thrombosis in vivo.  Our results demonstrate that assaying complex biol. pathways in primary human cells can identify potential chem. targets, toxicol. liabilities and mechanisms useful for elucidating adverse outcome pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8F6SVNipd_7Vg90H21EOLACvtfcHk0lijDEBdhoX6mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotFeqsrc%253D&md5=09336f8e859668a0374d8a27ca4a0ff6</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2914%26sid%3Dliteratum%253Aachs%26aulast%3DKleinstreuer%26aufirst%3DN.%2BC.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DBerg%26aufirst%3DE.%2BL.%26aulast%3DKnudsen%26aufirst%3DT.%2BB.%26aulast%3DRichard%26aufirst%3DA.%2BM.%26aulast%3DMartin%26aufirst%3DM.%2BT.%26aulast%3DReif%26aufirst%3DD.%2BM.%26aulast%3DJudson%26aufirst%3DR.%2BS.%26aulast%3DPolokoff%26aufirst%3DM.%26aulast%3DDix%26aufirst%3DD.%2BJ.%26aulast%3DKavlock%26aufirst%3DR.%2BJ.%26aulast%3DHouck%26aufirst%3DK.%2BA.%26atitle%3DPhenotypic%2520Screening%2520of%2520the%2520ToxCast%2520Chemical%2520Library%2520to%2520Classify%2520Toxic%2520and%2520Therapeutic%2520Mechanisms%26jtitle%3DNat.%2520Biotechnol.%26date%3D2014%26volume%3D32%26issue%3D6%26spage%3D583%26epage%3D591%26doi%3D10.1038%2Fnbt.2914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamanaka, S.</span></span> <span> </span><span class="NLM_article-title">Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>126</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">663</span>– <span class="NLM_lpage">676</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2006.07.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.cell.2006.07.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=16904174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD28Xpt1aktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2006&pages=663-676&issue=4&author=K.+Takahashiauthor=S.+Yamanaka&title=Induction+of+Pluripotent+Stem+Cells+from+Mouse+Embryonic+and+Adult+Fibroblast+Cultures+by+Defined+Factors&doi=10.1016%2Fj.cell.2006.07.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors</span></div><div class="casAuthors">Takahashi, Kazutoshi; Yamanaka, Shinya</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">663-676</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Differentiated cells can be reprogrammed to an embryonic-like state by transfer of nuclear contents into oocytes or by fusion with embryonic stem (ES) cells.  Little is known about factors that induce this reprogramming.  Here, we demonstrate induction of pluripotent stem cells from mouse embryonic or adult fibroblasts by introducing four factors, Oct3/4, Sox2, c-Myc, and Klf4, under ES cell culture conditions.  Unexpectedly, Nanog was dispensable.  These cells, which we designated iPS (induced pluripotent stem) cells, exhibit the morphol. and growth properties of ES cells and express ES cell marker genes.  S.c. transplantation of iPS cells into nude mice resulted in tumors contg. a variety of tissues from all three germ layers.  Following injection into blastocysts, iPS cells contributed to mouse embryonic development.  These data demonstrate that pluripotent stem cells can be directly generated from fibroblast cultures by the addn. of only a few defined factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptUUreum_VDbVg90H21EOLACvtfcHk0lijDEBdhoX6mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xpt1aktbs%253D&md5=a681feb59ef3b7e3641e4b52cd0c4e07</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.07.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.07.024%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DYamanaka%26aufirst%3DS.%26atitle%3DInduction%2520of%2520Pluripotent%2520Stem%2520Cells%2520from%2520Mouse%2520Embryonic%2520and%2520Adult%2520Fibroblast%2520Cultures%2520by%2520Defined%2520Factors%26jtitle%3DCell%26date%3D2006%26volume%3D126%26issue%3D4%26spage%3D663%26epage%3D676%26doi%3D10.1016%2Fj.cell.2006.07.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbaric, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gokhale, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, P. W.</span></span> <span> </span><span class="NLM_article-title">High-Content Screening of Small Compounds on Human Embryonic Stem Cells</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1050</span>, <span class="refDoi"> DOI: 10.1042/BST0381046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1042%2FBST0381046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=20659001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlylsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1046-1050&issue=4&author=I.+Barbaricauthor=P.+J.+Gokhaleauthor=P.+W.+Andrews&title=High-Content+Screening+of+Small+Compounds+on+Human+Embryonic+Stem+Cells&doi=10.1042%2FBST0381046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">High-content screening of small compounds on human embryonic stem cells</span></div><div class="casAuthors">Barbaric, Ivana; Gokhale, Paul J.; Andrews, Peter W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1046-1050</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Human ES (embryonic stem) cells and iPS (induced pluripotent stem) cells have been heralded as a source of differentiated cells that could be used in the treatment of degenerative diseases, such as Parkinson's disease or diabetes.  Despite the great potential for their use in regenerative therapy, the challenge remains to understand the basic biol. of these remarkable cells, in order to differentiate them into any functional cell type.  Given the scale of the task, high-throughput screening of agents and culture conditions offers one way to accelerate these studies.  The screening of small-compd. libraries is particularly amenable to such high-throughput methods.  Coupled with high-content screening technol. that enables simultaneous assessment of multiple cellular features in an automated and quant. way, this approach is proving powerful in identifying both small mols. as tools for manipulating stem cell fates and novel mechanisms of differentiation not previously assocd. with stem cell biol.  Such screens performed on human ES cells also demonstrate the usefulness of human ES/iPS cells as cellular models for pharmacol. testing of drug efficacy and toxicity, possibly a more imminent use of these cells than in regenerative medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1NpFqP6fszLVg90H21EOLACvtfcHk0lgoPVpT9FBnBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlylsLo%253D&md5=a5edb795b5ae7f3bbd992c30b75e4fc6</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1042%2FBST0381046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST0381046%26sid%3Dliteratum%253Aachs%26aulast%3DBarbaric%26aufirst%3DI.%26aulast%3DGokhale%26aufirst%3DP.%2BJ.%26aulast%3DAndrews%26aufirst%3DP.%2BW.%26atitle%3DHigh-Content%2520Screening%2520of%2520Small%2520Compounds%2520on%2520Human%2520Embryonic%2520Stem%2520Cells%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2010%26volume%3D38%26issue%3D4%26spage%3D1046%26epage%3D1050%26doi%3D10.1042%2FBST0381046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCarroll, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gendelev, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keiser, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokel, D.</span></span> <span> </span><span class="NLM_article-title">Leveraging Large-Scale Behavioral Profiling in Zebrafish to Explore Neuroactive Polypharmacology</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">842</span>– <span class="NLM_lpage">849</span>, <span class="refDoi"> DOI: 10.1021/acschembio.5b00800</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00800" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVSlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=842-849&issue=4&author=M.+N.+McCarrollauthor=L.+Gendelevauthor=M.+J.+Keiserauthor=D.+Kokel&title=Leveraging+Large-Scale+Behavioral+Profiling+in+Zebrafish+to+Explore+Neuroactive+Polypharmacology&doi=10.1021%2Facschembio.5b00800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Leveraging Large-scale Behavioral Profiling in Zebrafish to Explore Neuroactive Polypharmacology</span></div><div class="casAuthors">McCarroll, Matthew N.; Gendelev, Leo; Keiser, Michael J.; Kokel, David</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">842-849</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Many psychiatric drugs modulate the nervous system through multitarget mechanisms.  However, systematic identification of multitarget compds. has been difficult using traditional in vitro screening assays.  New approaches to phenotypic profiling in zebrafish can help researchers identify novel compds. with complex polypharmacol.  For example, large-scale behavior-based chem. screens can rapidly identify large nos. of structurally diverse and phenotype-related compds.  Once these compds. have been identified, a systems-level anal. of their structures may help to identify statistically enriched target pathways.  Together, systematic behavioral profiling and multitarget predictions may help researchers identify new behavior-modifying pathways and CNS therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3QN11t7PEEbVg90H21EOLACvtfcHk0lgoPVpT9FBnBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVSlsL8%253D&md5=6d69351d9c3e6c711881947aac517e75</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00800%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarroll%26aufirst%3DM.%2BN.%26aulast%3DGendelev%26aufirst%3DL.%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DKokel%26aufirst%3DD.%26atitle%3DLeveraging%2520Large-Scale%2520Behavioral%2520Profiling%2520in%2520Zebrafish%2520to%2520Explore%2520Neuroactive%2520Polypharmacology%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26issue%3D4%26spage%3D842%26epage%3D849%26doi%3D10.1021%2Facschembio.5b00800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonoshita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scopton, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ung, P. M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silber, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Real, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cagan, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dar, A. C.</span></span> <span> </span><span class="NLM_article-title">A Whole-Animal Platform to Advance a Clinical Kinase Inhibitor into New Disease Space</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2556</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnchembio.2556" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29355849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtl2msrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=291-298&issue=3&author=M.+Sonoshitaauthor=A.+P.+Scoptonauthor=P.+M.+U.+Ungauthor=M.+A.+Murrayauthor=L.+Silberauthor=A.+Y.+Maldonadoauthor=A.+Realauthor=A.+Schlessingerauthor=R.+L.+Caganauthor=A.+C.+Dar&title=A+Whole-Animal+Platform+to+Advance+a+Clinical+Kinase+Inhibitor+into+New+Disease+Space&doi=10.1038%2Fnchembio.2556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">A whole-animal platform to advance a clinical kinase inhibitor into new disease space</span></div><div class="casAuthors">Sonoshita, Masahiro; Scopton, Alex P.; Ung, Peter M. U.; Murray, Matthew A.; Silber, Lisa; Maldonado, Andres Y.; Real, Alexander; Schlessinger, Avner; Cagan, Ross L.; Dar, Arvin C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">291-298</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Synthetic tailoring of approved drugs for new indications is often difficult, as the most appropriate targets may not be readily apparent, and therefore few roadmaps exist to guide chem.  Here, we report a multidisciplinary approach for accessing novel target and chem. space starting from an FDA-approved kinase inhibitor.  By combining chem. and genetic modifier screening with computational modeling, we identify distinct kinases that strongly enhance ('pro-targets') or limit ('anti-targets') whole-animal activity of the clin. kinase inhibitor sorafenib in a Drosophila medullary thyroid carcinoma (MTC) model.  We demonstrate that RAF-the original intended sorafenib target-and MKNK kinases function as pharmacol. liabilities because of inhibitor-induced transactivation and neg. feedback, resp.  Through progressive synthetic refinement, we report a new class of 'tumor calibrated inhibitors' with unique polypharmacol. and strongly improved therapeutic index in fly and human MTC xenograft models.  This platform provides a rational approach to creating new high-efficacy and low-toxicity drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokPGDBCxqaILVg90H21EOLACvtfcHk0lgoPVpT9FBnBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtl2msrk%253D&md5=54fd159e29ffa581e7c53983d92dd134</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2556%26sid%3Dliteratum%253Aachs%26aulast%3DSonoshita%26aufirst%3DM.%26aulast%3DScopton%26aufirst%3DA.%2BP.%26aulast%3DUng%26aufirst%3DP.%2BM.%2BU.%26aulast%3DMurray%26aufirst%3DM.%2BA.%26aulast%3DSilber%26aufirst%3DL.%26aulast%3DMaldonado%26aufirst%3DA.%2BY.%26aulast%3DReal%26aufirst%3DA.%26aulast%3DSchlessinger%26aufirst%3DA.%26aulast%3DCagan%26aufirst%3DR.%2BL.%26aulast%3DDar%26aufirst%3DA.%2BC.%26atitle%3DA%2520Whole-Animal%2520Platform%2520to%2520Advance%2520a%2520Clinical%2520Kinase%2520Inhibitor%2520into%2520New%2520Disease%2520Space%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2018%26volume%3D14%26issue%3D3%26spage%3D291%26epage%3D298%26doi%3D10.1038%2Fnchembio.2556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span> <span> </span><span class="NLM_article-title">Network Pharmacology: The next Paradigm in Drug Discovery</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">682</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1038/nchembio.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnchembio.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=18936753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=682-690&issue=11&author=A.+L.+Hopkins&title=Network+Pharmacology%3A+The+next+Paradigm+in+Drug+Discovery&doi=10.1038%2Fnchembio.118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology: the next paradigm in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">682-690</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is the concept of designing maximally selective ligands to act on individual drug targets.  However, many effective drugs act via modulation of multiple proteins rather than single targets.  Advances in systems biol. are revealing a phenotypic robustness and a network structure that strongly suggests that exquisitely selective compds., compared with multi-target drugs, may exhibit lower than desired clin. efficacy.  This new appreciation of the role of polypharmacol. has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity.  Integrating network biol. and polypharmacol. holds the promise of expanding the current opportunity space for druggable targets.  However, the rational design of polypharmacol. faces considerable challenges in the need for new methods to validate target combinations and optimize multiple structure-activity relationships while maintaining drug-like properties.  Advances in these areas are creating the foundation of the next paradigm in drug discovery: network pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqHy4FqkK-h7Vg90H21EOLACvtfcHk0lgoPVpT9FBnBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK&md5=03b8be3ddbcab7dc65afd17df7ee8395</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.118%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DNetwork%2520Pharmacology%253A%2520The%2520next%2520Paradigm%2520in%2520Drug%2520Discovery%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26issue%3D11%26spage%3D682%26epage%3D690%26doi%3D10.1038%2Fnchembio.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z.</span></span> <span> </span><span class="NLM_article-title">Advances in Computational Approaches in Identifying Synergistic Drug Combinations</span>. <i>Briefings Bioinf.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>, <span class="refDoi"> DOI: 10.1093/bib/bbx047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1093%2Fbib%2Fbbx047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=26822098" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Z.+Shengauthor=Y.+Sunauthor=Z.+Yinauthor=K.+Tangauthor=Z.+Cao&title=Advances+in+Computational+Approaches+in+Identifying+Synergistic+Drug+Combinations&doi=10.1093%2Fbib%2Fbbx047"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1093%2Fbib%2Fbbx047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbib%252Fbbx047%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DTang%26aufirst%3DK.%26aulast%3DCao%26aufirst%3DZ.%26atitle%3DAdvances%2520in%2520Computational%2520Approaches%2520in%2520Identifying%2520Synergistic%2520Drug%2520Combinations%26jtitle%3DBriefings%2520Bioinf.%26date%3D2017%26doi%3D10.1093%2Fbib%2Fbbx047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chua, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhowmick, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker-Kellogg, L.</span></span> <span> </span><span class="NLM_article-title">Synergistic Target Combination Prediction from Curated Signaling Networks: Machine Learning Meets Systems Biology and Pharmacology</span>. <i>Methods</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">60</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1016/j.ymeth.2017.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.ymeth.2017.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28552265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpsVKjur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=60-80&author=H.+E.+Chuaauthor=S.+S.+Bhowmickauthor=L.+Tucker-Kellogg&title=Synergistic+Target+Combination+Prediction+from+Curated+Signaling+Networks%3A+Machine+Learning+Meets+Systems+Biology+and+Pharmacology&doi=10.1016%2Fj.ymeth.2017.05.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic target combination prediction from curated signaling networks: Machine learning meets systems biology and pharmacology</span></div><div class="casAuthors">Chua, Huey Eng; Bhowmick, Sourav S.; Tucker-Kellogg, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Methods (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">60-80</span>CODEN:
                <span class="NLM_cas:coden">MTHDE9</span>;
        ISSN:<span class="NLM_cas:issn">1046-2023</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Given a signaling network, the target combination prediction problem aims to predict efficacious and safe target combinations for combination therapy.  State-of-the-art in silico methods use Monte Carlo simulated annealing (MCSA) to modify a candidate soln. stochastically, and use the Metropolis criterion to accept or reject the proposed modifications.  However, such stochastic modifications ignore the impact of the choice of targets and their activities on the combination's therapeutic effect and off-target effects, which directly affect the soln. quality.  In this paper, we present MASCOT, a method that addresses this limitation by leveraging two addnl. heuristic criteria to minimize off-target effects and achieve synergy for candidate modification.  Specifically, off-target effects measure the unintended response of a signaling network to the target combination and is often assocd. with toxicity.  Synergy occurs when a pair of targets exerts effects that are greater than the sum of their individual effects, and is generally a beneficial strategy for maximizing effect while minimizing toxicity. MASCOT leverages on a machine learning-based target prioritization method which prioritizes potential targets in a given disease-assocd. network to select more effective targets (better therapeutic effect and/or lower off-target effects); and on Loewe additivity theory from pharmacol. which assesses the non-additive effects in a combination drug treatment to select synergistic target activities.  Our exptl. study on two disease-related signaling networks demonstrates the superiority of MASCOT in comparison to existing approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0NdKdd4aa5rVg90H21EOLACvtfcHk0lhpdt-zNR5TKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpsVKjur0%253D&md5=aeb07b7c7c6a58e6c4e7e70418e6fdec</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.ymeth.2017.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymeth.2017.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DChua%26aufirst%3DH.%2BE.%26aulast%3DBhowmick%26aufirst%3DS.%2BS.%26aulast%3DTucker-Kellogg%26aufirst%3DL.%26atitle%3DSynergistic%2520Target%2520Combination%2520Prediction%2520from%2520Curated%2520Signaling%2520Networks%253A%2520Machine%2520Learning%2520Meets%2520Systems%2520Biology%2520and%2520Pharmacology%26jtitle%3DMethods%26date%3D2017%26volume%3D129%26spage%3D60%26epage%3D80%26doi%3D10.1016%2Fj.ymeth.2017.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Ali, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danzi, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nassif, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennerberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemmon, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bixby, J. L.</span></span> <span> </span><span class="NLM_article-title">Rational Polypharmacology: Systematically Identifying and Engaging Multiple Drug Targets To Promote Axon Growth</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1939</span>– <span class="NLM_lpage">1951</span>, <span class="refDoi"> DOI: 10.1021/acschembio.5b00289</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00289" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVShtrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1939-1951&issue=8&author=H.+Al-Aliauthor=D.-H.+Leeauthor=M.+C.+Danziauthor=H.+Nassifauthor=P.+Gautamauthor=K.+Wennerbergauthor=B.+Zuercherauthor=D.+H.+Drewryauthor=J.+K.+Leeauthor=V.+P.+Lemmonauthor=J.+L.+Bixby&title=Rational+Polypharmacology%3A+Systematically+Identifying+and+Engaging+Multiple+Drug+Targets+To+Promote+Axon+Growth&doi=10.1021%2Facschembio.5b00289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Polypharmacology: Systematically Identifying and Engaging Multiple Drug Targets To Promote Axon Growth</span></div><div class="casAuthors">Al-Ali, Hassan; Lee, Do-Hun; Danzi, Matt C.; Nassif, Houssam; Gautam, Prson; Wennerberg, Krister; Zuercher, Bill; Drewry, David H.; Lee, Jae K.; Lemmon, Vance P.; Bixby, John L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1939-1951</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mammalian central nervous system (CNS) neurons regrow their axons poorly following injury, resulting in irreversible functional losses.  Identifying therapeutics that encourage CNS axon repair has been difficult, in part because multiple etiologies underlie this regenerative failure.  This suggests a particular need for drugs that engage multiple mol. targets.  Although multitarget drugs are generally more effective than highly selective alternatives, we lack systematic methods for discovering such drugs.  Target-based screening is an efficient technique for identifying potent modulators of individual targets.  In contrast, phenotypic screening can identify drugs with multiple targets; however, these targets remain unknown.  To address this gap, we combined the two drug discovery approaches using machine learning and information theory.  We screened compds. in a phenotypic assay with primary CNS neurons and also in a panel of kinase enzyme assays.  We used learning algorithms to relate the compds.' kinase inhibition profiles to their influence on neurite outgrowth.  This allowed us to identify kinases that may serve as targets for promoting neurite outgrowth as well as others whose targeting should be avoided.  We found that compds. that inhibit multiple targets (polypharmacol.) promote robust neurite outgrowth in vitro.  One compd. with exemplary polypharmacol. was found to promote axon growth in a rodent spinal cord injury model.  A more general applicability of our approach is suggested by its ability to deconvolve known targets for a breast cancer cell line as well as targets recently shown to mediate drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp0BRepIT6uLVg90H21EOLACvtfcHk0lhpdt-zNR5TKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVShtrbP&md5=5acb16e8a679f39a3b31b76449742d2a</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00289%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Ali%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DD.-H.%26aulast%3DDanzi%26aufirst%3DM.%2BC.%26aulast%3DNassif%26aufirst%3DH.%26aulast%3DGautam%26aufirst%3DP.%26aulast%3DWennerberg%26aufirst%3DK.%26aulast%3DZuercher%26aufirst%3DB.%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BK.%26aulast%3DLemmon%26aufirst%3DV.%2BP.%26aulast%3DBixby%26aufirst%3DJ.%2BL.%26atitle%3DRational%2520Polypharmacology%253A%2520Systematically%2520Identifying%2520and%2520Engaging%2520Multiple%2520Drug%2520Targets%2520To%2520Promote%2520Axon%2520Growth%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26issue%3D8%26spage%3D1939%26epage%3D1951%26doi%3D10.1021%2Facschembio.5b00289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinelli, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheikh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korkut, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crago, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, C.</span></span> <span> </span><span class="NLM_article-title">Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma Identifies CDK4 and IGF1R as Synergistic Drug Targets</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">294</span>),  <span class="NLM_fpage">ra85</span>, <span class="refDoi"> DOI: 10.1126/scisignal.2004014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1126%2Fscisignal.2004014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=24065146" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=ra85&issue=294&author=M.+L.+Millerauthor=E.+J.+Molinelliauthor=J.+S.+Nairauthor=T.+Sheikhauthor=R.+Samyauthor=X.+Jingauthor=Q.+Heauthor=A.+Korkutauthor=A.+M.+Cragoauthor=S.+Singerauthor=G.+K.+Schwartzauthor=C.+Sander&title=Drug+Synergy+Screen+and+Network+Modeling+in+Dedifferentiated+Liposarcoma+Identifies+CDK4+and+IGF1R+as+Synergistic+Drug+Targets&doi=10.1126%2Fscisignal.2004014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.2004014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.2004014%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BL.%26aulast%3DMolinelli%26aufirst%3DE.%2BJ.%26aulast%3DNair%26aufirst%3DJ.%2BS.%26aulast%3DSheikh%26aufirst%3DT.%26aulast%3DSamy%26aufirst%3DR.%26aulast%3DJing%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DQ.%26aulast%3DKorkut%26aufirst%3DA.%26aulast%3DCrago%26aufirst%3DA.%2BM.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26aulast%3DSander%26aufirst%3DC.%26atitle%3DDrug%2520Synergy%2520Screen%2520and%2520Network%2520Modeling%2520in%2520Dedifferentiated%2520Liposarcoma%2520Identifies%2520CDK4%2520and%2520IGF1R%2520as%2520Synergistic%2520Drug%2520Targets%26jtitle%3DSci.%2520Signaling%26date%3D2013%26volume%3D6%26issue%3D294%26spage%3Dra85%26doi%3D10.1126%2Fscisignal.2004014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulesskiy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saarela, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turunen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennerberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aittokallio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span> <span> </span><span class="NLM_article-title">Methods for High-Throughput Drug Combination Screening and Synergy Scoring</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>1711</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-7493-1_17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1007%2F978-1-4939-7493-1_17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29344898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFKrsLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1711&publication_year=2018&pages=351-398&author=L.+Heauthor=E.+Kulesskiyauthor=J.+Saarelaauthor=L.+Turunenauthor=K.+Wennerbergauthor=T.+Aittokallioauthor=J.+Tang&title=Methods+for+High-Throughput+Drug+Combination+Screening+and+Synergy+Scoring&doi=10.1007%2F978-1-4939-7493-1_17"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Methods for high-throughput drug combination screening and synergy scoring</span></div><div class="casAuthors">He, Liye; Kulesskiy, Evgeny; Saarela, Jani; Turunen, Laura; Wennerberg, Krister; Aittokallio, Tero; Tang, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">1711</span>
        (<span class="NLM_cas:issue">Cancer Systems Biology</span>),
    <span class="NLM_cas:pages">351-398</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Gene products or pathways that are aberrantly activated in cancer but not in normal tissue hold great promises for being effective and safe anticancer therapeutic targets.  Many targeted drugs have entered clin. trials but so far showed limited efficacy mostly due to variability in treatment responses and often rapidly emerging resistance.  Toward more effective treatment options, we will need multi-targeted drugs or drug combinations, which selectively inhibit the viability and growth of cancer cells and block distinct escape mechanisms for the cells to become resistant.  Functional profiling of drug combinations requires careful exptl. design and robust data anal. approaches.  At the Institute for Mol. Medicine Finland (FIMM), we have developed an exptl.-computational pipeline for high-throughput screening of drug combination effects in cancer cells.  The integration of automated screening techniques with advanced synergy scoring tools allows for efficient and reliable detection of synergistic drug interactions within a specific window of concns., hence accelerating the identification of potential drug combinations for further confirmatory studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfgjBJ4FdnaLVg90H21EOLACvtfcHk0ljCfCf4cO080w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFKrsLnK&md5=f1cd93a614aa72ecbe2261500e405b85</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-7493-1_17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-7493-1_17%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DL.%26aulast%3DKulesskiy%26aufirst%3DE.%26aulast%3DSaarela%26aufirst%3DJ.%26aulast%3DTurunen%26aufirst%3DL.%26aulast%3DWennerberg%26aufirst%3DK.%26aulast%3DAittokallio%26aufirst%3DT.%26aulast%3DTang%26aufirst%3DJ.%26atitle%3DMethods%2520for%2520High-Throughput%2520Drug%2520Combination%2520Screening%2520and%2520Synergy%2520Scoring%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2018%26volume%3D1711%26spage%3D351%26epage%3D398%26doi%3D10.1007%2F978-1-4939-7493-1_17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kashif, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansoori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nygren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafsson, M. G.</span></span> <span> </span><span class="NLM_article-title">Bliss and Loewe Interaction Analyses of Clinically Relevant Drug Combinations in Human Colon Cancer Cell Lines Reveal Complex Patterns of Synergy and Antagonism</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">103952</span>– <span class="NLM_lpage">103967</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.21895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.18632%2Foncotarget.21895" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=103952-103967&author=M.+Kashifauthor=C.+Anderssonauthor=S.+Mansooriauthor=R.+Larssonauthor=P.+Nygrenauthor=M.+G.+Gustafsson&title=Bliss+and+Loewe+Interaction+Analyses+of+Clinically+Relevant+Drug+Combinations+in+Human+Colon+Cancer+Cell+Lines+Reveal+Complex+Patterns+of+Synergy+and+Antagonism&doi=10.18632%2Foncotarget.21895"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.21895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.21895%26sid%3Dliteratum%253Aachs%26aulast%3DKashif%26aufirst%3DM.%26aulast%3DAndersson%26aufirst%3DC.%26aulast%3DMansoori%26aufirst%3DS.%26aulast%3DLarsson%26aufirst%3DR.%26aulast%3DNygren%26aufirst%3DP.%26aulast%3DGustafsson%26aufirst%3DM.%2BG.%26atitle%3DBliss%2520and%2520Loewe%2520Interaction%2520Analyses%2520of%2520Clinically%2520Relevant%2520Drug%2520Combinations%2520in%2520Human%2520Colon%2520Cancer%2520Cell%2520Lines%2520Reveal%2520Complex%2520Patterns%2520of%2520Synergy%2520and%2520Antagonism%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D103952%26epage%3D103967%26doi%3D10.18632%2Foncotarget.21895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wambaugh, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakya, V. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvey, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. C. S.</span></span> <span> </span><span class="NLM_article-title">High-Throughput Identification and Rational Design of Synergistic Small-Molecule Pairs for Combating and Bypassing Antibiotic Resistance</span>. <i>PLoS Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">e2001644</span>, <span class="refDoi"> DOI: 10.1371/journal.pbio.2001644</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1371%2Fjournal.pbio.2001644" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=e2001644&issue=6&author=M.+A.+Wambaughauthor=V.+P.+S.+Shakyaauthor=A.+J.+Lewisauthor=M.+A.+Mulveyauthor=J.+C.+S.+Brown&title=High-Throughput+Identification+and+Rational+Design+of+Synergistic+Small-Molecule+Pairs+for+Combating+and+Bypassing+Antibiotic+Resistance&doi=10.1371%2Fjournal.pbio.2001644"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.2001644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.2001644%26sid%3Dliteratum%253Aachs%26aulast%3DWambaugh%26aufirst%3DM.%2BA.%26aulast%3DShakya%26aufirst%3DV.%2BP.%2BS.%26aulast%3DLewis%26aufirst%3DA.%2BJ.%26aulast%3DMulvey%26aufirst%3DM.%2BA.%26aulast%3DBrown%26aufirst%3DJ.%2BC.%2BS.%26atitle%3DHigh-Throughput%2520Identification%2520and%2520Rational%2520Design%2520of%2520Synergistic%2520Small-Molecule%2520Pairs%2520for%2520Combating%2520and%2520Bypassing%2520Antibiotic%2520Resistance%26jtitle%3DPLoS%2520Biol.%26date%3D2017%26volume%3D15%26issue%3D6%26spage%3De2001644%26doi%3D10.1371%2Fjournal.pbio.2001644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mason, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashenden, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakoc, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meral, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuru, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cokol, M.</span></span> <span> </span><span class="NLM_article-title">Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3902</span>– <span class="NLM_lpage">3912</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00204</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00204" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3902-3912&issue=9&author=D.+J.+Masonauthor=I.+Stottauthor=S.+Ashendenauthor=Z.+B.+Weinsteinauthor=I.+Karakocauthor=S.+Meralauthor=N.+Kuruauthor=A.+Benderauthor=M.+Cokol&title=Prediction+of+Antibiotic+Interactions+Using+Descriptors+Derived+from+Molecular+Structure&doi=10.1021%2Facs.jmedchem.7b00204"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00204%26sid%3Dliteratum%253Aachs%26aulast%3DMason%26aufirst%3DD.%2BJ.%26aulast%3DStott%26aufirst%3DI.%26aulast%3DAshenden%26aufirst%3DS.%26aulast%3DWeinstein%26aufirst%3DZ.%2BB.%26aulast%3DKarakoc%26aufirst%3DI.%26aulast%3DMeral%26aufirst%3DS.%26aulast%3DKuru%26aufirst%3DN.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DCokol%26aufirst%3DM.%26atitle%3DPrediction%2520of%2520Antibiotic%2520Interactions%2520Using%2520Descriptors%2520Derived%2520from%2520Molecular%2520Structure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D9%26spage%3D3902%26epage%3D3912%26doi%3D10.1021%2Facs.jmedchem.7b00204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span> <span> </span><span class="NLM_article-title">Predicting Synergistic Effects between Compounds through Their Structural Similarity and Effects on Transcriptomes</span>. <i>Bioinformatics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">3782</span>– <span class="NLM_lpage">3789</span>, <span class="refDoi"> DOI: 10.1093/bioinformatics/btw509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1093%2Fbioinformatics%2Fbtw509" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2016&pages=3782-3789&issue=24&author=Y.+Liuauthor=H.+Zhao&title=Predicting+Synergistic+Effects+between+Compounds+through+Their+Structural+Similarity+and+Effects+on+Transcriptomes&doi=10.1093%2Fbioinformatics%2Fbtw509"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1093%2Fbioinformatics%2Fbtw509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbioinformatics%252Fbtw509%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DH.%26atitle%3DPredicting%2520Synergistic%2520Effects%2520between%2520Compounds%2520through%2520Their%2520Structural%2520Similarity%2520and%2520Effects%2520on%2520Transcriptomes%26jtitle%3DBioinformatics%26date%3D2016%26volume%3D32%26issue%3D24%26spage%3D3782%26epage%3D3789%26doi%3D10.1093%2Fbioinformatics%2Fbtw509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Preuer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R. P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochreiter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulusu, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klambauer, G.</span></span> <span> </span><span class="NLM_article-title">DeepSynergy: Predicting Anti-Cancer Drug Synergy with Deep Learning</span>. <i>Bioinformatics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1538</span>– <span class="NLM_lpage">1546</span>, <span class="refDoi"> DOI: 10.1093/bioinformatics/btx806</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1093%2Fbioinformatics%2Fbtx806" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29253077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC1Mzislajtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2018&pages=1538-1546&issue=9&author=K.+Preuerauthor=R.+P.+I.+Lewisauthor=S.+Hochreiterauthor=A.+Benderauthor=K.+C.+Bulusuauthor=G.+Klambauer&title=DeepSynergy%3A+Predicting+Anti-Cancer+Drug+Synergy+with+Deep+Learning&doi=10.1093%2Fbioinformatics%2Fbtx806"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">DeepSynergy: predicting anti-cancer drug synergy with Deep Learning</span></div><div class="casAuthors">Preuer Kristina; Hochreiter Sepp; Klambauer Gunter; Lewis Richard P I; Bender Andreas; Bulusu Krishna C; Bulusu Krishna C</div><div class="citationInfo"><span class="NLM_cas:title">Bioinformatics (Oxford, England)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1538-1546</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Motivation:  While drug combination therapies are a well-established concept in cancer treatment, identifying novel synergistic combinations is challenging due to the size of combinatorial space.  However, computational approaches have emerged as a time- and cost-efficient way to prioritize combinations to test, based on recently available large-scale combination screening data.  Recently, Deep Learning has had an impact in many research areas by achieving new state-of-the-art model performance.  However, Deep Learning has not yet been applied to drug synergy prediction, which is the approach we present here, termed DeepSynergy.  DeepSynergy uses chemical and genomic information as input information, a normalization strategy to account for input data heterogeneity, and conical layers to model drug synergies.  Results:  DeepSynergy was compared to other machine learning methods such as Gradient Boosting Machines, Random Forests, Support Vector Machines and Elastic Nets on the largest publicly available synergy dataset with respect to mean squared error.  DeepSynergy significantly outperformed the other methods with an improvement of 7.2% over the second best method at the prediction of novel drug combinations within the space of explored drugs and cell lines.  At this task, the mean Pearson correlation coefficient between the measured and the predicted values of DeepSynergy was 0.73.  Applying DeepSynergy for classification of these novel drug combinations resulted in a high predictive performance of an AUC of 0.90.  Furthermore, we found that all compared methods exhibit low predictive performance when extrapolating to unexplored drugs or cell lines, which we suggest is due to limitations in the size and diversity of the dataset.  We envision that DeepSynergy could be a valuable tool for selecting novel synergistic drug combinations.  Availability and implementation:  DeepSynergy is available via www.bioinf.jku.at/software/DeepSynergy.  Contact:  <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="c6adaaa7aba4a7b3a3b486a4afa9afa8a0e8acadb3e8a7b2e8">[email protected]</a>  Supplementary information:  Supplementary data are available at Bioinformatics online.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRXGLh7DBe7VohLSh9fo81bfW6udTcc2eZY7Df0VeRdh7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mzislajtw%253D%253D&md5=0ee7b03378f719879f22935abf033f23</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1093%2Fbioinformatics%2Fbtx806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbioinformatics%252Fbtx806%26sid%3Dliteratum%253Aachs%26aulast%3DPreuer%26aufirst%3DK.%26aulast%3DLewis%26aufirst%3DR.%2BP.%2BI.%26aulast%3DHochreiter%26aufirst%3DS.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DBulusu%26aufirst%3DK.%2BC.%26aulast%3DKlambauer%26aufirst%3DG.%26atitle%3DDeepSynergy%253A%2520Predicting%2520Anti-Cancer%2520Drug%2520Synergy%2520with%2520Deep%2520Learning%26jtitle%3DBioinformatics%26date%3D2018%26volume%3D34%26issue%3D9%26spage%3D1538%26epage%3D1546%26doi%3D10.1093%2Fbioinformatics%2Fbtx806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span> <span> </span><span class="NLM_article-title">Prediction of Synergistic Anti-Cancer Drug Combinations Based on Drug Target Network and Drug Induced Gene Expression Profiles</span>. <i>Artif. Intell. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/j.artmed.2017.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.artmed.2017.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28583437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC1cnlt1Wksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2017&pages=35-43&author=X.+Liauthor=Y.+Xuauthor=H.+Cuiauthor=T.+Huangauthor=D.+Wangauthor=B.+Lianauthor=W.+Liauthor=G.+Qinauthor=L.+Chenauthor=L.+Xie&title=Prediction+of+Synergistic+Anti-Cancer+Drug+Combinations+Based+on+Drug+Target+Network+and+Drug+Induced+Gene+Expression+Profiles&doi=10.1016%2Fj.artmed.2017.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles</span></div><div class="casAuthors">Li Xiangyi; Xu Yingjie; Cui Hui; Huang Tao; Wang Disong; Lian Baofeng; Li Wei; Qin Guangrong; Xie Lu; Chen Lanming</div><div class="citationInfo"><span class="NLM_cas:title">Artificial intelligence in medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35-43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Synergistic drug combinations are promising therapies for cancer treatment.  However, effective prediction of synergistic drug combinations is quite challenging as mechanisms of drug synergism are still unclear.  Various features such as drug response, and target networks may contribute to prediction of synergistic drug combinations.  In this study, we aimed to construct a computational model to predict synergistic drug combinations.  METHODS:  We designed drug physicochemical features and network features, including drug chemical structure similarity, target distance in protein-protein network and targeted pathway similarity.  At the same time, we designed fifteen pharmacogenomics features using drug treated gene expression profiles based on the background of cancer-related biology network.  Based on these eighteen features, we built a prediction model for Synergistic Drug combination using Random forest algorithm (SyDRa).  RESULTS:  Our model achieved a quite good performance with AUC value of 0.89 and Out-of-bag estimate error rate of 0.15 in training dataset.  Using the random anti-cancer drug combinations which have transcriptional profile data in the Connectivity Map dataset as the testing dataset, we identified 28 potentially synergistic drug combinations, three out of which had been reported to be effective drug combinations by literatures.  CONCLUSIONS:  We studied eighteen features for drug combinations and built a computational model using random forest algorithm.  The model was evaluated using an independent test dataset.  Our model provides an efficient strategy to identify potentially synergistic drug combinations for cancer and may help reduce the search space for high-throughput synergistic drug combinations screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6H7lqLOqCvfh3YQQtAhNufW6udTcc2ebmsugUg5F2Zbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnlt1Wksw%253D%253D&md5=093e100976796fd5b4d58616357005be</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.artmed.2017.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.artmed.2017.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DCui%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DLian%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DQin%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DXie%26aufirst%3DL.%26atitle%3DPrediction%2520of%2520Synergistic%2520Anti-Cancer%2520Drug%2520Combinations%2520Based%2520on%2520Drug%2520Target%2520Network%2520and%2520Drug%2520Induced%2520Gene%2520Expression%2520Profiles%26jtitle%3DArtif.%2520Intell.%2520Med.%26date%3D2017%26volume%3D83%26spage%3D35%26epage%3D43%26doi%3D10.1016%2Fj.artmed.2017.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gayvert, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aly, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosenberg, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stern, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elemento, O.</span></span> <span> </span><span class="NLM_article-title">A Computational Approach for Identifying Synergistic Drug Combinations</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">e1005308</span>, <span class="refDoi"> DOI: 10.1371/journal.pcbi.1005308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1371%2Fjournal.pcbi.1005308" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=e1005308&issue=1&author=K.+M.+Gayvertauthor=O.+Alyauthor=J.+Plattauthor=M.+W.+Bosenbergauthor=D.+F.+Sternauthor=O.+Elemento&title=A+Computational+Approach+for+Identifying+Synergistic+Drug+Combinations&doi=10.1371%2Fjournal.pcbi.1005308"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1005308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1005308%26sid%3Dliteratum%253Aachs%26aulast%3DGayvert%26aufirst%3DK.%2BM.%26aulast%3DAly%26aufirst%3DO.%26aulast%3DPlatt%26aufirst%3DJ.%26aulast%3DBosenberg%26aufirst%3DM.%2BW.%26aulast%3DStern%26aufirst%3DD.%2BF.%26aulast%3DElemento%26aufirst%3DO.%26atitle%3DA%2520Computational%2520Approach%2520for%2520Identifying%2520Synergistic%2520Drug%2520Combinations%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2017%26volume%3D13%26issue%3D1%26spage%3De1005308%26doi%3D10.1371%2Fjournal.pcbi.1005308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, G.</span></span> <span> </span><span class="NLM_article-title">NLLSS: Predicting Synergistic Drug Combinations Based on Semi-Supervised Learning</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">e1004975</span>, <span class="refDoi"> DOI: 10.1371/journal.pcbi.1004975</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1371%2Fjournal.pcbi.1004975" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=e1004975&issue=7&author=X.+Chenauthor=B.+Renauthor=M.+Chenauthor=Q.+Wangauthor=L.+Zhangauthor=G.+Yan&title=NLLSS%3A+Predicting+Synergistic+Drug+Combinations+Based+on+Semi-Supervised+Learning&doi=10.1371%2Fjournal.pcbi.1004975"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1004975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1004975%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DG.%26atitle%3DNLLSS%253A%2520Predicting%2520Synergistic%2520Drug%2520Combinations%2520Based%2520on%2520Semi-Supervised%2520Learning%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2016%26volume%3D12%26issue%3D7%26spage%3De1004975%26doi%3D10.1371%2Fjournal.pcbi.1004975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerby-Arnon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arafeh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auslander, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGarry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amzallag, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atias, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stossel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buzhor, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterfall, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannenhalli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuels, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanks, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruppin, E.</span></span> <span> </span><span class="NLM_article-title">Harnessing Synthetic Lethality to Predict the Response to Cancer Treatment</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2546</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-04647-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fs41467-018-04647-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29959327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FjsVKqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=2546&author=J.+S.+Leeauthor=A.+Dasauthor=L.+Jerby-Arnonauthor=R.+Arafehauthor=N.+Auslanderauthor=M.+Davidsonauthor=L.+McGarryauthor=D.+Jamesauthor=A.+Amzallagauthor=S.+G.+Parkauthor=K.+Chengauthor=W.+Robinsonauthor=D.+Atiasauthor=C.+Stosselauthor=E.+Buzhorauthor=G.+Steinauthor=J.+J.+Waterfallauthor=P.+S.+Meltzerauthor=T.+Golanauthor=S.+Hannenhalliauthor=E.+Gottliebauthor=C.+H.+Benesauthor=Y.+Samuelsauthor=E.+Shanksauthor=E.+Ruppin&title=Harnessing+Synthetic+Lethality+to+Predict+the+Response+to+Cancer+Treatment&doi=10.1038%2Fs41467-018-04647-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Harnessing synthetic lethality to predict the response to cancer treatment</span></div><div class="casAuthors">Lee Joo Sang; Das Avinash; Auslander Noam; Park Seung Gu; Cheng Kuoyuan; Robinson Welles; Hannenhalli Sridhar; Ruppin Eytan; Lee Joo Sang; Auslander Noam; Cheng Kuoyuan; Robinson Welles; Ruppin Eytan; Jerby-Arnon Livnat; Ruppin Eytan; Arafeh Rand; Samuels Yardena; Davidson Matthew; McGarry Lynn; James Daniel; Gottlieb Eyal; Shanks Emma; Amzallag Arnaud; Benes Cyril H; Amzallag Arnaud; Benes Cyril H; Amzallag Arnaud; Atias Dikla; Stossel Chani; Buzhor Ella; Golan Talia; Stein Gidi; Golan Talia; Ruppin Eytan; Waterfall Joshua J; Meltzer Paul S</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2546</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">While synthetic lethality (SL) holds promise in developing effective cancer therapies, SL candidates found via experimental screens often have limited translational value.  Here we present a data-driven approach, ISLE (identification of clinically relevant synthetic lethality), that mines TCGA cohort to identify the most likely clinically relevant SL interactions (cSLi) from a given candidate set of lab-screened SLi.  We first validate ISLE via a benchmark of large-scale drug response screens and by predicting drug efficacy in mouse xenograft models.  We then experimentally test a select set of predicted cSLi via new screening experiments, validating their predicted context-specific sensitivity in hypoxic vs normoxic conditions and demonstrating cSLi's utility in predicting synergistic drug combinations.  We show that cSLi can successfully predict patients' drug treatment response and provide patient stratification signatures.  ISLE thus complements existing actionable mutation-based methods for precision cancer therapy, offering an opportunity to expand its scope to the whole genome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfgXJ7_Tz1NpagfuraLLzSfW6udTcc2ebmsugUg5F2Zbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FjsVKqtQ%253D%253D&md5=05a6a5dbfd882962d4c5f1e1db007c30</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-04647-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-04647-1%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DDas%26aufirst%3DA.%26aulast%3DJerby-Arnon%26aufirst%3DL.%26aulast%3DArafeh%26aufirst%3DR.%26aulast%3DAuslander%26aufirst%3DN.%26aulast%3DDavidson%26aufirst%3DM.%26aulast%3DMcGarry%26aufirst%3DL.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DAmzallag%26aufirst%3DA.%26aulast%3DPark%26aufirst%3DS.%2BG.%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DRobinson%26aufirst%3DW.%26aulast%3DAtias%26aufirst%3DD.%26aulast%3DStossel%26aufirst%3DC.%26aulast%3DBuzhor%26aufirst%3DE.%26aulast%3DStein%26aufirst%3DG.%26aulast%3DWaterfall%26aufirst%3DJ.%2BJ.%26aulast%3DMeltzer%26aufirst%3DP.%2BS.%26aulast%3DGolan%26aufirst%3DT.%26aulast%3DHannenhalli%26aufirst%3DS.%26aulast%3DGottlieb%26aufirst%3DE.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DSamuels%26aufirst%3DY.%26aulast%3DShanks%26aufirst%3DE.%26aulast%3DRuppin%26aufirst%3DE.%26atitle%3DHarnessing%2520Synthetic%2520Lethality%2520to%2520Predict%2520the%2520Response%2520to%2520Cancer%2520Treatment%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D2546%26doi%3D10.1038%2Fs41467-018-04647-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cava, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castiglioni, I.</span></span> <span> </span><span class="NLM_article-title">In Silico Identification of Drug Target Pathways in Breast Cancer Subtypes Using Pathway Cross-Talk Inhibition</span>. <i>J. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">154</span>, <span class="refDoi"> DOI: 10.1186/s12967-018-1535-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1186%2Fs12967-018-1535-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29871693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC1Mbkt1Gguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=154&author=C.+Cavaauthor=G.+Bertoliauthor=I.+Castiglioni&title=In+Silico+Identification+of+Drug+Target+Pathways+in+Breast+Cancer+Subtypes+Using+Pathway+Cross-Talk+Inhibition&doi=10.1186%2Fs12967-018-1535-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">In silico identification of drug target pathways in breast cancer subtypes using pathway cross-talk inhibition</span></div><div class="casAuthors">Cava Claudia; Bertoli Gloria; Castiglioni Isabella</div><div class="citationInfo"><span class="NLM_cas:title">Journal of translational medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">154</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Despite great development in genome and proteome high-throughput methods, treatment failure is a critical point in the management of most solid cancers, including breast cancer (BC).  Multiple alternative mechanisms upon drug treatment are involved to offset therapeutic effects, eventually causing drug resistance or treatment failure.  METHODS:  Here, we optimized a computational method to discover novel drug target pathways in cancer subtypes using pathway cross-talk inhibition (PCI).  The in silico method is based on the detection and quantification of the pathway cross-talk for distinct cancer subtypes.  From a BC data set of The Cancer Genome Atlas, we have identified different networks of cross-talking pathways for different BC subtypes, validated using an independent BC dataset from Gene Expression Omnibus.  Then, we predicted in silico the effects of new or approved drugs on different BC subtypes by silencing individual or combined subtype-derived pathways with the aim to find new potential drugs or more effective synergistic combinations of drugs.  RESULTS:  Overall, we identified a set of new potential drug target pathways for distinct BC subtypes on which therapeutic agents could synergically act showing antitumour effects and impacting on cross-talk inhibition.  CONCLUSIONS:  We believe that in silico methods based on PCI could offer valuable approaches to identifying more tailored and effective treatments in particular in heterogeneous cancer diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQSqcxLTfVhn7t7lRqEFUJVfW6udTcc2eZgH5UZ9RfbHLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mbkt1Gguw%253D%253D&md5=ec52e2c82ddc83df8fb1b6c377564176</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1186%2Fs12967-018-1535-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12967-018-1535-2%26sid%3Dliteratum%253Aachs%26aulast%3DCava%26aufirst%3DC.%26aulast%3DBertoli%26aufirst%3DG.%26aulast%3DCastiglioni%26aufirst%3DI.%26atitle%3DIn%2520Silico%2520Identification%2520of%2520Drug%2520Target%2520Pathways%2520in%2520Breast%2520Cancer%2520Subtypes%2520Using%2520Pathway%2520Cross-Talk%2520Inhibition%26jtitle%3DJ.%2520Transl.%2520Med.%26date%3D2018%26volume%3D16%26spage%3D154%26doi%3D10.1186%2Fs12967-018-1535-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaushik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robillard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barthelet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandyopadhyay, S.</span></span> <span> </span><span class="NLM_article-title">A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">918</span>– <span class="NLM_lpage">929</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2018.03.093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.celrep.2018.03.093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29669295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnvFegtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=918-929&issue=3&author=H.-M.+Huauthor=X.+Zhaoauthor=S.+Kaushikauthor=L.+Robillardauthor=A.+Bartheletauthor=K.+K.+Linauthor=K.+N.+Shahauthor=A.+D.+Simmonsauthor=M.+Raponiauthor=T.+C.+Hardingauthor=S.+Bandyopadhyay&title=A+Quantitative+Chemotherapy+Genetic+Interaction+Map+Reveals+Factors+Associated+with+PARP+Inhibitor+Resistance&doi=10.1016%2Fj.celrep.2018.03.093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance</span></div><div class="casAuthors">Hu, Hsien-Ming; Zhao, Xin; Kaushik, Swati; Robillard, Lilliane; Barthelet, Antoine; Lin, Kevin K.; Shah, Khyati N.; Simmons, Andy D.; Raponi, Mitch; Harding, Thomas C.; Bandyopadhyay, Sourav</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">918-929</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Chemotherapy is used to treat most cancer patients, yet our understanding of factors that dictate response and resistance to such drugs remains limited.  We report the generation of a quant. chem.-genetic interaction map in human mammary epithelial cells charting the impact of the knockdown of 625 genes related to cancer and DNA repair on sensitivity to 29 drugs, covering all classes of chemotherapy.  This quant. map is predictive of interactions maintained in other cell lines, identifies DNA-repair factors, predicts cancer cell line responses to therapy, and prioritizes synergistic drug combinations.  We identify that ARID1A loss confers resistance to PARP inhibitors in cells and ovarian cancer patients and that loss of GPBP1 causes resistance to cisplatin and PARP inhibitors through the regulation of genes involved in homologous recombination.  This map helps navigate patient genomic data and optimize chemotherapeutic regimens by delineating factors involved in the response to specific types of DNA damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1CE_IqnfDF7Vg90H21EOLACvtfcHk0liD0e0Otql__w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnvFegtbY%253D&md5=b920d06e7f251411140d5a1a56c68c01</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2018.03.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2018.03.093%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DH.-M.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DKaushik%26aufirst%3DS.%26aulast%3DRobillard%26aufirst%3DL.%26aulast%3DBarthelet%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DK.%2BK.%26aulast%3DShah%26aufirst%3DK.%2BN.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DBandyopadhyay%26aufirst%3DS.%26atitle%3DA%2520Quantitative%2520Chemotherapy%2520Genetic%2520Interaction%2520Map%2520Reveals%2520Factors%2520Associated%2520with%2520PARP%2520Inhibitor%2520Resistance%26jtitle%3DCell%2520Rep.%26date%3D2018%26volume%3D23%26issue%3D3%26spage%3D918%26epage%3D929%26doi%3D10.1016%2Fj.celrep.2018.03.093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Predicting Drug Combination Index and Simulating the Network-Regulation Dynamics by Mathematical Modeling of Drug-Targeted EGFR-ERK Signaling Pathway</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">40752</span>, <span class="refDoi"> DOI: 10.1038/srep40752</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fsrep40752" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28102344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVamtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=40752&author=L.+Huangauthor=Y.+Jiangauthor=Y.+Chen&title=Predicting+Drug+Combination+Index+and+Simulating+the+Network-Regulation+Dynamics+by+Mathematical+Modeling+of+Drug-Targeted+EGFR-ERK+Signaling+Pathway&doi=10.1038%2Fsrep40752"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting Drug Combination Index and Simulating the Network-Regulation Dynamics by Mathematical Modeling of Drug-Targeted EGFR-ERK Signaling Pathway</span></div><div class="casAuthors">Huang, Lu; Jiang, Yuyang; Chen, Yuzong</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40752</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Synergistic drug combinations enable enhanced therapeutics.  Their discovery typically involves the measurement and assessment of drug combination index (CI), which can be facilitated by the development and applications of in-silico CI predictive tools.  In this work, we developed and tested the ability of a math. model of drug-targeted EGFR-ERK pathway in predicting CIs and in analyzing multiple synergistic drug combinations against observations.  Our math. model was validated against the literature reported signaling, drug response dynamics, and EGFR-MEK drug combination effect.  The predicted CIs and combination therapeutic effects of the EGFR-BRaf, BRaf-MEK, FTI-MEK, and FTI-BRaf inhibitor combinations showed consistent synergism.  Our results suggest that existing pathway models may be potentially extended for developing drug-targeted pathway models to predict drug combination CI values, isobolograms, and drug-response surfaces as well as to analyze the dynamics of individual and combinations of drugs.  With our model, the efficacy of potential drug combinations can be predicted.  Our method complements the developed in-silico methods (e.g. the chemogenomic profile and the statistically-inferenced network models) by predicting drug combination effects from the perspectives of pathway dynamics using exptl. or validated mol. kinetic consts., thereby facilitating the collective prediction of drug combination effects in diverse ranges of disease systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgLnzX2o0XaLVg90H21EOLACvtfcHk0liD0e0Otql__w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVamtb0%253D&md5=fa97d8382b872562b83c69ef917c92c3</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1038%2Fsrep40752&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep40752%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DPredicting%2520Drug%2520Combination%2520Index%2520and%2520Simulating%2520the%2520Network-Regulation%2520Dynamics%2520by%2520Mathematical%2520Modeling%2520of%2520Drug-Targeted%2520EGFR-ERK%2520Signaling%2520Pathway%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D40752%26doi%3D10.1038%2Fsrep40752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jaeger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igea, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arroyo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcalde, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canovas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orozco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebreda, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aloy, P.</span></span> <span> </span><span class="NLM_article-title">Quantification of Pathway Cross-Talk Reveals Novel Synergistic Drug Combinations for Breast Cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-16-0097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1158%2F0008-5472.CAN-16-0097" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=459-469&issue=2&author=S.+Jaegerauthor=A.+Igeaauthor=R.+Arroyoauthor=V.+Alcaldeauthor=B.+Canovasauthor=M.+Orozcoauthor=A.+R.+Nebredaauthor=P.+Aloy&title=Quantification+of+Pathway+Cross-Talk+Reveals+Novel+Synergistic+Drug+Combinations+for+Breast+Cancer&doi=10.1158%2F0008-5472.CAN-16-0097"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-16-0097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-16-0097%26sid%3Dliteratum%253Aachs%26aulast%3DJaeger%26aufirst%3DS.%26aulast%3DIgea%26aufirst%3DA.%26aulast%3DArroyo%26aufirst%3DR.%26aulast%3DAlcalde%26aufirst%3DV.%26aulast%3DCanovas%26aufirst%3DB.%26aulast%3DOrozco%26aufirst%3DM.%26aulast%3DNebreda%26aufirst%3DA.%2BR.%26aulast%3DAloy%26aufirst%3DP.%26atitle%3DQuantification%2520of%2520Pathway%2520Cross-Talk%2520Reveals%2520Novel%2520Synergistic%2520Drug%2520Combinations%2520for%2520Breast%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D2%26spage%3D459%26epage%3D469%26doi%3D10.1158%2F0008-5472.CAN-16-0097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pei, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titus, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobanoglu, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousavi, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shun, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fioravanti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlisle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedlander, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahar, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lezon, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stern, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schurdak, M. E.</span></span> <span> </span><span class="NLM_article-title">Connecting Neuronal Cell Protective Pathways and Drug Combinations in a Huntington’s Disease Model through the Application of Quantitative Systems Pharmacology</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">17803</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-17378-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fs41598-017-17378-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29259176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC1Mzjtlaruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=17803&author=F.+Peiauthor=H.+Liauthor=M.+J.+Hendersonauthor=S.+A.+Titusauthor=A.+Jadhavauthor=A.+Simeonovauthor=M.+C.+Cobanogluauthor=S.+H.+Mousaviauthor=T.+Shunauthor=L.+McDermottauthor=P.+Iyerauthor=M.+Fioravantiauthor=D.+Carlisleauthor=R.+M.+Friedlanderauthor=I.+Baharauthor=D.+L.+Taylorauthor=T.+R.+Lezonauthor=A.+M.+Sternauthor=M.+E.+Schurdak&title=Connecting+Neuronal+Cell+Protective+Pathways+and+Drug+Combinations+in+a+Huntington%E2%80%99s+Disease+Model+through+the+Application+of+Quantitative+Systems+Pharmacology&doi=10.1038%2Fs41598-017-17378-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Connecting Neuronal Cell Protective Pathways and Drug Combinations in a Huntington's Disease Model through the Application of Quantitative Systems Pharmacology</span></div><div class="casAuthors">Pei Fen; Li Hongchun; Cobanoglu Murat Can; Bahar Ivet; Taylor D Lansing; Lezon Timothy R; Stern Andrew M; Schurdak Mark E; Henderson Mark J; Titus Steven A; Jadhav Ajit; Simeonov Anton; Mousavi Seyed H; Carlisle Diane; Friedlander Robert M; Shun Tongying; Bahar Ivet; Taylor D Lansing; Lezon Timothy R; Stern Andrew M; Schurdak Mark E; McDermott Lee; Iyer Prema; Fioravanti Michael; Friedlander Robert M; Taylor D Lansing</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17803</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Quantitative Systems Pharmacology (QSP) is a drug discovery approach that integrates computational and experimental methods in an iterative way to gain a comprehensive, unbiased understanding of disease processes to inform effective therapeutic strategies.  We report the implementation of QSP to Huntington's Disease, with the application of a chemogenomics platform to identify strategies to protect neuronal cells from mutant huntingtin induced death.  Using the STHdh (Q111) cell model, we investigated the protective effects of small molecule probes having diverse canonical modes-of-action to infer pathways of neuronal cell protection connected to drug mechanism.  Several mechanistically diverse protective probes were identified, most of which showed less than 50% efficacy.  Specific combinations of these probes were synergistic in enhancing efficacy.  Computational analysis of these probes revealed a convergence of pathways indicating activation of PKA.  Analysis of phospho-PKA levels showed lower cytoplasmic levels in STHdh (Q111) cells compared to wild type STHdh (Q7) cells, and these levels were increased by several of the protective compounds.  Pharmacological inhibition of PKA activity reduced protection supporting the hypothesis that protection may be working, in part, through activation of the PKA network.  The systems-level studies described here can be broadly applied to any discovery strategy involving small molecule modulation of disease phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTdeIFfZgL8lmmbXvSEQle5fW6udTcc2eaN4BCE8N7IWrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mzjtlaruw%253D%253D&md5=cdbe288a8900ce2cca6ee314f4ed81a1</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-17378-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-17378-y%26sid%3Dliteratum%253Aachs%26aulast%3DPei%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DHenderson%26aufirst%3DM.%2BJ.%26aulast%3DTitus%26aufirst%3DS.%2BA.%26aulast%3DJadhav%26aufirst%3DA.%26aulast%3DSimeonov%26aufirst%3DA.%26aulast%3DCobanoglu%26aufirst%3DM.%2BC.%26aulast%3DMousavi%26aufirst%3DS.%2BH.%26aulast%3DShun%26aufirst%3DT.%26aulast%3DMcDermott%26aufirst%3DL.%26aulast%3DIyer%26aufirst%3DP.%26aulast%3DFioravanti%26aufirst%3DM.%26aulast%3DCarlisle%26aufirst%3DD.%26aulast%3DFriedlander%26aufirst%3DR.%2BM.%26aulast%3DBahar%26aufirst%3DI.%26aulast%3DTaylor%26aufirst%3DD.%2BL.%26aulast%3DLezon%26aufirst%3DT.%2BR.%26aulast%3DStern%26aufirst%3DA.%2BM.%26aulast%3DSchurdak%26aufirst%3DM.%2BE.%26atitle%3DConnecting%2520Neuronal%2520Cell%2520Protective%2520Pathways%2520and%2520Drug%2520Combinations%2520in%2520a%2520Huntington%25E2%2580%2599s%2520Disease%2520Model%2520through%2520the%2520Application%2520of%2520Quantitative%2520Systems%2520Pharmacology%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D17803%26doi%3D10.1038%2Fs41598-017-17378-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barthorpe, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lightfoot, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, U.</span></span> <span> </span><span class="NLM_article-title">High-Throughput RNAi Screen for Essential Genes and Drug Synergistic Combinations in Colorectal Cancer</span>. <i>Sci. Data</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">170139</span>, <span class="refDoi"> DOI: 10.1038/sdata.2017.139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fsdata.2017.139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28972570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsF2hu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2017&pages=170139&author=S.+P.+Williamsauthor=A.+S.+Barthorpeauthor=H.+Lightfootauthor=M.+J.+Garnettauthor=U.+McDermott&title=High-Throughput+RNAi+Screen+for+Essential+Genes+and+Drug+Synergistic+Combinations+in+Colorectal+Cancer&doi=10.1038%2Fsdata.2017.139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput RNAi screen for essential genes and drug synergistic combinations in colorectal cancer</span></div><div class="casAuthors">Williams, Steven P.; Barthorpe, Andrew S.; Lightfoot, Howard; Garnett, Mathew J.; McDermott, Ultan</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Data</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">170139</span>CODEN:
                <span class="NLM_cas:coden">SDCABS</span>;
        ISSN:<span class="NLM_cas:issn">2052-4463</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Metastatic colorectal cancer is a leading cause of cancer death.  However, current therapy options are limited to chemotherapy, with the addn. of anti-EGFR antibodies for patients with RAS wild-type tumors.  Novel drug targets, or drug combinations that induce a synergistic response, would be of great benefit to patients.  The identification of genes that are essential for cell survival can be undertaken using functional genomics screens.  Furthermore, performing such screens in the presence of a targeted agent would allow the identification of combinations that result in a synthetic lethal interaction.  Here, we present a dataset contg. the results of a large scale RNAi screen (815 genes) to detect essential genes as well as synergistic combinations with targeted therapeutic agents using a panel of 27 colorectal cancer cell lines.  These data identify genes that are essential for colorectal cancer cell survival as well as synthetic lethal treatment combinations using novel computational approaches.  Moreover, this dataset could be utilized in combination with genomic profiling to identify predictive biomarkers of response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmsoqrQFmfcbVg90H21EOLACvtfcHk0lhIb8ee6-zlTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsF2hu7jI&md5=262c9e934f2722bcd2d5ee3095a5292c</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fsdata.2017.139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsdata.2017.139%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DS.%2BP.%26aulast%3DBarthorpe%26aufirst%3DA.%2BS.%26aulast%3DLightfoot%26aufirst%3DH.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DMcDermott%26aufirst%3DU.%26atitle%3DHigh-Throughput%2520RNAi%2520Screen%2520for%2520Essential%2520Genes%2520and%2520Drug%2520Synergistic%2520Combinations%2520in%2520Colorectal%2520Cancer%26jtitle%3DSci.%2520Data%26date%3D2017%26volume%3D4%26spage%3D170139%26doi%3D10.1038%2Fsdata.2017.139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span> <span> </span><span class="NLM_article-title">Dynamic Simulations on the Arachidonic Acid Metabolic Network</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">e55</span>, <span class="refDoi"> DOI: 10.1371/journal.pcbi.0030055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1371%2Fjournal.pcbi.0030055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=e55&issue=3&author=K.+Yangauthor=W.+Maauthor=H.+Liangauthor=Q.+Ouyangauthor=C.+Tangauthor=L.+Lai&title=Dynamic+Simulations+on+the+Arachidonic+Acid+Metabolic+Network&doi=10.1371%2Fjournal.pcbi.0030055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.0030055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.0030055%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DLiang%26aufirst%3DH.%26aulast%3DOuyang%26aufirst%3DQ.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DDynamic%2520Simulations%2520on%2520the%2520Arachidonic%2520Acid%2520Metabolic%2520Network%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2007%26volume%3D3%26issue%3D3%26spage%3De55%26doi%3D10.1371%2Fjournal.pcbi.0030055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span> <span> </span><span class="NLM_article-title">Dynamic Eicosanoid Responses upon Different Inhibitor and Combination Treatments on the Arachidonic Acid Metabolic Network</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1585</span>– <span class="NLM_lpage">1594</span>, <span class="refDoi"> DOI: 10.1039/c2mb05503a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1039%2Fc2mb05503a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=22446875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38XltFKntLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=1585-1594&issue=5&author=C.+Heauthor=Y.+Wuauthor=Y.+Laiauthor=Z.+Caiauthor=Y.+Liuauthor=L.+Lai&title=Dynamic+Eicosanoid+Responses+upon+Different+Inhibitor+and+Combination+Treatments+on+the+Arachidonic+Acid+Metabolic+Network&doi=10.1039%2Fc2mb05503a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Dynamic eicosanoid responses upon different inhibitor and combination treatments on the arachidonic acid metabolic network</span></div><div class="casAuthors">He, Chong; Wu, Yiran; Lai, Yongquan; Cai, Zongwei; Liu, Ying; Lai, Luhua</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1585-1594</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-2051</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The arachidonic acid (AA) metabolic network produces key inflammatory mediators which have been considered as hallmark contributors in various inflammatory related diseases.  Enzymes in this network, such as 5-lipoxygenase (5-LOX), cyclooxygenase (COX), leukotriene A4 hydrolase (LTA4H) and prostaglandin E synthase (PGES), have been used as targets for anti-inflammatory drug discovery.  Multi-target drugs and drug combinations have also been developed for this network.  However, how the inhibitors alter the dynamics of metabolite prodn. and which combinatorial target intervention solns. are better needs further exploration.  We did a system based intervention anal. on the AA metabolic network.  Using an LC-MS/MS method, we quant. studied the eicosanoid metabolites responses of AA metabolic network during stimulation of Sprague Dawley rat blood samples with the calcium ionophore.  Our results indicate that inhibiting the upstream rather than the downstream target of 5-LOX pathway will simultaneously alter the AA metab. to the COX pathway (and vice versa).  Therefore, single-target inhibitors cannot control all the inflammatory mediators at the same time.  We also suggest that in the case of multiple-target anti-inflammatory solns., the combination of inhibitors of the downstream enzymes may have stronger inhibition efficiency and cause less side-effects compared to the other solns.  One therapeutic strategy, LTA4H/COX inhibition soln., was found promising for the intervention of inflammatory mediator biosynthesis and at the same time stimulating the prodn. of anti-inflammatory agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGkE3Yt-wJU7Vg90H21EOLACvtfcHk0lgFNQdj4Q8WhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltFKntLc%253D&md5=958dfa73394a65b501d2c884ed1aef79</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1039%2Fc2mb05503a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2mb05503a%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DDynamic%2520Eicosanoid%2520Responses%2520upon%2520Different%2520Inhibitor%2520and%2520Combination%2520Treatments%2520on%2520the%2520Arachidonic%2520Acid%2520Metabolic%2520Network%26jtitle%3DMol.%2520BioSyst.%26date%3D2012%26volume%3D8%26issue%3D5%26spage%3D1585%26epage%3D1594%26doi%3D10.1039%2Fc2mb05503a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, P. J.</span></span> <span> </span><span class="NLM_article-title">Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">1–3</span>),  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(96)00423-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2FS0169-409X%2896%2900423-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=3-25&issue=1%E2%80%933&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+Computational+Approaches+to+Estimate+Solubility+and+Permeability+in+Drug+Discovery+and+Development+Settings&doi=10.1016%2FS0169-409X%2896%2900423-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is >500 and the calcd. Log P (CLogP) is >5.  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon9gEeZ7cboLVg90H21EOLACvtfcHk0lgFNQdj4Q8WhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D&md5=405f70b0594d428f1275e1d56642cd3a</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900423-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900423-1%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520Computational%2520Approaches%2520to%2520Estimate%2520Solubility%2520and%2520Permeability%2520in%2520Drug%2520Discovery%2520and%2520Development%2520Settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D23%26issue%3D1%25E2%2580%25933%26spage%3D3%26epage%3D25%26doi%3D10.1016%2FS0169-409X%2896%2900423-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W. W.</span></span> <span> </span><span class="NLM_article-title">A History of Antipsychotic Drug Development</span>. <i>Compr. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">414</span>, <span class="refDoi"> DOI: 10.1016/S0010-440X(99)90082-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2FS0010-440X%2899%2990082-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10579370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BD3c%252Fktl2ksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1999&pages=407-414&issue=6&author=W.+W.+Shen&title=A+History+of+Antipsychotic+Drug+Development&doi=10.1016%2FS0010-440X%2899%2990082-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">A history of antipsychotic drug development</span></div><div class="casAuthors">Shen W W</div><div class="citationInfo"><span class="NLM_cas:title">Comprehensive psychiatry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">407-14</span>
        ISSN:<span class="NLM_cas:issn">0010-440X</span>.
    </div><div class="casAbstract">The history of antipsychotic drug development has had a long and torturous course, often based on chance findings that bear little relationship to the intellectual background driving observations.  In 1891, Paul Ehrlich observed the antimalarial effects of methylene blue, a phenothiazine derivative.  Later, the phenothiazines were developed for their antihistaminergic properties.  In 1951, Laborit and Huguenard administered the aliphatic phenothiazine, chlorpromazine, to patients for its potential anesthetic effects during surgery.  Shortly thereafter, Hamon et al. and Delay et al. extended the use of this treatment in psychiatric patients and serendipitously uncovered its antipsychotic activity.  Between 1954 and 1975, about 15 antipsychotic drugs were introduced in the United States and about 40 throughout the world.  Thereafter, there was a hiatus in the development of antipsychotics until the introduction of clozapine treatment in the United States in 1990 opened the era of "atypical" antipsychotic drugs, which show a reduced potential to induce extrapyramidal symptoms (EPS), an increased efficacy for the negative symptoms of schizophrenia, no elevation of prolactin after chronic use (except risperidone), and, at least for clozapine, effectiveness in some patients previously regarded as treatment-refractory.  This review describes the available atypical antipsychotic drugs and their characteristics, and concludes by highlighting those in the pharmaceutical "pipeline."</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTfq-A7dxNj3D69zv1FsJFMfW6udTcc2eYKD9CHzQF477ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c%252Fktl2ksw%253D%253D&md5=6e5146aabdc053671288d4f1e4a0e968</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2FS0010-440X%2899%2990082-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0010-440X%252899%252990082-2%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DW.%2BW.%26atitle%3DA%2520History%2520of%2520Antipsychotic%2520Drug%2520Development%26jtitle%3DCompr.%2520Psychiatry%26date%3D1999%26volume%3D40%26issue%3D6%26spage%3D407%26epage%3D414%26doi%3D10.1016%2FS0010-440X%2899%2990082-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandraiah, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramaniam, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tancer, M.</span></span> <span> </span><span class="NLM_article-title">The Story of Antipsychotics: Past and Present</span>. <i>Indian J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.4103/0019-5545.58304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.4103%2F0019-5545.58304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=20048463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252FgsFKjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2009&pages=324-326&issue=4&author=C.+T.+Ramachandraiahauthor=N.+Subramaniamauthor=M.+Tancer&title=The+Story+of+Antipsychotics%3A+Past+and+Present&doi=10.4103%2F0019-5545.58304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">The story of antipsychotics: Past and present</span></div><div class="casAuthors">Ramachandraiah Chaitra T; Subramaniam Narayana; Tancer Manuel</div><div class="citationInfo"><span class="NLM_cas:title">Indian journal of psychiatry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">324-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQNjpw-2FH1bp0d-O_J5C0AfW6udTcc2eYKD9CHzQF477ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252FgsFKjug%253D%253D&md5=4f9545ed29d3cac2a35c5a3f91d44d75</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.4103%2F0019-5545.58304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0019-5545.58304%26sid%3Dliteratum%253Aachs%26aulast%3DRamachandraiah%26aufirst%3DC.%2BT.%26aulast%3DSubramaniam%26aufirst%3DN.%26aulast%3DTancer%26aufirst%3DM.%26atitle%3DThe%2520Story%2520of%2520Antipsychotics%253A%2520Past%2520and%2520Present%26jtitle%3DIndian%2520J.%2520Psychiatry%26date%3D2009%26volume%3D51%26issue%3D4%26spage%3D324%26epage%3D326%26doi%3D10.4103%2F0019-5545.58304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pistollato, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderón Iglesias, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzul Lopez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giampieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battino, M.</span></span> <span> </span><span class="NLM_article-title">The Use of Natural Compounds for the Targeting and Chemoprevention of Ovarian Cancer</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>411</i></span>,  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">200</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2017.09.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.canlet.2017.09.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29017913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1CmsLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=411&publication_year=2017&pages=191-200&author=F.+Pistollatoauthor=R.+Calder%C3%B3n+Iglesiasauthor=R.+Ruizauthor=S.+Aparicioauthor=J.+Crespoauthor=L.+Dzul+Lopezauthor=F.+Giampieriauthor=M.+Battino&title=The+Use+of+Natural+Compounds+for+the+Targeting+and+Chemoprevention+of+Ovarian+Cancer&doi=10.1016%2Fj.canlet.2017.09.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">The use of natural compounds for the targeting and chemoprevention of ovarian cancer</span></div><div class="casAuthors">Pistollato, Francesca; Calderon Iglesias, Ruben; Ruiz, Roberto; Aparicio, Silvia; Crespo, Jorge; Dzul Lopez, Luis; Giampieri, Francesca; Battino, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">411</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">191-200</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Among gynaecol. cancers, ovarian cancer represents the leading cause of death in women.  Current treatment for ovarian cancer entails surgery followed by combined chemotherapy with platinum and taxane, which are assocd., particularly cisplatin, with severe side effects.  While this treatment approach appears to be initially effective in a high no. of patients, nearly 70% of them suffer a relapse within a few months after initial treatment.  Therefore, more effective and better-tolerated treatment options are clearly needed.  In recent years, several natural compds. (such as curcumin, epigallocatechin 3-gallate (EGCG), resveratrol, sulforaphane and Withaferin-A), characterized by long-term safety and negligible and/or inexistent side effects, have been proposed as possible adjuvants of traditional chemotherapy.  Indeed, several in vitro and in vivo studies have shown that phytocompounds can effectively inhibit tumor cell proliferation, stimulate autophagy, induce apoptosis, and specifically target ovarian cancer stem cells (CSCs), which are generally considered to be responsible for tumor recurrence in several types of cancer.  Here we review current literature on the role of natural products in ovarian cancer chemoprevention, highlighting their effects particularly on the regulation of inflammation, autophagy, proliferation and apoptosis, chemotherapy resistance, and ovarian CSC growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq74PlqHyitSrVg90H21EOLACvtfcHk0lhxAXrGz6YjpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1CmsLzK&md5=7faae26a299516cc1c852b68e38fa74e</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2017.09.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2017.09.050%26sid%3Dliteratum%253Aachs%26aulast%3DPistollato%26aufirst%3DF.%26aulast%3DCalder%25C3%25B3n%2BIglesias%26aufirst%3DR.%26aulast%3DRuiz%26aufirst%3DR.%26aulast%3DAparicio%26aufirst%3DS.%26aulast%3DCrespo%26aufirst%3DJ.%26aulast%3DDzul%2BLopez%26aufirst%3DL.%26aulast%3DGiampieri%26aufirst%3DF.%26aulast%3DBattino%26aufirst%3DM.%26atitle%3DThe%2520Use%2520of%2520Natural%2520Compounds%2520for%2520the%2520Targeting%2520and%2520Chemoprevention%2520of%2520Ovarian%2520Cancer%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D411%26spage%3D191%26epage%3D200%26doi%3D10.1016%2Fj.canlet.2017.09.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rejhová, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opattová, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Čumová, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slíva, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vodička, P.</span></span> <span> </span><span class="NLM_article-title">Natural Compounds and Combination Therapy in Colorectal Cancer Treatment</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">582</span>– <span class="NLM_lpage">594</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.12.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.ejmech.2017.12.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29289883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ymtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2018&pages=582-594&author=A.+Rejhov%C3%A1author=A.+Opattov%C3%A1author=A.+%C4%8Cumov%C3%A1author=D.+Sl%C3%ADvaauthor=P.+Vodi%C4%8Dka&title=Natural+Compounds+and+Combination+Therapy+in+Colorectal+Cancer+Treatment&doi=10.1016%2Fj.ejmech.2017.12.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Natural compounds and combination therapy in colorectal cancer treatment</span></div><div class="casAuthors">Rejhova, A.; Opattova, A.; Cumova, A.; Sliva, D.; Vodicka, P.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">582-594</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Colorectal cancer (CRC) therapy using conventional chemotherapeutics represents a considerable burden for the patient's organism because of high toxicity while the response is relatively low.  Our review summarizes the findings about natural compds. as chemoprotective agents for decreasing risk of CRC.  It also identifies natural compds. which possess anti-tumor effects of various characteristics, mainly in vitro on colorectal cell lines or in vivo studies on exptl. models, but also in a few clin. trials.  Many of natural compds. suppress proliferation by inducing cell cycle arrest or induce apoptosis of CRC cells resulting in the inhibition of tumor growth.  A novel employment of natural substances is a so-called combination therapy - administration of two or more substances - conventional chemotherapeutics and a natural compd. or more natural compds. at a time.  Some natural compds. may sensitize to conventional cytotoxic therapy, reinforce the drug effective concn., intensify the combined effect of both administered therapeutics or exert cytotoxic effects specifically on tumor cells.  Moreover, combined therapy by targeting multiple signaling pathways, uses various mechanisms to reduce the development of resistance to antitumor drugs.  The desired effect could be to diminish burden on the patient's organism by replacing part of the dose of a conventional chemotherapeutic with a natural substance with a defined effect.  Many natural compds. are well tolerated by the patients and do not cause toxic effects even at high doses.  Interaction of conventional chemotherapeutics with natural compds. introduces a new aspect in the research and therapy of cancer.  It could be a promising approach to potentially achieve improvements, while minimizing of adverse effects assocd. with conventional chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4RG5snrknlbVg90H21EOLACvtfcHk0lhxAXrGz6YjpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ymtQ%253D%253D&md5=f8cc865f414f69e3dc24fedae9d33dea</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.12.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.12.039%26sid%3Dliteratum%253Aachs%26aulast%3DRejhov%25C3%25A1%26aufirst%3DA.%26aulast%3DOpattov%25C3%25A1%26aufirst%3DA.%26aulast%3D%25C4%258Cumov%25C3%25A1%26aufirst%3DA.%26aulast%3DSl%25C3%25ADva%26aufirst%3DD.%26aulast%3DVodi%25C4%258Dka%26aufirst%3DP.%26atitle%3DNatural%2520Compounds%2520and%2520Combination%2520Therapy%2520in%2520Colorectal%2520Cancer%2520Treatment%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D144%26spage%3D582%26epage%3D594%26doi%3D10.1016%2Fj.ejmech.2017.12.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amelio, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisitsa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonov, A.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology of Approved Anticancer Drugs</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">543</span>, <span class="refDoi"> DOI: 10.2174/1389450117666160301095233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F1389450117666160301095233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=26926468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjslSjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=534-543&issue=5&author=I.+Amelioauthor=A.+Lisitsaauthor=R.+Knightauthor=G.+Melinoauthor=A.+Antonov&title=Polypharmacology+of+Approved+Anticancer+Drugs&doi=10.2174%2F1389450117666160301095233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology of Approved Anticancer Drugs</span></div><div class="casAuthors">Amelio, Ivano; Lisitsa, Andrey; Knight, Richard A.; Melino, Gerry; Antonov, Alexey V.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">534-543</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The major drug discovery efforts in oncol. have been concd. on the development of selective mols. that are supposed to act specifically on one anticancer mechanism by modulating a single or several closely related drug targets.  However, a bird's eye view on data from multiple available bioassays implies that most approved anticancer agents do, in fact, target many more proteins with different functions.  Here we will review and systematize currently available information on the targets of several anticancer drugs along with revision of their potential mechanisms of action.  Polypharmacol. of the current antineoplastic agents suggests that drug clin. efficacy in oncol. can be achieved only via modulation of multiple cellular mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZWxZCVA_iIrVg90H21EOLACvtfcHk0lhxAXrGz6YjpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjslSjtrc%253D&md5=316e3ae08072b1b984523b7642b8d271</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.2174%2F1389450117666160301095233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389450117666160301095233%26sid%3Dliteratum%253Aachs%26aulast%3DAmelio%26aufirst%3DI.%26aulast%3DLisitsa%26aufirst%3DA.%26aulast%3DKnight%26aufirst%3DR.%26aulast%3DMelino%26aufirst%3DG.%26aulast%3DAntonov%26aufirst%3DA.%26atitle%3DPolypharmacology%2520of%2520Approved%2520Anticancer%2520Drugs%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2017%26volume%3D18%26issue%3D5%26spage%3D534%26epage%3D543%26doi%3D10.2174%2F1389450117666160301095233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Lera, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">Epigenetic Polypharmacology: From Combination Therapy to Multitargeted Drugs</span>. <i>Clin. Epigenet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">105</span>, <span class="refDoi"> DOI: 10.1186/s13148-016-0271-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1186%2Fs13148-016-0271-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27752293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslOgsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=105&author=A.+R.+de+Leraauthor=A.+Ganesan&title=Epigenetic+Polypharmacology%3A+From+Combination+Therapy+to+Multitargeted+Drugs&doi=10.1186%2Fs13148-016-0271-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic polypharmacology: from combination therapy to multitargeted drugs</span></div><div class="casAuthors">de Lera, Angel R.; Ganesan, A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Epigenetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105/1-105/21</span>CODEN:
                <span class="NLM_cas:coden">CELPCI</span>;
        ISSN:<span class="NLM_cas:issn">1868-7083</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  The modern drug discovery process has largely focused its attention in the so-called magic bullets, single chem. entities that exhibit high selectivity and potency for a particular target.  This approach was based on the assumption that the deregulation of a protein was causally linked to a disease state, and the pharmacol. intervention through inhibition of the deregulated target was able to restore normal cell function.  However, the use of cocktails or multicomponent drugs to address several targets simultaneously is also popular to treat multifactorial diseases such as cancer and neurol. disorders.  We review the state of the art with such combinations that have an epigenetic target as one of their mechanisms of action.  Epigenetic drug discovery is a rapidly advancing field, and drugs targeting epigenetic enzymes are in the clinic for the treatment of hematol. cancers.  Approved and exptl. epigenetic drugs are undergoing clin. trials in combination with other therapeutic agents via fused or linked pharmacophores in order to benefit from synergistic effects of polypharmacol.  In addn., ligands are being discovered which, as single chem. entities, are able to modulate multiple epigenetic targets simultaneously (multitarget epigenetic drugs).  These multiple ligands should in principle have a lower risk of drug-drug interactions and drug resistance compared to cocktails or multicomponent drugs.  This new generation may rival the so-called magic bullets in the treatment of diseases that arise as a consequence of the deregulation of multiple signaling pathways provided the challenge of optimization of the activities shown by the pharmacophores with the different targets is addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphm-KIEGyYKrVg90H21EOLACvtfcHk0lj1dtds_EBeJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslOgsbY%253D&md5=7cd89a93a22121cc9db2c7118e2e23f1</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1186%2Fs13148-016-0271-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13148-016-0271-9%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BLera%26aufirst%3DA.%2BR.%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DEpigenetic%2520Polypharmacology%253A%2520From%2520Combination%2520Therapy%2520to%2520Multitargeted%2520Drugs%26jtitle%3DClin.%2520Epigenet.%26date%3D2016%26volume%3D8%26spage%3D105%26doi%3D10.1186%2Fs13148-016-0271-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wencewicz, T. A.</span></span> <span> </span><span class="NLM_article-title">Prospects for New Antibiotics: A Molecule-Centered Perspective</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1038/ja.2013.49</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fja.2013.49" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=23756684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1yitrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2014&pages=7-22&issue=1&author=C.+T.+Walshauthor=T.+A.+Wencewicz&title=Prospects+for+New+Antibiotics%3A+A+Molecule-Centered+Perspective&doi=10.1038%2Fja.2013.49"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Prospects for new antibiotics: a molecule-centered perspective</span></div><div class="casAuthors">Walsh, Christopher T.; Wencewicz, Timothy A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-22</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  There is a continuous need for iterative cycles of antibiotic discovery and development to deal with the selection of resistant pathogens that emerge as therapeutic application of an antibiotic becomes widespread.  A short golden age of antibiotic discovery from nature followed by a subsequent golden half century of medicinal chem. optimization of existing mol. scaffolds emphasizes the need for new antibiotic mol. frameworks.  The authors bring a mol.-centered perspective to the questions of where will new scaffolds come from, when will chemogenetic approaches yield useful new antibiotics and what existing bacterial targets merit contemporary re-examn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8hr8BTzzMG7Vg90H21EOLACvtfcHk0lj1dtds_EBeJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1yitrc%253D&md5=fb100c0954679a78210c497daa4fab1d</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1038%2Fja.2013.49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fja.2013.49%26sid%3Dliteratum%253Aachs%26aulast%3DWalsh%26aufirst%3DC.%2BT.%26aulast%3DWencewicz%26aufirst%3DT.%2BA.%26atitle%3DProspects%2520for%2520New%2520Antibiotics%253A%2520A%2520Molecule-Centered%2520Perspective%26jtitle%3DJ.%2520Antibiot.%26date%3D2014%26volume%3D67%26issue%3D1%26spage%3D7%26epage%3D22%26doi%3D10.1038%2Fja.2013.49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silver, L. L.</span></span> <span> </span><span class="NLM_article-title">Multi-Targeting by Monotherapeutic Antibacterials</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1038/nrd2202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnrd2202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=17159922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlGktbfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=41-55&issue=1&author=L.+L.+Silver&title=Multi-Targeting+by+Monotherapeutic+Antibacterials&doi=10.1038%2Fnrd2202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-targeting by monotherapeutic antibacterials</span></div><div class="casAuthors">Silver, Lynn L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-55</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Antibacterial discovery research has been driven, medically, com. and intellectually, by the need for new therapeutics that are not subject to the resistance mechanisms that have evolved to combat previous generations of antibacterial agents.  This need has often been equated with the identification and exploitation of novel targets.  But efforts towards discovery and development of inhibitors of novel targets have proved frustrating.  It might be that the 'good old targets' are qual. different from the crop of all possible novel targets.  What has been learned from existing targets that can be applied to the quest for new antibacterials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpItQysyGWT8LVg90H21EOLACvtfcHk0lj1dtds_EBeJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlGktbfN&md5=49d78749fc31f5f0546b859e17b31c47</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1038%2Fnrd2202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2202%26sid%3Dliteratum%253Aachs%26aulast%3DSilver%26aufirst%3DL.%2BL.%26atitle%3DMulti-Targeting%2520by%2520Monotherapeutic%2520Antibacterials%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26issue%3D1%26spage%3D41%26epage%3D55%26doi%3D10.1038%2Fnrd2202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J. J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, R. C.</span></span> <span> </span><span class="NLM_article-title">Targeting Protein Multiple Conformations: A Structure-Based Strategy for Kinase Drug Design</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">1394</span>– <span class="NLM_lpage">1407</span>, <span class="refDoi"> DOI: 10.2174/156802607781696783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F156802607781696783" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=17692028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1SmtbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=1394-1407&issue=14&author=J.+J.-L.+Liaoauthor=R.+C.+Andrews&title=Targeting+Protein+Multiple+Conformations%3A+A+Structure-Based+Strategy+for+Kinase+Drug+Design&doi=10.2174%2F156802607781696783"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting protein multiple conformations: a structure-based strategy for kinase drug design</span></div><div class="casAuthors">Liao, Jeffrey Jie-Lou; Andrews, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1394-1407</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Multiple conformations of a protein kinase target offer an opportunity to design small-mol. inhibitors with distinct but clin. useful profiles.  This article analyzes and classifies the binding pockets in the kinase catalytic cleft in different conformational states.  Targeting kinase multiple conformations as an emerging strategy in the field is exemplified with important small-mol. agents in the clinic.  The structure-based anal. in the paper provides a rationale for thwarting the development of drug-resistant mutations in antikinase therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWOkJq0JBN2rVg90H21EOLACvtfcHk0lj1dtds_EBeJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1SmtbrF&md5=db6aa8c76bf20857cfe31c71625ffa9e</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.2174%2F156802607781696783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802607781696783%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DJ.%2BJ.-L.%26aulast%3DAndrews%26aufirst%3DR.%2BC.%26atitle%3DTargeting%2520Protein%2520Multiple%2520Conformations%253A%2520A%2520Structure-Based%2520Strategy%2520for%2520Kinase%2520Drug%2520Design%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26issue%3D14%26spage%3D1394%26epage%3D1407%26doi%3D10.2174%2F156802607781696783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelloff, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigman, C. C.</span></span> <span> </span><span class="NLM_article-title">Cancer Biomarkers: Selecting the Right Drug for the Right Patient</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1038/nrd3651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnrd3651" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=201-214&issue=3&author=G.+J.+Kelloffauthor=C.+C.+Sigman&title=Cancer+Biomarkers%3A+Selecting+the+Right+Drug+for+the+Right+Patient&doi=10.1038%2Fnrd3651"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1038%2Fnrd3651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3651%26sid%3Dliteratum%253Aachs%26aulast%3DKelloff%26aufirst%3DG.%2BJ.%26aulast%3DSigman%26aufirst%3DC.%2BC.%26atitle%3DCancer%2520Biomarkers%253A%2520Selecting%2520the%2520Right%2520Drug%2520for%2520the%2520Right%2520Patient%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26issue%3D3%26spage%3D201%26epage%3D214%26doi%3D10.1038%2Fnrd3651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zumla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodoo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeurer, M.</span></span> <span> </span><span class="NLM_article-title">Potential of Immunomodulatory Agents as Adjunct Host-Directed Therapies for Multidrug-Resistant Tuberculosis</span>. <i>BMC Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">89</span>, <span class="refDoi"> DOI: 10.1186/s12916-016-0635-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1186%2Fs12916-016-0635-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27301245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsFKjsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=89&author=A.+Zumlaauthor=M.+Raoauthor=E.+Dodooauthor=M.+Maeurer&title=Potential+of+Immunomodulatory+Agents+as+Adjunct+Host-Directed+Therapies+for+Multidrug-Resistant+Tuberculosis&doi=10.1186%2Fs12916-016-0635-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis</span></div><div class="casAuthors">Zumla, Alimuddin; Rao, Martin; Dodoo, Ernest; Maeurer, Markus</div><div class="citationInfo"><span class="NLM_cas:title">BMC Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89/1-89/12</span>CODEN:
                <span class="NLM_cas:coden">BMMECZ</span>;
        ISSN:<span class="NLM_cas:issn">1741-7015</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Treatment of multidrug-resistant tuberculosis (MDR-TB) is extremely challenging due to the virulence of the etiol. strains of Mycobacterium tuberculosis (M. tb), the aberrant host immune responses and the diminishing treatment options with TB drugs.  New treatment regimens incorporating therapeutics targeting both M. tb and host factors are urgently needed to improve the clin. management outcomes of MDR-TB.  Host-directed therapies (HDT) could avert destructive tuberculous lung pathol., facilitate eradication of M. tb, improve survival and prevent long-term functional disability.  In this review we (1) discuss the use of HDT for cancer and other infections, drawing parallels and the precedent they set for MDR-TB treatment, (2) highlight preclin. studies of pharmacol. agents commonly used in clin. practice which have HDT potential, and (3) outline developments in cellular therapy to promote clin. beneficial immunomodulation to improve treatment outcomes in patients with pulmonary MDR-TB.  The use of HDTs as adjuncts to MDR-TB therapy requires urgent evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowPseOXg3VsrVg90H21EOLACvtfcHk0li31KstxEsPAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsFKjsb0%253D&md5=77b9104c346199b178e9eca372feb029</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1186%2Fs12916-016-0635-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12916-016-0635-1%26sid%3Dliteratum%253Aachs%26aulast%3DZumla%26aufirst%3DA.%26aulast%3DRao%26aufirst%3DM.%26aulast%3DDodoo%26aufirst%3DE.%26aulast%3DMaeurer%26aufirst%3DM.%26atitle%3DPotential%2520of%2520Immunomodulatory%2520Agents%2520as%2520Adjunct%2520Host-Directed%2520Therapies%2520for%2520Multidrug-Resistant%2520Tuberculosis%26jtitle%3DBMC%2520Med.%26date%3D2016%26volume%3D14%26spage%3D89%26doi%3D10.1186%2Fs12916-016-0635-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Designed Multiple Ligands: An Emerging Anti-HIV Drug Discovery Paradigm</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1893</span>– <span class="NLM_lpage">1917</span>, <span class="refDoi"> DOI: 10.2174/138161209788453266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F138161209788453266" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=1893-1917&issue=16&author=P.+Zhanauthor=X.+Liu&title=Designed+Multiple+Ligands%3A+An+Emerging+Anti-HIV+Drug+Discovery+Paradigm&doi=10.2174%2F138161209788453266"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.2174%2F138161209788453266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161209788453266%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DDesigned%2520Multiple%2520Ligands%253A%2520An%2520Emerging%2520Anti-HIV%2520Drug%2520Discovery%2520Paradigm%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2009%26volume%3D15%26issue%3D16%26spage%3D1893%26epage%3D1917%26doi%3D10.2174%2F138161209788453266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, B. B.</span></span> <span> </span><span class="NLM_article-title">Serendipity in Cancer Drug Discovery: Rational or Coincidence?</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2016.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.tips.2016.03.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=435-450&issue=6&author=S.+Prasadauthor=S.+C.+Guptaauthor=B.+B.+Aggarwal&title=Serendipity+in+Cancer+Drug+Discovery%3A+Rational+or+Coincidence%3F&doi=10.1016%2Fj.tips.2016.03.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2016.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2016.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DPrasad%26aufirst%3DS.%26aulast%3DGupta%26aufirst%3DS.%2BC.%26aulast%3DAggarwal%26aufirst%3DB.%2BB.%26atitle%3DSerendipity%2520in%2520Cancer%2520Drug%2520Discovery%253A%2520Rational%2520or%2520Coincidence%253F%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2016%26volume%3D37%26issue%3D6%26spage%3D435%26epage%3D450%26doi%3D10.1016%2Fj.tips.2016.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peereboom, D. M.</span></span> <span> </span><span class="NLM_article-title">From Serendipity to Design: The Evolution of Drug Development in Oncology</span>. <i>Cleve. Clin. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>64</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.3949/ccjm.64.3.155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.3949%2Fccjm.64.3.155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=9068226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADyaK2s3itFWitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1997&pages=155-163&issue=3&author=M.+Markmanauthor=D.+M.+Peereboom&title=From+Serendipity+to+Design%3A+The+Evolution+of+Drug+Development+in+Oncology&doi=10.3949%2Fccjm.64.3.155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">From serendipity to design: the evolution of drug development in oncology</span></div><div class="casAuthors">Markman M; Peereboom D M</div><div class="citationInfo"><span class="NLM_cas:title">Cleveland Clinic journal of medicine</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">155-63</span>
        ISSN:<span class="NLM_cas:issn">0891-1150</span>.
    </div><div class="casAbstract">Although screening of natural products remains the major method of discovering new anticancer drugs, newer techniques of rational drug design, computer-aided drug design, and combinatorial synthesis promise to broaden the scope of compounds available for screening.  Recent changes in Food and Drug Administration rules allow for accelerated approval of drugs for treating cancer and other life-threatening illnesses, although the three-phase process of clinical trials remains largely unchanged.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTby-nTegdkY_SAs_PE1QvifW6udTcc2eatuBn2W28sYLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s3itFWitw%253D%253D&md5=7948481b317c7ccfbee7c5b307b357c5</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.3949%2Fccjm.64.3.155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3949%252Fccjm.64.3.155%26sid%3Dliteratum%253Aachs%26aulast%3DMarkman%26aufirst%3DM.%26aulast%3DPeereboom%26aufirst%3DD.%2BM.%26atitle%3DFrom%2520Serendipity%2520to%2520Design%253A%2520The%2520Evolution%2520of%2520Drug%2520Development%2520in%2520Oncology%26jtitle%3DCleve.%2520Clin.%2520J.%2520Med.%26date%3D1997%26volume%3D64%26issue%3D3%26spage%3D155%26epage%3D163%26doi%3D10.3949%2Fccjm.64.3.155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, A.</span>; <span class="NLM_string-name">García-Echeverría, C.</span></span> <span> </span><span class="NLM_article-title">Identification and Optimization of Dual PI3K/mTOR Inhibitors</span>. In  <i>Designing Multi-Target Drugs</i>; <span class="NLM_publisher-name">Royal Society of Chemistry</span>: <span class="NLM_publisher-loc">Cambridge, UK</span>, <span class="NLM_year">2012</span>; Chapter 13, pp  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">220</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1039%2F9781849734912-00206" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=206-220&author=A.+Karlsson&author=C.+Garc%C3%ADa-Echeverr%C3%ADa&title=Designing+Multi-Target+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1039%2F9781849734912-00206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1039%252F9781849734912-00206%26sid%3Dliteratum%253Aachs%26aulast%3DKarlsson%26aufirst%3DA.%26atitle%3DIdentification%2520and%2520Optimization%2520of%2520Dual%2520PI3K%252FmTOR%2520Inhibitors%26btitle%3DDesigning%2520Multi-Target%2520Drugs%26pub%3DRoyal%2520Society%2520of%2520Chemistry%26date%3D2012%26spage%3D206%26epage%3D220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-{4-[5-(4-Fluorophenyl)-3-Methyl-2-Methylsulfanyl-3H-Imidazol-4-Yl]-Pyridin-2-Yl}-Acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">5290</span>– <span class="NLM_lpage">5305</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01647</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01647" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5290-5305&issue=13&author=W.+Albrechtauthor=A.+Ungerauthor=S.+M.+Bauerauthor=S.+A.+Laufer&title=Discovery+of+N-%7B4-%5B5-%284-Fluorophenyl%29-3-Methyl-2-Methylsulfanyl-3H-Imidazol-4-Yl%5D-Pyridin-2-Yl%7D-Acetamide+%28CBS-3595%29%2C+a+Dual+p38%CE%B1+MAPK%2FPDE-4+Inhibitor+with+Activity+against+TNF%CE%B1-Related+Diseases&doi=10.1021%2Facs.jmedchem.6b01647"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01647%26sid%3Dliteratum%253Aachs%26aulast%3DAlbrecht%26aufirst%3DW.%26aulast%3DUnger%26aufirst%3DA.%26aulast%3DBauer%26aufirst%3DS.%2BM.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DDiscovery%2520of%2520N-%257B4-%255B5-%25284-Fluorophenyl%2529-3-Methyl-2-Methylsulfanyl-3H-Imidazol-4-Yl%255D-Pyridin-2-Yl%257D-Acetamide%2520%2528CBS-3595%2529%252C%2520a%2520Dual%2520p38%25CE%25B1%2520MAPK%252FPDE-4%2520Inhibitor%2520with%2520Activity%2520against%2520TNF%25CE%25B1-Related%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D13%26spage%3D5290%26epage%3D5305%26doi%3D10.1021%2Facs.jmedchem.6b01647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wess, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enhsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baringhaus, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glombik, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müllner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bock, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleine, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckermann, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Bile Acid - Drug Conjugates: Potential Drug - Shuttles for Liver Specific Targeting</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">819</span>– <span class="NLM_lpage">822</span>, <span class="refDoi"> DOI: 10.1016/0040-4039(93)89021-H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2F0040-4039%2893%2989021-H" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1993&pages=819-822&issue=5&author=G.+Wessauthor=W.+Kramerauthor=G.+Schubertauthor=A.+Enhsenauthor=K.+H.+Baringhausauthor=H.+Glombikauthor=S.+M%C3%BCllnerauthor=K.+Bockauthor=H.+Kleineauthor=M.+Johnauthor=O.+Neckermannauthor=A.+Hoffmann&title=Synthesis+of+Bile+Acid+-+Drug+Conjugates%3A+Potential+Drug+-+Shuttles+for+Liver+Specific+Targeting&doi=10.1016%2F0040-4039%2893%2989021-H"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2F0040-4039%2893%2989021-H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4039%252893%252989021-H%26sid%3Dliteratum%253Aachs%26aulast%3DWess%26aufirst%3DG.%26aulast%3DKramer%26aufirst%3DW.%26aulast%3DSchubert%26aufirst%3DG.%26aulast%3DEnhsen%26aufirst%3DA.%26aulast%3DBaringhaus%26aufirst%3DK.%2BH.%26aulast%3DGlombik%26aufirst%3DH.%26aulast%3DM%25C3%25BCllner%26aufirst%3DS.%26aulast%3DBock%26aufirst%3DK.%26aulast%3DKleine%26aufirst%3DH.%26aulast%3DJohn%26aufirst%3DM.%26aulast%3DNeckermann%26aufirst%3DO.%26aulast%3DHoffmann%26aufirst%3DA.%26atitle%3DSynthesis%2520of%2520Bile%2520Acid%2520-%2520Drug%2520Conjugates%253A%2520Potential%2520Drug%2520-%2520Shuttles%2520for%2520Liver%2520Specific%2520Targeting%26jtitle%3DTetrahedron%2520Lett.%26date%3D1993%26volume%3D34%26issue%3D5%26spage%3D819%26epage%3D822%26doi%3D10.1016%2F0040-4039%2893%2989021-H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wess, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bickel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girbig, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutjahr, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalewski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baringhaus, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enhsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glombik, H.</span></span> <span> </span><span class="NLM_article-title">Liver-Specific Drug Targeting by Coupling to Bile Acids</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>267</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">18598</span>– <span class="NLM_lpage">18604</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=18598-18604&issue=26&author=W.+Kramerauthor=G.+Wessauthor=G.+Schubertauthor=M.+Bickelauthor=F.+Girbigauthor=U.+Gutjahrauthor=S.+Kowalewskiauthor=K.+H.+Baringhausauthor=A.+Enhsenauthor=H.+Glombik&title=Liver-Specific+Drug+Targeting+by+Coupling+to+Bile+Acids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKramer%26aufirst%3DW.%26aulast%3DWess%26aufirst%3DG.%26aulast%3DSchubert%26aufirst%3DG.%26aulast%3DBickel%26aufirst%3DM.%26aulast%3DGirbig%26aufirst%3DF.%26aulast%3DGutjahr%26aufirst%3DU.%26aulast%3DKowalewski%26aufirst%3DS.%26aulast%3DBaringhaus%26aufirst%3DK.%2BH.%26aulast%3DEnhsen%26aufirst%3DA.%26aulast%3DGlombik%26aufirst%3DH.%26atitle%3DLiver-Specific%2520Drug%2520Targeting%2520by%2520Coupling%2520to%2520Bile%2520Acids%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26issue%3D26%26spage%3D18598%26epage%3D18604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Braun, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pramanik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gwinner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köberle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, E.</span></span> <span> </span><span class="NLM_article-title">Sideromycins: Tools and Antibiotics</span>. <i>BioMetals</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1007/s10534-008-9199-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1007%2Fs10534-008-9199-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=3-13&issue=1&author=V.+Braunauthor=A.+Pramanikauthor=T.+Gwinnerauthor=M.+K%C3%B6berleauthor=E.+Bohn&title=Sideromycins%3A+Tools+and+Antibiotics&doi=10.1007%2Fs10534-008-9199-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1007%2Fs10534-008-9199-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10534-008-9199-7%26sid%3Dliteratum%253Aachs%26aulast%3DBraun%26aufirst%3DV.%26aulast%3DPramanik%26aufirst%3DA.%26aulast%3DGwinner%26aufirst%3DT.%26aulast%3DK%25C3%25B6berle%26aufirst%3DM.%26aulast%3DBohn%26aufirst%3DE.%26atitle%3DSideromycins%253A%2520Tools%2520and%2520Antibiotics%26jtitle%3DBioMetals%26date%3D2009%26volume%3D22%26issue%3D1%26spage%3D3%26epage%3D13%26doi%3D10.1007%2Fs10534-008-9199-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möllmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claypool, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolter, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suckow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajicek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. J.</span></span> <span> </span><span class="NLM_article-title">Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter Baumannii Both in Vitro and in Vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4577</span>– <span class="NLM_lpage">4583</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00102</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00102" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktFOmtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4577-4583&issue=11&author=M.+Ghoshauthor=P.+A.+Millerauthor=U.+M%C3%B6llmannauthor=W.+D.+Claypoolauthor=V.+A.+Schroederauthor=W.+R.+Wolterauthor=M.+Suckowauthor=H.+Yuauthor=S.+Liauthor=W.+Huangauthor=J.+Zajicekauthor=M.+J.+Miller&title=Targeted+Antibiotic+Delivery%3A+Selective+Siderophore+Conjugation+with+Daptomycin+Confers+Potent+Activity+against+Multidrug+Resistant+Acinetobacter+Baumannii+Both+in+Vitro+and+in+Vivo&doi=10.1021%2Facs.jmedchem.7b00102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo</span></div><div class="casAuthors">Ghosh, Manuka; Miller, Patricia A.; Mollmann, Ute; Claypool, William D.; Schroeder, Valerie A.; Wolter, William R.; Suckow, Mark; Yu, Honglin; Li, Shuang; Huang, Weiqiang; Zajicek, Jaroslav; Miller, Marvin J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4577-4583</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To address the dire need for new antibiotics to treat specific strains of drug resistant Gram-neg. bacterial infections, a mixed ligand analog of the natural Acinetobacter baumannii selective siderophore, fimsbactin, was coupled to daptomycin, a Gram-pos. only antibiotic.  The resulting conjugate, 11, has potent activity against multi-drug resistant strains of A. baumannii, both in vitro and in vivo.  The study also indicates that conjugation of siderophores to "drugs" that are much larger than the siderophore (iron transport agent) itself facilitates active uptake that circumvents the normal permeability problems in Gram-neg. bacteria.  The results demonstrate the ability to extend activity of a normally Gram-pos. only antibiotic to create a potent and targeted Gram-neg. antibiotic using a bacterial iron transport based sideromycin Trojan Horse strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr19eZoVK9_KbVg90H21EOLACvtfcHk0lgMXs6dFkDWtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktFOmtrs%253D&md5=d5393857fecd38662c4dd084e11e204a</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00102%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DP.%2BA.%26aulast%3DM%25C3%25B6llmann%26aufirst%3DU.%26aulast%3DClaypool%26aufirst%3DW.%2BD.%26aulast%3DSchroeder%26aufirst%3DV.%2BA.%26aulast%3DWolter%26aufirst%3DW.%2BR.%26aulast%3DSuckow%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DZajicek%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DM.%2BJ.%26atitle%3DTargeted%2520Antibiotic%2520Delivery%253A%2520Selective%2520Siderophore%2520Conjugation%2520with%2520Daptomycin%2520Confers%2520Potent%2520Activity%2520against%2520Multidrug%2520Resistant%2520Acinetobacter%2520Baumannii%2520Both%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D11%26spage%3D4577%26epage%3D4583%26doi%3D10.1021%2Facs.jmedchem.7b00102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vakulenko, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggess, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. J.</span></span> <span> </span><span class="NLM_article-title">A Synthetic Dual Drug Sideromycin Induces Gram-Negative Bacteria To Commit Suicide with a Gram-Positive Antibiotic</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3845</span>– <span class="NLM_lpage">3854</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00218</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00218" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltV2rsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3845-3854&issue=9&author=R.+Liuauthor=P.+A.+Millerauthor=S.+B.+Vakulenkoauthor=N.+K.+Stewartauthor=W.+C.+Boggessauthor=M.+J.+Miller&title=A+Synthetic+Dual+Drug+Sideromycin+Induces+Gram-Negative+Bacteria+To+Commit+Suicide+with+a+Gram-Positive+Antibiotic&doi=10.1021%2Facs.jmedchem.8b00218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">A Synthetic Dual Drug Sideromycin Induces Gram-Negative Bacteria To Commit Suicide with a Gram-Positive Antibiotic</span></div><div class="casAuthors">Liu, Rui; Miller, Patricia A.; Vakulenko, Sergei B.; Stewart, Nichole K.; Boggess, William C.; Miller, Marvin J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3845-3854</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Many antibiotics lack activity against Gram-neg. bacteria because they cannot permeate the outer membrane or suffer from efflux and, in the case of β-lactams, are degraded by β-lactamases.  Herein, we describe the synthesis and studies of a dual drug conjugate (1) of a siderophore linked to a cephalosporin with an attached oxazolidinone.  The cephalosporin component of 1 is rapidly hydrolyzed by purified ADC-1 β-lactamase to release the oxazolidinone.  Conjugate 1 is active against clin. isolates of Acinetobacter baumannii as well as strains producing large amts. of ADC-1 β-lactamase.  Overall, the results are consistent with siderophore-mediated active uptake, inherent activity of the delivered dual drug, and in the presence of β-lactamases, intracellular release of the oxazolidinone upon cleavage of the cephalosporin to allow the freed oxazolidinone to inactivate its target.  The ultimate result demonstrates that Gram-pos. oxazolidinone antibiotics can be made to be effective against Gram-neg. bacteria by β-lactamase triggered release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq97JjdswWmrVg90H21EOLACvtfcHk0lhQOYU_jERPPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltV2rsbk%253D&md5=0c3db140a8cd4e7c9f533120a2407cf6</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00218%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DP.%2BA.%26aulast%3DVakulenko%26aufirst%3DS.%2BB.%26aulast%3DStewart%26aufirst%3DN.%2BK.%26aulast%3DBoggess%26aufirst%3DW.%2BC.%26aulast%3DMiller%26aufirst%3DM.%2BJ.%26atitle%3DA%2520Synthetic%2520Dual%2520Drug%2520Sideromycin%2520Induces%2520Gram-Negative%2520Bacteria%2520To%2520Commit%2520Suicide%2520with%2520a%2520Gram-Positive%2520Antibiotic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D9%26spage%3D3845%26epage%3D3854%26doi%3D10.1021%2Facs.jmedchem.8b00218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wencewicz, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möllmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. J.</span></span> <span> </span><span class="NLM_article-title">Trihydroxamate Siderophore-Fluoroquinolone Conjugates Are Selective Sideromycin Antibiotics That Target Staphylococcus Aureus</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">486</span>, <span class="refDoi"> DOI: 10.1021/bc300610f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc300610f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVemsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=473-486&issue=3&author=T.+A.+Wencewiczauthor=T.+E.+Longauthor=U.+M%C3%B6llmannauthor=M.+J.+Miller&title=Trihydroxamate+Siderophore-Fluoroquinolone+Conjugates+Are+Selective+Sideromycin+Antibiotics+That+Target+Staphylococcus+Aureus&doi=10.1021%2Fbc300610f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Trihydroxamate Siderophore-Fluoroquinolone Conjugates Are Selective Sideromycin Antibiotics that Target Staphylococcus aureus</span></div><div class="casAuthors">Wencewicz, Timothy A.; Long, Timothy E.; Mollmann, Ute; Miller, Marvin J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">473-486</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Siderophores are multidentate iron(III) chelators used by bacteria for iron assimilation.  Sideromycins, also called siderophore-antibiotic conjugates, are a unique subset of siderophores that enter bacterial cells via siderophore uptake pathways and deliver the toxic antibiotic in a Trojan horse fashion.  Sideromycins represent a novel antibiotic delivery technol. with untapped potential for developing sophisticated microbe-selective antibacterial agents that limit the emergence of bacterial resistance.  The chem. synthesis of a series of mono-, bis-, and trihydroxamate sideromycins are described here along with their biol. evaluation in antibacterial susceptibility assays.  The linear hydroxamate siderophores used for the sideromycins in this study were derived from the ferrioxamine family and inspired by the naturally occurring salmycin sideromycins.  The antibacterial agents used were a β-lactam carbacepholosporin, Lorabid, and a fluoroquinolone, ciprofloxacin, chosen for the different locations of their biol. targets, the periplasm (extracellular) and the cytoplasm (intracellular).  The linear hydroxamate-based sideromycins were selectively toxic toward Gram-pos. bacteria, esp. Staphylococcus aureus SG511 (MIC = 1.0 μM for the trihydroxamate-fluoroquinolone sideromycin).  Siderophore-sideromycin competition assays demonstrated that only the fluoroquinolone sideromycins required membrane transport to reach their cytoplasmic biol. target and that a trihydroxamate siderophore backbone was required for protein-mediated active transport of the sideromycins into S. aureus cells via siderophore uptake pathways.  This work represents a comprehensive study of linear hydroxamate sideromycins and teaches how to build effective hydroxamate-based sideromycins as Gram-pos. selective antibiotic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqb9eWs7Rjn7Vg90H21EOLACvtfcHk0lhQOYU_jERPPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVemsr0%253D&md5=21278dfc61acf0135945eb3052bef2d2</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1021%2Fbc300610f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc300610f%26sid%3Dliteratum%253Aachs%26aulast%3DWencewicz%26aufirst%3DT.%2BA.%26aulast%3DLong%26aufirst%3DT.%2BE.%26aulast%3DM%25C3%25B6llmann%26aufirst%3DU.%26aulast%3DMiller%26aufirst%3DM.%2BJ.%26atitle%3DTrihydroxamate%2520Siderophore-Fluoroquinolone%2520Conjugates%2520Are%2520Selective%2520Sideromycin%2520Antibiotics%2520That%2520Target%2520Staphylococcus%2520Aureus%26jtitle%3DBioconjugate%2520Chem.%26date%3D2013%26volume%3D24%26issue%3D3%26spage%3D473%26epage%3D486%26doi%3D10.1021%2Fbc300610f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wencewicz, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. J.</span></span> <span> </span><span class="NLM_article-title">Biscatecholate-Monohydroxamate Mixed Ligand Siderophore-Carbacephalosporin Conjugates Are Selective Sideromycin Antibiotics That Target Acinetobacter Baumannii</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4044</span>– <span class="NLM_lpage">4052</span>, <span class="refDoi"> DOI: 10.1021/jm400265k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400265k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4044-4052&issue=10&author=T.+A.+Wencewiczauthor=M.+J.+Miller&title=Biscatecholate-Monohydroxamate+Mixed+Ligand+Siderophore-Carbacephalosporin+Conjugates+Are+Selective+Sideromycin+Antibiotics+That+Target+Acinetobacter+Baumannii&doi=10.1021%2Fjm400265k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1021%2Fjm400265k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400265k%26sid%3Dliteratum%253Aachs%26aulast%3DWencewicz%26aufirst%3DT.%2BA.%26aulast%3DMiller%26aufirst%3DM.%2BJ.%26atitle%3DBiscatecholate-Monohydroxamate%2520Mixed%2520Ligand%2520Siderophore-Carbacephalosporin%2520Conjugates%2520Are%2520Selective%2520Sideromycin%2520Antibiotics%2520That%2520Target%2520Acinetobacter%2520Baumannii%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D10%26spage%3D4044%26epage%3D4052%26doi%3D10.1021%2Fjm400265k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, M. W.</span></span> <span> </span><span class="NLM_article-title">Cefiderocol: A Novel Siderophore Cephalosporin</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1080/13543784.2018.1426745</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1080%2F13543784.2018.1426745" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=193-197&issue=2&author=J.+J.+Choiauthor=M.+W.+McCarthy&title=Cefiderocol%3A+A+Novel+Siderophore+Cephalosporin&doi=10.1080%2F13543784.2018.1426745"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1080%2F13543784.2018.1426745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2018.1426745%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DJ.%2BJ.%26aulast%3DMcCarthy%26aufirst%3DM.%2BW.%26atitle%3DCefiderocol%253A%2520A%2520Novel%2520Siderophore%2520Cephalosporin%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2018%26volume%3D27%26issue%3D2%26spage%3D193%26epage%3D197%26doi%3D10.1080%2F13543784.2018.1426745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wainwright, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meegan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dempster, N.</span></span> <span> </span><span class="NLM_article-title">Phenothiazinium-Fluoroquinolone Drug Conjugates</span>. <i>Int. J. Antimicrob. Agents</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.1016/j.ijantimicag.2009.11.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.ijantimicag.2009.11.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=20060690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitlSqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=405-409&issue=4&author=M.+Wainwrightauthor=A.+Shahauthor=K.+Meeganauthor=C.+Loughranauthor=A.+Smithauthor=N.+Valliauthor=N.+Dempster&title=Phenothiazinium-Fluoroquinolone+Drug+Conjugates&doi=10.1016%2Fj.ijantimicag.2009.11.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Phenothiazinium-fluoroquinolone drug conjugates</span></div><div class="casAuthors">Wainwright, Mark; Shah, Ami; Meegan, Katie; Loughran, Ciara; Smith, Andy; Valli, Nasima; Dempster, Nicola</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">405-409</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Synthesis and antibacterial screening of a homologous series of 3-dialkylaminophenothiazinium-7-norfloxacin conjugates was carried out alongside a corresponding series of sym. methylene blue derivs.  The norfloxacin conjugates maintained typical methylene blue deriv. photoproperties, such as long wavelength absorption, but produced no measurable singlet oxygen in the std. assay and provided no significant increase in the magnitude of photoantibacterial action, this being similar to the methylene blue homologs, although both the conjugates and homologs were considerably more active than methylene blue itself both against Staphylococcus aureus and Escherichia coli.  DNA binding via intercalation was considerably greater for the series of norfloxacin conjugates than for the methylene blue homologs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql2ey1XSf0yrVg90H21EOLACvtfcHk0lhQOYU_jERPPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitlSqtrw%253D&md5=ce3592aa7650d7cb6bd5819a45905648</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2009.11.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2009.11.022%26sid%3Dliteratum%253Aachs%26aulast%3DWainwright%26aufirst%3DM.%26aulast%3DShah%26aufirst%3DA.%26aulast%3DMeegan%26aufirst%3DK.%26aulast%3DLoughran%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DValli%26aufirst%3DN.%26aulast%3DDempster%26aufirst%3DN.%26atitle%3DPhenothiazinium-Fluoroquinolone%2520Drug%2520Conjugates%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2010%26volume%3D35%26issue%3D4%26spage%3D405%26epage%3D409%26doi%3D10.1016%2Fj.ijantimicag.2009.11.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchikama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, Z.</span></span> <span> </span><span class="NLM_article-title">Antibody-Drug Conjugates: Recent Advances in Conjugation and Linker Chemistries</span>. <i>Protein Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1007/s13238-016-0323-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1007%2Fs13238-016-0323-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27743348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslSlsrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=33-46&issue=1&author=K.+Tsuchikamaauthor=Z.+An&title=Antibody-Drug+Conjugates%3A+Recent+Advances+in+Conjugation+and+Linker+Chemistries&doi=10.1007%2Fs13238-016-0323-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates: recent advances in conjugation and linker chemistries</span></div><div class="casAuthors">Tsuchikama, Kyoji; An, Zhiqiang</div><div class="citationInfo"><span class="NLM_cas:title">Protein & Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-46</span>CODEN:
                <span class="NLM_cas:coden">PCREFB</span>;
        ISSN:<span class="NLM_cas:issn">1674-800X</span>.
    
            (<span class="NLM_cas:orgname">Higher Education Press</span>)
        </div><div class="casAbstract">The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small mols. (payloads) through chem. linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy.  This new antibody-based mol. platform enables selective delivery of a potent cytotoxic payload to target cancer cells, resulting in improved efficacy, reduced systemic toxicity, and preferable pharmacokinetics (PK)/pharmacodynamics (PD) and biodistribution compared to traditional chemotherapy.  Boosted by the successes of FDA-approved Adcetris and Kadcyla, this drug class has been rapidly growing along with about 60 ADCs currently in clin. trials.  In this article, we briefly review mol. aspects of each component (the antibody, payload, and linker) of ADCs, and then mainly discuss traditional and new technologies of the conjugation and linker chemistries for successful construction of clin. effective ADCs.  Current efforts in the conjugation and linker chemistries will provide greater insights into mol. design and strategies for clin. effective ADCs from medicinal chem. and pharmacol. standpoints.  The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an esp. promising path to improving ADC design, which will open the way for novel cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQM6rnMshPgrVg90H21EOLACvtfcHk0liasTHil1liaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslSlsrjJ&md5=774905d4270dfdbf53456f7ef6e2b7b6</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1007%2Fs13238-016-0323-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13238-016-0323-0%26sid%3Dliteratum%253Aachs%26aulast%3DTsuchikama%26aufirst%3DK.%26aulast%3DAn%26aufirst%3DZ.%26atitle%3DAntibody-Drug%2520Conjugates%253A%2520Recent%2520Advances%2520in%2520Conjugation%2520and%2520Linker%2520Chemistries%26jtitle%3DProtein%2520Cell%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D33%26epage%3D46%26doi%3D10.1007%2Fs13238-016-0323-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasarao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galliford, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, P. S.</span></span> <span> </span><span class="NLM_article-title">Principles in the Design of Ligand-Targeted Cancer Therapeutics and Imaging Agents</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1038/nrd4519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnrd4519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=25698644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtVylsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=203-219&issue=3&author=M.+Srinivasaraoauthor=C.+V.+Gallifordauthor=P.+S.+Low&title=Principles+in+the+Design+of+Ligand-Targeted+Cancer+Therapeutics+and+Imaging+Agents&doi=10.1038%2Fnrd4519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Principles in the design of ligand-targeted cancer therapeutics and imaging agents</span></div><div class="casAuthors">Srinivasarao, Madduri; Galliford, Chris V.; Low, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-219</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most cancer drugs are designed to interfere with one or more events in cell proliferation or survival.  As healthy cells may also need to proliferate and avoid apoptosis, anticancer agents can be toxic to such cells.  To minimize these toxicities, strategies have been developed wherein the therapeutic agent is targeted to tumor cells through conjugation to a tumor-cell-specific small-mol. ligand, thereby reducing delivery to normal cells and the assocd. collateral toxicity.  This Review describes the major principles in the design of ligand-targeted drugs and provides an overview of ligand-drug conjugates and ligand-imaging-agent conjugates that are currently in development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSVpXZcVlh_bVg90H21EOLACvtfcHk0liasTHil1liaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtVylsb4%253D&md5=71e2e7ad51f7f55415ccddb9ed1ea3db</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1038%2Fnrd4519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4519%26sid%3Dliteratum%253Aachs%26aulast%3DSrinivasarao%26aufirst%3DM.%26aulast%3DGalliford%26aufirst%3DC.%2BV.%26aulast%3DLow%26aufirst%3DP.%2BS.%26atitle%3DPrinciples%2520in%2520the%2520Design%2520of%2520Ligand-Targeted%2520Cancer%2520Therapeutics%2520and%2520Imaging%2520Agents%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26issue%3D3%26spage%3D203%26epage%3D219%26doi%3D10.1038%2Fnrd4519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walles, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hainzl, D.</span></span> <span> </span><span class="NLM_article-title">ADME and Safety Aspects of Non-Cleavable Linkers in Drug Discovery and Development</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">32</span>),  <span class="NLM_fpage">3463</span>– <span class="NLM_lpage">3475</span>, <span class="refDoi"> DOI: 10.2174/1568026618666180118153502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F1568026618666180118153502" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=3463-3475&issue=32&author=M.+Wallesauthor=A.+Connorauthor=D.+Hainzl&title=ADME+and+Safety+Aspects+of+Non-Cleavable+Linkers+in+Drug+Discovery+and+Development&doi=10.2174%2F1568026618666180118153502"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.2174%2F1568026618666180118153502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026618666180118153502%26sid%3Dliteratum%253Aachs%26aulast%3DWalles%26aufirst%3DM.%26aulast%3DConnor%26aufirst%3DA.%26aulast%3DHainzl%26aufirst%3DD.%26atitle%3DADME%2520and%2520Safety%2520Aspects%2520of%2520Non-Cleavable%2520Linkers%2520in%2520Drug%2520Discovery%2520and%2520Development%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2018%26volume%3D17%26issue%3D32%26spage%3D3463%26epage%3D3475%26doi%3D10.2174%2F1568026618666180118153502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seidi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenjob, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespy, D.</span></span> <span> </span><span class="NLM_article-title">Designing Smart Polymer Conjugates for Controlled Release of Payloads</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>118</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3965</span>– <span class="NLM_lpage">4036</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.8b00006</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.8b00006" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkt1Kru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2018&pages=3965-4036&issue=7&author=F.+Seidiauthor=R.+Jenjobauthor=D.+Crespy&title=Designing+Smart+Polymer+Conjugates+for+Controlled+Release+of+Payloads&doi=10.1021%2Facs.chemrev.8b00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Designing Smart Polymer Conjugates for Controlled Release of Payloads</span></div><div class="casAuthors">Seidi, Farzad; Jenjob, Ratchapol; Crespy, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3965-4036</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Incorporating labile bonds inside polymer backbone and side chains yields interesting polymer materials that are responsive to change of environmental stimuli.  Drugs can be conjugated to various polymers through different conjugation linkages and spacers.  One of the key factors influencing the release profile of conjugated drugs is the hydrolytic stability of the conjugated linkage.  Generally, the hydrolysis of acid-labile linkages, including acetal, imine, hydrazone, and to some extent β-thiopropionate, are relatively fast and the conjugated drug can be completely released in the range of several hours to a few days.  The cleavage of ester linkages are usually slow, which is beneficial for continuous and prolonged release.  Another key structural factor is the water soly. of polymer-drug conjugates.  Generally, the release rate from highly water-sol. prodrugs is fast.  In prodrugs with large hydrophobic segments, the hydrophobic drugs are usually located in the hydrophobic core of micelles and nanoparticles, which limits the access to the water, hence lowering significantly the hydrolysis rate.  Finally, self-immolative polymers are also an intriguing new class of materials.  New synthetic pathways are needed to overcome the fact that much of the small mols. produced upon degrdn. are not active mols. useful for biomedical applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoncOdguQX5UrVg90H21EOLACvtfcHk0liasTHil1liaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkt1Kru74%253D&md5=969466bfe9567e44f0e703910fa8fb0f</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.8b00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.8b00006%26sid%3Dliteratum%253Aachs%26aulast%3DSeidi%26aufirst%3DF.%26aulast%3DJenjob%26aufirst%3DR.%26aulast%3DCrespy%26aufirst%3DD.%26atitle%3DDesigning%2520Smart%2520Polymer%2520Conjugates%2520for%2520Controlled%2520Release%2520of%2520Payloads%26jtitle%3DChem.%2520Rev.%26date%3D2018%26volume%3D118%26issue%3D7%26spage%3D3965%26epage%3D4036%26doi%3D10.1021%2Facs.chemrev.8b00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frigerio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyle, A. F.</span></span> <span> </span><span class="NLM_article-title">The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">32</span>),  <span class="NLM_fpage">3393</span>– <span class="NLM_lpage">3424</span>, <span class="refDoi"> DOI: 10.2174/1568026618666180118155847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F1568026618666180118155847" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=3393-3424&issue=32&author=M.+Frigerioauthor=A.+F.+Kyle&title=The+Chemical+Design+and+Synthesis+of+Linkers+Used+in+Antibody+Drug+Conjugates&doi=10.2174%2F1568026618666180118155847"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.2174%2F1568026618666180118155847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026618666180118155847%26sid%3Dliteratum%253Aachs%26aulast%3DFrigerio%26aufirst%3DM.%26aulast%3DKyle%26aufirst%3DA.%2BF.%26atitle%3DThe%2520Chemical%2520Design%2520and%2520Synthesis%2520of%2520Linkers%2520Used%2520in%2520Antibody%2520Drug%2520Conjugates%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2018%26volume%3D17%26issue%3D32%26spage%3D3393%26epage%3D3424%26doi%3D10.2174%2F1568026618666180118155847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castañeda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chudasama, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chester, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caddick, S.</span></span> <span> </span><span class="NLM_article-title">Acid-Cleavable Thiomaleamic Acid Linker for Homogeneous Antibody–drug Conjugation</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">74</span>),  <span class="NLM_fpage">8187</span>, <span class="refDoi"> DOI: 10.1039/c3cc45220d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1039%2Fc3cc45220d" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=8187&issue=74&author=L.+Casta%C3%B1edaauthor=A.+Maruaniauthor=F.+F.+Schumacherauthor=E.+Mirandaauthor=V.+Chudasamaauthor=K.+A.+Chesterauthor=J.+R.+Bakerauthor=M.+E.+B.+Smithauthor=S.+Caddick&title=Acid-Cleavable+Thiomaleamic+Acid+Linker+for+Homogeneous+Antibody%E2%80%93drug+Conjugation&doi=10.1039%2Fc3cc45220d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1039%2Fc3cc45220d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3cc45220d%26sid%3Dliteratum%253Aachs%26aulast%3DCasta%25C3%25B1eda%26aufirst%3DL.%26aulast%3DMaruani%26aufirst%3DA.%26aulast%3DSchumacher%26aufirst%3DF.%2BF.%26aulast%3DMiranda%26aufirst%3DE.%26aulast%3DChudasama%26aufirst%3DV.%26aulast%3DChester%26aufirst%3DK.%2BA.%26aulast%3DBaker%26aufirst%3DJ.%2BR.%26aulast%3DSmith%26aufirst%3DM.%2BE.%2BB.%26aulast%3DCaddick%26aufirst%3DS.%26atitle%3DAcid-Cleavable%2520Thiomaleamic%2520Acid%2520Linker%2520for%2520Homogeneous%2520Antibody%25E2%2580%2593drug%2520Conjugation%26jtitle%3DChem.%2520Commun.%26date%3D2013%26volume%3D49%26issue%3D74%26spage%3D8187%26doi%3D10.1039%2Fc3cc45220d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubowchik, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofstead, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosure, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knipe, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasch, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trail, P. A.</span></span> <span> </span><span class="NLM_article-title">Cathepsin B-Labile Dipeptide Linkers for Lysosomal Release of Doxorubicin from Internalizing Immunoconjugates: Model Studies of Enzymatic Drug Release and Antigen-Specific in Vitro Anticancer Activity</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">869</span>, <span class="refDoi"> DOI: 10.1021/bc025536j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc025536j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD38XksFentr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=855-869&issue=4&author=G.+M.+Dubowchikauthor=R.+A.+Firestoneauthor=L.+Padillaauthor=D.+Willnerauthor=S.+J.+Hofsteadauthor=K.+Mosureauthor=J.+O.+Knipeauthor=S.+J.+Laschauthor=P.+A.+Trail&title=Cathepsin+B-Labile+Dipeptide+Linkers+for+Lysosomal+Release+of+Doxorubicin+from+Internalizing+Immunoconjugates%3A+Model+Studies+of+Enzymatic+Drug+Release+and+Antigen-Specific+in+Vitro+Anticancer+Activity&doi=10.1021%2Fbc025536j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin B-Labile Dipeptide Linkers for Lysosomal Release of Doxorubicin from Internalizing Immunoconjugates: Model Studies of Enzymatic Drug Release and Antigen-Specific In Vitro Anticancer Activity</span></div><div class="casAuthors">Dubowchik, Gene M.; Firestone, Raymond A.; Padilla, Linda; Willner, David; Hofstead, Sandra J.; Mosure, Kathleen; Knipe, Jay O.; Lasch, Shirley J.; Trail, Pamela A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">855-869</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The anticancer drug doxorubicin (DOX) was linked to chimeric BR96, an internalizing monoclonal antibody that binds to a Lewisy-related, tumor-assocd. antigen, through 2 lysosomally cleavable dipeptides, Phe-Lys and Val-Cit, giving immunoconjugates (I and II).  A self-immolative p-aminobenzyloxycarbonyl (PABC) spacer between the dipeptides and the DOX was required for rapid and quant. generation of free drug. DOX release from the model substrate Z-Phe-Lys-PABC-DOX was 30-fold faster than from Z-Val-Cit-PABC-DOX with the cysteine protease cathepsin B alone, but rates were identical in a rat liver lysosomal prepn. suggesting the participation of more than one enzyme.  Conjugates I and II showed rapid and near quant. drug release with cathepsin B and in a lysosomal prepn., while demonstrating excellent stability in human plasma.  Against tumor cell lines with varying levels of BR96 expression, both conjugates showed potent, antigen-specific cytotoxic activity, suggesting that they will be effective in delivering DOX selectively to antigen-expressing carcinomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqolCImqg5WKbVg90H21EOLACvtfcHk0lhHyUab7okR5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksFentr8%253D&md5=09fb70d94d8997033b109fa3b5e79621</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Fbc025536j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc025536j%26sid%3Dliteratum%253Aachs%26aulast%3DDubowchik%26aufirst%3DG.%2BM.%26aulast%3DFirestone%26aufirst%3DR.%2BA.%26aulast%3DPadilla%26aufirst%3DL.%26aulast%3DWillner%26aufirst%3DD.%26aulast%3DHofstead%26aufirst%3DS.%2BJ.%26aulast%3DMosure%26aufirst%3DK.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DLasch%26aufirst%3DS.%2BJ.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26atitle%3DCathepsin%2520B-Labile%2520Dipeptide%2520Linkers%2520for%2520Lysosomal%2520Release%2520of%2520Doxorubicin%2520from%2520Internalizing%2520Immunoconjugates%253A%2520Model%2520Studies%2520of%2520Enzymatic%2520Drug%2520Release%2520and%2520Antigen-Specific%2520in%2520Vitro%2520Anticancer%2520Activity%26jtitle%3DBioconjugate%2520Chem.%26date%3D2002%26volume%3D13%26issue%3D4%26spage%3D855%26epage%3D869%26doi%3D10.1021%2Fbc025536j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mhidia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bézière, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanpain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommery, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnyk, O.</span></span> <span> </span><span class="NLM_article-title">Assembly/disassembly of Drug Conjugates Using Imide Ligation</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">3982</span>– <span class="NLM_lpage">3985</span>, <span class="refDoi"> DOI: 10.1021/ol101049g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol101049g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=3982-3985&issue=18&author=R.+Mhidiaauthor=N.+B%C3%A9zi%C3%A8reauthor=A.+Blanpainauthor=N.+Pommeryauthor=O.+Melnyk&title=Assembly%2Fdisassembly+of+Drug+Conjugates+Using+Imide+Ligation&doi=10.1021%2Fol101049g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1021%2Fol101049g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol101049g%26sid%3Dliteratum%253Aachs%26aulast%3DMhidia%26aufirst%3DR.%26aulast%3DB%25C3%25A9zi%25C3%25A8re%26aufirst%3DN.%26aulast%3DBlanpain%26aufirst%3DA.%26aulast%3DPommery%26aufirst%3DN.%26aulast%3DMelnyk%26aufirst%3DO.%26atitle%3DAssembly%252Fdisassembly%2520of%2520Drug%2520Conjugates%2520Using%2520Imide%2520Ligation%26jtitle%3DOrg.%2520Lett.%26date%3D2010%26volume%3D12%26issue%3D18%26spage%3D3982%26epage%3D3985%26doi%3D10.1021%2Fol101049g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, S.
C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreyka, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardt, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kissler, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kline, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenox, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moser, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okeley, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span> <span> </span><span class="NLM_article-title">Development and Properties of β-Glucuronide Linkers for Monoclonal Antibody-Drug Conjugates</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">840</span>, <span class="refDoi"> DOI: 10.1021/bc0600214</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc0600214" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD28XktVert78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=831-840&issue=3&author=S.%0AC.+Jeffreyauthor=J.+B.+Andreykaauthor=S.+X.+Bernhardtauthor=K.+M.+Kisslerauthor=T.+Klineauthor=J.+S.+Lenoxauthor=R.+F.+Moserauthor=M.+T.+Nguyenauthor=N.+M.+Okeleyauthor=I.+J.+Stoneauthor=X.+Zhangauthor=P.+D.+Senter&title=Development+and+Properties+of+%CE%B2-Glucuronide+Linkers+for+Monoclonal+Antibody-Drug+Conjugates&doi=10.1021%2Fbc0600214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Development and Properties of β-Glucuronide Linkers for Monoclonal Antibody-Drug Conjugates</span></div><div class="casAuthors">Jeffrey, Scott C.; Andreyka, Jamie B.; Bernhardt, Starr X.; Kissler, Kim M.; Kline, Toni; Lenox, Joel S.; Moser, Ruth F.; Nguyen, Minh T.; Okeley, Nicole M.; Stone, Ivan J.; Zhang, Xinqun; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">831-840</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A β-glucuronide-based linker for attaching cytotoxic agents to monoclonal antibodies (mAbs) was designed and evaluated.  We employed the cytotoxic Monomethyl auristatin E (MMAE) and Monomethyl auristatin F (MMAF)and doxorubicin propyloxazoline (DPO) to give the β-glucuronide MMAE, Β-glucuronide MMAF, and (I), resp.  Cysteine-quenched derivs. of Β-glucuronide MMAF and I were detd. to be substrates for E. Coli β-glucuronidase, resulting in facile drug release.  The β-glucuronide MMAF was highly stable in rat plasma with an extrapolated half-life of 81 days.  Each drug-linker when conjugated to mAbs c1F6 (anti-CD70) and cAC10 (anti-CD30) gave monomeric antibody-drug conjugates (ADCs) with as many as eight drugs per mAb and had high levels of immunol. specific cytotoxic activity on cancer cell lines.  CAC10-β-glucuronide MMAE displayed pronounced antitumor activity in a s.c. Karpas 299 lymphoma tumor model.  A single dose treatment led to cures in all animals at the 0.5 mg/kg dose level and above, and the conjugate was well tolerated at 100 mg/kg.  In mice with s.c. renal cell carcinoma xenografts, the MMAF conjugate c1F6-Β-glucuronide MMAF was tolerated at 25 mg/kg and efficacious at 0.75 mg/kg.  These results demonstrate that the β-glucuronide linker system is an effective strategy for targeting cytotoxic agents providing ADCs with high degrees of efficacy at well-tolerated doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoubdLz5MUdl7Vg90H21EOLACvtfcHk0lh587jQ11iSlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktVert78%253D&md5=eebae444d27717c44b521eeb8d6c7ed7</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Fbc0600214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc0600214%26sid%3Dliteratum%253Aachs%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26aulast%3DAndreyka%26aufirst%3DJ.%2BB.%26aulast%3DBernhardt%26aufirst%3DS.%2BX.%26aulast%3DKissler%26aufirst%3DK.%2BM.%26aulast%3DKline%26aufirst%3DT.%26aulast%3DLenox%26aufirst%3DJ.%2BS.%26aulast%3DMoser%26aufirst%3DR.%2BF.%26aulast%3DNguyen%26aufirst%3DM.%2BT.%26aulast%3DOkeley%26aufirst%3DN.%2BM.%26aulast%3DStone%26aufirst%3DI.%2BJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DDevelopment%2520and%2520Properties%2520of%2520%25CE%25B2-Glucuronide%2520Linkers%2520for%2520Monoclonal%2520Antibody-Drug%2520Conjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D2006%26volume%3D17%26issue%3D3%26spage%3D831%26epage%3D840%26doi%3D10.1021%2Fbc0600214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span>; <span class="NLM_string-name">Bauer, U.</span>; <span class="NLM_string-name">Engkvist, O.</span></span> <span> </span><span class="NLM_article-title">Merged Multiple Ligands</span>. In  <i>Drug Selectivity</i>; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>, <span class="NLM_year">2017</span>; pp  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">274</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2F9783527674381.ch9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=247-274&author=H.+Chen&author=U.+Bauer&author=O.+Engkvist&title=Drug+Selectivity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1002%2F9783527674381.ch9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527674381.ch9%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26atitle%3DMerged%2520Multiple%2520Ligands%26btitle%3DDrug%2520Selectivity%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2017%26spage%3D247%26epage%3D274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalinowsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">5235</span>– <span class="NLM_lpage">5266</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01287</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01287" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1elsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5235-5266&issue=13&author=E.+Proschakauthor=P.+Heitelauthor=L.+Kalinowskyauthor=D.+Merk&title=Opportunities+and+Challenges+for+Fatty+Acid+Mimetics+in+Drug+Discovery&doi=10.1021%2Facs.jmedchem.6b01287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery</span></div><div class="casAuthors">Proschak, Ewgenij; Heitel, Pascal; Kalinowsky, Lena; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5235-5266</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fatty acids beyond their role as an endogenous energy source and storage are increasingly considered as signaling mols. regulating various physiol. effects in metab. and inflammation.  Accordingly, the mol. targets involved in formation and physiol. activities of fatty acids hold significant therapeutic potential.  A no. of these fatty acid targets are addressed by some of the oldest and most widely used drugs such as cyclooxygenase inhibiting NSAIDs, whereas others remain unexploited.  Compds. orthosterically binding to proteins that endogenously bind fatty acids are considered as fatty acid mimetics.  On the basis of their structural resemblance, fatty acid mimetics constitute a family of bioactive compds. showing specific binding thermodn. and following similar pharmacokinetic mechanisms.  This perspective systematically evaluates targets for fatty acid mimetics, investigates their common structural characteristics, and highlights demands in their discovery and design.  In summary, fatty acid mimetics share particularly favorable characteristics justifying the conclusion that their therapeutic potential vastly outweighs the challenges in their design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjMjaOmukt7bVg90H21EOLACvtfcHk0lh587jQ11iSlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1elsrw%253D&md5=78a3a6be0a9d9bfd672c5e851abffc3e</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01287%26sid%3Dliteratum%253Aachs%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DHeitel%26aufirst%3DP.%26aulast%3DKalinowsky%26aufirst%3DL.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DOpportunities%2520and%2520Challenges%2520for%2520Fatty%2520Acid%2520Mimetics%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D13%26spage%3D5235%26epage%3D5266%26doi%3D10.1021%2Facs.jmedchem.6b01287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahon, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V. L.</span></span> <span> </span><span class="NLM_article-title">Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1423</span>– <span class="NLM_lpage">1438</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201100145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fcmdc.201100145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=21608133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptFKrtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=1423-1438&issue=8&author=P.+M.+Woodauthor=L.+W.+L.+Wooauthor=M.+P.+Thomasauthor=M.+F.+Mahonauthor=A.+Purohitauthor=B.+V.+L.+Potter&title=Aromatase+and+Dual+Aromatase-Steroid+Sulfatase+Inhibitors+from+the+Letrozole+and+Vorozole+Templates&doi=10.1002%2Fcmdc.201100145"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates</span></div><div class="casAuthors">Wood, Paul M.; Woo, L. W. Lawrence; Thomas, Mark P.; Mahon, Mary F.; Purohit, Atul; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1423-1438</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Concurrent inhibition of aromatase and steroid sulfatase (STS) may provide a more effective treatment for hormone-dependent breast cancer than monotherapy against individual enzymes, and several dual aromatase-sulfatase inhibitors (DASIs) have been reported.  Three aromatase inhibitors with sub-nanomolar potency, better than the benchmark agent letrozole, were designed.  To further explore the DASI concept, a new series of letrozole-derived sulfamates and a vorozole-based sulfamate were designed and biol. evaluated in JEG-3 cells to reveal structure-activity relationships.  Amongst achiral and racemic compds., 2-bromo-4-(2-(4-cyanophenyl)-2-(1H-1,2,4-triazol-1-yl)ethyl)phenyl sulfamate is the most potent DASI (aromatase: IC50=0.87 nM; STS: IC50=593 nM).  The enantiomers of the phenolic precursor to this compd. were sepd. by chiral HPLC and their abs. configuration detd. by X-ray crystallog.  Following conversion to their corresponding sulfamates, the S-(+)-enantiomer was found to inhibit aromatase and sulfatase most potently (aromatase: IC50=0.52 nM; STS: IC50=280 nM).  The docking of each enantiomer and other ligands into the aromatase and sulfatase active sites was also investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq91XsDqvKlHrVg90H21EOLACvtfcHk0lh587jQ11iSlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptFKrtrw%253D&md5=94dae7013fdf874ffe1540b8d31122c5</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100145%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DP.%2BM.%26aulast%3DWoo%26aufirst%3DL.%2BW.%2BL.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DMahon%26aufirst%3DM.%2BF.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL.%26atitle%3DAromatase%2520and%2520Dual%2520Aromatase-Steroid%2520Sulfatase%2520Inhibitors%2520from%2520the%2520Letrozole%2520and%2520Vorozole%2520Templates%26jtitle%3DChemMedChem%26date%3D2011%26volume%3D6%26issue%3D8%26spage%3D1423%26epage%3D1438%26doi%3D10.1002%2Fcmdc.201100145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V. L.</span></span> <span> </span><span class="NLM_article-title">Hybrid Dual Aromatase-Steroid Sulfatase Inhibitors with Exquisite Picomolar Inhibitory Activity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1021/ml100273k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100273k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1ags7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=243-247&issue=3&author=L.+W.+L.+Wooauthor=C.+Bubertauthor=A.+Purohitauthor=B.+V.+L.+Potter&title=Hybrid+Dual+Aromatase-Steroid+Sulfatase+Inhibitors+with+Exquisite+Picomolar+Inhibitory+Activity&doi=10.1021%2Fml100273k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrid Dual Aromatase-Steroid Sulfatase Inhibitors with Exquisite Picomolar Inhibitory Activity</span></div><div class="casAuthors">Woo, L. W. Lawrence; Bubert, Christian; Purohit, Atul; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">243-247</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Single agents against multiple drug targets are highly topical.  Hormone-dependent breast cancer (HDBC) may be more effectively treated by dual inhibition of aromatase and steroid sulfatase (STS), and several dual aromatase-sulfatase inhibitors (DASIs) have been recently reported.  The best compds. from two leading classes of DASI, 3 and 9, are low nanomolar inhibitors.  In search of a novel class of DASI, core motifs of two leading classes were combined to give a series of hybrid structures, with several compds. showing markedly improved dual inhibitory activities in the picomolar range in JEG-3 cells.  Thus, DASIs 14 (I, IC50: aromatase, 15 pM; STS, 830 pM) and 15 (IC50: aromatase, 18 pM; STS, 130 pM) are the first examples of an exceptional new class of highly potent dual inhibitor that should encourage further development toward multitargeted therapeutic intervention in HDBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_WoO0V3JbF7Vg90H21EOLACvtfcHk0liyAkWBFErJ9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1ags7zK&md5=2805cabcf0c8210afec7bf65825b24c7</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1021%2Fml100273k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100273k%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DL.%2BW.%2BL.%26aulast%3DBubert%26aufirst%3DC.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL.%26atitle%3DHybrid%2520Dual%2520Aromatase-Steroid%2520Sulfatase%2520Inhibitors%2520with%2520Exquisite%2520Picomolar%2520Inhibitory%2520Activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26issue%3D3%26spage%3D243%26epage%3D247%26doi%3D10.1021%2Fml100273k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W.
L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-Triazol-4-Yl)amino]methyl}phenyl Sulfamate</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">799</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201300015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fcmdc.201300015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=23495205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVentLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=779-799&issue=5&author=L.+W.%0AL.+Wooauthor=P.+M.+Woodauthor=C.+Bubertauthor=M.+P.+Thomasauthor=A.+Purohitauthor=B.+V.+L.+Potter&title=Synthesis+and+Structure-Activity+Relationship+Studies+of+Derivatives+of+the+Dual+Aromatase-Sulfatase+Inhibitor+4-%7B%5B%284-Cyanophenyl%29%284H-1%2C2%2C4-Triazol-4-Yl%29amino%5Dmethyl%7Dphenyl+Sulfamate&doi=10.1002%2Fcmdc.201300015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationship studies of derivatives of the dual aromatase-sulfatase inhibitor 4-{[(4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate</span></div><div class="casAuthors">Woo, L. W. Lawrence; Wood, Paul M.; Bubert, Christian; Thomas, Mark P.; Purohit, Atul; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">779-799</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivs. are first-generation dual aromatase and sulfatase inhibitors (DASIs).  Structure-activity relationship studies were performed on these compds., and various modifications were made to their structures involving relocation of the halogen atom, introduction of more halogen atoms, replacement of the halogen with another group, replacement of the methylene linker with a difluoromethylene linker, replacement of the para-cyanophenyl ring with other ring structures, and replacement of the triazolyl group with an imidazolyl group.  The most potent in vitro DASI discovered is an imidazole deriv. with IC50 values against aromatase and steroid sulfatase in a JEG-3 cell prepn. of 0.2 and 2.5 nM, resp.  The parent phenol of this compd. inhibits aromatase with an IC50 value of 0.028 nM in the same assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDg_Fo94VkELVg90H21EOLACvtfcHk0liyAkWBFErJ9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVentLo%253D&md5=2d34b5f5c7e29c46c959dabd15c441e5</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300015%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DL.%2BW.%2BL.%26aulast%3DWood%26aufirst%3DP.%2BM.%26aulast%3DBubert%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL.%26atitle%3DSynthesis%2520and%2520Structure-Activity%2520Relationship%2520Studies%2520of%2520Derivatives%2520of%2520the%2520Dual%2520Aromatase-Sulfatase%2520Inhibitor%25204-%257B%255B%25284-Cyanophenyl%2529%25284H-1%252C2%252C4-Triazol-4-Yl%2529amino%255Dmethyl%257Dphenyl%2520Sulfamate%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26issue%3D5%26spage%3D779%26epage%3D799%26doi%3D10.1002%2Fcmdc.201300015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutcliffe, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chander, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahon, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V. L.</span></span> <span> </span><span class="NLM_article-title">Dual Aromatase-Steroid Sulfatase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">3540</span>– <span class="NLM_lpage">3560</span>, <span class="refDoi"> DOI: 10.1021/jm061462b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061462b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1CjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=3540-3560&issue=15&author=L.+W.+L.+Wooauthor=C.+Bubertauthor=O.+B.+Sutcliffeauthor=A.+Smithauthor=S.+K.+Chanderauthor=M.+F.+Mahonauthor=A.+Purohitauthor=M.+J.+Reedauthor=B.+V.+L.+Potter&title=Dual+Aromatase-Steroid+Sulfatase+Inhibitors&doi=10.1021%2Fjm061462b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Aromatase-Steroid Sulfatase Inhibitors</span></div><div class="casAuthors">Woo, L. W. Lawrence; Bubert, Christian; Sutcliffe, Oliver B.; Smith, Andrew; Chander, Surinder K.; Mahon, Mary F.; Purohit, Atul; Reed, Michael J.; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3540-3560</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By introducing the steroid sulfatase inhibitory pharmacophore into aromatase inhibitor 1 (YM511), two series of single agent dual aromatase-sulfatase inhibitors (DASIs) were generated.  Two best DASIs (I and II) in vitro (JEG-3 cells) had IC50(aromatase) = 0.82 nM; IC50(sulfatase) = 39 nM, and IC50(aromatase) = 0.77 nM; IC50(sulfatase) = 590 nM, resp.  X-ray crystallog. of I, and docking studies of selected compds. into an aromatase homol. model and the steroid sulfatase crystal structure are presented.  Both I and II inhibit aromatase and sulfatase in PMSG pretreated adult female Wistar rats potently 3 h after a single oral 10 mg/kg dose.  Almost complete dual inhibition is obsd. for I but the levels were reduced to 85% (aromatase) and 72% (sulfatase) after 24 h.  DASI I did not inhibit aldosterone synthesis.  The development of a potent and selective DASI should allow the therapeutic potential of dual aromatase-sulfatase inhibition in hormone-dependent breast cancer to be assessed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPvCTamzS0qbVg90H21EOLACvtfcHk0liyAkWBFErJ9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1CjtLs%253D&md5=69641aaecd430daad1c2f8074be4b436</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1021%2Fjm061462b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061462b%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DL.%2BW.%2BL.%26aulast%3DBubert%26aufirst%3DC.%26aulast%3DSutcliffe%26aufirst%3DO.%2BB.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DChander%26aufirst%3DS.%2BK.%26aulast%3DMahon%26aufirst%3DM.%2BF.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DReed%26aufirst%3DM.%2BJ.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL.%26atitle%3DDual%2520Aromatase-Steroid%2520Sulfatase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D15%26spage%3D3540%26epage%3D3560%26doi%3D10.1021%2Fjm061462b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenney, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titeler, M.</span></span> <span> </span><span class="NLM_article-title">5-HT1 and 5-HT2 Binding Characteristics of Some Quipazine Analogues</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2375</span>– <span class="NLM_lpage">2380</span>, <span class="refDoi"> DOI: 10.1021/jm00161a038</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00161a038" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADyaL2sXltVWmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1986&pages=2375-2380&issue=11&author=R.+A.+Glennonauthor=R.+M.+Slusherauthor=J.+D.+McKenneyauthor=R.+A.+Lyonauthor=M.+Titeler&title=5-HT1+and+5-HT2+Binding+Characteristics+of+Some+Quipazine+Analogues&doi=10.1021%2Fjm00161a038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT1 and 5-HT2:  binding characteristics of some quipazine analogs</span></div><div class="casAuthors">Glennon, Richard A.; Slusher, R. M.; Lyon, Robert A.; Titeler, Milt; McKenney, J. D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2375-80</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Quipazine analogs, e.g., I (R = H, Me; R1 = MeO), II (R2 = piperidino, Pr2N, NH2), and 1-(2-naphthyl)piperazine were prepd.  Thus, 2-chloro-8-methoxyquinoline was treated with N-methylpiperazine to give I (R = Me, R1 = MeO).  The compds. were tested for 5-HT1 and 5-HT2 agonist activity.  The unsubstituted benzene ring of quipazine (I, R = R1 = H) and 1-(2-naphthyl)piperazine make a significant contribution to the binding of these agents to 5-HT2 sites and may account for their 5-HT2 agonist properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR_O2JFtM667Vg90H21EOLACvtfcHk0lim42Ge0KTnkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXltVWmuw%253D%253D&md5=dffa4f48a420e86d8d4f0496d747dc91</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1021%2Fjm00161a038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00161a038%26sid%3Dliteratum%253Aachs%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26aulast%3DSlusher%26aufirst%3DR.%2BM.%26aulast%3DMcKenney%26aufirst%3DJ.%2BD.%26aulast%3DLyon%26aufirst%3DR.%2BA.%26aulast%3DTiteler%26aufirst%3DM.%26atitle%3D5-HT1%2520and%25205-HT2%2520Binding%2520Characteristics%2520of%2520Some%2520Quipazine%2520Analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1986%26volume%3D29%26issue%3D11%26spage%3D2375%26epage%3D2380%26doi%3D10.1021%2Fjm00161a038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagel, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heym, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinick, F. J.</span></span> <span> </span><span class="NLM_article-title">1-Naphthylpiperazine Derivatives as Potential Atypical Antipsychotic Agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1860</span>– <span class="NLM_lpage">1866</span>, <span class="refDoi"> DOI: 10.1021/jm00110a016</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00110a016" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1991&pages=1860-1866&author=J.+A.+Loweauthor=T.+F.+Seegerauthor=A.+A.+Nagelauthor=H.+R.+Howardauthor=P.+A.+Seymourauthor=J.+H.+Heymauthor=F.+E.+Ewingauthor=M.+E.+Newmanauthor=A.+W.+Schmidtauthor=J.+S.+Furmanauthor=L.+A.+Vincentauthor=P.+R.+Maloneyauthor=G.+L.+Robinsonauthor=L.+S.+Reynoldsauthor=F.+J.+Vinick&title=1-Naphthylpiperazine+Derivatives+as+Potential+Atypical+Antipsychotic+Agents&doi=10.1021%2Fjm00110a016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Fjm00110a016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00110a016%26sid%3Dliteratum%253Aachs%26aulast%3DLowe%26aufirst%3DJ.%2BA.%26aulast%3DSeeger%26aufirst%3DT.%2BF.%26aulast%3DNagel%26aufirst%3DA.%2BA.%26aulast%3DHoward%26aufirst%3DH.%2BR.%26aulast%3DSeymour%26aufirst%3DP.%2BA.%26aulast%3DHeym%26aufirst%3DJ.%2BH.%26aulast%3DEwing%26aufirst%3DF.%2BE.%26aulast%3DNewman%26aufirst%3DM.%2BE.%26aulast%3DSchmidt%26aufirst%3DA.%2BW.%26aulast%3DFurman%26aufirst%3DJ.%2BS.%26aulast%3DVincent%26aufirst%3DL.%2BA.%26aulast%3DMaloney%26aufirst%3DP.%2BR.%26aulast%3DRobinson%26aufirst%3DG.%2BL.%26aulast%3DReynolds%26aufirst%3DL.%2BS.%26aulast%3DVinick%26aufirst%3DF.%2BJ.%26atitle%3D1-Naphthylpiperazine%2520Derivatives%2520as%2520Potential%2520Atypical%2520Antipsychotic%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1991%26volume%3D34%26spage%3D1860%26epage%3D1866%26doi%3D10.1021%2Fjm00110a016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howard, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorn, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrone, J.</span></span> <span> </span><span class="NLM_article-title">3-Benzisothiazolylpiperazine Derivatives as Potential Atypical Antipsychotic Agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.1021/jm950625l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm950625l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=143-148&issue=1&author=H.+R.+Howardauthor=J.+A.+Loweauthor=T.+F.+Seegerauthor=P.+A.+Seymourauthor=S.+H.+Zornauthor=P.+R.+Maloneyauthor=F.+E.+Ewingauthor=M.+E.+Newmanauthor=A.+W.+Schmidtauthor=J.+S.+Furmanauthor=G.+L.+Robinsonauthor=E.+Jacksonauthor=C.+Johnsonauthor=J.+Morrone&title=3-Benzisothiazolylpiperazine+Derivatives+as+Potential+Atypical+Antipsychotic+Agents&doi=10.1021%2Fjm950625l"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1021%2Fjm950625l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm950625l%26sid%3Dliteratum%253Aachs%26aulast%3DHoward%26aufirst%3DH.%2BR.%26aulast%3DLowe%26aufirst%3DJ.%2BA.%26aulast%3DSeeger%26aufirst%3DT.%2BF.%26aulast%3DSeymour%26aufirst%3DP.%2BA.%26aulast%3DZorn%26aufirst%3DS.%2BH.%26aulast%3DMaloney%26aufirst%3DP.%2BR.%26aulast%3DEwing%26aufirst%3DF.%2BE.%26aulast%3DNewman%26aufirst%3DM.%2BE.%26aulast%3DSchmidt%26aufirst%3DA.%2BW.%26aulast%3DFurman%26aufirst%3DJ.%2BS.%26aulast%3DRobinson%26aufirst%3DG.%2BL.%26aulast%3DJackson%26aufirst%3DE.%26aulast%3DJohnson%26aufirst%3DC.%26aulast%3DMorrone%26aufirst%3DJ.%26atitle%3D3-Benzisothiazolylpiperazine%2520Derivatives%2520as%2520Potential%2520Atypical%2520Antipsychotic%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26issue%3D1%26spage%3D143%26epage%3D148%26doi%3D10.1021%2Fjm950625l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bautista-Aguilera, Ó. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagenow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palomino-Antolin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farré-Alins, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismaili, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joffrin, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soukup, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janočková, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalinowsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iriepa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraleda, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwed, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero Martínez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López-Muñoz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chioua, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egea, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H3R Antagonism for Neurodegenerative Diseases</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">41</span>),  <span class="NLM_fpage">12765</span>– <span class="NLM_lpage">12769</span>, <span class="refDoi"> DOI: 10.1002/anie.201706072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fanie.201706072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVekt73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=12765-12769&issue=41&author=%C3%93.+M.+Bautista-Aguileraauthor=S.+Hagenowauthor=A.+Palomino-Antolinauthor=V.+Farr%C3%A9-Alinsauthor=L.+Ismailiauthor=P.+L.+Joffrinauthor=M.+L.+Jimenoauthor=O.+Soukupauthor=J.+Jano%C4%8Dkov%C3%A1author=L.+Kalinowskyauthor=E.+Proschakauthor=I.+Iriepaauthor=I.+Moraledaauthor=J.+S.+Schwedauthor=A.+Romero+Mart%C3%ADnezauthor=F.+L%C3%B3pez-Mu%C3%B1ozauthor=M.+Chiouaauthor=J.+Egeaauthor=R.+R.+Ramsayauthor=J.+Marco-Contellesauthor=H.+Stark&title=Multitarget-Directed+Ligands+Combining+Cholinesterase+and+Monoamine+Oxidase+Inhibition+with+Histamine+H3R+Antagonism+for+Neurodegenerative+Diseases&doi=10.1002%2Fanie.201706072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H3R Antagonism for Neurodegenerative Diseases</span></div><div class="casAuthors">Bautista-Aguilera, Oscar M.; Hagenow, Stefanie; Palomino-Antolin, Alejandra; Farre-Alins, Victor; Ismaili, Lhassane; Joffrin, Pierre-Louis; Jimeno, Maria L.; Soukup, Ondrej; Janockova, Jana; Kalinowsky, Lena; Proschak, Ewgenij; Iriepa, Isabel; Moraleda, Ignacio; Schwed, Johannes S.; Romero Martinez, Alejandro; Lopez-Munoz, Francisco; Chioua, Mourad; Egea, Javier; Ramsay, Rona R.; Marco-Contelles, Jose; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">12765-12769</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The therapy of complex neurodegenerative diseases requires the development of multitarget-directed drugs (MTDs).  Novel indole derivs. with inhibitory activity towards acetyl/butyrylcholinesterases and monoamine oxidases A/B as well as the histamine H3 receptor (H3R) were obtained by optimization of the neuroprotectant ASS234 by incorporating generally accepted H3R pharmacophore motifs.  These small-mol. hits demonstrated balanced activities at the targets, mostly in the nanomolar concn. range.  Addnl. in vitro studies showed antioxidative neuroprotective effects as well as the ability to penetrate the blood-brain barrier.  With this promising in vitro profile, contilisant (at 1 mg kg-1 i.p.) also significantly improved lipopolysaccharide-induced cognitive deficits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2wNLAClUFULVg90H21EOLACvtfcHk0lim42Ge0KTnkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVekt73L&md5=4a962ad1ada3f5b8e8102add09cd4e60</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1002%2Fanie.201706072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201706072%26sid%3Dliteratum%253Aachs%26aulast%3DBautista-Aguilera%26aufirst%3D%25C3%2593.%2BM.%26aulast%3DHagenow%26aufirst%3DS.%26aulast%3DPalomino-Antolin%26aufirst%3DA.%26aulast%3DFarr%25C3%25A9-Alins%26aufirst%3DV.%26aulast%3DIsmaili%26aufirst%3DL.%26aulast%3DJoffrin%26aufirst%3DP.%2BL.%26aulast%3DJimeno%26aufirst%3DM.%2BL.%26aulast%3DSoukup%26aufirst%3DO.%26aulast%3DJano%25C4%258Dkov%25C3%25A1%26aufirst%3DJ.%26aulast%3DKalinowsky%26aufirst%3DL.%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DIriepa%26aufirst%3DI.%26aulast%3DMoraleda%26aufirst%3DI.%26aulast%3DSchwed%26aufirst%3DJ.%2BS.%26aulast%3DRomero%2BMart%25C3%25ADnez%26aufirst%3DA.%26aulast%3DL%25C3%25B3pez-Mu%25C3%25B1oz%26aufirst%3DF.%26aulast%3DChioua%26aufirst%3DM.%26aulast%3DEgea%26aufirst%3DJ.%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DMultitarget-Directed%2520Ligands%2520Combining%2520Cholinesterase%2520and%2520Monoamine%2520Oxidase%2520Inhibition%2520with%2520Histamine%2520H3R%2520Antagonism%2520for%2520Neurodegenerative%2520Diseases%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26issue%3D41%26spage%3D12765%26epage%3D12769%26doi%3D10.1002%2Fanie.201706072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bento, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaulton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellis, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krüger, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Light, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGlinchey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowotka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadatos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span> <span> </span><span class="NLM_article-title">The ChEMBL Bioactivity Database: An Update</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">D1083</span>– <span class="NLM_lpage">D1090</span>, <span class="refDoi"> DOI: 10.1093/nar/gkt1031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1093%2Fnar%2Fgkt1031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=24214965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXoslWl" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=D1083-D1090&author=A.+P.+Bentoauthor=A.+Gaultonauthor=A.+Herseyauthor=L.+J.+Bellisauthor=J.+Chambersauthor=M.+Daviesauthor=F.+A.+Kr%C3%BCgerauthor=Y.+Lightauthor=L.+Makauthor=S.+McGlincheyauthor=M.+Nowotkaauthor=G.+Papadatosauthor=R.+Santosauthor=J.+P.+Overington&title=The+ChEMBL+Bioactivity+Database%3A+An+Update&doi=10.1093%2Fnar%2Fgkt1031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">The ChEMBL bioactivity database: an update</span></div><div class="casAuthors">Bento, A. Patricia; Gaulton, Anna; Hersey, Anne; Bellis, Louisa J.; Chambers, Jon; Davies, Mark; Krueger, Felix A.; Light, Yvonne; Mak, Lora; McGlinchey, Shaun; Nowotka, Michal; Papadatos, George; Santos, Rita; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D1083-D1090</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">ChEMBL is an open large-scale bioactivity database (https://www.ebi.ac.uk/chembl), previously described in the 2012 Nucleic Acids Research Database Issue.  Since then, a variety of new data sources and improvements in functionality have contributed to the growth and utility of the resource.  In particular, more comprehensive tracking of compds. from research stages through clin. development to market is provided through the inclusion of data from United States Adopted Name applications; a new richer data model for representing drug targets has been developed; and a no. of methods have been put in place to allow users to more easily identify reliable data.  Finally, access to ChEMBL is now available via a new Resource Description Framework format, in addn. to the web-based interface, data downloads and web services.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXb5k1IvJNaLVg90H21EOLACvtfcHk0liHQsup9w4p0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXoslWl&md5=31b832d03d56ea3065d7aa29618362bc</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkt1031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkt1031%26sid%3Dliteratum%253Aachs%26aulast%3DBento%26aufirst%3DA.%2BP.%26aulast%3DGaulton%26aufirst%3DA.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DBellis%26aufirst%3DL.%2BJ.%26aulast%3DChambers%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DM.%26aulast%3DKr%25C3%25BCger%26aufirst%3DF.%2BA.%26aulast%3DLight%26aufirst%3DY.%26aulast%3DMak%26aufirst%3DL.%26aulast%3DMcGlinchey%26aufirst%3DS.%26aulast%3DNowotka%26aufirst%3DM.%26aulast%3DPapadatos%26aufirst%3DG.%26aulast%3DSantos%26aufirst%3DR.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520ChEMBL%2520Bioactivity%2520Database%253A%2520An%2520Update%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2014%26volume%3D42%26spage%3DD1083%26epage%3DD1090%26doi%3D10.1093%2Fnar%2Fgkt1031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gindulyte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiessen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">PubChem BioAssay: 2017 Update</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">D1</span>),  <span class="NLM_fpage">D955</span>– <span class="NLM_lpage">D963</span>, <span class="refDoi"> DOI: 10.1093/nar/gkw1118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1093%2Fnar%2Fgkw1118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27899599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslWhsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=D955-D963&issue=D1&author=Y.+Wangauthor=S.+H.+Bryantauthor=T.+Chengauthor=J.+Wangauthor=A.+Gindulyteauthor=B.+A.+Shoemakerauthor=P.+A.+Thiessenauthor=S.+Heauthor=J.+Zhang&title=PubChem+BioAssay%3A+2017+Update&doi=10.1093%2Fnar%2Fgkw1118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">PubChem BioAssay: 2017 update</span></div><div class="casAuthors">Wang, Yanli; Bryant, Stephen H.; Cheng, Tiejun; Wang, Jiyao; Gindulyte, Asta; Shoemaker, Benjamin A.; Thiessen, Paul A.; He, Siqian; Zhang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D955-D963</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">PubChem's BioAssay database (https://pubchem.ncbi.nlm.nih.gov) has served as a public repository for small-mol. and RNAi screening data since 2004 providing open access of its data content to the community.  PubChem accepts data submission from worldwide researchers at academia, industry and government agencies.  PubChem also collaborates with other chem. biol. database stakeholders with data exchange.  With over a decade's development effort, it becomes an important information resource supporting drug discovery and chem. biol. research.  To facilitate data discovery, PubChem is integrated with all other databases at NCBI.  In this work, we provide an update for the Pub- Chem BioAssay database describing several recent development including added sources of research data, redesigned BioAssay record page, new BioAssay classification browser and new features in the Upload system facilitating data sharing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptFOpprG7GhLVg90H21EOLACvtfcHk0liHQsup9w4p0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslWhsbw%253D&md5=4043316b6be487277f360fb4cc2beabb</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkw1118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkw1118%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DBryant%26aufirst%3DS.%2BH.%26aulast%3DCheng%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGindulyte%26aufirst%3DA.%26aulast%3DShoemaker%26aufirst%3DB.%2BA.%26aulast%3DThiessen%26aufirst%3DP.%2BA.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DPubChem%2520BioAssay%253A%25202017%2520Update%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2017%26volume%3D45%26issue%3DD1%26spage%3DD955%26epage%3DD963%26doi%3D10.1093%2Fnar%2Fgkw1118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, M.</span></span> <span> </span><span class="NLM_article-title">Extended-Connectivity Fingerprints</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">754</span>, <span class="refDoi"> DOI: 10.1021/ci100050t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci100050t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlt1Onsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=742-754&issue=5&author=D.+Rogersauthor=M.+Hahn&title=Extended-Connectivity+Fingerprints&doi=10.1021%2Fci100050t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Extended-Connectivity Fingerprints</span></div><div class="casAuthors">Rogers, David; Hahn, Mathew</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">742-754</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Extended-connectivity fingerprints (ECFPs) are a novel class of topol. fingerprints for mol. characterization.  Historically, topol. fingerprints were developed for substructure and similarity searching.  ECFPs were developed specifically for structure-activity modeling.  ECFPs are circular fingerprints with a no. of useful qualities: they can be very rapidly calcd.; they are not predefined and can represent an essentially infinite no. of different mol. features (including stereochem. information); their features represent the presence of particular substructures, allowing easier interpretation of anal. results; and the ECFP algorithm can be tailored to generate different types of circular fingerprints, optimized for different uses.  While the use of ECFPs has been widely adopted and validated, a description of their implementation has not previously been presented in the literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra43orI-Y7lbVg90H21EOLACvtfcHk0liHQsup9w4p0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlt1Onsbg%253D&md5=cd6c736cd7a3d280b67f5316acce8006</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1021%2Fci100050t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci100050t%26sid%3Dliteratum%253Aachs%26aulast%3DRogers%26aufirst%3DD.%26aulast%3DHahn%26aufirst%3DM.%26atitle%3DExtended-Connectivity%2520Fingerprints%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2010%26volume%3D50%26issue%3D5%26spage%3D742%26epage%3D754%26doi%3D10.1021%2Fci100050t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnby, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span> <span> </span><span class="NLM_article-title">Circular Fingerprints: Flexible Molecular Descriptors with Applications from Physical Chemistry to ADME</span>. <i>IDrugs</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">204</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=16523386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD28Xjt12jtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2006&pages=199-204&issue=3&author=R.+C.+Glenauthor=A.+Benderauthor=C.+H.+Arnbyauthor=L.+Carlssonauthor=S.+Boyerauthor=J.+Smith&title=Circular+Fingerprints%3A+Flexible+Molecular+Descriptors+with+Applications+from+Physical+Chemistry+to+ADME"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Circular fingerprints: flexible molecular descriptors with applications from physical chemistry to ADME</span></div><div class="casAuthors">Glen, Robert C.; Bender, Andreas; Arnby, Catrin H.; Carlsson, Lars; Boyer, Scott; Smith, James</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">199-204</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">1369-7056</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  Circular fingerprints - the representation of mol. structures by atom neighborhoods - have been applied to a wide range of applications, such as similarity searching and the prediction of absorption, distribution, metab., excretion and toxicity properties.  In recent years there has been a surge in applications resulting from the superior performance of circular fingerprints in comparative studies.  This feature examines the nature of circular fingerprints as well as their applications, including virtual screening, metab. prediction and the estn. of pKa consts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXLQM7euMKYrVg90H21EOLACvtfcHk0liHQsup9w4p0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xjt12jtbk%253D&md5=40c48ee2893434e833a843aa793dcdad</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DArnby%26aufirst%3DC.%2BH.%26aulast%3DCarlsson%26aufirst%3DL.%26aulast%3DBoyer%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DJ.%26atitle%3DCircular%2520Fingerprints%253A%2520Flexible%2520Molecular%2520Descriptors%2520with%2520Applications%2520from%2520Physical%2520Chemistry%2520to%2520ADME%26jtitle%3DIDrugs%26date%3D2006%26volume%3D9%26issue%3D3%26spage%3D199%26epage%3D204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jasper, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbeck, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkjost, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, O.</span></span> <span> </span><span class="NLM_article-title">A Novel Interaction Fingerprint Derived from per Atom Score Contributions: Exhaustive Evaluation of Interaction Fingerprint Performance in Docking Based Virtual Screening</span>. <i>J. Cheminf.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">15</span>, <span class="refDoi"> DOI: 10.1186/s13321-018-0264-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1186%2Fs13321-018-0264-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtFWhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=15&author=J.+B.+Jasperauthor=L.+Humbeckauthor=T.+Brinkjostauthor=O.+Koch&title=A+Novel+Interaction+Fingerprint+Derived+from+per+Atom+Score+Contributions%3A+Exhaustive+Evaluation+of+Interaction+Fingerprint+Performance+in+Docking+Based+Virtual+Screening&doi=10.1186%2Fs13321-018-0264-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">A novel interaction fingerprint derived from per atom score contributions: exhaustive evaluation of interaction fingerprint performance in docking based virtual screening</span></div><div class="casAuthors">Jasper, Julia B.; Humbeck, Lina; Brinkjost, Tobias; Koch, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cheminformatics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15/1-15/13</span>CODEN:
                <span class="NLM_cas:coden">JCOHB3</span>;
        ISSN:<span class="NLM_cas:issn">1758-2946</span>.
    
            (<span class="NLM_cas:orgname">Chemistry Central Ltd.</span>)
        </div><div class="casAbstract">Protein ligand interaction fingerprints are a powerful approach for the anal. and assessment of docking poses to improve docking performance in virtual screening.  In this study, a novel interaction fingerprint approach (PADIF, protein per atom score contributions derived interaction fingerprint) is presented which was specifically designed for utilizing the GOLD scoring functions' atom contributions together with a specific scoring scheme.  This allows the incorporation of known protein-ligand complex structures for a target-specific scoring.  Unlike many other methods, this approach uses weighting factors reflecting the relative frequency of a specific interaction in the refs. and penalizes destabilizing interactions.  In addn., and for the first time, an exhaustive validation study was performed that assesses the performance of PADIF and two other interaction fingerprints in virtual screening.  Here, PADIF shows superior results, and some rules of thumb for a successful use of interaction fingerprints could be identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqafuamkpf1x7Vg90H21EOLACvtfcHk0ljXS-RsSzxWCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtFWhs7s%253D&md5=ffee53311343c44c37879e0d105daad0</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1186%2Fs13321-018-0264-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13321-018-0264-0%26sid%3Dliteratum%253Aachs%26aulast%3DJasper%26aufirst%3DJ.%2BB.%26aulast%3DHumbeck%26aufirst%3DL.%26aulast%3DBrinkjost%26aufirst%3DT.%26aulast%3DKoch%26aufirst%3DO.%26atitle%3DA%2520Novel%2520Interaction%2520Fingerprint%2520Derived%2520from%2520per%2520Atom%2520Score%2520Contributions%253A%2520Exhaustive%2520Evaluation%2520of%2520Interaction%2520Fingerprint%2520Performance%2520in%2520Docking%2520Based%2520Virtual%2520Screening%26jtitle%3DJ.%2520Cheminf.%26date%3D2018%26volume%3D10%26spage%3D15%26doi%3D10.1186%2Fs13321-018-0264-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Méndez-Lucio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kooistra, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graaf, C. de</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina-Franco, J. L.</span></span> <span> </span><span class="NLM_article-title">Analyzing Multitarget Activity Landscapes Using Protein-Ligand Interaction Fingerprints: Interaction Cliffs</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1021/ci500721x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci500721x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtl2js7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2015&pages=251-262&issue=2&author=O.+M%C3%A9ndez-Lucioauthor=A.+J.+Kooistraauthor=C.+de+Graafauthor=A.+Benderauthor=J.+L.+Medina-Franco&title=Analyzing+Multitarget+Activity+Landscapes+Using+Protein-Ligand+Interaction+Fingerprints%3A+Interaction+Cliffs&doi=10.1021%2Fci500721x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Analyzing Multitarget Activity Landscapes Using Protein-Ligand Interaction Fingerprints: Interaction Cliffs</span></div><div class="casAuthors">Mendez-Lucio, Oscar; Kooistra, Albert J.; Graaf, Chris de; Bender, Andreas; Medina-Franco, Jose L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">251-262</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Activity landscape modeling is mostly a descriptive technique that allows rationalizing continuous and discontinuous SARs.  Nevertheless, the interpretation of some landscape features, esp. of activity cliffs, is not straightforward.  As the nature of activity cliffs depends on the ligand and the target, information regarding both should be included in the anal.  A specific way to include this information is using protein-ligand interaction fingerprints (IFPs).  In this paper we report the activity landscape modeling of 507 ligand-kinase complexes (from the KLIFS database) including IFP, which facilitates the anal. and interpretation of activity cliffs.  Here we introduce the structure-activity-interaction similarity (SAIS) maps that incorporate information on ligand-target contact similarity.  We also introduce the concept of interaction cliffs defined as ligand-target complexes with high structural and interaction similarity but have a large potency difference of the ligands.  Moreover, the information retrieved regarding the specific interaction allowed the identification of activity cliff hot spots, which help to rationalize activity cliffs from the target point of view.  In general, the information provided by IFPs provides a structure-based understanding of some activity landscape features.  This paper shows examples of analyses that can be carried out when IFPs are added to the activity landscape model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWirYbPsbpybVg90H21EOLACvtfcHk0ljXS-RsSzxWCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtl2js7s%253D&md5=49e68e735c4ef76024a2f6ffaaebb883</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1021%2Fci500721x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci500721x%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A9ndez-Lucio%26aufirst%3DO.%26aulast%3DKooistra%26aufirst%3DA.%2BJ.%26aulast%3DGraaf%26aufirst%3DC.%2Bde%26aulast%3DBender%26aufirst%3DA.%26aulast%3DMedina-Franco%26aufirst%3DJ.%2BL.%26atitle%3DAnalyzing%2520Multitarget%2520Activity%2520Landscapes%2520Using%2520Protein-Ligand%2520Interaction%2520Fingerprints%253A%2520Interaction%2520Cliffs%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2015%26volume%3D55%26issue%3D2%26spage%3D251%26epage%3D262%26doi%3D10.1021%2Fci500721x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Da, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kireev, D.</span></span> <span> </span><span class="NLM_article-title">Structural Protein-Ligand Interaction Fingerprints (SPLIF) for Structure-Based Virtual Screening: Method and Benchmark Study</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2555</span>– <span class="NLM_lpage">2561</span>, <span class="refDoi"> DOI: 10.1021/ci500319f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci500319f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtleqt7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2014&pages=2555-2561&issue=9&author=C.+Daauthor=D.+Kireev&title=Structural+Protein-Ligand+Interaction+Fingerprints+%28SPLIF%29+for+Structure-Based+Virtual+Screening%3A+Method+and+Benchmark+Study&doi=10.1021%2Fci500319f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Protein-Ligand Interaction Fingerprints (SPLIF) for Structure-Based Virtual Screening: Method and Benchmark Study</span></div><div class="casAuthors">Da, C.; Kireev, D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2555-2561</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Accurate and affordable assessment of ligand-protein affinity for structure-based virtual screening (SB-VS) is a standing challenge.  Hence, empirical postdocking filters making use of various types of structure-activity information may prove useful.  Here, the authors introduce one such filter based upon three-dimensional structural protein-ligand interaction fingerprints (SPLIF).  SPLIF permits quant. assessment of whether a docking pose interacts with the protein target similarly to a known ligand and rescues active compds. penalized by poor initial docking scores.  An extensive benchmark study on 10 diverse data sets selected from the DUD-E database has been performed to evaluate the abs. and relative efficiency of this method.  SPLIF demonstrated an overall better performance than relevant std. methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBHPcDLkZEQrVg90H21EOLACvtfcHk0ljXS-RsSzxWCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtleqt7fP&md5=cef74887e6a233a638c79d44cdd44023</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1021%2Fci500319f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci500319f%26sid%3Dliteratum%253Aachs%26aulast%3DDa%26aufirst%3DC.%26aulast%3DKireev%26aufirst%3DD.%26atitle%3DStructural%2520Protein-Ligand%2520Interaction%2520Fingerprints%2520%2528SPLIF%2529%2520for%2520Structure-Based%2520Virtual%2520Screening%253A%2520Method%2520and%2520Benchmark%2520Study%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2014%26volume%3D54%26issue%3D9%26spage%3D2555%26epage%3D2561%26doi%3D10.1021%2Fci500319f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reutlinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todoroff, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span> <span> </span><span class="NLM_article-title">Chemically Advanced Template Search (CATS) for Scaffold-Hopping and Prospective Target Prediction for “Orphan” Molecules</span>. <i>Mol. Inf.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1002/minf.201200141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fminf.201200141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=23956801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitFeisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=133-138&issue=2&author=M.+Reutlingerauthor=C.+P.+Kochauthor=D.+Rekerauthor=N.+Todoroffauthor=P.+Schneiderauthor=T.+Rodriguesauthor=G.+Schneider&title=Chemically+Advanced+Template+Search+%28CATS%29+for+Scaffold-Hopping+and+Prospective+Target+Prediction+for+%E2%80%9COrphan%E2%80%9D+Molecules&doi=10.1002%2Fminf.201200141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically Advanced Template Search (CATS) for Scaffold-Hopping and Prospective Target Prediction for Orphan' Molecules</span></div><div class="casAuthors">Reutlinger, Michael; Koch, Christian P.; Reker, Daniel; Todoroff, Nickolay; Schneider, Petra; Rodrigues, Tiago; Schneider, Gisbert</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Informatics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-138</span>CODEN:
                <span class="NLM_cas:coden">MIONBS</span>;
        ISSN:<span class="NLM_cas:issn">1868-1743</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">In this study, the authors compared several popular two-dimensional mol. representations for their ability to retrieve actives (enrichment potential) and chemotypes (scaffold-hopping potential) from a collection of drug-like bioactive substances.  Subsequently the applied chem. advanced template search (CATS) was applied to predicting potential drug targets for a virtually assembled combinatorial compd. library, from which we synthesized and successfully tested candidate compds.  The results demonstrate that CATS is not only suited for its intended purpose of NCE retrieval by scaffold-hopping, but also for reliable target profiling of 'orphan' virtual mols.  This study's results corroborate CATS + SOM as a useful similarity-based approach for identifying pairs of mols. with similar bioactivity but different mol. scaffolds.  Inclusion of the arom. feature type in the CATS2 implementation increased enrichment in a retrospective anal.  Results of a preliminary prospective target-profiling study demonstrate that (i) the CATS2 descriptor may be employed to predict targets of virtually generated compds. with potential applications in de novo design and drug re-purposing, (ii) relying only on a single prediction algorithm bears the danger of missing relevant drug targets or focusing on false-pos. predictions, and (iii) different mol. descriptors (here: CATS2; SEA with ECFP4 fingerprints) in combination with its assocd. knowledge base (here: COBRA or ChEMBL) complement each other in their domains of applicability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjMpux8IBXebVg90H21EOLACvtfcHk0lgNobnOc9Dnfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitFeisLY%253D&md5=77426afd74fd95c09723429280cc0ffc</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1002%2Fminf.201200141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fminf.201200141%26sid%3Dliteratum%253Aachs%26aulast%3DReutlinger%26aufirst%3DM.%26aulast%3DKoch%26aufirst%3DC.%2BP.%26aulast%3DReker%26aufirst%3DD.%26aulast%3DTodoroff%26aufirst%3DN.%26aulast%3DSchneider%26aufirst%3DP.%26aulast%3DRodrigues%26aufirst%3DT.%26aulast%3DSchneider%26aufirst%3DG.%26atitle%3DChemically%2520Advanced%2520Template%2520Search%2520%2528CATS%2529%2520for%2520Scaffold-Hopping%2520and%2520Prospective%2520Target%2520Prediction%2520for%2520%25E2%2580%259COrphan%25E2%2580%259D%2520Molecules%26jtitle%3DMol.%2520Inf.%26date%3D2013%26volume%3D32%26issue%3D2%26spage%3D133%26epage%3D138%26doi%3D10.1002%2Fminf.201200141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nikolic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavridis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bautista-Aguilera, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">do Carmo Carreiras, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massarelli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agbaba, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, J. B. O.</span></span> <span> </span><span class="NLM_article-title">Predicting Targets of Compounds against Neurological Diseases Using Cheminformatic Methodology</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1007/s10822-014-9816-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1007%2Fs10822-014-9816-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=183-198&issue=2&author=K.+Nikolicauthor=L.+Mavridisauthor=O.+M.+Bautista-Aguileraauthor=J.+Marco-Contellesauthor=H.+Starkauthor=M.+do+Carmo+Carreirasauthor=I.+Rossiauthor=P.+Massarelliauthor=D.+Agbabaauthor=R.+R.+Ramsayauthor=J.+B.+O.+Mitchell&title=Predicting+Targets+of+Compounds+against+Neurological+Diseases+Using+Cheminformatic+Methodology&doi=10.1007%2Fs10822-014-9816-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1007%2Fs10822-014-9816-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-014-9816-1%26sid%3Dliteratum%253Aachs%26aulast%3DNikolic%26aufirst%3DK.%26aulast%3DMavridis%26aufirst%3DL.%26aulast%3DBautista-Aguilera%26aufirst%3DO.%2BM.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DStark%26aufirst%3DH.%26aulast%3Ddo%2BCarmo%2BCarreiras%26aufirst%3DM.%26aulast%3DRossi%26aufirst%3DI.%26aulast%3DMassarelli%26aufirst%3DP.%26aulast%3DAgbaba%26aufirst%3DD.%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DMitchell%26aufirst%3DJ.%2BB.%2BO.%26atitle%3DPredicting%2520Targets%2520of%2520Compounds%2520against%2520Neurological%2520Diseases%2520Using%2520Cheminformatic%2520Methodology%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2015%26volume%3D29%26issue%3D2%26spage%3D183%26epage%3D198%26doi%3D10.1007%2Fs10822-014-9816-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wale, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karypis, G.</span></span> <span> </span><span class="NLM_article-title">Target Fishing for Chemical Compounds Using Target-Ligand Activity Data and Ranking Based Methods</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2190</span>– <span class="NLM_lpage">2201</span>, <span class="refDoi"> DOI: 10.1021/ci9000376</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci9000376" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFGiurfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=2190-2201&issue=10&author=N.+Waleauthor=G.+Karypis&title=Target+Fishing+for+Chemical+Compounds+Using+Target-Ligand+Activity+Data+and+Ranking+Based+Methods&doi=10.1021%2Fci9000376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Target fishing for chemical compounds using target-ligand activity data and ranking based methods</span></div><div class="casAuthors">Wale, Nikil; Karypis, George</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2190-2201</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In recent years, the development of computational techniques that identify all the likely targets for a given chem. compd., also termed as the problem of Target Fishing, has been an active area of research.  Identification of likely targets of a chem. compd. in the early stages of drug discovery helps to understand issues such as selectivity, off-target pharmacol., and toxicity.  In this paper, we present a set of techniques whose goal is to rank or prioritize targets in the context of a given chem. compd. so that most targets against which this compd. may show activity appear higher in the ranked list.  These methods are based on our extensions to the SVM and ranking perception algorithms for this problem.  Our extensive exptl. study shows that the methods developed in this work outperform previous approaches 2% to 60% under different evaluation criterions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8s3kPZTP7w7Vg90H21EOLACvtfcHk0lgNobnOc9Dnfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFGiurfF&md5=ebe62bd736132eae1966247529013b45</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1021%2Fci9000376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci9000376%26sid%3Dliteratum%253Aachs%26aulast%3DWale%26aufirst%3DN.%26aulast%3DKarypis%26aufirst%3DG.%26atitle%3DTarget%2520Fishing%2520for%2520Chemical%2520Compounds%2520Using%2520Target-Ligand%2520Activity%2520Data%2520and%2520Ranking%2520Based%2520Methods%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26issue%3D10%26spage%3D2190%26epage%3D2201%26doi%3D10.1021%2Fci9000376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raevsky, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhametov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigorev, V. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ustyugov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsay, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jih-Ru
Hwu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarla, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barreto, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliev, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachurin, S. O.</span></span> <span> </span><span class="NLM_article-title">Applications of Multi-Target Computer-Aided Methodologies in Molecular Design of CNS Drugs</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>, <span class="refDoi"> DOI: 10.2174/0929867324666170920154111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F0929867324666170920154111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28933295" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=O.+A.+Raevskyauthor=A.+Mukhametovauthor=V.+Y.+Grigorevauthor=A.+Ustyugovauthor=S.-C.+Tsayauthor=R.+Jih-Ru%0AHwuauthor=N.+S.+Yarlaauthor=G.+E.+Barretoauthor=G.+Alievauthor=S.+O.+Bachurin&title=Applications+of+Multi-Target+Computer-Aided+Methodologies+in+Molecular+Design+of+CNS+Drugs&doi=10.2174%2F0929867324666170920154111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.2174%2F0929867324666170920154111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867324666170920154111%26sid%3Dliteratum%253Aachs%26aulast%3DRaevsky%26aufirst%3DO.%2BA.%26aulast%3DMukhametov%26aufirst%3DA.%26aulast%3DGrigorev%26aufirst%3DV.%2BY.%26aulast%3DUstyugov%26aufirst%3DA.%26aulast%3DTsay%26aufirst%3DS.-C.%26aulast%3DJih-Ru%2BHwu%26aufirst%3DR.%26aulast%3DYarla%26aufirst%3DN.%2BS.%26aulast%3DBarreto%26aufirst%3DG.%2BE.%26aulast%3DAliev%26aufirst%3DG.%26aulast%3DBachurin%26aufirst%3DS.%2BO.%26atitle%3DApplications%2520of%2520Multi-Target%2520Computer-Aided%2520Methodologies%2520in%2520Molecular%2520Design%2520of%2520CNS%2520Drugs%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2017%26doi%3D10.2174%2F0929867324666170920154111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalash, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Val, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azuaje, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loza, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoufir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mervin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladds, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brea, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotelo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span> <span> </span><span class="NLM_article-title">Computer-Aided Design of Multi-Target Ligands at A1R, A2AR and PDE10A, Key Proteins in Neurodegenerative Diseases</span>. <i>J. Cheminf.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">67</span>, <span class="refDoi"> DOI: 10.1186/s13321-017-0249-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1186%2Fs13321-017-0249-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=67&author=L.+Kalashauthor=C.+Valauthor=J.+Azuajeauthor=M.+I.+Lozaauthor=F.+Svenssonauthor=A.+Zoufirauthor=L.+Mervinauthor=G.+Laddsauthor=J.+Breaauthor=R.+Glenauthor=E.+Soteloauthor=A.+Bender&title=Computer-Aided+Design+of+Multi-Target+Ligands+at+A1R%2C+A2AR+and+PDE10A%2C+Key+Proteins+in+Neurodegenerative+Diseases&doi=10.1186%2Fs13321-017-0249-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1186%2Fs13321-017-0249-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13321-017-0249-4%26sid%3Dliteratum%253Aachs%26aulast%3DKalash%26aufirst%3DL.%26aulast%3DVal%26aufirst%3DC.%26aulast%3DAzuaje%26aufirst%3DJ.%26aulast%3DLoza%26aufirst%3DM.%2BI.%26aulast%3DSvensson%26aufirst%3DF.%26aulast%3DZoufir%26aufirst%3DA.%26aulast%3DMervin%26aufirst%3DL.%26aulast%3DLadds%26aufirst%3DG.%26aulast%3DBrea%26aufirst%3DJ.%26aulast%3DGlen%26aufirst%3DR.%26aulast%3DSotelo%26aufirst%3DE.%26aulast%3DBender%26aufirst%3DA.%26atitle%3DComputer-Aided%2520Design%2520of%2520Multi-Target%2520Ligands%2520at%2520A1R%252C%2520A2AR%2520and%2520PDE10A%252C%2520Key%2520Proteins%2520in%2520Neurodegenerative%2520Diseases%26jtitle%3DJ.%2520Cheminf.%26date%3D2017%26volume%3D9%26spage%3D67%26doi%3D10.1186%2Fs13321-017-0249-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klabunde, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giegerich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, A.</span></span> <span> </span><span class="NLM_article-title">MARS: Computing Three-Dimensional Alignments for Multiple Ligands Using Pairwise Similarities</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2022</span>– <span class="NLM_lpage">2030</span>, <span class="refDoi"> DOI: 10.1021/ci3000369</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci3000369" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVaktrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=2022-2030&issue=8&author=T.+Klabundeauthor=C.+Giegerichauthor=A.+Evers&title=MARS%3A+Computing+Three-Dimensional+Alignments+for+Multiple+Ligands+Using+Pairwise+Similarities&doi=10.1021%2Fci3000369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">MARS: Computing Three-Dimensional Alignments for Multiple Ligands Using Pairwise Similarities</span></div><div class="casAuthors">Klabunde, Thomas; Giegerich, Clemens; Evers, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2022-2030</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The three-dimensional (3D) superimposition of mols. of one biol. target reflecting their relative bioactive orientation is key for several ligand-based drug design studies (e.g., QSAR studies, pharmacophore modeling).  However, with the lack of sufficient ligand-protein complex structures, an exptl. alignment is difficult or often impossible to obtain.  Several computational 3D alignment tools have been developed by academic or com. groups to address this challenge.  Here, we present a new approach, MARS (Multiple Alignments by ROCS-based Similarity), that is based on the pairwise alignment of all mols. within the data set using the tool ROCS (Rapid Overlay of Chem. Structures).  Each pairwise alignment is scored, and the results are captured in a score matrix.  The ideal superimposition of the compds. in the set is then identified by the anal. of the score matrix building stepwise a superimposition of all mols.  The algorithm exploits similarities among all mols. in the data set to compute an optimal 3D alignment.  This alignment tool presented here can be used for several applications, including pharmacophore model generation, 3D QSAR modeling, 3D clustering, identification of structural outliers, and addn. of compds. to an already existing alignment.  Case studies are shown, validating the 3D alignments for six different data sets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBgAGzrLYIwrVg90H21EOLACvtfcHk0lhI9bkYRSxzVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVaktrrO&md5=a5c741f942d8c7e5a091b02043308b34</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1021%2Fci3000369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci3000369%26sid%3Dliteratum%253Aachs%26aulast%3DKlabunde%26aufirst%3DT.%26aulast%3DGiegerich%26aufirst%3DC.%26aulast%3DEvers%26aufirst%3DA.%26atitle%3DMARS%253A%2520Computing%2520Three-Dimensional%2520Alignments%2520for%2520Multiple%2520Ligands%2520Using%2520Pairwise%2520Similarities%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26issue%3D8%26spage%3D2022%26epage%3D2030%26doi%3D10.1021%2Fci3000369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedrich, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grisoni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span> <span> </span><span class="NLM_article-title">De Novo Design of Bioactive Small Molecules by Artificial Intelligence</span>. <i>Mol. Inf.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1700153</span>, <span class="refDoi"> DOI: 10.1002/minf.201700153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fminf.201700153" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=1700153&issue=1&author=D.+Merkauthor=L.+Friedrichauthor=F.+Grisoniauthor=G.+Schneider&title=De+Novo+Design+of+Bioactive+Small+Molecules+by+Artificial+Intelligence&doi=10.1002%2Fminf.201700153"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1002%2Fminf.201700153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fminf.201700153%26sid%3Dliteratum%253Aachs%26aulast%3DMerk%26aufirst%3DD.%26aulast%3DFriedrich%26aufirst%3DL.%26aulast%3DGrisoni%26aufirst%3DF.%26aulast%3DSchneider%26aufirst%3DG.%26atitle%3DDe%2520Novo%2520Design%2520of%2520Bioactive%2520Small%2520Molecules%2520by%2520Artificial%2520Intelligence%26jtitle%3DMol.%2520Inf.%26date%3D2018%26volume%3D37%26issue%3D1%26spage%3D1700153%26doi%3D10.1002%2Fminf.201700153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Handler, N.</span></span> <span> </span><span class="NLM_article-title">Pharmacophore Generation for Multiple Ligands</span>. In  <i>Drug Selectivity</i>; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>, <span class="NLM_year">2017</span>; pp  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">312</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2F9783527674381.ch10" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=275-312&author=N.+Handler&title=Drug+Selectivity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1002%2F9783527674381.ch10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527674381.ch10%26sid%3Dliteratum%253Aachs%26aulast%3DHandler%26aufirst%3DN.%26atitle%3DPharmacophore%2520Generation%2520for%2520Multiple%2520Ligands%26btitle%3DDrug%2520Selectivity%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2017%26spage%3D275%26epage%3D312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolber, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendix, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, T.</span></span> <span> </span><span class="NLM_article-title">Molecule-Pharmacophore Superpositioning and Pattern Matching in Computational Drug Design</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2007.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.drudis.2007.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=18190860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsVWhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=23-29&author=G.+Wolberauthor=T.+Seidelauthor=F.+Bendixauthor=T.+Langer&title=Molecule-Pharmacophore+Superpositioning+and+Pattern+Matching+in+Computational+Drug+Design&doi=10.1016%2Fj.drudis.2007.09.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Molecule-pharmacophore superpositioning and pattern matching in computational drug design</span></div><div class="casAuthors">Wolber, Gerhard; Seidel, Thomas; Bendix, Fabian; Langer, Thierry</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">23-29</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Three-dimensional (3D) pharmacophore modeling is a technique for describing the interaction of a small mol. ligand with a macromol. target.  Since chem. features in a pharmacophore model are well known and highly transparent for medicinal chemists, these models are intuitively understandable and have been increasingly successful in computational drug discovery in the past few years.  The performance and applicability of pharmacophore modeling depends on two main factors: the definition and placement of pharmacophoric features and the alignment techniques used to overlay 3D pharmacophore models and small mols.  An overview of key technologies and latest developments in the area of 3D pharmacophores is given and provides insight into different approaches as implemented by the 3D pharmacophore modeling packages like Catalyst, MOE, Phase and LigandScout.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf1WZmfDtNXLVg90H21EOLACvtfcHk0lhI9bkYRSxzVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsVWhtA%253D%253D&md5=ce232a83e23dac545e35b600de6aeb33</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2007.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2007.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DWolber%26aufirst%3DG.%26aulast%3DSeidel%26aufirst%3DT.%26aulast%3DBendix%26aufirst%3DF.%26aulast%3DLanger%26aufirst%3DT.%26atitle%3DMolecule-Pharmacophore%2520Superpositioning%2520and%2520Pattern%2520Matching%2520in%2520Computational%2520Drug%2520Design%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2008%26volume%3D13%26spage%3D23%26epage%3D29%26doi%3D10.1016%2Fj.drudis.2007.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. Y.</span></span> <span> </span><span class="NLM_article-title">Pharmacophore Modeling and Applications in Drug Discovery: Challenges and Recent Advances</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">11–12</span>),  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2010.03.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.drudis.2010.03.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=20362693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntVSltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=444-450&issue=11%E2%80%9312&author=S.+Y.+Yang&title=Pharmacophore+Modeling+and+Applications+in+Drug+Discovery%3A+Challenges+and+Recent+Advances&doi=10.1016%2Fj.drudis.2010.03.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacophore modeling and applications in drug discovery: challenges and recent advances</span></div><div class="casAuthors">Yang, Sheng-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11/12</span>),
    <span class="NLM_cas:pages">444-450</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Pharmacophore approaches have become one of the major tools in drug discovery after the past century's development.  Various ligand-based and structure-based methods have been developed for improved pharmacophore modeling and have been successfully and extensively applied in virtual screening, de novo design and lead optimization.  Despite these successes, pharmacophore approaches have not reached their expected full capacity, particularly in facing the demand for reducing the current expensive overall cost assocd. with drug discovery and development.  Here, the challenges of pharmacophore modeling and applications in drug discovery are discussed and recent advances and latest developments are described, which provide useful clues to the further development and application of pharmacophore approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqpfM_Jzed17Vg90H21EOLACvtfcHk0lhI9bkYRSxzVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntVSltbg%253D&md5=ff2899e0a75c87a9ec202ace7c3acb6a</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.03.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.03.013%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DPharmacophore%2520Modeling%2520and%2520Applications%2520in%2520Drug%2520Discovery%253A%2520Challenges%2520and%2520Recent%2520Advances%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2010%26volume%3D15%26issue%3D11%25E2%2580%259312%26spage%3D444%26epage%3D450%26doi%3D10.1016%2Fj.drudis.2010.03.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koutsoukas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simms, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchmair, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitmore, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span> <span> </span><span class="NLM_article-title">From in Silico Target Prediction to Multi-Target Drug Design: Current Databases, Methods and Applications</span>. <i>J. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2554</span>– <span class="NLM_lpage">2574</span>, <span class="refDoi"> DOI: 10.1016/j.jprot.2011.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.jprot.2011.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=21621023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOjtrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2011&pages=2554-2574&issue=12&author=A.+Koutsoukasauthor=B.+Simmsauthor=J.+Kirchmairauthor=P.+J.+Bondauthor=A.+V.+Whitmoreauthor=S.+Zimmerauthor=M.+P.+Youngauthor=J.+L.+Jenkinsauthor=M.+Glickauthor=R.+C.+Glenauthor=A.+Bender&title=From+in+Silico+Target+Prediction+to+Multi-Target+Drug+Design%3A+Current+Databases%2C+Methods+and+Applications&doi=10.1016%2Fj.jprot.2011.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">From in silico target prediction to multi-target drug design: Current databases, methods and applications</span></div><div class="casAuthors">Koutsoukas, Alexios; Simms, Benjamin; Kirchmair, Johannes; Bond, Peter J.; Whitmore, Alan V.; Zimmer, Steven; Young, Malcolm P.; Jenkins, Jeremy L.; Glick, Meir; Glen, Robert C.; Bender, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteomics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2554-2574</span>CODEN:
                <span class="NLM_cas:coden">JPORFQ</span>;
        ISSN:<span class="NLM_cas:issn">1874-3919</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Given the tremendous growth of bioactivity databases, the use of computational tools to predict protein targets of small mols. has been gaining importance in recent years.  Applications span a wide range, from the designed polypharmacol.' of compds. to mode-of-action anal.  In this review, we firstly survey databases that can be used for ligand-based target prediction and which have grown tremendously in size in the past.  We furthermore outline methods for target prediction that exist, both based on the knowledge of bioactivities from the ligand side and methods that can be applied in situations when a protein structure is known.  Applications of successful in silico target identification attempts are discussed in detail, which were based partly or in whole on computational target predictions in the first instance.  This includes the authors' own experience using target prediction tools, in this case considering phenotypic antibacterial screens and the anal. of high-throughput screening data.  Finally, we will conclude with the prospective application of databases to not only predict, retrospectively, the protein targets of a small mol., but also how to design ligands with desired polypharmacol. in a prospective manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQAhthzL8wiLVg90H21EOLACvtfcHk0lgjb4B5OphrtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOjtrfE&md5=3fd699639ef3faf347537ef400030dd9</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1016%2Fj.jprot.2011.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jprot.2011.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DKoutsoukas%26aufirst%3DA.%26aulast%3DSimms%26aufirst%3DB.%26aulast%3DKirchmair%26aufirst%3DJ.%26aulast%3DBond%26aufirst%3DP.%2BJ.%26aulast%3DWhitmore%26aufirst%3DA.%2BV.%26aulast%3DZimmer%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DM.%2BP.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DBender%26aufirst%3DA.%26atitle%3DFrom%2520in%2520Silico%2520Target%2520Prediction%2520to%2520Multi-Target%2520Drug%2520Design%253A%2520Current%2520Databases%252C%2520Methods%2520and%2520Applications%26jtitle%3DJ.%2520Proteomics%26date%3D2011%26volume%3D74%26issue%3D12%26spage%3D2554%26epage%3D2574%26doi%3D10.1016%2Fj.jprot.2011.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rollinger, J. M.</span></span> <span> </span><span class="NLM_article-title">Accessing Target Information by Virtual Parallel Screening-The Impact on Natural Product Research</span>. <i>Phytochem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1016/j.phytol.2008.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.phytol.2008.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvFahs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=53-58&issue=2&author=J.+M.+Rollinger&title=Accessing+Target+Information+by+Virtual+Parallel+Screening-The+Impact+on+Natural+Product+Research&doi=10.1016%2Fj.phytol.2008.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Accessing target information by virtual parallel screening-the impact on natural product research</span></div><div class="casAuthors">Rollinger, Judith M.</div><div class="citationInfo"><span class="NLM_cas:title">Phytochemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">53-58</span>CODEN:
                <span class="NLM_cas:coden">PLHEBK</span>;
        ISSN:<span class="NLM_cas:issn">1874-3900</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Secondary metabolites exhibit an astonishing multitude of functionalities and enormous chem. diversity and these qualities are responsible for their favored selection as drug leads.  The complex process of finding natural products' bioactivities is largely based on trial and error, and is therefore risky, time- and cost-intensive.  In recent decades, computer-assisted techniques have emerged as promising tools to manage the huge amt. of available structural data of macromol. targets and compds. annotated to specific functions, and to ext. knowledge from these data for the prediction of new events.  The novel concept of virtual parallel screening aims to access a pharmacol. profile for each compd. screened using an array of macromol. targets.  Providing putative ligand-target interactions, this in silico multitarget application meets the requirements for natural product research in a complementary way.  It enables (i) a fast identification of potential targets (target fishing), (ii) insight into a putative mol. mechanism, and (iii) an estn. of the bioactivity profile which allows for prioritizing exptl. investigations.  The first application examples in natural product research are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyrrYT3SqUHLVg90H21EOLACvtfcHk0lgjb4B5OphrtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvFahs7w%253D&md5=c7749d7d2566615cbaacb36131f89786</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1016%2Fj.phytol.2008.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phytol.2008.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DRollinger%26aufirst%3DJ.%2BM.%26atitle%3DAccessing%2520Target%2520Information%2520by%2520Virtual%2520Parallel%2520Screening-The%2520Impact%2520on%2520Natural%2520Product%2520Research%26jtitle%3DPhytochem.%2520Lett.%26date%3D2009%26volume%3D2%26issue%3D2%26spage%3D53%26epage%3D58%26doi%3D10.1016%2Fj.phytol.2008.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Pharmacophore-Based Virtual Screening</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1018</span>– <span class="NLM_lpage">1024</span>, <span class="refDoi"> DOI: 10.2174/092986708784049630</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F092986708784049630" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=18393859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVyiur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=1018-1024&issue=10&author=H.+Sun&title=Pharmacophore-Based+Virtual+Screening&doi=10.2174%2F092986708784049630"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacophore-based virtual screening</span></div><div class="casAuthors">Sun, Hongmao</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1018-1024</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Virtual screening (VS) is an important component of cheminformatics and mol. modeling.  An abundance of structural information, indicated by both the ever-increasing availability of 3-dimensional (3D) protein structures and the readiness of free conformational databases of com. available compds., such as ZINC, supplies a broad platform for VS.  At the same time, new technol. enables the implementation of more accurate and sophisticated pharmacophore models and the screening of millions of compds. within a manageable period.  Therefore, VS is expected to play a more important role in future drug discovery efforts.  This paper will examine and compare the advantages and disadvantages of VS against exptl. high-throughput screening (HTS).  It will also evaluate pharmacophore-based VS against docking-based VS.  The strategies leading to successful pharmacophore-based VS are outlined, including how to enumerate a conformational database efficiently, how to select chem. features for a specific pharmacophore model, how to incorporate excluded vols. to enhance the geog. restrictions, and how to optimize a pharmacophore model.  Successful examples of pharmacophore-based VS will be presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2Kf1nFO8hd7Vg90H21EOLACvtfcHk0lgjb4B5OphrtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVyiur0%253D&md5=32cb02879bb83e4e07f061c991386f83</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.2174%2F092986708784049630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708784049630%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26atitle%3DPharmacophore-Based%2520Virtual%2520Screening%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26issue%3D10%26spage%3D1018%26epage%3D1024%26doi%3D10.2174%2F092986708784049630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolber, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, T.</span></span> <span> </span><span class="NLM_article-title">LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">160</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1021/ci049885e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci049885e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BD2M%252FktVKrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=160-169&issue=1&author=G.+Wolberauthor=T.+Langer&title=LigandScout%3A+3-D+Pharmacophores+Derived+from+Protein-Bound+Ligands+and+Their+Use+as+Virtual+Screening+Filters&doi=10.1021%2Fci049885e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters</span></div><div class="casAuthors">Wolber Gerhard; Langer Thierry</div><div class="citationInfo"><span class="NLM_cas:title">Journal of chemical information and modeling</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">160-9</span>
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    </div><div class="casAbstract">From the historically grown archive of protein-ligand complexes in the Protein Data Bank small organic ligands are extracted and interpreted in terms of their chemical characteristics and features.  Subsequently, pharmacophores representing ligand-receptor interaction are derived from each of these small molecules and its surrounding amino acids.  Based on a defined set of only six types of chemical features and volume constraints, three-dimensional pharmacophore models are constructed, which are sufficiently selective to identify the described binding mode and are thus a useful tool for in-silico screening of large compound databases.  The algorithms for ligand extraction and interpretation as well as the pharmacophore creation technique from the automatically interpreted data are presented and applied to a rhinovirus capsid complex as application example.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQVi_-excgTX2BAiYWy6n3SfW6udTcc2ebmE2A5X58SMLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M%252FktVKrtg%253D%253D&md5=31f8ff7a2fa4c9411d54b001b7e1da50</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1021%2Fci049885e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci049885e%26sid%3Dliteratum%253Aachs%26aulast%3DWolber%26aufirst%3DG.%26aulast%3DLanger%26aufirst%3DT.%26atitle%3DLigandScout%253A%25203-D%2520Pharmacophores%2520Derived%2520from%2520Protein-Bound%2520Ligands%2520and%2520Their%2520Use%2520as%2520Virtual%2520Screening%2520Filters%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2005%26volume%3D45%26issue%3D1%26spage%3D160%26epage%3D169%26doi%3D10.1021%2Fci049885e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barillari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rognan, D.</span></span> <span> </span><span class="NLM_article-title">Hot-Spots-Guided Receptor-Based Pharmacophores (HS-Pharm): A Knowledge-Based Approach to Identify Ligand-Anchoring Atoms in Protein Cavities and Prioritize Structure-Based Pharmacophores</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1396</span>– <span class="NLM_lpage">1410</span>, <span class="refDoi"> DOI: 10.1021/ci800064z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci800064z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFGktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=1396-1410&issue=7&author=C.+Barillariauthor=G.+Marcouauthor=D.+Rognan&title=Hot-Spots-Guided+Receptor-Based+Pharmacophores+%28HS-Pharm%29%3A+A+Knowledge-Based+Approach+to+Identify+Ligand-Anchoring+Atoms+in+Protein+Cavities+and+Prioritize+Structure-Based+Pharmacophores&doi=10.1021%2Fci800064z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Hot-Spots-Guided Receptor-Based Pharmacophores (HS-Pharm): A Knowledge-Based Approach to Identify Ligand-Anchoring Atoms in Protein Cavities and Prioritize Structure-Based Pharmacophores</span></div><div class="casAuthors">Barillari, Caterina; Marcou, Gilles; Rognan, Didier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1396-1410</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design of biol. active compds. from ligand-free protein structures using a structure-based approach is still a major challenge.  In this paper, we present a fast knowledge-based approach (HS-Pharm) that allows the prioritization of cavity atoms that should be targeted for ligand binding, by training machine learning algorithms with atom-based fingerprints of known ligand-binding pockets.  The knowledge of hot spots for ligand binding is here used for focusing structure-based pharmacophore models.  Three targets of pharmacol. interest (neuraminidase, β2 adrenergic receptor, and cyclooxygenase-2) were used to test the evaluated methodol., and the derived structure-based pharmacophores were used in retrospective virtual screening studies.  The current study shows that structure-based pharmacophore screening is a powerful technique for the fast identification of potential hits in a chem. library, and that it is a valid alternative to virtual screening by mol. docking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1wuGUqc3VZbVg90H21EOLACvtfcHk0lhZYQjqCCB09w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFGktrg%253D&md5=75c0bc3d0e89f62f8382d3ff7e85fecc</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1021%2Fci800064z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci800064z%26sid%3Dliteratum%253Aachs%26aulast%3DBarillari%26aufirst%3DC.%26aulast%3DMarcou%26aufirst%3DG.%26aulast%3DRognan%26aufirst%3DD.%26atitle%3DHot-Spots-Guided%2520Receptor-Based%2520Pharmacophores%2520%2528HS-Pharm%2529%253A%2520A%2520Knowledge-Based%2520Approach%2520to%2520Identify%2520Ligand-Anchoring%2520Atoms%2520in%2520Protein%2520Cavities%2520and%2520Prioritize%2520Structure-Based%2520Pharmacophores%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2008%26volume%3D48%26issue%3D7%26spage%3D1396%26epage%3D1410%26doi%3D10.1021%2Fci800064z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tintori, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corradi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botta, M.</span></span> <span> </span><span class="NLM_article-title">Targets Looking for Drugs: A Multistep Computational Protocol for the Development of Structure-Based Pharmacophores and Their Applications for Hit Discovery</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2166</span>– <span class="NLM_lpage">2179</span>, <span class="refDoi"> DOI: 10.1021/ci800105p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci800105p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1OlsbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=2166-2179&issue=11&author=C.+Tintoriauthor=V.+Corradiauthor=M.+Magnaniauthor=F.+Manettiauthor=M.+Botta&title=Targets+Looking+for+Drugs%3A+A+Multistep+Computational+Protocol+for+the+Development+of+Structure-Based+Pharmacophores+and+Their+Applications+for+Hit+Discovery&doi=10.1021%2Fci800105p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Targets Looking for Drugs: A Multistep Computational Protocol for the Development of Structure-Based Pharmacophores and Their Applications for Hit Discovery</span></div><div class="casAuthors">Tintori, Cristina; Corradi, Valentina; Magnani, Matteo; Manetti, Fabrizio; Botta, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2166-2179</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pharmacophores, three-dimensional (3D) arrangements of essential features enabling a mol. to exert a particular biol. effect, constitute a very useful tool in drug design both in hit discovery and hit-to-lead optimization process.  Two basic approaches for pharmacophoric model generation can be used by chemists, depending on the availability or not of the target 3D structure.  In view of the rapidly growing no. of protein structures that are now available, receptor-based pharmacophore generation methods are becoming more and more used.  Since most of them require the knowledge of the 3D structure of the ligand-target complex, they cannot be applied when no compds. targeting the binding site of interest are known.  Here, a GRID-based procedure for the generation of receptor-based pharmacophores starting from knowledge solely of the protein structure is described and successfully applied to address three different tasks in the field of medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoptMpdGcbXALVg90H21EOLACvtfcHk0lhZYQjqCCB09w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1OlsbzO&md5=b61f3550c41ed8007f160bb537526d0d</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1021%2Fci800105p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci800105p%26sid%3Dliteratum%253Aachs%26aulast%3DTintori%26aufirst%3DC.%26aulast%3DCorradi%26aufirst%3DV.%26aulast%3DMagnani%26aufirst%3DM.%26aulast%3DManetti%26aufirst%3DF.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DTargets%2520Looking%2520for%2520Drugs%253A%2520A%2520Multistep%2520Computational%2520Protocol%2520for%2520the%2520Development%2520of%2520Structure-Based%2520Pharmacophores%2520and%2520Their%2520Applications%2520for%2520Hit%2520Discovery%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2008%26volume%3D48%26issue%3D11%26spage%3D2166%26epage%3D2179%26doi%3D10.1021%2Fci800105p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, M.
P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, A. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarzycka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolaes, G. A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klomp, J. P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De
Vlieg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Rio, A.</span></span> <span> </span><span class="NLM_article-title">Comparative Analysis of Pharmacophore Screening Tools</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1607</span>– <span class="NLM_lpage">1620</span>, <span class="refDoi"> DOI: 10.1021/ci2005274</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci2005274" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnslahsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=1607-1620&issue=6&author=M.%0AP.+A.+Sandersauthor=A.+J.+M.+Barbosaauthor=B.+Zarzyckaauthor=G.+A.+F.+Nicolaesauthor=J.+P.+G.+Klompauthor=J.+De%0AVliegauthor=A.+Del+Rio&title=Comparative+Analysis+of+Pharmacophore+Screening+Tools&doi=10.1021%2Fci2005274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Analysis of Pharmacophore Screening Tools</span></div><div class="casAuthors">Sanders, Marijn P. A.; Barbosa, Armenio J. M.; Zarzycka, Barbara; Nicolaes, Gerry A. F.; Klomp, Jan P. G.; de Vlieg, Jacob; Del Rio, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1607-1620</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pharmacophore concept is of central importance in computer-aided drug design (CADD) mainly because of its successful application in medicinal chem. and, in particular, high-throughput virtual screening (HTVS).  The simplicity of the pharmacophore definition enables the complexity of mol. interactions between ligand and receptor to be reduced to a handful set of features.  With many pharmacophore screening softwares available, it is of the utmost interest to explore the behavior of these tools when applied to different biol. systems.  In this work, we present a comparative anal. of eight pharmacophore screening algorithms (Catalyst, Unity, LigandScout, Phase, Pharao, MOE, Pharmer, and POT) for their use in typical HTVS campaigns against four different biol. targets by using default settings.  The results herein presented show how the performance of each pharmacophore screening tool might be specifically related to factors such as the characteristics of the binding pocket, the use of specific pharmacophore features, and the use of these techniques in specific steps/contexts of the drug discovery pipeline.  Algorithms with rmsd-based scoring functions are able to predict more compd. poses correctly as overlay-based scoring functions.  However, the ratio of correctly predicted compd. poses vs. incorrectly predicted poses is better for overlay-based scoring functions that also ensure better performances in compd. library enrichments.  While the ensemble of these observations can be used to choose the most appropriate class of algorithm for specific virtual screening projects, we remarked that pharmacophore algorithms are often equally good, and in this respect, we also analyzed how pharmacophore algorithms can be combined together in order to increase the success of hit compd. identification.  This study provides a valuable benchmark set for further developments in the field of pharmacophore search algorithms, e.g., by using pose predictions and compd. library enrichment criteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqC2VxEmjeKbVg90H21EOLACvtfcHk0lj69rJJ0xvnqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnslahsr4%253D&md5=2aef6c2e53097c2a25283f5a08ee900a</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1021%2Fci2005274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci2005274%26sid%3Dliteratum%253Aachs%26aulast%3DSanders%26aufirst%3DM.%2BP.%2BA.%26aulast%3DBarbosa%26aufirst%3DA.%2BJ.%2BM.%26aulast%3DZarzycka%26aufirst%3DB.%26aulast%3DNicolaes%26aufirst%3DG.%2BA.%2BF.%26aulast%3DKlomp%26aufirst%3DJ.%2BP.%2BG.%26aulast%3DDe%2BVlieg%26aufirst%3DJ.%26aulast%3DDel%2BRio%26aufirst%3DA.%26atitle%3DComparative%2520Analysis%2520of%2520Pharmacophore%2520Screening%2520Tools%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26issue%3D6%26spage%3D1607%26epage%3D1620%26doi%3D10.1021%2Fci2005274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Triballeau, N.</span>; <span class="NLM_string-name">Bertrand, H. O.</span>; <span class="NLM_string-name">Acher, F.</span></span> <span> </span><span class="NLM_article-title">Are You Sure You Have a Good Model?</span> In  <i>Pharmacophores and Pharmacophore Searches</i>; <span class="NLM_publisher-name">Wiley-Blackwell</span>, <span class="NLM_year">2006</span>; pp  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">364</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2F3527609164.ch15" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=325-364&author=N.+Triballeau&author=H.+O.+Bertrand&author=F.+Acher&title=Pharmacophores+and+Pharmacophore+Searches"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1002%2F3527609164.ch15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F3527609164.ch15%26sid%3Dliteratum%253Aachs%26aulast%3DTriballeau%26aufirst%3DN.%26atitle%3DAre%2520You%2520Sure%2520You%2520Have%2520a%2520Good%2520Model%253F%26btitle%3DPharmacophores%2520and%2520Pharmacophore%2520Searches%26pub%3DWiley-Blackwell%26date%3D2006%26spage%3D325%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of Multitarget Inhibitors by Combining Molecular Docking with Common Pharmacophore Matching</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">7882</span>– <span class="NLM_lpage">7888</span>, <span class="refDoi"> DOI: 10.1021/jm8010096</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8010096" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKlu7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7882-7888&issue=24&author=D.+Weiauthor=X.+Jiangauthor=L.+Zhouauthor=J.+Chenauthor=Z.+Chenauthor=C.+Heauthor=K.+Yangauthor=Y.+Liuauthor=J.+Peiauthor=L.+Lai&title=Discovery+of+Multitarget+Inhibitors+by+Combining+Molecular+Docking+with+Common+Pharmacophore+Matching&doi=10.1021%2Fjm8010096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Multitarget Inhibitors by Combining Molecular Docking with Common Pharmacophore Matching</span></div><div class="casAuthors">Wei, Dengguo; Jiang, Xiaolu; Zhou, Lu; Chen, Jing; Chen, Zheng; He, Chong; Yang, Kun; Liu, Ying; Pei, Jianfeng; Lai, Luhua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7882-7888</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multitarget drugs have been to be found effective in controlling complex diseases.  However, how to design multitarget drugs presents a great challenge. We have developed a computer-assisted strategy to screen for multitarget inhibitors using a combination of mol. docking and common pharmacophore matching.  This strategy was successfully applied to screen for dual-target inhibitors against both the human leukotriene A4 hydrolase (LTA4H-h) and the human nonpancreatic secretory phospholipase A2 (hnps-PLA2).  Three compds. screened from the chem. database MDL Available Chem. Directory were found to inhibit these two enzymes at the 10 μM level.  Moreover, one synthetic compd. matching the common pharmacophores inhibits LTA4H-h and hnps-PLA2 with IC50 values of 35 nM and 7.3 μM, resp.  The common pharmacophore model can also be used to search small mol. databases or collections of existing inhibitors, as well as to guide combinatorial library design to search for ideal multitarget inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJgzU8gGUcMrVg90H21EOLACvtfcHk0lj69rJJ0xvnqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKlu7nK&md5=0039b1caccc0518b554a20ed1e2e42c9</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1021%2Fjm8010096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010096%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPei%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520Multitarget%2520Inhibitors%2520by%2520Combining%2520Molecular%2520Docking%2520with%2520Common%2520Pharmacophore%2520Matching%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D24%26spage%3D7882%26epage%3D7888%26doi%3D10.1021%2Fjm8010096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arooj, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakkiah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. W.</span></span> <span> </span><span class="NLM_article-title">An Innovative Strategy for Dual Inhibitor Design and Its Application in Dual Inhibition of Human Thymidylate Synthase and Dihydrofolate Reductase Enzymes</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e60470</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0060470</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1371%2Fjournal.pone.0060470" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e60470&author=M.+Aroojauthor=S.+Sakkiahauthor=G.+P.+Caoauthor=K.+W.+Lee&title=An+Innovative+Strategy+for+Dual+Inhibitor+Design+and+Its+Application+in+Dual+Inhibition+of+Human+Thymidylate+Synthase+and+Dihydrofolate+Reductase+Enzymes&doi=10.1371%2Fjournal.pone.0060470"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0060470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0060470%26sid%3Dliteratum%253Aachs%26aulast%3DArooj%26aufirst%3DM.%26aulast%3DSakkiah%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DG.%2BP.%26aulast%3DLee%26aufirst%3DK.%2BW.%26atitle%3DAn%2520Innovative%2520Strategy%2520for%2520Dual%2520Inhibitor%2520Design%2520and%2520Its%2520Application%2520in%2520Dual%2520Inhibition%2520of%2520Human%2520Thymidylate%2520Synthase%2520and%2520Dihydrofolate%2520Reductase%2520Enzymes%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De60470%26doi%3D10.1371%2Fjournal.pone.0060470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morissette, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouthillier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marceau, F.</span></span> <span> </span><span class="NLM_article-title">Dual Antagonists of the Bradykinin B1 and B2 Receptors Based on a Postulated Common Pharmacophore from Existing Non-Peptide Antagonists</span>. <i>Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>387</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">194</span>, <span class="refDoi"> DOI: 10.1515/BC.2006.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1515%2FBC.2006.025" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2006&pages=189-194&author=G.+Morissetteauthor=J.+Bouthillierauthor=F.+Marceau&title=Dual+Antagonists+of+the+Bradykinin+B1+and+B2+Receptors+Based+on+a+Postulated+Common+Pharmacophore+from+Existing+Non-Peptide+Antagonists&doi=10.1515%2FBC.2006.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1515%2FBC.2006.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252FBC.2006.025%26sid%3Dliteratum%253Aachs%26aulast%3DMorissette%26aufirst%3DG.%26aulast%3DBouthillier%26aufirst%3DJ.%26aulast%3DMarceau%26aufirst%3DF.%26atitle%3DDual%2520Antagonists%2520of%2520the%2520Bradykinin%2520B1%2520and%2520B2%2520Receptors%2520Based%2520on%2520a%2520Postulated%2520Common%2520Pharmacophore%2520from%2520Existing%2520Non-Peptide%2520Antagonists%26jtitle%3DBiol.%2520Chem.%26date%3D2006%26volume%3D387%26spage%3D189%26epage%3D194%26doi%3D10.1515%2FBC.2006.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sindhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, P.</span></span> <span> </span><span class="NLM_article-title">Identification of Potential Dual Agonists of FXR and TGR5 Using E-Pharmacophore Based Virtual Screening</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1305</span>– <span class="NLM_lpage">1318</span>, <span class="refDoi"> DOI: 10.1039/C5MB00137D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1039%2FC5MB00137D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=25787676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFegsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=1305-1318&issue=5&author=T.+Sindhuauthor=P.+Srinivasan&title=Identification+of+Potential+Dual+Agonists+of+FXR+and+TGR5+Using+E-Pharmacophore+Based+Virtual+Screening&doi=10.1039%2FC5MB00137D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of potential dual agonists of FXR and TGR5 using e-pharmacophore based virtual screening</span></div><div class="casAuthors">Sindhu, Thangaraj; Srinivasan, Pappu</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1305-1318</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-2051</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Farnesoid X receptor and Takeda G-protein-coupled receptor-5 are well known bile acid receptors and act as promising targets for the drug development and treatment of diabetes.  Agonists of both the bile acid receptors increase insulin sensitivity and control glucose, lipids and bile acid homeostasis.  The current study deals with the identification of novel dual agonists using ligand and structure-based virtual screening.  Initially, an exptl. proven well-known dual agonist of FXR and TGR5, namely INT-767, was docked into the binding sites of FXR and TGR5 to det. the protein residues important for ligand binding.  The docked complexes FXRINT-767 and TGR5INT-767 were used to generate e-pharmacophore hypotheses.  Ligand-based virtual screening was carried out using the hypothetical e-pharmacophore model against the ChemBridge database.  Further, structure-based virtual screening was performed with screened hits to find potential agonists of FXR and TGR5.  A total of four best agonists were identified based on their affinity and mode of interactions with the receptors.  The binding mode of these compds. with both receptors was analyzed in detail.  Furthermore, mol. dynamics, ADME toxicity prediction, d. functional theory and binding free energy calcns. were carried out to rank the compds.  Based on the above analyses, the most potent compd., ChemBridge_9149693, was selected for further in vitro studies.  The results of in vitro assays suggested that ChemBridge_9149693 is a potent and promising drug for the treatment of type II diabetes.  Thus, the compd. could be used for further drug design and development of dual agonists of FXR and TGR5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBxCMs-xT3KLVg90H21EOLACvtfcHk0lg1Py8dzIRFNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFegsbw%253D&md5=9da5dd11001aabfb51b227b2cc960a7e</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1039%2FC5MB00137D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MB00137D%26sid%3Dliteratum%253Aachs%26aulast%3DSindhu%26aufirst%3DT.%26aulast%3DSrinivasan%26aufirst%3DP.%26atitle%3DIdentification%2520of%2520Potential%2520Dual%2520Agonists%2520of%2520FXR%2520and%2520TGR5%2520Using%2520E-Pharmacophore%2520Based%2520Virtual%2520Screening%26jtitle%3DMol.%2520BioSyst.%26date%3D2015%26volume%3D11%26issue%3D5%26spage%3D1305%26epage%3D1318%26doi%3D10.1039%2FC5MB00137D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewska, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achenbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buscató, E. la</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klingler, F.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhilber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span> <span> </span><span class="NLM_article-title">Dual-Target Virtual Screening by Pharmacophore Elucidation and Molecular Shape Filtering</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1021/ml200286e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200286e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=155-158&issue=2&author=D.+Moserauthor=J.+M.+Wisniewskaauthor=S.+Hahnauthor=J.+Achenbachauthor=E.+la+Buscat%C3%B3author=F.-M.+Klinglerauthor=B.+Hofmannauthor=D.+Steinhilberauthor=E.+Proschak&title=Dual-Target+Virtual+Screening+by+Pharmacophore+Elucidation+and+Molecular+Shape+Filtering&doi=10.1021%2Fml200286e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1021%2Fml200286e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200286e%26sid%3Dliteratum%253Aachs%26aulast%3DMoser%26aufirst%3DD.%26aulast%3DWisniewska%26aufirst%3DJ.%2BM.%26aulast%3DHahn%26aufirst%3DS.%26aulast%3DAchenbach%26aufirst%3DJ.%26aulast%3DBuscat%25C3%25B3%26aufirst%3DE.%2Bla%26aulast%3DKlingler%26aufirst%3DF.-M.%26aulast%3DHofmann%26aufirst%3DB.%26aulast%3DSteinhilber%26aufirst%3DD.%26aulast%3DProschak%26aufirst%3DE.%26atitle%3DDual-Target%2520Virtual%2520Screening%2520by%2520Pharmacophore%2520Elucidation%2520and%2520Molecular%2520Shape%2520Filtering%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26issue%3D2%26spage%3D155%26epage%3D158%26doi%3D10.1021%2Fml200286e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartenfeller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zettl, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reisen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weggen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span> <span> </span><span class="NLM_article-title">DOGS: Reaction-Driven de Novo Design of Bioactive Compounds</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">e1002380</span>, <span class="refDoi"> DOI: 10.1371/journal.pcbi.1002380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1371%2Fjournal.pcbi.1002380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=22359493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Sjtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=e1002380&issue=2&author=M.+Hartenfellerauthor=H.+Zettlauthor=M.+Walterauthor=M.+Ruppauthor=F.+Reisenauthor=E.+Proschakauthor=S.+Weggenauthor=H.+Starkauthor=G.+Schneider&title=DOGS%3A+Reaction-Driven+de+Novo+Design+of+Bioactive+Compounds&doi=10.1371%2Fjournal.pcbi.1002380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">DOGS: reaction-driven de novo design of bioactive compounds</span></div><div class="casAuthors">Hartenfeller, Markus; Zettl, Heiko; Walter, Miriam; Rupp, Matthias; Reisen, Felix; Proschak, Ewgenij; Weggen, Sascha; Stark, Holger; Schneider, Gisbert</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e1002380</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">We present a computational method for the reaction-based de novo design of drug-like mols.  The software DOGS (Design of Genuine Structures) features a ligand-based strategy for automated 'in silico' assembly of potentially novel bioactive compds.  The quality of the designed compds. is assessed by a graph kernel method measuring their similarity to known bioactive ref. ligands in terms of structural and pharmacophoric features.  We implemented a deterministic compd. construction procedure that explicitly considers compd. synthesizability, based on a compilation of 25'144 readily available synthetic building blocks and 58 established reaction principles.  This enables the software to suggest a synthesis route for each designed compd.  Two prospective case studies are presented together with details on the algorithm and its implementation.  De novo designed ligand candidates for the human histamine H4 receptor and γ-secretase were synthesized as suggested by the software.  The computational approach proved to be suitable for scaffold-hopping from known ligands to novel chemotypes and for generating bioactive mols. with drug-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBGMIXUGjYJrVg90H21EOLACvtfcHk0lg1Py8dzIRFNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Sjtr0%253D&md5=cdcf6905d52761614c33ab068b608ac5</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1002380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1002380%26sid%3Dliteratum%253Aachs%26aulast%3DHartenfeller%26aufirst%3DM.%26aulast%3DZettl%26aufirst%3DH.%26aulast%3DWalter%26aufirst%3DM.%26aulast%3DRupp%26aufirst%3DM.%26aulast%3DReisen%26aufirst%3DF.%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DWeggen%26aufirst%3DS.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DSchneider%26aufirst%3DG.%26atitle%3DDOGS%253A%2520Reaction-Driven%2520de%2520Novo%2520Design%2520of%2520Bioactive%2520Compounds%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2012%26volume%3D8%26issue%3D2%26spage%3De1002380%26doi%3D10.1371%2Fjournal.pcbi.1002380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tschinke, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, N. C.</span></span> <span> </span><span class="NLM_article-title">The NEWLEAD Program: A New Method for the Design of Candidate Structures from Pharmacophoric Hypotheses</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">3863</span>– <span class="NLM_lpage">3870</span>, <span class="refDoi"> DOI: 10.1021/jm00076a016</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00076a016" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=3863-3870&issue=24&author=V.+Tschinkeauthor=N.+C.+Cohen&title=The+NEWLEAD+Program%3A+A+New+Method+for+the+Design+of+Candidate+Structures+from+Pharmacophoric+Hypotheses&doi=10.1021%2Fjm00076a016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1021%2Fjm00076a016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00076a016%26sid%3Dliteratum%253Aachs%26aulast%3DTschinke%26aufirst%3DV.%26aulast%3DCohen%26aufirst%3DN.%2BC.%26atitle%3DThe%2520NEWLEAD%2520Program%253A%2520A%2520New%2520Method%2520for%2520the%2520Design%2520of%2520Candidate%2520Structures%2520from%2520Pharmacophoric%2520Hypotheses%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26issue%3D24%26spage%3D3863%26epage%3D3870%26doi%3D10.1021%2Fjm00076a016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartenfeller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span> <span> </span><span class="NLM_article-title">De Novo Drug Design</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>672</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">323</span>, <span class="refDoi"> DOI: 10.1007/978-1-60761-839-3_12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1007%2F978-1-60761-839-3_12" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=672&publication_year=2010&pages=299-323&author=M.+Hartenfellerauthor=G.+Schneider&title=De+Novo+Drug+Design&doi=10.1007%2F978-1-60761-839-3_12"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1007%2F978-1-60761-839-3_12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-60761-839-3_12%26sid%3Dliteratum%253Aachs%26aulast%3DHartenfeller%26aufirst%3DM.%26aulast%3DSchneider%26aufirst%3DG.%26atitle%3DDe%2520Novo%2520Drug%2520Design%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2010%26volume%3D672%26spage%3D299%26epage%3D323%26doi%3D10.1007%2F978-1-60761-839-3_12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span> <span> </span><span class="NLM_article-title">De Novo Design at the Edge of Chaos</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">4077</span>– <span class="NLM_lpage">4086</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01849</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01849" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFahsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4077-4086&issue=9&author=P.+Schneiderauthor=G.+Schneider&title=De+Novo+Design+at+the+Edge+of+Chaos&doi=10.1021%2Facs.jmedchem.5b01849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">De Novo Design at the Edge of Chaos</span></div><div class="casAuthors">Schneider, Petra; Schneider, Gisbert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4077-4086</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Computational medicinal chem. offers viable strategies for finding, characterizing, and optimizing innovative pharmacol. active compds.  Technol. advances in both computer hardware and software as well as biol. chem. have enabled a renaissance of computer-assisted "de novo" design of mols. with desired pharmacol. properties.  Here, we present our current perspective on the concept of automated mol. generation by highlighting chemocentric methods that may capture druglike chem. space, consider ligand promiscuity for hit and lead finding, and provide fresh ideas for the rational design of customized screening of compd. libraries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvGnpbXPAgt7Vg90H21EOLACvtfcHk0lhOeFVKXYe9nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFahsLs%253D&md5=db6cc1e505e43d4721b2f89ce2cbe91a</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01849%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DP.%26aulast%3DSchneider%26aufirst%3DG.%26atitle%3DDe%2520Novo%2520Design%2520at%2520the%2520Edge%2520of%2520Chaos%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D9%26spage%3D4077%26epage%3D4086%26doi%3D10.1021%2Facs.jmedchem.5b01849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Network Analysis of Drug-Target Interactions: A Study on FDA-Approved New Molecular Entities Between 2000 to 2015</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">12230</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-12061-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fs41598-017-12061-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28947756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252Fit1yksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=12230&issue=1&author=H.-H.+Linauthor=L.-L.+Zhangauthor=R.+Yanauthor=J.-J.+Luauthor=Y.+Hu&title=Network+Analysis+of+Drug-Target+Interactions%3A+A+Study+on+FDA-Approved+New+Molecular+Entities+Between+2000+to+2015&doi=10.1038%2Fs41598-017-12061-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Network Analysis of Drug-target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015</span></div><div class="casAuthors">Lin Hui-Heng; Zhang Le-Le; Yan Ru; Lu Jin-Jian; Hu Yuanjia</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12230</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The U.S.  Food and Drug Administration (FDA) approves new drugs every year.  Drug targets are some of the most important interactive molecules for drugs, as they have a significant impact on the therapeutic effects of drugs.  In this work, we thoroughly analyzed the data of small molecule drugs approved by the U.S.  FDA between 2000 and 2015.  Specifically, we focused on seven classes of new molecular entity (NME) classified by the anatomic therapeutic chemical (ATC) classification system.  They were NMEs and their corresponding targets for the cardiovascular system, respiratory system, nerve system, general anti-infective systemic, genito-urinary system and sex hormones, alimentary tract and metabolisms, and antineoplastic and immunomodulating agents.  To study the drug-target interaction on the systems level, we employed network topological analysis and multipartite network projections.  As a result, the drug-target relations of different kinds of drugs were comprehensively characterized and global pictures of drug-target, drug-drug, and target-target interactions were visualized and analyzed from the perspective of network models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbYvmqnyNWSv3jf77P2BG3fW6udTcc2ebEZ6kQSSoij7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252Fit1yksA%253D%253D&md5=2317e913a77fbb6fda31a06742c84c29</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-12061-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-12061-8%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.-H.%26aulast%3DZhang%26aufirst%3DL.-L.%26aulast%3DYan%26aufirst%3DR.%26aulast%3DLu%26aufirst%3DJ.-J.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DNetwork%2520Analysis%2520of%2520Drug-Target%2520Interactions%253A%2520A%2520Study%2520on%2520FDA-Approved%2520New%2520Molecular%2520Entities%2520Between%25202000%2520to%25202015%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26issue%3D1%26spage%3D12230%26doi%3D10.1038%2Fs41598-017-12061-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-T.</span></span> <span> </span><span class="NLM_article-title">Multi-Target Drugs: The Trend of Drug Research and Development</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">e40262</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0040262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1371%2Fjournal.pone.0040262" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e40262&issue=6&author=J.-J.+Luauthor=W.+Panauthor=Y.-J.+Huauthor=Y.-T.+Wang&title=Multi-Target+Drugs%3A+The+Trend+of+Drug+Research+and+Development&doi=10.1371%2Fjournal.pone.0040262"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0040262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0040262%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DJ.-J.%26aulast%3DPan%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DY.-J.%26aulast%3DWang%26aufirst%3DY.-T.%26atitle%3DMulti-Target%2520Drugs%253A%2520The%2520Trend%2520of%2520Drug%2520Research%2520and%2520Development%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26issue%3D6%26spage%3De40262%26doi%3D10.1371%2Fjournal.pone.0040262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wermuth, C. G.</span></span> <span> </span><span class="NLM_article-title">Selective Optimization of Side Activities: Another Way for Drug Discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1303</span>– <span class="NLM_lpage">1314</span>, <span class="refDoi"> DOI: 10.1021/jm030480f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030480f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1303-1314&issue=6&author=C.+G.+Wermuth&title=Selective+Optimization+of+Side+Activities%3A+Another+Way+for+Drug+Discovery&doi=10.1021%2Fjm030480f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1021%2Fjm030480f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030480f%26sid%3Dliteratum%253Aachs%26aulast%3DWermuth%26aufirst%3DC.%2BG.%26atitle%3DSelective%2520Optimization%2520of%2520Side%2520Activities%253A%2520Another%2520Way%2520for%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26issue%3D6%26spage%3D1303%26epage%3D1314%26doi%3D10.1021%2Fjm030480f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langer, T.</span>; <span class="NLM_string-name">Wermuth, C.-G.</span></span> <span> </span><span class="NLM_article-title">Selective Optimization of Side Activities (SOSA): A Promising Way for Drug Discovery</span>. In  <i>Polypharmacology in Drug Discovery</i>; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">2012</span>; pp  <span class="NLM_fpage">227</span>– <span class="NLM_lpage">243</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2F9781118098141.ch11" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=227-243&author=T.+Langer&author=C.-G.+Wermuth&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch11%26sid%3Dliteratum%253Aachs%26aulast%3DLanger%26aufirst%3DT.%26atitle%3DSelective%2520Optimization%2520of%2520Side%2520Activities%2520%2528SOSA%2529%253A%2520A%2520Promising%2520Way%2520for%2520Drug%2520Discovery%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2012%26spage%3D227%26epage%3D243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vitale, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercuro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castiglioni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornoldi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volterrani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosano, G. M. C.</span></span> <span> </span><span class="NLM_article-title">Metabolic Effect of Telmisartan and Losartan in Hypertensive Patients with Metabolic Syndrome</span>. <i>Cardiovasc. Diabetol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">6</span>, <span class="refDoi"> DOI: 10.1186/1475-2840-4-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1186%2F1475-2840-4-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=15892894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BD2Mzlt1CktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=6&issue=1&author=C.+Vitaleauthor=G.+Mercuroauthor=C.+Castiglioniauthor=A.+Cornoldiauthor=A.+Tulliauthor=M.+Finiauthor=M.+Volterraniauthor=G.+M.+C.+Rosano&title=Metabolic+Effect+of+Telmisartan+and+Losartan+in+Hypertensive+Patients+with+Metabolic+Syndrome&doi=10.1186%2F1475-2840-4-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome</span></div><div class="casAuthors">Vitale Cristiana; Mercuro Giuseppe; Castiglioni Carlotta; Cornoldi Alessandra; Tulli Arianna; Fini Massimo; Volterrani Maurizio; Rosano Giuseppe M C</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular diabetology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Metabolic syndrome is a cluster of common cardiovascular risk factors that includes hypertension and insulin resistance.  Hypertension and diabetes mellitus are frequent comorbidities and, like metabolic syndrome, increase the risk of cardiovascular events.  Telmisartan, an antihypertensive agent with evidence of partial peroxisome proliferator-activated receptor activity-gamma (PPARgamma) activity, may improve insulin sensitivity and lipid profile in patients with metabolic syndrome.  METHODS:  In a double-blind, parallel-group, randomized study, patients with World Health Organization criteria for metabolic syndrome received once-daily doses of telmisartan (80 mg, n = 20) or losartan (50 mg, n = 20) for 3 months.  At baseline and end of treatment, fasting and postprandial plasma glucose, insulin sensitivity, glycosylated haemoglobin (HBA1c) and 24-hour mean systolic and diastolic blood pressures were determined.  RESULTS:  Telmisartan, but not losartan, significantly (p < 0.05) reduced free plasma glucose, free plasma insulin, homeostasis model assessment of insulin resistance and HbAic.  Following treatment, plasma glucose and insulin were reduced during the oral glucose tolerance test by telmisartan, but not by losartan.  Telmisartan also significantly reduced 24-hour mean systolic blood pressure (p < 0.05) and diastolic blood pressure (p < 0.05) compared with losartan.  CONCLUSION:  As well as providing superior 24-hour blood pressure control, telmisartan, unlike losartan, displayed insulin-sensitizing activity, which may be explained by its partial PPARgamma activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnNx7JI9Biv3WEEzDrymxmfW6udTcc2eb6PJZrk1SYD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mzlt1CktQ%253D%253D&md5=a964c88094a8a08133efddc102d23e0a</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1186%2F1475-2840-4-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1475-2840-4-6%26sid%3Dliteratum%253Aachs%26aulast%3DVitale%26aufirst%3DC.%26aulast%3DMercuro%26aufirst%3DG.%26aulast%3DCastiglioni%26aufirst%3DC.%26aulast%3DCornoldi%26aufirst%3DA.%26aulast%3DTulli%26aufirst%3DA.%26aulast%3DFini%26aufirst%3DM.%26aulast%3DVolterrani%26aufirst%3DM.%26aulast%3DRosano%26aufirst%3DG.%2BM.%2BC.%26atitle%3DMetabolic%2520Effect%2520of%2520Telmisartan%2520and%2520Losartan%2520in%2520Hypertensive%2520Patients%2520with%2520Metabolic%2520Syndrome%26jtitle%3DCardiovasc.%2520Diabetol.%26date%3D2005%26volume%3D4%26issue%3D1%26spage%3D6%26doi%3D10.1186%2F1475-2840-4-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, X.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Telmisartan Improves Insulin Resistance: A Meta-Analysis</span>. <i>Am. J. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_fpage">1</span>, <span class="refDoi"> DOI: 10.1097/MJT.0000000000000733</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1097%2FMJT.0000000000000733" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=1&author=Y.+Wangauthor=S.+Qiaoauthor=D.-W.+Hanauthor=X.-R.+Rongauthor=Y.-X.+Wangauthor=J.-J.+Xueauthor=J.+Yang&title=Telmisartan+Improves+Insulin+Resistance%3A+A+Meta-Analysis&doi=10.1097%2FMJT.0000000000000733"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1097%2FMJT.0000000000000733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMJT.0000000000000733%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DQiao%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DD.-W.%26aulast%3DRong%26aufirst%3DX.-R.%26aulast%3DWang%26aufirst%3DY.-X.%26aulast%3DXue%26aufirst%3DJ.-J.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DTelmisartan%2520Improves%2520Insulin%2520Resistance%253A%2520A%2520Meta-Analysis%26jtitle%3DAm.%2520J.%2520Ther.%26date%3D2018%26spage%3D1%26doi%3D10.1097%2FMJT.0000000000000733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goebel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staels, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kintscher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gust, R.</span></span> <span> </span><span class="NLM_article-title">Characterization of New PPARgamma Agonists: Benzimidazole Derivatives - the Importance of Position 2</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1142</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200900067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fcmdc.200900067" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=1136-1142&issue=7&author=M.+Goebelauthor=B.+Staelsauthor=T.+Ungerauthor=U.+Kintscherauthor=R.+Gust&title=Characterization+of+New+PPARgamma+Agonists%3A+Benzimidazole+Derivatives+-+the+Importance+of+Position+2&doi=10.1002%2Fcmdc.200900067"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900067%26sid%3Dliteratum%253Aachs%26aulast%3DGoebel%26aufirst%3DM.%26aulast%3DStaels%26aufirst%3DB.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DKintscher%26aufirst%3DU.%26aulast%3DGust%26aufirst%3DR.%26atitle%3DCharacterization%2520of%2520New%2520PPARgamma%2520Agonists%253A%2520Benzimidazole%2520Derivatives%2520-%2520the%2520Importance%2520of%2520Position%25202%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26issue%3D7%26spage%3D1136%26epage%3D1142%26doi%3D10.1002%2Fcmdc.200900067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goebel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemenz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staels, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kintscher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gust, R.</span></span> <span> </span><span class="NLM_article-title">Characterization of New PPARgamma Agonists: Analysis of Telmisartan’s Structural Components</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">445</span>– <span class="NLM_lpage">456</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200800285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fcmdc.200800285" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=445-456&issue=3&author=M.+Goebelauthor=M.+Clemenzauthor=B.+Staelsauthor=T.+Ungerauthor=U.+Kintscherauthor=R.+Gust&title=Characterization+of+New+PPARgamma+Agonists%3A+Analysis+of+Telmisartan%E2%80%99s+Structural+Components&doi=10.1002%2Fcmdc.200800285"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200800285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200800285%26sid%3Dliteratum%253Aachs%26aulast%3DGoebel%26aufirst%3DM.%26aulast%3DClemenz%26aufirst%3DM.%26aulast%3DStaels%26aufirst%3DB.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DKintscher%26aufirst%3DU.%26aulast%3DGust%26aufirst%3DR.%26atitle%3DCharacterization%2520of%2520New%2520PPARgamma%2520Agonists%253A%2520Analysis%2520of%2520Telmisartan%25E2%2580%2599s%2520Structural%2520Components%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26issue%3D3%26spage%3D445%26epage%3D456%26doi%3D10.1002%2Fcmdc.200800285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Besnard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruda, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abecassis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norval, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassano, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidah, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constam, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bickerton, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span> <span> </span><span class="NLM_article-title">Automated Design of Ligands to Polypharmacological Profiles</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>492</i></span> (<span class="NLM_issue">7428</span>),  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1038/nature11691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnature11691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=23235874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=492&publication_year=2012&pages=215-220&issue=7428&author=J.+Besnardauthor=G.+F.+Rudaauthor=V.+Setolaauthor=K.+Abecassisauthor=R.+M.+Rodriguizauthor=X.-P.+Huangauthor=S.+Norvalauthor=M.+F.+Sassanoauthor=A.+I.+Shinauthor=L.+A.+Websterauthor=F.+R.+C.+Simeonsauthor=L.+Stojanovskiauthor=A.+Pratauthor=N.+G.+Seidahauthor=D.+B.+Constamauthor=G.+R.+Bickertonauthor=K.+D.+Readauthor=W.+C.+Wetselauthor=I.+H.+Gilbertauthor=B.+L.+Rothauthor=A.+L.+Hopkins&title=Automated+Design+of+Ligands+to+Polypharmacological+Profiles&doi=10.1038%2Fnature11691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Automated design of ligands to polypharmacological profiles</span></div><div class="casAuthors">Besnard, Jeremy; Ruda, Gian Filippo; Setola, Vincent; Abecassis, Keren; Rodriguiz, Ramona M.; Huang, Xi-Ping; Norval, Suzanne; Sassano, Maria F.; Shin, Antony I.; Webster, Lauren A.; Simeons, Frederick R. C.; Stojanovski, Laste; Prat, Annik; Seidah, Nabil G.; Constam, Daniel B.; Bickerton, G. Richard; Read, Kevin D.; Wetsel, William C.; Gilbert, Ian H.; Roth, Bryan L.; Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">492</span>
        (<span class="NLM_cas:issue">7428</span>),
    <span class="NLM_cas:pages">215-220</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy and safety of a drug is detd. by its activity profile across many proteins in the proteome.  However, designing drugs with a specific multi-target profile is both complex and difficult.  Therefore methods to design drugs rationally a priori against profiles of several proteins would have immense value in drug discovery.  Here is described a new approach for the automated design of ligands against profiles of multiple drug targets.  The method is demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug donepezil (I) into brain-penetrable ligands with either specific polypharmacol. or exquisite selectivity profiles for G-protein-coupled receptors.  Overall, 800 ligand-target predictions of prospectively designed ligands were tested exptl., of which 75% were confirmed to be correct.  Target engagement in vivo is also demonstrated.  The approach can be a useful source of drug leads when multi-target profiles are required to achieve either selectivity over other drug targets or a desired polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNu5bwrBD3tbVg90H21EOLACvtfcHk0ljlQIOIPyyucw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN&md5=ace6cced250cf968d327b482a5bf1798</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1038%2Fnature11691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11691%26sid%3Dliteratum%253Aachs%26aulast%3DBesnard%26aufirst%3DJ.%26aulast%3DRuda%26aufirst%3DG.%2BF.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DAbecassis%26aufirst%3DK.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DShin%26aufirst%3DA.%2BI.%26aulast%3DWebster%26aufirst%3DL.%2BA.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DSeidah%26aufirst%3DN.%2BG.%26aulast%3DConstam%26aufirst%3DD.%2BB.%26aulast%3DBickerton%26aufirst%3DG.%2BR.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DAutomated%2520Design%2520of%2520Ligands%2520to%2520Polypharmacological%2520Profiles%26jtitle%3DNature%26date%3D2012%26volume%3D492%26issue%3D7428%26spage%3D215%26epage%3D220%26doi%3D10.1038%2Fnature11691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schierle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flauaus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goebel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahnt, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhilber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurglics, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rovati, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidtko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Boosting Anti-Inflammatory Potency of Zafirlukast by Designed Polypharmacology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">5758</span>– <span class="NLM_lpage">5764</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00458</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00458" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5758-5764&issue=13&author=S.+Schierleauthor=C.+Flauausauthor=P.+Heitelauthor=S.+Willemsauthor=J.+Schmidtauthor=A.+Kaiserauthor=L.+Weizelauthor=T.+Goebelauthor=A.+S.+Kahntauthor=G.+Geisslingerauthor=D.+Steinhilberauthor=M.+Wurglicsauthor=G.+E.+Rovatiauthor=A.+Schmidtkoauthor=E.+Proschakauthor=D.+Merk&title=Boosting+Anti-Inflammatory+Potency+of+Zafirlukast+by+Designed+Polypharmacology&doi=10.1021%2Facs.jmedchem.8b00458"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00458%26sid%3Dliteratum%253Aachs%26aulast%3DSchierle%26aufirst%3DS.%26aulast%3DFlauaus%26aufirst%3DC.%26aulast%3DHeitel%26aufirst%3DP.%26aulast%3DWillems%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DJ.%26aulast%3DKaiser%26aufirst%3DA.%26aulast%3DWeizel%26aufirst%3DL.%26aulast%3DGoebel%26aufirst%3DT.%26aulast%3DKahnt%26aufirst%3DA.%2BS.%26aulast%3DGeisslinger%26aufirst%3DG.%26aulast%3DSteinhilber%26aufirst%3DD.%26aulast%3DWurglics%26aufirst%3DM.%26aulast%3DRovati%26aufirst%3DG.%2BE.%26aulast%3DSchmidtko%26aufirst%3DA.%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DBoosting%2520Anti-Inflammatory%2520Potency%2520of%2520Zafirlukast%2520by%2520Designed%2520Polypharmacology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D13%26spage%3D5758%26epage%3D5764%26doi%3D10.1021%2Facs.jmedchem.8b00458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hann, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, G.</span></span> <span> </span><span class="NLM_article-title">Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery</span>. <i>J. Chem. Inf. Comput. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">856</span>– <span class="NLM_lpage">864</span>, <span class="refDoi"> DOI: 10.1021/ci000403i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci000403i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFynt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2001&pages=856-864&issue=3&author=M.+M.+Hannauthor=A.+R.+Leachauthor=G.+Harper&title=Molecular+Complexity+and+Its+Impact+on+the+Probability+of+Finding+Leads+for+Drug+Discovery&doi=10.1021%2Fci000403i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery</span></div><div class="casAuthors">Hann, Michael M.; Leach, Andrew R.; Harper, Gavin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Computer Sciences</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">856-864</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">0095-2338</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Using a simple model of ligand-receptor interactions, the interactions between ligands and receptors of varying complexities are studied and the probabilities of binding calcd.  It is obsd. that as the systems become more complex the chance of observing a useful interaction for a randomly chosen ligand falls dramatically.  The implications of this for the design of combinatorial libraries is explored.  A large set of drug leads and optimized compds. is profiled using several different properties relevant to mol. recognition.  The changes obsd. for these properties during the drug optimization phase support the hypothesis that less complex mols. are more common starting points for the discovery of drugs.  An extreme example of the use of simple mols. for directed screening against thrombin is provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7ed40mt9qb7Vg90H21EOLACvtfcHk0lhgaYj8YT0oWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFynt7w%253D&md5=e89e76c8fb83fc5012369ae30f20e6b7</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1021%2Fci000403i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci000403i%26sid%3Dliteratum%253Aachs%26aulast%3DHann%26aufirst%3DM.%2BM.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DHarper%26aufirst%3DG.%26atitle%3DMolecular%2520Complexity%2520and%2520Its%2520Impact%2520on%2520the%2520Probability%2520of%2520Finding%2520Leads%2520for%2520Drug%2520Discovery%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Comput.%2520Sci.%26date%3D2001%26volume%3D41%26issue%3D3%26spage%3D856%26epage%3D864%26doi%3D10.1021%2Fci000403i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Achenbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klingler, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blöcher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Häfner, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rödl, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kretschmer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krüger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löhr, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhilber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span> <span> </span><span class="NLM_article-title">Exploring the Chemical Space of Multitarget Ligands Using Aligned Self-Organizing Maps</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1169</span>– <span class="NLM_lpage">1172</span>, <span class="refDoi"> DOI: 10.1021/ml4002562</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml4002562" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Kkt7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1169-1172&issue=12&author=J.+Achenbachauthor=F.+M.+Klinglerauthor=R.+Bl%C3%B6cherauthor=D.+Moserauthor=A.+K.+H%C3%A4fnerauthor=C.+B.+R%C3%B6dlauthor=S.+Kretschmerauthor=B.+Kr%C3%BCgerauthor=F.+L%C3%B6hrauthor=H.+Starkauthor=B.+Hofmannauthor=D.+Steinhilberauthor=E.+Proschak&title=Exploring+the+Chemical+Space+of+Multitarget+Ligands+Using+Aligned+Self-Organizing+Maps&doi=10.1021%2Fml4002562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the Chemical Space of Multitarget Ligands Using Aligned Self-Organizing Maps</span></div><div class="casAuthors">Achenbach, Janosch; Klingler, Franca-Maria; Bloecher, Rene; Moser, Daniel; Haefner, Ann-Kathrin; Roedl, Carmen B.; Kretschmer, Simon; Krueger, Bjoern; Loehr, Frank; Stark, Holger; Hofmann, Bettina; Steinhilber, Dieter; Proschak, Ewgenij</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1169-1172</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Design of multitarget drugs and polypharmacol. compds. has become popular during the past decade.  However, the main approach to design such compds. is to link two selective ligands via a flexible linker.  Although such chimeric ligands often have reasonable potency in vitro, the in vivo efficacy is low due to high mol. wt., low ligand efficiency, and poor pharmacokinetic profile.  We developed an unprecedented in silico approach for fragment-based design of multitarget ligands.  It relies on superposition of the chem. spaces related to the affinity on single targets represented by self-organizing maps.  We used this approach for screening of mol. fragments, which bind to the enzymes 5-lipoxygenase (5-LO) and sol. epoxide hydrolase (sEH).  Using STD-NMR and activity-based assays, we were able to identify fragments binding to both targets.  Furthermore, we were able to expand one of the fragments to a potent dual inhibitor bearing a reasonable mol. wt. (MW = 446) and high affinity to both targets (IC50 of 0.03 μM toward 5-LO and 0.17 μM toward sEH).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp120TeMy83c7Vg90H21EOLACvtfcHk0lhgaYj8YT0oWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Kkt7fL&md5=4231074e150dd7db7b92242d4c1664ff</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1021%2Fml4002562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4002562%26sid%3Dliteratum%253Aachs%26aulast%3DAchenbach%26aufirst%3DJ.%26aulast%3DKlingler%26aufirst%3DF.%2BM.%26aulast%3DBl%25C3%25B6cher%26aufirst%3DR.%26aulast%3DMoser%26aufirst%3DD.%26aulast%3DH%25C3%25A4fner%26aufirst%3DA.%2BK.%26aulast%3DR%25C3%25B6dl%26aufirst%3DC.%2BB.%26aulast%3DKretschmer%26aufirst%3DS.%26aulast%3DKr%25C3%25BCger%26aufirst%3DB.%26aulast%3DL%25C3%25B6hr%26aufirst%3DF.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DHofmann%26aufirst%3DB.%26aulast%3DSteinhilber%26aufirst%3DD.%26aulast%3DProschak%26aufirst%3DE.%26atitle%3DExploring%2520the%2520Chemical%2520Space%2520of%2520Multitarget%2520Ligands%2520Using%2520Aligned%2520Self-Organizing%2520Maps%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26issue%3D12%26spage%3D1169%26epage%3D1172%26doi%3D10.1021%2Fml4002562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bottegoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veronesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisignano, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kacker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favia, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span> <span> </span><span class="NLM_article-title">Development and Application of a Virtual Screening Protocol for the Identification of Multitarget Fragments</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1259</span>– <span class="NLM_lpage">1263</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500521</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fcmdc.201500521" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1259-1263&issue=12&author=G.+Bottegoniauthor=M.+Veronesiauthor=P.+Bisignanoauthor=P.+Kackerauthor=A.+D.+Faviaauthor=A.+Cavalli&title=Development+and+Application+of+a+Virtual+Screening+Protocol+for+the+Identification+of+Multitarget+Fragments&doi=10.1002%2Fcmdc.201500521"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500521%26sid%3Dliteratum%253Aachs%26aulast%3DBottegoni%26aufirst%3DG.%26aulast%3DVeronesi%26aufirst%3DM.%26aulast%3DBisignano%26aufirst%3DP.%26aulast%3DKacker%26aufirst%3DP.%26aulast%3DFavia%26aufirst%3DA.%2BD.%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DDevelopment%2520and%2520Application%2520of%2520a%2520Virtual%2520Screening%2520Protocol%2520for%2520the%2520Identification%2520of%2520Multitarget%2520Fragments%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26issue%3D12%26spage%3D1259%26epage%3D1263%26doi%3D10.1002%2Fcmdc.201500521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Simone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armirotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrisano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Castillo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massenzio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polito, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatino, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottegoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">3,4-Dihydro-1,3,5-Triazin-2(1H)-Ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer’s Disease</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1665</span>– <span class="NLM_lpage">1682</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00121</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00121" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFKkt73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1665-1682&issue=10&author=F.+Pratiauthor=A.+De+Simoneauthor=A.+Armirottiauthor=M.+Summaauthor=D.+Pizziraniauthor=R.+Scarpelliauthor=S.+M.+Bertozziauthor=D.+I.+Perezauthor=V.+Andrisanoauthor=A.+Perez-Castilloauthor=B.+Montiauthor=F.+Massenzioauthor=L.+Politoauthor=M.+Racchiauthor=P.+Sabatinoauthor=G.+Bottegoniauthor=A.+Martinezauthor=A.+Cavalliauthor=M.+L.+Bolognesi&title=3%2C4-Dihydro-1%2C3%2C5-Triazin-2%281H%29-Ones+as+the+First+Dual+BACE-1%2FGSK-3%CE%B2+Fragment+Hits+against+Alzheimer%E2%80%99s+Disease&doi=10.1021%2Facschemneuro.5b00121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer's Disease</span></div><div class="casAuthors">Prati, Federica; De Simone, Angela; Armirotti, Andrea; Summa, Maria; Pizzirani, Daniela; Scarpelli, Rita; Bertozzi, Sine Mandrup; Perez, Daniel I.; Andrisano, Vincenza; Perez-Castillo, Ana; Monti, Barbara; Massenzio, Francesca; Polito, Letizia; Racchi, Marco; Sabatino, Piera; Bottegoni, Giovanni; Martinez, Ana; Cavalli, Andrea; Bolognesi, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1665-1682</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">One of the main obstacles toward the discovery of effective anti-Alzheimer drugs is the multifactorial nature of its etiopathol.  Therefore, the use of multitarget-directed ligands has emerged as particularly suitable.  Such ligands, able to modulate different neurodegenerative pathways, for example, amyloid and tau cascades, as well as cognitive and neurogenic functions, are fostered to come.  In this respect, we report herein on the first class of BACE-1/GSK-3β dual inhibitors based on a 3,4-dihydro-1,3,5-triazin-2(1H)-one skeleton, whose hit compd. 1 showed interesting properties in a preliminary investigation.  Notably, compd. 2, endowed with well-balanced potencies against the two isolated enzymes (IC50 of 16 and 7 μM against BACE-1 and GSK-3β, resp.), displayed effective neuroprotective and neurogenic activities and no neurotoxicity in cell-based assays.  It also showed good brain permeability in a pharmacokinetic assessment in mice.  Overall, triazinone derivs., thanks to the simultaneous modulation of multiple points of the diseased network, might emerge as suitable candidates to be tested in in vivo Alzheimer's disease models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9gpkNszZOQ7Vg90H21EOLACvtfcHk0ljMCQtxy-uQxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFKkt73O&md5=5d02342f3164a73e41eb17c4f87fb4fa</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00121%26sid%3Dliteratum%253Aachs%26aulast%3DPrati%26aufirst%3DF.%26aulast%3DDe%2BSimone%26aufirst%3DA.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DSumma%26aufirst%3DM.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DBertozzi%26aufirst%3DS.%2BM.%26aulast%3DPerez%26aufirst%3DD.%2BI.%26aulast%3DAndrisano%26aufirst%3DV.%26aulast%3DPerez-Castillo%26aufirst%3DA.%26aulast%3DMonti%26aufirst%3DB.%26aulast%3DMassenzio%26aufirst%3DF.%26aulast%3DPolito%26aufirst%3DL.%26aulast%3DRacchi%26aufirst%3DM.%26aulast%3DSabatino%26aufirst%3DP.%26aulast%3DBottegoni%26aufirst%3DG.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3D3%252C4-Dihydro-1%252C3%252C5-Triazin-2%25281H%2529-Ones%2520as%2520the%2520First%2520Dual%2520BACE-1%252FGSK-3%25CE%25B2%2520Fragment%2520Hits%2520against%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2015%26volume%3D6%26issue%3D10%26spage%3D1665%26epage%3D1682%26doi%3D10.1021%2Facschemneuro.5b00121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span> <span> </span><span class="NLM_article-title">De Novo Design of Multitarget Ligands with an Iterative Fragment-Growing Strategy</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1235</span>– <span class="NLM_lpage">1241</span>, <span class="refDoi"> DOI: 10.1021/ci500021v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci500021v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjvVOnsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2014&pages=1235-1241&issue=4&author=E.+Shangauthor=Y.+Yuanauthor=X.+Chenauthor=Y.+Liuauthor=J.+Peiauthor=L.+Lai&title=De+Novo+Design+of+Multitarget+Ligands+with+an+Iterative+Fragment-Growing+Strategy&doi=10.1021%2Fci500021v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">De Novo Design of Multitarget Ligands with an Iterative Fragment-Growing Strategy</span></div><div class="casAuthors">Shang, Erchang; Yuan, Yaxia; Chen, Xinyi; Liu, Ying; Pei, Jianfeng; Lai, Luhua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1235-1241</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of multitarget drugs has recently attracted much attention.  Most of the reported multitarget ligands have been serendipitous discoveries.  Although a few methods have been developed for rational multitarget drug discovery, there is a lack of elegant methods for de novo multitarget drug design and optimization, esp. for multiple targets with large differences in their binding sites.  In this paper, we report the first de novo multitarget ligand design method, with an iterative fragment-growing strategy.  Using this method, dual-target inhibitors for COX-2 and LTA4H were designed, with the most potent one inhibiting PGE2 and LTB4 prodn. in the human whole blood assay with IC50 values of 7.0 and 7.1 μM, resp.  Our strategy is generally applicable in rational and efficient multitarget drug design, esp. for the design of highly integrated inhibitors for proteins with dissimilar binding pockets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYeSpPS20iL7Vg90H21EOLACvtfcHk0ljMCQtxy-uQxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjvVOnsbY%253D&md5=964c8053de5457730dc369cf8f8ca6a7</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1021%2Fci500021v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci500021v%26sid%3Dliteratum%253Aachs%26aulast%3DShang%26aufirst%3DE.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPei%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DDe%2520Novo%2520Design%2520of%2520Multitarget%2520Ligands%2520with%2520an%2520Iterative%2520Fragment-Growing%2520Strategy%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2014%26volume%3D54%26issue%3D4%26spage%3D1235%26epage%3D1241%26doi%3D10.1021%2Fci500021v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D.
R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehra, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perreault, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erbe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krupka, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">England, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plotnikov, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Signaevsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kral, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantwell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settachatgull, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Womack, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlasuk, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobin, J. F.</span></span> <span> </span><span class="NLM_article-title">Scaffold-Based Discovery of Indeglitazar, a PPAR Pan-Active Anti-Diabetic Agent</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">262</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1073/pnas.0811325106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1073%2Fpnas.0811325106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=19116277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltF2rtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=262-267&issue=1&author=D.%0AR.+Artisauthor=J.+J.+Linauthor=C.+Zhangauthor=W.+Wangauthor=U.+Mehraauthor=M.+Perreaultauthor=D.+Erbeauthor=H.+I.+Krupkaauthor=B.+P.+Englandauthor=J.+Arnoldauthor=A.+N.+Plotnikovauthor=A.+Marimuthuauthor=H.+Nguyenauthor=S.+Willauthor=M.+Signaevskyauthor=J.+Kralauthor=J.+Cantwellauthor=C.+Settachatgullauthor=D.+S.+Yanauthor=D.+Fongauthor=A.+Ohauthor=S.+Shiauthor=P.+Womackauthor=B.+Powellauthor=G.+Habetsauthor=B.+L.+Westauthor=K.+Y.+J.+Zhangauthor=M.+V.+Milburnauthor=G.+P.+Vlasukauthor=K.+P.+Hirthauthor=K.+Nolopauthor=G.+Bollagauthor=P.+N.+Ibrahimauthor=J.+F.+Tobin&title=Scaffold-Based+Discovery+of+Indeglitazar%2C+a+PPAR+Pan-Active+Anti-Diabetic+Agent&doi=10.1073%2Fpnas.0811325106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent</span></div><div class="casAuthors">Artis, Dean R.; Lin, Jack J.; Zhang, Chao; Wang, Weiru; Mehra, Upasana; Perreault, Mylene; Erbe, David; Krupka, Heike I.; England, Bruce P.; Arnold, James; Plotnikov, Alexander N.; Marimuthu, Adhirai; Nguyen, Hoa; Will, Sarah; Signaevsky, Maxime; Kral, John; Cantwell, John; Settachatgull, Alvin; Yan, Douglas S.; Fong, Daniel; Oh, Angela; Shi, Shenghua; Womack, Patrick; Powell, Benjamin; Habets, Gaston; West, Brian L.; Zhang, Kam Y. J.; Milburn, Michael V.; Vlasuk, George P.; Hirth, K. Peter; Nolop, Keith; Bollag, Gideon; Ibrahim, Prabha N.; Tobin, James F.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">262-267</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">In a search for more effective anti-diabetic treatment, we used a process coupling low-affinity biochem. screening with high-throughput co-crystallog. in the design of a series of compds. that selectively modulate the activities of all three peroxisome proliferator-activated receptors (PPARs), PPARα, PPARγ, and PPARδ.  Transcriptional transactivation assays were used to select compds. from this chem. series with a bias toward partial agonism toward PPARγ, to circumvent the clin. obsd. side effects of full PPARγ agonists.  Co-crystallog. characterization of the lead mol., indeglitazar, in complex with each of the 3 PPARs revealed the structural basis for its PPAR pan-activity and its partial agonistic response toward PPARγ.  Compared with full PPARγ-agonists, indeglitazar is less potent in promoting adipocyte differentiation and only partially effective in stimulating adiponectin gene expression.  Evaluation of the compd. in vivo confirmed the reduced adiponectin response in animal models of obesity and diabetes while revealing strong beneficial effects on glucose, triglycerides, cholesterol, body wt., and other metabolic parameters.  Indeglitazar has now progressed to Phase II clin. evaluations for Type 2 diabetes mellitus (T2DM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiPwFlRHVN2bVg90H21EOLACvtfcHk0ljMCQtxy-uQxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltF2rtg%253D%253D&md5=29503488bc79c51644c81d83add9040a</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0811325106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0811325106%26sid%3Dliteratum%253Aachs%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DMehra%26aufirst%3DU.%26aulast%3DPerreault%26aufirst%3DM.%26aulast%3DErbe%26aufirst%3DD.%26aulast%3DKrupka%26aufirst%3DH.%2BI.%26aulast%3DEngland%26aufirst%3DB.%2BP.%26aulast%3DArnold%26aufirst%3DJ.%26aulast%3DPlotnikov%26aufirst%3DA.%2BN.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DWill%26aufirst%3DS.%26aulast%3DSignaevsky%26aufirst%3DM.%26aulast%3DKral%26aufirst%3DJ.%26aulast%3DCantwell%26aufirst%3DJ.%26aulast%3DSettachatgull%26aufirst%3DC.%26aulast%3DYan%26aufirst%3DD.%2BS.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DOh%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DWomack%26aufirst%3DP.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DVlasuk%26aufirst%3DG.%2BP.%26aulast%3DHirth%26aufirst%3DK.%2BP.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DTobin%26aufirst%3DJ.%2BF.%26atitle%3DScaffold-Based%2520Discovery%2520of%2520Indeglitazar%252C%2520a%2520PPAR%2520Pan-Active%2520Anti-Diabetic%2520Agent%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26issue%3D1%26spage%3D262%26epage%3D267%26doi%3D10.1073%2Fpnas.0811325106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blundell, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhoti, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, C.</span></span> <span> </span><span class="NLM_article-title">High-Throughput Crystallography for Lead Discovery in Drug Design</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1038/nrd706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnrd706" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=45-54&issue=1&author=T.+L.+Blundellauthor=H.+Jhotiauthor=C.+Abell&title=High-Throughput+Crystallography+for+Lead+Discovery+in+Drug+Design&doi=10.1038%2Fnrd706"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1038%2Fnrd706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd706%26sid%3Dliteratum%253Aachs%26aulast%3DBlundell%26aufirst%3DT.%2BL.%26aulast%3DJhoti%26aufirst%3DH.%26aulast%3DAbell%26aufirst%3DC.%26atitle%3DHigh-Throughput%2520Crystallography%2520for%2520Lead%2520Discovery%2520in%2520Drug%2520Design%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26issue%3D1%26spage%3D45%26epage%3D54%26doi%3D10.1038%2Fnrd706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span> <span> </span><span class="NLM_article-title">Comparative Assessment of Scoring Functions on an Updated Benchmark: 1. Compilation of the Test Set</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1700</span>– <span class="NLM_lpage">1716</span>, <span class="refDoi"> DOI: 10.1021/ci500080q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci500080q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvFensbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2014&pages=1700-1716&issue=6&author=Y.+Liauthor=Z.+Liuauthor=J.+Liauthor=L.+Hanauthor=J.+Liuauthor=Z.+Zhaoauthor=R.+Wang&title=Comparative+Assessment+of+Scoring+Functions+on+an+Updated+Benchmark%3A+1.+Compilation+of+the+Test+Set&doi=10.1021%2Fci500080q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Assessment of Scoring Functions on an Updated Benchmark: 1. Compilation of the Test Set</span></div><div class="casAuthors">Li, Yan; Liu, Zhihai; Li, Jie; Han, Li; Liu, Jie; Zhao, Zhixiong; Wang, Renxiao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1700-1716</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Scoring functions are often applied in combination with mol. docking methods to predict ligand binding poses and ligand binding affinities or to identify active compds. through virtual screening.  An objective benchmark for assessing the performance of current scoring functions is expected to provide practical guidance for the users to make smart choices among available methods.  It can also elucidate the common weakness in current methods for future improvements.  The primary goal of our comparative assessment of scoring functions (CASF) project is to provide a high-std., publicly accessible benchmark of this type.  Our latest study, i.e., CASF-2013, evaluated 20 popular scoring functions on an updated set of protein-ligand complexes.  This data set was selected out of 8302 protein-ligand complexes recorded in the PDBbind database (version 2013) through a fairly complicated process.  Sample selection was made by considering the quality of complex structures as well as binding data.  Finally, qualified complexes were clustered by 90% similarity in protein sequences.  Three representative complexes were chosen from each cluster to control sample redundancy.  The final outcome, namely, the PDBbind core set (version 2013), consists of 195 protein-ligand complexes in 65 clusters with binding consts. spanning nearly 10 orders of magnitude.  In this data set, 82% of the ligand mols. are "druglike" and 78% of the protein mols. are validated or potential drug targets.  Correlation between binding consts. and several key properties of ligands are discussed.  Methods and results of the scoring function evaluation will be described in a companion work in this issue (doi: 10.1021/ci500081m).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO1hheW8ZvHrVg90H21EOLACvtfcHk0lilQUJ2rLdn7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvFensbk%253D&md5=c10b25fcdad140d69489c2f47dc9c511</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1021%2Fci500080q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci500080q%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DR.%26atitle%3DComparative%2520Assessment%2520of%2520Scoring%2520Functions%2520on%2520an%2520Updated%2520Benchmark%253A%25201.%2520Compilation%2520of%2520the%2520Test%2520Set%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2014%26volume%3D54%26issue%3D6%26spage%3D1700%26epage%3D1716%26doi%3D10.1021%2Fci500080q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schiebel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krimmer, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Röwer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knörlein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stieler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrmann, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radeva, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krug, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huschmann, F. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glöckner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heine, A.</span></span> <span> </span><span class="NLM_article-title">High-Throughput Crystallography: Reliable and Efficient Identification of Fragment Hits</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1398</span>– <span class="NLM_lpage">1409</span>, <span class="refDoi"> DOI: 10.1016/j.str.2016.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.str.2016.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27452405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1eju7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1398-1409&issue=8&author=J.+Schiebelauthor=S.+G.+Krimmerauthor=K.+R%C3%B6werauthor=A.+Kn%C3%B6rleinauthor=X.+Wangauthor=A.+Y.+Parkauthor=M.+Stielerauthor=F.+R.+Ehrmannauthor=K.+Fuauthor=N.+Radevaauthor=M.+Krugauthor=F.+U.+Huschmannauthor=S.+Gl%C3%B6cknerauthor=M.+S.+Weissauthor=U.+Muellerauthor=G.+Klebeauthor=A.+Heine&title=High-Throughput+Crystallography%3A+Reliable+and+Efficient+Identification+of+Fragment+Hits&doi=10.1016%2Fj.str.2016.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">High-Throughput Crystallography: Reliable and Efficient Identification of Fragment Hits</span></div><div class="casAuthors">Schiebel, Johannes; Krimmer, Stefan G.; Roewer, Karine; Knoerlein, Anna; Wang, Xiaojie; Park, Ah Young; Stieler, Martin; Ehrmann, Frederik R.; Fu, Kan; Radeva, Nedyalka; Krug, Michael; Huschmann, Franziska U.; Gloeckner, Steffen; Weiss, Manfred S.; Mueller, Uwe; Klebe, Gerhard; Heine, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1398-1409</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Today the identification of lead structures for drug development often starts from small fragment-like mols. raising the chances to find compds. that successfully pass clin. trials.  At the heart of the screening for fragments binding to a specific target, crystallog. delivers structural information essential for subsequent drug design.  While it is common to search for bound ligands in electron densities calcd. directly after an initial refinement cycle, we raise the important question whether this strategy is viable for fragments characterized by low affinities.  Here, we describe and provide a collection of high-quality diffraction data obtained from 364 protein crystals treated with diverse fragments.  Subsequent data anal. showed that ∼25% of all hits would have been missed without further refining the resulting structures.  To enable fast and reliable hit identification, we have designed an automated refinement pipeline that will inspire the development of optimized tools facilitating the successful application of fragment-based methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZbbkxT06l9rVg90H21EOLACvtfcHk0lilQUJ2rLdn7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1eju7fN&md5=206c30aa2349a4ab285b6f51b746801d</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2016.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2016.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DSchiebel%26aufirst%3DJ.%26aulast%3DKrimmer%26aufirst%3DS.%2BG.%26aulast%3DR%25C3%25B6wer%26aufirst%3DK.%26aulast%3DKn%25C3%25B6rlein%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DPark%26aufirst%3DA.%2BY.%26aulast%3DStieler%26aufirst%3DM.%26aulast%3DEhrmann%26aufirst%3DF.%2BR.%26aulast%3DFu%26aufirst%3DK.%26aulast%3DRadeva%26aufirst%3DN.%26aulast%3DKrug%26aufirst%3DM.%26aulast%3DHuschmann%26aufirst%3DF.%2BU.%26aulast%3DGl%25C3%25B6ckner%26aufirst%3DS.%26aulast%3DWeiss%26aufirst%3DM.%2BS.%26aulast%3DMueller%26aufirst%3DU.%26aulast%3DKlebe%26aufirst%3DG.%26aulast%3DHeine%26aufirst%3DA.%26atitle%3DHigh-Throughput%2520Crystallography%253A%2520Reliable%2520and%2520Efficient%2520Identification%2520of%2520Fragment%2520Hits%26jtitle%3DStructure%26date%3D2016%26volume%3D24%26issue%3D8%26spage%3D1398%26epage%3D1409%26doi%3D10.1016%2Fj.str.2016.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Targeting the Cancer Kinome through Polypharmacology</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1038/nrc2787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnrc2787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=20094047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=130-137&issue=2&author=Z.+A.+Knightauthor=H.+Linauthor=K.+M.+Shokat&title=Targeting+the+Cancer+Kinome+through+Polypharmacology&doi=10.1038%2Fnrc2787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer kinome through polypharmacology</span></div><div class="casAuthors">Knight, Zachary A.; Lin, Henry; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-137</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Kinase inhibitors are the largest class of new cancer drugs.  However, it is already apparent that most tumors can escape from the inhibition of any single kinase.  If it is necessary to inhibit multiple kinases, how do we choose which ones.  In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDv2FeeH58rVg90H21EOLACvtfcHk0lhSykCi3un2pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D&md5=9aaa314e54b43889e147a9f11ac77072</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1038%2Fnrc2787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2787%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DTargeting%2520the%2520Cancer%2520Kinome%2520through%2520Polypharmacology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26issue%3D2%26spage%3D130%26epage%3D137%26doi%3D10.1038%2Fnrc2787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aronov, A.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClain, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moody, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murcko, M. A.</span></span> <span> </span><span class="NLM_article-title">Kinase-Likeness and Kinase-Privileged Fragments: Toward Virtual Polypharmacology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1214</span>– <span class="NLM_lpage">1222</span>, <span class="refDoi"> DOI: 10.1021/jm701021b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701021b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1214-1222&issue=5&author=A.%0AM.+Aronovauthor=B.+McClainauthor=C.+S.+Moodyauthor=M.+A.+Murcko&title=Kinase-Likeness+and+Kinase-Privileged+Fragments%3A+Toward+Virtual+Polypharmacology&doi=10.1021%2Fjm701021b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1021%2Fjm701021b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701021b%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26aulast%3DMcClain%26aufirst%3DB.%26aulast%3DMoody%26aufirst%3DC.%2BS.%26aulast%3DMurcko%26aufirst%3DM.%2BA.%26atitle%3DKinase-Likeness%2520and%2520Kinase-Privileged%2520Fragments%253A%2520Toward%2520Virtual%2520Polypharmacology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D5%26spage%3D1214%26epage%3D1222%26doi%3D10.1021%2Fjm701021b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref226"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref226'); return false;" data-citation="" class="refNumLink">226</a></strong><div class="NLM_citation" id="cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frett, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moccia, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brescia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federico, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Falco, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Admire, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Discovery of a Dual Pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">30</span>),  <span class="NLM_fpage">8717</span>– <span class="NLM_lpage">8721</span>, <span class="refDoi"> DOI: 10.1002/anie.201501104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fanie.201501104" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=8717-8721&issue=30&author=B.+Frettauthor=F.+Carlomagnoauthor=M.+L.+Mocciaauthor=A.+Bresciaauthor=G.+Federicoauthor=V.+De+Falcoauthor=B.+Admireauthor=Z.+Chenauthor=W.+Qiauthor=M.+Santoroauthor=H.+Li&title=Fragment-Based+Discovery+of+a+Dual+Pan-RET%2FVEGFR2+Kinase+Inhibitor+Optimized+for+Single-Agent+Polypharmacology&doi=10.1002%2Fanie.201501104"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1002%2Fanie.201501104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201501104%26sid%3Dliteratum%253Aachs%26aulast%3DFrett%26aufirst%3DB.%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DMoccia%26aufirst%3DM.%2BL.%26aulast%3DBrescia%26aufirst%3DA.%26aulast%3DFederico%26aufirst%3DG.%26aulast%3DDe%2BFalco%26aufirst%3DV.%26aulast%3DAdmire%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DFragment-Based%2520Discovery%2520of%2520a%2520Dual%2520Pan-RET%252FVEGFR2%2520Kinase%2520Inhibitor%2520Optimized%2520for%2520Single-Agent%2520Polypharmacology%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26issue%3D30%26spage%3D8717%26epage%3D8721%26doi%3D10.1002%2Fanie.201501104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref227"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref227'); return false;" data-citation="" class="refNumLink">227</a></strong><div class="NLM_citation" id="cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dar, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cagan, R. L.</span></span> <span> </span><span class="NLM_article-title">Chemical Genetic Discovery of Targets and Anti-Targets for Cancer Polypharmacology</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>486</i></span> (<span class="NLM_issue">7401</span>),  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1038/nature11127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnature11127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=22678283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot1Cnu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=80-84&issue=7401&author=A.+C.+Darauthor=T.+K.+Dasauthor=K.+M.+Shokatauthor=R.+L.+Cagan&title=Chemical+Genetic+Discovery+of+Targets+and+Anti-Targets+for+Cancer+Polypharmacology&doi=10.1038%2Fnature11127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genetic discovery of targets and anti-targets for cancer polypharmacology</span></div><div class="casAuthors">Dar, Arvin C.; Das, Tirtha K.; Shokat, Kevan M.; Cagan, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">7401</span>),
    <span class="NLM_cas:pages">80-84</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The complexity of cancer has led to recent interest in polypharmacol. approaches for developing kinase-inhibitor drugs; however, optimal kinase-inhibition profiles remain difficult to predict.  Using a Ret-kinase-driven Drosophila model of multiple endocrine neoplasia type 2 and kinome-wide drug profiling, here the authors identify that AD57 rescues oncogenic Ret-induced lethality, whereas related Ret inhibitors imparted reduced efficacy and enhanced toxicity.  Drosophila genetics and compd. profiling defined three pathways accounting for the mechanistic basis of efficacy and dose-limiting toxicity.  Inhibition of Ret plus Raf, Src and S6K was required for optimal animal survival, whereas inhibition of the anti-target' Tor led to toxicity owing to release of neg. feedback.  Rational synthetic tailoring to eliminate Tor binding afforded AD80 and AD81, compds. featuring balanced pathway inhibition, improved efficacy and low toxicity in Drosophila and mammalian multiple endocrine neoplasia type 2 models.  Combining kinase-focused chem., kinome-wide profiling and Drosophila genetics provides a powerful systems pharmacol. approach towards developing compds. with a maximal therapeutic index.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3OjBELXO9TbVg90H21EOLACvtfcHk0lhSykCi3un2pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot1Cnu7w%253D&md5=4ed2f85f51453c1b38ee390a0a5f14db</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1038%2Fnature11127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11127%26sid%3Dliteratum%253Aachs%26aulast%3DDar%26aufirst%3DA.%2BC.%26aulast%3DDas%26aufirst%3DT.%2BK.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DCagan%26aufirst%3DR.%2BL.%26atitle%3DChemical%2520Genetic%2520Discovery%2520of%2520Targets%2520and%2520Anti-Targets%2520for%2520Cancer%2520Polypharmacology%26jtitle%3DNature%26date%3D2012%26volume%3D486%26issue%3D7401%26spage%3D80%26epage%3D84%26doi%3D10.1038%2Fnature11127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref228"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref228'); return false;" data-citation="" class="refNumLink">228</a></strong><div class="NLM_citation" id="cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pries, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldmann, H.</span></span> <span> </span><span class="NLM_article-title">Target Identification for Small Bioactive Molecules: Finding the Needle in the Haystack</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2744</span>– <span class="NLM_lpage">2792</span>, <span class="refDoi"> DOI: 10.1002/anie.201208749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fanie.201208749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3sXislSksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=2744-2792&issue=10&author=S.+Zieglerauthor=V.+Priesauthor=C.+Hedbergauthor=H.+Waldmann&title=Target+Identification+for+Small+Bioactive+Molecules%3A+Finding+the+Needle+in+the+Haystack&doi=10.1002%2Fanie.201208749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Target Identification for Small Bioactive Molecules: Finding the Needle in the Haystack</span></div><div class="casAuthors">Ziegler, Slava; Pries, Verena; Hedberg, Christian; Waldmann, Herbert</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2744-2792</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Identification and confirmation of bioactive small-mol. targets is a crucial, often decisive step both in academic and pharmaceutical research.  Through the development and availability of several new exptl. techniques, target identification is, in principle, feasible, and the no. of successful examples steadily grows.  However, a generic methodol. that can successfully be applied in the majority of the cases has not yet been established.  Herein we summarize current methods for target identification of small mols., primarily for a chem. audience but also the biol. community, for example, the chemist or biologist attempting to identify the target of a given bioactive compd.  We describe the most frequently employed exptl. approaches for target identification and provide several representative examples illustrating the state-of-the-art.  Among the techniques currently available, protein affinity isolation using suitable small-mol. probes (pulldown) and subsequent mass spectrometric anal. of the isolated proteins appears to be most powerful and most frequently applied.  To provide guidance for rapid entry into the field and based on our own experience we propose a typical workflow for target identification, which centers on the application of chem. proteomics as the key step to generate hypotheses for potential target proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYC9-7L3abMrVg90H21EOLACvtfcHk0lhSykCi3un2pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXislSksLk%253D&md5=3a124205e3a57a53f479b889073bda76</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1002%2Fanie.201208749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201208749%26sid%3Dliteratum%253Aachs%26aulast%3DZiegler%26aufirst%3DS.%26aulast%3DPries%26aufirst%3DV.%26aulast%3DHedberg%26aufirst%3DC.%26aulast%3DWaldmann%26aufirst%3DH.%26atitle%3DTarget%2520Identification%2520for%2520Small%2520Bioactive%2520Molecules%253A%2520Finding%2520the%2520Needle%2520in%2520the%2520Haystack%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26issue%3D10%26spage%3D2744%26epage%3D2792%26doi%3D10.1002%2Fanie.201208749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref229"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref229'); return false;" data-citation="" class="refNumLink">229</a></strong><div class="NLM_citation" id="cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, C.</span></span> <span> </span><span class="NLM_article-title">Identification of Protein Binding Partners of Small Molecules Using Label-Free Methods</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1017</span>– <span class="NLM_lpage">1025</span>, <span class="refDoi"> DOI: 10.1080/17460441.2016.1227316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1080%2F17460441.2016.1227316" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1017-1025&issue=10&author=C.+Saxena&title=Identification+of+Protein+Binding+Partners+of+Small+Molecules+Using+Label-Free+Methods&doi=10.1080%2F17460441.2016.1227316"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1080%2F17460441.2016.1227316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2016.1227316%26sid%3Dliteratum%253Aachs%26aulast%3DSaxena%26aufirst%3DC.%26atitle%3DIdentification%2520of%2520Protein%2520Binding%2520Partners%2520of%2520Small%2520Molecules%2520Using%2520Label-Free%2520Methods%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2016%26volume%3D11%26issue%3D10%26spage%3D1017%26epage%3D1025%26doi%3D10.1080%2F17460441.2016.1227316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref230"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref230'); return false;" data-citation="" class="refNumLink">230</a></strong><div class="NLM_citation" id="cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lomenick, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aghajan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warburton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlschlegel, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vondriska, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herschman, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clardy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span> <span> </span><span class="NLM_article-title">Target Identification Using Drug Affinity Responsive Target Stability (DARTS)</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">51</span>),  <span class="NLM_fpage">21984</span>– <span class="NLM_lpage">21989</span>, <span class="refDoi"> DOI: 10.1073/pnas.0910040106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1073%2Fpnas.0910040106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=19995983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlt1aiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=21984-21989&issue=51&author=B.+Lomenickauthor=R.+Haoauthor=N.+Jonaiauthor=R.+M.+Chinauthor=M.+Aghajanauthor=S.+Warburtonauthor=J.+Wangauthor=R.+P.+Wuauthor=F.+Gomezauthor=J.+A.+Looauthor=J.+A.+Wohlschlegelauthor=T.+M.+Vondriskaauthor=J.+Pelletierauthor=H.+R.+Herschmanauthor=J.+Clardyauthor=C.+F.+Clarkeauthor=J.+Huang&title=Target+Identification+Using+Drug+Affinity+Responsive+Target+Stability+%28DARTS%29&doi=10.1073%2Fpnas.0910040106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Target identification using drug affinity responsive target stability (DARTS)</span></div><div class="casAuthors">Lomenick, Brett; Hao, Rui; Jonai, Nao; Chin, Randall M.; Aghajan, Mariam; Warburton, Sarah; Wang, Jianing; Wu, Raymond P.; Gomez, Fernando; Loo, Joseph A.; Wohlschlegel, James A.; Vondriska, Thomas M.; Pelletier, Jerry; Herschman, Harvey R.; Clardy, Jon; Clarke, Catherine F.; Huang, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">21984-21989, S21984/1-S21984/14</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Identifying the mol. targets for the beneficial or detrimental effects of small-mol. drugs is an important and currently unmet challenge.  We have developed a method, drug affinity responsive target stability (DARTS), which takes advantage of a redn. in the protease susceptibility of the target protein upon drug binding.  DARTS is universally applicable because it requires no modification of the drug and is independent of the mechanism of drug action.  We demonstrate use of DARTS to identify known small-mol.-protein interactions and to reveal the eukaryotic translation initiation machinery as a mol. target for the longevity-enhancing plant natural product resveratrol.  We envisage that DARTS will also be useful in global mapping of protein-metabolite interaction networks and in label-free screening of unlimited varieties of compds. for development as mol. imaging agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBFsvOPfmmaLVg90H21EOLACvtfcHk0lgO5ErJyvBTCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlt1aiug%253D%253D&md5=0f14bce633a1ce0af6d95ad13876e405</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0910040106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0910040106%26sid%3Dliteratum%253Aachs%26aulast%3DLomenick%26aufirst%3DB.%26aulast%3DHao%26aufirst%3DR.%26aulast%3DJonai%26aufirst%3DN.%26aulast%3DChin%26aufirst%3DR.%2BM.%26aulast%3DAghajan%26aufirst%3DM.%26aulast%3DWarburton%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DR.%2BP.%26aulast%3DGomez%26aufirst%3DF.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DWohlschlegel%26aufirst%3DJ.%2BA.%26aulast%3DVondriska%26aufirst%3DT.%2BM.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DHerschman%26aufirst%3DH.%2BR.%26aulast%3DClardy%26aufirst%3DJ.%26aulast%3DClarke%26aufirst%3DC.%2BF.%26aulast%3DHuang%26aufirst%3DJ.%26atitle%3DTarget%2520Identification%2520Using%2520Drug%2520Affinity%2520Responsive%2520Target%2520Stability%2520%2528DARTS%2529%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26issue%3D51%26spage%3D21984%26epage%3D21989%26doi%3D10.1073%2Fpnas.0910040106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref231"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref231'); return false;" data-citation="" class="refNumLink">231</a></strong><div class="NLM_citation" id="cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez Molina, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jafari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ignatushchenko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreekumar, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordlund, P.</span></span> <span> </span><span class="NLM_article-title">Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1126/science.1233606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1126%2Fscience.1233606" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=23828940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC3sjotlOqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2013&pages=84-87&author=D.+Martinez+Molinaauthor=R.+Jafariauthor=M.+Ignatushchenkoauthor=T.+Sekiauthor=E.+A.+Larssonauthor=C.+Danauthor=L.+Sreekumarauthor=Y.+Caoauthor=P.+Nordlund&title=Monitoring+Drug+Target+Engagement+in+Cells+and+Tissues+Using+the+Cellular+Thermal+Shift+Assay&doi=10.1126%2Fscience.1233606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay</span></div><div class="casAuthors">Martinez Molina Daniel; Jafari Rozbeh; Ignatushchenko Marina; Seki Takahiro; Larsson E Andreas; Dan Chen; Sreekumar Lekshmy; Cao Yihai; Nordlund Par</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">6141</span>),
    <span class="NLM_cas:pages">84-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The efficacy of therapeutics is dependent on a drug binding to its cognate target.  Optimization of target engagement by drugs in cells is often challenging, because drug binding cannot be monitored inside cells.  We have developed a method for evaluating drug binding to target proteins in cells and tissue samples.  This cellular thermal shift assay (CETSA) is based on the biophysical principle of ligand-induced thermal stabilization of target proteins.  Using this assay, we validated drug binding for a set of important clinical targets and monitored processes of drug transport and activation, off-target effects and drug resistance in cancer cell lines, as well as drug distribution in tissues.  CETSA is likely to become a valuable tool for the validation and optimization of drug target engagement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRRn5K_mF1rcrHHuJhbyicZfW6udTcc2eZWzwnGxi_ki7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjotlOqtA%253D%253D&md5=a73bb49adb0d4f445223ea6f74fe3c10</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1126%2Fscience.1233606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1233606%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%2BMolina%26aufirst%3DD.%26aulast%3DJafari%26aufirst%3DR.%26aulast%3DIgnatushchenko%26aufirst%3DM.%26aulast%3DSeki%26aufirst%3DT.%26aulast%3DLarsson%26aufirst%3DE.%2BA.%26aulast%3DDan%26aufirst%3DC.%26aulast%3DSreekumar%26aufirst%3DL.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DNordlund%26aufirst%3DP.%26atitle%3DMonitoring%2520Drug%2520Target%2520Engagement%2520in%2520Cells%2520and%2520Tissues%2520Using%2520the%2520Cellular%2520Thermal%2520Shift%2520Assay%26jtitle%3DScience%26date%3D2013%26volume%3D341%26spage%3D84%26epage%3D87%26doi%3D10.1126%2Fscience.1233606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref232"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref232'); return false;" data-citation="" class="refNumLink">232</a></strong><div class="NLM_citation" id="cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schulz-Fincke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robaa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kürner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greve, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haydn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lübbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lüdeke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schüle, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Studies on N-Substituted Tranylcypromine Derivatives Lead to Selective Inhibitors of Lysine Specific Demethylase 1 (LSD1) and Potent Inducers of Leukemic Cell Differentiation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">52</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.ejmech.2017.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29247860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFyju7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2018&pages=52-67&author=J.+Schulz-Finckeauthor=M.+Hauauthor=J.+Barthauthor=D.+Robaaauthor=D.+Willmannauthor=A.+K%C3%BCrnerauthor=J.+Haasauthor=G.+Greveauthor=T.+Haydnauthor=S.+Fuldaauthor=M.+L%C3%BCbbertauthor=S.+L%C3%BCdekeauthor=T.+Bergauthor=W.+Sipplauthor=R.+Sch%C3%BCleauthor=M.+Jung&title=Structure-Activity+Studies+on+N-Substituted+Tranylcypromine+Derivatives+Lead+to+Selective+Inhibitors+of+Lysine+Specific+Demethylase+1+%28LSD1%29+and+Potent+Inducers+of+Leukemic+Cell+Differentiation&doi=10.1016%2Fj.ejmech.2017.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation</span></div><div class="casAuthors">Schulz-Fincke, Johannes; Hau, Mirjam; Barth, Jessica; Robaa, Dina; Willmann, Dominica; Kuerner, Andreas; Haas, Julian; Greve, Gabriele; Haydn, Tinka; Fulda, Simone; Luebbert, Michael; Luedeke, Steffen; Berg, Tobias; Sippl, Wolfgang; Schuele, Roland; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">52-67</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">FAD-dependent lysine-specific demethylase 1 (LSD1) is overexpressed or deregulated in many cancers such as AML and prostate cancer and hence is a promising anticancer target with first inhibitors in clin. trials.  Clin. candidates are N-substituted derivs. of the dual LSD1-/monoamine oxidase-inhibitor tranylcypromine (2-PCPA) with a basic amine function in the N-substituent.  These derivs. are selective over monoamine oxidases.  So far, only very limited information on structure-activity studies about this important class of LSD1 inhibitors is published in peer reviewed journals.  Here, we show that N-substituted 2-PCPA derivs. without a basic function or even a polar group are still potent inhibitors of LSD1 in vitro and effectively inhibit colony formation of leukemic cells in culture.  Yet, these lipophilic inhibitors also block the structurally related monoamine oxidases (MAO-A and MAO-B), which may be of interest for the treatment of neurodegenerative disorders, but this property is undesired for applications in cancer treatment.  The introduction of a polar, non-basic function led to optimized structures that retain potent LSD1 inhibitors but exhibit selectivity over MAOs and are highly potent in the suppression of colony formation of cultured leukemic cells.  Cellular target engagement is shown via a Cellular Thermal Shift Assay (CETSA) for LSD1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS7XCIKeZiVrVg90H21EOLACvtfcHk0ljSBq-0we9ARw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFyju7zN&md5=f9460e47baf69fb33d4e314564591bd4</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DSchulz-Fincke%26aufirst%3DJ.%26aulast%3DHau%26aufirst%3DM.%26aulast%3DBarth%26aufirst%3DJ.%26aulast%3DRobaa%26aufirst%3DD.%26aulast%3DWillmann%26aufirst%3DD.%26aulast%3DK%25C3%25BCrner%26aufirst%3DA.%26aulast%3DHaas%26aufirst%3DJ.%26aulast%3DGreve%26aufirst%3DG.%26aulast%3DHaydn%26aufirst%3DT.%26aulast%3DFulda%26aufirst%3DS.%26aulast%3DL%25C3%25BCbbert%26aufirst%3DM.%26aulast%3DL%25C3%25BCdeke%26aufirst%3DS.%26aulast%3DBerg%26aufirst%3DT.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DSch%25C3%25BCle%26aufirst%3DR.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DStructure-Activity%2520Studies%2520on%2520N-Substituted%2520Tranylcypromine%2520Derivatives%2520Lead%2520to%2520Selective%2520Inhibitors%2520of%2520Lysine%2520Specific%2520Demethylase%25201%2520%2528LSD1%2529%2520and%2520Potent%2520Inducers%2520of%2520Leukemic%2520Cell%2520Differentiation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D144%26spage%3D52%26epage%3D67%26doi%3D10.1016%2Fj.ejmech.2017.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref233"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref233'); return false;" data-citation="" class="refNumLink">233</a></strong><div class="NLM_citation" id="cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franken, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Childs, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweetman, G. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tögel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doce, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gade, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhard, F. B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savitski, M. M.</span></span> <span> </span><span class="NLM_article-title">Thermal Proteome Profiling for Unbiased Identification of Direct and Indirect Drug Targets Using Multiplexed Quantitative Mass Spectrometry</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1567</span>– <span class="NLM_lpage">1593</span>, <span class="refDoi"> DOI: 10.1038/nprot.2015.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnprot.2015.101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=26379230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVyrtbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1567-1593&issue=10&author=H.+Frankenauthor=T.+Mathiesonauthor=D.+Childsauthor=G.+M.+A.+Sweetmanauthor=T.+Wernerauthor=I.+T%C3%B6gelauthor=C.+Doceauthor=S.+Gadeauthor=M.+Bantscheffauthor=G.+Drewesauthor=F.+B.+M.+Reinhardauthor=W.+Huberauthor=M.+M.+Savitski&title=Thermal+Proteome+Profiling+for+Unbiased+Identification+of+Direct+and+Indirect+Drug+Targets+Using+Multiplexed+Quantitative+Mass+Spectrometry&doi=10.1038%2Fnprot.2015.101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry</span></div><div class="casAuthors">Franken, Holger; Mathieson, Toby; Childs, Dorothee; Sweetman, Gavain M. A.; Werner, Thilo; Toegel, Ina; Doce, Carola; Gade, Stephan; Bantscheff, Marcus; Drewes, Gerard; Reinhard, Friedrich B. M.; Huber, Wolfgang; Savitski, Mikhail M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1567-1593</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The direct detection of drug-protein interactions in living cells is a major challenge in drug discovery research.  Recently, the authors introduced an approach termed thermal proteome profiling (TPP), which enables the monitoring of changes in protein thermal stability across the proteome using quant. mass spectrometry.  The authors detd. the intracellular thermal profiles for up to 7000 proteins, and by comparing profiles derived from cultured mammalian cells in the presence or absence of a drug it was possible to identify direct and indirect targets of drugs in living cells in an unbiased manner.  Here the authors demonstrate the complete workflow using the histone deacetylase inhibitor panobinostat.  The key to this approach is the use of isobaric tandem mass tag 10-plex (TMT10) reagents to label digested protein samples corresponding to each temp. point in the melting curve so that the samples can be analyzed by multiplexed quant. mass spectrometry.  Important steps in the bioinformatic anal. include data normalization, melting curve fitting and statistical significance detn. of compd. concn.-dependent changes in protein stability.  All anal. tools are made freely available as R and Python packages.  The workflow can be completed in 2 wk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS4LU9YprZqLVg90H21EOLACvtfcHk0ljSBq-0we9ARw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVyrtbzN&md5=d9c225616a35fc5dcc97db234452d7e1</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2015.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2015.101%26sid%3Dliteratum%253Aachs%26aulast%3DFranken%26aufirst%3DH.%26aulast%3DMathieson%26aufirst%3DT.%26aulast%3DChilds%26aufirst%3DD.%26aulast%3DSweetman%26aufirst%3DG.%2BM.%2BA.%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DT%25C3%25B6gel%26aufirst%3DI.%26aulast%3DDoce%26aufirst%3DC.%26aulast%3DGade%26aufirst%3DS.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DReinhard%26aufirst%3DF.%2BB.%2BM.%26aulast%3DHuber%26aufirst%3DW.%26aulast%3DSavitski%26aufirst%3DM.%2BM.%26atitle%3DThermal%2520Proteome%2520Profiling%2520for%2520Unbiased%2520Identification%2520of%2520Direct%2520and%2520Indirect%2520Drug%2520Targets%2520Using%2520Multiplexed%2520Quantitative%2520Mass%2520Spectrometry%26jtitle%3DNat.%2520Protoc.%26date%3D2015%26volume%3D10%26issue%3D10%26spage%3D1567%26epage%3D1593%26doi%3D10.1038%2Fnprot.2015.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref234"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref234'); return false;" data-citation="" class="refNumLink">234</a></strong><div class="NLM_citation" id="cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reinhard, F. B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberhard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franken, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Childs, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doce, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savitski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savitski, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span> <span> </span><span class="NLM_article-title">Thermal Proteome Profiling Monitors Ligand Interactions with Cellular Membrane Proteins</span>. <i>Nat. Methods</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1129</span>– <span class="NLM_lpage">1131</span>, <span class="refDoi"> DOI: 10.1038/nmeth.3652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnmeth.3652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=26524241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKgt7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=1129-1131&issue=12&author=F.+B.+M.+Reinhardauthor=D.+Eberhardauthor=T.+Wernerauthor=H.+Frankenauthor=D.+Childsauthor=C.+Doceauthor=M.+F.+Savitskiauthor=W.+Huberauthor=M.+Bantscheffauthor=M.+M.+Savitskiauthor=G.+Drewes&title=Thermal+Proteome+Profiling+Monitors+Ligand+Interactions+with+Cellular+Membrane+Proteins&doi=10.1038%2Fnmeth.3652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">Thermal proteome profiling monitors ligand interactions with cellular membrane proteins</span></div><div class="casAuthors">Reinhard, Friedrich B. M.; Eberhard, Dirk; Werner, Thilo; Franken, Holger; Childs, Dorothee; Doce, Carola; Savitski, Maria Faelth; Huber, Wolfgang; Bantscheff, Marcus; Savitski, Mikhail M.; Drewes, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Methods</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1129-1131</span>CODEN:
                <span class="NLM_cas:coden">NMAEA3</span>;
        ISSN:<span class="NLM_cas:issn">1548-7091</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We extended thermal proteome profiling to detect transmembrane protein-small mol. interactions in cultured human cells.  When we assessed the effects of detergents on ATP-binding profiles, we obsd. shifts in denaturation temp. for ATP-binding transmembrane proteins.  We also obsd. cellular thermal shifts in pervanadate-induced T cell-receptor signaling, delineating the membrane target CD45 and components of the downstream pathway, and with drugs affecting the transmembrane transporters ATP1A1 and MDR1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo45i1e8jbFF7Vg90H21EOLACvtfcHk0ljSBq-0we9ARw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKgt7fO&md5=ec4651a2753f7969b16811faa8affa23</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1038%2Fnmeth.3652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmeth.3652%26sid%3Dliteratum%253Aachs%26aulast%3DReinhard%26aufirst%3DF.%2BB.%2BM.%26aulast%3DEberhard%26aufirst%3DD.%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DFranken%26aufirst%3DH.%26aulast%3DChilds%26aufirst%3DD.%26aulast%3DDoce%26aufirst%3DC.%26aulast%3DSavitski%26aufirst%3DM.%2BF.%26aulast%3DHuber%26aufirst%3DW.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DSavitski%26aufirst%3DM.%2BM.%26aulast%3DDrewes%26aufirst%3DG.%26atitle%3DThermal%2520Proteome%2520Profiling%2520Monitors%2520Ligand%2520Interactions%2520with%2520Cellular%2520Membrane%2520Proteins%26jtitle%3DNat.%2520Methods%26date%3D2015%26volume%3D12%26issue%3D12%26spage%3D1129%26epage%3D1131%26doi%3D10.1038%2Fnmeth.3652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref235"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref235'); return false;" data-citation="" class="refNumLink">235</a></strong><div class="NLM_citation" id="cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savitski, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhard, F. B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franken, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savitski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberhard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez
Molina, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jafari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dovega, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaeger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuster, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordlund, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span> <span> </span><span class="NLM_article-title">Tracking Cancer Drugs in Living Cells by Thermal Profiling of the Proteome</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>346</i></span> (<span class="NLM_issue">6205</span>),  <span class="NLM_fpage">1255784</span>, <span class="refDoi"> DOI: 10.1126/science.1255784</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1126%2Fscience.1255784" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=25278616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC2M7ntVKgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2014&pages=1255784&issue=6205&author=M.+M.+Savitskiauthor=F.+B.+M.+Reinhardauthor=H.+Frankenauthor=T.+Wernerauthor=M.+F.+Savitskiauthor=D.+Eberhardauthor=D.+Martinez%0AMolinaauthor=R.+Jafariauthor=R.+B.+Dovegaauthor=S.+Klaegerauthor=B.+Kusterauthor=P.+Nordlundauthor=M.+Bantscheffauthor=G.+Drewes&title=Tracking+Cancer+Drugs+in+Living+Cells+by+Thermal+Profiling+of+the+Proteome&doi=10.1126%2Fscience.1255784"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Tracking cancer drugs in living cells by thermal profiling of the proteome</span></div><div class="casAuthors">Savitski Mikhail M; Reinhard Friedrich B M; Franken Holger; Werner Thilo; Savitski Maria Falth; Eberhard Dirk; Bantscheff Marcus; Drewes Gerard; Martinez Molina Daniel; Jafari Rozbeh; Dovega Rebecca Bakszt; Klaeger Susan; Kuster Bernhard; Nordlund Par</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">6205</span>),
    <span class="NLM_cas:pages">1255784</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The thermal stability of proteins can be used to assess ligand binding in living cells.  We have generalized this concept by determining the thermal profiles of more than 7000 proteins in human cells by means of mass spectrometry.  Monitoring the effects of small-molecule ligands on the profiles delineated more than 50 targets for the kinase inhibitor staurosporine.  We identified the heme biosynthesis enzyme ferrochelatase as a target of kinase inhibitors and suggest that its inhibition causes the phototoxicity observed with vemurafenib and alectinib.  Thermal shifts were also observed for downstream effectors of drug treatment.  In live cells, dasatinib induced shifts in BCR-ABL pathway proteins, including CRK/CRKL.  Thermal proteome profiling provides an unbiased measure of drug-target engagement and facilitates identification of markers for drug efficacy and toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0ur3d8ba-Bu2mnZh2OgS0fW6udTcc2eaiSNzGfFewDLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7ntVKgsg%253D%253D&md5=493a89ad107e656e0f0786ff5c8e5f63</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1126%2Fscience.1255784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1255784%26sid%3Dliteratum%253Aachs%26aulast%3DSavitski%26aufirst%3DM.%2BM.%26aulast%3DReinhard%26aufirst%3DF.%2BB.%2BM.%26aulast%3DFranken%26aufirst%3DH.%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DSavitski%26aufirst%3DM.%2BF.%26aulast%3DEberhard%26aufirst%3DD.%26aulast%3DMartinez%2BMolina%26aufirst%3DD.%26aulast%3DJafari%26aufirst%3DR.%26aulast%3DDovega%26aufirst%3DR.%2BB.%26aulast%3DKlaeger%26aufirst%3DS.%26aulast%3DKuster%26aufirst%3DB.%26aulast%3DNordlund%26aufirst%3DP.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DDrewes%26aufirst%3DG.%26atitle%3DTracking%2520Cancer%2520Drugs%2520in%2520Living%2520Cells%2520by%2520Thermal%2520Profiling%2520of%2520the%2520Proteome%26jtitle%3DScience%26date%3D2014%26volume%3D346%26issue%3D6205%26spage%3D1255784%26doi%3D10.1126%2Fscience.1255784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref236"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref236'); return false;" data-citation="" class="refNumLink">236</a></strong><div class="NLM_citation" id="cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hengst, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geffert, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kester, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughran, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulson, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claxton, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J. K.</span></span> <span> </span><span class="NLM_article-title">SKI-178: A Multitargeted Inhibitor of Sphingosine Kinase and Microtubule Dynamics Demonstrating Therapeutic Efficacy in Acute Myeloid Leukemia Models</span>. <i>Cancer Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.4103/ctm.ctm_7_17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.4103%2Fctm.ctm_7_17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28890935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFOhtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=109-121&issue=4&author=J.+A.+Hengstauthor=T.+E.+Dickauthor=A.+Sharmaauthor=K.+Doiauthor=S.+Hegdeauthor=S.-F.+Tanauthor=L.+M.+Geffertauthor=T.+E.+Foxauthor=A.+K.+Sharmaauthor=D.+Desaiauthor=S.+Aminauthor=M.+Kesterauthor=T.+P.+Loughranauthor=R.+F.+Paulsonauthor=D.+F.+Claxtonauthor=H.-G.+Wangauthor=J.+K.+Yun&title=SKI-178%3A+A+Multitargeted+Inhibitor+of+Sphingosine+Kinase+and+Microtubule+Dynamics+Demonstrating+Therapeutic+Efficacy+in+Acute+Myeloid+Leukemia+Models&doi=10.4103%2Fctm.ctm_7_17"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">SKI-178: a multitargeted inhibitor of sphingosine kinase and microtubule dynamics demonstrating therapeutic efficacy in acute myeloid leukemia models</span></div><div class="casAuthors">Hengst, Jeremy A.; Dick, Taryn E.; Sharma, Arati; Doi, Kenichiro; Hegde, Shailaja; Tan, Su-Fern; Geffert, Laura M.; Fox, Todd E.; Sharma, Arun K.; Desai, Dhimant; Amin, Shantu; Kester, Mark; Loughran, Thomas P.; Paulson, Robert F.; Claxton, David F.; Wang, Hong-Gang; Yun, Jong K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Translational Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">109-121, S1</span>CODEN:
                <span class="NLM_cas:coden">CTMABE</span>;
        ISSN:<span class="NLM_cas:issn">2395-3012</span>.
    
            (<span class="NLM_cas:orgname">Medknow Publications</span>)
        </div><div class="casAbstract">Aim: To further characterize the selectivity, mechanism of action, and therapeutic efficacy of the novel small mol. inhibitor, SKI-178.  Methods: We used the state-of-the-art cellular thermal shift assay technique to detect "direct target engagement" of proteins in intact cells.  In vitro and in vivo assays, pharmacol. assays, and multiple mouse models of acute myeloid leukemia (AML) were also used.  Results: Herein, we demonstrate that SKI-178 directly target engages both sphingosine kinase 1 and 2 (SphK1 and 2).  We also present evidence that, in addn. to its actions as a sphingosine kinase inhibitor, SKI-178 functions as a microtubule network disrupting agent both in vitro and in intact cells.  Interestingly, we sep. demonstrate that simultaneous SphK inhibition and microtubule disruption synergistically induce apoptosis in AML cell lines.  Furthermore, we demonstrate that SKI-178 is well tolerated in normal healthy mice.  Most importantly, we demonstrate that SKI-178 has therapeutic efficacy in several mouse models of AML.  Conclusion: SKI-178 is a multitargeted agent that functions both as an inhibitor of the SphKs as well as a disruptor of the microtubule network.  SKI-178-induced apoptosis arises from a synergistic interaction of these two activities.  SKI-178 is safe and effective in mouse models of AML, supporting its further development as a multitargeted anticancer therapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4CVSGc0jL9LVg90H21EOLACvtfcHk0liC6R8kvW1icg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFOhtL7I&md5=ef8a162ad34dbdc947433d302cced3d7</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.4103%2Fctm.ctm_7_17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252Fctm.ctm_7_17%26sid%3Dliteratum%253Aachs%26aulast%3DHengst%26aufirst%3DJ.%2BA.%26aulast%3DDick%26aufirst%3DT.%2BE.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DDoi%26aufirst%3DK.%26aulast%3DHegde%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DS.-F.%26aulast%3DGeffert%26aufirst%3DL.%2BM.%26aulast%3DFox%26aufirst%3DT.%2BE.%26aulast%3DSharma%26aufirst%3DA.%2BK.%26aulast%3DDesai%26aufirst%3DD.%26aulast%3DAmin%26aufirst%3DS.%26aulast%3DKester%26aufirst%3DM.%26aulast%3DLoughran%26aufirst%3DT.%2BP.%26aulast%3DPaulson%26aufirst%3DR.%2BF.%26aulast%3DClaxton%26aufirst%3DD.%2BF.%26aulast%3DWang%26aufirst%3DH.-G.%26aulast%3DYun%26aufirst%3DJ.%2BK.%26atitle%3DSKI-178%253A%2520A%2520Multitargeted%2520Inhibitor%2520of%2520Sphingosine%2520Kinase%2520and%2520Microtubule%2520Dynamics%2520Demonstrating%2520Therapeutic%2520Efficacy%2520in%2520Acute%2520Myeloid%2520Leukemia%2520Models%26jtitle%3DCancer%2520Transl.%2520Med.%26date%3D2017%26volume%3D3%26issue%3D4%26spage%3D109%26epage%3D121%26doi%3D10.4103%2Fctm.ctm_7_17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref237"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref237'); return false;" data-citation="" class="refNumLink">237</a></strong><div class="NLM_citation" id="cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberhard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastuck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boesche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reader, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweetman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouwmeester, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsden, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuster, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span> <span> </span><span class="NLM_article-title">Quantitative Chemical Proteomics Reveals Mechanisms of Action of Clinical ABL Kinase Inhibitors</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1035</span>– <span class="NLM_lpage">1044</span>, <span class="refDoi"> DOI: 10.1038/nbt1328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnbt1328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=17721511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVWksLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=1035-1044&issue=9&author=M.+Bantscheffauthor=D.+Eberhardauthor=Y.+Abrahamauthor=S.+Bastuckauthor=M.+Boescheauthor=S.+Hobsonauthor=T.+Mathiesonauthor=J.+Perrinauthor=M.+Raidaauthor=C.+Rauauthor=V.+Readerauthor=G.+Sweetmanauthor=A.+Bauerauthor=T.+Bouwmeesterauthor=C.+Hopfauthor=U.+Kruseauthor=G.+Neubauerauthor=N.+Ramsdenauthor=J.+Rickauthor=B.+Kusterauthor=G.+Drewes&title=Quantitative+Chemical+Proteomics+Reveals+Mechanisms+of+Action+of+Clinical+ABL+Kinase+Inhibitors&doi=10.1038%2Fnbt1328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors</span></div><div class="casAuthors">Bantscheff, Marcus; Eberhard, Dirk; Abraham, Yann; Bastuck, Sonja; Boesche, Markus; Hobson, Scott; Mathieson, Toby; Perrin, Jessica; Raida, Manfred; Rau, Christina; Reader, Valerie; Sweetman, Gavain; Bauer, Andreas; Bouwmeester, Tewis; Hopf, Carsten; Kruse, Ulrich; Neubauer, Gitte; Ramsden, Nigel; Rick, Jens; Kuster, Bernhard; Drewes, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1035-1044</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors describe a chem. proteomics approach to profile the interaction of small mols. with hundreds of endogenously expressed protein kinases and purine-binding proteins.  This subproteome is captured by immobilized nonselective kinase inhibitors (kinobeads), and the bound proteins are quantified in parallel by mass spectrometry using isobaric tags for relative and abs. quantification (iTRAQ).  By measuring the competition with the affinity matrix, the authors assess the binding of drugs to their targets in cell lysates and in cells.  By mapping drug-induced changes in the phosphorylation state of the captured proteome, the authors also analyze signaling pathways downstream of target kinases.  Quant. profiling of the drugs imatinib (Gleevec), dasatinib (Sprycel) and bosutinib in K562 cells confirms known targets including ABL and SRC family kinases and identifies the receptor tyrosine kinase DDR1 and the oxidoreductase NQO2 as novel targets of imatinib.  The data suggest that the approach is a valuable tool for drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsC3OpIuhl8LVg90H21EOLACvtfcHk0liC6R8kvW1icg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVWksLvF&md5=ed20d4684a8a6733aba24ca64602bae8</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1038%2Fnbt1328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1328%26sid%3Dliteratum%253Aachs%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DEberhard%26aufirst%3DD.%26aulast%3DAbraham%26aufirst%3DY.%26aulast%3DBastuck%26aufirst%3DS.%26aulast%3DBoesche%26aufirst%3DM.%26aulast%3DHobson%26aufirst%3DS.%26aulast%3DMathieson%26aufirst%3DT.%26aulast%3DPerrin%26aufirst%3DJ.%26aulast%3DRaida%26aufirst%3DM.%26aulast%3DRau%26aufirst%3DC.%26aulast%3DReader%26aufirst%3DV.%26aulast%3DSweetman%26aufirst%3DG.%26aulast%3DBauer%26aufirst%3DA.%26aulast%3DBouwmeester%26aufirst%3DT.%26aulast%3DHopf%26aufirst%3DC.%26aulast%3DKruse%26aufirst%3DU.%26aulast%3DNeubauer%26aufirst%3DG.%26aulast%3DRamsden%26aufirst%3DN.%26aulast%3DRick%26aufirst%3DJ.%26aulast%3DKuster%26aufirst%3DB.%26aulast%3DDrewes%26aufirst%3DG.%26atitle%3DQuantitative%2520Chemical%2520Proteomics%2520Reveals%2520Mechanisms%2520of%2520Action%2520of%2520Clinical%2520ABL%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26issue%3D9%26spage%3D1035%26epage%3D1044%26doi%3D10.1038%2Fnbt1328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref238"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref238'); return false;" data-citation="" class="refNumLink">238</a></strong><div class="NLM_citation" id="cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mazaleuskaya, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesaros, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricciotti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FitzGerald, G. A.</span></span> <span> </span><span class="NLM_article-title">A Broad-Spectrum Lipidomics Screen of Antiinflammatory Drug Combinations in Human Blood</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">e87031</span>, <span class="refDoi"> DOI: 10.1172/jci.insight.87031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1172%2Fjci.insight.87031" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=e87031&author=L.+L.+Mazaleuskayaauthor=J.+A.+Lawsonauthor=X.+Liauthor=G.+Grantauthor=C.+Mesarosauthor=T.+Grosserauthor=I.+A.+Blairauthor=E.+Ricciottiauthor=G.+A.+FitzGerald&title=A+Broad-Spectrum+Lipidomics+Screen+of+Antiinflammatory+Drug+Combinations+in+Human+Blood&doi=10.1172%2Fjci.insight.87031"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.87031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.87031%26sid%3Dliteratum%253Aachs%26aulast%3DMazaleuskaya%26aufirst%3DL.%2BL.%26aulast%3DLawson%26aufirst%3DJ.%2BA.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DGrant%26aufirst%3DG.%26aulast%3DMesaros%26aufirst%3DC.%26aulast%3DGrosser%26aufirst%3DT.%26aulast%3DBlair%26aufirst%3DI.%2BA.%26aulast%3DRicciotti%26aufirst%3DE.%26aulast%3DFitzGerald%26aufirst%3DG.%2BA.%26atitle%3DA%2520Broad-Spectrum%2520Lipidomics%2520Screen%2520of%2520Antiinflammatory%2520Drug%2520Combinations%2520in%2520Human%2520Blood%26jtitle%3DJCI%2520Insight%26date%3D2016%26volume%3D1%26spage%3De87031%26doi%3D10.1172%2Fjci.insight.87031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref239"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref239'); return false;" data-citation="" class="refNumLink">239</a></strong><div class="NLM_citation" id="cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meirer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhilber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the Arachidonic Acid Cascade: Interfering with Multiple Pathways</span>. <i>Basic Clin. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1111/bcpt.12134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1111%2Fbcpt.12134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=24015667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFGktL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2014&pages=83-91&issue=1&author=K.+Meirerauthor=D.+Steinhilberauthor=E.+Proschak&title=Inhibitors+of+the+Arachidonic+Acid+Cascade%3A+Interfering+with+Multiple+Pathways&doi=10.1111%2Fbcpt.12134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of the Arachidonic Acid Cascade: Interfering with Multiple Pathways</span></div><div class="casAuthors">Meirer, Karin; Steinhilber, Dieter; Proschak, Ewgenij</div><div class="citationInfo"><span class="NLM_cas:title">Basic & Clinical Pharmacology & Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">83-91</span>CODEN:
                <span class="NLM_cas:coden">BCPTBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-7835</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Modulators of the arachidonic acid cascade have been in the focus of research for treatments of inflammation and pain for several decades.  Targeting this complex pathway experiences a paradigm change towards the design and development of multi-target inhibitors, exhibiting improved efficacy and less undesired side effects.  This minireview summarizes recent developments in the field of designed multi-target ligands of the arachidonic acid cascade.  In addn. to the well-known dual inhibitors of 5-lipoxygenase and cyclooxygenase-2 such as licofelone, very recent developments are discussed.  Esp., multi-target inhibitors interfering with the cytochrome P 450 pathway via inhibition of sol. epoxide hydrolase seem to offer a novel opportunity for development of novel anti-inflammatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxIto5Wb10iLVg90H21EOLACvtfcHk0liTGb18bESi-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFGktL%252FF&md5=1b7c01f7e30d699dc57b25c215e4da9e</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1111%2Fbcpt.12134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcpt.12134%26sid%3Dliteratum%253Aachs%26aulast%3DMeirer%26aufirst%3DK.%26aulast%3DSteinhilber%26aufirst%3DD.%26aulast%3DProschak%26aufirst%3DE.%26atitle%3DInhibitors%2520of%2520the%2520Arachidonic%2520Acid%2520Cascade%253A%2520Interfering%2520with%2520Multiple%2520Pathways%26jtitle%3DBasic%2520Clin.%2520Pharmacol.%2520Toxicol.%26date%3D2014%26volume%3D114%26issue%3D1%26spage%3D83%26epage%3D91%26doi%3D10.1111%2Fbcpt.12134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref240"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref240'); return false;" data-citation="" class="refNumLink">240</a></strong><div class="NLM_citation" id="cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dijkman, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castell, O. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz-Garcia, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Graaf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, A.</span></span> <span> </span><span class="NLM_article-title">Dynamic Tuneable G Protein-Coupled Receptor Monomer-Dimer Populations</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1710</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-03727-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fs41467-018-03727-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29703992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC1MjnsFGgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1710&author=P.+M.+Dijkmanauthor=O.+K.+Castellauthor=A.+D.+Goddardauthor=J.+C.+Munoz-Garciaauthor=C.+de+Graafauthor=M.+I.+Wallaceauthor=A.+Watts&title=Dynamic+Tuneable+G+Protein-Coupled+Receptor+Monomer-Dimer+Populations&doi=10.1038%2Fs41467-018-03727-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">Dynamic tuneable G protein-coupled receptor monomer-dimer populations</span></div><div class="casAuthors">Dijkman Patricia M; Goddard Alan D; Munoz-Garcia Juan C; Watts Anthony; Dijkman Patricia M; Castell Oliver K; Wallace Mark I; Castell Oliver K; Goddard Alan D; Munoz-Garcia Juan C; de Graaf Chris; Wallace Mark I</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1710</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are the largest class of membrane receptors, playing a key role in the regulation of processes as varied as neurotransmission and immune response.  Evidence for GPCR oligomerisation has been accumulating that challenges the idea that GPCRs function solely as monomeric receptors; however, GPCR oligomerisation remains controversial primarily due to the difficulties in comparing evidence from very different types of structural and dynamic data.  Using a combination of single-molecule and ensemble FRET, double electron-electron resonance spectroscopy, and simulations, we show that dimerisation of the GPCR neurotensin receptor 1 is regulated by receptor density and is dynamically tuneable over the physiological range.  We propose a "rolling dimer" interface model in which multiple dimer conformations co-exist and interconvert.  These findings unite previous seemingly conflicting observations, provide a compelling mechanism for regulating receptor signalling, and act as a guide for future physiological studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLYxi4q-LtzEEgZCMqtRBifW6udTcc2eagrwZUZdXFSrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjnsFGgsw%253D%253D&md5=6a47bd3d5eb25e32ee6a6ca229f98dcc</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-03727-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-03727-6%26sid%3Dliteratum%253Aachs%26aulast%3DDijkman%26aufirst%3DP.%2BM.%26aulast%3DCastell%26aufirst%3DO.%2BK.%26aulast%3DGoddard%26aufirst%3DA.%2BD.%26aulast%3DMunoz-Garcia%26aufirst%3DJ.%2BC.%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26aulast%3DWallace%26aufirst%3DM.%2BI.%26aulast%3DWatts%26aufirst%3DA.%26atitle%3DDynamic%2520Tuneable%2520G%2520Protein-Coupled%2520Receptor%2520Monomer-Dimer%2520Populations%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D1710%26doi%3D10.1038%2Fs41467-018-03727-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref241"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref241'); return false;" data-citation="" class="refNumLink">241</a></strong><div class="NLM_citation" id="cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhilber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert-Zsilavecz, M.</span></span> <span> </span><span class="NLM_article-title">Small Molecules with Anti-Inflammatory Properties in Clinical Development</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2015.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.pharmthera.2015.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=26627986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFertbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2016&pages=163-187&author=T.+Hankeauthor=D.+Merkauthor=D.+Steinhilberauthor=G.+Geisslingerauthor=M.+Schubert-Zsilavecz&title=Small+Molecules+with+Anti-Inflammatory+Properties+in+Clinical+Development&doi=10.1016%2Fj.pharmthera.2015.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit241R"><div class="casContent"><span class="casTitleNuber">241</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecules with anti-inflammatory properties in clinical development</span></div><div class="casAuthors">Hanke, Thomas; Merk, Daniel; Steinhilber, Dieter; Geisslinger, Gerd; Schubert-Zsilavecz, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">163-187</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Inflammation is a crucial physiol. response of our body to any kind of noxa be it an infection or tissue injury.  However, this physiol. process can be detrimental if dysregulated, and when the acute inflammatory response fails to resolve the cause of inflammation, there can be a switch to chronification.  According to ICD 10 (WHO) over 3.000 diseases exist with the suffix "-itis" which terms an inflammatory disease.  For the treatment of inflammation, non-steroidal anti-inflammatory drugs (NSAIDs) are the most widespread drugs while glucocorticoids are among our strongest weapons against inflammation, making them emergency treatments for acute episodes of chronic inflammation.  For the treatment of many inflammatory disorders, both are not satisfying.  Consequently, industrial and academic research on anti-inflammatory drugs is very intensive.  In this review, we evaluate current treatments and unmet needs of chronic inflammatory diseases with high prevalence (rheumatoid arthritis, multiple sclerosis, chronic obstructive pulmonary disease, inflammatory bowel disease, and psoriasis), and systematically review small mols. with anti-inflammatory properties presently in clin. trials for the aforementioned diseases.  As the pathophysiol. knowledge of diseases increased over the last decades, a more specific intervention of inflammatory pathways becomes possible.  After one hundred years of NSAIDs and over fifty years of glucocorticoids, more specific drugs for anti-inflammatory therapy such as roflumilast or fingolimod are rising.  The aim of this article is to critically review the literature on small anti-inflammatory mols. in clin. trials to generate an idea of what we can expect in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOd16UM0wRSbVg90H21EOLACvtfcHk0liTGb18bESi-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFertbfM&md5=a9f5e04d82aad54d600e21307ca4bfb2</span></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2015.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2015.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DHanke%26aufirst%3DT.%26aulast%3DMerk%26aufirst%3DD.%26aulast%3DSteinhilber%26aufirst%3DD.%26aulast%3DGeisslinger%26aufirst%3DG.%26aulast%3DSchubert-Zsilavecz%26aufirst%3DM.%26atitle%3DSmall%2520Molecules%2520with%2520Anti-Inflammatory%2520Properties%2520in%2520Clinical%2520Development%26jtitle%3DPharmacol.%2520Ther.%26date%3D2016%26volume%3D157%26spage%3D163%26epage%3D187%26doi%3D10.1016%2Fj.pharmthera.2015.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref242"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref242'); return false;" data-citation="" class="refNumLink">242</a></strong><div class="NLM_citation" id="cit242"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dalli, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serhan, C. N.</span></span> <span> </span><span class="NLM_article-title">Identification and Structure Elucidation of the Proresolving Mediators Provides Novel Leads for Resolution Pharmacology</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>, <span class="refDoi"> DOI: 10.1111/bph.14336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1111%2Fbph.14336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29679485" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=J.+Dalliauthor=C.+N.+Serhan&title=Identification+and+Structure+Elucidation+of+the+Proresolving+Mediators+Provides+Novel+Leads+for+Resolution+Pharmacology&doi=10.1111%2Fbph.14336"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1111%2Fbph.14336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14336%26sid%3Dliteratum%253Aachs%26aulast%3DDalli%26aufirst%3DJ.%26aulast%3DSerhan%26aufirst%3DC.%2BN.%26atitle%3DIdentification%2520and%2520Structure%2520Elucidation%2520of%2520the%2520Proresolving%2520Mediators%2520Provides%2520Novel%2520Leads%2520for%2520Resolution%2520Pharmacology%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2018%26doi%3D10.1111%2Fbph.14336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref243"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref243'); return false;" data-citation="" class="refNumLink">243</a></strong><div class="NLM_citation" id="cit243"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tronci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francardo, V.</span></span> <span> </span><span class="NLM_article-title">Animal Models of L-DOPA-Induced Dyskinesia: The 6-OHDA-Lesioned Rat and Mouse</span>. <i>J. Neural Transm.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">1137</span>– <span class="NLM_lpage">1144</span>, <span class="refDoi"> DOI: 10.1007/s00702-017-1825-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1007%2Fs00702-017-1825-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2018&pages=1137-1144&author=E.+Tronciauthor=V.+Francardo&title=Animal+Models+of+L-DOPA-Induced+Dyskinesia%3A+The+6-OHDA-Lesioned+Rat+and+Mouse&doi=10.1007%2Fs00702-017-1825-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1007%2Fs00702-017-1825-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00702-017-1825-5%26sid%3Dliteratum%253Aachs%26aulast%3DTronci%26aufirst%3DE.%26aulast%3DFrancardo%26aufirst%3DV.%26atitle%3DAnimal%2520Models%2520of%2520L-DOPA-Induced%2520Dyskinesia%253A%2520The%25206-OHDA-Lesioned%2520Rat%2520and%2520Mouse%26jtitle%3DJ.%2520Neural%2520Transm.%26date%3D2018%26volume%3D125%26spage%3D1137%26epage%3D1144%26doi%3D10.1007%2Fs00702-017-1825-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref244"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref244'); return false;" data-citation="" class="refNumLink">244</a></strong><div class="NLM_citation" id="cit244"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porras, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezard, E.</span></span> <span> </span><span class="NLM_article-title">Modeling Parkinson’s Disease in Primates: The MPTP Model</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">a009308</span>– <span class="NLM_lpage">a009308</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a009308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1101%2Fcshperspect.a009308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=22393538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlenu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=a009308-a009308&issue=3&author=G.+Porrasauthor=Q.+Liauthor=E.+Bezard&title=Modeling+Parkinson%E2%80%99s+Disease+in+Primates%3A+The+MPTP+Model&doi=10.1101%2Fcshperspect.a009308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling Parkinson's disease in primates: the MPTP model</span></div><div class="casAuthors">Porras, Gregory; Li, Qin; Bezard, Erwan</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">a009308/1-a009308/10</span>CODEN:
                <span class="NLM_cas:coden">CSHPFV</span>;
        ISSN:<span class="NLM_cas:issn">2157-1422</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate models of Parkinson's disease (PD) reproduce most, although not all, of the clin. and pathol. hallmarks of PD.  The present, contribution presents the possibilities offered by the MPTP monkey models of PD to readers with minimal knowledge of PD, emphasizing the diversity of species, route and regimen of administration, symptoms and pathol. features.  Readers would eventually find out that there is not a single MPTP monkey model of PD but instead MPTP monkey models of PD, each addressing a specific exptl. need.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxcavMuixlTbVg90H21EOLACvtfcHk0liINO8jLP_Lbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlenu7c%253D&md5=ebcddd49aae2ff04944e5d5766cd0d69</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a009308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a009308%26sid%3Dliteratum%253Aachs%26aulast%3DPorras%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DBezard%26aufirst%3DE.%26atitle%3DModeling%2520Parkinson%25E2%2580%2599s%2520Disease%2520in%2520Primates%253A%2520The%2520MPTP%2520Model%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2012%26volume%3D2%26issue%3D3%26spage%3Da009308%26epage%3Da009308%26doi%3D10.1101%2Fcshperspect.a009308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref245"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref245'); return false;" data-citation="" class="refNumLink">245</a></strong><div class="NLM_citation" id="cit245"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ernsberger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koletsky, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kline, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedol, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, J. E.</span></span> <span> </span><span class="NLM_article-title">The SHROB Model of Syndrome X: Effects of Excess Dietary Sucrose</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>892</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.1999.tb07806.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1111%2Fj.1749-6632.1999.tb07806.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=892&publication_year=1999&pages=315-318&author=P.+Ernsbergerauthor=R.+J.+Koletskyauthor=D.+D.+Klineauthor=D.+M.+Bedolauthor=J.+E.+Friedman&title=The+SHROB+Model+of+Syndrome+X%3A+Effects+of+Excess+Dietary+Sucrose&doi=10.1111%2Fj.1749-6632.1999.tb07806.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.1999.tb07806.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.1999.tb07806.x%26sid%3Dliteratum%253Aachs%26aulast%3DErnsberger%26aufirst%3DP.%26aulast%3DKoletsky%26aufirst%3DR.%2BJ.%26aulast%3DKline%26aufirst%3DD.%2BD.%26aulast%3DBedol%26aufirst%3DD.%2BM.%26aulast%3DFriedman%26aufirst%3DJ.%2BE.%26atitle%3DThe%2520SHROB%2520Model%2520of%2520Syndrome%2520X%253A%2520Effects%2520of%2520Excess%2520Dietary%2520Sucrose%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D1999%26volume%3D892%26spage%3D315%26epage%3D318%26doi%3D10.1111%2Fj.1749-6632.1999.tb07806.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref246"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref246'); return false;" data-citation="" class="refNumLink">246</a></strong><div class="NLM_citation" id="cit246"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casimiro-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filzen, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigge, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmunds, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esmaeil, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heemstra, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalaie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohren, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostroski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaum, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoner, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Series of Imidazo[4,5- B]pyridines with Dual Activity at Angiotensin II Type 1 Receptor and Peroxisome Proliferator-Activated Receptor-γ</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4219</span>– <span class="NLM_lpage">4233</span>, <span class="refDoi"> DOI: 10.1021/jm200409s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200409s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4219-4233&issue=12&author=A.+Casimiro-Garciaauthor=G.+F.+Filzenauthor=D.+Flynnauthor=C.+F.+Biggeauthor=J.+Chenauthor=J.+A.+Davisauthor=D.+A.+Dudleyauthor=J.+J.+Edmundsauthor=N.+Esmaeilauthor=A.+Geyerauthor=R.+J.+Heemstraauthor=M.+Jalaieauthor=J.+F.+Ohrenauthor=R.+Ostroskiauthor=T.+Ellisauthor=R.+P.+Schaumauthor=C.+Stoner&title=Discovery+of+a+Series+of+Imidazo%5B4%2C5-+B%5Dpyridines+with+Dual+Activity+at+Angiotensin+II+Type+1+Receptor+and+Peroxisome+Proliferator-Activated+Receptor-%CE%B3&doi=10.1021%2Fjm200409s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=10.1021%2Fjm200409s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200409s%26sid%3Dliteratum%253Aachs%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26aulast%3DFilzen%26aufirst%3DG.%2BF.%26aulast%3DFlynn%26aufirst%3DD.%26aulast%3DBigge%26aufirst%3DC.%2BF.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DJ.%2BA.%26aulast%3DDudley%26aufirst%3DD.%2BA.%26aulast%3DEdmunds%26aufirst%3DJ.%2BJ.%26aulast%3DEsmaeil%26aufirst%3DN.%26aulast%3DGeyer%26aufirst%3DA.%26aulast%3DHeemstra%26aufirst%3DR.%2BJ.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DOhren%26aufirst%3DJ.%2BF.%26aulast%3DOstroski%26aufirst%3DR.%26aulast%3DEllis%26aufirst%3DT.%26aulast%3DSchaum%26aufirst%3DR.%2BP.%26aulast%3DStoner%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520a%2520Series%2520of%2520Imidazo%255B4%252C5-%2520B%255Dpyridines%2520with%2520Dual%2520Activity%2520at%2520Angiotensin%2520II%2520Type%25201%2520Receptor%2520and%2520Peroxisome%2520Proliferator-Activated%2520Receptor-%25CE%25B3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D12%26spage%3D4219%26epage%3D4233%26doi%3D10.1021%2Fjm200409s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref300"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref300'); return false;" data-citation="" class="refNumLink">247</a></strong><div class="NLM_citation" id="cit300"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imig, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hye Khan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B.</span></span> <span> </span><span class="NLM_article-title">Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats</span>. <i>Exp. Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>237</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1402</span>– <span class="NLM_lpage">1412</span>, <span class="refDoi"> DOI: 10.1258/ebm.2012.012225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref300/cit300&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1258%2Febm.2012.012225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref300/cit300&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFagtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=237&publication_year=2012&pages=1402-1412&issue=12&author=J.+Imigauthor=K.+Walshauthor=M.+A.+Hye+Khanauthor=T.+Nagasawaauthor=M.+C.+Shawauthor=S.+M.+Shawauthor=B.+Hammock&title=Soluble+epoxide+hydrolase+inhibition+and+peroxisome+proliferator+activated+receptor+%CE%B3+agonist+improve+vascular+function+and+decrease+renal+injury+in+hypertensive+obese+rats&doi=10.1258%2Febm.2012.012225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit300R"><div class="casContent"><span class="casTitleNuber">300</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats</span></div><div class="casAuthors">Imig, John D.; Walsh, Katie A.; Abdul Hye Khan, Md; Nagasawa, Tasuku; Cherian-Shaw, Mary; Shaw, Sean M.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Biology and Medicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">237</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1402-1412</span>CODEN:
                <span class="NLM_cas:coden">EBMMBE</span>;
        ISSN:<span class="NLM_cas:issn">1535-3702</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Cardiometabolic syndrome occurs with obesity and consists of pathophysiol. factors that increase the risk for cardiovascular events.  Sol. epoxide hydrolase inhibition (sEHi) is a novel therapeutic approach that exerts renal and cardiovascular protection.  Although sEHi as a therapeutic approach is promising, it could be more effective for the treatment of cardiometabolic syndrome when combined with peroxisome proliferator activated receptor γ (PPARγ) agonists.  We hypothesized that the PPARγ agonist, rosiglitazone in combination with a sEHi (tAUCB) will provide synergistic actions to decrease blood pressure, improve vascular function, decrease inflammation, and prevent renal damage in spontaneously hypertensive obese rats (SHROB).  SHROB were treated with rosiglitazone, tAUCB or the combination of tAUCB and rosiglitazone for four-weeks and compared with spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) rats.  Blood pressure increased in SHROB (164 ± 7 mmHg) and decreased 10 mmHg when treated with rosiglitazone, tAUCB, or tAUCB and rosiglitazone.  Mesenteric artery dilation to the KATP channel opener pinacidil was attenuated in SHROB (EMax = 77 ± 7%), compared with WKY (EMax = 115 ± 19) and SHR (EMax = 93 ± 12%).  Vasodilation to pinacidil was improved by rosiglitazone (EMax = 92 ± 14%) but not tAUCB.  Renal macrophage infiltration increased in SHROB and significantly decreased with rosiglitazone or tAUCB and rosiglitazone treatment.  Albuminuria was increased in SHROB (90 ± 20 mg/d) and was significantly decreased by the combination of tAUCB and rosiglitazone (37 ± 9 mg/d).  Glomerular injury in SHROB was also significantly decreased by tAUCB and rosiglitazone.  These results indicate that even though sEHi or PPARγ agonist have benefits when used individually, the combination is more beneficial for the multidisease features in cardiometabolic syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoq2SjZgeqAHrVg90H21EOLACvtfcHk0lhty61YRTOvDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFagtbk%253D&md5=d22fb0c9e2e8acf30dd6ce7614ad403c</span></div><a href="/servlet/linkout?suffix=cit300&amp;dbid=16384&amp;doi=10.1258%2Febm.2012.012225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1258%252Febm.2012.012225%26sid%3Dliteratum%253Aachs%26aulast%3DImig%26aufirst%3DJ.%26aulast%3DWalsh%26aufirst%3DK.%26aulast%3DHye%2BKhan%26aufirst%3DM.%2BA.%26aulast%3DNagasawa%26aufirst%3DT.%26aulast%3DShaw%26aufirst%3DM.%2BC.%26aulast%3DShaw%26aufirst%3DS.%2BM.%26aulast%3DHammock%26aufirst%3DB.%26atitle%3DSoluble%2520epoxide%2520hydrolase%2520inhibition%2520and%2520peroxisome%2520proliferator%2520activated%2520receptor%2520%25CE%25B3%2520agonist%2520improve%2520vascular%2520function%2520and%2520decrease%2520renal%2520injury%2520in%2520hypertensive%2520obese%2520rats%26jtitle%3DExp.%2520Biol.%2520Med.%26date%3D2012%26volume%3D237%26issue%3D12%26spage%3D1402%26epage%3D1412%26doi%3D10.1258%2Febm.2012.012225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref301"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref301'); return false;" data-citation="" class="refNumLink">248</a></strong><div class="NLM_citation" id="cit301"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hye Khan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skibba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blöcher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imig, J.</span></span> <span> </span><span class="NLM_article-title">A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>, <span class="refDoi"> DOI: 10.1007/s00125-018-4685-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref301/cit301&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1007%2Fs00125-018-4685-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=M.+A.+Hye+Khanauthor=L.+Kolbauthor=M.+Skibbaauthor=M.+Hartmannauthor=R.+Bl%C3%B6cherauthor=E.+Proschakauthor=J.+Imig&title=A+novel+dual+PPAR-%CE%B3+agonist%2FsEH+inhibitor+treats+diabetic+complications+in+a+rat+model+of+type+2+diabetes&doi=10.1007%2Fs00125-018-4685-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit301&amp;dbid=16384&amp;doi=10.1007%2Fs00125-018-4685-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-018-4685-0%26sid%3Dliteratum%253Aachs%26aulast%3DHye%2BKhan%26aufirst%3DM.%2BA.%26aulast%3DKolb%26aufirst%3DL.%26aulast%3DSkibba%26aufirst%3DM.%26aulast%3DHartmann%26aufirst%3DM.%26aulast%3DBl%25C3%25B6cher%26aufirst%3DR.%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DImig%26aufirst%3DJ.%26atitle%3DA%2520novel%2520dual%2520PPAR-%25CE%25B3%2520agonist%252FsEH%2520inhibitor%2520treats%2520diabetic%2520complications%2520in%2520a%2520rat%2520model%2520of%2520type%25202%2520diabetes%26jtitle%3DDiabetologia%26date%3D2018%26doi%3D10.1007%2Fs00125-018-4685-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref247"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref247'); return false;" data-citation="" class="refNumLink">249</a></strong><div class="NLM_citation" id="cit247"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kotagal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnen, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppe, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albin, R. L.</span></span> <span> </span><span class="NLM_article-title">Serotonin, Beta-Amyloid, and Cognition in Parkinson Disease</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>83</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">994</span>– <span class="NLM_lpage">1002</span>, <span class="refDoi"> DOI: 10.1002/ana.25236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fana.25236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29665066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Wrur3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2018&pages=994-1002&issue=5&author=V.+Kotagalauthor=C.+Spinoauthor=N.+I.+Bohnenauthor=R.+A.+Koeppeauthor=R.+L.+Albin&title=Serotonin%2C+Beta-Amyloid%2C+and+Cognition+in+Parkinson+Disease&doi=10.1002%2Fana.25236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit247R"><div class="casContent"><span class="casTitleNuber">247</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin, β-amyloid, and cognition in Parkinson disease</span></div><div class="casAuthors">Kotagal, Vikas; Spino, Cathie; Bohnen, Nicolaas I.; Koeppe, Robert; Albin, Roger L.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">994-1002</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : Serotoninergic neurotransmission may modulate β-amyloid peptide (Aβ) metab. through upregulation of α-secretase.  Early Parkinson disease (PD) shows variable serotoninergic denervation, which may impact Aβ deposition.  Methods : We conducted 3 analyses to explore assocns. between serotoninergic neurotransmission and cerebral Aβ burden in PD.  The first was a cross-sectional imaging study of PD subjects (n = 23) using the serotoninergic transporter positron emission tomog. (PET) ligand [11C]3-amino-4-(2-dimethylaminomethyl-phenylsulfaryl)-benzonitrile (DASB) and amyloid PET Pittsburgh compd. B ([11C]PiB).  The second was a baseline study of Parkinson's Progression Markers Initiative (PPMI) subjects exploring the influence of serotoninergic medications on cerebrospinal fluid (CSF) Aβ-42 levels (n = 389), controlling for age, sex, Geriatric Depression Scale, disease duration, and education.  Third, we fit an interval censored proportional hazard model with longitudinal PPMI data (n = 367) to test whether serotoninergic medication use assocs. with reduced risk of PD cognitive decline, defined as time to reach a Montreal Cognitive Assessment score ≤ 20, adjusting for baseline caudate dopamine transporter [123I]ioflupane single photon emission computed tomog. and CSF Aβ-42 levels.  Results : Serotoninergic DASB distribution vol. ratio (DVR) inversely assocd. with PiB DVR in the cerebral cortex (Pearson r = -0.478, p = 0.021) but not the striatum (r = -0.264, p = 0.224).  In the baseline PPMI anal., serotoninergic medication use for ≥6 mo assocd. with a lower level of CSF Aβ-42 (t = -2.20, p = 0.029).  In the longitudinal PPMI model, baseline serotoninergic medication use assocd. with a reduced risk of cognitive decline (t = -2.03, p = 0.043) after controlling for covariates.  Interpretation : Cortical Aβ burden in PD assocs. inversely with serotoninergic innervation.  Serotoninergic medications may alter Aβ metab. and reduce the risk of PD cognitive decline.  Ann Neurol 2018;83:994-1002.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSfO7_QmYx_LVg90H21EOLACvtfcHk0lhty61YRTOvDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Wrur3F&md5=ae40a9f624232a1282f95bf439e0676f</span></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=10.1002%2Fana.25236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.25236%26sid%3Dliteratum%253Aachs%26aulast%3DKotagal%26aufirst%3DV.%26aulast%3DSpino%26aufirst%3DC.%26aulast%3DBohnen%26aufirst%3DN.%2BI.%26aulast%3DKoeppe%26aufirst%3DR.%2BA.%26aulast%3DAlbin%26aufirst%3DR.%2BL.%26atitle%3DSerotonin%252C%2520Beta-Amyloid%252C%2520and%2520Cognition%2520in%2520Parkinson%2520Disease%26jtitle%3DAnn.%2520Neurol.%26date%3D2018%26volume%3D83%26issue%3D5%26spage%3D994%26epage%3D1002%26doi%3D10.1002%2Fana.25236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref248"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref248'); return false;" data-citation="" class="refNumLink">250</a></strong><div class="NLM_citation" id="cit248"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huot, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sgambato-Faure, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCreary, A. C.</span></span> <span> </span><span class="NLM_article-title">Serotonergic Approaches in Parkinson’s Disease: Translational Perspectives, an Update</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">973</span>– <span class="NLM_lpage">986</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.6b00440</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.6b00440" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvVems7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=973-986&issue=5&author=P.+Huotauthor=V.+Sgambato-Faureauthor=S.+H.+Foxauthor=A.+C.+McCreary&title=Serotonergic+Approaches+in+Parkinson%E2%80%99s+Disease%3A+Translational+Perspectives%2C+an+Update&doi=10.1021%2Facschemneuro.6b00440"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit248R"><div class="casContent"><span class="casTitleNuber">248</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an Update</span></div><div class="casAuthors">Huot, Philippe; Sgambato-Faure, Veronique; Fox, Susan H.; McCreary, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">973-986</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease (PD) has long been seen as a disorder caused by degeneration of the dopaminergic system, leading to the classic motor manifestations of the disease.  However, there is now overwhelming evidence that PD is more than a disease merely caused by dopamine depletion.  It is well known that a myriad of other neurotransmitters are affected by the disease process.  One such neurotransmitter is serotonin (5-HT). 5-HT has been shown to play a role in several motor and non-motor manifestations of PD, including tremor, cognition, depression and psychosis.  5-HT also seems to play a crit. role in L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia.  A breadth of pre-clin. studies and clin. trials have been conducted aimed at modulating the 5-HT system in order to alleviate depression, cognitive deficits, psychosis and dyskinesia.  In this review article, we summarize recent advances in the 5-HT field in PD, but with a translational emphasis.  We start by presenting a novel non-human primate model of PD that presents with dual dopamine and 5-HT lesions.  We then present pre-clin. and clin. data that introduce new concepts, such as the use of biased and partial agonists, as well as mols. recently introduced to the field of PD, such as eltoprazine, pimavanserin, nelotanserin and SYN-120, to enhance therapeutic benefit while minimizing adverse events, notably on parkinsonian disability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq42fCs4QfDtrVg90H21EOLACvtfcHk0lhty61YRTOvDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvVems7Y%253D&md5=13809198c78bc8053440fb976207b972</span></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.6b00440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.6b00440%26sid%3Dliteratum%253Aachs%26aulast%3DHuot%26aufirst%3DP.%26aulast%3DSgambato-Faure%26aufirst%3DV.%26aulast%3DFox%26aufirst%3DS.%2BH.%26aulast%3DMcCreary%26aufirst%3DA.%2BC.%26atitle%3DSerotonergic%2520Approaches%2520in%2520Parkinson%25E2%2580%2599s%2520Disease%253A%2520Translational%2520Perspectives%252C%2520an%2520Update%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D8%26issue%3D5%26spage%3D973%26epage%3D986%26doi%3D10.1021%2Facschemneuro.6b00440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref249"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref249'); return false;" data-citation="" class="refNumLink">251</a></strong><div class="NLM_citation" id="cit249"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bezard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imbert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, C. E.</span></span> <span> </span><span class="NLM_article-title">Experimental Models of Parkinson’s Disease: From the Static to the Dynamic</span>. <i>Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1515/REVNEURO.1998.9.2.71</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1515%2FREVNEURO.1998.9.2.71" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=9711900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADyaK1cznsFOiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1998&pages=71-90&author=E.+Bezardauthor=C.+Imbertauthor=C.+E.+Gross&title=Experimental+Models+of+Parkinson%E2%80%99s+Disease%3A+From+the+Static+to+the+Dynamic&doi=10.1515%2FREVNEURO.1998.9.2.71"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit249R"><div class="casContent"><span class="casTitleNuber">249</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental models of Parkinson's disease: from the static to the dynamic</span></div><div class="casAuthors">Bezard E; Imbert C; Gross C E</div><div class="citationInfo"><span class="NLM_cas:title">Reviews in the neurosciences</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">71-90</span>
        ISSN:<span class="NLM_cas:issn">0334-1763</span>.
    </div><div class="casAbstract">The experimental models of Parkinson's disease (PD) available today can be divided into two categories according to the mode of action of the compound used: transient pharmacological impairment of dopaminergic transmission along the nigrostriatal pathway or selective destruction by a neurotoxic agent of the dopaminergic neurons of the substantia nigra pars compacta.  The present article looks at the relative merits of each model, the clinical symptoms and neuronal impairment it induces, and the contribution it could make to the development of a truly dynamic model.  It is becoming more and more clear that there is an urgent need for a chronic model integrating all the clinical features of PD including resting tremor, and reproducing the gradual but continuous nigral degeneration observed in the human pathology.  Discrepancies have been reported several times between results obtained in classic animal models and those described in PD, and it would seem probable that such contradictions can be ascribed to the fact that animal models do not, as yet, reproduce the continuous evolution of the human disease.  Dynamic experimental models which come closer to the progressive neurodegeneration and gradual intensification of motor disability so characteristic of human PD will enable us to investigate crucial aspects of the disease, such as compensatory mechanisms and dyskinesia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQd6n-IVQ0JJUwlCcfExbvbfW6udTcc2eaCCPve-DzIQbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1cznsFOiug%253D%253D&md5=848c4fbf975277adc0937c5245991964</span></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=10.1515%2FREVNEURO.1998.9.2.71&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252FREVNEURO.1998.9.2.71%26sid%3Dliteratum%253Aachs%26aulast%3DBezard%26aufirst%3DE.%26aulast%3DImbert%26aufirst%3DC.%26aulast%3DGross%26aufirst%3DC.%2BE.%26atitle%3DExperimental%2520Models%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%253A%2520From%2520the%2520Static%2520to%2520the%2520Dynamic%26jtitle%3DRev.%2520Neurosci.%26date%3D1998%26volume%3D9%26spage%3D71%26epage%3D90%26doi%3D10.1515%2FREVNEURO.1998.9.2.71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref250"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref250'); return false;" data-citation="" class="refNumLink">252</a></strong><div class="NLM_citation" id="cit250"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ko, W. K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezard, E.</span></span> <span> </span><span class="NLM_article-title">Experimental Animal Models of Parkinson’s Disease: A Transition from Assessing Symptomatology to α-Synuclein Targeted Disease Modification</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>298</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1016/j.expneurol.2017.07.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.expneurol.2017.07.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28764902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Oku7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2017&pages=172-179&author=W.+K.+D.+Koauthor=E.+Bezard&title=Experimental+Animal+Models+of+Parkinson%E2%80%99s+Disease%3A+A+Transition+from+Assessing+Symptomatology+to+%CE%B1-Synuclein+Targeted+Disease+Modification&doi=10.1016%2Fj.expneurol.2017.07.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to α-synuclein targeted disease modification</span></div><div class="casAuthors">Ko, Wai Kin D.; Bezard, Erwan</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">Part_B</span>),
    <span class="NLM_cas:pages">172-179</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">With the understanding that α-synuclein plays a major role in the pathogenesis of Parkinson's disease (PD), novel animal models have been developed for conducting preclin. research in screening novel disease modifying therapies.  Advancements in research techniques in α-synuclein targeted disease modification have utilized methods such as viral mediated expression of human α-synuclein, as well as the inoculation of pathogenic α-synuclein species from Lewy Bodies of PD patients, for accurately modeling progressive self-propagating neurodegeneration.  In applying these cutting-edge research tools with sophisticated trial designs in preclin. drug trials, a useful platform has emerged for developing candidate agents with disease modifying actions, promising a greater chance of success for clin. translation.  In this article, we describe the transition of well-established animal models of PD symptomatol. to newly developed models of PD pathogenesis, with specific focus on methods of viral-mediated and inoculation of pathogenic α-synuclein, that aim to aid scientific translation of neuroprotective strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1K3iVMQhVULVg90H21EOLACvtfcHk0lgyV9fw8owJQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Oku7jM&md5=c388159e19f8a705f68370c6e7092216</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1016%2Fj.expneurol.2017.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.expneurol.2017.07.020%26sid%3Dliteratum%253Aachs%26aulast%3DKo%26aufirst%3DW.%2BK.%2BD.%26aulast%3DBezard%26aufirst%3DE.%26atitle%3DExperimental%2520Animal%2520Models%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%253A%2520A%2520Transition%2520from%2520Assessing%2520Symptomatology%2520to%2520%25CE%25B1-Synuclein%2520Targeted%2520Disease%2520Modification%26jtitle%3DExp.%2520Neurol.%26date%3D2017%26volume%3D298%26spage%3D172%26epage%3D179%26doi%3D10.1016%2Fj.expneurol.2017.07.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224'],'ref225':['cit225'],'ref226':['cit226'],'ref227':['cit227'],'ref228':['cit228'],'ref229':['cit229'],'ref230':['cit230'],'ref231':['cit231'],'ref232':['cit232'],'ref233':['cit233'],'ref234':['cit234'],'ref235':['cit235'],'ref236':['cit236'],'ref237':['cit237'],'ref238':['cit238'],'ref239':['cit239'],'ref240':['cit240'],'ref241':['cit241'],'ref242':['cit242'],'ref243':['cit243'],'ref244':['cit244'],'ref245':['cit245'],'ref246':['cit246'],'ref300':['cit300'],'ref301':['cit301'],'ref247':['cit247'],'ref248':['cit248'],'ref249':['cit249'],'ref250':['cit250']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 132 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Lina Humbeck, Jette Pretzel, Saskia Spitzer, <span class="NLM_string-name hlFld-ContribAuthor">Oliver Koch</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of an Unexpected Similarity in Ligand Binding between BRD4 and PPARγ. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2021,</strong> <em>16 </em>
                                    (7)
                                     , 1255-1265. <a href="https://doi.org/10.1021/acschembio.1c00323" title="DOI URL">https://doi.org/10.1021/acschembio.1c00323</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.1c00323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.1c00323%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DDiscovery%252Bof%252Ban%252BUnexpected%252BSimilarity%252Bin%252BLigand%252BBinding%252Bbetween%252BBRD4%252Band%252BPPAR%2525CE%2525B3%26aulast%3DHumbeck%26aufirst%3DLina%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D30042021%26date%3D07062021%26date%3D28062021%26volume%3D16%26issue%3D7%26spage%3D1255%26epage%3D1265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Moritz Helmstädter, Astrid Kaiser, Steffen Brunst, Jurema Schmidt, Riccardo Ronchetti, Lilia Weizel, Ewgenij Proschak, <span class="NLM_string-name hlFld-ContribAuthor">Daniel Merk</span>. </span><span class="cited-content_cbyCitation_article-title">Second-Generation Dual FXR/sEH Modulators with Optimized Pharmacokinetics. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (13)
                                     , 9525-9536. <a href="https://doi.org/10.1021/acs.jmedchem.1c00831" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00831</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00831%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSecond-Generation%252BDual%252BFXR%25252FsEH%252BModulators%252Bwith%252BOptimized%252BPharmacokinetics%26aulast%3DHelmst%25C3%25A4dter%26aufirst%3DMoritz%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D07052021%26date%3D24062021%26volume%3D64%26issue%3D13%26spage%3D9525%26epage%3D9536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Wen Shuai, Guan Wang, Yiwen Zhang, Faqian Bu, Sicheng Zhang, Duane D. Miller, Wei Li, Liang Ouyang, <span class="NLM_string-name hlFld-ContribAuthor">Yuxi Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 7963-7990. <a href="https://doi.org/10.1021/acs.jmedchem.1c00100" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00100</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00100%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BProgress%252Bon%252BTubulin%252BInhibitors%252Bwith%252BDual%252BTargeting%252BCapabilities%252Bfor%252BCancer%252BTherapy%26aulast%3DShuai%26aufirst%3DWen%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D19012021%26date%3D08062021%26volume%3D64%26issue%3D12%26spage%3D7963%26epage%3D7990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Antonino N. Fallica, Valeria Pittalà, Maria N. Modica, Loredana Salerno, Giuseppe Romeo, Agostino Marrazzo, Mohamed A. Helal, <span class="NLM_string-name hlFld-ContribAuthor">Sebastiano Intagliata</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Development of Sigma Receptor Ligands as Cytotoxic Agents: A Medicinal Chemistry Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 7926-7962. <a href="https://doi.org/10.1021/acs.jmedchem.0c02265" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02265</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02265%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDevelopment%252Bof%252BSigma%252BReceptor%252BLigands%252Bas%252BCytotoxic%252BAgents%25253A%252BA%252BMedicinal%252BChemistry%252BPerspective%26aulast%3DFallica%26aufirst%3DAntonino%2BN.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D31122020%26date%3D02062021%26volume%3D64%26issue%3D12%26spage%3D7926%26epage%3D7962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Brian Kawahara, Kym F. Faull, Carla Janzen, <span class="NLM_string-name hlFld-ContribAuthor">Pradip K. Mascharak</span>. </span><span class="cited-content_cbyCitation_article-title">Carbon Monoxide Inhibits Cytochrome P450 Enzymes CYP3A4/2C8 in Human Breast Cancer Cells, Increasing Sensitivity to Paclitaxel. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8437-8446. <a href="https://doi.org/10.1021/acs.jmedchem.1c00404" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00404</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00404%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCarbon%252BMonoxide%252BInhibits%252BCytochrome%252BP450%252BEnzymes%252BCYP3A4%25252F2C8%252Bin%252BHuman%252BBreast%252BCancer%252BCells%25252C%252BIncreasing%252BSensitivity%252Bto%252BPaclitaxel%26aulast%3DKawahara%26aufirst%3DBrian%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D05032021%26date%3D07062021%26volume%3D64%26issue%3D12%26spage%3D8437%26epage%3D8446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Moritz Helmstädter, Jurema Schmidt, Astrid Kaiser, Lilia Weizel, Ewgenij Proschak, <span class="NLM_string-name hlFld-ContribAuthor">Daniel Merk</span>. </span><span class="cited-content_cbyCitation_article-title">Differential Therapeutic Effects of FXR Activation, sEH Inhibition, and Dual FXR/sEH Modulation in NASH in Diet-Induced Obese Mice. </span><span class="cited-content_cbyCitation_journal-name">ACS Pharmacology & Translational Science</span><span> <strong>2021,</strong> <em>4 </em>
                                    (2)
                                     , 966-979. <a href="https://doi.org/10.1021/acsptsci.1c00041" title="DOI URL">https://doi.org/10.1021/acsptsci.1c00041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsptsci.1c00041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsptsci.1c00041%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Pharmacology%2520%2526%2520Translational%2520Science%26atitle%3DDifferential%252BTherapeutic%252BEffects%252Bof%252BFXR%252BActivation%25252C%252BsEH%252BInhibition%25252C%252Band%252BDual%252BFXR%25252FsEH%252BModulation%252Bin%252BNASH%252Bin%252BDiet-Induced%252BObese%252BMice%26aulast%3DHelmst%25C3%25A4dter%26aufirst%3DMoritz%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D28012021%26date%3D29032021%26volume%3D4%26issue%3D2%26spage%3D966%26epage%3D979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Feng He, C. James Chou, Matthias Scheiner, Eleonora Poeta, Natalia Yuan Chen, Sandra Gunesch, Matthias Hoffmann, Christoph Sotriffer, Barbara Monti, Tangui Maurice, <span class="NLM_string-name hlFld-ContribAuthor">Michael Decker</span>. </span><span class="cited-content_cbyCitation_article-title">Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects In Vitro and Neuroprotective Effects in a Pharmacological Alzheimer’s Disease Mouse Model. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 3794-3812. <a href="https://doi.org/10.1021/acs.jmedchem.0c01940" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01940</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01940%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMelatonin-%252Band%252BFerulic%252BAcid-Based%252BHDAC6%252BSelective%252BInhibitors%252BExhibit%252BPronounced%252BImmunomodulatory%252BEffects%252BIn%252BVitro%252Band%252BNeuroprotective%252BEffects%252Bin%252Ba%252BPharmacological%252BAlzheimer%2525E2%252580%252599s%252BDisease%252BMouse%252BModel%26aulast%3DHe%26aufirst%3DFeng%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D09112020%26date%3D26032021%26volume%3D64%26issue%3D7%26spage%3D3794%26epage%3D3812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Eliška Procházková, Oleksandr Kucherak, Eva Stodůlková, Zdeněk Tošner, Ivana Císařová, Miroslav Flieger, Miroslav Kolařík, <span class="NLM_string-name hlFld-ContribAuthor">Ondřej Baszczyňski</span>. </span><span class="cited-content_cbyCitation_article-title">NMR Structure Elucidation of Naphthoquinones from Quambalaria cyanescens. </span><span class="cited-content_cbyCitation_journal-name">Journal of Natural Products</span><span> <strong>2021,</strong> <em>84 </em>
                                    (1)
                                     , 46-55. <a href="https://doi.org/10.1021/acs.jnatprod.0c00930" title="DOI URL">https://doi.org/10.1021/acs.jnatprod.0c00930</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jnatprod.0c00930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jnatprod.0c00930%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Natural%2520Products%26atitle%3DNMR%252BStructure%252BElucidation%252Bof%252BNaphthoquinones%252Bfrom%252BQuambalaria%252Bcyanescens%26aulast%3DProch%25C3%25A1zkov%25C3%25A1%26aufirst%3DEli%25C5%25A1ka%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D24082020%26date%3D19122020%26volume%3D84%26issue%3D1%26spage%3D46%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Angela De Simone, Vincenzo Tumiatti, Vincenza Andrisano, <span class="NLM_string-name hlFld-ContribAuthor">Andrea Milelli</span>. </span><span class="cited-content_cbyCitation_article-title">Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer’s Disease Multitarget Drug Discovery?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 26-41. <a href="https://doi.org/10.1021/acs.jmedchem.0c00931" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00931</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00931%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DGlycogen%252BSynthase%252BKinase%252B3%2525CE%2525B2%25253A%252BA%252BNew%252BGold%252BRush%252Bin%252BAnti-Alzheimer%2525E2%252580%252599s%252BDisease%252BMultitarget%252BDrug%252BDiscovery%25253F%26aulast%3DDe%2BSimone%26aufirst%3DAngela%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D01062020%26date%3D21122020%26volume%3D64%26issue%3D1%26spage%3D26%26epage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Christian Feldmann, Dimitar Yonchev, Dagmar Stumpfe, <span class="NLM_string-name hlFld-ContribAuthor">Jürgen Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Systematic Data Analysis and Diagnostic Machine Learning Reveal Differences between Compounds with Single- and Multitarget Activity. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2020,</strong> <em>17 </em>
                                    (12)
                                     , 4652-4666. <a href="https://doi.org/10.1021/acs.molpharmaceut.0c00901" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.0c00901</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.0c00901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.0c00901%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DSystematic%252BData%252BAnalysis%252Band%252BDiagnostic%252BMachine%252BLearning%252BReveal%252BDifferences%252Bbetween%252BCompounds%252Bwith%252BSingle-%252Band%252BMultitarget%252BActivity%26aulast%3DFeldmann%26aufirst%3DChristian%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04092020%26date%3D23102020%26date%3D02102020%26date%3D05112020%26volume%3D17%26issue%3D12%26spage%3D4652%26epage%3D4666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yue Zhong, Run-Ze Qiu, Shan-Liang Sun, Chao Zhao, Tian-Yuan Fan, Min Chen, Nian-Guang Li, <span class="NLM_string-name hlFld-ContribAuthor">Zhi-Hao Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12403-12428. <a href="https://doi.org/10.1021/acs.jmedchem.0c00696" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00696</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00696%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BFms-like%252BTyrosine%252BKinase%252B3%252BInhibitors%25253A%252BAn%252BAttractive%252Band%252BEfficient%252BMethod%252Bfor%252Bthe%252BTreatment%252Bof%252BAcute%252BMyeloid%252BLeukemia%26aulast%3DZhong%26aufirst%3DYue%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26042020%26date%3D21072020%26date%3D13072020%26volume%3D63%26issue%3D21%26spage%3D12403%26epage%3D12428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Simon Gonzalez, Maria Dumitrascuta, Emilie Eiselt, Stevany Louis, Linda Kunze, Annalisa Blasiol, Mélanie Vivancos, Santo Previti, Elke Dewolf, Charlotte Martin, Dirk Tourwé, Florine Cavelier, Louis Gendron, Philippe Sarret, Mariana Spetea, <span class="NLM_string-name hlFld-ContribAuthor">Steven Ballet</span>. </span><span class="cited-content_cbyCitation_article-title">Optimized Opioid-Neurotensin Multitarget Peptides: From Design to Structure–Activity Relationship Studies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12929-12941. <a href="https://doi.org/10.1021/acs.jmedchem.0c01376" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01376</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01376%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOptimized%252BOpioid-Neurotensin%252BMultitarget%252BPeptides%25253A%252BFrom%252BDesign%252Bto%252BStructure%2525E2%252580%252593Activity%252BRelationship%252BStudies%26aulast%3DGonzalez%26aufirst%3DSimon%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D05082020%26date%3D23092020%26date%3D09092020%26volume%3D63%26issue%3D21%26spage%3D12929%26epage%3D12941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Simone Schierle, Sebastian Neumann, Pascal Heitel, Sabine Willems, Astrid Kaiser, Julius Pollinger, <span class="NLM_string-name hlFld-ContribAuthor">Daniel Merk</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Structural Optimization of Dual FXR/PPARδ Activators. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (15)
                                     , 8369-8379. <a href="https://doi.org/10.1021/acs.jmedchem.0c00618" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00618</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00618%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BStructural%252BOptimization%252Bof%252BDual%252BFXR%25252FPPAR%2525CE%2525B4%252BActivators%26aulast%3DSchierle%26aufirst%3DSimone%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15042020%26date%3D20072020%26volume%3D63%26issue%3D15%26spage%3D8369%26epage%3D8379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lena Hefke, Kerstin Hiesinger, W. Felix Zhu, Jan S. Kramer, <span class="NLM_string-name hlFld-ContribAuthor">Ewgenij Proschak</span>. </span><span class="cited-content_cbyCitation_article-title">Computer-Aided Fragment Growing Strategies to Design Dual Inhibitors of Soluble Epoxide Hydrolase and LTA4 Hydrolase. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (6)
                                     , 1244-1249. <a href="https://doi.org/10.1021/acsmedchemlett.0c00102" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00102</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00102%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DComputer-Aided%252BFragment%252BGrowing%252BStrategies%252Bto%252BDesign%252BDual%252BInhibitors%252Bof%252BSoluble%252BEpoxide%252BHydrolase%252Band%252BLTA4%252BHydrolase%26aulast%3DHefke%26aufirst%3DLena%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D29022020%26date%3D08042020%26date%3D11052020%26date%3D08042020%26volume%3D11%26issue%3D6%26spage%3D1244%26epage%3D1249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ashish Thakur, Gregory J. Tawa, Mark J. Henderson, Carina Danchik, Suiyang Liu, Pranav Shah, Amy Q. Wang, Garrett Dunn, Md Kabir, Elias C. Padilha, Xin Xu, Anton Simeonov, Surender Kharbanda, Richard Stone, <span class="NLM_string-name hlFld-ContribAuthor">Gurmit Grewal</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (8)
                                     , 4256-4292. <a href="https://doi.org/10.1021/acs.jmedchem.0c00193" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00193</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00193%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BQuinazolin-4-one-Based%252BHydroxamic%252BAcids%252Bas%252BDual%252BPI3K%25252FHDAC%252BInhibitors%26aulast%3DThakur%26aufirst%3DAshish%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03022020%26date%3D08042020%26date%3D26032020%26volume%3D63%26issue%3D8%26spage%3D4256%26epage%3D4292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tsuneyuki Kobayashi, Takamitsu Hosoya, <span class="NLM_string-name hlFld-ContribAuthor">Suguru Yoshida</span>. </span><span class="cited-content_cbyCitation_article-title">Consecutive Aryne Generation Strategy for the Synthesis of 1,3-Diarylpyrazoles. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (6)
                                     , 4448-4462. <a href="https://doi.org/10.1021/acs.joc.0c00172" title="DOI URL">https://doi.org/10.1021/acs.joc.0c00172</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c00172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c00172%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DConsecutive%252BAryne%252BGeneration%252BStrategy%252Bfor%252Bthe%252BSynthesis%252Bof%252B1%25252C3-Diarylpyrazoles%26aulast%3DKobayashi%26aufirst%3DTsuneyuki%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D22012020%26date%3D24022020%26date%3D06022020%26volume%3D85%26issue%3D6%26spage%3D4448%26epage%3D4462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kerstin Hiesinger, Annika Schott, Jan S. Kramer, René Blöcher, Finja Witt, Sandra K. Wittmann, Dieter Steinhilber, Denys Pogoryelov, Jana Gerstmeier, Oliver Werz, <span class="NLM_string-name hlFld-ContribAuthor">Ewgenij Proschak</span>. </span><span class="cited-content_cbyCitation_article-title">Design of Dual Inhibitors of Soluble Epoxide Hydrolase and LTA4 Hydrolase. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (3)
                                     , 298-302. <a href="https://doi.org/10.1021/acsmedchemlett.9b00330" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00330</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00330%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Bof%252BDual%252BInhibitors%252Bof%252BSoluble%252BEpoxide%252BHydrolase%252Band%252BLTA4%252BHydrolase%26aulast%3DHiesinger%26aufirst%3DKerstin%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22072019%26date%3D30102019%26date%3D26112019%26date%3D30102019%26volume%3D11%26issue%3D3%26spage%3D298%26epage%3D302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Žiga Skok, Nace Zidar, Danijel Kikelj, <span class="NLM_string-name hlFld-ContribAuthor">Janez Ilaš</span>. </span><span class="cited-content_cbyCitation_article-title">Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (3)
                                     , 884-904. <a href="https://doi.org/10.1021/acs.jmedchem.9b00726" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00726</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00726%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual%252BInhibitors%252Bof%252BHuman%252BDNA%252BTopoisomerase%252BII%252Band%252BOther%252BCancer-Related%252BTargets%26aulast%3DSkok%26aufirst%3D%25C5%25BDiga%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D03052019%26date%3D21102019%26date%3D08102019%26volume%3D63%26issue%3D3%26spage%3D884%26epage%3D904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Luca Pinzi, <span class="NLM_string-name hlFld-ContribAuthor">Giulio Rastelli</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Target Associations for Polypharmacology from Analysis of Crystallographic Ligands of the Protein Data Bank. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (1)
                                     , 372-390. <a href="https://doi.org/10.1021/acs.jcim.9b00821" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00821</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00821%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DIdentification%252Bof%252BTarget%252BAssociations%252Bfor%252BPolypharmacology%252Bfrom%252BAnalysis%252Bof%252BCrystallographic%252BLigands%252Bof%252Bthe%252BProtein%252BData%252BBank%26aulast%3DPinzi%26aufirst%3DLuca%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D20092019%26date%3D19122019%26date%3D04122019%26volume%3D60%26issue%3D1%26spage%3D372%26epage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Leonardo Brunetti, Fulvio Loiodice, Luca Piemontese, Paolo Tortorella, <span class="NLM_string-name hlFld-ContribAuthor">Antonio Laghezza</span>. </span><span class="cited-content_cbyCitation_article-title">New Approaches to Cancer Therapy: Combining Fatty Acid Amide Hydrolase (FAAH) Inhibition with Peroxisome Proliferator-Activated Receptors (PPARs) Activation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (24)
                                     , 10995-11003. <a href="https://doi.org/10.1021/acs.jmedchem.9b00885" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00885</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00885%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNew%252BApproaches%252Bto%252BCancer%252BTherapy%25253A%252BCombining%252BFatty%252BAcid%252BAmide%252BHydrolase%252B%252528FAAH%252529%252BInhibition%252Bwith%252BPeroxisome%252BProliferator-Activated%252BReceptors%252B%252528PPARs%252529%252BActivation%26aulast%3DBrunetti%26aufirst%3DLeonardo%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D31052019%26date%3D22082019%26date%3D13082019%26volume%3D62%26issue%3D24%26spage%3D10995%26epage%3D11003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Carina Lemke, Joscha Christmann, Jiafei Yin, José M. Alonso, Estefanía Serrano, Mourad Chioua, Lhassane Ismaili, María Angeles Martínez-Grau, Christopher D. Beadle, Tatiana Vetman, Florian M. Dato, Ulrike Bartz, Paul W. Elsinghorst, Markus Pietsch, Christa E. Müller, Isabel Iriepa, Timo Wille, José Marco-Contelles, <span class="NLM_string-name hlFld-ContribAuthor">Michael Gütschow</span>. </span><span class="cited-content_cbyCitation_article-title">Chromenones as Multineurotargeting Inhibitors of Human Enzymes. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (26)
                                     , 22161-22168. <a href="https://doi.org/10.1021/acsomega.9b03409" title="DOI URL">https://doi.org/10.1021/acsomega.9b03409</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.9b03409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.9b03409%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DChromenones%252Bas%252BMultineurotargeting%252BInhibitors%252Bof%252BHuman%252BEnzymes%26aulast%3DLemke%26aufirst%3DCarina%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14102019%26date%3D21112019%26date%3D11122019%26volume%3D4%26issue%3D26%26spage%3D22161%26epage%3D22168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lorenzo Cianni, Christian Wolfgang Feldmann, Erik Gilberg, Michael Gütschow, Luiz Juliano, Andrei Leitão, Jürgen Bajorath, <span class="NLM_string-name hlFld-ContribAuthor">Carlos A. Montanari</span>. </span><span class="cited-content_cbyCitation_article-title">Can Cysteine Protease Cross-Class Inhibitors Achieve Selectivity?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (23)
                                     , 10497-10525. <a href="https://doi.org/10.1021/acs.jmedchem.9b00683" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00683</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00683%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCan%252BCysteine%252BProtease%252BCross-Class%252BInhibitors%252BAchieve%252BSelectivity%25253F%26aulast%3DCianni%26aufirst%3DLorenzo%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D25042019%26date%3D15082019%26date%3D30072019%26volume%3D62%26issue%3D23%26spage%3D10497%26epage%3D10525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Junting Zhou, Xueyang Jiang, Siyu He, Hongli Jiang, Feng Feng, Wenyuan Liu, Wei Qu, <span class="NLM_string-name hlFld-ContribAuthor">Haopeng Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (20)
                                     , 8881-8914. <a href="https://doi.org/10.1021/acs.jmedchem.9b00017" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00017%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRational%252BDesign%252Bof%252BMultitarget-Directed%252BLigands%25253A%252BStrategies%252Band%252BEmerging%252BParadigms%26aulast%3DZhou%26aufirst%3DJunting%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D04012019%26date%3D28052019%26date%3D13052019%26volume%3D62%26issue%3D20%26spage%3D8881%26epage%3D8914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Matthias Scheiner, Dominik Dolles, Sandra Gunesch, Matthias Hoffmann, Massimo Nabissi, Oliviero Marinelli, Marina Naldi, Manuela Bartolini, Sabrina Petralla, Eleonora Poeta, Barbara Monti, Christina Falkeis, Michael Vieth, Harald Hübner, Peter Gmeiner, Rangan Maitra, Tangui Maurice, <span class="NLM_string-name hlFld-ContribAuthor">Michael Decker</span>. </span><span class="cited-content_cbyCitation_article-title">Dual-Acting Cholinesterase–Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (20)
                                     , 9078-9102. <a href="https://doi.org/10.1021/acs.jmedchem.9b00623" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00623</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00623%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual-Acting%252BCholinesterase%2525E2%252580%252593Human%252BCannabinoid%252BReceptor%252B2%252BLigands%252BShow%252BPronounced%252BNeuroprotection%252Bin%252BVitro%252Band%252BOveradditive%252Band%252BDisease-Modifying%252BNeuroprotective%252BEffects%252Bin%252BVivo%26aulast%3DScheiner%26aufirst%3DMatthias%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D30042019%26date%3D14102019%26volume%3D62%26issue%3D20%26spage%3D9078%26epage%3D9102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kehui Zhang, Fangfang Lai, Songwen Lin, Ming Ji, Jingbo Zhang, Yan Zhang, Jing Jin, Rong Fu, Deyu Wu, Hua Tian, Nina Xue, Li Sheng, Xiaowen Zou, Yan Li, Xiaoguang Chen, <span class="NLM_string-name hlFld-ContribAuthor">Heng Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (15)
                                     , 6992-7014. <a href="https://doi.org/10.1021/acs.jmedchem.9b00390" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00390</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00390%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252B4-Methyl%252BQuinazoline%252BDerivatives%252Bas%252BAnticancer%252BAgents%252BSimultaneously%252BTargeting%252BPhosphoinositide%252B3-Kinases%252Band%252BHistone%252BDeacetylases%26aulast%3DZhang%26aufirst%3DKehui%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D03032019%26date%3D29052019%26date%3D22052019%26volume%3D62%26issue%3D15%26spage%3D6992%26epage%3D7014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Aimie
E. Garces, <span class="NLM_string-name hlFld-ContribAuthor">Michael J. Stocks</span>. </span><span class="cited-content_cbyCitation_article-title">Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (10)
                                     , 4815-4850. <a href="https://doi.org/10.1021/acs.jmedchem.8b01492" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01492</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01492%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DClass%252B1%252BPI3K%252BClinical%252BCandidates%252Band%252BRecent%252BInhibitor%252BDesign%252BStrategies%25253A%252BA%252BMedicinal%252BChemistry%252BPerspective%26aulast%3DGarces%26aufirst%3DAimie%2BE.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D25092018%26date%3D24122018%26volume%3D62%26issue%3D10%26spage%3D4815%26epage%3D4850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Maria Laura Bolognesi</span>. </span><span class="cited-content_cbyCitation_article-title">Harnessing Polypharmacology with Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (3)
                                     , 273-275. <a href="https://doi.org/10.1021/acsmedchemlett.9b00039" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00039%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DHarnessing%252BPolypharmacology%252Bwith%252BMedicinal%252BChemistry%26aulast%3DBolognesi%26aufirst%3DMaria%2BLaura%26date%3D2019%26date%3D2019%26date%3D15022019%26volume%3D10%26issue%3D3%26spage%3D273%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jacob
T. Andring, Wolfgang Dohle, Chingkuang Tu, Barry V. L. Potter, <span class="NLM_string-name hlFld-ContribAuthor">Robert McKenna</span>. </span><span class="cited-content_cbyCitation_article-title">3,17β-Bis-sulfamoyloxy-2-methoxyestra-1,3,5(10)-triene and Nonsteroidal Sulfamate Derivatives Inhibit Carbonic Anhydrase IX: Structure–Activity Optimization for Isoform Selectivity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (4)
                                     , 2202-2212. <a href="https://doi.org/10.1021/acs.jmedchem.8b01990" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01990</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01990%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D3%25252C17%2525CE%2525B2-Bis-sulfamoyloxy-2-methoxyestra-1%25252C3%25252C5%25252810%252529-triene%252Band%252BNonsteroidal%252BSulfamate%252BDerivatives%252BInhibit%252BCarbonic%252BAnhydrase%252BIX%25253A%252BStructure%2525E2%252580%252593Activity%252BOptimization%252Bfor%252BIsoform%252BSelectivity%26aulast%3DAndring%26aufirst%3DJacob%2BT.%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D19122018%26date%3D18022019%26date%3D05022019%26volume%3D62%26issue%3D4%26spage%3D2202%26epage%3D2212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Erik Gilberg, <span class="NLM_string-name hlFld-ContribAuthor">Jürgen Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Progress in Structure-Based Evaluation of Compound Promiscuity. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (2)
                                     , 2758-2765. <a href="https://doi.org/10.1021/acsomega.8b03639" title="DOI URL">https://doi.org/10.1021/acsomega.8b03639</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.8b03639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.8b03639%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DRecent%252BProgress%252Bin%252BStructure-Based%252BEvaluation%252Bof%252BCompound%252BPromiscuity%26aulast%3DGilberg%26aufirst%3DErik%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D27122018%26date%3D29012019%26volume%3D4%26issue%3D2%26spage%3D2758%26epage%3D2765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Feldmann</span>, <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Machine learning reveals that structural features distinguishing promiscuous and non-promiscuous compounds depend on target combinations. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-021-87042-z" title="DOI URL">https://doi.org/10.1038/s41598-021-87042-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-021-87042-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-021-87042-z%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DMachine%252Blearning%252Breveals%252Bthat%252Bstructural%252Bfeatures%252Bdistinguishing%252Bpromiscuous%252Band%252Bnon-promiscuous%252Bcompounds%252Bdepend%252Bon%252Btarget%252Bcombinations%26aulast%3DFeldmann%26aufirst%3DChristian%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefanie  Kampen</span>, <span class="hlFld-ContribAuthor ">Duc  Duy Vo</span>, <span class="hlFld-ContribAuthor ">Xiaoqun  Zhang</span>, <span class="hlFld-ContribAuthor ">Nicolas  Panel</span>, <span class="hlFld-ContribAuthor ">Yunting  Yang</span>, <span class="hlFld-ContribAuthor ">Mariama  Jaiteh</span>, <span class="hlFld-ContribAuthor ">Pierre  Matricon</span>, <span class="hlFld-ContribAuthor ">Per  Svenningsson</span>, <span class="hlFld-ContribAuthor ">Jose  Brea</span>, <span class="hlFld-ContribAuthor ">Maria Isabel  Loza</span>, <span class="hlFld-ContribAuthor ">Jan  Kihlberg</span>, <span class="hlFld-ContribAuthor ">Jens  Carlsson</span>. </span><span class="cited-content_cbyCitation_article-title">Structure‐Guided Design of G‐Protein‐Coupled Receptor Polypharmacology. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2021,</strong> <em>60 </em>
                                    (33)
                                     , 18022-18030. <a href="https://doi.org/10.1002/anie.202101478" title="DOI URL">https://doi.org/10.1002/anie.202101478</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202101478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202101478%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DStructure%2525E2%252580%252590Guided%252BDesign%252Bof%252BG%2525E2%252580%252590Protein%2525E2%252580%252590Coupled%252BReceptor%252BPolypharmacology%26aulast%3DKampen%26aufirst%3DStefanie%26date%3D2021%26date%3D2021%26volume%3D60%26issue%3D33%26spage%3D18022%26epage%3D18030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefanie  Kampen</span>, <span class="hlFld-ContribAuthor ">Duc  Duy Vo</span>, <span class="hlFld-ContribAuthor ">Xiaoqun  Zhang</span>, <span class="hlFld-ContribAuthor ">Nicolas  Panel</span>, <span class="hlFld-ContribAuthor ">Yunting  Yang</span>, <span class="hlFld-ContribAuthor ">Mariama  Jaiteh</span>, <span class="hlFld-ContribAuthor ">Pierre  Matricon</span>, <span class="hlFld-ContribAuthor ">Per  Svenningsson</span>, <span class="hlFld-ContribAuthor ">Jose  Brea</span>, <span class="hlFld-ContribAuthor ">Maria Isabel  Loza</span>, <span class="hlFld-ContribAuthor ">Jan  Kihlberg</span>, <span class="hlFld-ContribAuthor ">Jens  Carlsson</span>. </span><span class="cited-content_cbyCitation_article-title">Structure‐Guided Design of G‐Protein‐Coupled Receptor Polypharmacology. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2021,</strong> <em>133 </em>
                                    (33)
                                     , 18170-18178. <a href="https://doi.org/10.1002/ange.202101478" title="DOI URL">https://doi.org/10.1002/ange.202101478</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202101478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202101478%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DStructure%2525E2%252580%252590Guided%252BDesign%252Bof%252BG%2525E2%252580%252590Protein%2525E2%252580%252590Coupled%252BReceptor%252BPolypharmacology%26aulast%3DKampen%26aufirst%3DStefanie%26date%3D2021%26date%3D2021%26volume%3D133%26issue%3D33%26spage%3D18170%26epage%3D18178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas  Blaschke</span>, <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Compound dataset and custom code for deep generative multi-target compound design. </span><span class="cited-content_cbyCitation_journal-name">Future Science OA</span><span> <strong>2021,</strong> <em>7 </em>
                                    (6)
                                     , FSO715. <a href="https://doi.org/10.2144/fsoa-2021-0033" title="DOI URL">https://doi.org/10.2144/fsoa-2021-0033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2144/fsoa-2021-0033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2144%2Ffsoa-2021-0033%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Science%2520OA%26atitle%3DCompound%252Bdataset%252Band%252Bcustom%252Bcode%252Bfor%252Bdeep%252Bgenerative%252Bmulti-target%252Bcompound%252Bdesign%26aulast%3DBlaschke%26aufirst%3DThomas%26date%3D2021%26volume%3D7%26issue%3D6%26spage%3DFSO715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lukas  Gorecki</span>, <span class="hlFld-ContribAuthor ">Anna  Misiachna</span>, <span class="hlFld-ContribAuthor ">Jiri  Damborsky</span>, <span class="hlFld-ContribAuthor ">Rafael  Dolezal</span>, <span class="hlFld-ContribAuthor ">Jan  Korabecny</span>, <span class="hlFld-ContribAuthor ">Lada  Cejkova</span>, <span class="hlFld-ContribAuthor ">Kristina  Hakenova</span>, <span class="hlFld-ContribAuthor ">Marketa  Chvojkova</span>, <span class="hlFld-ContribAuthor ">Jana Zdarova  Karasova</span>, <span class="hlFld-ContribAuthor ">Lukas  Prchal</span>, <span class="hlFld-ContribAuthor ">Martin  Novak</span>, <span class="hlFld-ContribAuthor ">Marharyta  Kolcheva</span>, <span class="hlFld-ContribAuthor ">Stepan  Kortus</span>, <span class="hlFld-ContribAuthor ">Karel  Vales</span>, <span class="hlFld-ContribAuthor ">Martin  Horak</span>, <span class="hlFld-ContribAuthor ">Ondrej  Soukup</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-activity relationships of dually-acting acetylcholinesterase inhibitors derived from tacrine on N-methyl-d-Aspartate receptors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>219 </em>, 113434. <a href="https://doi.org/10.1016/j.ejmech.2021.113434" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113434</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113434%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-activity%252Brelationships%252Bof%252Bdually-acting%252Bacetylcholinesterase%252Binhibitors%252Bderived%252Bfrom%252Btacrine%252Bon%252BN-methyl-d-Aspartate%252Breceptors%26aulast%3DGorecki%26aufirst%3DLukas%26date%3D2021%26volume%3D219%26spage%3D113434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kojo  Mensa-Wilmot</span>. </span><span class="cited-content_cbyCitation_article-title">How Physiologic Targets Can Be Distinguished from Drug-Binding Proteins. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmacology</span><span> <strong>2021,</strong> <em>100 </em>
                                    (1)
                                     , 1-6. <a href="https://doi.org/10.1124/molpharm.120.000186" title="DOI URL">https://doi.org/10.1124/molpharm.120.000186</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/molpharm.120.000186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fmolpharm.120.000186%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmacology%26atitle%3DHow%252BPhysiologic%252BTargets%252BCan%252BBe%252BDistinguished%252Bfrom%252BDrug-Binding%252BProteins%26aulast%3DMensa-Wilmot%26aufirst%3DKojo%26date%3D2021%26date%3D2021%26volume%3D100%26issue%3D1%26spage%3D1%26epage%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria Giovanna  Chini</span>, <span class="hlFld-ContribAuthor ">Gianluigi  Lauro</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Bifulco</span>. </span><span class="cited-content_cbyCitation_article-title">Addressing the Target Identification and Accelerating the Repositioning of Anti‐Inflammatory/Anti‐Cancer Organic Compounds by Computational Approaches. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>2021 </em>
                                    (21)
                                     , 2966-2981. <a href="https://doi.org/10.1002/ejoc.202100245" title="DOI URL">https://doi.org/10.1002/ejoc.202100245</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202100245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202100245%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DAddressing%252Bthe%252BTarget%252BIdentification%252Band%252BAccelerating%252Bthe%252BRepositioning%252Bof%252BAnti%2525E2%252580%252590Inflammatory%25252FAnti%2525E2%252580%252590Cancer%252BOrganic%252BCompounds%252Bby%252BComputational%252BApproaches%26aulast%3DChini%26aufirst%3DMaria%2BGiovanna%26date%3D2021%26date%3D2021%26volume%3D2021%26issue%3D21%26spage%3D2966%26epage%3D2981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Feldmann</span>, <span class="hlFld-ContribAuthor ">Dimitar  Yonchev</span>, <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Structured data sets of compounds with multi-target and corresponding single-target activity from biological assays. </span><span class="cited-content_cbyCitation_journal-name">Future Science OA</span><span> <strong>2021,</strong> <em>7 </em>
                                    (5)
                                     , FSO685. <a href="https://doi.org/10.2144/fsoa-2020-0209" title="DOI URL">https://doi.org/10.2144/fsoa-2020-0209</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2144/fsoa-2020-0209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2144%2Ffsoa-2020-0209%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Science%2520OA%26atitle%3DStructured%252Bdata%252Bsets%252Bof%252Bcompounds%252Bwith%252Bmulti-target%252Band%252Bcorresponding%252Bsingle-target%252Bactivity%252Bfrom%252Bbiological%252Bassays%26aulast%3DFeldmann%26aufirst%3DChristian%26date%3D2021%26volume%3D7%26issue%3D5%26spage%3DFSO685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Attila  Egyed</span>, <span class="hlFld-ContribAuthor ">Ádám A.  Kelemen</span>, <span class="hlFld-ContribAuthor ">Márton  Vass</span>, <span class="hlFld-ContribAuthor ">András  Visegrády</span>, <span class="hlFld-ContribAuthor ">Stephanie A.  Thee</span>, <span class="hlFld-ContribAuthor ">Zhiyong  Wang</span>, <span class="hlFld-ContribAuthor ">Chris  de Graaf</span>, <span class="hlFld-ContribAuthor ">Jose  Brea</span>, <span class="hlFld-ContribAuthor ">Maria Isabel  Loza</span>, <span class="hlFld-ContribAuthor ">Rob  Leurs</span>, <span class="hlFld-ContribAuthor ">György M.  Keserű</span>. </span><span class="cited-content_cbyCitation_article-title">Controlling the selectivity of aminergic GPCR ligands from the extracellular vestibule. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>111 </em>, 104832. <a href="https://doi.org/10.1016/j.bioorg.2021.104832" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104832</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104832%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DControlling%252Bthe%252Bselectivity%252Bof%252Baminergic%252BGPCR%252Bligands%252Bfrom%252Bthe%252Bextracellular%252Bvestibule%26aulast%3DEgyed%26aufirst%3DAttila%26date%3D2021%26volume%3D111%26spage%3D104832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Albert A.  Antolin</span>, <span class="hlFld-ContribAuthor ">Paul A.  Clarke</span>, <span class="hlFld-ContribAuthor ">Ian  Collins</span>, <span class="hlFld-ContribAuthor ">Paul  Workman</span>, <span class="hlFld-ContribAuthor ">Bissan  Al-Lazikani</span>. </span><span class="cited-content_cbyCitation_article-title">Evolution of kinase polypharmacology across HSP90 drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2021,</strong> <em>5 </em><a href="https://doi.org/10.1016/j.chembiol.2021.05.004" title="DOI URL">https://doi.org/10.1016/j.chembiol.2021.05.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2021.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2021.05.004%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DEvolution%252Bof%252Bkinase%252Bpolypharmacology%252Bacross%252BHSP90%252Bdrug%252Bdiscovery%26aulast%3DAntolin%26aufirst%3DAlbert%2BA.%26date%3D2021%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dorota  Łażewska</span>, <span class="hlFld-ContribAuthor ">Paula  Zaręba</span>, <span class="hlFld-ContribAuthor ">Justyna  Godyń</span>, <span class="hlFld-ContribAuthor ">Agata  Doroz-Płonka</span>, <span class="hlFld-ContribAuthor ">Annika  Frank</span>, <span class="hlFld-ContribAuthor ">David  Reiner-Link</span>, <span class="hlFld-ContribAuthor ">Marek  Bajda</span>, <span class="hlFld-ContribAuthor ">Dorota  Stary</span>, <span class="hlFld-ContribAuthor ">Szczepan  Mogilski</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Olejarz-Maciej</span>, <span class="hlFld-ContribAuthor ">Maria  Kaleta</span>, <span class="hlFld-ContribAuthor ">Holger  Stark</span>, <span class="hlFld-ContribAuthor ">Barbara  Malawska</span>, <span class="hlFld-ContribAuthor ">Katarzyna  Kieć-Kononowicz</span>. </span><span class="cited-content_cbyCitation_article-title">Biphenylalkoxyamine Derivatives–Histamine H3 Receptor Ligands with Butyrylcholinesterase Inhibitory Activity. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (12)
                                     , 3580. <a href="https://doi.org/10.3390/molecules26123580" title="DOI URL">https://doi.org/10.3390/molecules26123580</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26123580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26123580%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBiphenylalkoxyamine%252BDerivatives%2525E2%252580%252593Histamine%252BH3%252BReceptor%252BLigands%252Bwith%252BButyrylcholinesterase%252BInhibitory%252BActivity%26aulast%3D%25C5%2581a%25C5%25BCewska%26aufirst%3DDorota%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D12%26spage%3D3580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Structural characteristics of compounds with multitarget activity. </span><span class="cited-content_cbyCitation_journal-name">Future Drug Discovery</span><span> <strong>2021,</strong> <em>3 </em>
                                    (2)
                                     , FDD60. <a href="https://doi.org/10.4155/fdd-2021-0003" title="DOI URL">https://doi.org/10.4155/fdd-2021-0003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fdd-2021-0003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffdd-2021-0003%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Drug%2520Discovery%26atitle%3DStructural%252Bcharacteristics%252Bof%252Bcompounds%252Bwith%252Bmultitarget%252Bactivity%26aulast%3DBajorath%26aufirst%3DJ%25C3%25BCrgen%26date%3D2021%26volume%3D3%26issue%3D2%26spage%3DFDD60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manuela  Jörg</span>, <span class="hlFld-ContribAuthor ">Katrina S.  Madden</span>. </span><span class="cited-content_cbyCitation_article-title">The right tools for the job: the central role for next generation chemical probes and chemistry-based target deconvolution methods in phenotypic drug discovery. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (5)
                                     , 646-665. <a href="https://doi.org/10.1039/D1MD00022E" title="DOI URL">https://doi.org/10.1039/D1MD00022E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1MD00022E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1MD00022E%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DThe%252Bright%252Btools%252Bfor%252Bthe%252Bjob%25253A%252Bthe%252Bcentral%252Brole%252Bfor%252Bnext%252Bgeneration%252Bchemical%252Bprobes%252Band%252Bchemistry-based%252Btarget%252Bdeconvolution%252Bmethods%252Bin%252Bphenotypic%252Bdrug%252Bdiscovery%26aulast%3DJ%25C3%25B6rg%26aufirst%3DManuela%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D5%26spage%3D646%26epage%3D665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simone  Schierle</span>, <span class="hlFld-ContribAuthor ">Steffen  Brunst</span>, <span class="hlFld-ContribAuthor ">Moritz  Helmstädter</span>, <span class="hlFld-ContribAuthor ">Roland  Ebert</span>, <span class="hlFld-ContribAuthor ">Jan S.  Kramer</span>, <span class="hlFld-ContribAuthor ">Dieter  Steinhilber</span>, <span class="hlFld-ContribAuthor ">Ewgenij  Proschak</span>, <span class="hlFld-ContribAuthor ">Daniel  Merk</span>. </span><span class="cited-content_cbyCitation_article-title">Development and in vitro Profiling of Dual FXR/LTA4H Modulators. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>62 </em><a href="https://doi.org/10.1002/cmdc.202100118" title="DOI URL">https://doi.org/10.1002/cmdc.202100118</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202100118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202100118%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DDevelopment%252Band%252Bin%2525E2%252580%252585vitro%252BProfiling%252Bof%252BDual%252BFXR%25252FLTA4H%252BModulators%26aulast%3DSchierle%26aufirst%3DSimone%26date%3D2021%26date%3D2021%26volume%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Atsushi  Yoshimori</span>, <span class="hlFld-ContribAuthor ">Huabin  Hu</span>, <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Adapting the DeepSARM approach for dual-target ligand design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Computer-Aided Molecular Design</span><span> <strong>2021,</strong> <em>35 </em>
                                    (5)
                                     , 587-600. <a href="https://doi.org/10.1007/s10822-021-00379-5" title="DOI URL">https://doi.org/10.1007/s10822-021-00379-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10822-021-00379-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10822-021-00379-5%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computer-Aided%2520Molecular%2520Design%26atitle%3DAdapting%252Bthe%252BDeepSARM%252Bapproach%252Bfor%252Bdual-target%252Bligand%252Bdesign%26aulast%3DYoshimori%26aufirst%3DAtsushi%26date%3D2021%26date%3D2021%26volume%3D35%26issue%3D5%26spage%3D587%26epage%3D600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dagmar  Stumpfe</span>, <span class="hlFld-ContribAuthor ">Alexander  Hoch</span>, <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Introducing the metacore concept for multi-target ligand design. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (4)
                                     , 628-635. <a href="https://doi.org/10.1039/D1MD00056J" title="DOI URL">https://doi.org/10.1039/D1MD00056J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1MD00056J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1MD00056J%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DIntroducing%252Bthe%252Bmetacore%252Bconcept%252Bfor%252Bmulti-target%252Bligand%252Bdesign%26aulast%3DStumpfe%26aufirst%3DDagmar%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D4%26spage%3D628%26epage%3D635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonardo L.G.  Ferreira</span>, <span class="hlFld-ContribAuthor ">Adriano D.  Andricopulo</span>. </span><span class="cited-content_cbyCitation_article-title">Structure‐Based Drug Design. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-54. <a href="https://doi.org/10.1002/0471266949.bmc141.pub2" title="DOI URL">https://doi.org/10.1002/0471266949.bmc141.pub2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc141.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc141.pub2%26sid%3Dliteratum%253Aachs%26atitle%3DStructure%2525E2%252580%252590Based%252BDrug%252BDesign%26aulast%3DFerreira%26aufirst%3DLeonardo%2BL.G.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D54%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Patrick O.  Sakyi</span>, <span class="hlFld-ContribAuthor ">Richard K.  Amewu</span>, <span class="hlFld-ContribAuthor ">Robert N. O. A.  Devine</span>, <span class="hlFld-ContribAuthor ">Alfred K.  Bienibuor</span>, <span class="hlFld-ContribAuthor ">Whelton A.  Miller</span>, <span class="hlFld-ContribAuthor ">Samuel K.  Kwofie</span>. </span><span class="cited-content_cbyCitation_article-title">Unravelling the myth surrounding sterol biosynthesis as plausible target for drug design against leishmaniasis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Parasitic Diseases</span><span> <strong>2021,</strong> <em>11 </em><a href="https://doi.org/10.1007/s12639-021-01390-1" title="DOI URL">https://doi.org/10.1007/s12639-021-01390-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12639-021-01390-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12639-021-01390-1%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Parasitic%2520Diseases%26atitle%3DUnravelling%252Bthe%252Bmyth%252Bsurrounding%252Bsterol%252Bbiosynthesis%252Bas%252Bplausible%252Btarget%252Bfor%252Bdrug%252Bdesign%252Bagainst%252Bleishmaniasis%26aulast%3DSakyi%26aufirst%3DPatrick%2BO.%26date%3D2021%26date%3D2021%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Resat  Cinar</span>, <span class="hlFld-ContribAuthor ">Malliga R.  Iyer</span>, <span class="hlFld-ContribAuthor ">George  Kunos</span>. </span><span class="cited-content_cbyCitation_article-title">Dual inhibition of CB
              1
              receptors and iNOS, as a potential novel approach to the pharmacological management of acute and long COVID‐19. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2021,</strong> <em>2 </em><a href="https://doi.org/10.1111/bph.15461" title="DOI URL">https://doi.org/10.1111/bph.15461</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.15461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.15461%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DDual%252Binhibition%252Bof%252BCB%252B1%252Breceptors%252Band%252BiNOS%25252C%252Bas%252Ba%252Bpotential%252Bnovel%252Bapproach%252Bto%252Bthe%252Bpharmacological%252Bmanagement%252Bof%252Bacute%252Band%252Blong%252BCOVID%2525E2%252580%25259019%26aulast%3DCinar%26aufirst%3DResat%26date%3D2021%26date%3D2021%26volume%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rohan  Gupta</span>, <span class="hlFld-ContribAuthor ">Devesh  Srivastava</span>, <span class="hlFld-ContribAuthor ">Mehar  Sahu</span>, <span class="hlFld-ContribAuthor ">Swati  Tiwari</span>, <span class="hlFld-ContribAuthor ">Rashmi K.  Ambasta</span>, <span class="hlFld-ContribAuthor ">Pravir  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Artificial intelligence to deep learning: machine intelligence approach for drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2021,</strong> <em>5 </em><a href="https://doi.org/10.1007/s11030-021-10217-3" title="DOI URL">https://doi.org/10.1007/s11030-021-10217-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-021-10217-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-021-10217-3%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DArtificial%252Bintelligence%252Bto%252Bdeep%252Blearning%25253A%252Bmachine%252Bintelligence%252Bapproach%252Bfor%252Bdrug%252Bdiscovery%26aulast%3DGupta%26aufirst%3DRohan%26date%3D2021%26date%3D2021%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Steffen  Brunst</span>, <span class="hlFld-ContribAuthor ">Jan S.  Kramer</span>, <span class="hlFld-ContribAuthor ">Whitney  Kilu</span>, <span class="hlFld-ContribAuthor ">Jan  Heering</span>, <span class="hlFld-ContribAuthor ">Julius  Pollinger</span>, <span class="hlFld-ContribAuthor ">Kerstin  Hiesinger</span>, <span class="hlFld-ContribAuthor ">Sven  George</span>, <span class="hlFld-ContribAuthor ">Dieter  Steinhilber</span>, <span class="hlFld-ContribAuthor ">Daniel  Merk</span>, <span class="hlFld-ContribAuthor ">Ewgenij  Proschak</span>. </span><span class="cited-content_cbyCitation_article-title">Systematic Assessment of Fragment Identification for Multitarget Drug Design. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (7)
                                     , 1088-1092. <a href="https://doi.org/10.1002/cmdc.202000858" title="DOI URL">https://doi.org/10.1002/cmdc.202000858</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000858%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DSystematic%252BAssessment%252Bof%252BFragment%252BIdentification%252Bfor%252BMultitarget%252BDrug%252BDesign%26aulast%3DBrunst%26aufirst%3DSteffen%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D7%26spage%3D1088%26epage%3D1092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bin  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhikun  Liu</span>, <span class="hlFld-ContribAuthor ">Shengjin  Xia</span>, <span class="hlFld-ContribAuthor ">Qingqing  Liu</span>, <span class="hlFld-ContribAuthor ">Shaohua  Gou</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>216 </em>, 113300. <a href="https://doi.org/10.1016/j.ejmech.2021.113300" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113300</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113300%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bsulfamoylphenyl-quinazoline%252Bderivatives%252Bas%252Bpotential%252BEGFR%25252FCAIX%252Bdual%252Binhibitors%26aulast%3DZhang%26aufirst%3DBin%26date%3D2021%26volume%3D216%26spage%3D113300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leila  Meziant</span>, <span class="hlFld-ContribAuthor ">Mostapha  Bachir-bey</span>, <span class="hlFld-ContribAuthor ">Chawki  Bensouici</span>, <span class="hlFld-ContribAuthor ">Fairouz  Saci</span>, <span class="hlFld-ContribAuthor ">Malika  Boutiche</span>, <span class="hlFld-ContribAuthor ">Hayette  Louaileche</span>. </span><span class="cited-content_cbyCitation_article-title">Assessment of inhibitory properties of flavonoid-rich fig (Ficus carica L.) peel extracts against tyrosinase, α-glucosidase, urease and cholinesterases enzymes, and relationship with antioxidant activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Integrative Medicine</span><span> <strong>2021,</strong> <em>43 </em>, 101272. <a href="https://doi.org/10.1016/j.eujim.2020.101272" title="DOI URL">https://doi.org/10.1016/j.eujim.2020.101272</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.eujim.2020.101272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.eujim.2020.101272%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Integrative%2520Medicine%26atitle%3DAssessment%252Bof%252Binhibitory%252Bproperties%252Bof%252Bflavonoid-rich%252Bfig%252B%252528Ficus%252Bcarica%252BL.%252529%252Bpeel%252Bextracts%252Bagainst%252Btyrosinase%25252C%252B%2525CE%2525B1-glucosidase%25252C%252Burease%252Band%252Bcholinesterases%252Benzymes%25252C%252Band%252Brelationship%252Bwith%252Bantioxidant%252Bactivity%26aulast%3DMeziant%26aufirst%3DLeila%26date%3D2021%26volume%3D43%26spage%3D101272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Felix F.  Lillich</span>, <span class="hlFld-ContribAuthor ">John D.  Imig</span>, <span class="hlFld-ContribAuthor ">Ewgenij  Proschak</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-Target Approaches in Metabolic Syndrome. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2021,</strong> <em>11 </em><a href="https://doi.org/10.3389/fphar.2020.554961" title="DOI URL">https://doi.org/10.3389/fphar.2020.554961</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2020.554961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2020.554961%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DMulti-Target%252BApproaches%252Bin%252BMetabolic%252BSyndrome%26aulast%3DLillich%26aufirst%3DFelix%2BF.%26date%3D2021%26date%3D2021%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nora  Khiar‐Fernández</span>, <span class="hlFld-ContribAuthor ">Jon  Macicior</span>, <span class="hlFld-ContribAuthor ">Beatriz  Marcos‐Ramiro</span>, <span class="hlFld-ContribAuthor ">Silvia  Ortega‐Gutiérrez</span>. </span><span class="cited-content_cbyCitation_article-title">Chemistry for the Identification of Therapeutic Targets: Recent Advances and Future Directions. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>2021 </em>
                                    (9)
                                     , 1307-1320. <a href="https://doi.org/10.1002/ejoc.202001507" title="DOI URL">https://doi.org/10.1002/ejoc.202001507</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202001507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202001507%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DChemistry%252Bfor%252Bthe%252BIdentification%252Bof%252BTherapeutic%252BTargets%25253A%252BRecent%252BAdvances%252Band%252BFuture%252BDirections%26aulast%3DKhiar%25E2%2580%2590Fern%25C3%25A1ndez%26aufirst%3DNora%26date%3D2021%26date%3D2021%26volume%3D2021%26issue%3D9%26spage%3D1307%26epage%3D1320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexandria M.  Chan</span>, <span class="hlFld-ContribAuthor ">Steven  Fletcher</span>. </span><span class="cited-content_cbyCitation_article-title">Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (2)
                                     , 178-196. <a href="https://doi.org/10.1039/D0MD00286K" title="DOI URL">https://doi.org/10.1039/D0MD00286K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00286K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00286K%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DShifting%252Bthe%252Bparadigm%252Bin%252Btreating%252Bmulti-factorial%252Bdiseases%25253A%252Bpolypharmacological%252Bco-inhibitors%252Bof%252BHDAC6%26aulast%3DChan%26aufirst%3DAlexandria%2BM.%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D2%26spage%3D178%26epage%3D196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Atukuri  Dorababu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent update on antibacterial and antifungal activity of quinoline scaffolds. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2021,</strong> <em>354 </em>
                                    (3)
                                     , 2000232. <a href="https://doi.org/10.1002/ardp.202000232" title="DOI URL">https://doi.org/10.1002/ardp.202000232</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.202000232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.202000232%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DRecent%252Bupdate%252Bon%252Bantibacterial%252Band%252Bantifungal%252Bactivity%252Bof%252Bquinoline%252Bscaffolds%26aulast%3DDorababu%26aufirst%3DAtukuri%26date%3D2021%26date%3D2020%26volume%3D354%26issue%3D3%26spage%3D2000232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pakhuri  Mehta</span>, <span class="hlFld-ContribAuthor ">Przemysław  Miszta</span>, <span class="hlFld-ContribAuthor ">Sławomir  Filipek</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Modeling of Histamine Receptors—Recent Advances in Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (6)
                                     , 1778. <a href="https://doi.org/10.3390/molecules26061778" title="DOI URL">https://doi.org/10.3390/molecules26061778</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26061778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26061778%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DMolecular%252BModeling%252Bof%252BHistamine%252BReceptors%2525E2%252580%252594Recent%252BAdvances%252Bin%252BDrug%252BDiscovery%26aulast%3DMehta%26aufirst%3DPakhuri%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D6%26spage%3D1778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gyeong Han  Jeong</span>, <span class="hlFld-ContribAuthor ">Seungil  Park</span>, <span class="hlFld-ContribAuthor ">Seong Bong  Kim</span>, <span class="hlFld-ContribAuthor ">Cheorun  Jo</span>, <span class="hlFld-ContribAuthor ">Tae Hoon  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular hybridization based on (−)-epigallocatechin gallate as a new class of antiglycation agents. </span><span class="cited-content_cbyCitation_journal-name">Bioscience, Biotechnology, and Biochemistry</span><span> <strong>2021,</strong> <em>67 </em><a href="https://doi.org/10.1093/bbb/zbab020" title="DOI URL">https://doi.org/10.1093/bbb/zbab020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/bbb/zbab020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fbbb%2Fzbab020%26sid%3Dliteratum%253Aachs%26jtitle%3DBioscience%252C%2520Biotechnology%252C%2520and%2520Biochemistry%26atitle%3DMolecular%252Bhybridization%252Bbased%252Bon%252B%252528%2525E2%252588%252592%252529-epigallocatechin%252Bgallate%252Bas%252Ba%252Bnew%252Bclass%252Bof%252Bantiglycation%252Bagents%26aulast%3DJeong%26aufirst%3DGyeong%2BHan%26date%3D2021%26date%3D2021%26volume%3D67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Srinivas Niranj  Chandrasekaran</span>, <span class="hlFld-ContribAuthor ">Hugo  Ceulemans</span>, <span class="hlFld-ContribAuthor ">Justin D.  Boyd</span>, <span class="hlFld-ContribAuthor ">Anne E.  Carpenter</span>. </span><span class="cited-content_cbyCitation_article-title">Image-based profiling for drug discovery: due for a machine-learning upgrade?. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2021,</strong> <em>20 </em>
                                    (2)
                                     , 145-159. <a href="https://doi.org/10.1038/s41573-020-00117-w" title="DOI URL">https://doi.org/10.1038/s41573-020-00117-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41573-020-00117-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41573-020-00117-w%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DImage-based%252Bprofiling%252Bfor%252Bdrug%252Bdiscovery%25253A%252Bdue%252Bfor%252Ba%252Bmachine-learning%252Bupgrade%25253F%26aulast%3DChandrasekaran%26aufirst%3DSrinivas%2BNiranj%26date%3D2021%26date%3D2020%26volume%3D20%26issue%3D2%26spage%3D145%26epage%3D159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Jenke</span>, <span class="hlFld-ContribAuthor ">Nina  Reßing</span>, <span class="hlFld-ContribAuthor ">Finn K.  Hansen</span>, <span class="hlFld-ContribAuthor ">Achim  Aigner</span>, <span class="hlFld-ContribAuthor ">Thomas  Büch</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (4)
                                     , 634. <a href="https://doi.org/10.3390/cancers13040634" title="DOI URL">https://doi.org/10.3390/cancers13040634</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13040634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13040634%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DAnticancer%252BTherapy%252Bwith%252BHDAC%252BInhibitors%25253A%252BMechanism-Based%252BCombination%252BStrategies%252Band%252BFuture%252BPerspectives%26aulast%3DJenke%26aufirst%3DRobert%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D4%26spage%3D634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ana  Lago-Fernandez</span>, <span class="hlFld-ContribAuthor ">Sara  Zarzo-Arias</span>, <span class="hlFld-ContribAuthor ">Nadine  Jagerovic</span>, <span class="hlFld-ContribAuthor ">Paula  Morales</span>. </span><span class="cited-content_cbyCitation_article-title">Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (3)
                                     , 1001. <a href="https://doi.org/10.3390/ijms22031001" title="DOI URL">https://doi.org/10.3390/ijms22031001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22031001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22031001%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DRelevance%252Bof%252BPeroxisome%252BProliferator%252BActivated%252BReceptors%252Bin%252BMultitarget%252BParadigm%252BAssociated%252Bwith%252Bthe%252BEndocannabinoid%252BSystem%26aulast%3DLago-Fernandez%26aufirst%3DAna%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D3%26spage%3D1001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Antoine  Daina</span>, <span class="hlFld-ContribAuthor ">Ute F.  Röhrig</span>, <span class="hlFld-ContribAuthor ">Vincent  Zoete</span>. </span><span class="cited-content_cbyCitation_article-title">Computer-Aided Drug Design for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 386-401. <a href="https://doi.org/10.1016/B978-0-12-801238-3.11670-8" title="DOI URL">https://doi.org/10.1016/B978-0-12-801238-3.11670-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-801238-3.11670-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-801238-3.11670-8%26sid%3Dliteratum%253Aachs%26atitle%3DComputer-Aided%252BDrug%252BDesign%252Bfor%252BCancer%252BTherapy%26aulast%3DDaina%26aufirst%3DAntoine%26date%3D2021%26spage%3D386%26epage%3D401%26pub%3DElsevier%26atitle%3DSystems%252BMedicine%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">György  Dormán</span>, <span class="hlFld-ContribAuthor ">Beáta  Flachner</span>, <span class="hlFld-ContribAuthor ">István  Hajdú</span>, <span class="hlFld-ContribAuthor ">Csaba  András</span>. </span><span class="cited-content_cbyCitation_article-title">Target identification and polypharmacology of nutraceuticals. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 315-343. <a href="https://doi.org/10.1016/B978-0-12-821038-3.00023-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-821038-3.00023-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-821038-3.00023-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-821038-3.00023-9%26sid%3Dliteratum%253Aachs%26atitle%3DTarget%252Bidentification%252Band%252Bpolypharmacology%252Bof%252Bnutraceuticals%26aulast%3DDorm%25C3%25A1n%26aufirst%3DGy%25C3%25B6rgy%26date%3D2021%26spage%3D315%26epage%3D343%26pub%3DElsevier%26atitle%3DNutraceuticals%26date%3D2021%26volume%3D113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xueyang  Jiang</span>, <span class="hlFld-ContribAuthor ">Yang  Wang</span>, <span class="hlFld-ContribAuthor ">Chang  Liu</span>, <span class="hlFld-ContribAuthor ">Caiyi  Xing</span>, <span class="hlFld-ContribAuthor ">Yingming  Wang</span>, <span class="hlFld-ContribAuthor ">Weiping  Lyu</span>, <span class="hlFld-ContribAuthor ">Saisai  Wang</span>, <span class="hlFld-ContribAuthor ">Qihang  Li</span>, <span class="hlFld-ContribAuthor ">Tingkai  Chen</span>, <span class="hlFld-ContribAuthor ">Yao  Chen</span>, <span class="hlFld-ContribAuthor ">Feng  Feng</span>, <span class="hlFld-ContribAuthor ">Wenyuan  Liu</span>, <span class="hlFld-ContribAuthor ">Haopeng  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer’s disease. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>30 </em>, 115940. <a href="https://doi.org/10.1016/j.bmc.2020.115940" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115940</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115940%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpotent%252Bglycogen%252Bsynthase%252Bkinase%252B3%25252Fcholinesterase%252Binhibitors%252Bwith%252Bneuroprotection%252Bas%252Bpotential%252Btherapeutic%252Bagent%252Bfor%252BAlzheimer%2525E2%252580%252599s%252Bdisease%26aulast%3DJiang%26aufirst%3DXueyang%26date%3D2021%26volume%3D30%26spage%3D115940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jan  Konecny</span>, <span class="hlFld-ContribAuthor ">Anna  Misiachna</span>, <span class="hlFld-ContribAuthor ">Martina  Hrabinova</span>, <span class="hlFld-ContribAuthor ">Lenka  Pulkrabkova</span>, <span class="hlFld-ContribAuthor ">Marketa  Benkova</span>, <span class="hlFld-ContribAuthor ">Lukas  Prchal</span>, <span class="hlFld-ContribAuthor ">Tomas  Kucera</span>, <span class="hlFld-ContribAuthor ">Tereza  Kobrlova</span>, <span class="hlFld-ContribAuthor ">Vladimir  Finger</span>, <span class="hlFld-ContribAuthor ">Marharyta  Kolcheva</span>, <span class="hlFld-ContribAuthor ">Stepan  Kortus</span>, <span class="hlFld-ContribAuthor ">Daniel  Jun</span>, <span class="hlFld-ContribAuthor ">Marian  Valko</span>, <span class="hlFld-ContribAuthor ">Martin  Horak</span>, <span class="hlFld-ContribAuthor ">Ondrej  Soukup</span>, <span class="hlFld-ContribAuthor ">Jan  Korabecny</span>. </span><span class="cited-content_cbyCitation_article-title">Pursuing the Complexity of Alzheimer’s Disease: Discovery of Fluoren-9-Amines as Selective Butyrylcholinesterase Inhibitors and N-Methyl-d-Aspartate Receptor Antagonists. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     , 3. <a href="https://doi.org/10.3390/biom11010003" title="DOI URL">https://doi.org/10.3390/biom11010003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom11010003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom11010003%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DPursuing%252Bthe%252BComplexity%252Bof%252BAlzheimer%2525E2%252580%252599s%252BDisease%25253A%252BDiscovery%252Bof%252BFluoren-9-Amines%252Bas%252BSelective%252BButyrylcholinesterase%252BInhibitors%252Band%252BN-Methyl-d-Aspartate%252BReceptor%252BAntagonists%26aulast%3DKonecny%26aufirst%3DJan%26date%3D2021%26date%3D2020%26volume%3D11%26issue%3D1%26spage%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rosaria  Ottanà</span>, <span class="hlFld-ContribAuthor ">Paolo  Paoli</span>, <span class="hlFld-ContribAuthor ">Mario  Cappiello</span>, <span class="hlFld-ContribAuthor ">Trung Ngoc  Nguyen</span>, <span class="hlFld-ContribAuthor ">Ilenia  Adornato</span>, <span class="hlFld-ContribAuthor ">Antonella  Del Corso</span>, <span class="hlFld-ContribAuthor ">Massimo  Genovese</span>, <span class="hlFld-ContribAuthor ">Ilaria  Nesi</span>, <span class="hlFld-ContribAuthor ">Roberta  Moschini</span>, <span class="hlFld-ContribAuthor ">Alexandra  Naß</span>, <span class="hlFld-ContribAuthor ">Gerhard  Wolber</span>, <span class="hlFld-ContribAuthor ">Rosanna  Maccari</span>. </span><span class="cited-content_cbyCitation_article-title">In Search for Multi-Target Ligands as Potential Agents for Diabetes Mellitus and Its Complications—A Structure-Activity Relationship Study on Inhibitors of Aldose Reductase and Protein Tyrosine Phosphatase 1B. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (2)
                                     , 330. <a href="https://doi.org/10.3390/molecules26020330" title="DOI URL">https://doi.org/10.3390/molecules26020330</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26020330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26020330%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DIn%252BSearch%252Bfor%252BMulti-Target%252BLigands%252Bas%252BPotential%252BAgents%252Bfor%252BDiabetes%252BMellitus%252Band%252BIts%252BComplications%2525E2%252580%252594A%252BStructure-Activity%252BRelationship%252BStudy%252Bon%252BInhibitors%252Bof%252BAldose%252BReductase%252Band%252BProtein%252BTyrosine%252BPhosphatase%252B1B%26aulast%3DOttan%25C3%25A0%26aufirst%3DRosaria%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D2%26spage%3D330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Loredana  Salerno</span>, <span class="hlFld-ContribAuthor ">Luca  Vanella</span>, <span class="hlFld-ContribAuthor ">Valeria  Sorrenti</span>, <span class="hlFld-ContribAuthor ">Valeria  Consoli</span>, <span class="hlFld-ContribAuthor ">Valeria  Ciaffaglione</span>, <span class="hlFld-ContribAuthor ">Antonino N.  Fallica</span>, <span class="hlFld-ContribAuthor ">Vittorio  Canale</span>, <span class="hlFld-ContribAuthor ">Paweł  Zajdel</span>, <span class="hlFld-ContribAuthor ">Rosario  Pignatello</span>, <span class="hlFld-ContribAuthor ">Sebastiano  Intagliata</span>. </span><span class="cited-content_cbyCitation_article-title">Novel mutual prodrug of 5-fluorouracil and heme oxygenase-1 inhibitor (5-FU/HO-1 hybrid): design and preliminary
              in vitro
              evaluation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2021,</strong> <em>36 </em>
                                    (1)
                                     , 1378-1386. <a href="https://doi.org/10.1080/14756366.2021.1928111" title="DOI URL">https://doi.org/10.1080/14756366.2021.1928111</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2021.1928111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2021.1928111%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bmutual%252Bprodrug%252Bof%252B5-fluorouracil%252Band%252Bheme%252Boxygenase-1%252Binhibitor%252B%2525285-FU%25252FHO-1%252Bhybrid%252529%25253A%252Bdesign%252Band%252Bpreliminary%252Bin%252Bvitro%252Bevaluation%26aulast%3DSalerno%26aufirst%3DLoredana%26date%3D2021%26date%3D2021%26volume%3D36%26issue%3D1%26spage%3D1378%26epage%3D1386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">, <span class="hlFld-ContribAuthor ">Anna  Pasieka</span>, , <span class="hlFld-ContribAuthor ">Dawid  Panek</span>, , <span class="hlFld-ContribAuthor ">Barbara  Malawska</span>, . </span><span class="cited-content_cbyCitation_article-title">Multifunctional Ligand Approach: Search for Effective Therapy Against Alzheimer’s Disease. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 181-203. <a href="https://doi.org/10.36255/exonpublications.alzheimersdisease.2020.ch11" title="DOI URL">https://doi.org/10.36255/exonpublications.alzheimersdisease.2020.ch11</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.36255/exonpublications.alzheimersdisease.2020.ch11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.36255%2Fexonpublications.alzheimersdisease.2020.ch11%26sid%3Dliteratum%253Aachs%26atitle%3DMultifunctional%252BLigand%252BApproach%25253A%252BSearch%252Bfor%252BEffective%252BTherapy%252BAgainst%252BAlzheimer%2525E2%252580%252599s%252BDisease%26aulast%3DPasieka%26aufirst%3DAnna%26date%3D2020%26date%3D2020%26spage%3D181%26epage%3D203%26pub%3DExon%2520Publications%26atitle%3DAlzheimer%2525E2%252580%252599s%252BDisease%25253A%252BDrug%252BDiscovery%26aulast%3DHuang%26aufirst%3DXudong%26date%3D2020%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sergey N.  Adamovich</span>, <span class="hlFld-ContribAuthor ">Evgeniy V.  Kondrashov</span>, <span class="hlFld-ContribAuthor ">Igor A.  Ushakov</span>, <span class="hlFld-ContribAuthor ">Nina S.  Shatokhina</span>, <span class="hlFld-ContribAuthor ">Elizaveta N.  Oborina</span>, <span class="hlFld-ContribAuthor ">Alexander V.  Vashchenko</span>, <span class="hlFld-ContribAuthor ">Lydmila A.  Belovezhets</span>, <span class="hlFld-ContribAuthor ">Igor B.  Rozentsveig</span>, <span class="hlFld-ContribAuthor ">Francis  Verpoort</span>. </span><span class="cited-content_cbyCitation_article-title">Isoxazole derivatives of silatrane: synthesis, characterization, in silico ADME profile, prediction of potential pharmacological activity and evaluation of antimicrobial action. </span><span class="cited-content_cbyCitation_journal-name">Applied Organometallic Chemistry</span><span> <strong>2020,</strong> <em>34 </em>
                                    (12)
                                     <a href="https://doi.org/10.1002/aoc.5976" title="DOI URL">https://doi.org/10.1002/aoc.5976</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/aoc.5976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Faoc.5976%26sid%3Dliteratum%253Aachs%26jtitle%3DApplied%2520Organometallic%2520Chemistry%26atitle%3DIsoxazole%252Bderivatives%252Bof%252Bsilatrane%25253A%252Bsynthesis%25252C%252Bcharacterization%25252C%252Bin%252Bsilico%252BADME%252Bprofile%25252C%252Bprediction%252Bof%252Bpotential%252Bpharmacological%252Bactivity%252Band%252Bevaluation%252Bof%252Bantimicrobial%252Baction%26aulast%3DAdamovich%26aufirst%3DSergey%2BN.%26date%3D2020%26date%3D2020%26volume%3D34%26issue%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mennatallah A.  Shaheen</span>, <span class="hlFld-ContribAuthor ">Ali A.  El-Emam</span>, <span class="hlFld-ContribAuthor ">Nadia S.  El-Gohary</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>105 </em>, 104274. <a href="https://doi.org/10.1016/j.bioorg.2020.104274" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104274</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104274%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnew%252Bseries%252Bof%252Bhexahydroquinoline%252Band%252Bfused%252Bquinoline%252Bderivatives%252Bas%252Bpotent%252Binhibitors%252Bof%252Bwild-type%252BEGFR%252Band%252Bmutant%252BEGFR%252B%252528L858R%252Band%252BT790M%252529%26aulast%3DShaheen%26aufirst%3DMennatallah%2BA.%26date%3D2020%26volume%3D105%26spage%3D104274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuhong  Dong</span>, <span class="hlFld-ContribAuthor ">Hao  Hu</span>, <span class="hlFld-ContribAuthor ">Yuwei  Sun</span>, <span class="hlFld-ContribAuthor ">Mingze  Qin</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Yunlei  Hou</span>, <span class="hlFld-ContribAuthor ">Yanfang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (23)
                                     , 127610. <a href="https://doi.org/10.1016/j.bmcl.2020.127610" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127610</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127610%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bc-Met%25252FHDAC%252Bdual%252Binhibitors%26aulast%3DDong%26aufirst%3DYuhong%26date%3D2020%26volume%3D30%26issue%3D23%26spage%3D127610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dorota  Łażewska</span>, <span class="hlFld-ContribAuthor ">Marek  Bajda</span>, <span class="hlFld-ContribAuthor ">Maria  Kaleta</span>, <span class="hlFld-ContribAuthor ">Paula  Zaręba</span>, <span class="hlFld-ContribAuthor ">Agata  Doroz-Płonka</span>, <span class="hlFld-ContribAuthor ">Agata  Siwek</span>, <span class="hlFld-ContribAuthor ">Alaa  Alachkar</span>, <span class="hlFld-ContribAuthor ">Szczepan  Mogilski</span>, <span class="hlFld-ContribAuthor ">Ali  Saad</span>, <span class="hlFld-ContribAuthor ">Kamil  Kuder</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Olejarz-Maciej</span>, <span class="hlFld-ContribAuthor ">Justyna  Godyń</span>, <span class="hlFld-ContribAuthor ">Dorota  Stary</span>, <span class="hlFld-ContribAuthor ">Sylwia  Sudoł</span>, <span class="hlFld-ContribAuthor ">Małgorzata  Więcek</span>, <span class="hlFld-ContribAuthor ">Gniewomir  Latacz</span>, <span class="hlFld-ContribAuthor ">Maria  Walczak</span>, <span class="hlFld-ContribAuthor ">Jadwiga  Handzlik</span>, <span class="hlFld-ContribAuthor ">Bassem  Sadek</span>, <span class="hlFld-ContribAuthor ">Barbara  Malawska</span>, <span class="hlFld-ContribAuthor ">Katarzyna  Kieć-Kononowicz</span>. </span><span class="cited-content_cbyCitation_article-title">Rational design of new multitarget histamine H3 receptor ligands as potential candidates for treatment of Alzheimer’s disease. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>207 </em>, 112743. <a href="https://doi.org/10.1016/j.ejmech.2020.112743" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112743</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112743&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112743%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRational%252Bdesign%252Bof%252Bnew%252Bmultitarget%252Bhistamine%252BH3%252Breceptor%252Bligands%252Bas%252Bpotential%252Bcandidates%252Bfor%252Btreatment%252Bof%252BAlzheimer%2525E2%252580%252599s%252Bdisease%26aulast%3D%25C5%2581a%25C5%25BCewska%26aufirst%3DDorota%26date%3D2020%26volume%3D207%26spage%3D112743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xueyang  Jiang</span>, <span class="hlFld-ContribAuthor ">Junting  Zhou</span>, <span class="hlFld-ContribAuthor ">Yang  Wang</span>, <span class="hlFld-ContribAuthor ">Lei  Chen</span>, <span class="hlFld-ContribAuthor ">Yan  Duan</span>, <span class="hlFld-ContribAuthor ">Jianping  Huang</span>, <span class="hlFld-ContribAuthor ">Chang  Liu</span>, <span class="hlFld-ContribAuthor ">Yao  Chen</span>, <span class="hlFld-ContribAuthor ">Wenyuan  Liu</span>, <span class="hlFld-ContribAuthor ">Haopeng  Sun</span>, <span class="hlFld-ContribAuthor ">Feng  Feng</span>, <span class="hlFld-ContribAuthor ">Wei  Qu</span>. </span><span class="cited-content_cbyCitation_article-title">Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer’s disease. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>207 </em>, 112751. <a href="https://doi.org/10.1016/j.ejmech.2020.112751" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112751</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112751%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRational%252Bdesign%252Band%252Bbiological%252Bevaluation%252Bof%252Ba%252Bnew%252Bclass%252Bof%252Bthiazolopyridyl%252Btetrahydroacridines%252Bas%252Bcholinesterase%252Band%252BGSK-3%252Bdual%252Binhibitors%252Bfor%252BAlzheimer%2525E2%252580%252599s%252Bdisease%26aulast%3DJiang%26aufirst%3DXueyang%26date%3D2020%26volume%3D207%26spage%3D112751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Albert A.  Antolin</span>, <span class="hlFld-ContribAuthor ">Malaka  Ameratunga</span>, <span class="hlFld-ContribAuthor ">Udai  Banerji</span>, <span class="hlFld-ContribAuthor ">Paul A.  Clarke</span>, <span class="hlFld-ContribAuthor ">Paul  Workman</span>, <span class="hlFld-ContribAuthor ">Bissan  Al-Lazikani</span>. </span><span class="cited-content_cbyCitation_article-title">The kinase polypharmacology landscape of clinical PARP inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-59074-4" title="DOI URL">https://doi.org/10.1038/s41598-020-59074-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-59074-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-59074-4%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DThe%252Bkinase%252Bpolypharmacology%252Blandscape%252Bof%252Bclinical%252BPARP%252Binhibitors%26aulast%3DAntolin%26aufirst%3DAlbert%2BA.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pascal  Heitel</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Faudone</span>, <span class="hlFld-ContribAuthor ">Moritz  Helmstädter</span>, <span class="hlFld-ContribAuthor ">Jurema  Schmidt</span>, <span class="hlFld-ContribAuthor ">Astrid  Kaiser</span>, <span class="hlFld-ContribAuthor ">Amelie  Tjaden</span>, <span class="hlFld-ContribAuthor ">Martin  Schröder</span>, <span class="hlFld-ContribAuthor ">Susanne  Müller</span>, <span class="hlFld-ContribAuthor ">Simone  Schierle</span>, <span class="hlFld-ContribAuthor ">Julius  Pollinger</span>, <span class="hlFld-ContribAuthor ">Daniel  Merk</span>. </span><span class="cited-content_cbyCitation_article-title">A triple farnesoid X receptor and peroxisome proliferator-activated receptor α/δ activator reverses hepatic fibrosis in diet-induced NASH in mice. </span><span class="cited-content_cbyCitation_journal-name">Communications Chemistry</span><span> <strong>2020,</strong> <em>3 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s42004-020-00411-z" title="DOI URL">https://doi.org/10.1038/s42004-020-00411-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s42004-020-00411-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs42004-020-00411-z%26sid%3Dliteratum%253Aachs%26jtitle%3DCommunications%2520Chemistry%26atitle%3DA%252Btriple%252Bfarnesoid%252BX%252Breceptor%252Band%252Bperoxisome%252Bproliferator-activated%252Breceptor%252B%2525CE%2525B1%25252F%2525CE%2525B4%252Bactivator%252Breverses%252Bhepatic%252Bfibrosis%252Bin%252Bdiet-induced%252BNASH%252Bin%252Bmice%26aulast%3DHeitel%26aufirst%3DPascal%26date%3D2020%26date%3D2020%26volume%3D3%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marcus J. G.W.  Ladds</span>, <span class="hlFld-ContribAuthor ">Gergana  Popova</span>, <span class="hlFld-ContribAuthor ">Andrés  Pastor-Fernández</span>, <span class="hlFld-ContribAuthor ">Srinivasaraghavan  Kannan</span>, <span class="hlFld-ContribAuthor ">Ingeborg M.M.  van Leeuwen</span>, <span class="hlFld-ContribAuthor ">Maria  Håkansson</span>, <span class="hlFld-ContribAuthor ">Björn  Walse</span>, <span class="hlFld-ContribAuthor ">Fredrik  Tholander</span>, <span class="hlFld-ContribAuthor ">Ravi  Bhatia</span>, <span class="hlFld-ContribAuthor ">Chandra S.  Verma</span>, <span class="hlFld-ContribAuthor ">David P.  Lane</span>, <span class="hlFld-ContribAuthor ">Sonia  Laín</span>. </span><span class="cited-content_cbyCitation_article-title">Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2020,</strong> <em>295 </em>
                                    (52)
                                     , 17935-17949. <a href="https://doi.org/10.1074/jbc.RA119.012056" title="DOI URL">https://doi.org/10.1074/jbc.RA119.012056</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/jbc.RA119.012056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fjbc.RA119.012056%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3DExploitation%252Bof%252Bdihydroorotate%252Bdehydrogenase%252B%252528DHODH%252529%252Band%252Bp53%252Bactivation%252Bas%252Btherapeutic%252Btargets%25253A%252BA%252Bcase%252Bstudy%252Bin%252Bpolypharmacology%26aulast%3DLadds%26aufirst%3DMarcus%2BJ.%2BG.W.%26date%3D2020%26volume%3D295%26issue%3D52%26spage%3D17935%26epage%3D17949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gyeong Han  Jeong</span>, <span class="hlFld-ContribAuthor ">Jae-Hyeon  Cho</span>, <span class="hlFld-ContribAuthor ">Cheorun  Jo</span>, <span class="hlFld-ContribAuthor ">Seungil  Park</span>, <span class="hlFld-ContribAuthor ">Seong Bong  Kim</span>, <span class="hlFld-ContribAuthor ">Tae Hoon  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Hybrid Molecules Based on (−)-Epigallocatechin Gallate as Potent Anti-adipogenic Agents. </span><span class="cited-content_cbyCitation_journal-name">Chemical and Pharmaceutical Bulletin</span><span> <strong>2020,</strong> <em>68 </em>
                                    (12)
                                     , 1155-1162. <a href="https://doi.org/10.1248/cpb.c20-00229" title="DOI URL">https://doi.org/10.1248/cpb.c20-00229</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1248/cpb.c20-00229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1248%2Fcpb.c20-00229%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520and%2520Pharmaceutical%2520Bulletin%26atitle%3DNovel%252BHybrid%252BMolecules%252BBased%252Bon%252B%252528%2525E2%252588%252592%252529-Epigallocatechin%252BGallate%252Bas%252BPotent%252BAnti-adipogenic%252BAgents%26aulast%3DJeong%26aufirst%3DGyeong%2BHan%26date%3D2020%26volume%3D68%26issue%3D12%26spage%3D1155%26epage%3D1162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Feldmann</span>, <span class="hlFld-ContribAuthor ">Dimitar  Yonchev</span>, <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Analysis of Biological Screening Compounds with Single- or Multi-Target Activity via Diagnostic Machine Learning. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2020,</strong> <em>10 </em>
                                    (12)
                                     , 1605. <a href="https://doi.org/10.3390/biom10121605" title="DOI URL">https://doi.org/10.3390/biom10121605</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom10121605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom10121605%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DAnalysis%252Bof%252BBiological%252BScreening%252BCompounds%252Bwith%252BSingle-%252Bor%252BMulti-Target%252BActivity%252Bvia%252BDiagnostic%252BMachine%252BLearning%26aulast%3DFeldmann%26aufirst%3DChristian%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D12%26spage%3D1605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Holger  Stark</span>. </span><span class="cited-content_cbyCitation_article-title">The chemical probe – scopes, limitations and challenges. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2020,</strong> <em>15 </em>
                                    (12)
                                     , 1365-1367. <a href="https://doi.org/10.1080/17460441.2020.1781086" title="DOI URL">https://doi.org/10.1080/17460441.2020.1781086</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2020.1781086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2020.1781086%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DThe%252Bchemical%252Bprobe%252B%2525E2%252580%252593%252Bscopes%25252C%252Blimitations%252Band%252Bchallenges%26aulast%3DStark%26aufirst%3DHolger%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D12%26spage%3D1365%26epage%3D1367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Parteek  Prasher</span>, <span class="hlFld-ContribAuthor ">Mousmee  Sharma</span>, <span class="hlFld-ContribAuthor ">Alaa A. A.  Aljabali</span>, <span class="hlFld-ContribAuthor ">Gaurav  Gupta</span>, <span class="hlFld-ContribAuthor ">Poonam  Negi</span>, <span class="hlFld-ContribAuthor ">Deepak N.  Kapoor</span>, <span class="hlFld-ContribAuthor ">Inderbir  Singh</span>, <span class="hlFld-ContribAuthor ">Flavia C.  Zacconi</span>, <span class="hlFld-ContribAuthor ">Terezinha  Jesus Andreoli Pinto</span>, <span class="hlFld-ContribAuthor ">Mateus Webba  Silva</span>, <span class="hlFld-ContribAuthor ">Hamid A.  Bakshi</span>, <span class="hlFld-ContribAuthor ">Dinesh Kumar  Chellappan</span>, <span class="hlFld-ContribAuthor ">Murtaza M.  Tambuwala</span>, <span class="hlFld-ContribAuthor ">Kamal  Dua</span>. </span><span class="cited-content_cbyCitation_article-title">Hybrid molecules based on 1,3,5‐triazine as potential therapeutics: A focused review. </span><span class="cited-content_cbyCitation_journal-name">Drug Development Research</span><span> <strong>2020,</strong> <em>81 </em>
                                    (7)
                                     , 837-858. <a href="https://doi.org/10.1002/ddr.21704" title="DOI URL">https://doi.org/10.1002/ddr.21704</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ddr.21704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fddr.21704%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Development%2520Research%26atitle%3DHybrid%252Bmolecules%252Bbased%252Bon%252B1%25252C3%25252C5%2525E2%252580%252590triazine%252Bas%252Bpotential%252Btherapeutics%25253A%252BA%252Bfocused%252Breview%26aulast%3DPrasher%26aufirst%3DParteek%26date%3D2020%26date%3D2020%26volume%3D81%26issue%3D7%26spage%3D837%26epage%3D858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eman T.  Warda</span>, <span class="hlFld-ContribAuthor ">Ihsan A.  Shehata</span>, <span class="hlFld-ContribAuthor ">Mahmoud B.  El-Ashmawy</span>, <span class="hlFld-ContribAuthor ">Nadia S.  El-Gohary</span>. </span><span class="cited-content_cbyCitation_article-title">New series of isoxazole derivatives targeting EGFR-TK: Synthesis, molecular modeling and antitumor evaluation. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (21)
                                     , 115674. <a href="https://doi.org/10.1016/j.bmc.2020.115674" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115674</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115674%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DNew%252Bseries%252Bof%252Bisoxazole%252Bderivatives%252Btargeting%252BEGFR-TK%25253A%252BSynthesis%25252C%252Bmolecular%252Bmodeling%252Band%252Bantitumor%252Bevaluation%26aulast%3DWarda%26aufirst%3DEman%2BT.%26date%3D2020%26volume%3D28%26issue%3D21%26spage%3D115674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hwangseo  Park</span>, <span class="hlFld-ContribAuthor ">Hoi-Yun  Jung</span>, <span class="hlFld-ContribAuthor ">Shinmee  Mah</span>, <span class="hlFld-ContribAuthor ">Kewon  Kim</span>, <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase and GPCR polypharmacological approach for the identification of efficient anticancer medicines. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2020,</strong> <em>18 </em>
                                    (41)
                                     , 8402-8413. <a href="https://doi.org/10.1039/D0OB01917H" title="DOI URL">https://doi.org/10.1039/D0OB01917H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0OB01917H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0OB01917H%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DKinase%252Band%252BGPCR%252Bpolypharmacological%252Bapproach%252Bfor%252Bthe%252Bidentification%252Bof%252Befficient%252Banticancer%252Bmedicines%26aulast%3DPark%26aufirst%3DHwangseo%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D41%26spage%3D8402%26epage%3D8413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katerina  Sobolova</span>, <span class="hlFld-ContribAuthor ">Martina  Hrabinova</span>, <span class="hlFld-ContribAuthor ">Vendula  Hepnarova</span>, <span class="hlFld-ContribAuthor ">Tomas  Kucera</span>, <span class="hlFld-ContribAuthor ">Tereza  Kobrlova</span>, <span class="hlFld-ContribAuthor ">Marketa  Benkova</span>, <span class="hlFld-ContribAuthor ">Jana  Janockova</span>, <span class="hlFld-ContribAuthor ">Rafael  Dolezal</span>, <span class="hlFld-ContribAuthor ">Lukas  Prchal</span>, <span class="hlFld-ContribAuthor ">Ondrej  Benek</span>, <span class="hlFld-ContribAuthor ">Eva  Mezeiova</span>, <span class="hlFld-ContribAuthor ">Daniel  Jun</span>, <span class="hlFld-ContribAuthor ">Ondrej  Soukup</span>, <span class="hlFld-ContribAuthor ">Jan  Korabecny</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel berberine derivatives with balanced cholinesterase and prolyl oligopeptidase inhibition profile. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>203 </em>, 112593. <a href="https://doi.org/10.1016/j.ejmech.2020.112593" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112593</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112593%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bberberine%252Bderivatives%252Bwith%252Bbalanced%252Bcholinesterase%252Band%252Bprolyl%252Boligopeptidase%252Binhibition%252Bprofile%26aulast%3DSobolova%26aufirst%3DKaterina%26date%3D2020%26volume%3D203%26spage%3D112593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yosselin  Huentupil</span>, <span class="hlFld-ContribAuthor ">Patricio  Chung</span>, <span class="hlFld-ContribAuthor ">Néstor  Novoa</span>, <span class="hlFld-ContribAuthor ">Rodrigo  Arancibia</span>, <span class="hlFld-ContribAuthor ">Pascal  Roussel</span>, <span class="hlFld-ContribAuthor ">Juan  Oyarzo</span>, <span class="hlFld-ContribAuthor ">A. Hugo  Klahn</span>, <span class="hlFld-ContribAuthor ">Carlos  Silva</span>, <span class="hlFld-ContribAuthor ">Carme  Calvis</span>, <span class="hlFld-ContribAuthor ">Ramon  Messeguer</span>, <span class="hlFld-ContribAuthor ">Ramón  Bosque</span>, <span class="hlFld-ContribAuthor ">Concepción  López</span>. </span><span class="cited-content_cbyCitation_article-title">Novel multifunctional and multitarget homo- (Fe
              2
              ) and heterobimetallic [(Fe,M) with M = Re or Mn] sulfonyl hydrazones. </span><span class="cited-content_cbyCitation_journal-name">Dalton Transactions</span><span> <strong>2020,</strong> <em>49 </em>
                                    (35)
                                     , 12249-12265. <a href="https://doi.org/10.1039/D0DT01756F" title="DOI URL">https://doi.org/10.1039/D0DT01756F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0DT01756F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0DT01756F%26sid%3Dliteratum%253Aachs%26jtitle%3DDalton%2520Transactions%26atitle%3DNovel%252Bmultifunctional%252Band%252Bmultitarget%252Bhomo-%252B%252528Fe%252B2%252B%252529%252Band%252Bheterobimetallic%252B%25255B%252528Fe%25252CM%252529%252Bwith%252BM%252B%25253D%252BRe%252Bor%252BMn%25255D%252Bsulfonyl%252Bhydrazones%26aulast%3DHuentupil%26aufirst%3DYosselin%26date%3D2020%26date%3D2020%26volume%3D49%26issue%3D35%26spage%3D12249%26epage%3D12265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mziyanda  Mbaba</span>, <span class="hlFld-ContribAuthor ">Laura M. K.  Dingle</span>, <span class="hlFld-ContribAuthor ">Tarryn  Swart</span>, <span class="hlFld-ContribAuthor ">Devon  Cash</span>, <span class="hlFld-ContribAuthor ">Dustin  Laming</span>, <span class="hlFld-ContribAuthor ">Jo‐Anne  Mare</span>, <span class="hlFld-ContribAuthor ">Dale  Taylor</span>, <span class="hlFld-ContribAuthor ">Heinrich C.  Hoppe</span>, <span class="hlFld-ContribAuthor ">Christophe  Biot</span>, <span class="hlFld-ContribAuthor ">Adrienne L.  Edkins</span>, <span class="hlFld-ContribAuthor ">Setshaba D.  Khanye</span>. </span><span class="cited-content_cbyCitation_article-title">The
              in Vitro
              Antiplasmodial and Antiproliferative Activity of New Ferrocene‐Based α‐Aminocresols Targeting Hemozoin Inhibition and DNA Interaction. </span><span class="cited-content_cbyCitation_journal-name">ChemBioChem</span><span> <strong>2020,</strong> <em>21 </em>
                                    (18)
                                     , 2643-2658. <a href="https://doi.org/10.1002/cbic.202000132" title="DOI URL">https://doi.org/10.1002/cbic.202000132</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbic.202000132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbic.202000132%26sid%3Dliteratum%253Aachs%26jtitle%3DChemBioChem%26atitle%3DThe%252Bin%252BVitro%252BAntiplasmodial%252Band%252BAntiproliferative%252BActivity%252Bof%252BNew%252BFerrocene%2525E2%252580%252590Based%252B%2525CE%2525B1%2525E2%252580%252590Aminocresols%252BTargeting%252BHemozoin%252BInhibition%252Band%252BDNA%252BInteraction%26aulast%3DMbaba%26aufirst%3DMziyanda%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D18%26spage%3D2643%26epage%3D2658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anuraj  Nayarisseri</span>. </span><span class="cited-content_cbyCitation_article-title">Experimental and Computational Approaches to Improve Binding Affinity in Chemical Biology and Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (19)
                                     , 1651-1660. <a href="https://doi.org/10.2174/156802662019200701164759" title="DOI URL">https://doi.org/10.2174/156802662019200701164759</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/156802662019200701164759&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F156802662019200701164759%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DExperimental%252Band%252BComputational%252BApproaches%252Bto%252BImprove%252BBinding%252BAffinity%252Bin%252BChemical%252BBiology%252Band%252BDrug%252BDiscovery%26aulast%3DNayarisseri%26aufirst%3DAnuraj%26date%3D2020%26volume%3D20%26issue%3D19%26spage%3D1651%26epage%3D1660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongguang  Ma</span>, <span class="hlFld-ContribAuthor ">Boshi  Huang</span>, <span class="hlFld-ContribAuthor ">Yan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2020,</strong> <em>25 </em>
                                    (9)
                                     , 1682-1692. <a href="https://doi.org/10.1016/j.drudis.2020.07.004" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.07.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.07.004%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DRecent%252Badvances%252Bin%252Bmultitarget-directed%252Bligands%252Btargeting%252BG-protein-coupled%252Breceptors%26aulast%3DMa%26aufirst%3DHongguang%26date%3D2020%26volume%3D25%26issue%3D9%26spage%3D1682%26epage%3D1692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angelica  Galieni</span>, <span class="hlFld-ContribAuthor ">Beatrice  Falcinelli</span>, <span class="hlFld-ContribAuthor ">Fabio  Stagnari</span>, <span class="hlFld-ContribAuthor ">Alessandro  Datti</span>, <span class="hlFld-ContribAuthor ">Paolo  Benincasa</span>. </span><span class="cited-content_cbyCitation_article-title">Sprouts and Microgreens: Trends, Opportunities, and Horizons for Novel Research. </span><span class="cited-content_cbyCitation_journal-name">Agronomy</span><span> <strong>2020,</strong> <em>10 </em>
                                    (9)
                                     , 1424. <a href="https://doi.org/10.3390/agronomy10091424" title="DOI URL">https://doi.org/10.3390/agronomy10091424</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/agronomy10091424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fagronomy10091424%26sid%3Dliteratum%253Aachs%26jtitle%3DAgronomy%26atitle%3DSprouts%252Band%252BMicrogreens%25253A%252BTrends%25252C%252BOpportunities%25252C%252Band%252BHorizons%252Bfor%252BNovel%252BResearch%26aulast%3DGalieni%26aufirst%3DAngelica%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D9%26spage%3D1424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  Czopek</span>, <span class="hlFld-ContribAuthor ">Anna  Partyka</span>, <span class="hlFld-ContribAuthor ">Adam  Bucki</span>, <span class="hlFld-ContribAuthor ">Maciej  Pawłowski</span>, <span class="hlFld-ContribAuthor ">Marcin  Kołaczkowski</span>, <span class="hlFld-ContribAuthor ">Agata  Siwek</span>, <span class="hlFld-ContribAuthor ">Monika  Głuch-Lutwin</span>, <span class="hlFld-ContribAuthor ">Paulina  Koczurkiewicz</span>, <span class="hlFld-ContribAuthor ">Elżbieta  Pękala</span>, <span class="hlFld-ContribAuthor ">Anna  Jaromin</span>, <span class="hlFld-ContribAuthor ">Bożena  Tyliszczak</span>, <span class="hlFld-ContribAuthor ">Anna  Wesołowska</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Zagórska</span>. </span><span class="cited-content_cbyCitation_article-title">Impact of N-Alkylamino Substituents on Serotonin Receptor (5-HTR) Affinity and Phosphodiesterase 10A (PDE10A) Inhibition of Isoindole-1,3-dione Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (17)
                                     , 3868. <a href="https://doi.org/10.3390/molecules25173868" title="DOI URL">https://doi.org/10.3390/molecules25173868</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25173868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25173868%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DImpact%252Bof%252BN-Alkylamino%252BSubstituents%252Bon%252BSerotonin%252BReceptor%252B%2525285-HTR%252529%252BAffinity%252Band%252BPhosphodiesterase%252B10A%252B%252528PDE10A%252529%252BInhibition%252Bof%252BIsoindole-1%25252C3-dione%252BDerivatives%26aulast%3DCzopek%26aufirst%3DAnna%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D17%26spage%3D3868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Masako  Yumura</span>, <span class="hlFld-ContribAuthor ">Tatsuya  Nagano</span>, <span class="hlFld-ContribAuthor ">Yoshihiro  Nishimura</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Multitarget Therapies for Lung Cancer and Respiratory Disease. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (17)
                                     , 3987. <a href="https://doi.org/10.3390/molecules25173987" title="DOI URL">https://doi.org/10.3390/molecules25173987</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25173987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25173987%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DNovel%252BMultitarget%252BTherapies%252Bfor%252BLung%252BCancer%252Band%252BRespiratory%252BDisease%26aulast%3DYumura%26aufirst%3DMasako%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D17%26spage%3D3987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rajan  Chaudhari</span>, <span class="hlFld-ContribAuthor ">Long Wolf  Fong</span>, <span class="hlFld-ContribAuthor ">Zhi  Tan</span>, <span class="hlFld-ContribAuthor ">Beibei  Huang</span>, <span class="hlFld-ContribAuthor ">Shuxing  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">An up-to-date overview of computational polypharmacology in modern drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2020,</strong> <em>15 </em>
                                    (9)
                                     , 1025-1044. <a href="https://doi.org/10.1080/17460441.2020.1767063" title="DOI URL">https://doi.org/10.1080/17460441.2020.1767063</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2020.1767063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2020.1767063%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DAn%252Bup-to-date%252Boverview%252Bof%252Bcomputational%252Bpolypharmacology%252Bin%252Bmodern%252Bdrug%252Bdiscovery%26aulast%3DChaudhari%26aufirst%3DRajan%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D9%26spage%3D1025%26epage%3D1044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuedong  He</span>, <span class="hlFld-ContribAuthor ">Lu  Zhao</span>, <span class="hlFld-ContribAuthor ">Weihe  Zhong</span>, <span class="hlFld-ContribAuthor ">Hsin-Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaoting  Shan</span>, <span class="hlFld-ContribAuthor ">Ning  Tang</span>, <span class="hlFld-ContribAuthor ">Calvin Yu-Chian  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Insight into potent leads for alzheimer's disease by using several artificial intelligence algorithms. </span><span class="cited-content_cbyCitation_journal-name">Biomedicine & Pharmacotherapy</span><span> <strong>2020,</strong> <em>129 </em>, 110360. <a href="https://doi.org/10.1016/j.biopha.2020.110360" title="DOI URL">https://doi.org/10.1016/j.biopha.2020.110360</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biopha.2020.110360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biopha.2020.110360%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicine%2520%2526%2520Pharmacotherapy%26atitle%3DInsight%252Binto%252Bpotent%252Bleads%252Bfor%252Balzheimer%252527s%252Bdisease%252Bby%252Busing%252Bseveral%252Bartificial%252Bintelligence%252Balgorithms%26aulast%3DHe%26aufirst%3DXuedong%26date%3D2020%26volume%3D129%26spage%3D110360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angel R.  de Lera</span>, <span class="hlFld-ContribAuthor ">A.  Ganesan</span>. </span><span class="cited-content_cbyCitation_article-title">Two-hit wonders: The expanding universe of multitargeting epigenetic agents. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2020,</strong> <em>57 </em>, 135-154. <a href="https://doi.org/10.1016/j.cbpa.2020.05.009" title="DOI URL">https://doi.org/10.1016/j.cbpa.2020.05.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2020.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2020.05.009%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DTwo-hit%252Bwonders%25253A%252BThe%252Bexpanding%252Buniverse%252Bof%252Bmultitargeting%252Bepigenetic%252Bagents%26aulast%3Dde%2BLera%26aufirst%3DAngel%2BR.%26date%3D2020%26volume%3D57%26spage%3D135%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Perihan A.  Elzahhar</span>, <span class="hlFld-ContribAuthor ">Shrouk M.  Abd El Wahab</span>, <span class="hlFld-ContribAuthor ">Mohamed  Elagawany</span>, <span class="hlFld-ContribAuthor ">Hoda  Daabees</span>, <span class="hlFld-ContribAuthor ">Ahmed S.F.  Belal</span>, <span class="hlFld-ContribAuthor ">Ahmed F.  EL-Yazbi</span>, <span class="hlFld-ContribAuthor ">Ali H.  Eid</span>, <span class="hlFld-ContribAuthor ">Rana  Alaaeddine</span>, <span class="hlFld-ContribAuthor ">Rehab R.  Hegazy</span>, <span class="hlFld-ContribAuthor ">Rasha M.  Allam</span>, <span class="hlFld-ContribAuthor ">Maged W.  Helmy</span>, <span class="hlFld-ContribAuthor ">Bahaa Elgendy</span>, <span class="hlFld-ContribAuthor ">Andrea  Angeli</span>, <span class="hlFld-ContribAuthor ">Soad A.  El-Hawash</span>, <span class="hlFld-ContribAuthor ">Claudiu T.  Supuran</span>. </span><span class="cited-content_cbyCitation_article-title">Expanding the anticancer potential of 1,2,3-triazoles via simultaneously targeting Cyclooxygenase-2, 15-lipoxygenase and tumor-associated carbonic anhydrases. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>200 </em>, 112439. <a href="https://doi.org/10.1016/j.ejmech.2020.112439" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112439</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112439%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DExpanding%252Bthe%252Banticancer%252Bpotential%252Bof%252B1%25252C2%25252C3-triazoles%252Bvia%252Bsimultaneously%252Btargeting%252BCyclooxygenase-2%25252C%252B15-lipoxygenase%252Band%252Btumor-associated%252Bcarbonic%252Banhydrases%26aulast%3DElzahhar%26aufirst%3DPerihan%2BA.%26date%3D2020%26volume%3D200%26spage%3D112439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katia  Pane</span>, <span class="hlFld-ContribAuthor ">Peppino  Mirabelli</span>, <span class="hlFld-ContribAuthor ">Luigi  Coppola</span>, <span class="hlFld-ContribAuthor ">Ester  Illiano</span>, <span class="hlFld-ContribAuthor ">Marco  Salvatore</span>, <span class="hlFld-ContribAuthor ">Monica  Franzese</span>. </span><span class="cited-content_cbyCitation_article-title">New Roadmaps for Non-muscle-invasive Bladder Cancer With Unfavorable Prognosis. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2020,</strong> <em>8 </em><a href="https://doi.org/10.3389/fchem.2020.00600" title="DOI URL">https://doi.org/10.3389/fchem.2020.00600</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2020.00600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2020.00600%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DNew%252BRoadmaps%252Bfor%252BNon-muscle-invasive%252BBladder%252BCancer%252BWith%252BUnfavorable%252BPrognosis%26aulast%3DPane%26aufirst%3DKatia%26date%3D2020%26date%3D2020%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Temitope O.  Olomola</span>, <span class="hlFld-ContribAuthor ">Malose J.  Mphahlele</span>, <span class="hlFld-ContribAuthor ">Samantha  Gildenhuys</span>. </span><span class="cited-content_cbyCitation_article-title">Benzofuran-selenadiazole hybrids as novel α-glucosidase and cyclooxygenase-2 inhibitors with antioxidant and cytotoxic properties. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>100 </em>, 103945. <a href="https://doi.org/10.1016/j.bioorg.2020.103945" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103945</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103945%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DBenzofuran-selenadiazole%252Bhybrids%252Bas%252Bnovel%252B%2525CE%2525B1-glucosidase%252Band%252Bcyclooxygenase-2%252Binhibitors%252Bwith%252Bantioxidant%252Band%252Bcytotoxic%252Bproperties%26aulast%3DOlomola%26aufirst%3DTemitope%2BO.%26date%3D2020%26volume%3D100%26spage%3D103945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ondrej  Benek</span>, <span class="hlFld-ContribAuthor ">Jan  Korabecny</span>, <span class="hlFld-ContribAuthor ">Ondrej  Soukup</span>. </span><span class="cited-content_cbyCitation_article-title">A Perspective on Multi-target Drugs for Alzheimer’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Trends in Pharmacological Sciences</span><span> <strong>2020,</strong> <em>41 </em>
                                    (7)
                                     , 434-445. <a href="https://doi.org/10.1016/j.tips.2020.04.008" title="DOI URL">https://doi.org/10.1016/j.tips.2020.04.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tips.2020.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tips.2020.04.008%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Pharmacological%2520Sciences%26atitle%3DA%252BPerspective%252Bon%252BMulti-target%252BDrugs%252Bfor%252BAlzheimer%2525E2%252580%252599s%252BDisease%26aulast%3DBenek%26aufirst%3DOndrej%26date%3D2020%26volume%3D41%26issue%3D7%26spage%3D434%26epage%3D445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Feldmann</span>, <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Compounds with multitarget activity: structure-based analysis and machine learning. </span><span class="cited-content_cbyCitation_journal-name">Future Drug Discovery</span><span> <strong>2020,</strong> <em>2 </em>
                                    (3)
                                     , FDD44. <a href="https://doi.org/10.4155/fdd-2020-0014" title="DOI URL">https://doi.org/10.4155/fdd-2020-0014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fdd-2020-0014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffdd-2020-0014%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Drug%2520Discovery%26atitle%3DCompounds%252Bwith%252Bmultitarget%252Bactivity%25253A%252Bstructure-based%252Banalysis%252Band%252Bmachine%252Blearning%26aulast%3DFeldmann%26aufirst%3DChristian%26date%3D2020%26volume%3D2%26issue%3D3%26spage%3DFDD44" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudia  Albertini</span>, <span class="hlFld-ContribAuthor ">Alessandra  Salerno</span>, <span class="hlFld-ContribAuthor ">Pedro  Sena Murteira Pinheiro</span>, <span class="hlFld-ContribAuthor ">Maria L.  Bolognesi</span>. </span><span class="cited-content_cbyCitation_article-title">From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2020,</strong> <em>10 </em><a href="https://doi.org/10.1002/med.21699" title="DOI URL">https://doi.org/10.1002/med.21699</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21699%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DFrom%252Bcombinations%252Bto%252Bmultitarget%2525E2%252580%252590directed%252Bligands%25253A%252BA%252Bcontinuum%252Bin%252BAlzheimer%252527s%252Bdisease%252Bpolypharmacology%26aulast%3DAlbertini%26aufirst%3DClaudia%26date%3D2020%26date%3D2020%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zh. V.  Ignatovich</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of chimeric amides of 2-arilaminopyrimidine series. </span><span class="cited-content_cbyCitation_journal-name">Proceedings of the National Academy of Sciences of Belarus, Chemical Series</span><span> <strong>2020,</strong> <em>56 </em>
                                    (2)
                                     , 166-180. <a href="https://doi.org/10.29235/1561-8331-2020-56-2-38-166-180" title="DOI URL">https://doi.org/10.29235/1561-8331-2020-56-2-38-166-180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.29235/1561-8331-2020-56-2-38-166-180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.29235%2F1561-8331-2020-56-2-38-166-180%26sid%3Dliteratum%253Aachs%26jtitle%3DProceedings%2520of%2520the%2520National%2520Academy%2520of%2520Sciences%2520of%2520Belarus%252C%2520Chemical%2520Series%26atitle%3DSynthesis%252Bof%252Bchimeric%252Bamides%252Bof%252B2-arilaminopyrimidine%252Bseries%26aulast%3DIgnatovich%26aufirst%3DZh.%2BV.%26date%3D2020%26date%3D2020%26volume%3D56%26issue%3D2%26spage%3D166%26epage%3D180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Facs.jmedchem.8b00760&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-2%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00760&amp;citedByCount=132&amp;pagesCount=2&amp;pageNumber=-1" title="Load all citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="”true”" class="icon-angle-double-down"></i><span>Load all citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/medium/jm-2018-00760f_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/medium/jm-2018-00760f_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Multitarget Agents Can Arise from Linking Pharmacophores with Stable or Biodegradable Linkers, Fusing of Pharmacophores, or Merging of Pharmacophores for the Biological Targets of Interest</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/medium/jm-2018-00760f_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Dual p38α/MAPK/PDE-4 Inhibitor CBS-3595 (<b>1</b>), Which Is the Product of a Serendipitously Discovered Multitarget Profile and Subsequent Optimization of the Dual Activity</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/medium/jm-2018-00760f_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0005.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Sideromycins (<b>2a</b>–<b>c</b>, Examples),<a onclick="showRef(event, 'ref146 ref147 ref150'); return false;" href="javascript:void(0);" class="ref ref146 ref147 ref150">(146,147,150)</a> Conjugates Composed of a Siderphore and a Potent Antibiotic, Exploit Bacterial Iron Uptake Mechanisms to Furnish Active Transport of the Conjugates into Bacteria Where the Conjugate Is Cleaved to Release the Antibiotic; Cefiderocol (<b>2c</b>) Has Already Entered Clinical Development</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/medium/jm-2018-00760f_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Typical Cleavable Linkers (Examples) Are Either Labile to Acidic Conditions or Reducing Agents, or Designed to Be Specifically Cleaved by Certain Enzymes</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/medium/jm-2018-00760f_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0007.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Self-Immolative Spacers (Examples)<a onclick="showRef(event, 'ref155 ref156'); return false;" href="javascript:void(0);" class="ref ref155 ref156">(155,156)</a> Undergo Intramolecular Reactions to Entirely Release the Linked Drugs from the Conjugate</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/medium/jm-2018-00760f_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0008.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Examples for Rational Design of Merged Lead Pharmacophores in Multiple Ligand Development<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(A) Introduction of the steroid sulfatase inhibition pharmacophore phenolsulfamate from <b>3b</b> into aromatase inhibitor <b>3a</b> was sufficient to design merged dual aromatase/steroid sulfatase inhibitor <b>3c</b>. Subsequent SAR studies and scaffold hopping yielded several series of potent dual inhibitors such as <b>3d</b>. (B) Minimal pharmacophores for farnesoid X receptor (FXR) activation (<b>4a</b>) and soluble epoxide hydrolase (sEH) inhibition (<b>4b</b>) were compatible for merging in dual lead pharmacophore <b>4c</b> exhibiting moderate dual potency. <b>4c</b> was systematically optimized towards both targets resulting in dual modulator <b>4d</b> with low nanomolar dual activity. (C) The atypical antipsychotic ziprasidone (<b>5a</b>) was discovered by merging pharmacophores for serotonin 5-HT<sub>2</sub> receptor antagonism (<b>5b</b>) and dopamine (<b>5c</b>) receptor antagonism producing the dual antagonist <b>5d</b> which was systematically optimized to <b>5a</b>. (D) Design of the triple lead pharmacophore <b>6c</b> incorporating pharmacophore elements for choline esterase (ChE) inhibition (adopted from <b>6b</b>), monoamine oxidase (MAO) inhibition (<b>6b</b>) and histamine H<sub>3</sub> receptor antagonism (<b>6a</b>) depicts that even activity on three individual targets can be rationally designed in a single small molecule. Minor structural changes were then sufficient to optimize <b>6c</b> to the potent triple modulator <b>6d</b>.</p></p></figure><figure data-id="fig1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/medium/jm-2018-00760f_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0001.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. A ligand-based dual pharmacophore approach<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> individually generated pharmacophore models for soluble epoxide hydrolase inhibitors and 5-lipoexigenase inhibitors. Subsequent graph-based alignment of the resulting models produced a dual consensus pharmacophore that was used in virtual screening which yielded a novel dual inhibitor (<b>7</b>) of both enzymes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/medium/jm-2018-00760f_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0009.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Clinical Observations of Improved Insulin Sensitivity under Telmisartan (<b>8a</b>) Treatment Led to Identification of Its PPARγ Activating Potential Which Was Then Optimized by Minor Structural Changes (<b>8b</b>) while Conserving the Original AT1R Antagonistic Activity</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/medium/jm-2018-00760f_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0002.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Successful structural optimization of multiple ligands has been achieved by various strategies. (A) A fully automated optimization approach of donepezil (<b>9a</b>) to multiple ligands of serotonin and dopamine receptors employing Bayesian probability models resulted in several highly potent multiple ligands such as <b>9b</b> as well as selective ligands of neurotransmitter receptors. (B) Systematic exploration of substituent vectors allowing dual optimization on multiple ligands scaffold <b>4c</b> allowed stepwise optimization of dual FXR/sEH modulation. Final combination of all SAR knowledge yielded the highly potent dual modulator <b>4d</b>. (C) Relying on molecular docking results, zafirlukast (<b>10a</b>) was optimized to a potent triple ligand (<b>10b</b>) of peroxisome proliferator-activated receptor γ (PPARγ), soluble epoxide hydrolase (sEH), and cysteinylleukotriene receptor 1 (CysLT<sub>1</sub>R) by very minor structural changes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/medium/jm-2018-00760f_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0010.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Multitarget Fragment Examples<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b00760/20190116/images/large/jm-2018-00760f_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00760&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>The dual inhibitor of β-secretase 1 (BACE-1) and glycogen synthase kinase 3β (GSK-3β) <b>11</b> was computationally identified based on a common H-bond hypothesis and confirmed as inhibitor of both enzymes by NMR-based functional screening. Triazinone <b>12</b> was rationally designed as dual inhibitor of BACE-1 and GSK-3β by combining structural motifs required for interaction with the two enzymes. The approved drug indeglitazar (<b>13</b>) activating the nuclear receptors PPARα, PPARγ, and PPARδ was developed from fragment <b>13a</b> which had been identified as active on the three receptors in a fragment library screening. The structural optimization was guided by co-crystal structure data for <b>13a</b> with all three PPARs.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i44">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17188" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17188" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 252 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amin, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attur, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramson, S. B.</span></span> <span> </span><span class="NLM_article-title">The Pleiotropic Functions of Aspirin: Mechanisms of Action</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">3–4</span>),  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1007/s000180050432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1007%2Fs000180050432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=11212358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADyaK1MXntVGhu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1999&pages=305-312&issue=3%E2%80%934&author=A.+R.+Aminauthor=M.+G.+Atturauthor=M.+Pillingerauthor=S.+B.+Abramson&title=The+Pleiotropic+Functions+of+Aspirin%3A+Mechanisms+of+Action&doi=10.1007%2Fs000180050432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The pleiotropic functions of aspirin. Mechanisms of action</span></div><div class="casAuthors">Amin, A. R.; Attur, M. G.; Pillinger, M.; Abramson, S. B.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3/4</span>),
    <span class="NLM_cas:pages">305-312</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review is given with 62 refs. on the various mechanisms of action of aspirin-like compds. and their relevance to clin. disease and therapy.  Recent studies have suggested that aspirin and aspirin-like compds. have a variety of actions in addn. to their well-studied ability to inhibit cyclooxygenases.  These actions include inhibition of the uncoupling of oxidative phosphorylation, decreases in ATP stores, increases in extracellular adenosine, down regulation of the expression and activity of inducible NO synthetase, inhibition and/or stimulation of various mitogen-activated protein kinase activities and inhibition of nuclear factor binding κB site (NF-κB) activation.  Moreover, aspirin-like compds. have recently been shown to have previously unappreciated clin. and biol. effects, some apparently independent of cyclooxygenase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoebZMQgc7dILVg90H21EOLACvtfcHk0lig_MrCrp9nzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntVGhu78%253D&md5=ad427051259cc9163246e5fa5828d55f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2Fs000180050432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs000180050432%26sid%3Dliteratum%253Aachs%26aulast%3DAmin%26aufirst%3DA.%2BR.%26aulast%3DAttur%26aufirst%3DM.%2BG.%26aulast%3DPillinger%26aufirst%3DM.%26aulast%3DAbramson%26aufirst%3DS.%2BB.%26atitle%3DThe%2520Pleiotropic%2520Functions%2520of%2520Aspirin%253A%2520Mechanisms%2520of%2520Action%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D1999%26volume%3D56%26issue%3D3%25E2%2580%25934%26spage%3D305%26epage%3D312%26doi%3D10.1007%2Fs000180050432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dzeshka, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shantsila, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lip, G. Y. H.</span></span> <span> </span><span class="NLM_article-title">Effects of Aspirin on Endothelial Function and Hypertension</span>. <i>Curr. Hypertens. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">83</span>, <span class="refDoi"> DOI: 10.1007/s11906-016-0688-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1007%2Fs11906-016-0688-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27787837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC2sngtlektQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=83&issue=11&author=M.+S.+Dzeshkaauthor=A.+Shantsilaauthor=G.+Y.+H.+Lip&title=Effects+of+Aspirin+on+Endothelial+Function+and+Hypertension&doi=10.1007%2Fs11906-016-0688-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Aspirin on Endothelial Function and Hypertension</span></div><div class="casAuthors">Dzeshka Mikhail S; Shantsila Alena; Lip Gregory Y H; Dzeshka Mikhail S; Lip Gregory Y H</div><div class="citationInfo"><span class="NLM_cas:title">Current hypertension reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">83</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  Endothelial dysfunction is intimately related to the development of various cardiovascular diseases, including hypertension, and is often used as a target for pharmacological treatment.  The scope of this review is to assess effects of aspirin on endothelial function and their clinical implication in arterial hypertension.  RECENT FINDINGS:  Emerging data indicate the role of platelets in the development of vascular inflammation due to the release of proinflammatory mediators, for example, triggered largely by thromboxane.  Vascular inflammation further promotes oxidative stress, diminished synthesis of vasodilators, proaggregatory and procoagulant state.  These changes translate into vasoconstriction, impaired circulation and thrombotic complications.  Aspirin inhibits thromboxane synthesis, abolishes platelets activation and acetylates enzymes switching them to the synthesis of anti-inflammatory substances.  Aspirin pleiotropic effects have not been fully elucidated yet.  In secondary prevention studies, the decrease in cardiovascular events with aspirin outweighs bleeding risks, but this is not the case in primary prevention settings.  Ongoing trials will provide more evidence on whether to expand the use of aspirin or stay within current recommendations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQG4GWzhjDUqtj_Vg2vObihfW6udTcc2eYxJXtlr8hwwLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sngtlektQ%253D%253D&md5=2c13c77197206bdebed0a365b1ef0e63</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs11906-016-0688-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11906-016-0688-8%26sid%3Dliteratum%253Aachs%26aulast%3DDzeshka%26aufirst%3DM.%2BS.%26aulast%3DShantsila%26aufirst%3DA.%26aulast%3DLip%26aufirst%3DG.%2BY.%2BH.%26atitle%3DEffects%2520of%2520Aspirin%2520on%2520Endothelial%2520Function%2520and%2520Hypertension%26jtitle%3DCurr.%2520Hypertens.%2520Rep.%26date%3D2016%26volume%3D18%26issue%3D11%26spage%3D83%26doi%3D10.1007%2Fs11906-016-0688-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horowitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rayner, C. K.</span></span> <span> </span><span class="NLM_article-title">New Insights into the Anti-Diabetic Actions of Metformin: From the Liver to the Gut</span>. <i>Expert Rev. Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1080/17474124.2017.1273769</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1080%2F17474124.2017.1273769" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27983877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFKltLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=157-166&issue=2&author=T.+Wuauthor=M.+Horowitzauthor=C.+K.+Rayner&title=New+Insights+into+the+Anti-Diabetic+Actions+of+Metformin%3A+From+the+Liver+to+the+Gut&doi=10.1080%2F17474124.2017.1273769"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into the anti-diabetic actions of metformin: from the liver to the gut</span></div><div class="casAuthors">Wu, Tongzhi; Horowitz, Michael; Rayner, Christopher K.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">157-166</span>CODEN:
                <span class="NLM_cas:coden">ERGHBD</span>;
        ISSN:<span class="NLM_cas:issn">1747-4124</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Metformin is established as the first-line therapy for type 2 diabetes (T2DM), but its mode of action remains elusive.  Elucidation of the mechanisms underlying the anti-diabetic action of metformin may have the potential to optimize its glucose-lowering efficacy and lead to the development of agents acting on novel targets for the management of type 2 diabetes.  This review highlights key pharmacokinetic features of metformin, summarises recent insights into its hepatic and gastrointestinal actions relevant to blood glucose homeostasis, and discusses the common gastrointestinal side effects of metformin.  Literature concerning these areas was reviewed on PubMed.  The mechanisms by which metformin improves glycemic control in type 2 diabetes are complex.  Although novel hepatic pathways continue to be reported in preclin. studies, there is a lack of human evidence for most of these.  Considering the fundamental role of the gastrointestinal tract in the regulation of blood glucose homeostasis and pleiotropic actions of metformin on several gastrointestinal targets relevant to glycemic control, the gut is likely to represent at least as important a site of metformin action as the liver in the management of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt4JeELrnJg7Vg90H21EOLACvtfcHk0lhVu7z0OAI7hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFKltLzM&md5=5e4e17674beae136f05304354cfe5c0f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1080%2F17474124.2017.1273769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17474124.2017.1273769%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DT.%26aulast%3DHorowitz%26aufirst%3DM.%26aulast%3DRayner%26aufirst%3DC.%2BK.%26atitle%3DNew%2520Insights%2520into%2520the%2520Anti-Diabetic%2520Actions%2520of%2520Metformin%253A%2520From%2520the%2520Liver%2520to%2520the%2520Gut%26jtitle%3DExpert%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2017%26volume%3D11%26issue%3D2%26spage%3D157%26epage%3D166%26doi%3D10.1080%2F17474124.2017.1273769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varjabedian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourafkari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nader, N. D.</span></span> <span> </span><span class="NLM_article-title">Cardioprotection by Metformin: Beneficial Effects Beyond Glucose Reduction</span>. <i>Am. J. Cardiovasc. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1007/s40256-018-0266-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1007%2Fs40256-018-0266-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=181-183&author=L.+Varjabedianauthor=M.+Bourjiauthor=L.+Pourafkariauthor=N.+D.+Nader&title=Cardioprotection+by+Metformin%3A+Beneficial+Effects+Beyond+Glucose+Reduction&doi=10.1007%2Fs40256-018-0266-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2Fs40256-018-0266-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40256-018-0266-3%26sid%3Dliteratum%253Aachs%26aulast%3DVarjabedian%26aufirst%3DL.%26aulast%3DBourji%26aufirst%3DM.%26aulast%3DPourafkari%26aufirst%3DL.%26aulast%3DNader%26aufirst%3DN.%2BD.%26atitle%3DCardioprotection%2520by%2520Metformin%253A%2520Beneficial%2520Effects%2520Beyond%2520Glucose%2520Reduction%26jtitle%3DAm.%2520J.%2520Cardiovasc.%2520Drugs%26date%3D2018%26volume%3D18%26spage%3D181%26epage%3D183%26doi%3D10.1007%2Fs40256-018-0266-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rogliani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Daniele, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauro, D.</span></span> <span> </span><span class="NLM_article-title">Pleiotropic Effects of Hypoglycemic Agents: Implications in Asthma and COPD</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2018.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.coph.2018.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29427967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFGjs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2018&pages=34-38&author=P.+Roglianiauthor=J.+Oraauthor=N.+Di+Danieleauthor=D.+Lauro&title=Pleiotropic+Effects+of+Hypoglycemic+Agents%3A+Implications+in+Asthma+and+COPD&doi=10.1016%2Fj.coph.2018.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Pleiotropic effects of hypoglycemic agents: implications in asthma and COPD</span></div><div class="casAuthors">Rogliani, Paola; Ora, Josuel; Di Daniele, Nicola; Lauro, Davide</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34-38</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Diabetes mellitus (DM) is a complex multifactorial disease due to the interaction between environmental noxae and genetic predisposition.  Furthermore, an increased assocn. between DM, esp. Type 2 diabetes mellitus (T2DM), and the onset of pulmonary function impairment with a bronchial hyperresponsiveness has been documented.  DM is a risk factor for accelerated decline in FEV1 and the development of asthma and COPD.  The increased blood glucose concns. along with higher levels of oxidative stress and inflammation can influence the pulmonary function and, since hypoglycemic drugs can act on these different defects we can hypothesize their direct effect on obstructive pulmonary diseases.  Metformin, a biguanide, is the mol. having several evidences of its action on asthma and COPD in patients with T2DM.  In this population, Metformin can ameliorate pulmonary outcomes reducing high glucose concns., inflammation through the activation of the AMP-activated protein kinase, leading to the decreased prodn. of pro-inflammatory cytokines and blunting allergic eosinophilic airway inflammation.  There are evidences of Pioglitazone role on asthma, since the activation of PPARγ Pioglitazone might inhibit the synthesis and release of pro-inflammatory cytokines.  Indeed, Pioglitazone can improve symptoms assocd. with asthma reducing episodes of exacerbation and oral steroid prescription.  Finally, randomized clin. trials using hypoglycemic agents on patients with asthma and COPD with and without DM should be proposed as well as the implementation of a new formulation of hypoglycemic agents to make it possible to administer it via aerosol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnU_B1xQOwP7Vg90H21EOLACvtfcHk0lhVu7z0OAI7hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFGjs7w%253D&md5=f01182738df2f8628d9110ece2dd3c4d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2018.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2018.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DRogliani%26aufirst%3DP.%26aulast%3DOra%26aufirst%3DJ.%26aulast%3DDi%2BDaniele%26aufirst%3DN.%26aulast%3DLauro%26aufirst%3DD.%26atitle%3DPleiotropic%2520Effects%2520of%2520Hypoglycemic%2520Agents%253A%2520Implications%2520in%2520Asthma%2520and%2520COPD%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2018%26volume%3D40%26spage%3D34%26epage%3D38%26doi%3D10.1016%2Fj.coph.2018.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sirtori, C. R.</span></span> <span> </span><span class="NLM_article-title">The Pharmacology of Statins</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2014.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.phrs.2014.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=24657242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlslWmtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2014&pages=3-11&author=C.+R.+Sirtori&title=The+Pharmacology+of+Statins&doi=10.1016%2Fj.phrs.2014.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacology of statins</span></div><div class="casAuthors">Sirtori, Cesare R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3-11</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Statins, inhibitors of the hydroxymethylglutaryl-CoA (HMG-CoA) reductase enzyme, are mols. of fungal origin.  By inhibiting a key step in the sterol biosynthetic pathway statins are powerful cholesterol lowering medications and have provided outstanding contributions to the prevention of cardiovascular disease.  Their detection in mycetes traces back to close to 40 years ago: there were, originally, widely opposing views on their therapeutic potential.  From then on, intensive pharmaceutical development has led to the final availability in the clinic of seven statin mols., characterized by differences in bioavailability, lipo/hydrophilicity, cytochrome P 450 mediated metab. and cellular transport mechanisms.  These differences are reflected in their relative power (mg LDL-cholesterol redn. per mg dose) and possibly in parenchymal or muscular toxicities.  The impact of the antagonism of statins on a crucial step of intermediary metab. leads, in fact, both to a redn. of cholesterol biosynthesis as well as to addnl. pharmacodynamic (so called "pleiotropic") effects.  In the face of an extraordinary clin. success, the emergence of some side effects, e.g. raised incidence of diabetes and cataracts as well as frequent muscular side effects, have led to increasing concern by physicians.  However, also in view of the present relatively low cost of these drugs, their impact on daily therapy of vascular patients is unlikely to change.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKIXZ12_20nrVg90H21EOLACvtfcHk0lhVu7z0OAI7hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlslWmtrc%253D&md5=47cb556de48f6a9f546b482088a7a191</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2014.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2014.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DSirtori%26aufirst%3DC.%2BR.%26atitle%3DThe%2520Pharmacology%2520of%2520Statins%26jtitle%3DPharmacol.%2520Res.%26date%3D2014%26volume%3D88%26spage%3D3%26epage%3D11%26doi%3D10.1016%2Fj.phrs.2014.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veillard, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, F.</span></span> <span> </span><span class="NLM_article-title">Statins: The New Aspirin?</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1771</span>– <span class="NLM_lpage">1786</span>, <span class="refDoi"> DOI: 10.1007/PL00012505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1007%2FPL00012505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=12530513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD38Xps1entLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2002&pages=1771-1786&issue=11&author=N.+R.+Veillardauthor=F.+Mach&title=Statins%3A+The+New+Aspirin%3F&doi=10.1007%2FPL00012505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Statins: the new aspirin?</span></div><div class="casAuthors">Veillard, N. R.; Mach, F.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1771-1786</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review.  3-Hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitors, or statins, have been described as the principal and the most effective class of drug to reduce serum cholesterol levels.  Statin therapies have been shown to reduce cardiovascular events, including myocardial infarction, stroke, and death, significantly, by altering vascular atherosclerosis development in patients with or without coronary artery disease symptoms.  Extensive use of statins has led to the increase of some undesirable effects that are heavily counterbalanced by the benefits.  Indeed, pleiotropic effects extend far beyond cholesterol redn. and involve non-lipid-related mechanisms that modify endothelial functions, immunoinflammatory responses, smooth muscle cell activation, proliferation and migration, atherosclerotic plaque stability, and thrombus formation.  In this review, we describe in detail the targets and mechanisms of action of statins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhnFGEBj4m1rVg90H21EOLACvtfcHk0ljKoZycQV6j0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xps1entLc%253D&md5=83a74b6ee6d68eb7b578cc416dafbf56</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2FPL00012505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FPL00012505%26sid%3Dliteratum%253Aachs%26aulast%3DVeillard%26aufirst%3DN.%2BR.%26aulast%3DMach%26aufirst%3DF.%26atitle%3DStatins%253A%2520The%2520New%2520Aspirin%253F%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2002%26volume%3D59%26issue%3D11%26spage%3D1771%26epage%3D1786%26doi%3D10.1007%2FPL00012505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed Multiple Ligands. An Emerging Drug Discovery Paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&issue=21&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+Multiple+Ligands.+An+Emerging+Drug+Discovery+Paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0ljKoZycQV6j0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520Multiple%2520Ligands.%2520An%2520Emerging%2520Drug%2520Discovery%2520Paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D21%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designing Multiple Ligands - Medicinal Chemistry Strategies and Challenges</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.2174/138161209787315594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F138161209787315594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=19199984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVSns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=587-600&issue=6&author=R.+Morphyauthor=Z.+Rankovic&title=Designing+Multiple+Ligands+-+Medicinal+Chemistry+Strategies+and+Challenges&doi=10.2174%2F138161209787315594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Designing multiple ligands - medicinal chemistry strategies and challenges</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">587-600</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  It has been widely recognized over the recent years that parallel modulation of multiple biol. targets can be beneficial for treatment of diseases with complex etiologies such as cancer asthma, and psychiatric disease.  In this article, current strategies for the generation of ligands with a specific multi-target profile (designed multiple ligands or DMLs) are described and a no. of illustrative example are given.  Designing multiple ligands is frequently a challenging endeavor for medicinal chemists, with the need to appropriately balance affinity for 2 or more targets while obtaining physicochem. and pharmacokinetic properties that are consistent with the administration of an oral drug.  Given that the properties of DMLs are influenced to a large extent by the proteomic superfamily to which the targets belong and the lead generation strategy that is pursued, an early assessment of the feasibility of any given DML project is essential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUo6NjoK5D-LVg90H21EOLACvtfcHk0ljKoZycQV6j0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVSns70%253D&md5=fa34039be6e9c3b489f530fc74fd0346</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2174%2F138161209787315594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161209787315594%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigning%2520Multiple%2520Ligands%2520-%2520Medicinal%2520Chemistry%2520Strategies%2520and%2520Challenges%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2009%26volume%3D15%26issue%3D6%26spage%3D587%26epage%3D600%26doi%3D10.2174%2F138161209787315594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">The Physicochemical Challenges of Designing Multiple Ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">4961</span>– <span class="NLM_lpage">4970</span>, <span class="refDoi"> DOI: 10.1021/jm0603015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0603015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4961-4970&issue=16&author=R.+Morphyauthor=Z.+Rankovic&title=The+Physicochemical+Challenges+of+Designing+Multiple+Ligands&doi=10.1021%2Fjm0603015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The Physicochemical Challenges of Designing Multiple Ligands</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4961-4970</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compds. designed to bind more than one target can provide a therapeutic benefit relative to highly target-selective ligands.  The physicochem. properties of designed multiple ligands were found to be less druglike than those for preclin. compds. in general.  These properties are controlled by the superfamily to which the targets belong and the lead discovery strategy that was followed.  The properties for peptide G-protein-coupled receptor (GPCR) ligands were the least favorable for oral delivery, whereas transporter, monoamine GPCR, and oxidase ligands were the most druglike.  The lead discovery strategy, framework combination or screening, exerts a profound influence on the property values.  Combining the frameworks from two selective ligands often results in large, complex dual ligands, but druglike ligands can be achieved if the degree of framework overlap is maximized and the size of the selective ligands minimized.  For some target combinations, a screening approach may provide a route to smaller, less complex leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonGHbXyxgv4LVg90H21EOLACvtfcHk0ljKoZycQV6j0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D&md5=c7a227848516d0aa58ed037a582943fe</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm0603015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603015%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DThe%2520Physicochemical%2520Challenges%2520of%2520Designing%2520Multiple%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D16%26spage%3D4961%26epage%3D4970%26doi%3D10.1021%2Fjm0603015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Fragments, Network Biology and Designing Multiple Ligands</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">3–4</span>),  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">160</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2006.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.drudis.2006.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=17275736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtleisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=156-160&issue=3%E2%80%934&author=R.+Morphyauthor=Z.+Rankovic&title=Fragments%2C+Network+Biology+and+Designing+Multiple+Ligands&doi=10.1016%2Fj.drudis.2006.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Fragments, network biology and designing multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3&4</span>),
    <span class="NLM_cas:pages">156-160</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Modulating multiple protein targets simultaneously can be beneficial for treating complex diseases.  The redundancy that exists within biol. networks means that modulating single proteins might not be sufficient to produce the desired efficacy while, at the same time, minimizing adverse effects.  Designing multi-target drugs can be challenging for medicinal chemists, with current lead-discovery strategies often producing large, complex mols. with low ligand efficiency and poor oral bioavailability.  Paradoxically, analyses of the relationship between the selectivity of biol. active compds. and their mol. size suggest that promiscuous compds. should typically be smaller than target-selective compds.  A fragment-based approach to multi-target drug discovery could lead to a new generation of compds. with improved physicochem. and pharmacokinetic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXRYwI33BCNLVg90H21EOLACvtfcHk0lgZZTbk7CcCqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtleisbs%253D&md5=64a3c7e8c3280db166dda799a77d689a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2006.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2006.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFragments%252C%2520Network%2520Biology%2520and%2520Designing%2520Multiple%2520Ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26issue%3D3%25E2%2580%25934%26spage%3D156%26epage%3D160%26doi%3D10.1016%2Fj.drudis.2006.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">From Magic Bullets to Designed Multiple Ligands</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(04)03163-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2FS1359-6446%2804%2903163-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=15279847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=641-651&issue=15&author=R.+Morphyauthor=C.+Kayauthor=Z.+Rankovic&title=From+Magic+Bullets+to+Designed+Multiple+Ligands&doi=10.1016%2FS1359-6446%2804%2903163-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">From magic bullets to designed multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Kay, Corinne; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">641-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major trend in medicinal chem. in the coming years will be the rational design of ligands that are capable of modulating multiple disease-relevant targets in a specific manner.  Increasingly, it is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand.  Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes.  A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile.  An anal. of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsGpfzZok5rVg90H21EOLACvtfcHk0lgZZTbk7CcCqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D&md5=cd2491baad707043dbee4f59ccad9e1d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903163-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903163-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DC.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFrom%2520Magic%2520Bullets%2520to%2520Designed%2520Multiple%2520Ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26issue%3D15%26spage%3D641%26epage%3D651%26doi%3D10.1016%2FS1359-6446%2804%2903163-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Turning from Monogamy to Strategic Promiscuity</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">736</span>– <span class="NLM_lpage">737</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(04)03208-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2FS1359-6446%2804%2903208-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=15450238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BD2cvot1Krtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=736-737&issue=17&author=H.+Stark&title=Turning+from+Monogamy+to+Strategic+Promiscuity&doi=10.1016%2FS1359-6446%2804%2903208-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Turning from monogamy to strategic promiscuity</span></div><div class="casAuthors">Stark Holger</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">736-7</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQr6xRqqEG95mgRQsDqrjW_fW6udTcc2eaT4AxkXx8IMrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cvot1Krtw%253D%253D&md5=c59c9e1d59c4b22203f842332fb51f4b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903208-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903208-8%26sid%3Dliteratum%253Aachs%26aulast%3DStark%26aufirst%3DH.%26atitle%3DTurning%2520from%2520Monogamy%2520to%2520Strategic%2520Promiscuity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26issue%3D17%26spage%3D736%26epage%3D737%26doi%3D10.1016%2FS1359-6446%2804%2903208-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span> <span> </span><span class="NLM_article-title">Can We Rationally Design Promiscuous Drugs?</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1016/j.sbi.2006.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.sbi.2006.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=16442279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=127-136&issue=1&author=A.+L.+Hopkinsauthor=J.+S.+Masonauthor=J.+P.+Overington&title=Can+We+Rationally+Design+Promiscuous+Drugs%3F&doi=10.1016%2Fj.sbi.2006.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Can we rationally design promiscuous drugs?</span></div><div class="casAuthors">Hopkins, Andrew L.; Mason, Jonathan S.; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-136</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Structure-based drug design is now used widely in modern medicinal chem.  The application of structural biol. to medicinal chem. has heralded the 'rational drug design' vision of discovering exquisitely selective ligands.  However, recent advances in post-genomic biol. are indicating that polypharmacol. may be a necessary trait for the efficacy of many drugs, therefore questioning the 'one drug, one target' assumption of current rational drug design.  By combining advances in chemoinformatics and structural biol., it might be possible to rationally design the next generation of promiscuous drugs with polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQWdh60x9AHrVg90H21EOLACvtfcHk0lihKpc4ozPKIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D&md5=8f9e95a41976b8e3ac790f2fff2c406f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2006.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2006.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DCan%2520We%2520Rationally%2520Design%2520Promiscuous%2520Drugs%253F%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2006%26volume%3D16%26issue%3D1%26spage%3D127%26epage%3D136%26doi%3D10.1016%2Fj.sbi.2006.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Handl, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mash, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillies, R. J.</span></span> <span> </span><span class="NLM_article-title">Hitting Multiple Targets with Multimeric Ligands</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">565</span>– <span class="NLM_lpage">586</span>, <span class="refDoi"> DOI: 10.1517/14728222.8.6.565</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1517%2F14728222.8.6.565" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=15584863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmt1eisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2004&pages=565-586&issue=6&author=H.+L.+Handlauthor=J.+Vagnerauthor=H.+Hanauthor=E.+Mashauthor=V.+J.+Hrubyauthor=R.+J.+Gillies&title=Hitting+Multiple+Targets+with+Multimeric+Ligands&doi=10.1517%2F14728222.8.6.565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Hitting multiple targets with multimeric ligands</span></div><div class="casAuthors">Handl, Heather L.; Vagner, Josef; Han, Haiyong; Mash, Eugene; Hruby, Victor J.; Gillies, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">565-586</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Multimeric ligands consist of multiple monomeric ligands attached to a single backbone mol., creating a multimer that can bind to multiple receptors or targets simultaneously.  Numerous examples of multimeric binding exist within nature.  Due to the multiple and simultaneous binding events, multimeric ligands bind with an increased affinity compared to their corresponding monomers.  Multimeric ligands may provide opportunities in the field of drug discovery by providing enhanced selectivity and affinity of binding interactions, thus providing mol.-based targeted therapies.  However, gaps in our knowledge currently exist regarding the quant. measures for important design characteristics, such as flexibility, length and orientation of the inter-ligand linkers, receptor d. and ligand sequence.  In this review, multimeric ligand binding in two sep. phases is examd.  The prerecruitment phase describes the binding of one ligand of a multimer to its corresponding receptor, an event similar to monomeric ligand binding.  This results in transient increases in the local concn. of the other ligands, leading to apparent cooperativity.  The postrecruitment phase only occurs once all receptors have been aligned and bound by their corresponding ligand.  This phase is analogous to DNA-DNA interactions in that the stability of the complex is derived from phys. orientation.  Multiple factors influence the kinetics and thermodn. of multimeric binding, and these are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7NOkX9Q-NcLVg90H21EOLACvtfcHk0lihKpc4ozPKIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmt1eisg%253D%253D&md5=8aad8ea5debf2373eb5d59f5bab63dc5</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1517%2F14728222.8.6.565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.8.6.565%26sid%3Dliteratum%253Aachs%26aulast%3DHandl%26aufirst%3DH.%2BL.%26aulast%3DVagner%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DH.%26aulast%3DMash%26aufirst%3DE.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26aulast%3DGillies%26aufirst%3DR.%2BJ.%26atitle%3DHitting%2520Multiple%2520Targets%2520with%2520Multimeric%2520Ligands%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2004%26volume%3D8%26issue%3D6%26spage%3D565%26epage%3D586%26doi%3D10.1517%2F14728222.8.6.565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehár, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, C. T.</span></span> <span> </span><span class="NLM_article-title">Multi-Target Therapeutics: When the Whole Is Greater than the Sum of the Parts</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2006.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.drudis.2006.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=17198971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=34-42&issue=1%E2%80%932&author=G.+R.+Zimmermannauthor=J.+Leh%C3%A1rauthor=C.+T.+Keith&title=Multi-Target+Therapeutics%3A+When+the+Whole+Is+Greater+than+the+Sum+of+the+Parts&doi=10.1016%2Fj.drudis.2006.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target therapeutics: when the whole is greater than the sum of the parts</span></div><div class="casAuthors">Zimmermann Grant R; Lehar Joseph; Keith Curtis T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">34-42</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">Drugs designed to act against individual molecular targets cannot usually combat multigenic diseases such as cancer, or diseases that affect multiple tissues or cell types such as diabetes and immunoinflammatory disorders.  Combination drugs that impact multiple targets simultaneously are better at controlling complex disease systems, are less prone to drug resistance and are the standard of care in many important therapeutic areas.  The combination drugs currently employed are primarily of rational design, but the increased efficacy they provide justifies in vitro discovery efforts for identifying novel multi-target mechanisms.  In this review, we discuss the biological rationale for combination therapeutics, review some existing combination drugs and present a systematic approach to identify interactions between molecular pathways that could be leveraged for therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTI14vYK2Q1LENHe_gFldTbfW6udTcc2ebqHZ42iMpnubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D&md5=66715499ce21c2855dc6c477aa87f161</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2006.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2006.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DG.%2BR.%26aulast%3DLeh%25C3%25A1r%26aufirst%3DJ.%26aulast%3DKeith%26aufirst%3DC.%2BT.%26atitle%3DMulti-Target%2520Therapeutics%253A%2520When%2520the%2520Whole%2520Is%2520Greater%2520than%2520the%2520Sum%2520of%2520the%2520Parts%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26issue%3D1%25E2%2580%25932%26spage%3D34%26epage%3D42%26doi%3D10.1016%2Fj.drudis.2006.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Costantino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlocco, D.</span></span> <span> </span><span class="NLM_article-title">Designed Multiple Ligands: Basic Research vs Clinical Outcomes</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">3353</span>– <span class="NLM_lpage">3387</span>, <span class="refDoi"> DOI: 10.2174/092986712801215883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F092986712801215883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=22680630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOhtrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=3353-3387&issue=20&author=L.+Costantinoauthor=D.+Barlocco&title=Designed+Multiple+Ligands%3A+Basic+Research+vs+Clinical+Outcomes&doi=10.2174%2F092986712801215883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Designed multiple ligands: basic research vs clinical outcomes</span></div><div class="casAuthors">Costantino, L.; Barlocco, D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3353-3387</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The clin. treatment of multifactorial pathologies (e.g. cancer, Alzheimer's disease, psychiatric disorders), is still a major challenge.  Many researches have been published dealing with the design of multiple ligands, able to act at the same time towards several targets relevant for a given pathol.  In the present review, the clin. results about these compds. have been reported, together with the design strategy adopted, in order to allow a crit. evaluation of the outcomes of these efforts.  What is emerging is that several effective design strategies of multitarget compds. are available, and the choice among these appears to be dependent on the therapeutic area considered.  However, at present, besides multitarget drugs discovered during optimization efforts by means of phenotypic assays, drug coadministrations or fixed dose formulations appear to be more useful therapeutic options than designed multiple ligands; this scenario will change when systems biol. will be able to select crit. targets, i.e. nodal proteins that should be inhibited in order to obtain a therapeutic action; at this point, the design of multiple ligands will allow a renaissance of medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobv_P2UM6L_7Vg90H21EOLACvtfcHk0lihKpc4ozPKIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOhtrrN&md5=82123bbafc10a19c65a0bc0c5be72546</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2174%2F092986712801215883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986712801215883%26sid%3Dliteratum%253Aachs%26aulast%3DCostantino%26aufirst%3DL.%26aulast%3DBarlocco%26aufirst%3DD.%26atitle%3DDesigned%2520Multiple%2520Ligands%253A%2520Basic%2520Research%2520vs%2520Clinical%2520Outcomes%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2012%26volume%3D19%26issue%3D20%26spage%3D3353%26epage%3D3387%26doi%3D10.2174%2F092986712801215883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silakari, O.</span></span> <span> </span><span class="NLM_article-title">Multifunctional Compounds: Smart Molecules for Multifactorial Diseases</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.01.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.ejmech.2014.01.060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=24565571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFyqu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2014&pages=31-42&author=Y.+Bansalauthor=O.+Silakari&title=Multifunctional+Compounds%3A+Smart+Molecules+for+Multifactorial+Diseases&doi=10.1016%2Fj.ejmech.2014.01.060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Multifunctional compounds: Smart molecules for multifactorial diseases</span></div><div class="casAuthors">Bansal, Yogita; Silakari, Om</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31-42</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Multifunctional compds. (MFCs) are designed broadly as hybrid or conjugated drugs or as chimeric drugs from two or more pharmacophores/drugs having specific pharmacol. activities.  These are capable of eliciting multiple pharmacol. actions and have emerged as magic bullets in treatment of multifactorial diseases.  Many research articles disclosing the development of such compds. for treatment of multifactorial diseases are published during last 7 years.  Some successful MFC candidates for multifactorial CNS disorders include ziprasidone, duloxetine, ladostigil and M-30 whereas sunitinib, lapatinib and synthetic oleandane triterpinoids are the successful MFC candidates for various cancers.  Many more compds. derived from berberine, tacrine, artemisnin, quinine, NSAIDs, pralidoxine, donepezil, rivastigmine, curcumin and various antioxidants are under investigations for exploration of their multifunctional potential.  In general, MFCs possess the advantages of reduced molecularity, no drug-drug interactions and improved pharmacokinetics and pharmacodynamics.  A MFC derived from two or more different pharmacophores exerts its activities by interacting with resp. receptors of its constituent pharmacophores.  It may also exhibit addnl. binding interactions with the receptor sites that may be responsible for significantly improved or addnl. activities.  The present review discusses various MFCs developed for specific class of disorders with an aim to provide an insight into the strategies in medicinal chem. for development of such compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr5doWQJHIRbVg90H21EOLACvtfcHk0lgiNeGd_xaQ3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFyqu7w%253D&md5=53392637dc34c3369831a3e3da359557</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.01.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.01.060%26sid%3Dliteratum%253Aachs%26aulast%3DBansal%26aufirst%3DY.%26aulast%3DSilakari%26aufirst%3DO.%26atitle%3DMultifunctional%2520Compounds%253A%2520Smart%2520Molecules%2520for%2520Multifactorial%2520Diseases%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D76%26spage%3D31%26epage%3D42%26doi%3D10.1016%2Fj.ejmech.2014.01.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span> <span> </span><span class="NLM_article-title">Computational Multitarget Drug Design</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">403</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.6b00491</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.6b00491" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFCntr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=403-412&issue=3&author=W.+Zhangauthor=J.+Peiauthor=L.+Lai&title=Computational+Multitarget+Drug+Design&doi=10.1021%2Facs.jcim.6b00491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Computational Multitarget Drug Design</span></div><div class="casAuthors">Zhang, Weilin; Pei, Jianfeng; Lai, Luhua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">403-412</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Designing drugs that can simultaneously interact with multiple targets is a promising approach for treating complicated diseases.  Compared to using combinations of single target drugs, multitarget drugs have advantages of higher efficacy, improved safety profile, and simpler administration.  Many in silico methods have been developed to approach different aspects of this polypharmacol.-guided drug design, particularly for drug repurposing and multitarget drug design.  In this review, the authors summarize recent progress in computational multitarget drug design and discuss their advantages and limitations.  Perspectives for future drug development will also be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-J4p0tdEUR7Vg90H21EOLACvtfcHk0lgiNeGd_xaQ3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFCntr8%253D&md5=e00ed6650471d786a04b828a8064f5e9</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.6b00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.6b00491%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DPei%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DComputational%2520Multitarget%2520Drug%2520Design%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2017%26volume%3D57%26issue%3D3%26spage%3D403%26epage%3D412%26doi%3D10.1021%2Facs.jcim.6b00491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Oliveira Pedrosa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte da Cruz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira Viana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olimpio de Moura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishiki, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa Filho, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diniz, M. F. F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scotti, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scotti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezerra
Mendonca, F. J.</span></span> <span> </span><span class="NLM_article-title">Hybrid Compounds as Direct Multitarget Ligands: A Review</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1044</span>– <span class="NLM_lpage">1079</span>, <span class="refDoi"> DOI: 10.2174/1568026616666160927160620</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F1568026616666160927160620" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27697048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC2svmtlOnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=1044-1079&issue=9&author=M.+de%0AOliveira+Pedrosaauthor=R.+M.+Duarte+da+Cruzauthor=J.+de+Oliveira+Vianaauthor=R.+Olimpio+de+Mouraauthor=H.+M.+Ishikiauthor=J.+M.+Barbosa+Filhoauthor=M.+F.+F.+M.+Dinizauthor=M.+T.+Scottiauthor=L.+Scottiauthor=F.+J.+Bezerra%0AMendonca&title=Hybrid+Compounds+as+Direct+Multitarget+Ligands%3A+A+Review&doi=10.2174%2F1568026616666160927160620"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrid Compounds as Direct Multitarget Ligands: A Review</span></div><div class="casAuthors">de Oliveira Pedrosa Michelle; Duarte da Cruz Rayssa Marques; de Oliveira Viana Jessika; de Moura Ricardo Olimpio; Ishiki Hamilton Mitsugu; Barbosa Filho Jose Maria; Diniz Margareth F F M; Scotti Marcus Tullius; Scotti Luciana; Bezerra Mendonca Francisco Jaime</div><div class="citationInfo"><span class="NLM_cas:title">Current topics in medicinal chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1044-1079</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Molecular Hybridization is an approach in rational drug design where new chemical entities are obtained by combining two or more pharmacophoric units from different bioactive compounds into a single molecule.  Through this approach, medicinal chemists hope that the new hybrid derivative presents: better affinity and efficacy when compared to the parent drugs; a modified selectivity profile with improvement over pharmacokinetic and pharmacodynamic restrictions; dual or multiple modes of action; reduction of undesirable side effects; decreases in drug-drug interactions; reduced emergence or spread of drug resistance in microorganisms and protozoans; and lower cost.  The approach has been successfully used by many research groups around the world and has had very promising results with diseases having multifactorial profiles, like Alzheimer's, Parkinson's disease, cancer, inflammation, and hypertension among others.  The purpose of this paper is to conduct an updated review of molecular hybridization and multitarget profiling (a rational drug design approach), and its applications to the design and discovery of novel hybrid compounds with anti-inflammatory, antimicrobial, anticancer and antiprotozoal (leishmaniasis, malaria, and schistosomiasis) activities over the last six years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSlAS_CHdfHQvupmecNw_lfW6udTcc2eaC2zAbMRjfNrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svmtlOnsA%253D%253D&md5=17567b4c0f16fa6af0ad0823532a56bc</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2174%2F1568026616666160927160620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026616666160927160620%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BOliveira%2BPedrosa%26aufirst%3DM.%26aulast%3DDuarte%2Bda%2BCruz%26aufirst%3DR.%2BM.%26aulast%3Dde%2BOliveira%2BViana%26aufirst%3DJ.%26aulast%3DOlimpio%2Bde%2BMoura%26aufirst%3DR.%26aulast%3DIshiki%26aufirst%3DH.%2BM.%26aulast%3DBarbosa%2BFilho%26aufirst%3DJ.%2BM.%26aulast%3DDiniz%26aufirst%3DM.%2BF.%2BF.%2BM.%26aulast%3DScotti%26aufirst%3DM.%2BT.%26aulast%3DScotti%26aufirst%3DL.%26aulast%3DBezerra%2BMendonca%26aufirst%3DF.%2BJ.%26atitle%3DHybrid%2520Compounds%2520as%2520Direct%2520Multitarget%2520Ligands%253A%2520A%2520Review%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2017%26volume%3D17%26issue%3D9%26spage%3D1044%26epage%3D1079%26doi%3D10.2174%2F1568026616666160927160620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korcsmáros, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szalay, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böde, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovács, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csermely, P.</span></span> <span> </span><span class="NLM_article-title">How to Design Multi-Target Drugs</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">799</span>– <span class="NLM_lpage">808</span>, <span class="refDoi"> DOI: 10.1517/17460441.2.6.799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1517%2F17460441.2.6.799" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=799-808&issue=6&author=T.+Korcsm%C3%A1rosauthor=M.+S.+Szalayauthor=C.+B%C3%B6deauthor=I.+A.+Kov%C3%A1csauthor=P.+Csermely&title=How+to+Design+Multi-Target+Drugs&doi=10.1517%2F17460441.2.6.799"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1517%2F17460441.2.6.799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2.6.799%26sid%3Dliteratum%253Aachs%26aulast%3DKorcsm%25C3%25A1ros%26aufirst%3DT.%26aulast%3DSzalay%26aufirst%3DM.%2BS.%26aulast%3DB%25C3%25B6de%26aufirst%3DC.%26aulast%3DKov%25C3%25A1cs%26aufirst%3DI.%2BA.%26aulast%3DCsermely%26aufirst%3DP.%26atitle%3DHow%2520to%2520Design%2520Multi-Target%2520Drugs%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2007%26volume%3D2%26issue%3D6%26spage%3D799%26epage%3D808%26doi%3D10.1517%2F17460441.2.6.799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravikumar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aittokallio, T.</span></span> <span> </span><span class="NLM_article-title">Improving the Efficacy-Safety Balance of Polypharmacology in Multi-Target Drug Discovery</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1080/17460441.2018.1413089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1080%2F17460441.2018.1413089" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=179-192&issue=2&author=B.+Ravikumarauthor=T.+Aittokallio&title=Improving+the+Efficacy-Safety+Balance+of+Polypharmacology+in+Multi-Target+Drug+Discovery&doi=10.1080%2F17460441.2018.1413089"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1080%2F17460441.2018.1413089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2018.1413089%26sid%3Dliteratum%253Aachs%26aulast%3DRavikumar%26aufirst%3DB.%26aulast%3DAittokallio%26aufirst%3DT.%26atitle%3DImproving%2520the%2520Efficacy-Safety%2520Balance%2520of%2520Polypharmacology%2520in%2520Multi-Target%2520Drug%2520Discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2018%26volume%3D13%26issue%3D2%26spage%3D179%26epage%3D192%26doi%3D10.1080%2F17460441.2018.1413089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. U.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology - Foe or Friend?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">8955</span>– <span class="NLM_lpage">8971</span>, <span class="refDoi"> DOI: 10.1021/jm400856t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400856t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8955-8971&issue=22&author=J.+U.+Peters&title=Polypharmacology+-+Foe+or+Friend%3F&doi=10.1021%2Fjm400856t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BU.%26atitle%3DPolypharmacology%2520-%2520Foe%2520or%2520Friend%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D22%26spage%3D8955%26epage%3D8971%26doi%3D10.1021%2Fjm400856t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. U.</span></span> <i>Polypharmacology in Drug Discovery</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J.-U.</span></span>, Ed.; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2F9781118098141" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=J.+U.+Petersauthor=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2F9781118098141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BU.%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26aulast%3DPeters%26aufirst%3DJ.-U.%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteban, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bautista-Aguilera, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inokuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraleda, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iriepa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández Fernández, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricardo-Martínez-Murillo</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unzeta, M.</span></span> <span> </span><span class="NLM_article-title">Donepezil + Propargylamine + 8-Hydroxyquinoline Hybrids as New Multifunctional Metal-Chelators, ChE and MAO Inhibitors for the Potential Treatment of Alzheimer’s Disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">561</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.04.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.ejmech.2014.04.078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=24813882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVensL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2014&pages=543-561&author=L.+Wangauthor=G.+Estebanauthor=M.+Ojimaauthor=O.+M.+Bautista-Aguileraauthor=T.+Inokuchiauthor=I.+Moraledaauthor=I.+Iriepaauthor=A.+Samadiauthor=M.+B.+H.+Youdimauthor=A.+Romeroauthor=E.+Sorianoauthor=R.+Herreroauthor=A.+P.+Fern%C3%A1ndez+Fern%C3%A1ndezauthor=+Ricardo-Mart%C3%ADnez-Murilloauthor=J.+Marco-Contellesauthor=M.+Unzeta&title=Donepezil+%2B+Propargylamine+%2B+8-Hydroxyquinoline+Hybrids+as+New+Multifunctional+Metal-Chelators%2C+ChE+and+MAO+Inhibitors+for+the+Potential+Treatment+of+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.ejmech.2014.04.078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease</span></div><div class="casAuthors">Wang, Li; Esteban, Gerard; Ojima, Masaki; Bautista-Aguilera, Oscar M.; Inokuchi, Tsutomu; Moraleda, Ignacio; Iriepa, Isabel; Samadi, Abdelouahid; Youdim, Moussa B. H.; Romero, Alejandro; Soriano, Elena; Herrero, Raquel; Fernandez Fernandez, Ana Patricia; Ricardo-Martinez-Murillo; Marco-Contelles, Jose; Unzeta, Mercedes</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">543-561</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The synthesis, biochem. evaluation, ADMET, toxicity and mol. modeling of novel multi-target-directed Donepezil + Propargylamine + 8-Hydroxyquinoline (DPH) hybrids for the potential prevention and treatment of Alzheimer's disease is described.  The most interesting deriv. was racemic α-aminotrile4-(1-benzylpiperidin-4-yl)-2-(((8-hydroxyquinolin-5-yl)methyl)(prop-2-yn-1-yl)amino) butanenitrile (DPH6) [MAO A (IC50 = 6.2±0.7 μM); MAO B (IC50 = 10.2±0.9 μM); AChE (IC50 = 1.8±0.1 μM); BuChE (IC50 = 1.6±0.25 μM)], an irreversible MAO A/B inhibitor and mixed-type AChE inhibitor with metal-chelating properties.  According to docking studies, both DPH6 enantiomers interact simultaneously with the catalytic and peripheral site of EeAChE through a linker of appropriate length, supporting the obsd. mixed-type AChE inhibition.  Both enantiomers exhibited a relatively similar position of both hydroxyquinoline and benzyl moieties with the rest of the mol. easily accommodated in the relatively large cavity of MAO A.  For MAO B, the quinoline system was hosted at the cavity entrance, whereas for MAO A this system occupied the substrate cavity.  In this disposition the quinoline moiety interacted directly with the FAD arom. ring.  Very similar binding affinity values were also obsd. for both enantiomers with ChE and MAO enzymes.  DPH derivs. exhibited moderate to good ADMET properties and brain penetration capacity for CNS activity.  DPH6 was less toxic than donepezil at high concns.; while at low concns. both displayed a similar cell viability profile.  Finally, in a passive avoidance task, the antiamnesic effect of DPH6 was tested on mice with exptl. induced amnesia.  DPH6 was capable to significantly decrease scopolamine-induced learning deficits in healthy adult mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphrIxeM4RW2rVg90H21EOLACvtfcHk0lgiD2JYRSaq4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVensL8%253D&md5=2e1f262b4002653cbac7a6dafabe3548</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.04.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.04.078%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DEsteban%26aufirst%3DG.%26aulast%3DOjima%26aufirst%3DM.%26aulast%3DBautista-Aguilera%26aufirst%3DO.%2BM.%26aulast%3DInokuchi%26aufirst%3DT.%26aulast%3DMoraleda%26aufirst%3DI.%26aulast%3DIriepa%26aufirst%3DI.%26aulast%3DSamadi%26aufirst%3DA.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%2BH.%26aulast%3DRomero%26aufirst%3DA.%26aulast%3DSoriano%26aufirst%3DE.%26aulast%3DHerrero%26aufirst%3DR.%26aulast%3DFern%25C3%25A1ndez%2BFern%25C3%25A1ndez%26aufirst%3DA.%2BP.%26aulast%3DRicardo-Mart%25C3%25ADnez-Murillo%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DUnzeta%26aufirst%3DM.%26atitle%3DDonepezil%2520%252B%2520Propargylamine%2520%252B%25208-Hydroxyquinoline%2520Hybrids%2520as%2520New%2520Multifunctional%2520Metal-Chelators%252C%2520ChE%2520and%2520MAO%2520Inhibitors%2520for%2520the%2520Potential%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D80%26spage%3D543%26epage%3D561%26doi%3D10.1016%2Fj.ejmech.2014.04.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Unzeta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteban, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolea, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fogel, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tipton, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span> <span> </span><span class="NLM_article-title">Multi-Target Directed Donepezil-Like Ligands for Alzheimer’s Disease</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">205</span>, <span class="refDoi"> DOI: 10.3389/fnins.2016.00205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.3389%2Ffnins.2016.00205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27252617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FmtV2hsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=205&author=M.+Unzetaauthor=G.+Estebanauthor=I.+Boleaauthor=W.+A.+Fogelauthor=R.+R.+Ramsayauthor=M.+B.+H.+Youdimauthor=K.+F.+Tiptonauthor=J.+Marco-Contelles&title=Multi-Target+Directed+Donepezil-Like+Ligands+for+Alzheimer%E2%80%99s+Disease&doi=10.3389%2Ffnins.2016.00205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease</span></div><div class="casAuthors">Unzeta Mercedes; Bolea Irene; Esteban Gerard; Tipton Keith F; Fogel Wieslawa A; Ramsay Rona R; Youdim Moussa B H; Marco-Contelles Jose</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">205</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">HIGHLIGHTS ASS234 is a MTDL compound containing a moiety from Donepezil and the propargyl group from the PF 9601N, a potent and selective MAO B inhibitor.  This compound is the most advanced anti-Alzheimer agent for preclinical studies identified in our laboratory.Derived from ASS234 both multipotent donepezil-indolyl (MTDL-1) and donepezil-pyridyl hybrids (MTDL-2) were designed and evaluated as inhibitors of AChE/BuChE and both MAO isoforms.  MTDL-2 showed more high affinity toward the four enzymes than MTDL-1.MTDL-3 and MTDL-4, were designed containing the N-benzylpiperidinium moiety from Donepezil, a metal- chelating 8-hydroxyquinoline group and linked to a N-propargyl core and they were pharmacologically evaluated.The presence of the cyano group in MTDL-3, enhanced binding to AChE, BuChE and MAO A.  It showed antioxidant behavior and it was able to strongly complex Cu(II), Zn(II) and Fe(III).MTDL-4 showed higher affinity toward AChE, BuChE.MTDL-3 exhibited good brain penetration capacity (ADMET) and less toxicity than Donepezil.  Memory deficits in scopolamine-lesioned animals were restored by MTDL-3.MTDL-3 particularly emerged as a ligand showing remarkable potential benefits for its use in AD therapy.  Alzheimer's disease (AD), the most common form of adult onset dementia, is an age-related neurodegenerative disorder characterized by progressive memory loss, decline in language skills, and other cognitive impairments.  Although its etiology is not completely known, several factors including deficits of acetylcholine, β-amyloid deposits, τ-protein phosphorylation, oxidative stress, and neuroinflammation are considered to play significant roles in the pathophysiology of this disease.  For a long time, AD patients have been treated with acetylcholinesterase inhibitors such as donepezil (Aricept®) but with limited therapeutic success.  This might be due to the complex multifactorial nature of AD, a fact that has prompted the design of new Multi-Target-Directed Ligands (MTDL) based on the "one molecule, multiple targets" paradigm.  Thus, in this context, different series of novel multifunctional molecules with antioxidant, anti-amyloid, anti-inflammatory, and metal-chelating properties able to interact with multiple enzymes of therapeutic interest in AD pathology including acetylcholinesterase, butyrylcholinesterase, and monoamine oxidases A and B have been designed and assessed biologically.  This review describes the multiple targets, the design rationale and an in-house MTDL library, bearing the N-benzylpiperidine motif present in donepezil, linked to different heterocyclic ring systems (indole, pyridine, or 8-hydroxyquinoline) with special emphasis on compound ASS234, an N-propargylindole derivative.  The description of the in vitro biological properties of the compounds and discussion of the corresponding structure-activity-relationships allows us to highlight new issues for the identification of more efficient MTDL for use in AD therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAKdUtVDXRPgpJitSxOdIlfW6udTcc2ebh2WekzRfj4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FmtV2hsw%253D%253D&md5=0904cb1e4e1c700e575e192e9d3bebb3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2016.00205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2016.00205%26sid%3Dliteratum%253Aachs%26aulast%3DUnzeta%26aufirst%3DM.%26aulast%3DEsteban%26aufirst%3DG.%26aulast%3DBolea%26aufirst%3DI.%26aulast%3DFogel%26aufirst%3DW.%2BA.%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%2BH.%26aulast%3DTipton%26aufirst%3DK.%2BF.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26atitle%3DMulti-Target%2520Directed%2520Donepezil-Like%2520Ligands%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DFront.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D205%26doi%3D10.3389%2Ffnins.2016.00205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simone
Tranches Dias, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viegas, C.</span></span> <span> </span><span class="NLM_article-title">Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the Treatment of Alzheimer’s Disease</span>. <i>Curr. Neuropharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.2174/1570159X1203140511153200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F1570159X1203140511153200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=24851088" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=239-255&issue=3&author=K.+Simone%0ATranches+Diasauthor=C.+Viegas&title=Multi-Target+Directed+Drugs%3A+A+Modern+Approach+for+Design+of+New+Drugs+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease&doi=10.2174%2F1570159X1203140511153200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2174%2F1570159X1203140511153200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570159X1203140511153200%26sid%3Dliteratum%253Aachs%26aulast%3DSimone%2BTranches%2BDias%26aufirst%3DK.%26aulast%3DViegas%26aufirst%3DC.%26atitle%3DMulti-Target%2520Directed%2520Drugs%253A%2520A%2520Modern%2520Approach%2520for%2520Design%2520of%2520New%2520Drugs%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2014%26volume%3D12%26issue%3D3%26spage%3D239%26epage%3D255%26doi%3D10.2174%2F1570159X1203140511153200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majekova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valoti, M.</span></span> <span> </span><span class="NLM_article-title">Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">375</span>, <span class="refDoi"> DOI: 10.3389/fnins.2016.00375</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.3389%2Ffnins.2016.00375" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27597816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC2sznvFKhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=375&author=R.+R.+Ramsayauthor=M.+Majekovaauthor=M.+Medinaauthor=M.+Valoti&title=Key+Targets+for+Multi-Target+Ligands+Designed+to+Combat+Neurodegeneration&doi=10.3389%2Ffnins.2016.00375"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration</span></div><div class="casAuthors">Ramsay Rona R; Majekova Magdalena; Medina Milagros; Valoti Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">375</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">HIGHLIGHTS Compounds that interact with multiple targets but minimally with the cytochrome P450 system (CYP) address the many factors leading to neurodegeneration.Acetyl- and Butyryl-cholineEsterases (AChE, BChE) and Monoamine Oxidases A/B (MAO A, MAO B) are targets for Multi-Target Designed Ligands (MTDL).ASS234 is an irreversible inhibitor of MAO A >MAO B and has micromolar potency against the cholinesterases.ASS234 is a poor CYP substrate in human liver, yielding the depropargylated metabolite.SMe1EC2, a stobadine derivative, showed high radical scavenging property, in vitro and in vivo giving protection in head trauma and diabetic damage of endothelium.Control of mitochondrial function and morphology by manipulating fission and fusion is emerging as a target area for therapeutic strategies to decrease the pathological outcome of neurodegenerative diseases.  Growing evidence supports the view that neurodegenerative diseases have multiple and common mechanisms in their aetiologies.  These multifactorial aspects have changed the broadly common assumption that selective drugs are superior to "dirty drugs" for use in therapy.  This drives the research in studies of novel compounds that might have multiple action mechanisms.  In neurodegeneration, loss of neuronal signaling is a major cause of the symptoms, so preservation of neurotransmitters by inhibiting the breakdown enzymes is a first approach.  Acetylcholinesterase (AChE) inhibitors are the drugs preferentially used in AD and that one of these, rivastigmine, is licensed also for PD.  Several studies have shown that monoamine oxidase (MAO) B, located mainly in glial cells, increases with age and is elevated in Alzheimer (AD) and Parkinson's Disease's (PD).  Deprenyl, a MAO B inhibitor, significantly delays the initiation of levodopa treatment in PD patients.  These indications underline that AChE and MAO are considered a necessary part of multi-target designed ligands (MTDL).  However, both of these targets are simply symptomatic treatment so if new drugs are to prevent degeneration rather than compensate for loss of neurotransmitters, then oxidative stress and mitochondrial events must also be targeted.  MAO inhibitors can protect neurons from apoptosis by mechanisms unrelated to enzyme inhibition.  Understanding the involvement of MAO and other proteins in the induction and regulation of the apoptosis in mitochondria will aid progress toward strategies to prevent the loss of neurons.  In general, the oxidative stress observed both in PD and AD indicate that antioxidant properties are a desirable part of MTDL molecules.  After two or more properties are incorporated into one molecule, the passage from a lead compound to a therapeutic tool is strictly linked to its pharmacokinetic and toxicity.  In this context the interaction of any new molecules with cytochrome P450 and other xenobiotic metabolic processes is a crucial point.  The present review covers the biochemistry of enzymes targeted in the design of drugs against neurodegeneration and the cytochrome P450-dependent metabolism of MTDLs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQjOr1PdgGetEwlCcfExbvbfW6udTcc2ebh2WekzRfj4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sznvFKhsA%253D%253D&md5=d4262692b6fbea1a58815dca979f2c69</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2016.00375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2016.00375%26sid%3Dliteratum%253Aachs%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DMajekova%26aufirst%3DM.%26aulast%3DMedina%26aufirst%3DM.%26aulast%3DValoti%26aufirst%3DM.%26atitle%3DKey%2520Targets%2520for%2520Multi-Target%2520Ligands%2520Designed%2520to%2520Combat%2520Neurodegeneration%26jtitle%3DFront.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D375%26doi%3D10.3389%2Ffnins.2016.00375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer’s Disease</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">466</span>, <span class="refDoi"> DOI: 10.3390/molecules21040466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.3390%2Fmolecules21040466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27070562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWktLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=466&issue=4&author=F.+Pratiauthor=A.+Cavalliauthor=M.+L.+Bolognesi&title=Navigating+the+Chemical+Space+of+Multitarget-Directed+Ligands%3A+From+Hybrids+to+Fragments+in+Alzheimer%E2%80%99s+Disease&doi=10.3390%2Fmolecules21040466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Navigating the chemical space of multitarget-directed ligands: from hybrids to fragments in Alzheimer's disease</span></div><div class="casAuthors">Prati, Federica; Cavalli, Andrea; Bolognesi, Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">466/1-466/12</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Multitarget drug discovery is one of the hottest topics and most active fields in the search for new mols. against Alzheimer's disease (AD).  Over the last 20 years, many promising multitarget-directed ligands (MTDLs) have been identified and developed at a pre-clin. level.  However, how to design them in a rational way remains the most fundamental challenge of medicinal chemists.  This is related to the foundational question of achieving an optimized activity towards multiple targets of interest, while preserving drug-like properties.  In this respect, large hybrid mols. and small fragments are poles apart.  In this review article, our aim is to appraise what we have accomplished in the development of both hybrid- and fragment-like mols. directed to diverse AD targets (i.e., acetylcholinesterase, NMDA receptors, metal chelation, BACE-1 and GSK-3β).  In addn., we attempt to highlight what are the persistent needs that deserve to be improved and cared for, with the ultimate goal of moving an MTDL to AD clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAXsoof4raqbVg90H21EOLACvtfcHk0ljxzaMmK724Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWktLjI&md5=3653a0ef6b41711663e8d2f2d4ae74f6</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.3390%2Fmolecules21040466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules21040466%26sid%3Dliteratum%253Aachs%26aulast%3DPrati%26aufirst%3DF.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DNavigating%2520the%2520Chemical%2520Space%2520of%2520Multitarget-Directed%2520Ligands%253A%2520From%2520Hybrids%2520to%2520Fragments%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DMolecules%26date%3D2016%26volume%3D21%26issue%3D4%26spage%3D466%26doi%3D10.3390%2Fmolecules21040466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchiorre, C.</span></span> <span> </span><span class="NLM_article-title">Memoquin: A Multi-Target-Directed Ligand as an Innovative Therapeutic Opportunity for Alzheimer’s Disease</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">152</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1016/j.nurt.2008.10.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.nurt.2008.10.042" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=152-162&issue=1&author=M.+L.+Bolognesiauthor=A.+Cavalliauthor=C.+Melchiorre&title=Memoquin%3A+A+Multi-Target-Directed+Ligand+as+an+Innovative+Therapeutic+Opportunity+for+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.nurt.2008.10.042"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.nurt.2008.10.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nurt.2008.10.042%26sid%3Dliteratum%253Aachs%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DMemoquin%253A%2520A%2520Multi-Target-Directed%2520Ligand%2520as%2520an%2520Innovative%2520Therapeutic%2520Opportunity%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DNeurotherapeutics%26date%3D2009%26volume%3D6%26issue%3D1%26spage%3D152%26epage%3D162%26doi%3D10.1016%2Fj.nurt.2008.10.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geldenhuys, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Schyf, C. J.</span></span> <span> </span><span class="NLM_article-title">Rationally Designed Multi-Targeted Agents against Neurodegenerative Diseases</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1662</span>– <span class="NLM_lpage">1672</span>, <span class="refDoi"> DOI: 10.2174/09298673113209990112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F09298673113209990112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=23410161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotl2jtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1662-1672&issue=13&author=W.+J.+Geldenhuysauthor=C.+J.+Van+der+Schyf&title=Rationally+Designed+Multi-Targeted+Agents+against+Neurodegenerative+Diseases&doi=10.2174%2F09298673113209990112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Rationally designed multi-targeted agents against neurodegenerative diseases</span></div><div class="casAuthors">Geldenhuys, W. J.; Van der Schyf, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1662-1672</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Neurodegenerative diseases are complex disorders with several pathoetiol. pathways leading to cell death.  Rationally designed multi-targeted agents, or "multi-targeted designed drugs" (MTDD) show significant promise in preclin. studies as neuroprotective and disease-modifying agents.  In this review, we highlight the use of chem. scaffolds that lend themselves exquisitely to the development of MTDDs in neurodegeneration.  Notably, synthetic polycyclic cage compds. have served as scaffolds for novel voltage-gated calcium channel blockers, NMDA receptor antagonists, and sigma-receptor ligands - attractive targets in neurodegeneration.  In an entirely different approach, compds. contg. the thiazolidinedione moiety (referred to as glitazones) alter mitochondrial function through the mitochondrial protein mitoNEET, an attractive new drug target for the treatment of neurodegenerative diseases.  The design strategy for yet another agent, ladostigil, employed the amalgamation of active chem. moieties of the AChE inhibitor rivastigmine, and the monoamine oxidase-B (MAO-B) inhibitor rasagiline, leading to a single compd. that targets both enzymes simultaneously.  Natural products have also served as design templates for several MTDD design studies.  In particular, the stilbene scaffold has become popular in particular due to the neuroprotective effects of the non-flavonoid natural product resveratrol.  Recently, stilbene scaffold-based compds. were developed to reduce - through chelation with metal ions that interact with beta-amyloid - both metal-induced beta-amyloid protein aggregation, and ROS generated from this aggregate.  Other subtle modifications of the stilbene motif led to the creation of reversible, non-competitive MAO inhibitors.  Finally, compds. derived from the xanthine scaffold afford neuroprotection in Parkinson's disease through mechanisms that include dual adenosine A2A receptor antagonism and MAO-B inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqZJN4lAGwOrVg90H21EOLACvtfcHk0lhLUt-7Nx1VyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotl2jtbw%253D&md5=626f69acb3b3ff995e31b042e48dfba3</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.2174%2F09298673113209990112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F09298673113209990112%26sid%3Dliteratum%253Aachs%26aulast%3DGeldenhuys%26aufirst%3DW.%2BJ.%26aulast%3DVan%2Bder%2BSchyf%26aufirst%3DC.%2BJ.%26atitle%3DRationally%2520Designed%2520Multi-Targeted%2520Agents%2520against%2520Neurodegenerative%2520Diseases%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26issue%3D13%26spage%3D1662%26epage%3D1672%26doi%3D10.2174%2F09298673113209990112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bawa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradeep, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choonara, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillay, V.</span></span> <span> </span><span class="NLM_article-title">Multi-Target Therapeutics for Neuropsychiatric and Neurodegenerative Disorders</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1886</span>– <span class="NLM_lpage">1914</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.drudis.2016.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27506871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlaiu7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=1886-1914&issue=12&author=P.+Bawaauthor=P.+Pradeepauthor=P.+Kumarauthor=Y.+E.+Choonaraauthor=G.+Modiauthor=V.+Pillay&title=Multi-Target+Therapeutics+for+Neuropsychiatric+and+Neurodegenerative+Disorders&doi=10.1016%2Fj.drudis.2016.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders</span></div><div class="casAuthors">Bawa, Priya; Pradeep, Priyamvada; Kumar, Pradeep; Choonara, Yahya E.; Modi, Girish; Pillay, Viness</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1886-1914</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Historically, neuropsychiatric and neurodegenerative disease treatments focused on the 'magic bullet' concept; however multi-targeted strategies are increasingly attractive gauging from the escalating research in this area.  Because these diseases are typically co-morbid, multi-targeted drugs capable of interacting with multiple targets will expand treatment to the co-morbid disease condition.  Despite their theor. efficacy, there are significant impediments to clin. success (e.g., difficulty titrating individual aspects of the drug and inconclusive pathophysiol. mechanisms).  The new and revised diagnostic frameworks along with studies detailing the endophenotypic characteristics of the diseases promise to provide the foundation for the circumvention of these impediments.  This review serves to evaluate the various marketed and nonmarketed multi-targeted drugs with particular emphasis on their design strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaUcziq8vK_bVg90H21EOLACvtfcHk0lhLUt-7Nx1VyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlaiu7rL&md5=47734b25b4b55be4f04f3ef936dfa313</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DBawa%26aufirst%3DP.%26aulast%3DPradeep%26aufirst%3DP.%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DChoonara%26aufirst%3DY.%2BE.%26aulast%3DModi%26aufirst%3DG.%26aulast%3DPillay%26aufirst%3DV.%26atitle%3DMulti-Target%2520Therapeutics%2520for%2520Neuropsychiatric%2520and%2520Neurodegenerative%2520Disorders%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26issue%3D12%26spage%3D1886%26epage%3D1914%26doi%3D10.1016%2Fj.drudis.2016.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span> <span> </span><span class="NLM_article-title">One for All? Hitting Multiple Alzheimer’s Disease Targets with One Drug</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">177</span>, <span class="refDoi"> DOI: 10.3389/fnins.2016.00177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.3389%2Ffnins.2016.00177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27199640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FhsV2lug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=177&author=R.+E.+Hughesauthor=K.+Nikolicauthor=R.+R.+Ramsay&title=One+for+All%3F+Hitting+Multiple+Alzheimer%E2%80%99s+Disease+Targets+with+One+Drug&doi=10.3389%2Ffnins.2016.00177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug</span></div><div class="casAuthors">Hughes Rebecca E; Ramsay Rona R; Nikolic Katarina</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">177</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">HIGHLIGHTS Many AD target combinations are being explored for multi-target drug design.New databases and models increase the potential of computational drug designLiraglutide and other antidiabetics are strong candidates for repurposing to AD.Donecopride a dual 5-HT/AChE inhibitor shows promise in pre-clinical studies Alzheimer's Disease is a complex and multifactorial disease for which the mechanism is still not fully understood.  As new insights into disease progression are discovered, new drugs must be designed to target those aspects of the disease that cause neuronal damage rather than just the symptoms currently addressed by single target drugs.  It is becoming possible to target several aspects of the disease pathology at once using multi-target drugs (MTDs).  Intended as an introduction for non-experts, this review describes the key MTD design approaches, namely structure-based, in silico, and data-mining, to evaluate what is preventing compounds progressing through the clinic to the market.  Repurposing current drugs using their off-target effects reduces the cost of development, time to launch, and the uncertainty associated with safety and pharmacokinetics.  The most promising drugs currently being investigated for repurposing to Alzheimer's Disease are rasagiline, originally developed for the treatment of Parkinson's Disease, and liraglutide, an antidiabetic.  Rational drug design can combine pharmacophores of multiple drugs, systematically change functional groups, and rank them by virtual screening.  Hits confirmed experimentally are rationally modified to generate an effective multi-potent lead compound.  Examples from this approach are ASS234 with properties similar to rasagiline, and donecopride, a hybrid of an acetylcholinesterase inhibitor and a 5-HT4 receptor agonist with pro-cognitive effects.  Exploiting these interdisciplinary approaches, public-private collaborative lead factories promise faster delivery of new drugs to the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnTES9o7fNJJHZzFRCXxVKfW6udTcc2ebtNwWAaY3-V7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FhsV2lug%253D%253D&md5=771f4dce4dc9504cc6078715e954a308</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2016.00177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2016.00177%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DR.%2BE.%26aulast%3DNikolic%26aufirst%3DK.%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26atitle%3DOne%2520for%2520All%253F%2520Hitting%2520Multiple%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Targets%2520with%2520One%2520Drug%26jtitle%3DFront.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D177%26doi%3D10.3389%2Ffnins.2016.00177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dekeyne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brocco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loiseau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivet, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Cara, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cremers, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flik, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fone, K. C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, D. J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serres, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cespuglio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavielle, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millan, M. J.</span></span> <span> </span><span class="NLM_article-title">S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/ 2-Adrenoceptor Antagonist and Potential Antidepressant: II. A Behavioral, Neurochemical, and Electrophysiological Characterization</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>340</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">765</span>– <span class="NLM_lpage">780</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.187534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1124%2Fjpet.111.187534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=22178753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtVSksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=2012&pages=765-780&issue=3&author=A.+Dekeyneauthor=M.+Broccoauthor=F.+Loiseauauthor=A.+Gobertauthor=J.-M.+Rivetauthor=B.+Di+Caraauthor=T.+I.+Cremersauthor=G.+Flikauthor=K.+C.+F.+Foneauthor=D.+J.+G.+Watsonauthor=M.+Pappauthor=T.+Sharpauthor=F.+Serresauthor=R.+Cespuglioauthor=B.+Olivierauthor=J.+S.+W.+Chanauthor=G.+Lavielleauthor=M.+J.+Millan&title=S32212%2C+a+Novel+Serotonin+Type+2C+Receptor+Inverse+Agonist%2F+2-Adrenoceptor+Antagonist+and+Potential+Antidepressant%3A+II.+A+Behavioral%2C+Neurochemical%2C+and+Electrophysiological+Characterization&doi=10.1124%2Fjpet.111.187534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization</span></div><div class="casAuthors">Dekeyne, Anne; Brocco, Mauricette; Loiseau, Florence; Gobert, Alain; Rivet, Jean-Michel; Di Cara, Benjamin; Cremers, Thomas I.; Flik, Gunnar; Fone, Kevin C. F.; Watson, David J. G.; Papp, Mariusz; Sharp, Trevor; Serres, Florence; Cespuglio, Raymond; Olivier, Berend; Chan, Johnny S. W.; Lavielle, Gilbert; Millan, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">765-780</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The present studies characterized the functional profile of N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-1,2-dihydro-3H-benzo[e]indole-3-carboxamide) (S32212), a combined serotonin (5-HT)2C receptor inverse agonist and α2-adrenoceptor antagonist that also possesses 5-HT2A antagonist properties.  Upon parenteral and/or oral administration, dose-dependent (0.63-40.0 mg/kg) actions were obsd. in diverse procedures.  Both acute and subchronic administration of S32212 reduced immobility time in a forced-swim test in rats.  Acutely, it also suppressed marble burying and aggressive behavior in mice.  Long-term administration of S32212 was assocd. with rapid (1 wk) and sustained (5 wk) normalization of sucrose intake in rats exposed to chronic mild stress and with elevated levels of mRNA encoding brain-derived neurotrophic factor in hippocampus and amygdala (2 wk).  S32212 accelerated the firing rate of adrenergic perikarya in the locus coeruleus and elevated dialysis levels of noradrenaline in the frontal cortex and hippocampus of freely moving rats.  S32212 also elevated the frontocortical levels of dopamine and acetylcholine, whereas 5-HT, amino acids, and histamine were unaffected.  These neurochem. actions were paralleled by "promnemonic" properties: blockade of scopolamine-induced deficits in radial maze performance and social recognition and reversal of delay-induced impairments in social recognition, social novelty discrimination, and novel object recognition.  It also showed anxiolytic actions in a Vogel conflict procedure.  Furthermore, in an electroencephalog. study of sleep architecture, S32212 enhanced slow-wave and rapid eye movement sleep, while decreasing waking.  Finally, chronic administration of S32212 neither elevated body wt. nor perturbed sexual behavior in male rats.  In conclusion, S32212 displays a functional profile consistent with improved mood and cognitive performance, together with satisfactory tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDWoTa3Y74A7Vg90H21EOLACvtfcHk0lj9TtIovbGz7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtVSksrc%253D&md5=eb76f053470c98aee181108d01fe2513</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187534%26sid%3Dliteratum%253Aachs%26aulast%3DDekeyne%26aufirst%3DA.%26aulast%3DBrocco%26aufirst%3DM.%26aulast%3DLoiseau%26aufirst%3DF.%26aulast%3DGobert%26aufirst%3DA.%26aulast%3DRivet%26aufirst%3DJ.-M.%26aulast%3DDi%2BCara%26aufirst%3DB.%26aulast%3DCremers%26aufirst%3DT.%2BI.%26aulast%3DFlik%26aufirst%3DG.%26aulast%3DFone%26aufirst%3DK.%2BC.%2BF.%26aulast%3DWatson%26aufirst%3DD.%2BJ.%2BG.%26aulast%3DPapp%26aufirst%3DM.%26aulast%3DSharp%26aufirst%3DT.%26aulast%3DSerres%26aufirst%3DF.%26aulast%3DCespuglio%26aufirst%3DR.%26aulast%3DOlivier%26aufirst%3DB.%26aulast%3DChan%26aufirst%3DJ.%2BS.%2BW.%26aulast%3DLavielle%26aufirst%3DG.%26aulast%3DMillan%26aufirst%3DM.%2BJ.%26atitle%3DS32212%252C%2520a%2520Novel%2520Serotonin%2520Type%25202C%2520Receptor%2520Inverse%2520Agonist%252F%25202-Adrenoceptor%2520Antagonist%2520and%2520Potential%2520Antidepressant%253A%2520II.%2520A%2520Behavioral%252C%2520Neurochemical%252C%2520and%2520Electrophysiological%2520Characterization%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D340%26issue%3D3%26spage%3D765%26epage%3D780%26doi%3D10.1124%2Fjpet.111.187534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Millan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannoury la Cour, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanrion, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupuis, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Cara, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audinot, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cussac, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman-Tancredi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jockers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bockaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dekeyne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavielle, G.</span></span> <span> </span><span class="NLM_article-title">S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/ 2-Adrenoceptor Antagonist and Potential Antidepressant: I. A Mechanistic Characterization</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>340</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">750</span>– <span class="NLM_lpage">764</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.187468</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1124%2Fjpet.111.187468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=22178752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtVSksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=2012&pages=750-764&issue=3&author=M.+J.+Millanauthor=C.+Mannoury+la+Courauthor=B.+Chanrionauthor=D.+S.+Dupuisauthor=B.+Di+Caraauthor=V.+Audinotauthor=D.+Cussacauthor=A.+Newman-Tancrediauthor=M.+Kamalauthor=J.+A.+Boutinauthor=R.+Jockersauthor=P.+Marinauthor=J.+Bockaertauthor=O.+Mullerauthor=A.+Dekeyneauthor=G.+Lavielle&title=S32212%2C+a+Novel+Serotonin+Type+2C+Receptor+Inverse+Agonist%2F+2-Adrenoceptor+Antagonist+and+Potential+Antidepressant%3A+I.+A+Mechanistic+Characterization&doi=10.1124%2Fjpet.111.187468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">S32212, a novel serotonin type 2C receptor inverse agonist/α2 adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization</span></div><div class="casAuthors">Millan, Mark J.; La Cour, Clotilde Mannoury; Chanrion, Benjamin; Dupuis, Delphine S.; Di Cara, Benjamin; Audinot, Valerie; Cussac, Didier; Newman-Tancredi, Adrian; Kamal, Maud; Boutin, Jean A.; Jockers, Ralf; Marin, Philippe; Bockaert, Joel; Muller, Olivier; Dekeyne, Anne; Lavielle, Gilbert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">750-764</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Although most antidepressants suppress serotonin (5-HT) and/or noradrenaline reuptake, blockade of 5-HT2C receptors and α2-adrenoceptors likewise enhances monoaminergic transmission.  These sites are targeted by the urea deriv. N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-1,2-dihydro-3-H-benzo[e]indole-3-carboxamide (S32212).  S32212 was devoid of affinity for monoamine reuptake sites, yet displayed pronounced affinity (pKi, 8.2) for constitutively active human 5-HT2CINI (h5-HT2CINI) receptors, behaving as an inverse agonist in reducing basal Gαq activation, [3H]inositol-phosphate prodn., and the spontaneous assocn. of h5-HT2CINI-Renilla luciferase receptors with β-arrestin2-yellow fluorescent protein.  Furthermore, upon 18-h pretreatment, S32212 enhanced the plasma membrane expression of h5-HT2CINI receptors as visualized by confocal microscopy and quantified by ELISA.  Its actions were prevented by the neutral antagonist 6-chloro-5-methyl-N-[6-(2-methylpyridin-3-yloxy)pyridin-3-yl]indoline-1-carboxamide (SB242,084), which also impeded the induction by long-term exposure to S32212 of otherwise absent Ca2+ mobilization in mouse cortical neurons.  In vivo, S32212 blunted the inhibitory influence of the 5-HT2C agonist 2-(3-chlorobenzyloxy)-6-(1-piperazinyl)pyrazine (CP809,101) on ventrotegmental dopaminergic neurons.  S32212 also blocked 5-HT-induced Gαq and phospholipase C activation at the h5-HT2A and, less potently, h5-HT2B receptors and suppressed the discriminative stimulus properties of the 5-HT2A agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane in rats.  S32212 manifested marked affinity for human α2A- (pKi 7.2), α2B- (pKi 8.2), and α2C- (pKi 7.4) adrenoceptors, at which it abolished noradrenaline-induced recruitment of Gαi3, Gαo, adenylyl cyclase, and extracellular-regulated kinase1/2.  Moreover, S32212 dose-dependently abolished the discriminative stimulus effects of the α2-adrenoceptor agonist (S)-spiro[(1-oxa-2-amino-3-azacyclopent-2-ene)-4,2'-(1',2',3',4'-tetrahydronaphthalene)] (S18616).  Finally, S32212 displayed negligible affinity for α1A-adrenoceptors, histamine H1 receptors, and muscarinic M1 receptors.  In conclusion, S32212 behaves as an inverse agonist at h5-HT2C receptors and as an antagonist at human α2-adrenoceptors (and h5-HT2A receptors).  Its promising profile in preclin. models potentially relevant to the treatment of depression is described in.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpURy5Z1iERUrVg90H21EOLACvtfcHk0lj9TtIovbGz7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtVSksrY%253D&md5=9dc9462928ba6309d72a6a36179e71d9</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187468%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DM.%2BJ.%26aulast%3DMannoury%2Bla%2BCour%26aufirst%3DC.%26aulast%3DChanrion%26aufirst%3DB.%26aulast%3DDupuis%26aufirst%3DD.%2BS.%26aulast%3DDi%2BCara%26aufirst%3DB.%26aulast%3DAudinot%26aufirst%3DV.%26aulast%3DCussac%26aufirst%3DD.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26aulast%3DKamal%26aufirst%3DM.%26aulast%3DBoutin%26aufirst%3DJ.%2BA.%26aulast%3DJockers%26aufirst%3DR.%26aulast%3DMarin%26aufirst%3DP.%26aulast%3DBockaert%26aufirst%3DJ.%26aulast%3DMuller%26aufirst%3DO.%26aulast%3DDekeyne%26aufirst%3DA.%26aulast%3DLavielle%26aufirst%3DG.%26atitle%3DS32212%252C%2520a%2520Novel%2520Serotonin%2520Type%25202C%2520Receptor%2520Inverse%2520Agonist%252F%25202-Adrenoceptor%2520Antagonist%2520and%2520Potential%2520Antidepressant%253A%2520I.%2520A%2520Mechanistic%2520Characterization%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D340%26issue%3D3%26spage%3D750%26epage%3D764%26doi%3D10.1124%2Fjpet.111.187468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">East, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, L. L.</span></span> <span> </span><span class="NLM_article-title">Multitarget Ligands in Antibacterial Research: Progress and Opportunities</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1517/17460441.2013.743991</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1517%2F17460441.2013.743991" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=143-156&issue=2&author=S.+P.+Eastauthor=L.+L.+Silver&title=Multitarget+Ligands+in+Antibacterial+Research%3A+Progress+and+Opportunities&doi=10.1517%2F17460441.2013.743991"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1517%2F17460441.2013.743991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2013.743991%26sid%3Dliteratum%253Aachs%26aulast%3DEast%26aufirst%3DS.%2BP.%26aulast%3DSilver%26aufirst%3DL.%2BL.%26atitle%3DMultitarget%2520Ligands%2520in%2520Antibacterial%2520Research%253A%2520Progress%2520and%2520Opportunities%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2013%26volume%3D8%26issue%3D2%26spage%3D143%26epage%3D156%26doi%3D10.1517%2F17460441.2013.743991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, R.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, W.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, D.-F.</span></span> <span> </span><span class="NLM_article-title">Designing Multi-Targeted Agents: An Emerging Anticancer Drug Discovery Paradigm</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.ejmech.2017.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28494256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsV2rtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2017&pages=195-211&author=R.-G.+Fuauthor=Y.+Sunauthor=W.-B.+Shengauthor=D.-F.+Liao&title=Designing+Multi-Targeted+Agents%3A+An+Emerging+Anticancer+Drug+Discovery+Paradigm&doi=10.1016%2Fj.ejmech.2017.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Designing multi-targeted agents: An emerging anticancer drug discovery paradigm</span></div><div class="casAuthors">Fu, Rong-geng; Sun, Yuan; Sheng, Wen-bing; Liao, Duan-fang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">195-211</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is to design ligands with max. selectivity to act on individual drug targets.  With the target-based approach, many new chem. entities have been discovered, developed, and further approved as drugs.  However, there are a large no. of complex diseases such as cancer that cannot be effectively treated or cured only with one medicine to modulate the biol. function of a single target.  As simultaneous intervention of two (or multiple) cancer progression relevant targets has shown improved therapeutic efficacy, the innovation of multi-targeted drugs has become a promising and prevailing research topic and numerous multi-targeted anticancer agents are currently at various developmental stages.  However, most multi-pharmacophore scaffolds are usually discovered by serendipity or screening, while rational design by combining existing pharmacophore scaffolds remains an enormous challenge.  In this review, four types of multi-pharmacophore modes are discussed, and the examples from literature will be used to introduce attractive lead compds. with the capability of simultaneously interfering with different enzyme or signaling pathway of cancer progression, which will reveal the trends and insights to help the design of the next generation multi-targeted anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGjXR-zscrArVg90H21EOLACvtfcHk0lgwL_qGNdibFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsV2rtL8%253D&md5=511561bd2cd186d5dafa905b7257bf32</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DR.-G.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DW.-B.%26aulast%3DLiao%26aufirst%3DD.-F.%26atitle%3DDesigning%2520Multi-Targeted%2520Agents%253A%2520An%2520Emerging%2520Anticancer%2520Drug%2520Discovery%2520Paradigm%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D136%26spage%3D195%26epage%3D211%26doi%3D10.1016%2Fj.ejmech.2017.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raghavendra, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pingili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadasi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mettu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, S. V. U. M.</span></span> <span> </span><span class="NLM_article-title">Dual or Multi-Targeting Inhibitors: The next Generation Anticancer Agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">1277</span>– <span class="NLM_lpage">1300</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.10.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.ejmech.2017.10.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29126724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslyrt7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=1277-1300&author=N.+M.+Raghavendraauthor=D.+Pingiliauthor=S.+Kadasiauthor=A.+Mettuauthor=S.+V.+U.+M.+Prasad&title=Dual+or+Multi-Targeting+Inhibitors%3A+The+next+Generation+Anticancer+Agents&doi=10.1016%2Fj.ejmech.2017.10.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Dual or multi-targeting inhibitors: The next generation anticancer agents</span></div><div class="casAuthors">Raghavendra, Nulgumnalli Manjunathaiah; Pingili, Divya; Kadasi, Sundeep; Mettu, Akhila; Prasad, S. V. U. M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1277-1300</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Dual-targeting/Multi-targeting of oncoproteins by a single drug mol. represents an efficient, logical and alternative approach to drug combinations.  An increasing interest in this approach is indicated by a steady upsurge in the no. of articles on targeting dual/multi proteins published in the last 5 years.  Combining different inhibitors that destiny specific single target is the std. treatment for cancer.  A new generation of dual or multi-targeting drugs is emerging, where a single chem. entity can act on multiple mol. targets.  Dual/Multi-targeting agents are beneficial for solving limited efficiencies, poor safety and resistant profiles of an individual target.  Designing dual/multi-target inhibitors with predefined biol. profiles present a challenge.  The latest advances in bioinformatic tools and the availability of detailed structural information of target proteins have shown a way of discovering multi-targeting mols.  This neoteric artifice that amalgamates the mol. docking of small mols. with protein-based common pharmacophore to design multi-targeting inhibitors is gaining great importance in anticancer drug discovery.  Current review focus on the discoveries of dual targeting agents in cancer therapy using rational, computational, proteomic, bioinformatics and polypharmacol. approach that enables the discovery and rational design of effective and safe multi-target anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVpBUpxW1okLVg90H21EOLACvtfcHk0lgwL_qGNdibFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslyrt7jO&md5=a14783194c23f7dc5f200cf6eabf9269</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.10.021%26sid%3Dliteratum%253Aachs%26aulast%3DRaghavendra%26aufirst%3DN.%2BM.%26aulast%3DPingili%26aufirst%3DD.%26aulast%3DKadasi%26aufirst%3DS.%26aulast%3DMettu%26aufirst%3DA.%26aulast%3DPrasad%26aufirst%3DS.%2BV.%2BU.%2BM.%26atitle%3DDual%2520or%2520Multi-Targeting%2520Inhibitors%253A%2520The%2520next%2520Generation%2520Anticancer%2520Agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D1277%26epage%3D1300%26doi%3D10.1016%2Fj.ejmech.2017.10.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petrelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valabrega, G.</span></span> <span> </span><span class="NLM_article-title">Multitarget Drugs: The Present and the Future of Cancer Therapy</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1517/14656560902781907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1517%2F14656560902781907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=19284362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtF2mu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=589-600&issue=4&author=A.+Petrelliauthor=G.+Valabrega&title=Multitarget+Drugs%3A+The+Present+and+the+Future+of+Cancer+Therapy&doi=10.1517%2F14656560902781907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget drugs: the present and the future of cancer therapy</span></div><div class="casAuthors">Petrelli, Annalisa; Valabrega, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">589-600</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Target therapies for the treatment of human cancers have revolutionized the concept of oncol. medicine.  This type of therapeutic approach is directed to the inhibition of mol. targets that play a pivotal role in tumor progression - such as tyrosine kinase receptors (TKIs) controlling cell proliferation and survival - mainly by means of compds. able to block their activity.  In the beginning, the aim of target therapies was specifically to hit a single mol. expressed in neoplastic cells.  Now the prevailing idea is that inhibiting both cancer cells and cells of the stroma supporting the tumor would gain better results in fighting the disease.  Therefore, the single-target therapy is fading in favor of a multitarget approach and the new generation of TKIs is selected on the basis of their ability simultaneously to target different mols.  This review summarizes the mol. basis of multitarget therapies and the most relevant results obtained in different cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSM1xsRJGBX7Vg90H21EOLACvtfcHk0lgwL_qGNdibFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtF2mu70%253D&md5=c84e048407e6d9354a1f4a595fb4a468</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1517%2F14656560902781907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656560902781907%26sid%3Dliteratum%253Aachs%26aulast%3DPetrelli%26aufirst%3DA.%26aulast%3DValabrega%26aufirst%3DG.%26atitle%3DMultitarget%2520Drugs%253A%2520The%2520Present%2520and%2520the%2520Future%2520of%2520Cancer%2520Therapy%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2009%26volume%3D10%26issue%3D4%26spage%3D589%26epage%3D600%26doi%3D10.1517%2F14656560902781907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Z.</span></span> <span> </span><span class="NLM_article-title">Co-Targeting Cancer Drug Escape Pathways Confers Clinical Advantage for Multi-Target Anticancer Drugs</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2015.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.phrs.2015.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=26438971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1ShtbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2015&pages=123-131&author=L.+Taoauthor=F.+Zhuauthor=F.+Xuauthor=Z.+Chenauthor=Y.+Y.+Jiangauthor=Y.+Z.+Chen&title=Co-Targeting+Cancer+Drug+Escape+Pathways+Confers+Clinical+Advantage+for+Multi-Target+Anticancer+Drugs&doi=10.1016%2Fj.phrs.2015.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs</span></div><div class="casAuthors">Tao, Lin; Zhu, Feng; Xu, Feng; Chen, Zhe; Jiang, Yu Yang; Chen, Yu Zong</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">123-131</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Recent investigations have suggested that anticancer therapeutics may be enhanced by co-targeting the primary anticancer target and the corresponding drug escape pathways.  Whether this strategy confers statistically significant clin. advantage has not been systematically investigated.  This question was probed by the evaluation of the clin. status and the multiple targets of 23 approved and 136 clin. trial multi-target anticancer drugs with particular focus on those co-targeting EGFR, HER2, Abl, VEGFR2, mTOR, PI3K, Alk, MEK, KIT, and DNA topoisomerase, and some of the 14, 7, 13, 20, 6, 5, 7, 2, 4 and 10 cancer drug escape pathways resp.  Most of the approved (73.9%) and phase III (75.0%), the majority of the Phase II (62.8%) and I (53.6%), and the minority of the discontinued (35.3%) multi-target drugs were found to co-target cancer drug escape pathways.  This suggests that co-targeting anticancer targets and drug escape pathways confer significant clin. advantage and such strategy can be more extensively explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZKuYkoBNEebVg90H21EOLACvtfcHk0lgwL_qGNdibFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1ShtbnM&md5=8596b0d20f94e8e4ec7d74f6cb5c618a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2015.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2015.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DY.%2BY.%26aulast%3DChen%26aufirst%3DY.%2BZ.%26atitle%3DCo-Targeting%2520Cancer%2520Drug%2520Escape%2520Pathways%2520Confers%2520Clinical%2520Advantage%2520for%2520Multi-Target%2520Anticancer%2520Drugs%26jtitle%3DPharmacol.%2520Res.%26date%3D2015%26volume%3D102%26spage%3D123%26epage%3D131%26doi%3D10.1016%2Fj.phrs.2015.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gattrell, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, M.</span></span> <span> </span><span class="NLM_article-title">Designed Multiple Ligands in Metabolic Disease Research: From Concept to Platform</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">15–16</span>),  <span class="NLM_fpage">692</span>– <span class="NLM_lpage">696</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.drudis.2013.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=23454344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVertL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=692-696&issue=15%E2%80%9316&author=W.+Gattrellauthor=C.+Johnstoneauthor=S.+Patelauthor=C.+S.+Smithauthor=A.+Scheelauthor=M.+Schindler&title=Designed+Multiple+Ligands+in+Metabolic+Disease+Research%3A+From+Concept+to+Platform&doi=10.1016%2Fj.drudis.2013.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Designed multiple ligands in metabolic disease research: from concept to platform</span></div><div class="casAuthors">Gattrell, W.; Johnstone, C.; Patel, S.; Smith, C. Sambrook; Scheel, A.; Schindler, M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15-16</span>),
    <span class="NLM_cas:pages">692-696</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Type 2 diabetes mellitus (T2DM) is a multifactorial disease, and drug monotherapy typically results in unsatisfactory treatment outcomes for patients.  Even when used in combination, existing therapies lack efficacy in the long term.  Designed multiple ligands (DMLs) are compds. developed to modulate multiple targets relevant to a disease.  DMLs offer the potential to yield greater efficacy over monotherapies, either by modulating different biol. pathways, or by boosting a single one.  However, examples of DMLs progressing into clin. trials, or onto the market are rare; DML drug discovery is challenging, and perceived by some to be almost impossible.  Nevertheless, with the judicious selection of biol. targets, both from a biol. and chem. perspective, it is possible to develop drug-like DMLs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqsRea2XH7-7Vg90H21EOLACvtfcHk0ljx02oNNFPsyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVertL8%253D&md5=56204a6c37b64ee11d3f6bd617cad00b</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DGattrell%26aufirst%3DW.%26aulast%3DJohnstone%26aufirst%3DC.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DC.%2BS.%26aulast%3DScheel%26aufirst%3DA.%26aulast%3DSchindler%26aufirst%3DM.%26atitle%3DDesigned%2520Multiple%2520Ligands%2520in%2520Metabolic%2520Disease%2520Research%253A%2520From%2520Concept%2520to%2520Platform%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26issue%3D15%25E2%2580%259316%26spage%3D692%26epage%3D696%26doi%3D10.1016%2Fj.drudis.2013.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gellrich, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Potential of Peroxisome Proliferator-Activated Receptor Modulation in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis</span>. <i>Nucl. Recept. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">101310</span>, <span class="refDoi"> DOI: 10.11131/2017/101310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.11131%2F2017%2F101310" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2017&pages=101310&author=L.+Gellrichauthor=D.+Merk&title=Therapeutic+Potential+of+Peroxisome+Proliferator-Activated+Receptor+Modulation+in+Non-Alcoholic+Fatty+Liver+Disease+and+Non-Alcoholic+Steatohepatitis&doi=10.11131%2F2017%2F101310"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.11131%2F2017%2F101310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.11131%252F2017%252F101310%26sid%3Dliteratum%253Aachs%26aulast%3DGellrich%26aufirst%3DL.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DTherapeutic%2520Potential%2520of%2520Peroxisome%2520Proliferator-Activated%2520Receptor%2520Modulation%2520in%2520Non-Alcoholic%2520Fatty%2520Liver%2520Disease%2520and%2520Non-Alcoholic%2520Steatohepatitis%26jtitle%3DNucl.%2520Recept.%2520Res.%26date%3D2017%26volume%3D4%26spage%3D101310%26doi%3D10.11131%2F2017%2F101310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bisi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobbi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belluti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampa, A.</span></span> <span> </span><span class="NLM_article-title">Design of Multifunctional Compounds for Cardiovascular Disease: From Natural Scaffolds to “Classical” Multitarget Approach</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1759</span>– <span class="NLM_lpage">1782</span>, <span class="refDoi"> DOI: 10.2174/0929867311320130012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F0929867311320130012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=23410171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotl2juro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1759-1782&issue=13&author=A.+Bisiauthor=S.+Gobbiauthor=F.+Bellutiauthor=A.+Rampa&title=Design+of+Multifunctional+Compounds+for+Cardiovascular+Disease%3A+From+Natural+Scaffolds+to+%E2%80%9CClassical%E2%80%9D+Multitarget+Approach&doi=10.2174%2F0929867311320130012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Design of multifunctional compounds for cardiovascular disease: from natural scaffolds to "classical" multitarget approach</span></div><div class="casAuthors">Bisi, A.; Gobbi, S.; Belluti, F.; Rampa, A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1759-1782</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cardiovascular disease represents the main cause of death worldwide.  Novel therapies to reduce elevated blood pressure and treat resistant hypertension, to consequently reduce the assocd. cardiovascular risk factors, are still required.  Among the different strategies commonly used in medicinal chem. to develop new mols., the synthesis of multitarget/hybrid compds. combining two or more pharmacophore groups targeting simultaneously selected factors involved in cardiovascular diseases, has gained increasing interest.  This review will focus on the most recent literature on multifunctional cardiovascular drugs, paying particular attention on hybrid compds. bearing natural scaffolds, considering that compds. derived from medicinal exts. are generally appealing for the medicinal chemist as they often bear the so-called "privileged structures".  Moreover, taking into account many excellent reviews dealing with multitarget cardiovascular drugs published in the last few years, mainly devoted to RAAS inhibition and/or NO donors hybrid drugs, herein the most significant results obtained and the benefits and limitations of these approaches will be highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBZAxoIKJrM7Vg90H21EOLACvtfcHk0ljx02oNNFPsyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotl2juro%253D&md5=0d6cdd19a2850a461b8b4c576caabd2f</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2174%2F0929867311320130012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320130012%26sid%3Dliteratum%253Aachs%26aulast%3DBisi%26aufirst%3DA.%26aulast%3DGobbi%26aufirst%3DS.%26aulast%3DBelluti%26aufirst%3DF.%26aulast%3DRampa%26aufirst%3DA.%26atitle%3DDesign%2520of%2520Multifunctional%2520Compounds%2520for%2520Cardiovascular%2520Disease%253A%2520From%2520Natural%2520Scaffolds%2520to%2520%25E2%2580%259CClassical%25E2%2580%259D%2520Multitarget%2520Approach%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26issue%3D13%26spage%3D1759%26epage%3D1782%26doi%3D10.2174%2F0929867311320130012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span>; <span class="NLM_string-name">Schubert-Zsilavecz, M.</span></span> <span> </span><span class="NLM_article-title">The Linker Approach: Drug Conjugates</span>. In  <i>Drug Selectivity</i>; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>, <span class="NLM_year">2017</span>; pp  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">245</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2F9783527674381.ch8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=207-245&author=D.+Merk&author=M.+Schubert-Zsilavecz&title=Drug+Selectivity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2F9783527674381.ch8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527674381.ch8%26sid%3Dliteratum%253Aachs%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DThe%2520Linker%2520Approach%253A%2520Drug%2520Conjugates%26btitle%3DDrug%2520Selectivity%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2017%26spage%3D207%26epage%3D245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chittasupho, C.</span></span> <span> </span><span class="NLM_article-title">Multivalent Ligand: Design Principle for Targeted Therapeutic Delivery Approach</span>. <i>Ther. Delivery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1171</span>– <span class="NLM_lpage">1187</span>, <span class="refDoi"> DOI: 10.4155/tde.12.99</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.4155%2Ftde.12.99" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=23116010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFCrurbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1171-1187&issue=10&author=C.+Chittasupho&title=Multivalent+Ligand%3A+Design+Principle+for+Targeted+Therapeutic+Delivery+Approach&doi=10.4155%2Ftde.12.99"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Multivalent ligand: design principle for targeted therapeutic delivery approach</span></div><div class="casAuthors">Chittasupho, Chuda</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Delivery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1171-1187</span>CODEN:
                <span class="NLM_cas:coden">TDHEA7</span>;
        ISSN:<span class="NLM_cas:issn">2041-5990</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Multivalent interactions of biol. mols. play an important role in many biochem. events.  A multivalent ligand comprises of multiple copies of ligands conjugated to scaffolds, allowing the simultaneous binding of multivalent ligands to multiple binding sites or receptors.  Many research groups have successfully designed and synthesized multivalent ligands to increase the binding affinity, avidity and specificity of the ligand to the receptor.  A multimeric ligand is a promising option for the specific treatment of diseases.  In this review, the factors affecting multivalent interactions, including the size and shape of the ligand, geometry and an arrangement of ligands on the scaffold, linker length, thermodn., and kinetics of the interactions are discussed.  Examples of the multivalent ligand applications for therapeutic delivery are also summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWWDU1KszkuLVg90H21EOLACvtfcHk0ljx02oNNFPsyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFCrurbJ&md5=0b30d1d1675cfb7bbdc38dfbf7168b7e</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.4155%2Ftde.12.99&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ftde.12.99%26sid%3Dliteratum%253Aachs%26aulast%3DChittasupho%26aufirst%3DC.%26atitle%3DMultivalent%2520Ligand%253A%2520Design%2520Principle%2520for%2520Targeted%2520Therapeutic%2520Delivery%2520Approach%26jtitle%3DTher.%2520Delivery%26date%3D2012%26volume%3D3%26issue%3D10%26spage%3D1171%26epage%3D1187%26doi%3D10.4155%2Ftde.12.99" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minarini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumiatti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recanatini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchiorre, C.</span></span> <span> </span><span class="NLM_article-title">Multi-Target-Directed Ligands to Combat Neurodegenerative Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1021/jm7009364</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7009364" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=347-372&issue=3&author=A.+Cavalliauthor=M.+L.+Bolognesiauthor=A.+Minariniauthor=M.+Rosiniauthor=V.+Tumiattiauthor=M.+Recanatiniauthor=C.+Melchiorre&title=Multi-Target-Directed+Ligands+to+Combat+Neurodegenerative+Diseases&doi=10.1021%2Fjm7009364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target-Directed Ligands to Combat Neurodegenerative Diseases</span></div><div class="casAuthors">Cavalli, Andrea; Bolognesi, Maria Laura; Minarini, Anna; Rosini, Michela; Tumiatti, Vincenzo; Recanatini, Maurizio; Melchiorre, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-372</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The authors review the investigations reported in the past decade that illustrate the ability of medicinal chemists to design multi-target-directed ligands (MTDLs) to confront neurodegenerative diseases.  The authors briefly illustrate the multifactorial nature of these diseases before discussing the possible development of MTDLs in light of the known mol. bases of the main neurodegenerative pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYY0I0UHEir7Vg90H21EOLACvtfcHk0lgWIRBUpkwXTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D&md5=c682235151489316d043cf97f78e56f3</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm7009364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7009364%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DMinarini%26aufirst%3DA.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DTumiatti%26aufirst%3DV.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DMulti-Target-Directed%2520Ligands%2520to%2520Combat%2520Neurodegenerative%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D3%26spage%3D347%26epage%3D372%26doi%3D10.1021%2Fjm7009364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antolin, A.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Lazikani, B.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology in Precision Oncology: Current Applications and Future Prospects</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">46</span>),  <span class="NLM_fpage">6935</span>– <span class="NLM_lpage">6945</span>, <span class="refDoi"> DOI: 10.2174/1381612822666160923115828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F1381612822666160923115828" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=6935-6945&issue=46&author=A.%0AA.+Antolinauthor=P.+Workmanauthor=J.+Mestresauthor=B.+Al-Lazikani&title=Polypharmacology+in+Precision+Oncology%3A+Current+Applications+and+Future+Prospects&doi=10.2174%2F1381612822666160923115828"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.2174%2F1381612822666160923115828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612822666160923115828%26sid%3Dliteratum%253Aachs%26aulast%3DAntolin%26aufirst%3DA.%2BA.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DMestres%26aufirst%3DJ.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26atitle%3DPolypharmacology%2520in%2520Precision%2520Oncology%253A%2520Current%2520Applications%2520and%2520Future%2520Prospects%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2016%26volume%3D22%26issue%3D46%26spage%3D6935%26epage%3D6945%26doi%3D10.2174%2F1381612822666160923115828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anighoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: Challenges and Opportunities in Drug Discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">7874</span>– <span class="NLM_lpage">7887</span>, <span class="refDoi"> DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&issue=19&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+Challenges+and+Opportunities+in+Drug+Discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0lgWIRBUpkwXTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520Challenges%2520and%2520Opportunities%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D19%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Medina-Franco, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giulianotti, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welmaker, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghten, R. A.</span></span> <span> </span><span class="NLM_article-title">Shifting from the Single to the Multitarget Paradigm in Drug Discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">9–10</span>),  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.drudis.2013.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=23340113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC3szhsV2rsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=495-501&issue=9%E2%80%9310&author=J.+L.+Medina-Francoauthor=M.+A.+Giulianottiauthor=G.+S.+Welmakerauthor=R.+A.+Houghten&title=Shifting+from+the+Single+to+the+Multitarget+Paradigm+in+Drug+Discovery&doi=10.1016%2Fj.drudis.2013.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Shifting from the single to the multitarget paradigm in drug discovery</span></div><div class="casAuthors">Medina-Franco Jose L; Giulianotti Marc A; Welmaker Gregory S; Houghten Richard A</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9-10</span>),
    <span class="NLM_cas:pages">495-501</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Increasing evidence that several drug compounds exert their effects through interactions with multiple targets is boosting the development of research fields that challenge the data reductionism approach.  In this article, we review and discuss the concepts of drug repurposing, polypharmacology, chemogenomics, phenotypic screening and high-throughput in vivo testing of mixture-based libraries in an integrated manner.  These research fields offer alternatives to the current paradigm of drug discovery, from a one target-one drug model to a multiple-target approach.  Furthermore, the goals of lead identification are being expanded accordingly to identify not only 'key' compounds that fit with a single-target 'lock', but also 'master key' compounds that favorably interact with multiple targets (i.e. operate a set of desired locks to gain access to the expected clinical effects).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOFtVP-kWcL7qxQ2mb9Pu8fW6udTcc2eZaayURPlIj5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szhsV2rsQ%253D%253D&md5=b4f8c7d1ebbbf32ed4c6c87500baf66f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DMedina-Franco%26aufirst%3DJ.%2BL.%26aulast%3DGiulianotti%26aufirst%3DM.%2BA.%26aulast%3DWelmaker%26aufirst%3DG.%2BS.%26aulast%3DHoughten%26aufirst%3DR.%2BA.%26atitle%3DShifting%2520from%2520the%2520Single%2520to%2520the%2520Multitarget%2520Paradigm%2520in%2520Drug%2520Discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26issue%3D9%25E2%2580%259310%26spage%3D495%26epage%3D501%26doi%3D10.1016%2Fj.drudis.2013.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aronson, J. K.</span></span> <span> </span><span class="NLM_article-title">In Defence of Polypharmacy</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2004.02067.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1111%2Fj.1365-2125.2004.02067.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=14748809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252FkvVWmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2004&pages=119-120&issue=2&author=J.+K.+Aronson&title=In+Defence+of+Polypharmacy&doi=10.1111%2Fj.1365-2125.2004.02067.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">In defence of polypharmacy</span></div><div class="casAuthors">Aronson J K</div><div class="citationInfo"><span class="NLM_cas:title">British journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-20</span>
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKzbWDkHe77v3jf77P2BG3fW6udTcc2eZRNtdlGBELgLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252FkvVWmsA%253D%253D&md5=2f5c4c1825dd2de6229a02136b716a8d</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2004.02067.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2004.02067.x%26sid%3Dliteratum%253Aachs%26aulast%3DAronson%26aufirst%3DJ.%2BK.%26atitle%3DIn%2520Defence%2520of%2520Polypharmacy%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2004%26volume%3D57%26issue%3D2%26spage%3D119%26epage%3D120%26doi%3D10.1111%2Fj.1365-2125.2004.02067.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brückmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agbaba, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology of Dopamine Receptor Ligands</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1016/j.pneurobio.2016.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.pneurobio.2016.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27234980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC28XptVCmsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2016&pages=68-103&author=S.+Butiniauthor=K.+Nikolicauthor=S.+Kasselauthor=H.+Br%C3%BCckmannauthor=S.+Filipicauthor=D.+Agbabaauthor=S.+Gemmaauthor=S.+Brogiauthor=M.+Brindisiauthor=G.+Campianiauthor=H.+Stark&title=Polypharmacology+of+Dopamine+Receptor+Ligands&doi=10.1016%2Fj.pneurobio.2016.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology of dopamine receptor ligands</span></div><div class="casAuthors">Butini, S.; Nikolic, K.; Kassel, S.; Bruckmann, H.; Filipic, S.; Agbaba, D.; Gemma, S.; Brogi, S.; Brindisi, M.; Campiani, G.; Stark, H.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">68-103</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Most neurol. diseases have a multifactorial nature and the no. of mol. mechanisms discovered as underpinning these diseases is continuously evolving.  The old concept of developing selective agents for a single target does not fit with the medical need of most neurol. diseases.  The development of designed multiple ligands holds great promises and appears as the next step in drug development for the treatment of these multifactorial diseases.  Dopamine and its five receptor subtypes are intimately involved in numerous neurol. disorders.  Dopamine receptor ligands display a high degree of cross interactions with many other targets including G-protein coupled receptors, transporters, enzymes and ion channels.  For brain disorders like Parkinsons disease, schizophrenia and depression the dopaminergic system, being intertwined with many other signaling systems, plays a key role in pathogenesis and therapy.  The concept of designed multiple ligands and polypharmacol., which perfectly meets the therapeutic needs for these brain disorders, is herein discussed as a general ligand-based concept while focusing on dopaminergic agents and receptor subtypes in particular.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroyjxwUVpuobVg90H21EOLACvtfcHk0lgz2J13I-7FsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptVCmsLk%253D&md5=4e518d55c2b25e20b56a0ac4c5ff117c</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2016.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2016.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DButini%26aufirst%3DS.%26aulast%3DNikolic%26aufirst%3DK.%26aulast%3DKassel%26aufirst%3DS.%26aulast%3DBr%25C3%25BCckmann%26aufirst%3DH.%26aulast%3DFilipic%26aufirst%3DS.%26aulast%3DAgbaba%26aufirst%3DD.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DBrogi%26aufirst%3DS.%26aulast%3DBrindisi%26aufirst%3DM.%26aulast%3DCampiani%26aufirst%3DG.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DPolypharmacology%2520of%2520Dopamine%2520Receptor%2520Ligands%26jtitle%3DProg.%2520Neurobiol.%26date%3D2016%26volume%3D142%26spage%3D68%26epage%3D103%26doi%3D10.1016%2Fj.pneurobio.2016.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cook, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">March, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pangalos, M. N.</span></span> <span> </span><span class="NLM_article-title">Lessons Learned from the Fate of AstraZeneca’s Drug Pipeline: A Five-Dimensional Framework</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1038/nrd4309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnrd4309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=24833294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVyqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=419-431&issue=6&author=D.+Cookauthor=D.+Brownauthor=R.+Alexanderauthor=R.+Marchauthor=P.+Morganauthor=G.+Satterthwaiteauthor=M.+N.+Pangalos&title=Lessons+Learned+from+the+Fate+of+AstraZeneca%E2%80%99s+Drug+Pipeline%3A+A+Five-Dimensional+Framework&doi=10.1038%2Fnrd4309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework</span></div><div class="casAuthors">Cook, David; Brown, Dearg; Alexander, Robert; March, Ruth; Morgan, Paul; Satterthwaite, Gemma; Pangalos, Menelas N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">419-431</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Maintaining research and development (R&D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry.  In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-mol. drug projects from 2005 to 2010.  The anal. allowed us to establish a framework based on the five most important tech. determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right com. potential.  A sixth factor - the right culture - is also crucial in encouraging effective decision-making based on these tech. determinants.  AstraZeneca is currently applying this framework to guide its R&D teams, and although it is too early to demonstrate whether this has improved the company's R&D productivity, we present our data and anal. here in the hope that it may assist the industry overall in addressing this key challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4yhPFZOUNO7Vg90H21EOLACvtfcHk0lgz2J13I-7FsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVyqtrw%253D&md5=746a86c7223f170f7e6c4f9817760e5b</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnrd4309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4309%26sid%3Dliteratum%253Aachs%26aulast%3DCook%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DAlexander%26aufirst%3DR.%26aulast%3DMarch%26aufirst%3DR.%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DSatterthwaite%26aufirst%3DG.%26aulast%3DPangalos%26aufirst%3DM.%2BN.%26atitle%3DLessons%2520Learned%2520from%2520the%2520Fate%2520of%2520AstraZeneca%25E2%2580%2599s%2520Drug%2520Pipeline%253A%2520A%2520Five-Dimensional%2520Framework%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26issue%3D6%26spage%3D419%26epage%3D431%26doi%3D10.1038%2Fnrd4309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miceli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altucci, L.</span></span> <span> </span><span class="NLM_article-title">Targeting Epigenetic Networks with Polypharmacology: A New Avenue to Tackle Cancer</span>. <i>Epigenomics</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">742</span>, <span class="refDoi"> DOI: 10.2217/epi.10.62</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2217%2Fepi.10.62" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=731-742&issue=6&author=G.+Franciauthor=M.+Miceliauthor=L.+Altucci&title=Targeting+Epigenetic+Networks+with+Polypharmacology%3A+A+New+Avenue+to+Tackle+Cancer&doi=10.2217%2Fepi.10.62"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.2217%2Fepi.10.62&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fepi.10.62%26sid%3Dliteratum%253Aachs%26aulast%3DFranci%26aufirst%3DG.%26aulast%3DMiceli%26aufirst%3DM.%26aulast%3DAltucci%26aufirst%3DL.%26atitle%3DTargeting%2520Epigenetic%2520Networks%2520with%2520Polypharmacology%253A%2520A%2520New%2520Avenue%2520to%2520Tackle%2520Cancer%26jtitle%3DEpigenomics%26date%3D2010%26volume%3D2%26issue%3D6%26spage%3D731%26epage%3D742%26doi%3D10.2217%2Fepi.10.62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lötsch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span> <span> </span><span class="NLM_article-title">Low-Dose Drug Combinations along Molecular Pathways Could Maximize Therapeutic Effectiveness While Minimizing Collateral Adverse Effects</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">23–24</span>),  <span class="NLM_fpage">1001</span>– <span class="NLM_lpage">1006</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.drudis.2011.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=22016087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FjtVygtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=1001-1006&issue=23%E2%80%9324&author=J.+L%C3%B6tschauthor=G.+Geisslinger&title=Low-Dose+Drug+Combinations+along+Molecular+Pathways+Could+Maximize+Therapeutic+Effectiveness+While+Minimizing+Collateral+Adverse+Effects&doi=10.1016%2Fj.drudis.2011.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects</span></div><div class="casAuthors">Lotsch Jorn; Geisslinger Gerd</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">23-24</span>),
    <span class="NLM_cas:pages">1001-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Increasing knowledge of molecular signaling processes has enabled the identification of drug targets that synergistically address multifactorial symptoms along several contributing pathways.  The idea behind 'polypills' is that minor doses of pharmacodynamically interacting drugs would selectively achieve intended clinical effects.  Analogously, monofactorial symptoms could be addressed vertically along their main pathway.  Clinical selectivity follows from successive incomplete inhibitions of the pathological pathway at several steps.  Here, we discuss and exemplify of how successive inhibitions in the prostaglandin E2 (PGE(2)) signaling pathway could achieve anti-inflammatory and analgesic effects while preserving physiological PGE(2) signaling in organs of major toxicity.  Intentionally using intelligent low-dose drug combinations might provide an innovative therapeutic concept that directs combined small-drug effects towards a large, selective clinical effect with minor collateral damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRu7M3C_0-j-dfST00W0BcfW6udTcc2eY9hGS7EJmxirntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FjtVygtg%253D%253D&md5=f88337f88016a3736e13e493dc064089</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6tsch%26aufirst%3DJ.%26aulast%3DGeisslinger%26aufirst%3DG.%26atitle%3DLow-Dose%2520Drug%2520Combinations%2520along%2520Molecular%2520Pathways%2520Could%2520Maximize%2520Therapeutic%2520Effectiveness%2520While%2520Minimizing%2520Collateral%2520Adverse%2520Effects%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26issue%3D23%25E2%2580%259324%26spage%3D1001%26epage%3D1006%26doi%3D10.1016%2Fj.drudis.2011.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span> <span> </span><span class="NLM_article-title">The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">e0165737</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0165737</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1371%2Fjournal.pone.0165737" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0165737&issue=11&author=Y.+H.+Liauthor=P.+P.+Wangauthor=X.+X.+Liauthor=C.+Y.+Yuauthor=H.+Yangauthor=J.+Zhouauthor=W.+W.+Xueauthor=J.+Tanauthor=F.+Zhu&title=The+Human+Kinome+Targeted+by+FDA+Approved+Multi-Target+Drugs+and+Combination+Products%3A+A+Comparative+Study+from+the+Drug-Target+Interaction+Network+Perspective&doi=10.1371%2Fjournal.pone.0165737"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0165737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0165737%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%2BH.%26aulast%3DWang%26aufirst%3DP.%2BP.%26aulast%3DLi%26aufirst%3DX.%2BX.%26aulast%3DYu%26aufirst%3DC.%2BY.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DXue%26aufirst%3DW.%2BW.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DF.%26atitle%3DThe%2520Human%2520Kinome%2520Targeted%2520by%2520FDA%2520Approved%2520Multi-Target%2520Drugs%2520and%2520Combination%2520Products%253A%2520A%2520Comparative%2520Study%2520from%2520the%2520Drug-Target%2520Interaction%2520Network%2520Perspective%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26issue%3D11%26spage%3De0165737%26doi%3D10.1371%2Fjournal.pone.0165737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valant, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">Orthosteric/Allosteric Bitopic Ligands: Going Hybrid at GPCRs</span>. <i>Mol. Interventions</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1124/mi.9.3.6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1124%2Fmi.9.3.6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=125-135&issue=3&author=C.+Valantauthor=P.+M.+Sextonauthor=A.+Christopoulos&title=Orthosteric%2FAllosteric+Bitopic+Ligands%3A+Going+Hybrid+at+GPCRs&doi=10.1124%2Fmi.9.3.6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1124%2Fmi.9.3.6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmi.9.3.6%26sid%3Dliteratum%253Aachs%26aulast%3DValant%26aufirst%3DC.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DOrthosteric%252FAllosteric%2520Bitopic%2520Ligands%253A%2520Going%2520Hybrid%2520at%2520GPCRs%26jtitle%3DMol.%2520Interventions%26date%3D2009%26volume%3D9%26issue%3D3%26spage%3D125%26epage%3D135%26doi%3D10.1124%2Fmi.9.3.6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fronik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaiser, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sejer
Pedersen, D.</span></span> <span> </span><span class="NLM_article-title">Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4126</span>– <span class="NLM_lpage">4134</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01601</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01601" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVyktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4126-4134&issue=10&author=P.+Fronikauthor=B.+I.+Gaiserauthor=D.+Sejer%0APedersen&title=Bitopic+Ligands+and+Metastable+Binding+Sites%3A+Opportunities+for+G+Protein-Coupled+Receptor+%28GPCR%29+Medicinal+Chemistry&doi=10.1021%2Facs.jmedchem.6b01601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry</span></div><div class="casAuthors">Fronik, Philipp; Gaiser, Birgit I.; Sejer Pedersen, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4126-4134</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) belong to a large superfamily of membrane receptors mediating a variety of physiol. functions.  As such they are attractive targets for drug therapy.  However, it remains a challenge to develop subtype selective GPCR ligands, due to the high conservation of orthosteric binding sites.  Bitopic ligands have been employed to address the selectivity problem by combining (linking) an orthosteric ligand with an allosteric modulator, theor. leading to high-affinity subtype selective ligands.  However, it remains a challenge to identify suitable allosteric binding sites.  Computational studies on ligand binding to GPCRs have revealed transient, low-affinity binding sites, termed metastable binding sites.  Metastable binding sites may provide a new source of allosteric binding sites that could be exploited in the design of bitopic ligands.  Unlike the bitopic ligands that have been reported to date this type of bitopic ligands would be composed of two identical pharmacophores.  Herein, the authors outline the concept of bitopic ligands, review metastable binding sites and discuss their potential as a new source of allosteric binding sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpihAXt959S37Vg90H21EOLACvtfcHk0lhDRQj9NmFDSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVyktbw%253D&md5=a20875145b65a948c772e988ff1217bc</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01601%26sid%3Dliteratum%253Aachs%26aulast%3DFronik%26aufirst%3DP.%26aulast%3DGaiser%26aufirst%3DB.%2BI.%26aulast%3DSejer%2BPedersen%26aufirst%3DD.%26atitle%3DBitopic%2520Ligands%2520and%2520Metastable%2520Binding%2520Sites%253A%2520Opportunities%2520for%2520G%2520Protein-Coupled%2520Receptor%2520%2528GPCR%2529%2520Medicinal%2520Chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D10%26spage%3D4126%26epage%3D4134%26doi%3D10.1021%2Facs.jmedchem.6b01601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goebel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angioni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurglics, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahnt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhilber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase to Counter Nonalcoholic Steatohepatitis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">7703</span>– <span class="NLM_lpage">7724</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00398</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00398" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtl2ls73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7703-7724&issue=18&author=J.+Schmidtauthor=M.+Rotterauthor=T.+Weiserauthor=S.+Wittmannauthor=L.+Weizelauthor=A.+Kaiserauthor=J.+Heeringauthor=T.+Goebelauthor=C.+Angioniauthor=M.+Wurglicsauthor=A.+Paulkeauthor=G.+Geisslingerauthor=A.+Kahntauthor=D.+Steinhilberauthor=E.+Proschakauthor=D.+Merk&title=A+Dual+Modulator+of+Farnesoid+X+Receptor+and+Soluble+Epoxide+Hydrolase+to+Counter+Nonalcoholic+Steatohepatitis&doi=10.1021%2Facs.jmedchem.7b00398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis</span></div><div class="casAuthors">Schmidt, Jurema; Rotter, Marco; Weiser, Tim; Wittmann, Sandra; Weizel, Lilia; Kaiser, Astrid; Heering, Jan; Goebel, Tamara; Angioni, Carlo; Wurglics, Mario; Paulke, Alexander; Geisslinger, Gerd; Kahnt, Astrid; Steinhilber, Dieter; Proschak, Ewgenij; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7703-7724</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonalcoholic steatohepatitis arising from Western diet and lifestyle is characterized by accumulation of fat in liver causing inflammation and fibrosis.  It evolves as serious health burden with alarming incidence, but there is no satisfying pharmacol. therapy to date.  Considering the disease's multifactorial nature, modulation of multiple targets might provide superior therapeutic efficacy.  In particular, farnesoid X receptor (FXR) activation that revealed antisteatotic and antifibrotic effects in clin. trials combined with inhibition of sol. epoxide hydrolase (sEH) as anti-inflammatory strategy promises synergies.  To exploit this dual concept, we developed agents exerting partial FXR agonism and sEH inhibitory activity.  Merging known pharmacophores and systematic exploration of the structure-activity relationship on both targets produced dual modulators with low nanomolar potency.  Extensive in vitro characterization confirmed high dual efficacy in cellular context combined with low toxicity, and pilot in vivo data revealed favorable pharmacokinetics as well as engagement on both targets in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUx3OFEKCgyrVg90H21EOLACvtfcHk0liKu-2QhPNNUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtl2ls73J&md5=a35ceea141c78ed9885d7f9a99f4852b</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00398%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DJ.%26aulast%3DRotter%26aufirst%3DM.%26aulast%3DWeiser%26aufirst%3DT.%26aulast%3DWittmann%26aufirst%3DS.%26aulast%3DWeizel%26aufirst%3DL.%26aulast%3DKaiser%26aufirst%3DA.%26aulast%3DHeering%26aufirst%3DJ.%26aulast%3DGoebel%26aufirst%3DT.%26aulast%3DAngioni%26aufirst%3DC.%26aulast%3DWurglics%26aufirst%3DM.%26aulast%3DPaulke%26aufirst%3DA.%26aulast%3DGeisslinger%26aufirst%3DG.%26aulast%3DKahnt%26aufirst%3DA.%26aulast%3DSteinhilber%26aufirst%3DD.%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DA%2520Dual%2520Modulator%2520of%2520Farnesoid%2520X%2520Receptor%2520and%2520Soluble%2520Epoxide%2520Hydrolase%2520to%2520Counter%2520Nonalcoholic%2520Steatohepatitis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D18%26spage%3D7703%26epage%3D7724%26doi%3D10.1021%2Facs.jmedchem.7b00398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunesch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatonnet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohse, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabissi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationships and Computational Investigations into the Development of Potent and Balanced Dual-Acting Butyrylcholinesterase Inhibitors and Human Cannabinoid Receptor 2 Ligands with Pro-Cognitive in Vivo Profiles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1646</span>– <span class="NLM_lpage">1663</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1646-1663&issue=4&author=D.+Dollesauthor=M.+Hoffmannauthor=S.+Guneschauthor=O.+Marinelliauthor=J.+M%C3%B6llerauthor=G.+Santoniauthor=A.+Chatonnetauthor=M.+J.+Lohseauthor=H.+J.+Wittmannauthor=A.+Strasserauthor=M.+Nabissiauthor=T.+Mauriceauthor=M.+Decker&title=Structure-Activity+Relationships+and+Computational+Investigations+into+the+Development+of+Potent+and+Balanced+Dual-Acting+Butyrylcholinesterase+Inhibitors+and+Human+Cannabinoid+Receptor+2+Ligands+with+Pro-Cognitive+in+Vivo+Profiles&doi=10.1021%2Facs.jmedchem.7b01760"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01760%26sid%3Dliteratum%253Aachs%26aulast%3DDolles%26aufirst%3DD.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DGunesch%26aufirst%3DS.%26aulast%3DMarinelli%26aufirst%3DO.%26aulast%3DM%25C3%25B6ller%26aufirst%3DJ.%26aulast%3DSantoni%26aufirst%3DG.%26aulast%3DChatonnet%26aufirst%3DA.%26aulast%3DLohse%26aufirst%3DM.%2BJ.%26aulast%3DWittmann%26aufirst%3DH.%2BJ.%26aulast%3DStrasser%26aufirst%3DA.%26aulast%3DNabissi%26aufirst%3DM.%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DStructure-Activity%2520Relationships%2520and%2520Computational%2520Investigations%2520into%2520the%2520Development%2520of%2520Potent%2520and%2520Balanced%2520Dual-Acting%2520Butyrylcholinesterase%2520Inhibitors%2520and%2520Human%2520Cannabinoid%2520Receptor%25202%2520Ligands%2520with%2520Pro-Cognitive%2520in%2520Vivo%2520Profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D4%26spage%3D1646%26epage%3D1663%26doi%3D10.1021%2Facs.jmedchem.7b01760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Éliás, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovács, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wágner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Némethy, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarcsay, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, I.</span></span> <span> </span><span class="NLM_article-title">Charting the Chemical Space around the (Iso)indoline Scaffold, a Comprehensive Approach towards Multitarget Directed Ligands</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">4211</span>– <span class="NLM_lpage">4215</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.07.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.bmcl.2016.07.055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=4211-4215&issue=17&author=O.+%C3%89li%C3%A1sauthor=Z.+Kov%C3%A1csauthor=G.+W%C3%A1gnerauthor=Z.+N%C3%A9methyauthor=%C3%81.+Tarcsayauthor=I.+Greiner&title=Charting+the+Chemical+Space+around+the+%28Iso%29indoline+Scaffold%2C+a+Comprehensive+Approach+towards+Multitarget+Directed+Ligands&doi=10.1016%2Fj.bmcl.2016.07.055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.07.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.07.055%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2589li%25C3%25A1s%26aufirst%3DO.%26aulast%3DKov%25C3%25A1cs%26aufirst%3DZ.%26aulast%3DW%25C3%25A1gner%26aufirst%3DG.%26aulast%3DN%25C3%25A9methy%26aufirst%3DZ.%26aulast%3DTarcsay%26aufirst%3D%25C3%2581.%26aulast%3DGreiner%26aufirst%3DI.%26atitle%3DCharting%2520the%2520Chemical%2520Space%2520around%2520the%2520%2528Iso%2529indoline%2520Scaffold%252C%2520a%2520Comprehensive%2520Approach%2520towards%2520Multitarget%2520Directed%2520Ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D17%26spage%3D4211%26epage%3D4215%26doi%3D10.1016%2Fj.bmcl.2016.07.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Apsel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nazif, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aizenstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z. A.</span></span> <span> </span><span class="NLM_article-title">Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">691</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.1038/nchembio.117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnchembio.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=18849971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=691-699&issue=11&author=B.+Apselauthor=J.+A.+Blairauthor=B.+Gonzalezauthor=T.+M.+Nazifauthor=M.+E.+Feldmanauthor=B.+Aizensteinauthor=R.+Hoffmanauthor=R.+L.+Williamsauthor=K.+M.+Shokatauthor=Z.+A.+Knight&title=Targeted+Polypharmacology%3A+Discovery+of+Dual+Inhibitors+of+Tyrosine+and+Phosphoinositide+Kinases&doi=10.1038%2Fnchembio.117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases</span></div><div class="casAuthors">Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">691-699</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. success of multitargeted kinase inhibitors has stimulated efforts to identify promiscuous drugs with optimal selectivity profiles.  It remains unclear to what extent such drugs can be rationally designed, particularly for combinations of targets that are structurally divergent.  Here we report the systematic discovery of mols. that potently inhibit both tyrosine kinases and phosphatidylinositol-3-OH kinases, two protein families that are among the most intensely pursued cancer drug targets.  Through iterative chem. synthesis, X-ray crystallog. and kinome-level biochem. profiling, we identified compds. that inhibit a spectrum of new target combinations in these two families.  Crystal structures revealed that the dual selectivity of these mols. is controlled by a hydrophobic pocket conserved in both enzyme classes and accessible through a rotatable bond in the drug skeleton.  We show that compd. I blocks the proliferation of tumor cells by direct inhibition of oncogenic tyrosine kinases and phosphatidylinositol-3-OH kinases.  These mols. demonstrate the feasibility of accessing a chem. space that intersects two families of oncogenes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7xlegha5YF7Vg90H21EOLACvtfcHk0liKu-2QhPNNUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF&md5=4da10a973f6895f92a644ca82ca5cdcd</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.117%26sid%3Dliteratum%253Aachs%26aulast%3DApsel%26aufirst%3DB.%26aulast%3DBlair%26aufirst%3DJ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%26aulast%3DNazif%26aufirst%3DT.%2BM.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DAizenstein%26aufirst%3DB.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26atitle%3DTargeted%2520Polypharmacology%253A%2520Discovery%2520of%2520Dual%2520Inhibitors%2520of%2520Tyrosine%2520and%2520Phosphoinositide%2520Kinases%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26issue%3D11%26spage%3D691%26epage%3D699%26doi%3D10.1038%2Fnchembio.117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertinaria, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaikh, M. A. A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buccellati, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cena, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolando, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzarato, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruttero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoxha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rovati, G. E.</span></span> <span> </span><span class="NLM_article-title">Designing Multitarget Anti-Inflammatory Agents: Chemical Modulation of the Lumiracoxib Structure toward Dual Thromboxane Antagonists-COX-2 Inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1647</span>– <span class="NLM_lpage">1660</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201200272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fcmdc.201200272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=22865828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFahs7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1647-1660&issue=9&author=M.+Bertinariaauthor=M.+A.+A.+G.+Shaikhauthor=C.+Buccellatiauthor=C.+Cenaauthor=B.+Rolandoauthor=L.+Lazzaratoauthor=R.+Frutteroauthor=A.+Gascoauthor=M.+Hoxhaauthor=V.+Capraauthor=A.+Salaauthor=G.+E.+Rovati&title=Designing+Multitarget+Anti-Inflammatory+Agents%3A+Chemical+Modulation+of+the+Lumiracoxib+Structure+toward+Dual+Thromboxane+Antagonists-COX-2+Inhibitors&doi=10.1002%2Fcmdc.201200272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Designing Multitarget Anti-inflammatory Agents: Chemical Modulation of the Lumiracoxib Structure toward Dual Thromboxane Antagonists-COX-2 Inhibitors</span></div><div class="casAuthors">Bertinaria, Massimo; Shaikh, Mohammed Abrar Abdul Gaffar; Buccellati, Carola; Cena, Clara; Rolando, Barbara; Lazzarato, Loretta; Fruttero, Roberta; Gasco, Alberto; Hoxha, Malvina; Capra, Valerie; Sala, Angelo; Rovati, G. Enrico</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1647-1660</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A series of lumiracoxib derivs. were designed to explore the influence of isosteric substitution on balancing COX-2 inhibition and thromboxane A2 prostanoid (TP) receptor antagonism.  The compds. were synthesized through a copper-catalyzed coupling procedure and characterized for their pKa values.  TP receptor antagonism was assessed on human platelets; COX-2 inhibition was detd. on human isolated monocytes and human whole blood.  TPα receptor binding of the most promising compds. was evaluated through radioligand binding assays.  Some of the isosteric substitutions at the carboxylic acid group afforded compds. with improved TP receptor antagonism; of these, a tetrazole deriv. retained good COX-2 inhibitory activity and selectivity.  The identification of this tetrazole acting as a balanced dual-acting compd. in human whole blood, along with SAR anal. of the synthesized lumiracoxib derivs., might contribute to the rational design of a new class of cardioprotective anti-inflammatory agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWI0l-Gz0GzLVg90H21EOLACvtfcHk0ljHgv0iKdTDsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFahs7bE&md5=64521447d2f44ff168a657299f265ba2</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200272%26sid%3Dliteratum%253Aachs%26aulast%3DBertinaria%26aufirst%3DM.%26aulast%3DShaikh%26aufirst%3DM.%2BA.%2BA.%2BG.%26aulast%3DBuccellati%26aufirst%3DC.%26aulast%3DCena%26aufirst%3DC.%26aulast%3DRolando%26aufirst%3DB.%26aulast%3DLazzarato%26aufirst%3DL.%26aulast%3DFruttero%26aufirst%3DR.%26aulast%3DGasco%26aufirst%3DA.%26aulast%3DHoxha%26aufirst%3DM.%26aulast%3DCapra%26aufirst%3DV.%26aulast%3DSala%26aufirst%3DA.%26aulast%3DRovati%26aufirst%3DG.%2BE.%26atitle%3DDesigning%2520Multitarget%2520Anti-Inflammatory%2520Agents%253A%2520Chemical%2520Modulation%2520of%2520the%2520Lumiracoxib%2520Structure%2520toward%2520Dual%2520Thromboxane%2520Antagonists-COX-2%2520Inhibitors%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26issue%3D9%26spage%3D1647%26epage%3D1660%26doi%3D10.1002%2Fcmdc.201200272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mahony, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippakopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasater, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picaud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Dual Kinase-Bromodomain Inhibitors for Rationally Designed Polypharmacology</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnchembio.1471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=24584101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtl2itro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=305-312&issue=4&author=P.+Ciceriauthor=S.+M%C3%BCllerauthor=A.+O%E2%80%99Mahonyauthor=O.+Fedorovauthor=P.+Filippakopoulosauthor=J.+P.+Huntauthor=E.+A.+Lasaterauthor=G.+Pallaresauthor=S.+Picaudauthor=C.+Wellsauthor=S.+Martinauthor=L.+M.+Wodickaauthor=N.+P.+Shahauthor=D.+K.+Treiberauthor=S.+Knapp&title=Dual+Kinase-Bromodomain+Inhibitors+for+Rationally+Designed+Polypharmacology&doi=10.1038%2Fnchembio.1471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Dual kinase-bromodomain inhibitors for rationally designed polypharmacology</span></div><div class="casAuthors">Ciceri, Pietro; Mueller, Susanne; O'Mahony, Alison; Fedorov, Oleg; Filippakopoulos, Panagis; Hunt, Jeremy P.; Lasater, Elisabeth A.; Pallares, Gabriel; Picaud, Sarah; Wells, Christopher; Martin, Sarah; Wodicka, Lisa M.; Shah, Neil P.; Treiber, Daniel K.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">305-312</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Concomitant inhibition of multiple cancer-driving kinases is an established strategy to improve the durability of clin. responses to targeted therapies.  The difficulty of discovering kinase inhibitors with an appropriate multitarget profile has, however, necessitated the application of combination therapies, which can pose major clin. development challenges.  Epigenetic reader domains of the bromodomain family have recently emerged as new targets for cancer therapy.  Here the authors report that several clin. kinase inhibitors also inhibit bromodomains with therapeutically relevant potencies and are best classified as dual kinase-bromodomain inhibitors.  Nanomolar activity on BRD4 by BI-2536 and TG-101348, which are clin. PLK1 and JAK2-FLT3 kinase inhibitors, resp., is particularly noteworthy as these combinations of activities on independent oncogenic pathways exemplify a new strategy for rational single-agent polypharmacol. targeting.  Furthermore, structure-activity relationships and co-crystal structures identify design features that enable a general platform for the rational design of dual kinase-bromodomain inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotPedDED4FJLVg90H21EOLACvtfcHk0ljHgv0iKdTDsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtl2itro%253D&md5=a00117db2648ea38dd03750faf3b3cb9</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1471%26sid%3Dliteratum%253Aachs%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLasater%26aufirst%3DE.%2BA.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DWells%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DDual%2520Kinase-Bromodomain%2520Inhibitors%2520for%2520Rationally%2520Designed%2520Polypharmacology%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26issue%3D4%26spage%3D305%26epage%3D312%26doi%3D10.1038%2Fnchembio.1471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benson, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pershadsingh, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chittiboyina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pravenec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, T. W.</span></span> <span> </span><span class="NLM_article-title">Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist with Selective PPARγ-Modulating Activity</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">993</span>– <span class="NLM_lpage">1002</span>, <span class="refDoi"> DOI: 10.1161/01.HYP.0000123072.34629.57</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1161%2F01.HYP.0000123072.34629.57" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=993-1002&issue=5&author=S.+C.+Bensonauthor=H.+A.+Pershadsinghauthor=C.+I.+Hoauthor=A.+Chittiboyinaauthor=P.+Desaiauthor=M.+Pravenecauthor=N.+Qiauthor=J.+Wangauthor=M.+A.+Averyauthor=T.+W.+Kurtz&title=Identification+of+Telmisartan+as+a+Unique+Angiotensin+II+Receptor+Antagonist+with+Selective+PPAR%CE%B3-Modulating+Activity&doi=10.1161%2F01.HYP.0000123072.34629.57"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1161%2F01.HYP.0000123072.34629.57&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.HYP.0000123072.34629.57%26sid%3Dliteratum%253Aachs%26aulast%3DBenson%26aufirst%3DS.%2BC.%26aulast%3DPershadsingh%26aufirst%3DH.%2BA.%26aulast%3DHo%26aufirst%3DC.%2BI.%26aulast%3DChittiboyina%26aufirst%3DA.%26aulast%3DDesai%26aufirst%3DP.%26aulast%3DPravenec%26aufirst%3DM.%26aulast%3DQi%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAvery%26aufirst%3DM.%2BA.%26aulast%3DKurtz%26aufirst%3DT.%2BW.%26atitle%3DIdentification%2520of%2520Telmisartan%2520as%2520a%2520Unique%2520Angiotensin%2520II%2520Receptor%2520Antagonist%2520with%2520Selective%2520PPAR%25CE%25B3-Modulating%2520Activity%26jtitle%3DHypertension%26date%3D2004%26volume%3D43%26issue%3D5%26spage%3D993%26epage%3D1002%26doi%3D10.1161%2F01.HYP.0000123072.34629.57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casimiro-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heemstra, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigge, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciske, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esmaeil, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalaie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohren, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, N. A.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Evaluation of imidazo[4,5-C]pyridin-4-One Derivatives with Dual Activity at Angiotensin II Type 1 Receptor and Peroxisome Proliferator-Activated Receptor-γ</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">767</span>– <span class="NLM_lpage">772</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.11.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.bmcl.2012.11.088" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=767-772&issue=3&author=A.+Casimiro-Garciaauthor=R.+J.+Heemstraauthor=C.+F.+Biggeauthor=J.+Chenauthor=F.+A.+Ciskeauthor=J.+A.+Davisauthor=T.+Ellisauthor=N.+Esmaeilauthor=D.+Flynnauthor=S.+Hanauthor=M.+Jalaieauthor=J.+F.+Ohrenauthor=N.+A.+Powell&title=Design%2C+Synthesis%2C+and+Evaluation+of+imidazo%5B4%2C5-C%5Dpyridin-4-One+Derivatives+with+Dual+Activity+at+Angiotensin+II+Type+1+Receptor+and+Peroxisome+Proliferator-Activated+Receptor-%CE%B3&doi=10.1016%2Fj.bmcl.2012.11.088"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.11.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.11.088%26sid%3Dliteratum%253Aachs%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26aulast%3DHeemstra%26aufirst%3DR.%2BJ.%26aulast%3DBigge%26aufirst%3DC.%2BF.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCiske%26aufirst%3DF.%2BA.%26aulast%3DDavis%26aufirst%3DJ.%2BA.%26aulast%3DEllis%26aufirst%3DT.%26aulast%3DEsmaeil%26aufirst%3DN.%26aulast%3DFlynn%26aufirst%3DD.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DOhren%26aufirst%3DJ.%2BF.%26aulast%3DPowell%26aufirst%3DN.%2BA.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Evaluation%2520of%2520imidazo%255B4%252C5-C%255Dpyridin-4-One%2520Derivatives%2520with%2520Dual%2520Activity%2520at%2520Angiotensin%2520II%2520Type%25201%2520Receptor%2520and%2520Peroxisome%2520Proliferator-Activated%2520Receptor-%25CE%25B3%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D3%26spage%3D767%26epage%3D772%26doi%3D10.1016%2Fj.bmcl.2012.11.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamotte, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faucher, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sançon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pineau, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sautet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouchet, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beneton, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tousaint, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saintillan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ancellin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicodeme, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martres, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Indazole Derivatives as Dual Angiotensin II Antagonists and Partial PPARγ Agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1098</span>– <span class="NLM_lpage">1103</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.bmcl.2014.01.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=1098-1103&issue=4&author=Y.+Lamotteauthor=N.+Faucherauthor=J.+San%C3%A7onauthor=O.+Pineauauthor=S.+Sautetauthor=M.-H.+Fouchetauthor=V.+Benetonauthor=J.-J.+Tousaintauthor=Y.+Saintillanauthor=N.+Ancellinauthor=E.+Nicodemeauthor=D.+Grillotauthor=P.+Martres&title=Discovery+of+Novel+Indazole+Derivatives+as+Dual+Angiotensin+II+Antagonists+and+Partial+PPAR%CE%B3+Agonists&doi=10.1016%2Fj.bmcl.2014.01.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DLamotte%26aufirst%3DY.%26aulast%3DFaucher%26aufirst%3DN.%26aulast%3DSan%25C3%25A7on%26aufirst%3DJ.%26aulast%3DPineau%26aufirst%3DO.%26aulast%3DSautet%26aufirst%3DS.%26aulast%3DFouchet%26aufirst%3DM.-H.%26aulast%3DBeneton%26aufirst%3DV.%26aulast%3DTousaint%26aufirst%3DJ.-J.%26aulast%3DSaintillan%26aufirst%3DY.%26aulast%3DAncellin%26aufirst%3DN.%26aulast%3DNicodeme%26aufirst%3DE.%26aulast%3DGrillot%26aufirst%3DD.%26aulast%3DMartres%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520Novel%2520Indazole%2520Derivatives%2520as%2520Dual%2520Angiotensin%2520II%2520Antagonists%2520and%2520Partial%2520PPAR%25CE%25B3%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D4%26spage%3D1098%26epage%3D1103%26doi%3D10.1016%2Fj.bmcl.2014.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span>; <span class="NLM_string-name">Maggiora, G.</span></span> <i>Concepts and Applications of Molecular Similarity</i>; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">1990</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1990&author=M.+Johnson&author=G.+Maggiora&title=Concepts+and+Applications+of+Molecular+Similarity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DM.%26btitle%3DConcepts%2520and%2520Applications%2520of%2520Molecular%2520Similarity%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, Y.
C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kofron, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traphagen, L. M.</span></span> <span> </span><span class="NLM_article-title">Do Structurally Similar Molecules Have Similar Biological Activity?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">4350</span>– <span class="NLM_lpage">4358</span>, <span class="refDoi"> DOI: 10.1021/jm020155c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020155c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=4350-4358&issue=19&author=Y.%0AC.+Martinauthor=J.+L.+Kofronauthor=L.+M.+Traphagen&title=Do+Structurally+Similar+Molecules+Have+Similar+Biological+Activity%3F&doi=10.1021%2Fjm020155c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjm020155c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020155c%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DY.%2BC.%26aulast%3DKofron%26aufirst%3DJ.%2BL.%26aulast%3DTraphagen%26aufirst%3DL.%2BM.%26atitle%3DDo%2520Structurally%2520Similar%2520Molecules%2520Have%2520Similar%2520Biological%2520Activity%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26issue%3D19%26spage%3D4350%26epage%3D4358%26doi%3D10.1021%2Fjm020155c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lavecchia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerchia, C.</span></span> <span> </span><span class="NLM_article-title">In Silico Methods to Address Polypharmacology: Current Status, Applications and Future Perspectives</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">288</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2015.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.drudis.2015.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=26743596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=288-298&issue=2&author=A.+Lavecchiaauthor=C.+Cerchia&title=In+Silico+Methods+to+Address+Polypharmacology%3A+Current+Status%2C+Applications+and+Future+Perspectives&doi=10.1016%2Fj.drudis.2015.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">In silico methods to address polypharmacology: current status, applications and future perspectives</span></div><div class="casAuthors">Lavecchia, Antonio; Cerchia, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">288-298</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Polypharmacol., a new paradigm in drug discovery that focuses on multi-target drugs (MTDs), has potential application for drug repurposing, the process of finding new uses for existing approved drugs, prediction of off-target toxicities and rational design of MTDs.  In this scenario, computational strategies have demonstrated great potential in predicting polypharmacol. and in facilitating drug repurposing.  Here, we provide a comprehensive overview of various computational approaches that enable the prediction and anal. of in vitro and in vivo drug-response phenotypes and outline their potential for drug discovery.  We give an outlook on the latest advances in rational design of MTDs and discuss possible future directions of algorithm development in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbncXXqTB557Vg90H21EOLACvtfcHk0lhi4NFDP5wwwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCjtQ%253D%253D&md5=55201ecb13f4fee19e73fc4d76ee9f65</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DLavecchia%26aufirst%3DA.%26aulast%3DCerchia%26aufirst%3DC.%26atitle%3DIn%2520Silico%2520Methods%2520to%2520Address%2520Polypharmacology%253A%2520Current%2520Status%252C%2520Applications%2520and%2520Future%2520Perspectives%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26issue%3D2%26spage%3D288%26epage%3D298%26doi%3D10.1016%2Fj.drudis.2015.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span> <span> </span><span class="NLM_article-title">Strategies for Modern Biomarker and Drug Development in Oncology</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">70</span>, <span class="refDoi"> DOI: 10.1186/s13045-014-0070-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1186%2Fs13045-014-0070-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=25277503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsVOrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=70&author=A.+D.+Smithauthor=D.+Rodaauthor=T.+A.+Yap&title=Strategies+for+Modern+Biomarker+and+Drug+Development+in+Oncology&doi=10.1186%2Fs13045-014-0070-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for modern biomarker and drug development in oncology</span></div><div class="casAuthors">Smith, Alan D.; Roda, Desam; Yap, Timothy A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">70/1-70/16</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Technol. advancements in the mol. characterization of cancers have enabled researchers to identify an increasing no. of key mol. drivers of cancer progression.  These discoveries have led to multiple novel anticancer therapeutics, and clin. benefit in selected patient populations.  Despite this, the identification of clin. relevant predictive biomarkers of response continues to lag behind.  In this review, we discuss strategies for the mol. characterization of cancers and the importance of biomarkers for the development of novel antitumor therapeutics.  We also review crit. successes and failures in oncol., and detail the lessons learnt, which may aid in the acceleration of anticancer drug development and biomarker discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWNEkFi4M0pLVg90H21EOLACvtfcHk0lhi4NFDP5wwwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsVOrsQ%253D%253D&md5=735ba9bd2f866b407057dd5cb89e839f</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1186%2Fs13045-014-0070-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-014-0070-8%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%2BD.%26aulast%3DRoda%26aufirst%3DD.%26aulast%3DYap%26aufirst%3DT.%2BA.%26atitle%3DStrategies%2520for%2520Modern%2520Biomarker%2520and%2520Drug%2520Development%2520in%2520Oncology%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2014%26volume%3D7%26spage%3D70%26doi%3D10.1186%2Fs13045-014-0070-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jørgensen, J. T.</span></span> <span> </span><span class="NLM_article-title">The Importance of Predictive Biomarkers in Oncology Drug Development</span>. <i>Expert Rev. Mol. Diagn.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">807</span>– <span class="NLM_lpage">809</span>, <span class="refDoi"> DOI: 10.1080/14737159.2016.1199962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1080%2F14737159.2016.1199962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27282189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FosVChug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=807-809&issue=8&author=J.+T.+J%C3%B8rgensen&title=The+Importance+of+Predictive+Biomarkers+in+Oncology+Drug+Development&doi=10.1080%2F14737159.2016.1199962"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">The importance of predictive biomarkers in oncology drug development</span></div><div class="casAuthors">Jorgensen Jan Trost</div><div class="citationInfo"><span class="NLM_cas:title">Expert review of molecular diagnostics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">807-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpjsop5xOrXENoizSOkG_FfW6udTcc2eYIwX_oPLYCorntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FosVChug%253D%253D&md5=a98aabac63825ef0d86e882456e73061</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1080%2F14737159.2016.1199962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737159.2016.1199962%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25B8rgensen%26aufirst%3DJ.%2BT.%26atitle%3DThe%2520Importance%2520of%2520Predictive%2520Biomarkers%2520in%2520Oncology%2520Drug%2520Development%26jtitle%3DExpert%2520Rev.%2520Mol.%2520Diagn.%26date%3D2016%26volume%3D16%26issue%3D8%26spage%3D807%26epage%3D809%26doi%3D10.1080%2F14737159.2016.1199962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poornima, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blunder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efferth, T.</span></span> <span> </span><span class="NLM_article-title">Network Pharmacology of Cancer: From Understanding of Complex Interactomes to the Design of Multi-Target Specific Therapeutics from Nature</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">290</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2016.06.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.phrs.2016.06.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27329331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFShsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=290-302&author=P.+Poornimaauthor=J.+D.+Kumarauthor=Q.+Zhaoauthor=M.+Blunderauthor=T.+Efferth&title=Network+Pharmacology+of+Cancer%3A+From+Understanding+of+Complex+Interactomes+to+the+Design+of+Multi-Target+Specific+Therapeutics+from+Nature&doi=10.1016%2Fj.phrs.2016.06.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature</span></div><div class="casAuthors">Poornima, Paramasivan; Kumar, Jothi Dinesh; Zhao, Qiaoli; Blunder, Martina; Efferth, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">290-302</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Despite massive investments in drug research and development, the significant decline in the no. of new drugs approved or translated to clin. use raises the question, whether single targeted drug discovery is the right approach.  To combat complex systemic diseases that harbor robust biol. networks such as cancer, single target intervention is proved to be ineffective.  In such cases, network pharmacol. approaches are highly useful, because they differ from conventional drug discovery by addressing the ability of drugs to target numerous proteins or networks involved in a disease.  Pleiotropic natural products are one of the promising strategies due to their multi-targeting and due to lower side effects.  In this review, we discuss the application of network pharmacol. for cancer drug discovery.  We provide an overview of the current state of knowledge on network pharmacol., focus on different tech. approaches and implications for cancer therapy (e.g. polypharmacol. and synthetic lethality), and illustrate the therapeutic potential with selected examples green tea polyphenolics, Eleutherococcus senticosus, Rhodiola rosea, and Schisandra chinensis.  Finally, we present future perspectives on their plausible applications for diagnosis and therapy of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwqqjqEH_wtrVg90H21EOLACvtfcHk0ljvtcQvVUN_JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFShsr%252FM&md5=be3757ac287f3b90ebbcb69016a9410c</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.06.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.06.018%26sid%3Dliteratum%253Aachs%26aulast%3DPoornima%26aufirst%3DP.%26aulast%3DKumar%26aufirst%3DJ.%2BD.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DBlunder%26aufirst%3DM.%26aulast%3DEfferth%26aufirst%3DT.%26atitle%3DNetwork%2520Pharmacology%2520of%2520Cancer%253A%2520From%2520Understanding%2520of%2520Complex%2520Interactomes%2520to%2520the%2520Design%2520of%2520Multi-Target%2520Specific%2520Therapeutics%2520from%2520Nature%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D290%26epage%3D302%26doi%3D10.1016%2Fj.phrs.2016.06.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span> <span> </span><span class="NLM_article-title">Drug Discovery and Development for Rare Genetic Disorders</span>. <i>Am. J. Med. Genet., Part A</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>173</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2307</span>– <span class="NLM_lpage">2322</span>, <span class="refDoi"> DOI: 10.1002/ajmg.a.38326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fajmg.a.38326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28731526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC1cjpvFanuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2017&pages=2307-2322&issue=9&author=W.+Sunauthor=W.+Zhengauthor=A.+Simeonov&title=Drug+Discovery+and+Development+for+Rare+Genetic+Disorders&doi=10.1002%2Fajmg.a.38326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery and development for rare genetic disorders</span></div><div class="casAuthors">Sun Wei; Zheng Wei; Simeonov Anton</div><div class="citationInfo"><span class="NLM_cas:title">American journal of medical genetics. Part A</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2307-2322</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Approximately 7,000 rare diseases affect millions of individuals in the United States.  Although rare diseases taken together have an enormous impact, there is a significant gap between basic research and clinical interventions.  Opportunities now exist to accelerate drug development for the treatment of rare diseases.  Disease foundations and research centers worldwide focus on better understanding rare disorders.  Here, the state-of-the-art drug discovery strategies for small molecules and biological approaches for orphan diseases are reviewed.  Rare diseases are usually genetic diseases; hence, employing pharmacogenetics to develop treatments and using whole genome sequencing to identify the etiologies for such diseases are appropriate strategies to exploit.  Beginning with high throughput screening of small molecules, the benefits and challenges of target-based and phenotypic screens are discussed.  Explanations and examples of drug repurposing are given; drug repurposing as an approach to quickly move programs to clinical trials is evaluated.  Consideration is given to the category of biologics which include gene therapy, recombinant proteins, and autologous transplants.  Disease models, including animal models and induced pluripotent stem cells (iPSCs) derived from patients, are surveyed.  Finally, the role of biomarkers in drug discovery and development, as well as clinical trials, is elucidated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJyOLLVY88tAMthz5_Rx5rfW6udTcc2eYIwX_oPLYCorntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjpvFanuw%253D%253D&md5=75fdaeceb8cf3aeb80b609877f4125e2</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1002%2Fajmg.a.38326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajmg.a.38326%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DSimeonov%26aufirst%3DA.%26atitle%3DDrug%2520Discovery%2520and%2520Development%2520for%2520Rare%2520Genetic%2520Disorders%26jtitle%3DAm.%2520J.%2520Med.%2520Genet.%252C%2520Part%2520A%26date%3D2017%26volume%3D173%26issue%3D9%26spage%3D2307%26epage%3D2322%26doi%3D10.1002%2Fajmg.a.38326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bakkar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehringer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowser, R.</span></span> <span> </span><span class="NLM_article-title">Use of Biomarkers in ALS Drug Development and Clinical Trials</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1607</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2014.10.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.brainres.2014.10.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=25452025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVCktL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1607&publication_year=2015&pages=94-107&author=N.+Bakkarauthor=A.+Boehringerauthor=R.+Bowser&title=Use+of+Biomarkers+in+ALS+Drug+Development+and+Clinical+Trials&doi=10.1016%2Fj.brainres.2014.10.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Use of biomarkers in ALS drug development and clinical trials</span></div><div class="casAuthors">Bakkar, Nadine; Boehringer, Ashley; Bowser, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1607</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">94-107</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The past decade has seen a dramatic increase in the discovery of candidate biomarkers for ALS.  These biomarkers typically can either differentiate ALS from control subjects or predict disease course (slow vs. fast progression).  At the same time, late-stage clin. trials for ALS have failed to generate improved drug treatments for ALS patients.  Incorporation of biomarkers into the ALS drug development pipeline and the use of biol. and/or imaging biomarkers in early- and late-stage ALS clin. trials have been absent and only recently pursued in early-phase clin. trials.  Further clin. research studies are needed to validate biomarkers for disease progression and develop biomarkers that can help det. that a drug has reached its target within the central nervous system.  In this review we summarize recent progress in biomarkers across ALS model systems and patient population, and highlight continued research directions for biomarkers that stratify the patient population to enrich for patients that may best respond to a drug candidate, monitor disease progression and track drug responses in clin. trials.  It is crucial that we further develop and validate ALS biomarkers and incorporate these biomarkers into the ALS drug development process.  This article is part of a Special Issue entitled ALS complex pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA9RyxvK5C2rVg90H21EOLACvtfcHk0ljIObjHjWqzxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVCktL%252FP&md5=574c7b1ee968a171eb40219c6960381c</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2014.10.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2014.10.031%26sid%3Dliteratum%253Aachs%26aulast%3DBakkar%26aufirst%3DN.%26aulast%3DBoehringer%26aufirst%3DA.%26aulast%3DBowser%26aufirst%3DR.%26atitle%3DUse%2520of%2520Biomarkers%2520in%2520ALS%2520Drug%2520Development%2520and%2520Clinical%2520Trials%26jtitle%3DBrain%2520Res.%26date%3D2015%26volume%3D1607%26spage%3D94%26epage%3D107%26doi%3D10.1016%2Fj.brainres.2014.10.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, E. H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarazi, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahid, M.</span></span> <span> </span><span class="NLM_article-title">The Effectiveness of Multi-Target Agents in Schizophrenia and Mood Disorders: Relevance of Receptor Signature to Clinical Action</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>126</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2010.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.pharmthera.2010.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=20171983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksF2qur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2010&pages=173-185&issue=2&author=E.+H.+F.+Wongauthor=F.+I.+Taraziauthor=M.+Shahid&title=The+Effectiveness+of+Multi-Target+Agents+in+Schizophrenia+and+Mood+Disorders%3A+Relevance+of+Receptor+Signature+to+Clinical+Action&doi=10.1016%2Fj.pharmthera.2010.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">The effectiveness of multi-target agents in schizophrenia and mood disorders: relevance of receptor signature to clinical action</span></div><div class="casAuthors">Wong, Erik H. F.; Tarazi, Frank I.; Shahid, Mohammed</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">173-185</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Schizophrenia, bipolar disorder and unipolar depression are multi-dimensional and severely disabling psychiatric diseases with a strong need for improved pharmacotherapies with better adherence, long-term outcome and patient functionality.  Progress has been achieved with the emergence of tailored multi-target agents (MTAs), such as second-generation antipsychotics for schizophrenia, with expanding clin. utility in bipolar disorder and depression.  Better understanding of how these MTAs exert their beneficial and undesirable clin. effects in terms of receptor interaction remains an area for further elucidation, which may provide insight towards a new generation of individualized, and optimized therapies.  This review explores to what extent the receptor signature of MTAs informs about their clin. action and therapeutic utility.  Compelling clin. validation exists only for a limited no. of mol. targets (e.g. D2 receptor blockade, serotonin transport inhibition), indicating overall high attrition and poor translation of predictive preclin. pharmacol.  Nevertheless, recent advances have identified promising novel approaches for schizophrenia, bipolar disorder and depression that require further clin. validation.  It is hoped that the expanding clin. and mechanistic knowledge garnered from the use of existing MTAs will provide addnl. opportunities for "reverse translation" and towards target validation.  There is considerable scope for further developing and applying the knowledge linking receptor signature to clin. activity to drive stronger target validation, and ultimately support rational development of the next generation of MTAs for the improved treatment of schizophrenia and mood disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprA36orGSrq7Vg90H21EOLACvtfcHk0ljIObjHjWqzxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksF2qur8%253D&md5=3ecf4d69c5847b205e004f5379bf3b1a</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2010.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2010.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DE.%2BH.%2BF.%26aulast%3DTarazi%26aufirst%3DF.%2BI.%26aulast%3DShahid%26aufirst%3DM.%26atitle%3DThe%2520Effectiveness%2520of%2520Multi-Target%2520Agents%2520in%2520Schizophrenia%2520and%2520Mood%2520Disorders%253A%2520Relevance%2520of%2520Receptor%2520Signature%2520to%2520Clinical%2520Action%26jtitle%3DPharmacol.%2520Ther.%26date%3D2010%26volume%3D126%26issue%3D2%26spage%3D173%26epage%3D185%26doi%3D10.1016%2Fj.pharmthera.2010.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheffler, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroeze, W. K.</span></span> <span> </span><span class="NLM_article-title">Magic Shotguns versus Magic Bullets: Selectively Non-Selective Drugs for Mood Disorders and Schizophrenia</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">359</span>, <span class="refDoi"> DOI: 10.1038/nrd1346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnrd1346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=15060530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=353-359&issue=4&author=B.+L.+Rothauthor=D.+J.+Shefflerauthor=W.+K.+Kroeze&title=Magic+Shotguns+versus+Magic+Bullets%3A+Selectively+Non-Selective+Drugs+for+Mood+Disorders+and+Schizophrenia&doi=10.1038%2Fnrd1346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span></div><div class="casAuthors">Roth, Bryan L.; Sheffler, Douglas J.; Kroeze, Wesley K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-359</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most common central nervous system disorders - such as depression, bipolar disorder, and schizophrenia - seem to be polygenic in origin, and the most effective medications have exceedingly complex pharmacologies.  Attempts to develop more effective treatments for diseases such as schizophrenia and depression by discovering drugs selective for single mol. targets (i.e., 'magic bullets') have, not surprisingly, been largely unsuccessful.  Here the authors propose that designing selectively non-selective drugs (i.e., 'magic shotguns') that interact with several mol. targets will lead to new and more effective medications for a variety of central nervous system disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnSsuUXzmbirVg90H21EOLACvtfcHk0ljIObjHjWqzxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D&md5=77196583acccca65457fec7a67218463</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fnrd1346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1346%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DSheffler%26aufirst%3DD.%2BJ.%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26atitle%3DMagic%2520Shotguns%2520versus%2520Magic%2520Bullets%253A%2520Selectively%2520Non-Selective%2520Drugs%2520for%2520Mood%2520Disorders%2520and%2520Schizophrenia%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26issue%3D4%26spage%3D353%26epage%3D359%26doi%3D10.1038%2Fnrd1346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeshima, M.</span></span> <span> </span><span class="NLM_article-title">Treating Mixed Mania/hypomania: A Review and Synthesis of the Evidence</span>. <i>CNS Spectr.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1017/S1092852916000845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1017%2FS1092852916000845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28004626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC1c%252FnsVKksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=177-185&issue=2&author=M.+Takeshima&title=Treating+Mixed+Mania%2Fhypomania%3A+A+Review+and+Synthesis+of+the+Evidence&doi=10.1017%2FS1092852916000845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Treating mixed mania/hypomania: a review and synthesis of the evidence</span></div><div class="casAuthors">Takeshima Minoru</div><div class="citationInfo"><span class="NLM_cas:title">CNS spectrums</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">177-185</span>
        ISSN:<span class="NLM_cas:issn">1092-8529</span>.
    </div><div class="casAbstract">The DSM-5 incorporates a broad concept of mixed states and captured ≥3 nonoverlapping symptoms of the opposite polarity using a "with mixed features" specifier to be applied to manic/hypomanic and major depressive episodes.  Pharmacotherapy of mixed states is challenging because of the necessity to treat both manic/hypomanic and depressive symptoms concurrently.  High-potency antipsychotics used to treat manic symptoms and antidepressants can potentially deteriorate symptoms of the opposite polarity.  This review aimed to provide a synthesis of the current evidence for pharmacotherapy of mixed states with an emphasis on mixed mania/hypomania.  A PubMed search was conducted for randomized controlled trials (RCTs) that were at least moderately sized, included a placebo arm, and contained information on acute-phase and maintenance treatments of adult patients with mixed episodes or mania/hypomania with significant depressive symptoms.  Most studies were post-hoc subgroup and pooled analyses of the data from RCTs for acute manic and mixed episodes of bipolar I disorder; only two prospectively examined efficacy for mixed mania/hypomania specifically.  Aripiprazole, asenapine, carbamazepine, olanzapine, and ziprasidone showed the strongest evidence of efficacy in acute-phase treatment.  Quetiapine and divalproex/valproate were also efficacious.  Combination therapies with these atypical antipsychotics and mood stabilizers can be considered in severe cases.  Olanzapine and quetiapine (alone or in combination with lithium/divalproex) showed the strongest evidence of efficacy in maintenance treatment.  Lithium and lamotrigine may be beneficial given their preventive effects on suicide and depressive relapse.  Further prospective studies primarily focusing on mixed states are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5cBz8zkyS2Nj_Vg2vObihfW6udTcc2ebvfsDHyrW6vLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c%252FnsVKksQ%253D%253D&md5=87a4b1fe530051dc37c3aa50eb1b8e00</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1017%2FS1092852916000845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1092852916000845%26sid%3Dliteratum%253Aachs%26aulast%3DTakeshima%26aufirst%3DM.%26atitle%3DTreating%2520Mixed%2520Mania%252Fhypomania%253A%2520A%2520Review%2520and%2520Synthesis%2520of%2520the%2520Evidence%26jtitle%3DCNS%2520Spectr.%26date%3D2017%26volume%3D22%26issue%3D2%26spage%3D177%26epage%3D185%26doi%3D10.1017%2FS1092852916000845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tuplin, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holahan, M. R.</span></span> <span> </span><span class="NLM_article-title">Aripiprazole, A Drug That Displays Partial Agonism and Functional Selectivity</span>. <i>Curr. Neuropharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1192</span>– <span class="NLM_lpage">1207</span>, <span class="refDoi"> DOI: 10.2174/1570159X15666170413115754</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F1570159X15666170413115754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28412910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFens7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=1192-1207&issue=8&author=E.+W.+Tuplinauthor=M.+R.+Holahan&title=Aripiprazole%2C+A+Drug+That+Displays+Partial+Agonism+and+Functional+Selectivity&doi=10.2174%2F1570159X15666170413115754"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity</span></div><div class="casAuthors">Tuplin, Erin W.; Holahan, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1192-1207</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: The treatment of schizophrenia is challenging due to the wide range of symptoms (pos., neg., cognitive) assocd. with the disease.  Typical antipsychotics that antagonize D2 receptors are effective in treating pos. symptoms, but extrapyramidal side-effects (EPS) are a common occurrence.  Atypical antipsychotics targeting 5-HT2A and D2 receptors are more effective at treating cognitive and neg. symptoms compared to typical antipsychotics, but these drugs also result in side-effects such as metabolic syndromes.  Objective: To identify evidence in the literature that elucidates the pharmacol. profile of aripiprazole.s.  Methods: We searched PubMed for peer reviewed articles on aripiprazole and its clin. efficacy, side-effects, pharmacol., and effects in animal models of schizophrenia symptoms.  Results: Aripiprazole is a newer atypical antipsychotic that displays a unique pharmacol. profile, including partial D2 agonism and functionally selective properties.  Aripiprazole is effective at treating the pos. symptoms of schizophrenia and has the potential to treat neg. and cognitive symptoms at least as well as other atypical antipsychotics.  The drug has a favorable side-effect profile and has a low propensity to result in EPS or metabolic syndromes.  Animal models of schizophrenia have been used to det. the efficacy of aripiprazole in symptom management.  In these instances, aripiprazole resulted in the reversal of deficits in extinction, pre-pulse inhibition, and social withdrawal.  Because aripiprazole requires a greater than 90% occupancy rate at D2 receptors to be clin. active and does not produce EPS, this suggests a functionally selective effect on intracellular signaling pathways.  Conclusion: A combination of factors such as dopamine system stabilization via partial agonism, functional selectivity at D2 receptors, and serotonin-dopamine system interaction may contribute to the ability of aripiprazole to successfully manage schizophrenia symptoms.  This review examines these mechanisms of action to further clarify the pharmacol. actions of aripiprazole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiNaT3zwOCzLVg90H21EOLACvtfcHk0lixbKA8Sn3Oxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFens7vM&md5=a3e01bec5ee707325ac14bcee420a4d2</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.2174%2F1570159X15666170413115754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570159X15666170413115754%26sid%3Dliteratum%253Aachs%26aulast%3DTuplin%26aufirst%3DE.%2BW.%26aulast%3DHolahan%26aufirst%3DM.%2BR.%26atitle%3DAripiprazole%252C%2520A%2520Drug%2520That%2520Displays%2520Partial%2520Agonism%2520and%2520Functional%2520Selectivity%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2017%26volume%3D15%26issue%3D8%26spage%3D1192%26epage%3D1207%26doi%3D10.2174%2F1570159X15666170413115754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caraci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leggio, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drago, F.</span></span> <span> </span><span class="NLM_article-title">New Drugs in Psychiatry: Focus on New Pharmacological Targets</span>. <i>F1000Research</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">397</span>, <span class="refDoi"> DOI: 10.12688/f1000research.10233.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.12688%2Ff1000research.10233.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28408985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC1cvnslOhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=397&author=F.+Caraciauthor=G.+M.+Leggioauthor=S.+Salomoneauthor=F.+Drago&title=New+Drugs+in+Psychiatry%3A+Focus+on+New+Pharmacological+Targets&doi=10.12688%2Ff1000research.10233.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">New drugs in psychiatry: focus on new pharmacological targets</span></div><div class="casAuthors">Caraci Filippo; Caraci Filippo; Leggio Gian Marco; Salomone Salvatore; Drago Filippo</div><div class="citationInfo"><span class="NLM_cas:title">F1000Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">397</span>
        ISSN:<span class="NLM_cas:issn">2046-1402</span>.
    </div><div class="casAbstract">The approval of psychotropic drugs with novel mechanisms of action has been rare in recent years.  To address this issue, further analysis of the pathophysiology of neuropsychiatric disorders is essential for identifying new pharmacological targets for psychotropic medications.  In this report, we detail drug candidates being examined as treatments for psychiatric disorders.  Particular emphasis is placed on agents with novel mechanisms of action that are being tested as therapies for depression, schizophrenia, or Alzheimer's disease.  All of the compounds considered were recently approved for human use or are in advanced clinical trials.  Drugs included here are new antipsychotic medications endowed with a preferential affinity at dopamine D3 receptor (cariprazine) or at glutamatergic or cannabinoid receptors, as well as vortioxetine, a drug approved for managing the cognitive deficits associated with major depression.  New mechanistic approaches for the treatment of depression include intravenous ketamine or esketamine or intranasal esketamine.  As for Alzheimer's disease, the possible value of passive immunotherapy with agents such as aducanumab is considered to be a potential disease-modifying approach that could slow or halt the progressive decline associated with this devastating disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQm8I_QiD3OJNhSDZx9hyjKfW6udTcc2eaxTGcxNyo8j7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvnslOhsw%253D%253D&md5=a49356e1ef4094435d21d838138a120f</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.12688%2Ff1000research.10233.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12688%252Ff1000research.10233.1%26sid%3Dliteratum%253Aachs%26aulast%3DCaraci%26aufirst%3DF.%26aulast%3DLeggio%26aufirst%3DG.%2BM.%26aulast%3DSalomone%26aufirst%3DS.%26aulast%3DDrago%26aufirst%3DF.%26atitle%3DNew%2520Drugs%2520in%2520Psychiatry%253A%2520Focus%2520on%2520New%2520Pharmacological%2520Targets%26jtitle%3DF1000Research%26date%3D2017%26volume%3D6%26spage%3D397%26doi%3D10.12688%2Ff1000research.10233.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krause, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huhn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider-Thoma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bighelli, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolakopoulou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leucht, S.</span></span> <span> </span><span class="NLM_article-title">Antipsychotic Drugs for Patients with Schizophrenia and Predominant or Prominent Negative Symptoms: A Systematic Review and Meta-Analysis</span>. <i>Eur. Arch. Psychiatry Clin. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1007/s00406-018-0869-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1007%2Fs00406-018-0869-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29332205" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=1-15&author=M.+Krauseauthor=Y.+Zhuauthor=M.+Huhnauthor=J.+Schneider-Thomaauthor=I.+Bighelliauthor=A.+Nikolakopoulouauthor=S.+Leucht&title=Antipsychotic+Drugs+for+Patients+with+Schizophrenia+and+Predominant+or+Prominent+Negative+Symptoms%3A+A+Systematic+Review+and+Meta-Analysis&doi=10.1007%2Fs00406-018-0869-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1007%2Fs00406-018-0869-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00406-018-0869-3%26sid%3Dliteratum%253Aachs%26aulast%3DKrause%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DHuhn%26aufirst%3DM.%26aulast%3DSchneider-Thoma%26aufirst%3DJ.%26aulast%3DBighelli%26aufirst%3DI.%26aulast%3DNikolakopoulou%26aufirst%3DA.%26aulast%3DLeucht%26aufirst%3DS.%26atitle%3DAntipsychotic%2520Drugs%2520for%2520Patients%2520with%2520Schizophrenia%2520and%2520Predominant%2520or%2520Prominent%2520Negative%2520Symptoms%253A%2520A%2520Systematic%2520Review%2520and%2520Meta-Analysis%26jtitle%3DEur.%2520Arch.%2520Psychiatry%2520Clin.%2520Neurosci.%26date%3D2018%26spage%3D1%26epage%3D15%26doi%3D10.1007%2Fs00406-018-0869-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langedijk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantel-Teeuwisse, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slijkerman, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutjens, M.-H. D. B.</span></span> <span> </span><span class="NLM_article-title">Drug Repositioning and Repurposing: Terminology and Definitions in Literature</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1027</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2015.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.drudis.2015.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=25975957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC2MfktVCisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=1027-1034&issue=8&author=J.+Langedijkauthor=A.+K.+Mantel-Teeuwisseauthor=D.+S.+Slijkermanauthor=M.-H.+D.+B.+Schutjens&title=Drug+Repositioning+and+Repurposing%3A+Terminology+and+Definitions+in+Literature&doi=10.1016%2Fj.drudis.2015.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Drug repositioning and repurposing: terminology and definitions in literature</span></div><div class="casAuthors">Langedijk Joris; Mantel-Teeuwisse Aukje K; Slijkerman Diederick S; Schutjens Marie-Helene D B</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1027-34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug repositioning and similar terms have been a trending topic in literature and represent novel drug development strategies.  We analysed in a quantitative and qualitative manner how these terms were used and defined in the literature.  In total, 217 articles referred to 'drug repositioning', 'drug repurposing', 'drug reprofiling', 'drug redirecting' and/or 'drug rediscovery'.  Only 67 included a definition ranging from brief and general to extensive and specific.  No common definition was identified.  Nevertheless, four common features were found: concept, action, use and product.  The different wording used for these features often leads to essential differences in meaning between definitions.  In case a clear definition is needed, for example from a legal or regulatory perspective, the features can provide further guidance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFpzo98DHKlFVwdslNBF-tfW6udTcc2eaxTGcxNyo8j7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfktVCisg%253D%253D&md5=549b4e5ce337f19a6279764be580bdcd</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DLangedijk%26aufirst%3DJ.%26aulast%3DMantel-Teeuwisse%26aufirst%3DA.%2BK.%26aulast%3DSlijkerman%26aufirst%3DD.%2BS.%26aulast%3DSchutjens%26aufirst%3DM.-H.%2BD.%2BB.%26atitle%3DDrug%2520Repositioning%2520and%2520Repurposing%253A%2520Terminology%2520and%2520Definitions%2520in%2520Literature%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26issue%3D8%26spage%3D1027%26epage%3D1034%26doi%3D10.1016%2Fj.drudis.2015.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aubé, J.</span></span> <span> </span><span class="NLM_article-title">Drug Repurposing and the Medicinal Chemist</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">442</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1021/ml300114c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300114c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=442-444&issue=6&author=J.+Aub%C3%A9&title=Drug+Repurposing+and+the+Medicinal+Chemist&doi=10.1021%2Fml300114c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Fml300114c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300114c%26sid%3Dliteratum%253Aachs%26aulast%3DAub%25C3%25A9%26aufirst%3DJ.%26atitle%3DDrug%2520Repurposing%2520and%2520the%2520Medicinal%2520Chemist%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26issue%3D6%26spage%3D442%26epage%3D444%26doi%3D10.1021%2Fml300114c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasowski, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span> <span> </span><span class="NLM_article-title">In Silico Repositioning of Approved Drugs for Rare and Neglected Diseases</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">7–8</span>),  <span class="NLM_fpage">298</span>– <span class="NLM_lpage">310</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.02.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.drudis.2011.02.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=21376136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC3MvhslKguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=298-310&issue=7%E2%80%938&author=S.+Ekinsauthor=A.+J.+Williamsauthor=M.+D.+Krasowskiauthor=J.+S.+Freundlich&title=In+Silico+Repositioning+of+Approved+Drugs+for+Rare+and+Neglected+Diseases&doi=10.1016%2Fj.drudis.2011.02.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">In silico repositioning of approved drugs for rare and neglected diseases</span></div><div class="casAuthors">Ekins Sean; Williams Antony J; Krasowski Matthew D; Freundlich Joel S</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">298-310</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">One approach to speed up drug discovery is to examine new uses for existing approved drugs, so-called 'drug repositioning' or 'drug repurposing', which has become increasingly popular in recent years.  Analysis of the literature reveals many examples of US Food and Drug Administration-approved drugs that are active against multiple targets (also termed promiscuity) that can also be used to therapeutic advantage for repositioning for other neglected and rare diseases.  Using proof-of-principle examples, we suggest here that with current in silico technologies and databases of the structures and biological activities of chemical compounds (drugs) and related data, as well as close integration with in vitro screening data, improved opportunities for drug repurposing will emerge for neglected or rare/orphan diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT3t5Axd1gtboxhnOQkIHOxfW6udTcc2eb7IeCRPc-Oe7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MvhslKguw%253D%253D&md5=0789fe5c640cb922d93d16e2e759e563</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.02.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.02.016%26sid%3Dliteratum%253Aachs%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DA.%2BJ.%26aulast%3DKrasowski%26aufirst%3DM.%2BD.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26atitle%3DIn%2520Silico%2520Repositioning%2520of%2520Approved%2520Drugs%2520for%2520Rare%2520and%2520Neglected%2520Diseases%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26issue%3D7%25E2%2580%25938%26spage%3D298%26epage%3D310%26doi%3D10.1016%2Fj.drudis.2011.02.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bottegoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favia, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recanatini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span> <span> </span><span class="NLM_article-title">The Role of Fragment-Based and Computational Methods in Polypharmacology</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.drudis.2011.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=21864710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38Xns12gtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=23-34&issue=1%E2%80%932&author=G.+Bottegoniauthor=A.+D.+Faviaauthor=M.+Recanatiniauthor=A.+Cavalli&title=The+Role+of+Fragment-Based+and+Computational+Methods+in+Polypharmacology&doi=10.1016%2Fj.drudis.2011.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">The role of fragment-based and computational methods in polypharmacology</span></div><div class="casAuthors">Bottegoni, Giovanni; Favia, Angelo D.; Recanatini, Maurizio; Cavalli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">23-34</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Polypharmacol.-based strategies are gaining increased attention as a novel approach to obtaining potentially innovative medicines for multifactorial diseases.  However, some within the pharmaceutical community have resisted these strategies because they can be resource-hungry in the early stages of the drug discovery process.  Here, we report on fragment-based and computational methods that might accelerate and optimize the discovery of multitarget drugs.  In particular, we illustrate that fragment-based approaches can be particularly suited for polypharmacol., owing to the inherent promiscuous nature of fragments.  In parallel, we explain how computer-assisted protocols can provide invaluable insights into how to unveil compds. theor. able to bind to more than one protein.  Furthermore, several pragmatic aspects related to the use of these approaches are covered, thus offering the reader practical insights on multitarget-oriented drug discovery projects.  We report on fragment-based and computational approaches as possible ways to accelerate and optimize the discovery of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqX_beZ_hY17Vg90H21EOLACvtfcHk0ljgdyL6iluWQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xns12gtw%253D%253D&md5=c774326a467a2b8fef62c6e1224c2a78</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DBottegoni%26aufirst%3DG.%26aulast%3DFavia%26aufirst%3DA.%2BD.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DThe%2520Role%2520of%2520Fragment-Based%2520and%2520Computational%2520Methods%2520in%2520Polypharmacology%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26issue%3D1%25E2%2580%25932%26spage%3D23%26epage%3D34%26doi%3D10.1016%2Fj.drudis.2011.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovic-Nikolic, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uliassi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">A Perspective on Multi-Target Drug Discovery and Design for Complex Diseases</span>. <i>Clin. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">3</span>, <span class="refDoi"> DOI: 10.1186/s40169-017-0181-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1186%2Fs40169-017-0181-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29340951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC1MvhsVaiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=3&author=R.+R.+Ramsayauthor=M.+R.+Popovic-Nikolicauthor=K.+Nikolicauthor=E.+Uliassiauthor=M.+L.+Bolognesi&title=A+Perspective+on+Multi-Target+Drug+Discovery+and+Design+for+Complex+Diseases&doi=10.1186%2Fs40169-017-0181-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">A perspective on multi-target drug discovery and design for complex diseases</span></div><div class="casAuthors">Ramsay Rona R; Popovic-Nikolic Marija R; Nikolic Katarina; Uliassi Elisa; Bolognesi Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and translational medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3</span>
        ISSN:<span class="NLM_cas:issn">2001-1326</span>.
    </div><div class="casAbstract">Diseases of infection, of neurodegeneration (such as Alzheimer's and Parkinson's diseases), and of malignancy (cancers) have complex and varied causative factors.  Modern drug discovery has the power to identify potential modulators for multiple targets from millions of compounds.  Computational approaches allow the determination of the association of each compound with its target before chemical synthesis and biological testing is done.  These approaches depend on the prior identification of clinically and biologically validated targets.  This Perspective will focus on the molecular and computational approaches that underpin drug design by medicinal chemists to promote understanding and collaboration with clinical scientists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJhSGsWpifCZcXNb62YGmbfW6udTcc2eb7IeCRPc-Oe7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvhsVaiug%253D%253D&md5=5b05a73a3bbc955c77b9b2df93deb946</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1186%2Fs40169-017-0181-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40169-017-0181-2%26sid%3Dliteratum%253Aachs%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DPopovic-Nikolic%26aufirst%3DM.%2BR.%26aulast%3DNikolic%26aufirst%3DK.%26aulast%3DUliassi%26aufirst%3DE.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DA%2520Perspective%2520on%2520Multi-Target%2520Drug%2520Discovery%2520and%2520Design%2520for%2520Complex%2520Diseases%26jtitle%3DClin.%2520Transl.%2520Med.%26date%3D2018%26volume%3D7%26spage%3D3%26doi%3D10.1186%2Fs40169-017-0181-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talevi, A.</span></span> <span> </span><span class="NLM_article-title">Multi-Target Pharmacology: Possibilities and Limitations of The “skeleton Key Approach” from a Medicinal Chemist Perspective</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">205</span>, <span class="refDoi"> DOI: 10.3389/fphar.2015.00205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.3389%2Ffphar.2015.00205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=26441661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1amurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=205&author=A.+Talevi&title=Multi-Target+Pharmacology%3A+Possibilities+and+Limitations+of+The+%E2%80%9Cskeleton+Key+Approach%E2%80%9D+from+a+Medicinal+Chemist+Perspective&doi=10.3389%2Ffphar.2015.00205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective</span></div><div class="casAuthors">Talevi, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">205/1-205/7</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Multi-target drugs have raised considerable interest in the last decade owing to their advantages in the treatment of complex diseases and health conditions linked to drug resistance issues.  Prospective drug repositioning to treat comorbid conditions is an addnl., overlooked application of multi-target ligands.  While medicinal chemists usually rely on some version of the lock and key paradigm to design novel therapeutics, modern pharmacol. recognizes that the mid- and long-term effects of a given drug on a biol. system may depend not only on the specific ligand-target recognition events but also on the influence of the repeated administration of a drug on the cell gene signature.  The design of multi-target agents usually imposes challenging restrictions on the topol. or flexibility of the candidate drugs, which are briefly discussed in the present article.  Finally, computational strategies to approach the identification of novel multi-target agents are overviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSdZokyMjNSLVg90H21EOLACvtfcHk0lj9XB2gM4P3sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1amurnM&md5=169718a4644d962da33806772a9a33e3</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00205%26sid%3Dliteratum%253Aachs%26aulast%3DTalevi%26aufirst%3DA.%26atitle%3DMulti-Target%2520Pharmacology%253A%2520Possibilities%2520and%2520Limitations%2520of%2520The%2520%25E2%2580%259Cskeleton%2520Key%2520Approach%25E2%2580%259D%2520from%2520a%2520Medicinal%2520Chemist%2520Perspective%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D205%26doi%3D10.3389%2Ffphar.2015.00205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schaller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagenow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alpert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naß, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bermudez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolber, G.</span></span> <span> </span><span class="NLM_article-title">Systematic Data Mining Reveals Synergistic H3R/MCHR1 Ligands</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">648</span>– <span class="NLM_lpage">653</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00118</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00118" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=648-653&issue=6&author=D.+Schallerauthor=S.+Hagenowauthor=G.+Alpertauthor=A.+Na%C3%9Fauthor=R.+Schulzauthor=M.+Bermudezauthor=H.+Starkauthor=G.+Wolber&title=Systematic+Data+Mining+Reveals+Synergistic+H3R%2FMCHR1+Ligands&doi=10.1021%2Facsmedchemlett.7b00118"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00118%26sid%3Dliteratum%253Aachs%26aulast%3DSchaller%26aufirst%3DD.%26aulast%3DHagenow%26aufirst%3DS.%26aulast%3DAlpert%26aufirst%3DG.%26aulast%3DNa%25C3%259F%26aufirst%3DA.%26aulast%3DSchulz%26aufirst%3DR.%26aulast%3DBermudez%26aufirst%3DM.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DWolber%26aufirst%3DG.%26atitle%3DSystematic%2520Data%2520Mining%2520Reveals%2520Synergistic%2520H3R%252FMCHR1%2520Ligands%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D6%26spage%3D648%26epage%3D653%26doi%3D10.1021%2Facsmedchemlett.7b00118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Apelt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligneau, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertz, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrang, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganellin, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schunack, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Development of a New Class of Nonimidazole Histamine H3receptor Ligands with Combined Inhibitory Histamine N-Methyltransferase Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1128</span>– <span class="NLM_lpage">1141</span>, <span class="refDoi"> DOI: 10.1021/jm0110845</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0110845" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=1128-1141&issue=5&author=J.+Apeltauthor=X.+Ligneauauthor=H.+H.+Pertzauthor=J.+M.+Arrangauthor=C.+R.+Ganellinauthor=J.+C.+Schwartzauthor=W.+Schunackauthor=H.+Stark&title=Development+of+a+New+Class+of+Nonimidazole+Histamine+H3receptor+Ligands+with+Combined+Inhibitory+Histamine+N-Methyltransferase+Activity&doi=10.1021%2Fjm0110845"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Fjm0110845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0110845%26sid%3Dliteratum%253Aachs%26aulast%3DApelt%26aufirst%3DJ.%26aulast%3DLigneau%26aufirst%3DX.%26aulast%3DPertz%26aufirst%3DH.%2BH.%26aulast%3DArrang%26aufirst%3DJ.%2BM.%26aulast%3DGanellin%26aufirst%3DC.%2BR.%26aulast%3DSchwartz%26aufirst%3DJ.%2BC.%26aulast%3DSchunack%26aufirst%3DW.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DDevelopment%2520of%2520a%2520New%2520Class%2520of%2520Nonimidazole%2520Histamine%2520H3receptor%2520Ligands%2520with%2520Combined%2520Inhibitory%2520Histamine%2520N-Methyltransferase%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26issue%3D5%26spage%3D1128%26epage%3D1141%26doi%3D10.1021%2Fjm0110845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blöcher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brüggerhoff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boß, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schader, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Göbel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angioni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurglics, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostenis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brüne, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhilber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert-Zsilavecz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahnt, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span> <span> </span><span class="NLM_article-title">N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01239</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01239" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC28vksVWjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=61-81&issue=1&author=R.+Bl%C3%B6cherauthor=C.+Lamersauthor=S.+K.+Wittmannauthor=D.+Merkauthor=M.+Hartmannauthor=L.+Weizelauthor=O.+Diehlauthor=A.+Br%C3%BCggerhoffauthor=M.+Bo%C3%9Fauthor=A.+Kaiserauthor=T.+Schaderauthor=T.+G%C3%B6belauthor=M.+Grundmannauthor=C.+Angioniauthor=J.+Heeringauthor=G.+Geisslingerauthor=M.+Wurglicsauthor=E.+Kostenisauthor=B.+Br%C3%BCneauthor=D.+Steinhilberauthor=M.+Schubert-Zsilaveczauthor=A.+S.+Kahntauthor=E.+Proschak&title=N-Benzylbenzamides%3A+A+Novel+Merged+Scaffold+for+Orally+Available+Dual+Soluble+Epoxide+Hydrolase%2FPeroxisome+Proliferator-Activated+Receptor+%CE%B3+Modulators&doi=10.1021%2Facs.jmedchem.5b01239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators</span></div><div class="casAuthors">Blocher Rene; Lamers Christina; Wittmann Sandra K; Merk Daniel; Hartmann Markus; Weizel Lilia; Diehl Olaf; Bruggerhoff Astrid; Kaiser Astrid; Schader Tim; Gobel Tamara; Wurglics Mario; Steinhilber Dieter; Schubert-Zsilavecz Manfred; Kahnt Astrid S; Proschak Ewgenij; Boss Marcel; Brune Bernhard; Grundmann Manuel; Kostenis Evi; Angioni Carlo; Geisslinger Gerd; Heering Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-81</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Metabolic syndrome (MetS) is a multifactorial disease cluster that consists of dyslipidemia, cardiovascular disease, type 2 diabetes mellitus, and obesity.  MetS patients are strongly exposed to polypharmacy; however, the number of pharmacological compounds required for MetS treatment can be reduced by the application of multitarget compounds.  This study describes the design of dual-target ligands that target soluble epoxide hydrolase (sEH) and the peroxisome proliferator-activated receptor type γ (PPARγ).  Simultaneous modulation of sEH and PPARγ can improve diabetic conditions and hypertension at once.  N-Benzylbenzamide derivatives were determined to fit a merged sEH/PPARγ pharmacophore, and structure-activity relationship studies were performed on both targets, resulting in a submicromolar (sEH IC50 = 0.3 μM/PPARγ EC50 = 0.3 μM) modulator 14c.  In vitro and in vivo evaluations revealed good ADME properties qualifying 14c as a pharmacological tool compound for long-term animal models of MetS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQEKlCRcJ5_1JcXNb62YGmbfW6udTcc2eYhy706fRjuXLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vksVWjtA%253D%253D&md5=86c5861a77820ae8878382eae893b116</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01239%26sid%3Dliteratum%253Aachs%26aulast%3DBl%25C3%25B6cher%26aufirst%3DR.%26aulast%3DLamers%26aufirst%3DC.%26aulast%3DWittmann%26aufirst%3DS.%2BK.%26aulast%3DMerk%26aufirst%3DD.%26aulast%3DHartmann%26aufirst%3DM.%26aulast%3DWeizel%26aufirst%3DL.%26aulast%3DDiehl%26aufirst%3DO.%26aulast%3DBr%25C3%25BCggerhoff%26aufirst%3DA.%26aulast%3DBo%25C3%259F%26aufirst%3DM.%26aulast%3DKaiser%26aufirst%3DA.%26aulast%3DSchader%26aufirst%3DT.%26aulast%3DG%25C3%25B6bel%26aufirst%3DT.%26aulast%3DGrundmann%26aufirst%3DM.%26aulast%3DAngioni%26aufirst%3DC.%26aulast%3DHeering%26aufirst%3DJ.%26aulast%3DGeisslinger%26aufirst%3DG.%26aulast%3DWurglics%26aufirst%3DM.%26aulast%3DKostenis%26aufirst%3DE.%26aulast%3DBr%25C3%25BCne%26aufirst%3DB.%26aulast%3DSteinhilber%26aufirst%3DD.%26aulast%3DSchubert-Zsilavecz%26aufirst%3DM.%26aulast%3DKahnt%26aufirst%3DA.%2BS.%26aulast%3DProschak%26aufirst%3DE.%26atitle%3DN-Benzylbenzamides%253A%2520A%2520Novel%2520Merged%2520Scaffold%2520for%2520Orally%2520Available%2520Dual%2520Soluble%2520Epoxide%2520Hydrolase%252FPeroxisome%2520Proliferator-Activated%2520Receptor%2520%25CE%25B3%2520Modulators%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D1%26spage%3D61%26epage%3D81%26doi%3D10.1021%2Facs.jmedchem.5b01239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Graßmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apelt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligneau, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertz, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrang, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganellin, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schunack, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Search for Histamine H3 Receptor Ligands with Combined Inhibitory Potency at Histamine N-Methyltransferase: ω- Piperidinoalkanamine Derivatives</span>. <i>Arch. Pharm. (Weinheim, Ger.)</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>337</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1002/ardp.200400897</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fardp.200400897" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=15476285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsFCgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2004&pages=533-545&issue=10&author=S.+Gra%C3%9Fmannauthor=J.+Apeltauthor=X.+Ligneauauthor=H.+H.+Pertzauthor=J.+M.+Arrangauthor=C.+R.+Ganellinauthor=J.+C.+Schwartzauthor=W.+Schunackauthor=H.+Stark&title=Search+for+Histamine+H3+Receptor+Ligands+with+Combined+Inhibitory+Potency+at+Histamine+N-Methyltransferase%3A+%CF%89-+Piperidinoalkanamine+Derivatives&doi=10.1002%2Fardp.200400897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Search for histamine H3 receptor ligands with combined inhibitory potency at histamine N-methyltransferase: ω-piperidinoalkanamine derivatives</span></div><div class="casAuthors">Grassmann, Sven; Apelt, Joachim; Ligneau, Xavier; Pertz, Heinz H.; Arrang, Jean-Michel; Ganellin, C. Robin; Schwartz, Jean-Charles; Schunack, Walter; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">533-545</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">In an effort to design new hybrid compds. with dual properties, i.e. binding affinity at histamine H3 receptors and inhibitory potency at the catabolic enzyme histamine Nτ-methyltransferase (HMT), a novel series of 1-substituted piperidine derivs. was synthesized.  This alicyclic heterocycle is structurally linked via aminoalkyl spacers of variable lengths to addnl. arom. carbo- or heterocycles.  These new hybrid drugs were pharmacol. evaluated regarding their binding affinities at recombinant human H3 receptors, stably expressed in CHO cells, and in a functional assay for their inhibitory potencies at rat kidney HMT.  All compds. investigated proved to be H3 receptor ligands with binding affinities in the micro- to nanomolar concn. range despite significant differences in the type of the arom. moiety introduced.  The most potent compd. in this series was I [n = 5, R1 = Me, R2 = quinolin-4-yl] (Ki = 5.6 nM).  Likewise, all new ligands studied showed impressive HMT inhibitory activities, I [n = 3, 5, R1 = H, R2 = 5-amino-2-pyridinyl; n = 6, R1 = H, R2 = 2-pyrimidinyl; n = 2, 4, 5, R1 = Me, R2 = 4-pyridinyl, 4-quinolinyl] exhibiting submicromolar potencies (IC50 = 0.061-0.56 μM).  I [n = 4, R1 = Me, R2 = 4-quinolinyl] showed almost the same, well balanced nanomolar activities on both targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXgMhlJUXx07Vg90H21EOLACvtfcHk0lj85HD3BUkDSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsFCgsrk%253D&md5=5451de665cf9802ad3c0375397784d76</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1002%2Fardp.200400897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.200400897%26sid%3Dliteratum%253Aachs%26aulast%3DGra%25C3%259Fmann%26aufirst%3DS.%26aulast%3DApelt%26aufirst%3DJ.%26aulast%3DLigneau%26aufirst%3DX.%26aulast%3DPertz%26aufirst%3DH.%2BH.%26aulast%3DArrang%26aufirst%3DJ.%2BM.%26aulast%3DGanellin%26aufirst%3DC.%2BR.%26aulast%3DSchwartz%26aufirst%3DJ.%2BC.%26aulast%3DSchunack%26aufirst%3DW.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DSearch%2520for%2520Histamine%2520H3%2520Receptor%2520Ligands%2520with%2520Combined%2520Inhibitory%2520Potency%2520at%2520Histamine%2520N-Methyltransferase%253A%2520%25CF%2589-%2520Piperidinoalkanamine%2520Derivatives%26jtitle%3DArch.%2520Pharm.%2520%2528Weinheim%252C%2520Ger.%2529%26date%3D2004%26volume%3D337%26issue%3D10%26spage%3D533%26epage%3D545%26doi%3D10.1002%2Fardp.200400897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nurulain, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darras, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadek, B.</span></span> <span> </span><span class="NLM_article-title">The Dual-Acting H3 Receptor Antagonist and AChE Inhibitor UW-MD-71 Dose-Dependently Enhances Memory Retrieval and Reverses Dizocilpine-Induced Memory Impairment in Rats</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>297</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2015.10.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.bbr.2015.10.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=26467607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1yjsb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=297&publication_year=2016&pages=155-164&author=N.+Khanauthor=A.+Saadauthor=S.+M.+Nurulainauthor=F.+H.+Darrasauthor=M.+Deckerauthor=B.+Sadek&title=The+Dual-Acting+H3+Receptor+Antagonist+and+AChE+Inhibitor+UW-MD-71+Dose-Dependently+Enhances+Memory+Retrieval+and+Reverses+Dizocilpine-Induced+Memory+Impairment+in+Rats&doi=10.1016%2Fj.bbr.2015.10.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">The dual-acting H3 receptor antagonist and AChE inhibitor UW-MD-71 dose-dependently enhances memory retrieval and reverses dizocilpine-induced memory impairment in rats</span></div><div class="casAuthors">Khan, Nadia; Saad, Ali; Nurulain, Syed M.; Darras, Fouad H.; Decker, Michael; Sadek, Bassem</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">297</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">155-164</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Both the histamine H3 receptor (H3R) and acetylcholine esterase (AChE) are involved in the regulation of release and metab. of acetylcholine and several other central neurotransmitters.  Therefore, dual-active H3R antagonists and AChE inhibitors (AChEIs) have shown in several studies to hold promise to treat cognitive disorders like Alzheimer's disease (AD).  The novel dual-acting H3R antagonist and AChEI 7-(3-(piperidin-1-yl)propoxy)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline (UW-MD-71) with excellent selectivity profiles over both the three other HRs as well as the AChE's isoenzyme butyrylcholinesterase (BChE) shows high and balanced in vitro affinities at both H3R and AChE with IC50 of 33.9 nM and hH3R antagonism with Ki of 76.2 nM, resp.  In the present study, the effects of UW-MD-71 (1.25-5 mg/kg, i.p.) on acquisition, consolidation, and retrieval in a one-trial inhibitory avoidance task in male rats were investigated applying donepezil (DOZ) and pitolisant (PIT) as ref. drugs.  Furthermore, the effects of UW-MD-71 on memory deficits induced by the non-competitive N-methyl-D-aspartate (NMDA) antagonist dizocilpine (DIZ) were tested.  Our results indicate that administration of UW-MD-71 before the test session dose-dependently increased performance and enhanced procognitive effect on retrieval.  However neither pre- nor post-training acute systemic administration of UW-MD-71 facilitated acquisition or consolidation.  More importantly, UW-MD-71 (2.5 mg/kg, i.p.) ameliorated the DIZ-induced amnesic effects.  Furthermore, the procognitive activity of UW-MD-71 in retrieval was completely reversed and partly abrogated in DIZ-induced amnesia when rats were pretreated with the centrally-acting H2R antagonist zolantidine (ZOL), but not with the CNS penetrant H1R antagonist pyrilamine (PYR).  These results demonstrate the procognitive effects of UW-MD-71 in two in vivo memory models, and are to our knowledge the first demonstration in vivo that a potent dual-acting H3R antagonist and AChEI is effective in improving retrieval processes in the one-trial inhibitory avoidance task and provide evidence to such compds. to treat cognitive disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2h8BAnLwwwrVg90H21EOLACvtfcHk0lj85HD3BUkDSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1yjsb%252FM&md5=e283db0e6872d9cad9c3fb8294a0ab0f</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2015.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2015.10.022%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DN.%26aulast%3DSaad%26aufirst%3DA.%26aulast%3DNurulain%26aufirst%3DS.%2BM.%26aulast%3DDarras%26aufirst%3DF.%2BH.%26aulast%3DDecker%26aufirst%3DM.%26aulast%3DSadek%26aufirst%3DB.%26atitle%3DThe%2520Dual-Acting%2520H3%2520Receptor%2520Antagonist%2520and%2520AChE%2520Inhibitor%2520UW-MD-71%2520Dose-Dependently%2520Enhances%2520Memory%2520Retrieval%2520and%2520Reverses%2520Dizocilpine-Induced%2520Memory%2520Impairment%2520in%2520Rats%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2016%26volume%3D297%26spage%3D155%26epage%3D164%26doi%3D10.1016%2Fj.bbr.2015.10.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bountra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunnage, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buser-Doepner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanak, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederiksen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimshaw, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hepworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K. V. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotz, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mader, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsden, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller-Fahrnow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hagan, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundström, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Superti-Furga, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toledo-Sherman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walpole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span> <span> </span><span class="NLM_article-title">The Promise and Peril of Chemical Probes</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">536</span>– <span class="NLM_lpage">541</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1867</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnchembio.1867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=26196764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Wlu7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=536-541&issue=8&author=C.+H.+Arrowsmithauthor=J.+E.+Audiaauthor=C.+Austinauthor=J.+Baellauthor=J.+Bennettauthor=J.+Blaggauthor=C.+Bountraauthor=P.+E.+Brennanauthor=P.+J.+Brownauthor=M.+E.+Bunnageauthor=C.+Buser-Doepnerauthor=R.+M.+Campbellauthor=A.+J.+Carterauthor=P.+Cohenauthor=R.+A.+Copelandauthor=B.+Cravattauthor=J.+L.+Dahlinauthor=D.+Dhanakauthor=A.+M.+Edwardsauthor=M.+Frederiksenauthor=S.+V.+Fryeauthor=N.+Grayauthor=C.+E.+Grimshawauthor=D.+Hepworthauthor=T.+Howeauthor=K.+V.+M+Huberauthor=J.+Jinauthor=S.+Knappauthor=J.+D.+Kotzauthor=R.+G.+Krugerauthor=D.+Loweauthor=M.+M.+Maderauthor=B.+Marsdenauthor=A.+Mueller-Fahrnowauthor=S.+M%C3%BCllerauthor=R.+C.+O%E2%80%99Haganauthor=J.+P.+Overingtonauthor=D.+R.+Owenauthor=S.+H.+Rosenbergauthor=R.+Rossauthor=B.+Rothauthor=M.+Schapiraauthor=S.+L.+Schreiberauthor=B.+Shoichetauthor=M.+Sundstr%C3%B6mauthor=G.+Superti-Furgaauthor=J.+Tauntonauthor=L.+Toledo-Shermanauthor=C.+Walpoleauthor=M.+A.+Waltersauthor=T.+M.+Willsonauthor=P.+Workmanauthor=R.+N.+Youngauthor=W.+J.+Zuercher&title=The+Promise+and+Peril+of+Chemical+Probes&doi=10.1038%2Fnchembio.1867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">The promise and peril of chemical probes</span></div><div class="casAuthors">Arrowsmith, Cheryl H.; Audia, James E.; Austin, Christopher; Baell, Jonathan; Bennett, Jonathan; Blagg, Julian; Bountra, Chas; Brennan, Paul E.; Brown, Peter J.; Bunnage, Mark E.; Buser-Doepner, Carolyn; Campbell, Robert M.; Carter, Adrian J.; Cohen, Philip; Copeland, Robert A.; Cravatt, Ben; Dahlin, Jayme L.; Dhanak, Dashyant; Edwards, Aled M.; Frye, Stephen V.; Gray, Nathanael; Grimshaw, Charles E.; Hepworth, David; Howe, Trevor; Huber, Kilian V. M.; Jin, Jian; Knapp, Stefan; Kotz, Joanne D.; Kruger, Ryan G.; Lowe, Derek; Mader, Mary M.; Marsden, Brian; Mueller-Fahrnow, Anke; Muller, Susanne; O'Hagan, Ronan C.; Overington, John P.; Owen, Dafydd R.; Rosenberg, Saul H.; Roth, Brian; Ross, Ruth; Schapira, Matthieu; Schreiber, Stuart L.; Shoichet, Brian; Sundstrom, Michael; Superti-Furga, Giulio; Taunton, Jack; Toledo-Sherman, Leticia; Walpole, Chris; Walters, Michael A.; Willson, Timothy M.; Workman, Paul; Young, Robert N.; Zuercher, William J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">536-541</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chem. probes are powerful reagents with increasing impacts on biomedical research.  However, probes of poor quality or that are used incorrectly generate misleading results.  To help address these shortcomings, we will create a community-driven wiki resource to improve quality and convey current best practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-li4dxq487rVg90H21EOLACvtfcHk0lj85HD3BUkDSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Wlu7zO&md5=d8c7a7af94921ab4cdcc871487cceadd</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1867%26sid%3Dliteratum%253Aachs%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DAustin%26aufirst%3DC.%26aulast%3DBaell%26aufirst%3DJ.%26aulast%3DBennett%26aufirst%3DJ.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DBountra%26aufirst%3DC.%26aulast%3DBrennan%26aufirst%3DP.%2BE.%26aulast%3DBrown%26aufirst%3DP.%2BJ.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DBuser-Doepner%26aufirst%3DC.%26aulast%3DCampbell%26aufirst%3DR.%2BM.%26aulast%3DCarter%26aufirst%3DA.%2BJ.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DCravatt%26aufirst%3DB.%26aulast%3DDahlin%26aufirst%3DJ.%2BL.%26aulast%3DDhanak%26aufirst%3DD.%26aulast%3DEdwards%26aufirst%3DA.%2BM.%26aulast%3DFrederiksen%26aufirst%3DM.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DGrimshaw%26aufirst%3DC.%2BE.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DHowe%26aufirst%3DT.%26aulast%3DHuber%26aufirst%3DK.%2BV.%2BM%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DKotz%26aufirst%3DJ.%2BD.%26aulast%3DKruger%26aufirst%3DR.%2BG.%26aulast%3DLowe%26aufirst%3DD.%26aulast%3DMader%26aufirst%3DM.%2BM.%26aulast%3DMarsden%26aufirst%3DB.%26aulast%3DMueller-Fahrnow%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Hagan%26aufirst%3DR.%2BC.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26aulast%3DOwen%26aufirst%3DD.%2BR.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DRoss%26aufirst%3DR.%26aulast%3DRoth%26aufirst%3DB.%26aulast%3DSchapira%26aufirst%3DM.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DShoichet%26aufirst%3DB.%26aulast%3DSundstr%25C3%25B6m%26aufirst%3DM.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26aulast%3DTaunton%26aufirst%3DJ.%26aulast%3DToledo-Sherman%26aufirst%3DL.%26aulast%3DWalpole%26aufirst%3DC.%26aulast%3DWalters%26aufirst%3DM.%2BA.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DYoung%26aufirst%3DR.%2BN.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26atitle%3DThe%2520Promise%2520and%2520Peril%2520of%2520Chemical%2520Probes%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26issue%3D8%26spage%3D536%26epage%3D541%26doi%3D10.1038%2Fnchembio.1867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naidu, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, A. H.</span></span> <span> </span><span class="NLM_article-title">Synergy between Enzyme Inhibitors of Fatty Acid Amide Hydrolase and Cyclooxygenase in Visceral Nociception</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>329</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1124/jpet.108.143487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1124%2Fjpet.108.143487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=19118134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVKntb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=329&publication_year=2009&pages=48-56&issue=1&author=P.+S.+Naiduauthor=L.+Bookerauthor=B.+F.+Cravattauthor=A.+H.+Lichtman&title=Synergy+between+Enzyme+Inhibitors+of+Fatty+Acid+Amide+Hydrolase+and+Cyclooxygenase+in+Visceral+Nociception&doi=10.1124%2Fjpet.108.143487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception</span></div><div class="casAuthors">Naidu, Pattipati S.; Booker, Lamont; Cravatt, Benjamin F.; Lichtman, Aron H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">329</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-56</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The present study investigated whether inhibition of fatty acid amide hydrolase (FAAH), the enzyme responsible for anandamide catabolism, produces antinociception in the acetic acid-induced abdominal stretching model of visceral nociception.  Genetic deletion or pharmacol. inhibition of FAAH reduced acetic acid-induced abdominal stretching.  Transgenic mice that express FAAH exclusively in the nervous system displayed the antinociceptive phenotype, indicating the involvement of peripheral fatty acid amides.  The cannabinoid receptor 1 (CB1) receptor antagonist, rimonabant, but not the cannabinoid receptor 2 (CB2) receptor antagonist, SR144528, blocked the antinociceptive phenotype of FAAH(-/-) mice and the analgesic effects of URB597 (3'-carbamoyl-biphenyl-3-yl-cyclohexylcarbamate) or OL-135 (1-oxo-1[5-(2-pyridyl)-2-yl]-7-Ph heptane), resp. irreversible and reversible FAAH inhibitors, administered to C57BL/6 mice.  The opioid receptor antagonist, naltrexone, did not block the analgesic effects of either FAAH inhibitor.  URB597, ED50 [95% confidence interval (CI) = 2.1 (1.5-2.9) mg/kg], and the non-selective cyclooxygenase inhibitor, diclofenac sodium [ED50 (95% CI) = 9.8 (8.2-11.7) mg/kg], dose-dependently inhibited acetic acid-induced abdominal stretching.  Combinations of URB597 and diclofenac yielded synergistic analgesic interactions according to isobolog. anal.  It is important that FAAH(-/-) mice and URB597-treated mice displayed significant redns. in the severity of gastric irritation caused by diclofenac.  URB597 lost its gastroprotective effects in CB1(-/-) mice, whereas it maintained its efficacy in CB2(-/-) mice, indicating a CB1 mechanism of action.  Taken together, the results of the present study suggest that FAAH represents a promising target for the treatment of visceral pain, and a combination of FAAH inhibitors and NSAIDs may have great utility to treat visceral pain, with reduced gastric toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg5twrLEI_mbVg90H21EOLACvtfcHk0lj0aCVbxbZ8bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVKntb0%253D&md5=8efa156c1a389d8510fb62af14d2cd8b</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.143487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.143487%26sid%3Dliteratum%253Aachs%26aulast%3DNaidu%26aufirst%3DP.%2BS.%26aulast%3DBooker%26aufirst%3DL.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DLichtman%26aufirst%3DA.%2BH.%26atitle%3DSynergy%2520between%2520Enzyme%2520Inhibitors%2520of%2520Fatty%2520Acid%2520Amide%2520Hydrolase%2520and%2520Cyclooxygenase%2520in%2520Visceral%2520Nociception%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D329%26issue%3D1%26spage%3D48%26epage%3D56%26doi%3D10.1124%2Fjpet.108.143487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaempf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanna, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rofelty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">English, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolosky, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swords, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollyea, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medeiros, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tognon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span> <span> </span><span class="NLM_article-title">Molecularly Targeted Drug Combinations Demonstrate Selective Effectiveness for Myeloid- and Lymphoid-Derived Hematologic Malignancies</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">E7554</span>– <span class="NLM_lpage">E7563</span>, <span class="refDoi"> DOI: 10.1073/pnas.1703094114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1073%2Fpnas.1703094114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28784769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1yku7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=E7554-E7563&issue=36&author=S.+E.+Kurtzauthor=C.+A.+Eideauthor=A.+Kaempfauthor=V.+Khannaauthor=S.+L.+Savageauthor=A.+Rofeltyauthor=I.+Englishauthor=H.+Hoauthor=R.+Pandyaauthor=W.+J.+Boloskyauthor=H.+Poonauthor=M.+W.+Deiningerauthor=R.+Collinsauthor=R.+T.+Swordsauthor=J.+Wattsauthor=D.+A.+Pollyeaauthor=B.+C.+Medeirosauthor=E.+Traerauthor=C.+E.+Tognonauthor=M.+Moriauthor=B.+J.+Drukerauthor=J.+W.+Tyner&title=Molecularly+Targeted+Drug+Combinations+Demonstrate+Selective+Effectiveness+for+Myeloid-+and+Lymphoid-Derived+Hematologic+Malignancies&doi=10.1073%2Fpnas.1703094114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies</span></div><div class="casAuthors">Kurtz, Stephen E.; Eide, Christopher A.; Kaempf, Andy; Khanna, Vishesh; Savage, Samantha L.; Rofelty, Angela; English, Isabel; Ho, Hibery; Pandya, Ravi; Bolosky, William J.; Poon, Hoifung; Deininger, Michael W.; Collins, Robert; Swords, Ronan T.; Watts, Justin; Pollyea, Daniel A.; Medeiros, Bruno C.; Traer, Elie; Tognon, Cristina E.; Mori, Motomi; Druker, Brian J.; Tyner, Jeffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">E7554-E7563</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Translating the genetic and epigenetic heterogeneity underlying human cancers into therapeutic strategies is an ongoing challenge.  Large-scale sequencing efforts have uncovered a spectrum of mutations in many hematol. malignancies, including acute myeloid leukemia (AML), suggesting that combinations of agents will be required to treat these diseases effectively.  Combinatorial approaches will also be crit. for combating the emergence of genetically heterogeneous subclones, rescue signals in the microenvironment, and tumor-intrinsic feedback pathways that all contribute to disease relapse.  To identify novel and effective drug combinations, the authors performed ex vivo sensitivity profiling of 122 primary patient samples from a variety of hematol. malignancies against a panel of 48 drug combinations.  The combinations were designed as drug pairs that target nonoverlapping biol. pathways and comprise drugs from different classes, preferably with Food and Drug Administration approval.  A combination ratio (CR) was derived for each drug pair, and CRs were evaluated with respect to diagnostic categories as well as against genetic, cytogenetic, and cellular phenotypes of specimens from the two largest disease categories: AML and chronic lymphocytic leukemia (CLL).  Nearly all tested combinations involving a BCL2 inhibitor showed addnl. benefit in patients with myeloid malignancies, whereas select combinations involving PI3K, CSF1R, or bromodomain inhibitors showed preferential benefit in lymphoid malignancies.  Expanded analyses of patients with AML and CLL revealed specific patterns of ex vivo drug combination efficacy that were assocd. with select genetic, cytogenetic, and phenotypic disease subsets, warranting further evaluation.  These findings highlight the heuristic value of an integrated functional genomic approach to the identification of novel treatment strategies for hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS5BseZMmHHrVg90H21EOLACvtfcHk0lj0aCVbxbZ8bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1yku7jI&md5=1a8ece4125f7a943cffe2066b4d9b0ed</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1703094114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1703094114%26sid%3Dliteratum%253Aachs%26aulast%3DKurtz%26aufirst%3DS.%2BE.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DKaempf%26aufirst%3DA.%26aulast%3DKhanna%26aufirst%3DV.%26aulast%3DSavage%26aufirst%3DS.%2BL.%26aulast%3DRofelty%26aufirst%3DA.%26aulast%3DEnglish%26aufirst%3DI.%26aulast%3DHo%26aufirst%3DH.%26aulast%3DPandya%26aufirst%3DR.%26aulast%3DBolosky%26aufirst%3DW.%2BJ.%26aulast%3DPoon%26aufirst%3DH.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DSwords%26aufirst%3DR.%2BT.%26aulast%3DWatts%26aufirst%3DJ.%26aulast%3DPollyea%26aufirst%3DD.%2BA.%26aulast%3DMedeiros%26aufirst%3DB.%2BC.%26aulast%3DTraer%26aufirst%3DE.%26aulast%3DTognon%26aufirst%3DC.%2BE.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26atitle%3DMolecularly%2520Targeted%2520Drug%2520Combinations%2520Demonstrate%2520Selective%2520Effectiveness%2520for%2520Myeloid-%2520and%2520Lymphoid-Derived%2520Hematologic%2520Malignancies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26issue%3D36%26spage%3DE7554%26epage%3DE7563%26doi%3D10.1073%2Fpnas.1703094114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doudna, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charpentier, E.</span></span> <span> </span><span class="NLM_article-title">Genome Editing. The New Frontier of Genome Engineering with CRISPR-Cas9</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>346</i></span> (<span class="NLM_issue">6213</span>),  <span class="NLM_fpage">1258096</span>, <span class="refDoi"> DOI: 10.1126/science.1258096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1126%2Fscience.1258096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=25430774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC2MzhsVemtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2014&pages=1258096&issue=6213&author=J.+A.+Doudnaauthor=E.+Charpentier&title=Genome+Editing.+The+New+Frontier+of+Genome+Engineering+with+CRISPR-Cas9&doi=10.1126%2Fscience.1258096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Genome editing. The new frontier of genome engineering with CRISPR-Cas9</span></div><div class="casAuthors">Doudna Jennifer A; Charpentier Emmanuelle</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">6213</span>),
    <span class="NLM_cas:pages">1258096</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The advent of facile genome engineering using the bacterial RNA-guided CRISPR-Cas9 system in animals and plants is transforming biology.  We review the history of CRISPR (clustered regularly interspaced palindromic repeat) biology from its initial discovery through the elucidation of the CRISPR-Cas9 enzyme mechanism, which has set the stage for remarkable developments using this technology to modify, regulate, or mark genomic loci in a wide variety of cells and organisms from all three domains of life.  These results highlight a new era in which genomic manipulation is no longer a bottleneck to experiments, paving the way toward fundamental discoveries in biology, with applications in all branches of biotechnology, as well as strategies for human therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRrbUZVx6ve4TAEfvC7EH1LfW6udTcc2eZiUWg9EjOEK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MzhsVemtg%253D%253D&md5=ed025d7bc203eb757d935c9bdd671650</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1126%2Fscience.1258096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1258096%26sid%3Dliteratum%253Aachs%26aulast%3DDoudna%26aufirst%3DJ.%2BA.%26aulast%3DCharpentier%26aufirst%3DE.%26atitle%3DGenome%2520Editing.%2520The%2520New%2520Frontier%2520of%2520Genome%2520Engineering%2520with%2520CRISPR-Cas9%26jtitle%3DScience%26date%3D2014%26volume%3D346%26issue%3D6213%26spage%3D1258096%26doi%3D10.1126%2Fscience.1258096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhlik, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moxham, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomandl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sall, D. J.</span></span> <span> </span><span class="NLM_article-title">Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4527</span>– <span class="NLM_lpage">4538</span>, <span class="refDoi"> DOI: 10.1021/jm201649s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201649s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1OitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4527-4538&issue=10&author=J.+A.+Leeauthor=M.+T.+Uhlikauthor=C.+M.+Moxhamauthor=D.+Tomandlauthor=D.+J.+Sall&title=Modern+Phenotypic+Drug+Discovery+Is+a+Viable%2C+Neoclassic+Pharma+Strategy&doi=10.1021%2Fjm201649s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy</span></div><div class="casAuthors">Lee, Jonathan A.; Uhlik, Mark T.; Moxham, Christopher M.; Tomandl, Dirk; Sall, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4527-4538</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pharmaceutical industry (Pharma) is currently facing unprecedented challenges.  In addn. to strategic patent expirations, the rate of drug launches has been essentially const. for 60 years with overall productivity falling since the 1970s.  Similarly, the appearance of novel targets to FDA approved drugs, a measure of industry innovation, has not dramatically improved since the 1980s.  Although Pharma productivity is a multifaceted problem, detailed analyses of comprehensive, industry-wide data indicate that late stage clin. failures are a major contributor that has been attributed to poor target validation (TV) and the lack of predictive biomarkers that translate to the clinic.  In the spirit of "reinventing innovation" Pharma needs to introspectively identify areas for improvement.  This communication considers how choices in drug screening strategies may relate to target validation issues and influence the probability of identifying novel medicines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8CcODiYYNgLVg90H21EOLACvtfcHk0liacVYYYYjRug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1OitLs%253D&md5=1937641b632e348d7566c016ca4cf51d</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Fjm201649s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201649s%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BA.%26aulast%3DUhlik%26aufirst%3DM.%2BT.%26aulast%3DMoxham%26aufirst%3DC.%2BM.%26aulast%3DTomandl%26aufirst%3DD.%26aulast%3DSall%26aufirst%3DD.%2BJ.%26atitle%3DModern%2520Phenotypic%2520Drug%2520Discovery%2520Is%2520a%2520Viable%252C%2520Neoclassic%2520Pharma%2520Strategy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D10%26spage%3D4527%26epage%3D4538%26doi%3D10.1021%2Fjm201649s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Houck, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judson, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavlock, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, E. L.</span></span> <span> </span><span class="NLM_article-title">Profiling Bioactivity of the ToxCast Chemical Library Using BioMAP Primary Human Cell Systems</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1054</span>– <span class="NLM_lpage">1066</span>, <span class="refDoi"> DOI: 10.1177/1087057109345525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1177%2F1087057109345525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=19773588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVOltr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=1054-1066&issue=9&author=K.+A.+Houckauthor=D.+J.+Dixauthor=R.+S.+Judsonauthor=R.+J.+Kavlockauthor=J.+Yangauthor=E.+L.+Berg&title=Profiling+Bioactivity+of+the+ToxCast+Chemical+Library+Using+BioMAP+Primary+Human+Cell+Systems&doi=10.1177%2F1087057109345525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems</span></div><div class="casAuthors">Houck, Keith A.; Dix, David J.; Judson, Richard S.; Kavlock, Robert J.; Yang, Jian; Berg, Ellen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1054-1066</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The complexity of human biol. has made prediction of health effects as a consequence of exposure to environmental chems. esp. challenging.  Complex cell systems, such as the Biol. Multiplexed Activity Profiling (BioMAP) primary, human, cell-based disease models, leverage cellular regulatory networks to detect and distinguish chems. with a broad range of target mechanisms and biol. processes relevant to human toxicity.  Here the authors use the BioMAP human cell systems to characterize effects relevant to human tissue and inflammatory disease biol. following exposure to the 320 environmental chems. in the Environmental Protection Agency's (EPA's) ToxCast phase I library.  The ToxCast chems. were assayed at 4 concns. in 8 BioMAP cell systems, with a total of 87 assay endpoints resulting in more than 100,000 data points.  Within the context of the BioMAP database, ToxCast compds. could be classified based on their ability to cause overt cytotoxicity in primary human cell types or according to toxicity mechanism class derived from comparisons to activity profiles of BioMAP ref. compds.  ToxCast chems. with similarity to inducers of mitochondrial dysfunction, cAMP elevators, inhibitors of tubulin function, inducers of endoplasmic reticulum stress, or NFκB pathway inhibitors were identified based on this BioMAP anal.  This data set is being combined with addnl. ToxCast data sets for development of predictive toxicity models at the EPA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1Y56HtqVn8LVg90H21EOLACvtfcHk0liacVYYYYjRug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVOltr3F&md5=473d27ca0d6356c1d646234483b82454</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1177%2F1087057109345525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057109345525%26sid%3Dliteratum%253Aachs%26aulast%3DHouck%26aufirst%3DK.%2BA.%26aulast%3DDix%26aufirst%3DD.%2BJ.%26aulast%3DJudson%26aufirst%3DR.%2BS.%26aulast%3DKavlock%26aufirst%3DR.%2BJ.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DBerg%26aufirst%3DE.%2BL.%26atitle%3DProfiling%2520Bioactivity%2520of%2520the%2520ToxCast%2520Chemical%2520Library%2520Using%2520BioMAP%2520Primary%2520Human%2520Cell%2520Systems%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2009%26volume%3D14%26issue%3D9%26spage%3D1054%26epage%3D1066%26doi%3D10.1177%2F1087057109345525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kleinstreuer, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judson, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polokoff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavlock, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houck, K. A.</span></span> <span> </span><span class="NLM_article-title">Phenotypic Screening of the ToxCast Chemical Library to Classify Toxic and Therapeutic Mechanisms</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">583</span>– <span class="NLM_lpage">591</span>, <span class="refDoi"> DOI: 10.1038/nbt.2914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnbt.2914" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=24837663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotFeqsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=583-591&issue=6&author=N.+C.+Kleinstreuerauthor=J.+Yangauthor=E.+L.+Bergauthor=T.+B.+Knudsenauthor=A.+M.+Richardauthor=M.+T.+Martinauthor=D.+M.+Reifauthor=R.+S.+Judsonauthor=M.+Polokoffauthor=D.+J.+Dixauthor=R.+J.+Kavlockauthor=K.+A.+Houck&title=Phenotypic+Screening+of+the+ToxCast+Chemical+Library+to+Classify+Toxic+and+Therapeutic+Mechanisms&doi=10.1038%2Fnbt.2914"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms</span></div><div class="casAuthors">Kleinstreuer, Nicole C.; Yang, Jian; Berg, Ellen L.; Knudsen, Thomas B.; Richard, Ann M.; Martin, Matthew T.; Reif, David M.; Judson, Richard S.; Polokoff, Mark; Dix, David J.; Kavlock, Robert J.; Houck, Keith A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">583-591</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Addressing the safety aspects of drugs and environmental chems. has historically been undertaken through animal testing.  However, the quantity of chems. in need of assessment and the challenges of species extrapolation require the development of alternative approaches.  Our approach, the US Environmental Protection Agency's ToxCast program, utilizes a large suite of in vitro and model organism assays to interrogate important chem. libraries and computationally analyze bioactivity profiles.  Here we evaluated one component of the ToxCast program, the use of primary human cell systems, by screening for chems. that disrupt physiol. important pathways.  Chem.-response signatures for 87 endpoints covering mol. functions relevant to toxic and therapeutic pathways were generated in eight cell systems for 641 environmental chems. and 135 ref. pharmaceuticals and failed drugs.  Computational clustering of the profiling data provided insights into the polypharmacol. and potential off-target effects for many chems. that have limited or no toxicity information.  The endpoints measured can be closely linked to in vivo outcomes, such as the upregulation of tissue factor in endothelial cell systems by compds. linked to the risk of thrombosis in vivo.  Our results demonstrate that assaying complex biol. pathways in primary human cells can identify potential chem. targets, toxicol. liabilities and mechanisms useful for elucidating adverse outcome pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8F6SVNipd_7Vg90H21EOLACvtfcHk0liacVYYYYjRug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotFeqsrc%253D&md5=09336f8e859668a0374d8a27ca4a0ff6</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2914%26sid%3Dliteratum%253Aachs%26aulast%3DKleinstreuer%26aufirst%3DN.%2BC.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DBerg%26aufirst%3DE.%2BL.%26aulast%3DKnudsen%26aufirst%3DT.%2BB.%26aulast%3DRichard%26aufirst%3DA.%2BM.%26aulast%3DMartin%26aufirst%3DM.%2BT.%26aulast%3DReif%26aufirst%3DD.%2BM.%26aulast%3DJudson%26aufirst%3DR.%2BS.%26aulast%3DPolokoff%26aufirst%3DM.%26aulast%3DDix%26aufirst%3DD.%2BJ.%26aulast%3DKavlock%26aufirst%3DR.%2BJ.%26aulast%3DHouck%26aufirst%3DK.%2BA.%26atitle%3DPhenotypic%2520Screening%2520of%2520the%2520ToxCast%2520Chemical%2520Library%2520to%2520Classify%2520Toxic%2520and%2520Therapeutic%2520Mechanisms%26jtitle%3DNat.%2520Biotechnol.%26date%3D2014%26volume%3D32%26issue%3D6%26spage%3D583%26epage%3D591%26doi%3D10.1038%2Fnbt.2914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamanaka, S.</span></span> <span> </span><span class="NLM_article-title">Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>126</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">663</span>– <span class="NLM_lpage">676</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2006.07.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.cell.2006.07.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=16904174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD28Xpt1aktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2006&pages=663-676&issue=4&author=K.+Takahashiauthor=S.+Yamanaka&title=Induction+of+Pluripotent+Stem+Cells+from+Mouse+Embryonic+and+Adult+Fibroblast+Cultures+by+Defined+Factors&doi=10.1016%2Fj.cell.2006.07.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors</span></div><div class="casAuthors">Takahashi, Kazutoshi; Yamanaka, Shinya</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">663-676</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Differentiated cells can be reprogrammed to an embryonic-like state by transfer of nuclear contents into oocytes or by fusion with embryonic stem (ES) cells.  Little is known about factors that induce this reprogramming.  Here, we demonstrate induction of pluripotent stem cells from mouse embryonic or adult fibroblasts by introducing four factors, Oct3/4, Sox2, c-Myc, and Klf4, under ES cell culture conditions.  Unexpectedly, Nanog was dispensable.  These cells, which we designated iPS (induced pluripotent stem) cells, exhibit the morphol. and growth properties of ES cells and express ES cell marker genes.  S.c. transplantation of iPS cells into nude mice resulted in tumors contg. a variety of tissues from all three germ layers.  Following injection into blastocysts, iPS cells contributed to mouse embryonic development.  These data demonstrate that pluripotent stem cells can be directly generated from fibroblast cultures by the addn. of only a few defined factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptUUreum_VDbVg90H21EOLACvtfcHk0lhYixpmtM_o5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xpt1aktbs%253D&md5=a681feb59ef3b7e3641e4b52cd0c4e07</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.07.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.07.024%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DYamanaka%26aufirst%3DS.%26atitle%3DInduction%2520of%2520Pluripotent%2520Stem%2520Cells%2520from%2520Mouse%2520Embryonic%2520and%2520Adult%2520Fibroblast%2520Cultures%2520by%2520Defined%2520Factors%26jtitle%3DCell%26date%3D2006%26volume%3D126%26issue%3D4%26spage%3D663%26epage%3D676%26doi%3D10.1016%2Fj.cell.2006.07.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbaric, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gokhale, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, P. W.</span></span> <span> </span><span class="NLM_article-title">High-Content Screening of Small Compounds on Human Embryonic Stem Cells</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1050</span>, <span class="refDoi"> DOI: 10.1042/BST0381046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1042%2FBST0381046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=20659001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlylsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1046-1050&issue=4&author=I.+Barbaricauthor=P.+J.+Gokhaleauthor=P.+W.+Andrews&title=High-Content+Screening+of+Small+Compounds+on+Human+Embryonic+Stem+Cells&doi=10.1042%2FBST0381046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">High-content screening of small compounds on human embryonic stem cells</span></div><div class="casAuthors">Barbaric, Ivana; Gokhale, Paul J.; Andrews, Peter W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1046-1050</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Human ES (embryonic stem) cells and iPS (induced pluripotent stem) cells have been heralded as a source of differentiated cells that could be used in the treatment of degenerative diseases, such as Parkinson's disease or diabetes.  Despite the great potential for their use in regenerative therapy, the challenge remains to understand the basic biol. of these remarkable cells, in order to differentiate them into any functional cell type.  Given the scale of the task, high-throughput screening of agents and culture conditions offers one way to accelerate these studies.  The screening of small-compd. libraries is particularly amenable to such high-throughput methods.  Coupled with high-content screening technol. that enables simultaneous assessment of multiple cellular features in an automated and quant. way, this approach is proving powerful in identifying both small mols. as tools for manipulating stem cell fates and novel mechanisms of differentiation not previously assocd. with stem cell biol.  Such screens performed on human ES cells also demonstrate the usefulness of human ES/iPS cells as cellular models for pharmacol. testing of drug efficacy and toxicity, possibly a more imminent use of these cells than in regenerative medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1NpFqP6fszLVg90H21EOLACvtfcHk0lhYixpmtM_o5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlylsLo%253D&md5=a5edb795b5ae7f3bbd992c30b75e4fc6</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1042%2FBST0381046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST0381046%26sid%3Dliteratum%253Aachs%26aulast%3DBarbaric%26aufirst%3DI.%26aulast%3DGokhale%26aufirst%3DP.%2BJ.%26aulast%3DAndrews%26aufirst%3DP.%2BW.%26atitle%3DHigh-Content%2520Screening%2520of%2520Small%2520Compounds%2520on%2520Human%2520Embryonic%2520Stem%2520Cells%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2010%26volume%3D38%26issue%3D4%26spage%3D1046%26epage%3D1050%26doi%3D10.1042%2FBST0381046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCarroll, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gendelev, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keiser, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokel, D.</span></span> <span> </span><span class="NLM_article-title">Leveraging Large-Scale Behavioral Profiling in Zebrafish to Explore Neuroactive Polypharmacology</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">842</span>– <span class="NLM_lpage">849</span>, <span class="refDoi"> DOI: 10.1021/acschembio.5b00800</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00800" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVSlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=842-849&issue=4&author=M.+N.+McCarrollauthor=L.+Gendelevauthor=M.+J.+Keiserauthor=D.+Kokel&title=Leveraging+Large-Scale+Behavioral+Profiling+in+Zebrafish+to+Explore+Neuroactive+Polypharmacology&doi=10.1021%2Facschembio.5b00800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Leveraging Large-scale Behavioral Profiling in Zebrafish to Explore Neuroactive Polypharmacology</span></div><div class="casAuthors">McCarroll, Matthew N.; Gendelev, Leo; Keiser, Michael J.; Kokel, David</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">842-849</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Many psychiatric drugs modulate the nervous system through multitarget mechanisms.  However, systematic identification of multitarget compds. has been difficult using traditional in vitro screening assays.  New approaches to phenotypic profiling in zebrafish can help researchers identify novel compds. with complex polypharmacol.  For example, large-scale behavior-based chem. screens can rapidly identify large nos. of structurally diverse and phenotype-related compds.  Once these compds. have been identified, a systems-level anal. of their structures may help to identify statistically enriched target pathways.  Together, systematic behavioral profiling and multitarget predictions may help researchers identify new behavior-modifying pathways and CNS therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3QN11t7PEEbVg90H21EOLACvtfcHk0lhYixpmtM_o5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVSlsL8%253D&md5=6d69351d9c3e6c711881947aac517e75</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00800%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarroll%26aufirst%3DM.%2BN.%26aulast%3DGendelev%26aufirst%3DL.%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DKokel%26aufirst%3DD.%26atitle%3DLeveraging%2520Large-Scale%2520Behavioral%2520Profiling%2520in%2520Zebrafish%2520to%2520Explore%2520Neuroactive%2520Polypharmacology%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26issue%3D4%26spage%3D842%26epage%3D849%26doi%3D10.1021%2Facschembio.5b00800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonoshita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scopton, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ung, P. M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silber, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Real, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cagan, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dar, A. C.</span></span> <span> </span><span class="NLM_article-title">A Whole-Animal Platform to Advance a Clinical Kinase Inhibitor into New Disease Space</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2556</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnchembio.2556" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29355849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtl2msrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=291-298&issue=3&author=M.+Sonoshitaauthor=A.+P.+Scoptonauthor=P.+M.+U.+Ungauthor=M.+A.+Murrayauthor=L.+Silberauthor=A.+Y.+Maldonadoauthor=A.+Realauthor=A.+Schlessingerauthor=R.+L.+Caganauthor=A.+C.+Dar&title=A+Whole-Animal+Platform+to+Advance+a+Clinical+Kinase+Inhibitor+into+New+Disease+Space&doi=10.1038%2Fnchembio.2556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">A whole-animal platform to advance a clinical kinase inhibitor into new disease space</span></div><div class="casAuthors">Sonoshita, Masahiro; Scopton, Alex P.; Ung, Peter M. U.; Murray, Matthew A.; Silber, Lisa; Maldonado, Andres Y.; Real, Alexander; Schlessinger, Avner; Cagan, Ross L.; Dar, Arvin C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">291-298</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Synthetic tailoring of approved drugs for new indications is often difficult, as the most appropriate targets may not be readily apparent, and therefore few roadmaps exist to guide chem.  Here, we report a multidisciplinary approach for accessing novel target and chem. space starting from an FDA-approved kinase inhibitor.  By combining chem. and genetic modifier screening with computational modeling, we identify distinct kinases that strongly enhance ('pro-targets') or limit ('anti-targets') whole-animal activity of the clin. kinase inhibitor sorafenib in a Drosophila medullary thyroid carcinoma (MTC) model.  We demonstrate that RAF-the original intended sorafenib target-and MKNK kinases function as pharmacol. liabilities because of inhibitor-induced transactivation and neg. feedback, resp.  Through progressive synthetic refinement, we report a new class of 'tumor calibrated inhibitors' with unique polypharmacol. and strongly improved therapeutic index in fly and human MTC xenograft models.  This platform provides a rational approach to creating new high-efficacy and low-toxicity drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokPGDBCxqaILVg90H21EOLACvtfcHk0lgOGQ83PiKTfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtl2msrk%253D&md5=54fd159e29ffa581e7c53983d92dd134</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2556%26sid%3Dliteratum%253Aachs%26aulast%3DSonoshita%26aufirst%3DM.%26aulast%3DScopton%26aufirst%3DA.%2BP.%26aulast%3DUng%26aufirst%3DP.%2BM.%2BU.%26aulast%3DMurray%26aufirst%3DM.%2BA.%26aulast%3DSilber%26aufirst%3DL.%26aulast%3DMaldonado%26aufirst%3DA.%2BY.%26aulast%3DReal%26aufirst%3DA.%26aulast%3DSchlessinger%26aufirst%3DA.%26aulast%3DCagan%26aufirst%3DR.%2BL.%26aulast%3DDar%26aufirst%3DA.%2BC.%26atitle%3DA%2520Whole-Animal%2520Platform%2520to%2520Advance%2520a%2520Clinical%2520Kinase%2520Inhibitor%2520into%2520New%2520Disease%2520Space%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2018%26volume%3D14%26issue%3D3%26spage%3D291%26epage%3D298%26doi%3D10.1038%2Fnchembio.2556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span> <span> </span><span class="NLM_article-title">Network Pharmacology: The next Paradigm in Drug Discovery</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">682</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1038/nchembio.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnchembio.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=18936753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=682-690&issue=11&author=A.+L.+Hopkins&title=Network+Pharmacology%3A+The+next+Paradigm+in+Drug+Discovery&doi=10.1038%2Fnchembio.118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology: the next paradigm in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">682-690</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is the concept of designing maximally selective ligands to act on individual drug targets.  However, many effective drugs act via modulation of multiple proteins rather than single targets.  Advances in systems biol. are revealing a phenotypic robustness and a network structure that strongly suggests that exquisitely selective compds., compared with multi-target drugs, may exhibit lower than desired clin. efficacy.  This new appreciation of the role of polypharmacol. has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity.  Integrating network biol. and polypharmacol. holds the promise of expanding the current opportunity space for druggable targets.  However, the rational design of polypharmacol. faces considerable challenges in the need for new methods to validate target combinations and optimize multiple structure-activity relationships while maintaining drug-like properties.  Advances in these areas are creating the foundation of the next paradigm in drug discovery: network pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqHy4FqkK-h7Vg90H21EOLACvtfcHk0lgOGQ83PiKTfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK&md5=03b8be3ddbcab7dc65afd17df7ee8395</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.118%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DNetwork%2520Pharmacology%253A%2520The%2520next%2520Paradigm%2520in%2520Drug%2520Discovery%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26issue%3D11%26spage%3D682%26epage%3D690%26doi%3D10.1038%2Fnchembio.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z.</span></span> <span> </span><span class="NLM_article-title">Advances in Computational Approaches in Identifying Synergistic Drug Combinations</span>. <i>Briefings Bioinf.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>, <span class="refDoi"> DOI: 10.1093/bib/bbx047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1093%2Fbib%2Fbbx047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=26822098" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Z.+Shengauthor=Y.+Sunauthor=Z.+Yinauthor=K.+Tangauthor=Z.+Cao&title=Advances+in+Computational+Approaches+in+Identifying+Synergistic+Drug+Combinations&doi=10.1093%2Fbib%2Fbbx047"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1093%2Fbib%2Fbbx047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbib%252Fbbx047%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DTang%26aufirst%3DK.%26aulast%3DCao%26aufirst%3DZ.%26atitle%3DAdvances%2520in%2520Computational%2520Approaches%2520in%2520Identifying%2520Synergistic%2520Drug%2520Combinations%26jtitle%3DBriefings%2520Bioinf.%26date%3D2017%26doi%3D10.1093%2Fbib%2Fbbx047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chua, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhowmick, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker-Kellogg, L.</span></span> <span> </span><span class="NLM_article-title">Synergistic Target Combination Prediction from Curated Signaling Networks: Machine Learning Meets Systems Biology and Pharmacology</span>. <i>Methods</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">60</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1016/j.ymeth.2017.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.ymeth.2017.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28552265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpsVKjur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=60-80&author=H.+E.+Chuaauthor=S.+S.+Bhowmickauthor=L.+Tucker-Kellogg&title=Synergistic+Target+Combination+Prediction+from+Curated+Signaling+Networks%3A+Machine+Learning+Meets+Systems+Biology+and+Pharmacology&doi=10.1016%2Fj.ymeth.2017.05.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic target combination prediction from curated signaling networks: Machine learning meets systems biology and pharmacology</span></div><div class="casAuthors">Chua, Huey Eng; Bhowmick, Sourav S.; Tucker-Kellogg, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Methods (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">60-80</span>CODEN:
                <span class="NLM_cas:coden">MTHDE9</span>;
        ISSN:<span class="NLM_cas:issn">1046-2023</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Given a signaling network, the target combination prediction problem aims to predict efficacious and safe target combinations for combination therapy.  State-of-the-art in silico methods use Monte Carlo simulated annealing (MCSA) to modify a candidate soln. stochastically, and use the Metropolis criterion to accept or reject the proposed modifications.  However, such stochastic modifications ignore the impact of the choice of targets and their activities on the combination's therapeutic effect and off-target effects, which directly affect the soln. quality.  In this paper, we present MASCOT, a method that addresses this limitation by leveraging two addnl. heuristic criteria to minimize off-target effects and achieve synergy for candidate modification.  Specifically, off-target effects measure the unintended response of a signaling network to the target combination and is often assocd. with toxicity.  Synergy occurs when a pair of targets exerts effects that are greater than the sum of their individual effects, and is generally a beneficial strategy for maximizing effect while minimizing toxicity. MASCOT leverages on a machine learning-based target prioritization method which prioritizes potential targets in a given disease-assocd. network to select more effective targets (better therapeutic effect and/or lower off-target effects); and on Loewe additivity theory from pharmacol. which assesses the non-additive effects in a combination drug treatment to select synergistic target activities.  Our exptl. study on two disease-related signaling networks demonstrates the superiority of MASCOT in comparison to existing approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0NdKdd4aa5rVg90H21EOLACvtfcHk0lgOGQ83PiKTfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpsVKjur0%253D&md5=aeb07b7c7c6a58e6c4e7e70418e6fdec</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.ymeth.2017.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymeth.2017.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DChua%26aufirst%3DH.%2BE.%26aulast%3DBhowmick%26aufirst%3DS.%2BS.%26aulast%3DTucker-Kellogg%26aufirst%3DL.%26atitle%3DSynergistic%2520Target%2520Combination%2520Prediction%2520from%2520Curated%2520Signaling%2520Networks%253A%2520Machine%2520Learning%2520Meets%2520Systems%2520Biology%2520and%2520Pharmacology%26jtitle%3DMethods%26date%3D2017%26volume%3D129%26spage%3D60%26epage%3D80%26doi%3D10.1016%2Fj.ymeth.2017.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Ali, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danzi, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nassif, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennerberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemmon, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bixby, J. L.</span></span> <span> </span><span class="NLM_article-title">Rational Polypharmacology: Systematically Identifying and Engaging Multiple Drug Targets To Promote Axon Growth</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1939</span>– <span class="NLM_lpage">1951</span>, <span class="refDoi"> DOI: 10.1021/acschembio.5b00289</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00289" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVShtrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1939-1951&issue=8&author=H.+Al-Aliauthor=D.-H.+Leeauthor=M.+C.+Danziauthor=H.+Nassifauthor=P.+Gautamauthor=K.+Wennerbergauthor=B.+Zuercherauthor=D.+H.+Drewryauthor=J.+K.+Leeauthor=V.+P.+Lemmonauthor=J.+L.+Bixby&title=Rational+Polypharmacology%3A+Systematically+Identifying+and+Engaging+Multiple+Drug+Targets+To+Promote+Axon+Growth&doi=10.1021%2Facschembio.5b00289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Polypharmacology: Systematically Identifying and Engaging Multiple Drug Targets To Promote Axon Growth</span></div><div class="casAuthors">Al-Ali, Hassan; Lee, Do-Hun; Danzi, Matt C.; Nassif, Houssam; Gautam, Prson; Wennerberg, Krister; Zuercher, Bill; Drewry, David H.; Lee, Jae K.; Lemmon, Vance P.; Bixby, John L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1939-1951</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mammalian central nervous system (CNS) neurons regrow their axons poorly following injury, resulting in irreversible functional losses.  Identifying therapeutics that encourage CNS axon repair has been difficult, in part because multiple etiologies underlie this regenerative failure.  This suggests a particular need for drugs that engage multiple mol. targets.  Although multitarget drugs are generally more effective than highly selective alternatives, we lack systematic methods for discovering such drugs.  Target-based screening is an efficient technique for identifying potent modulators of individual targets.  In contrast, phenotypic screening can identify drugs with multiple targets; however, these targets remain unknown.  To address this gap, we combined the two drug discovery approaches using machine learning and information theory.  We screened compds. in a phenotypic assay with primary CNS neurons and also in a panel of kinase enzyme assays.  We used learning algorithms to relate the compds.' kinase inhibition profiles to their influence on neurite outgrowth.  This allowed us to identify kinases that may serve as targets for promoting neurite outgrowth as well as others whose targeting should be avoided.  We found that compds. that inhibit multiple targets (polypharmacol.) promote robust neurite outgrowth in vitro.  One compd. with exemplary polypharmacol. was found to promote axon growth in a rodent spinal cord injury model.  A more general applicability of our approach is suggested by its ability to deconvolve known targets for a breast cancer cell line as well as targets recently shown to mediate drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp0BRepIT6uLVg90H21EOLACvtfcHk0lgCWp17XzkoMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVShtrbP&md5=5acb16e8a679f39a3b31b76449742d2a</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00289%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Ali%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DD.-H.%26aulast%3DDanzi%26aufirst%3DM.%2BC.%26aulast%3DNassif%26aufirst%3DH.%26aulast%3DGautam%26aufirst%3DP.%26aulast%3DWennerberg%26aufirst%3DK.%26aulast%3DZuercher%26aufirst%3DB.%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BK.%26aulast%3DLemmon%26aufirst%3DV.%2BP.%26aulast%3DBixby%26aufirst%3DJ.%2BL.%26atitle%3DRational%2520Polypharmacology%253A%2520Systematically%2520Identifying%2520and%2520Engaging%2520Multiple%2520Drug%2520Targets%2520To%2520Promote%2520Axon%2520Growth%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26issue%3D8%26spage%3D1939%26epage%3D1951%26doi%3D10.1021%2Facschembio.5b00289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinelli, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheikh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korkut, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crago, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, C.</span></span> <span> </span><span class="NLM_article-title">Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma Identifies CDK4 and IGF1R as Synergistic Drug Targets</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">294</span>),  <span class="NLM_fpage">ra85</span>, <span class="refDoi"> DOI: 10.1126/scisignal.2004014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1126%2Fscisignal.2004014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=24065146" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=ra85&issue=294&author=M.+L.+Millerauthor=E.+J.+Molinelliauthor=J.+S.+Nairauthor=T.+Sheikhauthor=R.+Samyauthor=X.+Jingauthor=Q.+Heauthor=A.+Korkutauthor=A.+M.+Cragoauthor=S.+Singerauthor=G.+K.+Schwartzauthor=C.+Sander&title=Drug+Synergy+Screen+and+Network+Modeling+in+Dedifferentiated+Liposarcoma+Identifies+CDK4+and+IGF1R+as+Synergistic+Drug+Targets&doi=10.1126%2Fscisignal.2004014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.2004014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.2004014%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BL.%26aulast%3DMolinelli%26aufirst%3DE.%2BJ.%26aulast%3DNair%26aufirst%3DJ.%2BS.%26aulast%3DSheikh%26aufirst%3DT.%26aulast%3DSamy%26aufirst%3DR.%26aulast%3DJing%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DQ.%26aulast%3DKorkut%26aufirst%3DA.%26aulast%3DCrago%26aufirst%3DA.%2BM.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26aulast%3DSander%26aufirst%3DC.%26atitle%3DDrug%2520Synergy%2520Screen%2520and%2520Network%2520Modeling%2520in%2520Dedifferentiated%2520Liposarcoma%2520Identifies%2520CDK4%2520and%2520IGF1R%2520as%2520Synergistic%2520Drug%2520Targets%26jtitle%3DSci.%2520Signaling%26date%3D2013%26volume%3D6%26issue%3D294%26spage%3Dra85%26doi%3D10.1126%2Fscisignal.2004014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulesskiy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saarela, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turunen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennerberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aittokallio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span> <span> </span><span class="NLM_article-title">Methods for High-Throughput Drug Combination Screening and Synergy Scoring</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>1711</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-7493-1_17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1007%2F978-1-4939-7493-1_17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29344898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFKrsLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1711&publication_year=2018&pages=351-398&author=L.+Heauthor=E.+Kulesskiyauthor=J.+Saarelaauthor=L.+Turunenauthor=K.+Wennerbergauthor=T.+Aittokallioauthor=J.+Tang&title=Methods+for+High-Throughput+Drug+Combination+Screening+and+Synergy+Scoring&doi=10.1007%2F978-1-4939-7493-1_17"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Methods for high-throughput drug combination screening and synergy scoring</span></div><div class="casAuthors">He, Liye; Kulesskiy, Evgeny; Saarela, Jani; Turunen, Laura; Wennerberg, Krister; Aittokallio, Tero; Tang, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">1711</span>
        (<span class="NLM_cas:issue">Cancer Systems Biology</span>),
    <span class="NLM_cas:pages">351-398</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Gene products or pathways that are aberrantly activated in cancer but not in normal tissue hold great promises for being effective and safe anticancer therapeutic targets.  Many targeted drugs have entered clin. trials but so far showed limited efficacy mostly due to variability in treatment responses and often rapidly emerging resistance.  Toward more effective treatment options, we will need multi-targeted drugs or drug combinations, which selectively inhibit the viability and growth of cancer cells and block distinct escape mechanisms for the cells to become resistant.  Functional profiling of drug combinations requires careful exptl. design and robust data anal. approaches.  At the Institute for Mol. Medicine Finland (FIMM), we have developed an exptl.-computational pipeline for high-throughput screening of drug combination effects in cancer cells.  The integration of automated screening techniques with advanced synergy scoring tools allows for efficient and reliable detection of synergistic drug interactions within a specific window of concns., hence accelerating the identification of potential drug combinations for further confirmatory studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfgjBJ4FdnaLVg90H21EOLACvtfcHk0lgCWp17XzkoMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFKrsLnK&md5=f1cd93a614aa72ecbe2261500e405b85</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-7493-1_17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-7493-1_17%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DL.%26aulast%3DKulesskiy%26aufirst%3DE.%26aulast%3DSaarela%26aufirst%3DJ.%26aulast%3DTurunen%26aufirst%3DL.%26aulast%3DWennerberg%26aufirst%3DK.%26aulast%3DAittokallio%26aufirst%3DT.%26aulast%3DTang%26aufirst%3DJ.%26atitle%3DMethods%2520for%2520High-Throughput%2520Drug%2520Combination%2520Screening%2520and%2520Synergy%2520Scoring%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2018%26volume%3D1711%26spage%3D351%26epage%3D398%26doi%3D10.1007%2F978-1-4939-7493-1_17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kashif, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansoori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nygren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafsson, M. G.</span></span> <span> </span><span class="NLM_article-title">Bliss and Loewe Interaction Analyses of Clinically Relevant Drug Combinations in Human Colon Cancer Cell Lines Reveal Complex Patterns of Synergy and Antagonism</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">103952</span>– <span class="NLM_lpage">103967</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.21895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.18632%2Foncotarget.21895" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=103952-103967&author=M.+Kashifauthor=C.+Anderssonauthor=S.+Mansooriauthor=R.+Larssonauthor=P.+Nygrenauthor=M.+G.+Gustafsson&title=Bliss+and+Loewe+Interaction+Analyses+of+Clinically+Relevant+Drug+Combinations+in+Human+Colon+Cancer+Cell+Lines+Reveal+Complex+Patterns+of+Synergy+and+Antagonism&doi=10.18632%2Foncotarget.21895"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.21895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.21895%26sid%3Dliteratum%253Aachs%26aulast%3DKashif%26aufirst%3DM.%26aulast%3DAndersson%26aufirst%3DC.%26aulast%3DMansoori%26aufirst%3DS.%26aulast%3DLarsson%26aufirst%3DR.%26aulast%3DNygren%26aufirst%3DP.%26aulast%3DGustafsson%26aufirst%3DM.%2BG.%26atitle%3DBliss%2520and%2520Loewe%2520Interaction%2520Analyses%2520of%2520Clinically%2520Relevant%2520Drug%2520Combinations%2520in%2520Human%2520Colon%2520Cancer%2520Cell%2520Lines%2520Reveal%2520Complex%2520Patterns%2520of%2520Synergy%2520and%2520Antagonism%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D103952%26epage%3D103967%26doi%3D10.18632%2Foncotarget.21895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wambaugh, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakya, V. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvey, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. C. S.</span></span> <span> </span><span class="NLM_article-title">High-Throughput Identification and Rational Design of Synergistic Small-Molecule Pairs for Combating and Bypassing Antibiotic Resistance</span>. <i>PLoS Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">e2001644</span>, <span class="refDoi"> DOI: 10.1371/journal.pbio.2001644</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1371%2Fjournal.pbio.2001644" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=e2001644&issue=6&author=M.+A.+Wambaughauthor=V.+P.+S.+Shakyaauthor=A.+J.+Lewisauthor=M.+A.+Mulveyauthor=J.+C.+S.+Brown&title=High-Throughput+Identification+and+Rational+Design+of+Synergistic+Small-Molecule+Pairs+for+Combating+and+Bypassing+Antibiotic+Resistance&doi=10.1371%2Fjournal.pbio.2001644"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.2001644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.2001644%26sid%3Dliteratum%253Aachs%26aulast%3DWambaugh%26aufirst%3DM.%2BA.%26aulast%3DShakya%26aufirst%3DV.%2BP.%2BS.%26aulast%3DLewis%26aufirst%3DA.%2BJ.%26aulast%3DMulvey%26aufirst%3DM.%2BA.%26aulast%3DBrown%26aufirst%3DJ.%2BC.%2BS.%26atitle%3DHigh-Throughput%2520Identification%2520and%2520Rational%2520Design%2520of%2520Synergistic%2520Small-Molecule%2520Pairs%2520for%2520Combating%2520and%2520Bypassing%2520Antibiotic%2520Resistance%26jtitle%3DPLoS%2520Biol.%26date%3D2017%26volume%3D15%26issue%3D6%26spage%3De2001644%26doi%3D10.1371%2Fjournal.pbio.2001644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mason, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashenden, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakoc, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meral, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuru, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cokol, M.</span></span> <span> </span><span class="NLM_article-title">Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3902</span>– <span class="NLM_lpage">3912</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00204</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00204" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3902-3912&issue=9&author=D.+J.+Masonauthor=I.+Stottauthor=S.+Ashendenauthor=Z.+B.+Weinsteinauthor=I.+Karakocauthor=S.+Meralauthor=N.+Kuruauthor=A.+Benderauthor=M.+Cokol&title=Prediction+of+Antibiotic+Interactions+Using+Descriptors+Derived+from+Molecular+Structure&doi=10.1021%2Facs.jmedchem.7b00204"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00204%26sid%3Dliteratum%253Aachs%26aulast%3DMason%26aufirst%3DD.%2BJ.%26aulast%3DStott%26aufirst%3DI.%26aulast%3DAshenden%26aufirst%3DS.%26aulast%3DWeinstein%26aufirst%3DZ.%2BB.%26aulast%3DKarakoc%26aufirst%3DI.%26aulast%3DMeral%26aufirst%3DS.%26aulast%3DKuru%26aufirst%3DN.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DCokol%26aufirst%3DM.%26atitle%3DPrediction%2520of%2520Antibiotic%2520Interactions%2520Using%2520Descriptors%2520Derived%2520from%2520Molecular%2520Structure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D9%26spage%3D3902%26epage%3D3912%26doi%3D10.1021%2Facs.jmedchem.7b00204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span> <span> </span><span class="NLM_article-title">Predicting Synergistic Effects between Compounds through Their Structural Similarity and Effects on Transcriptomes</span>. <i>Bioinformatics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">3782</span>– <span class="NLM_lpage">3789</span>, <span class="refDoi"> DOI: 10.1093/bioinformatics/btw509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1093%2Fbioinformatics%2Fbtw509" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2016&pages=3782-3789&issue=24&author=Y.+Liuauthor=H.+Zhao&title=Predicting+Synergistic+Effects+between+Compounds+through+Their+Structural+Similarity+and+Effects+on+Transcriptomes&doi=10.1093%2Fbioinformatics%2Fbtw509"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1093%2Fbioinformatics%2Fbtw509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbioinformatics%252Fbtw509%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DH.%26atitle%3DPredicting%2520Synergistic%2520Effects%2520between%2520Compounds%2520through%2520Their%2520Structural%2520Similarity%2520and%2520Effects%2520on%2520Transcriptomes%26jtitle%3DBioinformatics%26date%3D2016%26volume%3D32%26issue%3D24%26spage%3D3782%26epage%3D3789%26doi%3D10.1093%2Fbioinformatics%2Fbtw509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Preuer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R. P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochreiter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulusu, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klambauer, G.</span></span> <span> </span><span class="NLM_article-title">DeepSynergy: Predicting Anti-Cancer Drug Synergy with Deep Learning</span>. <i>Bioinformatics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1538</span>– <span class="NLM_lpage">1546</span>, <span class="refDoi"> DOI: 10.1093/bioinformatics/btx806</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1093%2Fbioinformatics%2Fbtx806" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29253077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC1Mzislajtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2018&pages=1538-1546&issue=9&author=K.+Preuerauthor=R.+P.+I.+Lewisauthor=S.+Hochreiterauthor=A.+Benderauthor=K.+C.+Bulusuauthor=G.+Klambauer&title=DeepSynergy%3A+Predicting+Anti-Cancer+Drug+Synergy+with+Deep+Learning&doi=10.1093%2Fbioinformatics%2Fbtx806"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">DeepSynergy: predicting anti-cancer drug synergy with Deep Learning</span></div><div class="casAuthors">Preuer Kristina; Hochreiter Sepp; Klambauer Gunter; Lewis Richard P I; Bender Andreas; Bulusu Krishna C; Bulusu Krishna C</div><div class="citationInfo"><span class="NLM_cas:title">Bioinformatics (Oxford, England)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1538-1546</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Motivation:  While drug combination therapies are a well-established concept in cancer treatment, identifying novel synergistic combinations is challenging due to the size of combinatorial space.  However, computational approaches have emerged as a time- and cost-efficient way to prioritize combinations to test, based on recently available large-scale combination screening data.  Recently, Deep Learning has had an impact in many research areas by achieving new state-of-the-art model performance.  However, Deep Learning has not yet been applied to drug synergy prediction, which is the approach we present here, termed DeepSynergy.  DeepSynergy uses chemical and genomic information as input information, a normalization strategy to account for input data heterogeneity, and conical layers to model drug synergies.  Results:  DeepSynergy was compared to other machine learning methods such as Gradient Boosting Machines, Random Forests, Support Vector Machines and Elastic Nets on the largest publicly available synergy dataset with respect to mean squared error.  DeepSynergy significantly outperformed the other methods with an improvement of 7.2% over the second best method at the prediction of novel drug combinations within the space of explored drugs and cell lines.  At this task, the mean Pearson correlation coefficient between the measured and the predicted values of DeepSynergy was 0.73.  Applying DeepSynergy for classification of these novel drug combinations resulted in a high predictive performance of an AUC of 0.90.  Furthermore, we found that all compared methods exhibit low predictive performance when extrapolating to unexplored drugs or cell lines, which we suggest is due to limitations in the size and diversity of the dataset.  We envision that DeepSynergy could be a valuable tool for selecting novel synergistic drug combinations.  Availability and implementation:  DeepSynergy is available via www.bioinf.jku.at/software/DeepSynergy.  Contact:  <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="f09b9c919d9291859582b092999f999e96de9a9b85de9184de">[email protected]</a>  Supplementary information:  Supplementary data are available at Bioinformatics online.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRXGLh7DBe7VohLSh9fo81bfW6udTcc2eZjuP7j_jdFDLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mzislajtw%253D%253D&md5=0ee7b03378f719879f22935abf033f23</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1093%2Fbioinformatics%2Fbtx806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbioinformatics%252Fbtx806%26sid%3Dliteratum%253Aachs%26aulast%3DPreuer%26aufirst%3DK.%26aulast%3DLewis%26aufirst%3DR.%2BP.%2BI.%26aulast%3DHochreiter%26aufirst%3DS.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DBulusu%26aufirst%3DK.%2BC.%26aulast%3DKlambauer%26aufirst%3DG.%26atitle%3DDeepSynergy%253A%2520Predicting%2520Anti-Cancer%2520Drug%2520Synergy%2520with%2520Deep%2520Learning%26jtitle%3DBioinformatics%26date%3D2018%26volume%3D34%26issue%3D9%26spage%3D1538%26epage%3D1546%26doi%3D10.1093%2Fbioinformatics%2Fbtx806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span> <span> </span><span class="NLM_article-title">Prediction of Synergistic Anti-Cancer Drug Combinations Based on Drug Target Network and Drug Induced Gene Expression Profiles</span>. <i>Artif. Intell. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/j.artmed.2017.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.artmed.2017.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28583437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC1cnlt1Wksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2017&pages=35-43&author=X.+Liauthor=Y.+Xuauthor=H.+Cuiauthor=T.+Huangauthor=D.+Wangauthor=B.+Lianauthor=W.+Liauthor=G.+Qinauthor=L.+Chenauthor=L.+Xie&title=Prediction+of+Synergistic+Anti-Cancer+Drug+Combinations+Based+on+Drug+Target+Network+and+Drug+Induced+Gene+Expression+Profiles&doi=10.1016%2Fj.artmed.2017.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles</span></div><div class="casAuthors">Li Xiangyi; Xu Yingjie; Cui Hui; Huang Tao; Wang Disong; Lian Baofeng; Li Wei; Qin Guangrong; Xie Lu; Chen Lanming</div><div class="citationInfo"><span class="NLM_cas:title">Artificial intelligence in medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35-43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Synergistic drug combinations are promising therapies for cancer treatment.  However, effective prediction of synergistic drug combinations is quite challenging as mechanisms of drug synergism are still unclear.  Various features such as drug response, and target networks may contribute to prediction of synergistic drug combinations.  In this study, we aimed to construct a computational model to predict synergistic drug combinations.  METHODS:  We designed drug physicochemical features and network features, including drug chemical structure similarity, target distance in protein-protein network and targeted pathway similarity.  At the same time, we designed fifteen pharmacogenomics features using drug treated gene expression profiles based on the background of cancer-related biology network.  Based on these eighteen features, we built a prediction model for Synergistic Drug combination using Random forest algorithm (SyDRa).  RESULTS:  Our model achieved a quite good performance with AUC value of 0.89 and Out-of-bag estimate error rate of 0.15 in training dataset.  Using the random anti-cancer drug combinations which have transcriptional profile data in the Connectivity Map dataset as the testing dataset, we identified 28 potentially synergistic drug combinations, three out of which had been reported to be effective drug combinations by literatures.  CONCLUSIONS:  We studied eighteen features for drug combinations and built a computational model using random forest algorithm.  The model was evaluated using an independent test dataset.  Our model provides an efficient strategy to identify potentially synergistic drug combinations for cancer and may help reduce the search space for high-throughput synergistic drug combinations screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6H7lqLOqCvfh3YQQtAhNufW6udTcc2eZjuP7j_jdFDLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnlt1Wksw%253D%253D&md5=093e100976796fd5b4d58616357005be</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.artmed.2017.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.artmed.2017.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DCui%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DLian%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DQin%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DXie%26aufirst%3DL.%26atitle%3DPrediction%2520of%2520Synergistic%2520Anti-Cancer%2520Drug%2520Combinations%2520Based%2520on%2520Drug%2520Target%2520Network%2520and%2520Drug%2520Induced%2520Gene%2520Expression%2520Profiles%26jtitle%3DArtif.%2520Intell.%2520Med.%26date%3D2017%26volume%3D83%26spage%3D35%26epage%3D43%26doi%3D10.1016%2Fj.artmed.2017.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gayvert, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aly, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosenberg, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stern, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elemento, O.</span></span> <span> </span><span class="NLM_article-title">A Computational Approach for Identifying Synergistic Drug Combinations</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">e1005308</span>, <span class="refDoi"> DOI: 10.1371/journal.pcbi.1005308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1371%2Fjournal.pcbi.1005308" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=e1005308&issue=1&author=K.+M.+Gayvertauthor=O.+Alyauthor=J.+Plattauthor=M.+W.+Bosenbergauthor=D.+F.+Sternauthor=O.+Elemento&title=A+Computational+Approach+for+Identifying+Synergistic+Drug+Combinations&doi=10.1371%2Fjournal.pcbi.1005308"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1005308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1005308%26sid%3Dliteratum%253Aachs%26aulast%3DGayvert%26aufirst%3DK.%2BM.%26aulast%3DAly%26aufirst%3DO.%26aulast%3DPlatt%26aufirst%3DJ.%26aulast%3DBosenberg%26aufirst%3DM.%2BW.%26aulast%3DStern%26aufirst%3DD.%2BF.%26aulast%3DElemento%26aufirst%3DO.%26atitle%3DA%2520Computational%2520Approach%2520for%2520Identifying%2520Synergistic%2520Drug%2520Combinations%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2017%26volume%3D13%26issue%3D1%26spage%3De1005308%26doi%3D10.1371%2Fjournal.pcbi.1005308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, G.</span></span> <span> </span><span class="NLM_article-title">NLLSS: Predicting Synergistic Drug Combinations Based on Semi-Supervised Learning</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">e1004975</span>, <span class="refDoi"> DOI: 10.1371/journal.pcbi.1004975</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1371%2Fjournal.pcbi.1004975" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=e1004975&issue=7&author=X.+Chenauthor=B.+Renauthor=M.+Chenauthor=Q.+Wangauthor=L.+Zhangauthor=G.+Yan&title=NLLSS%3A+Predicting+Synergistic+Drug+Combinations+Based+on+Semi-Supervised+Learning&doi=10.1371%2Fjournal.pcbi.1004975"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1004975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1004975%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DG.%26atitle%3DNLLSS%253A%2520Predicting%2520Synergistic%2520Drug%2520Combinations%2520Based%2520on%2520Semi-Supervised%2520Learning%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2016%26volume%3D12%26issue%3D7%26spage%3De1004975%26doi%3D10.1371%2Fjournal.pcbi.1004975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerby-Arnon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arafeh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auslander, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGarry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amzallag, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atias, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stossel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buzhor, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterfall, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannenhalli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuels, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanks, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruppin, E.</span></span> <span> </span><span class="NLM_article-title">Harnessing Synthetic Lethality to Predict the Response to Cancer Treatment</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2546</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-04647-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fs41467-018-04647-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29959327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FjsVKqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=2546&author=J.+S.+Leeauthor=A.+Dasauthor=L.+Jerby-Arnonauthor=R.+Arafehauthor=N.+Auslanderauthor=M.+Davidsonauthor=L.+McGarryauthor=D.+Jamesauthor=A.+Amzallagauthor=S.+G.+Parkauthor=K.+Chengauthor=W.+Robinsonauthor=D.+Atiasauthor=C.+Stosselauthor=E.+Buzhorauthor=G.+Steinauthor=J.+J.+Waterfallauthor=P.+S.+Meltzerauthor=T.+Golanauthor=S.+Hannenhalliauthor=E.+Gottliebauthor=C.+H.+Benesauthor=Y.+Samuelsauthor=E.+Shanksauthor=E.+Ruppin&title=Harnessing+Synthetic+Lethality+to+Predict+the+Response+to+Cancer+Treatment&doi=10.1038%2Fs41467-018-04647-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Harnessing synthetic lethality to predict the response to cancer treatment</span></div><div class="casAuthors">Lee Joo Sang; Das Avinash; Auslander Noam; Park Seung Gu; Cheng Kuoyuan; Robinson Welles; Hannenhalli Sridhar; Ruppin Eytan; Lee Joo Sang; Auslander Noam; Cheng Kuoyuan; Robinson Welles; Ruppin Eytan; Jerby-Arnon Livnat; Ruppin Eytan; Arafeh Rand; Samuels Yardena; Davidson Matthew; McGarry Lynn; James Daniel; Gottlieb Eyal; Shanks Emma; Amzallag Arnaud; Benes Cyril H; Amzallag Arnaud; Benes Cyril H; Amzallag Arnaud; Atias Dikla; Stossel Chani; Buzhor Ella; Golan Talia; Stein Gidi; Golan Talia; Ruppin Eytan; Waterfall Joshua J; Meltzer Paul S</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2546</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">While synthetic lethality (SL) holds promise in developing effective cancer therapies, SL candidates found via experimental screens often have limited translational value.  Here we present a data-driven approach, ISLE (identification of clinically relevant synthetic lethality), that mines TCGA cohort to identify the most likely clinically relevant SL interactions (cSLi) from a given candidate set of lab-screened SLi.  We first validate ISLE via a benchmark of large-scale drug response screens and by predicting drug efficacy in mouse xenograft models.  We then experimentally test a select set of predicted cSLi via new screening experiments, validating their predicted context-specific sensitivity in hypoxic vs normoxic conditions and demonstrating cSLi's utility in predicting synergistic drug combinations.  We show that cSLi can successfully predict patients' drug treatment response and provide patient stratification signatures.  ISLE thus complements existing actionable mutation-based methods for precision cancer therapy, offering an opportunity to expand its scope to the whole genome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfgXJ7_Tz1NpagfuraLLzSfW6udTcc2ebd5Yt9qfyZH7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FjsVKqtQ%253D%253D&md5=05a6a5dbfd882962d4c5f1e1db007c30</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-04647-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-04647-1%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DDas%26aufirst%3DA.%26aulast%3DJerby-Arnon%26aufirst%3DL.%26aulast%3DArafeh%26aufirst%3DR.%26aulast%3DAuslander%26aufirst%3DN.%26aulast%3DDavidson%26aufirst%3DM.%26aulast%3DMcGarry%26aufirst%3DL.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DAmzallag%26aufirst%3DA.%26aulast%3DPark%26aufirst%3DS.%2BG.%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DRobinson%26aufirst%3DW.%26aulast%3DAtias%26aufirst%3DD.%26aulast%3DStossel%26aufirst%3DC.%26aulast%3DBuzhor%26aufirst%3DE.%26aulast%3DStein%26aufirst%3DG.%26aulast%3DWaterfall%26aufirst%3DJ.%2BJ.%26aulast%3DMeltzer%26aufirst%3DP.%2BS.%26aulast%3DGolan%26aufirst%3DT.%26aulast%3DHannenhalli%26aufirst%3DS.%26aulast%3DGottlieb%26aufirst%3DE.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DSamuels%26aufirst%3DY.%26aulast%3DShanks%26aufirst%3DE.%26aulast%3DRuppin%26aufirst%3DE.%26atitle%3DHarnessing%2520Synthetic%2520Lethality%2520to%2520Predict%2520the%2520Response%2520to%2520Cancer%2520Treatment%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D2546%26doi%3D10.1038%2Fs41467-018-04647-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cava, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castiglioni, I.</span></span> <span> </span><span class="NLM_article-title">In Silico Identification of Drug Target Pathways in Breast Cancer Subtypes Using Pathway Cross-Talk Inhibition</span>. <i>J. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">154</span>, <span class="refDoi"> DOI: 10.1186/s12967-018-1535-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1186%2Fs12967-018-1535-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29871693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC1Mbkt1Gguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=154&author=C.+Cavaauthor=G.+Bertoliauthor=I.+Castiglioni&title=In+Silico+Identification+of+Drug+Target+Pathways+in+Breast+Cancer+Subtypes+Using+Pathway+Cross-Talk+Inhibition&doi=10.1186%2Fs12967-018-1535-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">In silico identification of drug target pathways in breast cancer subtypes using pathway cross-talk inhibition</span></div><div class="casAuthors">Cava Claudia; Bertoli Gloria; Castiglioni Isabella</div><div class="citationInfo"><span class="NLM_cas:title">Journal of translational medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">154</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Despite great development in genome and proteome high-throughput methods, treatment failure is a critical point in the management of most solid cancers, including breast cancer (BC).  Multiple alternative mechanisms upon drug treatment are involved to offset therapeutic effects, eventually causing drug resistance or treatment failure.  METHODS:  Here, we optimized a computational method to discover novel drug target pathways in cancer subtypes using pathway cross-talk inhibition (PCI).  The in silico method is based on the detection and quantification of the pathway cross-talk for distinct cancer subtypes.  From a BC data set of The Cancer Genome Atlas, we have identified different networks of cross-talking pathways for different BC subtypes, validated using an independent BC dataset from Gene Expression Omnibus.  Then, we predicted in silico the effects of new or approved drugs on different BC subtypes by silencing individual or combined subtype-derived pathways with the aim to find new potential drugs or more effective synergistic combinations of drugs.  RESULTS:  Overall, we identified a set of new potential drug target pathways for distinct BC subtypes on which therapeutic agents could synergically act showing antitumour effects and impacting on cross-talk inhibition.  CONCLUSIONS:  We believe that in silico methods based on PCI could offer valuable approaches to identifying more tailored and effective treatments in particular in heterogeneous cancer diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQSqcxLTfVhn7t7lRqEFUJVfW6udTcc2ebd5Yt9qfyZH7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mbkt1Gguw%253D%253D&md5=ec52e2c82ddc83df8fb1b6c377564176</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1186%2Fs12967-018-1535-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12967-018-1535-2%26sid%3Dliteratum%253Aachs%26aulast%3DCava%26aufirst%3DC.%26aulast%3DBertoli%26aufirst%3DG.%26aulast%3DCastiglioni%26aufirst%3DI.%26atitle%3DIn%2520Silico%2520Identification%2520of%2520Drug%2520Target%2520Pathways%2520in%2520Breast%2520Cancer%2520Subtypes%2520Using%2520Pathway%2520Cross-Talk%2520Inhibition%26jtitle%3DJ.%2520Transl.%2520Med.%26date%3D2018%26volume%3D16%26spage%3D154%26doi%3D10.1186%2Fs12967-018-1535-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaushik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robillard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barthelet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandyopadhyay, S.</span></span> <span> </span><span class="NLM_article-title">A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">918</span>– <span class="NLM_lpage">929</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2018.03.093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.celrep.2018.03.093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29669295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnvFegtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=918-929&issue=3&author=H.-M.+Huauthor=X.+Zhaoauthor=S.+Kaushikauthor=L.+Robillardauthor=A.+Bartheletauthor=K.+K.+Linauthor=K.+N.+Shahauthor=A.+D.+Simmonsauthor=M.+Raponiauthor=T.+C.+Hardingauthor=S.+Bandyopadhyay&title=A+Quantitative+Chemotherapy+Genetic+Interaction+Map+Reveals+Factors+Associated+with+PARP+Inhibitor+Resistance&doi=10.1016%2Fj.celrep.2018.03.093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance</span></div><div class="casAuthors">Hu, Hsien-Ming; Zhao, Xin; Kaushik, Swati; Robillard, Lilliane; Barthelet, Antoine; Lin, Kevin K.; Shah, Khyati N.; Simmons, Andy D.; Raponi, Mitch; Harding, Thomas C.; Bandyopadhyay, Sourav</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">918-929</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Chemotherapy is used to treat most cancer patients, yet our understanding of factors that dictate response and resistance to such drugs remains limited.  We report the generation of a quant. chem.-genetic interaction map in human mammary epithelial cells charting the impact of the knockdown of 625 genes related to cancer and DNA repair on sensitivity to 29 drugs, covering all classes of chemotherapy.  This quant. map is predictive of interactions maintained in other cell lines, identifies DNA-repair factors, predicts cancer cell line responses to therapy, and prioritizes synergistic drug combinations.  We identify that ARID1A loss confers resistance to PARP inhibitors in cells and ovarian cancer patients and that loss of GPBP1 causes resistance to cisplatin and PARP inhibitors through the regulation of genes involved in homologous recombination.  This map helps navigate patient genomic data and optimize chemotherapeutic regimens by delineating factors involved in the response to specific types of DNA damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1CE_IqnfDF7Vg90H21EOLACvtfcHk0li3ybSP7MXmjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnvFegtbY%253D&md5=b920d06e7f251411140d5a1a56c68c01</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2018.03.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2018.03.093%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DH.-M.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DKaushik%26aufirst%3DS.%26aulast%3DRobillard%26aufirst%3DL.%26aulast%3DBarthelet%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DK.%2BK.%26aulast%3DShah%26aufirst%3DK.%2BN.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DBandyopadhyay%26aufirst%3DS.%26atitle%3DA%2520Quantitative%2520Chemotherapy%2520Genetic%2520Interaction%2520Map%2520Reveals%2520Factors%2520Associated%2520with%2520PARP%2520Inhibitor%2520Resistance%26jtitle%3DCell%2520Rep.%26date%3D2018%26volume%3D23%26issue%3D3%26spage%3D918%26epage%3D929%26doi%3D10.1016%2Fj.celrep.2018.03.093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Predicting Drug Combination Index and Simulating the Network-Regulation Dynamics by Mathematical Modeling of Drug-Targeted EGFR-ERK Signaling Pathway</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">40752</span>, <span class="refDoi"> DOI: 10.1038/srep40752</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fsrep40752" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28102344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVamtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=40752&author=L.+Huangauthor=Y.+Jiangauthor=Y.+Chen&title=Predicting+Drug+Combination+Index+and+Simulating+the+Network-Regulation+Dynamics+by+Mathematical+Modeling+of+Drug-Targeted+EGFR-ERK+Signaling+Pathway&doi=10.1038%2Fsrep40752"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting Drug Combination Index and Simulating the Network-Regulation Dynamics by Mathematical Modeling of Drug-Targeted EGFR-ERK Signaling Pathway</span></div><div class="casAuthors">Huang, Lu; Jiang, Yuyang; Chen, Yuzong</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40752</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Synergistic drug combinations enable enhanced therapeutics.  Their discovery typically involves the measurement and assessment of drug combination index (CI), which can be facilitated by the development and applications of in-silico CI predictive tools.  In this work, we developed and tested the ability of a math. model of drug-targeted EGFR-ERK pathway in predicting CIs and in analyzing multiple synergistic drug combinations against observations.  Our math. model was validated against the literature reported signaling, drug response dynamics, and EGFR-MEK drug combination effect.  The predicted CIs and combination therapeutic effects of the EGFR-BRaf, BRaf-MEK, FTI-MEK, and FTI-BRaf inhibitor combinations showed consistent synergism.  Our results suggest that existing pathway models may be potentially extended for developing drug-targeted pathway models to predict drug combination CI values, isobolograms, and drug-response surfaces as well as to analyze the dynamics of individual and combinations of drugs.  With our model, the efficacy of potential drug combinations can be predicted.  Our method complements the developed in-silico methods (e.g. the chemogenomic profile and the statistically-inferenced network models) by predicting drug combination effects from the perspectives of pathway dynamics using exptl. or validated mol. kinetic consts., thereby facilitating the collective prediction of drug combination effects in diverse ranges of disease systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgLnzX2o0XaLVg90H21EOLACvtfcHk0lgkknA8EGW2PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVamtb0%253D&md5=fa97d8382b872562b83c69ef917c92c3</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1038%2Fsrep40752&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep40752%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DPredicting%2520Drug%2520Combination%2520Index%2520and%2520Simulating%2520the%2520Network-Regulation%2520Dynamics%2520by%2520Mathematical%2520Modeling%2520of%2520Drug-Targeted%2520EGFR-ERK%2520Signaling%2520Pathway%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D40752%26doi%3D10.1038%2Fsrep40752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jaeger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igea, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arroyo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcalde, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canovas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orozco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebreda, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aloy, P.</span></span> <span> </span><span class="NLM_article-title">Quantification of Pathway Cross-Talk Reveals Novel Synergistic Drug Combinations for Breast Cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-16-0097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1158%2F0008-5472.CAN-16-0097" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=459-469&issue=2&author=S.+Jaegerauthor=A.+Igeaauthor=R.+Arroyoauthor=V.+Alcaldeauthor=B.+Canovasauthor=M.+Orozcoauthor=A.+R.+Nebredaauthor=P.+Aloy&title=Quantification+of+Pathway+Cross-Talk+Reveals+Novel+Synergistic+Drug+Combinations+for+Breast+Cancer&doi=10.1158%2F0008-5472.CAN-16-0097"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-16-0097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-16-0097%26sid%3Dliteratum%253Aachs%26aulast%3DJaeger%26aufirst%3DS.%26aulast%3DIgea%26aufirst%3DA.%26aulast%3DArroyo%26aufirst%3DR.%26aulast%3DAlcalde%26aufirst%3DV.%26aulast%3DCanovas%26aufirst%3DB.%26aulast%3DOrozco%26aufirst%3DM.%26aulast%3DNebreda%26aufirst%3DA.%2BR.%26aulast%3DAloy%26aufirst%3DP.%26atitle%3DQuantification%2520of%2520Pathway%2520Cross-Talk%2520Reveals%2520Novel%2520Synergistic%2520Drug%2520Combinations%2520for%2520Breast%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D2%26spage%3D459%26epage%3D469%26doi%3D10.1158%2F0008-5472.CAN-16-0097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pei, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titus, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobanoglu, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousavi, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shun, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fioravanti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlisle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedlander, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahar, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lezon, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stern, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schurdak, M. E.</span></span> <span> </span><span class="NLM_article-title">Connecting Neuronal Cell Protective Pathways and Drug Combinations in a Huntington’s Disease Model through the Application of Quantitative Systems Pharmacology</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">17803</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-17378-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fs41598-017-17378-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29259176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC1Mzjtlaruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=17803&author=F.+Peiauthor=H.+Liauthor=M.+J.+Hendersonauthor=S.+A.+Titusauthor=A.+Jadhavauthor=A.+Simeonovauthor=M.+C.+Cobanogluauthor=S.+H.+Mousaviauthor=T.+Shunauthor=L.+McDermottauthor=P.+Iyerauthor=M.+Fioravantiauthor=D.+Carlisleauthor=R.+M.+Friedlanderauthor=I.+Baharauthor=D.+L.+Taylorauthor=T.+R.+Lezonauthor=A.+M.+Sternauthor=M.+E.+Schurdak&title=Connecting+Neuronal+Cell+Protective+Pathways+and+Drug+Combinations+in+a+Huntington%E2%80%99s+Disease+Model+through+the+Application+of+Quantitative+Systems+Pharmacology&doi=10.1038%2Fs41598-017-17378-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Connecting Neuronal Cell Protective Pathways and Drug Combinations in a Huntington's Disease Model through the Application of Quantitative Systems Pharmacology</span></div><div class="casAuthors">Pei Fen; Li Hongchun; Cobanoglu Murat Can; Bahar Ivet; Taylor D Lansing; Lezon Timothy R; Stern Andrew M; Schurdak Mark E; Henderson Mark J; Titus Steven A; Jadhav Ajit; Simeonov Anton; Mousavi Seyed H; Carlisle Diane; Friedlander Robert M; Shun Tongying; Bahar Ivet; Taylor D Lansing; Lezon Timothy R; Stern Andrew M; Schurdak Mark E; McDermott Lee; Iyer Prema; Fioravanti Michael; Friedlander Robert M; Taylor D Lansing</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17803</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Quantitative Systems Pharmacology (QSP) is a drug discovery approach that integrates computational and experimental methods in an iterative way to gain a comprehensive, unbiased understanding of disease processes to inform effective therapeutic strategies.  We report the implementation of QSP to Huntington's Disease, with the application of a chemogenomics platform to identify strategies to protect neuronal cells from mutant huntingtin induced death.  Using the STHdh (Q111) cell model, we investigated the protective effects of small molecule probes having diverse canonical modes-of-action to infer pathways of neuronal cell protection connected to drug mechanism.  Several mechanistically diverse protective probes were identified, most of which showed less than 50% efficacy.  Specific combinations of these probes were synergistic in enhancing efficacy.  Computational analysis of these probes revealed a convergence of pathways indicating activation of PKA.  Analysis of phospho-PKA levels showed lower cytoplasmic levels in STHdh (Q111) cells compared to wild type STHdh (Q7) cells, and these levels were increased by several of the protective compounds.  Pharmacological inhibition of PKA activity reduced protection supporting the hypothesis that protection may be working, in part, through activation of the PKA network.  The systems-level studies described here can be broadly applied to any discovery strategy involving small molecule modulation of disease phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTdeIFfZgL8lmmbXvSEQle5fW6udTcc2eZphOXhpW-TFLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mzjtlaruw%253D%253D&md5=cdbe288a8900ce2cca6ee314f4ed81a1</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-17378-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-17378-y%26sid%3Dliteratum%253Aachs%26aulast%3DPei%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DHenderson%26aufirst%3DM.%2BJ.%26aulast%3DTitus%26aufirst%3DS.%2BA.%26aulast%3DJadhav%26aufirst%3DA.%26aulast%3DSimeonov%26aufirst%3DA.%26aulast%3DCobanoglu%26aufirst%3DM.%2BC.%26aulast%3DMousavi%26aufirst%3DS.%2BH.%26aulast%3DShun%26aufirst%3DT.%26aulast%3DMcDermott%26aufirst%3DL.%26aulast%3DIyer%26aufirst%3DP.%26aulast%3DFioravanti%26aufirst%3DM.%26aulast%3DCarlisle%26aufirst%3DD.%26aulast%3DFriedlander%26aufirst%3DR.%2BM.%26aulast%3DBahar%26aufirst%3DI.%26aulast%3DTaylor%26aufirst%3DD.%2BL.%26aulast%3DLezon%26aufirst%3DT.%2BR.%26aulast%3DStern%26aufirst%3DA.%2BM.%26aulast%3DSchurdak%26aufirst%3DM.%2BE.%26atitle%3DConnecting%2520Neuronal%2520Cell%2520Protective%2520Pathways%2520and%2520Drug%2520Combinations%2520in%2520a%2520Huntington%25E2%2580%2599s%2520Disease%2520Model%2520through%2520the%2520Application%2520of%2520Quantitative%2520Systems%2520Pharmacology%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D17803%26doi%3D10.1038%2Fs41598-017-17378-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barthorpe, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lightfoot, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, U.</span></span> <span> </span><span class="NLM_article-title">High-Throughput RNAi Screen for Essential Genes and Drug Synergistic Combinations in Colorectal Cancer</span>. <i>Sci. Data</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">170139</span>, <span class="refDoi"> DOI: 10.1038/sdata.2017.139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fsdata.2017.139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28972570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsF2hu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2017&pages=170139&author=S.+P.+Williamsauthor=A.+S.+Barthorpeauthor=H.+Lightfootauthor=M.+J.+Garnettauthor=U.+McDermott&title=High-Throughput+RNAi+Screen+for+Essential+Genes+and+Drug+Synergistic+Combinations+in+Colorectal+Cancer&doi=10.1038%2Fsdata.2017.139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput RNAi screen for essential genes and drug synergistic combinations in colorectal cancer</span></div><div class="casAuthors">Williams, Steven P.; Barthorpe, Andrew S.; Lightfoot, Howard; Garnett, Mathew J.; McDermott, Ultan</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Data</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">170139</span>CODEN:
                <span class="NLM_cas:coden">SDCABS</span>;
        ISSN:<span class="NLM_cas:issn">2052-4463</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Metastatic colorectal cancer is a leading cause of cancer death.  However, current therapy options are limited to chemotherapy, with the addn. of anti-EGFR antibodies for patients with RAS wild-type tumors.  Novel drug targets, or drug combinations that induce a synergistic response, would be of great benefit to patients.  The identification of genes that are essential for cell survival can be undertaken using functional genomics screens.  Furthermore, performing such screens in the presence of a targeted agent would allow the identification of combinations that result in a synthetic lethal interaction.  Here, we present a dataset contg. the results of a large scale RNAi screen (815 genes) to detect essential genes as well as synergistic combinations with targeted therapeutic agents using a panel of 27 colorectal cancer cell lines.  These data identify genes that are essential for colorectal cancer cell survival as well as synthetic lethal treatment combinations using novel computational approaches.  Moreover, this dataset could be utilized in combination with genomic profiling to identify predictive biomarkers of response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmsoqrQFmfcbVg90H21EOLACvtfcHk0lgkknA8EGW2PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsF2hu7jI&md5=262c9e934f2722bcd2d5ee3095a5292c</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fsdata.2017.139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsdata.2017.139%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DS.%2BP.%26aulast%3DBarthorpe%26aufirst%3DA.%2BS.%26aulast%3DLightfoot%26aufirst%3DH.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DMcDermott%26aufirst%3DU.%26atitle%3DHigh-Throughput%2520RNAi%2520Screen%2520for%2520Essential%2520Genes%2520and%2520Drug%2520Synergistic%2520Combinations%2520in%2520Colorectal%2520Cancer%26jtitle%3DSci.%2520Data%26date%3D2017%26volume%3D4%26spage%3D170139%26doi%3D10.1038%2Fsdata.2017.139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span> <span> </span><span class="NLM_article-title">Dynamic Simulations on the Arachidonic Acid Metabolic Network</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">e55</span>, <span class="refDoi"> DOI: 10.1371/journal.pcbi.0030055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1371%2Fjournal.pcbi.0030055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=e55&issue=3&author=K.+Yangauthor=W.+Maauthor=H.+Liangauthor=Q.+Ouyangauthor=C.+Tangauthor=L.+Lai&title=Dynamic+Simulations+on+the+Arachidonic+Acid+Metabolic+Network&doi=10.1371%2Fjournal.pcbi.0030055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.0030055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.0030055%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DLiang%26aufirst%3DH.%26aulast%3DOuyang%26aufirst%3DQ.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DDynamic%2520Simulations%2520on%2520the%2520Arachidonic%2520Acid%2520Metabolic%2520Network%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2007%26volume%3D3%26issue%3D3%26spage%3De55%26doi%3D10.1371%2Fjournal.pcbi.0030055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span> <span> </span><span class="NLM_article-title">Dynamic Eicosanoid Responses upon Different Inhibitor and Combination Treatments on the Arachidonic Acid Metabolic Network</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1585</span>– <span class="NLM_lpage">1594</span>, <span class="refDoi"> DOI: 10.1039/c2mb05503a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1039%2Fc2mb05503a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=22446875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38XltFKntLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=1585-1594&issue=5&author=C.+Heauthor=Y.+Wuauthor=Y.+Laiauthor=Z.+Caiauthor=Y.+Liuauthor=L.+Lai&title=Dynamic+Eicosanoid+Responses+upon+Different+Inhibitor+and+Combination+Treatments+on+the+Arachidonic+Acid+Metabolic+Network&doi=10.1039%2Fc2mb05503a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Dynamic eicosanoid responses upon different inhibitor and combination treatments on the arachidonic acid metabolic network</span></div><div class="casAuthors">He, Chong; Wu, Yiran; Lai, Yongquan; Cai, Zongwei; Liu, Ying; Lai, Luhua</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1585-1594</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-2051</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The arachidonic acid (AA) metabolic network produces key inflammatory mediators which have been considered as hallmark contributors in various inflammatory related diseases.  Enzymes in this network, such as 5-lipoxygenase (5-LOX), cyclooxygenase (COX), leukotriene A4 hydrolase (LTA4H) and prostaglandin E synthase (PGES), have been used as targets for anti-inflammatory drug discovery.  Multi-target drugs and drug combinations have also been developed for this network.  However, how the inhibitors alter the dynamics of metabolite prodn. and which combinatorial target intervention solns. are better needs further exploration.  We did a system based intervention anal. on the AA metabolic network.  Using an LC-MS/MS method, we quant. studied the eicosanoid metabolites responses of AA metabolic network during stimulation of Sprague Dawley rat blood samples with the calcium ionophore.  Our results indicate that inhibiting the upstream rather than the downstream target of 5-LOX pathway will simultaneously alter the AA metab. to the COX pathway (and vice versa).  Therefore, single-target inhibitors cannot control all the inflammatory mediators at the same time.  We also suggest that in the case of multiple-target anti-inflammatory solns., the combination of inhibitors of the downstream enzymes may have stronger inhibition efficiency and cause less side-effects compared to the other solns.  One therapeutic strategy, LTA4H/COX inhibition soln., was found promising for the intervention of inflammatory mediator biosynthesis and at the same time stimulating the prodn. of anti-inflammatory agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGkE3Yt-wJU7Vg90H21EOLACvtfcHk0lg6bnGA-yeqkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltFKntLc%253D&md5=958dfa73394a65b501d2c884ed1aef79</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1039%2Fc2mb05503a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2mb05503a%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DDynamic%2520Eicosanoid%2520Responses%2520upon%2520Different%2520Inhibitor%2520and%2520Combination%2520Treatments%2520on%2520the%2520Arachidonic%2520Acid%2520Metabolic%2520Network%26jtitle%3DMol.%2520BioSyst.%26date%3D2012%26volume%3D8%26issue%3D5%26spage%3D1585%26epage%3D1594%26doi%3D10.1039%2Fc2mb05503a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, P. J.</span></span> <span> </span><span class="NLM_article-title">Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">1–3</span>),  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(96)00423-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2FS0169-409X%2896%2900423-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=3-25&issue=1%E2%80%933&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+Computational+Approaches+to+Estimate+Solubility+and+Permeability+in+Drug+Discovery+and+Development+Settings&doi=10.1016%2FS0169-409X%2896%2900423-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is >500 and the calcd. Log P (CLogP) is >5.  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon9gEeZ7cboLVg90H21EOLACvtfcHk0lg6bnGA-yeqkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D&md5=405f70b0594d428f1275e1d56642cd3a</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900423-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900423-1%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520Computational%2520Approaches%2520to%2520Estimate%2520Solubility%2520and%2520Permeability%2520in%2520Drug%2520Discovery%2520and%2520Development%2520Settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D23%26issue%3D1%25E2%2580%25933%26spage%3D3%26epage%3D25%26doi%3D10.1016%2FS0169-409X%2896%2900423-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W. W.</span></span> <span> </span><span class="NLM_article-title">A History of Antipsychotic Drug Development</span>. <i>Compr. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">414</span>, <span class="refDoi"> DOI: 10.1016/S0010-440X(99)90082-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2FS0010-440X%2899%2990082-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10579370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BD3c%252Fktl2ksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1999&pages=407-414&issue=6&author=W.+W.+Shen&title=A+History+of+Antipsychotic+Drug+Development&doi=10.1016%2FS0010-440X%2899%2990082-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">A history of antipsychotic drug development</span></div><div class="casAuthors">Shen W W</div><div class="citationInfo"><span class="NLM_cas:title">Comprehensive psychiatry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">407-14</span>
        ISSN:<span class="NLM_cas:issn">0010-440X</span>.
    </div><div class="casAbstract">The history of antipsychotic drug development has had a long and torturous course, often based on chance findings that bear little relationship to the intellectual background driving observations.  In 1891, Paul Ehrlich observed the antimalarial effects of methylene blue, a phenothiazine derivative.  Later, the phenothiazines were developed for their antihistaminergic properties.  In 1951, Laborit and Huguenard administered the aliphatic phenothiazine, chlorpromazine, to patients for its potential anesthetic effects during surgery.  Shortly thereafter, Hamon et al. and Delay et al. extended the use of this treatment in psychiatric patients and serendipitously uncovered its antipsychotic activity.  Between 1954 and 1975, about 15 antipsychotic drugs were introduced in the United States and about 40 throughout the world.  Thereafter, there was a hiatus in the development of antipsychotics until the introduction of clozapine treatment in the United States in 1990 opened the era of "atypical" antipsychotic drugs, which show a reduced potential to induce extrapyramidal symptoms (EPS), an increased efficacy for the negative symptoms of schizophrenia, no elevation of prolactin after chronic use (except risperidone), and, at least for clozapine, effectiveness in some patients previously regarded as treatment-refractory.  This review describes the available atypical antipsychotic drugs and their characteristics, and concludes by highlighting those in the pharmaceutical "pipeline."</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTfq-A7dxNj3D69zv1FsJFMfW6udTcc2ebuhztNwFUGWLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c%252Fktl2ksw%253D%253D&md5=6e5146aabdc053671288d4f1e4a0e968</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2FS0010-440X%2899%2990082-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0010-440X%252899%252990082-2%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DW.%2BW.%26atitle%3DA%2520History%2520of%2520Antipsychotic%2520Drug%2520Development%26jtitle%3DCompr.%2520Psychiatry%26date%3D1999%26volume%3D40%26issue%3D6%26spage%3D407%26epage%3D414%26doi%3D10.1016%2FS0010-440X%2899%2990082-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandraiah, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramaniam, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tancer, M.</span></span> <span> </span><span class="NLM_article-title">The Story of Antipsychotics: Past and Present</span>. <i>Indian J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.4103/0019-5545.58304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.4103%2F0019-5545.58304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=20048463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252FgsFKjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2009&pages=324-326&issue=4&author=C.+T.+Ramachandraiahauthor=N.+Subramaniamauthor=M.+Tancer&title=The+Story+of+Antipsychotics%3A+Past+and+Present&doi=10.4103%2F0019-5545.58304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">The story of antipsychotics: Past and present</span></div><div class="casAuthors">Ramachandraiah Chaitra T; Subramaniam Narayana; Tancer Manuel</div><div class="citationInfo"><span class="NLM_cas:title">Indian journal of psychiatry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">324-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQNjpw-2FH1bp0d-O_J5C0AfW6udTcc2ebuhztNwFUGWLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252FgsFKjug%253D%253D&md5=4f9545ed29d3cac2a35c5a3f91d44d75</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.4103%2F0019-5545.58304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0019-5545.58304%26sid%3Dliteratum%253Aachs%26aulast%3DRamachandraiah%26aufirst%3DC.%2BT.%26aulast%3DSubramaniam%26aufirst%3DN.%26aulast%3DTancer%26aufirst%3DM.%26atitle%3DThe%2520Story%2520of%2520Antipsychotics%253A%2520Past%2520and%2520Present%26jtitle%3DIndian%2520J.%2520Psychiatry%26date%3D2009%26volume%3D51%26issue%3D4%26spage%3D324%26epage%3D326%26doi%3D10.4103%2F0019-5545.58304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pistollato, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderón Iglesias, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzul Lopez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giampieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battino, M.</span></span> <span> </span><span class="NLM_article-title">The Use of Natural Compounds for the Targeting and Chemoprevention of Ovarian Cancer</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>411</i></span>,  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">200</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2017.09.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.canlet.2017.09.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29017913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1CmsLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=411&publication_year=2017&pages=191-200&author=F.+Pistollatoauthor=R.+Calder%C3%B3n+Iglesiasauthor=R.+Ruizauthor=S.+Aparicioauthor=J.+Crespoauthor=L.+Dzul+Lopezauthor=F.+Giampieriauthor=M.+Battino&title=The+Use+of+Natural+Compounds+for+the+Targeting+and+Chemoprevention+of+Ovarian+Cancer&doi=10.1016%2Fj.canlet.2017.09.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">The use of natural compounds for the targeting and chemoprevention of ovarian cancer</span></div><div class="casAuthors">Pistollato, Francesca; Calderon Iglesias, Ruben; Ruiz, Roberto; Aparicio, Silvia; Crespo, Jorge; Dzul Lopez, Luis; Giampieri, Francesca; Battino, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">411</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">191-200</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Among gynaecol. cancers, ovarian cancer represents the leading cause of death in women.  Current treatment for ovarian cancer entails surgery followed by combined chemotherapy with platinum and taxane, which are assocd., particularly cisplatin, with severe side effects.  While this treatment approach appears to be initially effective in a high no. of patients, nearly 70% of them suffer a relapse within a few months after initial treatment.  Therefore, more effective and better-tolerated treatment options are clearly needed.  In recent years, several natural compds. (such as curcumin, epigallocatechin 3-gallate (EGCG), resveratrol, sulforaphane and Withaferin-A), characterized by long-term safety and negligible and/or inexistent side effects, have been proposed as possible adjuvants of traditional chemotherapy.  Indeed, several in vitro and in vivo studies have shown that phytocompounds can effectively inhibit tumor cell proliferation, stimulate autophagy, induce apoptosis, and specifically target ovarian cancer stem cells (CSCs), which are generally considered to be responsible for tumor recurrence in several types of cancer.  Here we review current literature on the role of natural products in ovarian cancer chemoprevention, highlighting their effects particularly on the regulation of inflammation, autophagy, proliferation and apoptosis, chemotherapy resistance, and ovarian CSC growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq74PlqHyitSrVg90H21EOLACvtfcHk0lgE9FC1Jbj9Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1CmsLzK&md5=7faae26a299516cc1c852b68e38fa74e</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2017.09.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2017.09.050%26sid%3Dliteratum%253Aachs%26aulast%3DPistollato%26aufirst%3DF.%26aulast%3DCalder%25C3%25B3n%2BIglesias%26aufirst%3DR.%26aulast%3DRuiz%26aufirst%3DR.%26aulast%3DAparicio%26aufirst%3DS.%26aulast%3DCrespo%26aufirst%3DJ.%26aulast%3DDzul%2BLopez%26aufirst%3DL.%26aulast%3DGiampieri%26aufirst%3DF.%26aulast%3DBattino%26aufirst%3DM.%26atitle%3DThe%2520Use%2520of%2520Natural%2520Compounds%2520for%2520the%2520Targeting%2520and%2520Chemoprevention%2520of%2520Ovarian%2520Cancer%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D411%26spage%3D191%26epage%3D200%26doi%3D10.1016%2Fj.canlet.2017.09.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rejhová, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opattová, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Čumová, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slíva, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vodička, P.</span></span> <span> </span><span class="NLM_article-title">Natural Compounds and Combination Therapy in Colorectal Cancer Treatment</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">582</span>– <span class="NLM_lpage">594</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.12.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.ejmech.2017.12.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29289883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ymtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2018&pages=582-594&author=A.+Rejhov%C3%A1author=A.+Opattov%C3%A1author=A.+%C4%8Cumov%C3%A1author=D.+Sl%C3%ADvaauthor=P.+Vodi%C4%8Dka&title=Natural+Compounds+and+Combination+Therapy+in+Colorectal+Cancer+Treatment&doi=10.1016%2Fj.ejmech.2017.12.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Natural compounds and combination therapy in colorectal cancer treatment</span></div><div class="casAuthors">Rejhova, A.; Opattova, A.; Cumova, A.; Sliva, D.; Vodicka, P.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">582-594</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Colorectal cancer (CRC) therapy using conventional chemotherapeutics represents a considerable burden for the patient's organism because of high toxicity while the response is relatively low.  Our review summarizes the findings about natural compds. as chemoprotective agents for decreasing risk of CRC.  It also identifies natural compds. which possess anti-tumor effects of various characteristics, mainly in vitro on colorectal cell lines or in vivo studies on exptl. models, but also in a few clin. trials.  Many of natural compds. suppress proliferation by inducing cell cycle arrest or induce apoptosis of CRC cells resulting in the inhibition of tumor growth.  A novel employment of natural substances is a so-called combination therapy - administration of two or more substances - conventional chemotherapeutics and a natural compd. or more natural compds. at a time.  Some natural compds. may sensitize to conventional cytotoxic therapy, reinforce the drug effective concn., intensify the combined effect of both administered therapeutics or exert cytotoxic effects specifically on tumor cells.  Moreover, combined therapy by targeting multiple signaling pathways, uses various mechanisms to reduce the development of resistance to antitumor drugs.  The desired effect could be to diminish burden on the patient's organism by replacing part of the dose of a conventional chemotherapeutic with a natural substance with a defined effect.  Many natural compds. are well tolerated by the patients and do not cause toxic effects even at high doses.  Interaction of conventional chemotherapeutics with natural compds. introduces a new aspect in the research and therapy of cancer.  It could be a promising approach to potentially achieve improvements, while minimizing of adverse effects assocd. with conventional chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4RG5snrknlbVg90H21EOLACvtfcHk0lgE9FC1Jbj9Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ymtQ%253D%253D&md5=f8cc865f414f69e3dc24fedae9d33dea</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.12.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.12.039%26sid%3Dliteratum%253Aachs%26aulast%3DRejhov%25C3%25A1%26aufirst%3DA.%26aulast%3DOpattov%25C3%25A1%26aufirst%3DA.%26aulast%3D%25C4%258Cumov%25C3%25A1%26aufirst%3DA.%26aulast%3DSl%25C3%25ADva%26aufirst%3DD.%26aulast%3DVodi%25C4%258Dka%26aufirst%3DP.%26atitle%3DNatural%2520Compounds%2520and%2520Combination%2520Therapy%2520in%2520Colorectal%2520Cancer%2520Treatment%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D144%26spage%3D582%26epage%3D594%26doi%3D10.1016%2Fj.ejmech.2017.12.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amelio, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisitsa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonov, A.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology of Approved Anticancer Drugs</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">543</span>, <span class="refDoi"> DOI: 10.2174/1389450117666160301095233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F1389450117666160301095233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=26926468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjslSjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=534-543&issue=5&author=I.+Amelioauthor=A.+Lisitsaauthor=R.+Knightauthor=G.+Melinoauthor=A.+Antonov&title=Polypharmacology+of+Approved+Anticancer+Drugs&doi=10.2174%2F1389450117666160301095233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology of Approved Anticancer Drugs</span></div><div class="casAuthors">Amelio, Ivano; Lisitsa, Andrey; Knight, Richard A.; Melino, Gerry; Antonov, Alexey V.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">534-543</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The major drug discovery efforts in oncol. have been concd. on the development of selective mols. that are supposed to act specifically on one anticancer mechanism by modulating a single or several closely related drug targets.  However, a bird's eye view on data from multiple available bioassays implies that most approved anticancer agents do, in fact, target many more proteins with different functions.  Here we will review and systematize currently available information on the targets of several anticancer drugs along with revision of their potential mechanisms of action.  Polypharmacol. of the current antineoplastic agents suggests that drug clin. efficacy in oncol. can be achieved only via modulation of multiple cellular mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZWxZCVA_iIrVg90H21EOLACvtfcHk0lgE9FC1Jbj9Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjslSjtrc%253D&md5=316e3ae08072b1b984523b7642b8d271</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.2174%2F1389450117666160301095233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389450117666160301095233%26sid%3Dliteratum%253Aachs%26aulast%3DAmelio%26aufirst%3DI.%26aulast%3DLisitsa%26aufirst%3DA.%26aulast%3DKnight%26aufirst%3DR.%26aulast%3DMelino%26aufirst%3DG.%26aulast%3DAntonov%26aufirst%3DA.%26atitle%3DPolypharmacology%2520of%2520Approved%2520Anticancer%2520Drugs%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2017%26volume%3D18%26issue%3D5%26spage%3D534%26epage%3D543%26doi%3D10.2174%2F1389450117666160301095233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Lera, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">Epigenetic Polypharmacology: From Combination Therapy to Multitargeted Drugs</span>. <i>Clin. Epigenet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">105</span>, <span class="refDoi"> DOI: 10.1186/s13148-016-0271-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1186%2Fs13148-016-0271-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27752293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslOgsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=105&author=A.+R.+de+Leraauthor=A.+Ganesan&title=Epigenetic+Polypharmacology%3A+From+Combination+Therapy+to+Multitargeted+Drugs&doi=10.1186%2Fs13148-016-0271-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic polypharmacology: from combination therapy to multitargeted drugs</span></div><div class="casAuthors">de Lera, Angel R.; Ganesan, A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Epigenetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105/1-105/21</span>CODEN:
                <span class="NLM_cas:coden">CELPCI</span>;
        ISSN:<span class="NLM_cas:issn">1868-7083</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  The modern drug discovery process has largely focused its attention in the so-called magic bullets, single chem. entities that exhibit high selectivity and potency for a particular target.  This approach was based on the assumption that the deregulation of a protein was causally linked to a disease state, and the pharmacol. intervention through inhibition of the deregulated target was able to restore normal cell function.  However, the use of cocktails or multicomponent drugs to address several targets simultaneously is also popular to treat multifactorial diseases such as cancer and neurol. disorders.  We review the state of the art with such combinations that have an epigenetic target as one of their mechanisms of action.  Epigenetic drug discovery is a rapidly advancing field, and drugs targeting epigenetic enzymes are in the clinic for the treatment of hematol. cancers.  Approved and exptl. epigenetic drugs are undergoing clin. trials in combination with other therapeutic agents via fused or linked pharmacophores in order to benefit from synergistic effects of polypharmacol.  In addn., ligands are being discovered which, as single chem. entities, are able to modulate multiple epigenetic targets simultaneously (multitarget epigenetic drugs).  These multiple ligands should in principle have a lower risk of drug-drug interactions and drug resistance compared to cocktails or multicomponent drugs.  This new generation may rival the so-called magic bullets in the treatment of diseases that arise as a consequence of the deregulation of multiple signaling pathways provided the challenge of optimization of the activities shown by the pharmacophores with the different targets is addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphm-KIEGyYKrVg90H21EOLACvtfcHk0lgE9FC1Jbj9Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslOgsbY%253D&md5=7cd89a93a22121cc9db2c7118e2e23f1</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1186%2Fs13148-016-0271-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13148-016-0271-9%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BLera%26aufirst%3DA.%2BR.%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DEpigenetic%2520Polypharmacology%253A%2520From%2520Combination%2520Therapy%2520to%2520Multitargeted%2520Drugs%26jtitle%3DClin.%2520Epigenet.%26date%3D2016%26volume%3D8%26spage%3D105%26doi%3D10.1186%2Fs13148-016-0271-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wencewicz, T. A.</span></span> <span> </span><span class="NLM_article-title">Prospects for New Antibiotics: A Molecule-Centered Perspective</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1038/ja.2013.49</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fja.2013.49" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=23756684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1yitrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2014&pages=7-22&issue=1&author=C.+T.+Walshauthor=T.+A.+Wencewicz&title=Prospects+for+New+Antibiotics%3A+A+Molecule-Centered+Perspective&doi=10.1038%2Fja.2013.49"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Prospects for new antibiotics: a molecule-centered perspective</span></div><div class="casAuthors">Walsh, Christopher T.; Wencewicz, Timothy A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-22</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  There is a continuous need for iterative cycles of antibiotic discovery and development to deal with the selection of resistant pathogens that emerge as therapeutic application of an antibiotic becomes widespread.  A short golden age of antibiotic discovery from nature followed by a subsequent golden half century of medicinal chem. optimization of existing mol. scaffolds emphasizes the need for new antibiotic mol. frameworks.  The authors bring a mol.-centered perspective to the questions of where will new scaffolds come from, when will chemogenetic approaches yield useful new antibiotics and what existing bacterial targets merit contemporary re-examn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8hr8BTzzMG7Vg90H21EOLACvtfcHk0ljVUN2Z56Vi9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1yitrc%253D&md5=fb100c0954679a78210c497daa4fab1d</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1038%2Fja.2013.49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fja.2013.49%26sid%3Dliteratum%253Aachs%26aulast%3DWalsh%26aufirst%3DC.%2BT.%26aulast%3DWencewicz%26aufirst%3DT.%2BA.%26atitle%3DProspects%2520for%2520New%2520Antibiotics%253A%2520A%2520Molecule-Centered%2520Perspective%26jtitle%3DJ.%2520Antibiot.%26date%3D2014%26volume%3D67%26issue%3D1%26spage%3D7%26epage%3D22%26doi%3D10.1038%2Fja.2013.49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silver, L. L.</span></span> <span> </span><span class="NLM_article-title">Multi-Targeting by Monotherapeutic Antibacterials</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1038/nrd2202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnrd2202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=17159922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlGktbfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=41-55&issue=1&author=L.+L.+Silver&title=Multi-Targeting+by+Monotherapeutic+Antibacterials&doi=10.1038%2Fnrd2202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-targeting by monotherapeutic antibacterials</span></div><div class="casAuthors">Silver, Lynn L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-55</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Antibacterial discovery research has been driven, medically, com. and intellectually, by the need for new therapeutics that are not subject to the resistance mechanisms that have evolved to combat previous generations of antibacterial agents.  This need has often been equated with the identification and exploitation of novel targets.  But efforts towards discovery and development of inhibitors of novel targets have proved frustrating.  It might be that the 'good old targets' are qual. different from the crop of all possible novel targets.  What has been learned from existing targets that can be applied to the quest for new antibacterials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpItQysyGWT8LVg90H21EOLACvtfcHk0ljVUN2Z56Vi9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlGktbfN&md5=49d78749fc31f5f0546b859e17b31c47</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1038%2Fnrd2202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2202%26sid%3Dliteratum%253Aachs%26aulast%3DSilver%26aufirst%3DL.%2BL.%26atitle%3DMulti-Targeting%2520by%2520Monotherapeutic%2520Antibacterials%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26issue%3D1%26spage%3D41%26epage%3D55%26doi%3D10.1038%2Fnrd2202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J. J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, R. C.</span></span> <span> </span><span class="NLM_article-title">Targeting Protein Multiple Conformations: A Structure-Based Strategy for Kinase Drug Design</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">1394</span>– <span class="NLM_lpage">1407</span>, <span class="refDoi"> DOI: 10.2174/156802607781696783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F156802607781696783" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=17692028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1SmtbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=1394-1407&issue=14&author=J.+J.-L.+Liaoauthor=R.+C.+Andrews&title=Targeting+Protein+Multiple+Conformations%3A+A+Structure-Based+Strategy+for+Kinase+Drug+Design&doi=10.2174%2F156802607781696783"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting protein multiple conformations: a structure-based strategy for kinase drug design</span></div><div class="casAuthors">Liao, Jeffrey Jie-Lou; Andrews, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1394-1407</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Multiple conformations of a protein kinase target offer an opportunity to design small-mol. inhibitors with distinct but clin. useful profiles.  This article analyzes and classifies the binding pockets in the kinase catalytic cleft in different conformational states.  Targeting kinase multiple conformations as an emerging strategy in the field is exemplified with important small-mol. agents in the clinic.  The structure-based anal. in the paper provides a rationale for thwarting the development of drug-resistant mutations in antikinase therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWOkJq0JBN2rVg90H21EOLACvtfcHk0ljVUN2Z56Vi9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1SmtbrF&md5=db6aa8c76bf20857cfe31c71625ffa9e</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.2174%2F156802607781696783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802607781696783%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DJ.%2BJ.-L.%26aulast%3DAndrews%26aufirst%3DR.%2BC.%26atitle%3DTargeting%2520Protein%2520Multiple%2520Conformations%253A%2520A%2520Structure-Based%2520Strategy%2520for%2520Kinase%2520Drug%2520Design%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26issue%3D14%26spage%3D1394%26epage%3D1407%26doi%3D10.2174%2F156802607781696783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelloff, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigman, C. C.</span></span> <span> </span><span class="NLM_article-title">Cancer Biomarkers: Selecting the Right Drug for the Right Patient</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1038/nrd3651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnrd3651" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=201-214&issue=3&author=G.+J.+Kelloffauthor=C.+C.+Sigman&title=Cancer+Biomarkers%3A+Selecting+the+Right+Drug+for+the+Right+Patient&doi=10.1038%2Fnrd3651"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1038%2Fnrd3651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3651%26sid%3Dliteratum%253Aachs%26aulast%3DKelloff%26aufirst%3DG.%2BJ.%26aulast%3DSigman%26aufirst%3DC.%2BC.%26atitle%3DCancer%2520Biomarkers%253A%2520Selecting%2520the%2520Right%2520Drug%2520for%2520the%2520Right%2520Patient%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26issue%3D3%26spage%3D201%26epage%3D214%26doi%3D10.1038%2Fnrd3651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zumla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodoo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeurer, M.</span></span> <span> </span><span class="NLM_article-title">Potential of Immunomodulatory Agents as Adjunct Host-Directed Therapies for Multidrug-Resistant Tuberculosis</span>. <i>BMC Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">89</span>, <span class="refDoi"> DOI: 10.1186/s12916-016-0635-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1186%2Fs12916-016-0635-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27301245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsFKjsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=89&author=A.+Zumlaauthor=M.+Raoauthor=E.+Dodooauthor=M.+Maeurer&title=Potential+of+Immunomodulatory+Agents+as+Adjunct+Host-Directed+Therapies+for+Multidrug-Resistant+Tuberculosis&doi=10.1186%2Fs12916-016-0635-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis</span></div><div class="casAuthors">Zumla, Alimuddin; Rao, Martin; Dodoo, Ernest; Maeurer, Markus</div><div class="citationInfo"><span class="NLM_cas:title">BMC Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89/1-89/12</span>CODEN:
                <span class="NLM_cas:coden">BMMECZ</span>;
        ISSN:<span class="NLM_cas:issn">1741-7015</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Treatment of multidrug-resistant tuberculosis (MDR-TB) is extremely challenging due to the virulence of the etiol. strains of Mycobacterium tuberculosis (M. tb), the aberrant host immune responses and the diminishing treatment options with TB drugs.  New treatment regimens incorporating therapeutics targeting both M. tb and host factors are urgently needed to improve the clin. management outcomes of MDR-TB.  Host-directed therapies (HDT) could avert destructive tuberculous lung pathol., facilitate eradication of M. tb, improve survival and prevent long-term functional disability.  In this review we (1) discuss the use of HDT for cancer and other infections, drawing parallels and the precedent they set for MDR-TB treatment, (2) highlight preclin. studies of pharmacol. agents commonly used in clin. practice which have HDT potential, and (3) outline developments in cellular therapy to promote clin. beneficial immunomodulation to improve treatment outcomes in patients with pulmonary MDR-TB.  The use of HDTs as adjuncts to MDR-TB therapy requires urgent evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowPseOXg3VsrVg90H21EOLACvtfcHk0lh57VTODb-tfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsFKjsb0%253D&md5=77b9104c346199b178e9eca372feb029</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1186%2Fs12916-016-0635-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12916-016-0635-1%26sid%3Dliteratum%253Aachs%26aulast%3DZumla%26aufirst%3DA.%26aulast%3DRao%26aufirst%3DM.%26aulast%3DDodoo%26aufirst%3DE.%26aulast%3DMaeurer%26aufirst%3DM.%26atitle%3DPotential%2520of%2520Immunomodulatory%2520Agents%2520as%2520Adjunct%2520Host-Directed%2520Therapies%2520for%2520Multidrug-Resistant%2520Tuberculosis%26jtitle%3DBMC%2520Med.%26date%3D2016%26volume%3D14%26spage%3D89%26doi%3D10.1186%2Fs12916-016-0635-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Designed Multiple Ligands: An Emerging Anti-HIV Drug Discovery Paradigm</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1893</span>– <span class="NLM_lpage">1917</span>, <span class="refDoi"> DOI: 10.2174/138161209788453266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F138161209788453266" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=1893-1917&issue=16&author=P.+Zhanauthor=X.+Liu&title=Designed+Multiple+Ligands%3A+An+Emerging+Anti-HIV+Drug+Discovery+Paradigm&doi=10.2174%2F138161209788453266"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.2174%2F138161209788453266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161209788453266%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DDesigned%2520Multiple%2520Ligands%253A%2520An%2520Emerging%2520Anti-HIV%2520Drug%2520Discovery%2520Paradigm%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2009%26volume%3D15%26issue%3D16%26spage%3D1893%26epage%3D1917%26doi%3D10.2174%2F138161209788453266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, B. B.</span></span> <span> </span><span class="NLM_article-title">Serendipity in Cancer Drug Discovery: Rational or Coincidence?</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2016.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.tips.2016.03.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=435-450&issue=6&author=S.+Prasadauthor=S.+C.+Guptaauthor=B.+B.+Aggarwal&title=Serendipity+in+Cancer+Drug+Discovery%3A+Rational+or+Coincidence%3F&doi=10.1016%2Fj.tips.2016.03.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2016.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2016.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DPrasad%26aufirst%3DS.%26aulast%3DGupta%26aufirst%3DS.%2BC.%26aulast%3DAggarwal%26aufirst%3DB.%2BB.%26atitle%3DSerendipity%2520in%2520Cancer%2520Drug%2520Discovery%253A%2520Rational%2520or%2520Coincidence%253F%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2016%26volume%3D37%26issue%3D6%26spage%3D435%26epage%3D450%26doi%3D10.1016%2Fj.tips.2016.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peereboom, D. M.</span></span> <span> </span><span class="NLM_article-title">From Serendipity to Design: The Evolution of Drug Development in Oncology</span>. <i>Cleve. Clin. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>64</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.3949/ccjm.64.3.155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.3949%2Fccjm.64.3.155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=9068226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADyaK2s3itFWitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1997&pages=155-163&issue=3&author=M.+Markmanauthor=D.+M.+Peereboom&title=From+Serendipity+to+Design%3A+The+Evolution+of+Drug+Development+in+Oncology&doi=10.3949%2Fccjm.64.3.155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">From serendipity to design: the evolution of drug development in oncology</span></div><div class="casAuthors">Markman M; Peereboom D M</div><div class="citationInfo"><span class="NLM_cas:title">Cleveland Clinic journal of medicine</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">155-63</span>
        ISSN:<span class="NLM_cas:issn">0891-1150</span>.
    </div><div class="casAbstract">Although screening of natural products remains the major method of discovering new anticancer drugs, newer techniques of rational drug design, computer-aided drug design, and combinatorial synthesis promise to broaden the scope of compounds available for screening.  Recent changes in Food and Drug Administration rules allow for accelerated approval of drugs for treating cancer and other life-threatening illnesses, although the three-phase process of clinical trials remains largely unchanged.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTby-nTegdkY_SAs_PE1QvifW6udTcc2ebT3Pt8puUaZrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s3itFWitw%253D%253D&md5=7948481b317c7ccfbee7c5b307b357c5</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.3949%2Fccjm.64.3.155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3949%252Fccjm.64.3.155%26sid%3Dliteratum%253Aachs%26aulast%3DMarkman%26aufirst%3DM.%26aulast%3DPeereboom%26aufirst%3DD.%2BM.%26atitle%3DFrom%2520Serendipity%2520to%2520Design%253A%2520The%2520Evolution%2520of%2520Drug%2520Development%2520in%2520Oncology%26jtitle%3DCleve.%2520Clin.%2520J.%2520Med.%26date%3D1997%26volume%3D64%26issue%3D3%26spage%3D155%26epage%3D163%26doi%3D10.3949%2Fccjm.64.3.155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, A.</span>; <span class="NLM_string-name">García-Echeverría, C.</span></span> <span> </span><span class="NLM_article-title">Identification and Optimization of Dual PI3K/mTOR Inhibitors</span>. In  <i>Designing Multi-Target Drugs</i>; <span class="NLM_publisher-name">Royal Society of Chemistry</span>: <span class="NLM_publisher-loc">Cambridge, UK</span>, <span class="NLM_year">2012</span>; Chapter 13, pp  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">220</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1039%2F9781849734912-00206" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=206-220&author=A.+Karlsson&author=C.+Garc%C3%ADa-Echeverr%C3%ADa&title=Designing+Multi-Target+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1039%2F9781849734912-00206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1039%252F9781849734912-00206%26sid%3Dliteratum%253Aachs%26aulast%3DKarlsson%26aufirst%3DA.%26atitle%3DIdentification%2520and%2520Optimization%2520of%2520Dual%2520PI3K%252FmTOR%2520Inhibitors%26btitle%3DDesigning%2520Multi-Target%2520Drugs%26pub%3DRoyal%2520Society%2520of%2520Chemistry%26date%3D2012%26spage%3D206%26epage%3D220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-{4-[5-(4-Fluorophenyl)-3-Methyl-2-Methylsulfanyl-3H-Imidazol-4-Yl]-Pyridin-2-Yl}-Acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">5290</span>– <span class="NLM_lpage">5305</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01647</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01647" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5290-5305&issue=13&author=W.+Albrechtauthor=A.+Ungerauthor=S.+M.+Bauerauthor=S.+A.+Laufer&title=Discovery+of+N-%7B4-%5B5-%284-Fluorophenyl%29-3-Methyl-2-Methylsulfanyl-3H-Imidazol-4-Yl%5D-Pyridin-2-Yl%7D-Acetamide+%28CBS-3595%29%2C+a+Dual+p38%CE%B1+MAPK%2FPDE-4+Inhibitor+with+Activity+against+TNF%CE%B1-Related+Diseases&doi=10.1021%2Facs.jmedchem.6b01647"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01647%26sid%3Dliteratum%253Aachs%26aulast%3DAlbrecht%26aufirst%3DW.%26aulast%3DUnger%26aufirst%3DA.%26aulast%3DBauer%26aufirst%3DS.%2BM.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DDiscovery%2520of%2520N-%257B4-%255B5-%25284-Fluorophenyl%2529-3-Methyl-2-Methylsulfanyl-3H-Imidazol-4-Yl%255D-Pyridin-2-Yl%257D-Acetamide%2520%2528CBS-3595%2529%252C%2520a%2520Dual%2520p38%25CE%25B1%2520MAPK%252FPDE-4%2520Inhibitor%2520with%2520Activity%2520against%2520TNF%25CE%25B1-Related%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D13%26spage%3D5290%26epage%3D5305%26doi%3D10.1021%2Facs.jmedchem.6b01647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wess, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enhsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baringhaus, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glombik, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müllner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bock, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleine, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckermann, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Bile Acid - Drug Conjugates: Potential Drug - Shuttles for Liver Specific Targeting</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">819</span>– <span class="NLM_lpage">822</span>, <span class="refDoi"> DOI: 10.1016/0040-4039(93)89021-H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2F0040-4039%2893%2989021-H" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1993&pages=819-822&issue=5&author=G.+Wessauthor=W.+Kramerauthor=G.+Schubertauthor=A.+Enhsenauthor=K.+H.+Baringhausauthor=H.+Glombikauthor=S.+M%C3%BCllnerauthor=K.+Bockauthor=H.+Kleineauthor=M.+Johnauthor=O.+Neckermannauthor=A.+Hoffmann&title=Synthesis+of+Bile+Acid+-+Drug+Conjugates%3A+Potential+Drug+-+Shuttles+for+Liver+Specific+Targeting&doi=10.1016%2F0040-4039%2893%2989021-H"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2F0040-4039%2893%2989021-H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4039%252893%252989021-H%26sid%3Dliteratum%253Aachs%26aulast%3DWess%26aufirst%3DG.%26aulast%3DKramer%26aufirst%3DW.%26aulast%3DSchubert%26aufirst%3DG.%26aulast%3DEnhsen%26aufirst%3DA.%26aulast%3DBaringhaus%26aufirst%3DK.%2BH.%26aulast%3DGlombik%26aufirst%3DH.%26aulast%3DM%25C3%25BCllner%26aufirst%3DS.%26aulast%3DBock%26aufirst%3DK.%26aulast%3DKleine%26aufirst%3DH.%26aulast%3DJohn%26aufirst%3DM.%26aulast%3DNeckermann%26aufirst%3DO.%26aulast%3DHoffmann%26aufirst%3DA.%26atitle%3DSynthesis%2520of%2520Bile%2520Acid%2520-%2520Drug%2520Conjugates%253A%2520Potential%2520Drug%2520-%2520Shuttles%2520for%2520Liver%2520Specific%2520Targeting%26jtitle%3DTetrahedron%2520Lett.%26date%3D1993%26volume%3D34%26issue%3D5%26spage%3D819%26epage%3D822%26doi%3D10.1016%2F0040-4039%2893%2989021-H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wess, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bickel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girbig, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutjahr, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalewski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baringhaus, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enhsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glombik, H.</span></span> <span> </span><span class="NLM_article-title">Liver-Specific Drug Targeting by Coupling to Bile Acids</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>267</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">18598</span>– <span class="NLM_lpage">18604</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=18598-18604&issue=26&author=W.+Kramerauthor=G.+Wessauthor=G.+Schubertauthor=M.+Bickelauthor=F.+Girbigauthor=U.+Gutjahrauthor=S.+Kowalewskiauthor=K.+H.+Baringhausauthor=A.+Enhsenauthor=H.+Glombik&title=Liver-Specific+Drug+Targeting+by+Coupling+to+Bile+Acids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKramer%26aufirst%3DW.%26aulast%3DWess%26aufirst%3DG.%26aulast%3DSchubert%26aufirst%3DG.%26aulast%3DBickel%26aufirst%3DM.%26aulast%3DGirbig%26aufirst%3DF.%26aulast%3DGutjahr%26aufirst%3DU.%26aulast%3DKowalewski%26aufirst%3DS.%26aulast%3DBaringhaus%26aufirst%3DK.%2BH.%26aulast%3DEnhsen%26aufirst%3DA.%26aulast%3DGlombik%26aufirst%3DH.%26atitle%3DLiver-Specific%2520Drug%2520Targeting%2520by%2520Coupling%2520to%2520Bile%2520Acids%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26issue%3D26%26spage%3D18598%26epage%3D18604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Braun, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pramanik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gwinner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köberle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, E.</span></span> <span> </span><span class="NLM_article-title">Sideromycins: Tools and Antibiotics</span>. <i>BioMetals</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1007/s10534-008-9199-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1007%2Fs10534-008-9199-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=3-13&issue=1&author=V.+Braunauthor=A.+Pramanikauthor=T.+Gwinnerauthor=M.+K%C3%B6berleauthor=E.+Bohn&title=Sideromycins%3A+Tools+and+Antibiotics&doi=10.1007%2Fs10534-008-9199-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1007%2Fs10534-008-9199-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10534-008-9199-7%26sid%3Dliteratum%253Aachs%26aulast%3DBraun%26aufirst%3DV.%26aulast%3DPramanik%26aufirst%3DA.%26aulast%3DGwinner%26aufirst%3DT.%26aulast%3DK%25C3%25B6berle%26aufirst%3DM.%26aulast%3DBohn%26aufirst%3DE.%26atitle%3DSideromycins%253A%2520Tools%2520and%2520Antibiotics%26jtitle%3DBioMetals%26date%3D2009%26volume%3D22%26issue%3D1%26spage%3D3%26epage%3D13%26doi%3D10.1007%2Fs10534-008-9199-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möllmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claypool, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolter, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suckow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajicek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. J.</span></span> <span> </span><span class="NLM_article-title">Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter Baumannii Both in Vitro and in Vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4577</span>– <span class="NLM_lpage">4583</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00102</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00102" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktFOmtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4577-4583&issue=11&author=M.+Ghoshauthor=P.+A.+Millerauthor=U.+M%C3%B6llmannauthor=W.+D.+Claypoolauthor=V.+A.+Schroederauthor=W.+R.+Wolterauthor=M.+Suckowauthor=H.+Yuauthor=S.+Liauthor=W.+Huangauthor=J.+Zajicekauthor=M.+J.+Miller&title=Targeted+Antibiotic+Delivery%3A+Selective+Siderophore+Conjugation+with+Daptomycin+Confers+Potent+Activity+against+Multidrug+Resistant+Acinetobacter+Baumannii+Both+in+Vitro+and+in+Vivo&doi=10.1021%2Facs.jmedchem.7b00102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo</span></div><div class="casAuthors">Ghosh, Manuka; Miller, Patricia A.; Mollmann, Ute; Claypool, William D.; Schroeder, Valerie A.; Wolter, William R.; Suckow, Mark; Yu, Honglin; Li, Shuang; Huang, Weiqiang; Zajicek, Jaroslav; Miller, Marvin J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4577-4583</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To address the dire need for new antibiotics to treat specific strains of drug resistant Gram-neg. bacterial infections, a mixed ligand analog of the natural Acinetobacter baumannii selective siderophore, fimsbactin, was coupled to daptomycin, a Gram-pos. only antibiotic.  The resulting conjugate, 11, has potent activity against multi-drug resistant strains of A. baumannii, both in vitro and in vivo.  The study also indicates that conjugation of siderophores to "drugs" that are much larger than the siderophore (iron transport agent) itself facilitates active uptake that circumvents the normal permeability problems in Gram-neg. bacteria.  The results demonstrate the ability to extend activity of a normally Gram-pos. only antibiotic to create a potent and targeted Gram-neg. antibiotic using a bacterial iron transport based sideromycin Trojan Horse strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr19eZoVK9_KbVg90H21EOLACvtfcHk0lijYEYMBP4cOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktFOmtrs%253D&md5=d5393857fecd38662c4dd084e11e204a</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00102%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DP.%2BA.%26aulast%3DM%25C3%25B6llmann%26aufirst%3DU.%26aulast%3DClaypool%26aufirst%3DW.%2BD.%26aulast%3DSchroeder%26aufirst%3DV.%2BA.%26aulast%3DWolter%26aufirst%3DW.%2BR.%26aulast%3DSuckow%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DZajicek%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DM.%2BJ.%26atitle%3DTargeted%2520Antibiotic%2520Delivery%253A%2520Selective%2520Siderophore%2520Conjugation%2520with%2520Daptomycin%2520Confers%2520Potent%2520Activity%2520against%2520Multidrug%2520Resistant%2520Acinetobacter%2520Baumannii%2520Both%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D11%26spage%3D4577%26epage%3D4583%26doi%3D10.1021%2Facs.jmedchem.7b00102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vakulenko, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggess, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. J.</span></span> <span> </span><span class="NLM_article-title">A Synthetic Dual Drug Sideromycin Induces Gram-Negative Bacteria To Commit Suicide with a Gram-Positive Antibiotic</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3845</span>– <span class="NLM_lpage">3854</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00218</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00218" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltV2rsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3845-3854&issue=9&author=R.+Liuauthor=P.+A.+Millerauthor=S.+B.+Vakulenkoauthor=N.+K.+Stewartauthor=W.+C.+Boggessauthor=M.+J.+Miller&title=A+Synthetic+Dual+Drug+Sideromycin+Induces+Gram-Negative+Bacteria+To+Commit+Suicide+with+a+Gram-Positive+Antibiotic&doi=10.1021%2Facs.jmedchem.8b00218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">A Synthetic Dual Drug Sideromycin Induces Gram-Negative Bacteria To Commit Suicide with a Gram-Positive Antibiotic</span></div><div class="casAuthors">Liu, Rui; Miller, Patricia A.; Vakulenko, Sergei B.; Stewart, Nichole K.; Boggess, William C.; Miller, Marvin J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3845-3854</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Many antibiotics lack activity against Gram-neg. bacteria because they cannot permeate the outer membrane or suffer from efflux and, in the case of β-lactams, are degraded by β-lactamases.  Herein, we describe the synthesis and studies of a dual drug conjugate (1) of a siderophore linked to a cephalosporin with an attached oxazolidinone.  The cephalosporin component of 1 is rapidly hydrolyzed by purified ADC-1 β-lactamase to release the oxazolidinone.  Conjugate 1 is active against clin. isolates of Acinetobacter baumannii as well as strains producing large amts. of ADC-1 β-lactamase.  Overall, the results are consistent with siderophore-mediated active uptake, inherent activity of the delivered dual drug, and in the presence of β-lactamases, intracellular release of the oxazolidinone upon cleavage of the cephalosporin to allow the freed oxazolidinone to inactivate its target.  The ultimate result demonstrates that Gram-pos. oxazolidinone antibiotics can be made to be effective against Gram-neg. bacteria by β-lactamase triggered release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq97JjdswWmrVg90H21EOLACvtfcHk0lijYEYMBP4cOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltV2rsbk%253D&md5=0c3db140a8cd4e7c9f533120a2407cf6</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00218%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DP.%2BA.%26aulast%3DVakulenko%26aufirst%3DS.%2BB.%26aulast%3DStewart%26aufirst%3DN.%2BK.%26aulast%3DBoggess%26aufirst%3DW.%2BC.%26aulast%3DMiller%26aufirst%3DM.%2BJ.%26atitle%3DA%2520Synthetic%2520Dual%2520Drug%2520Sideromycin%2520Induces%2520Gram-Negative%2520Bacteria%2520To%2520Commit%2520Suicide%2520with%2520a%2520Gram-Positive%2520Antibiotic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D9%26spage%3D3845%26epage%3D3854%26doi%3D10.1021%2Facs.jmedchem.8b00218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wencewicz, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möllmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. J.</span></span> <span> </span><span class="NLM_article-title">Trihydroxamate Siderophore-Fluoroquinolone Conjugates Are Selective Sideromycin Antibiotics That Target Staphylococcus Aureus</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">486</span>, <span class="refDoi"> DOI: 10.1021/bc300610f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc300610f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVemsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=473-486&issue=3&author=T.+A.+Wencewiczauthor=T.+E.+Longauthor=U.+M%C3%B6llmannauthor=M.+J.+Miller&title=Trihydroxamate+Siderophore-Fluoroquinolone+Conjugates+Are+Selective+Sideromycin+Antibiotics+That+Target+Staphylococcus+Aureus&doi=10.1021%2Fbc300610f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Trihydroxamate Siderophore-Fluoroquinolone Conjugates Are Selective Sideromycin Antibiotics that Target Staphylococcus aureus</span></div><div class="casAuthors">Wencewicz, Timothy A.; Long, Timothy E.; Mollmann, Ute; Miller, Marvin J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">473-486</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Siderophores are multidentate iron(III) chelators used by bacteria for iron assimilation.  Sideromycins, also called siderophore-antibiotic conjugates, are a unique subset of siderophores that enter bacterial cells via siderophore uptake pathways and deliver the toxic antibiotic in a Trojan horse fashion.  Sideromycins represent a novel antibiotic delivery technol. with untapped potential for developing sophisticated microbe-selective antibacterial agents that limit the emergence of bacterial resistance.  The chem. synthesis of a series of mono-, bis-, and trihydroxamate sideromycins are described here along with their biol. evaluation in antibacterial susceptibility assays.  The linear hydroxamate siderophores used for the sideromycins in this study were derived from the ferrioxamine family and inspired by the naturally occurring salmycin sideromycins.  The antibacterial agents used were a β-lactam carbacepholosporin, Lorabid, and a fluoroquinolone, ciprofloxacin, chosen for the different locations of their biol. targets, the periplasm (extracellular) and the cytoplasm (intracellular).  The linear hydroxamate-based sideromycins were selectively toxic toward Gram-pos. bacteria, esp. Staphylococcus aureus SG511 (MIC = 1.0 μM for the trihydroxamate-fluoroquinolone sideromycin).  Siderophore-sideromycin competition assays demonstrated that only the fluoroquinolone sideromycins required membrane transport to reach their cytoplasmic biol. target and that a trihydroxamate siderophore backbone was required for protein-mediated active transport of the sideromycins into S. aureus cells via siderophore uptake pathways.  This work represents a comprehensive study of linear hydroxamate sideromycins and teaches how to build effective hydroxamate-based sideromycins as Gram-pos. selective antibiotic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqb9eWs7Rjn7Vg90H21EOLACvtfcHk0li8AilzTA03DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVemsr0%253D&md5=21278dfc61acf0135945eb3052bef2d2</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1021%2Fbc300610f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc300610f%26sid%3Dliteratum%253Aachs%26aulast%3DWencewicz%26aufirst%3DT.%2BA.%26aulast%3DLong%26aufirst%3DT.%2BE.%26aulast%3DM%25C3%25B6llmann%26aufirst%3DU.%26aulast%3DMiller%26aufirst%3DM.%2BJ.%26atitle%3DTrihydroxamate%2520Siderophore-Fluoroquinolone%2520Conjugates%2520Are%2520Selective%2520Sideromycin%2520Antibiotics%2520That%2520Target%2520Staphylococcus%2520Aureus%26jtitle%3DBioconjugate%2520Chem.%26date%3D2013%26volume%3D24%26issue%3D3%26spage%3D473%26epage%3D486%26doi%3D10.1021%2Fbc300610f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wencewicz, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. J.</span></span> <span> </span><span class="NLM_article-title">Biscatecholate-Monohydroxamate Mixed Ligand Siderophore-Carbacephalosporin Conjugates Are Selective Sideromycin Antibiotics That Target Acinetobacter Baumannii</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4044</span>– <span class="NLM_lpage">4052</span>, <span class="refDoi"> DOI: 10.1021/jm400265k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400265k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4044-4052&issue=10&author=T.+A.+Wencewiczauthor=M.+J.+Miller&title=Biscatecholate-Monohydroxamate+Mixed+Ligand+Siderophore-Carbacephalosporin+Conjugates+Are+Selective+Sideromycin+Antibiotics+That+Target+Acinetobacter+Baumannii&doi=10.1021%2Fjm400265k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1021%2Fjm400265k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400265k%26sid%3Dliteratum%253Aachs%26aulast%3DWencewicz%26aufirst%3DT.%2BA.%26aulast%3DMiller%26aufirst%3DM.%2BJ.%26atitle%3DBiscatecholate-Monohydroxamate%2520Mixed%2520Ligand%2520Siderophore-Carbacephalosporin%2520Conjugates%2520Are%2520Selective%2520Sideromycin%2520Antibiotics%2520That%2520Target%2520Acinetobacter%2520Baumannii%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D10%26spage%3D4044%26epage%3D4052%26doi%3D10.1021%2Fjm400265k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, M. W.</span></span> <span> </span><span class="NLM_article-title">Cefiderocol: A Novel Siderophore Cephalosporin</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1080/13543784.2018.1426745</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1080%2F13543784.2018.1426745" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=193-197&issue=2&author=J.+J.+Choiauthor=M.+W.+McCarthy&title=Cefiderocol%3A+A+Novel+Siderophore+Cephalosporin&doi=10.1080%2F13543784.2018.1426745"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1080%2F13543784.2018.1426745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2018.1426745%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DJ.%2BJ.%26aulast%3DMcCarthy%26aufirst%3DM.%2BW.%26atitle%3DCefiderocol%253A%2520A%2520Novel%2520Siderophore%2520Cephalosporin%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2018%26volume%3D27%26issue%3D2%26spage%3D193%26epage%3D197%26doi%3D10.1080%2F13543784.2018.1426745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wainwright, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meegan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dempster, N.</span></span> <span> </span><span class="NLM_article-title">Phenothiazinium-Fluoroquinolone Drug Conjugates</span>. <i>Int. J. Antimicrob. Agents</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.1016/j.ijantimicag.2009.11.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.ijantimicag.2009.11.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=20060690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitlSqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=405-409&issue=4&author=M.+Wainwrightauthor=A.+Shahauthor=K.+Meeganauthor=C.+Loughranauthor=A.+Smithauthor=N.+Valliauthor=N.+Dempster&title=Phenothiazinium-Fluoroquinolone+Drug+Conjugates&doi=10.1016%2Fj.ijantimicag.2009.11.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Phenothiazinium-fluoroquinolone drug conjugates</span></div><div class="casAuthors">Wainwright, Mark; Shah, Ami; Meegan, Katie; Loughran, Ciara; Smith, Andy; Valli, Nasima; Dempster, Nicola</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">405-409</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Synthesis and antibacterial screening of a homologous series of 3-dialkylaminophenothiazinium-7-norfloxacin conjugates was carried out alongside a corresponding series of sym. methylene blue derivs.  The norfloxacin conjugates maintained typical methylene blue deriv. photoproperties, such as long wavelength absorption, but produced no measurable singlet oxygen in the std. assay and provided no significant increase in the magnitude of photoantibacterial action, this being similar to the methylene blue homologs, although both the conjugates and homologs were considerably more active than methylene blue itself both against Staphylococcus aureus and Escherichia coli.  DNA binding via intercalation was considerably greater for the series of norfloxacin conjugates than for the methylene blue homologs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql2ey1XSf0yrVg90H21EOLACvtfcHk0li8AilzTA03DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitlSqtrw%253D&md5=ce3592aa7650d7cb6bd5819a45905648</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2009.11.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2009.11.022%26sid%3Dliteratum%253Aachs%26aulast%3DWainwright%26aufirst%3DM.%26aulast%3DShah%26aufirst%3DA.%26aulast%3DMeegan%26aufirst%3DK.%26aulast%3DLoughran%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DValli%26aufirst%3DN.%26aulast%3DDempster%26aufirst%3DN.%26atitle%3DPhenothiazinium-Fluoroquinolone%2520Drug%2520Conjugates%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2010%26volume%3D35%26issue%3D4%26spage%3D405%26epage%3D409%26doi%3D10.1016%2Fj.ijantimicag.2009.11.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchikama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, Z.</span></span> <span> </span><span class="NLM_article-title">Antibody-Drug Conjugates: Recent Advances in Conjugation and Linker Chemistries</span>. <i>Protein Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1007/s13238-016-0323-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1007%2Fs13238-016-0323-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27743348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslSlsrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=33-46&issue=1&author=K.+Tsuchikamaauthor=Z.+An&title=Antibody-Drug+Conjugates%3A+Recent+Advances+in+Conjugation+and+Linker+Chemistries&doi=10.1007%2Fs13238-016-0323-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates: recent advances in conjugation and linker chemistries</span></div><div class="casAuthors">Tsuchikama, Kyoji; An, Zhiqiang</div><div class="citationInfo"><span class="NLM_cas:title">Protein & Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-46</span>CODEN:
                <span class="NLM_cas:coden">PCREFB</span>;
        ISSN:<span class="NLM_cas:issn">1674-800X</span>.
    
            (<span class="NLM_cas:orgname">Higher Education Press</span>)
        </div><div class="casAbstract">The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small mols. (payloads) through chem. linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy.  This new antibody-based mol. platform enables selective delivery of a potent cytotoxic payload to target cancer cells, resulting in improved efficacy, reduced systemic toxicity, and preferable pharmacokinetics (PK)/pharmacodynamics (PD) and biodistribution compared to traditional chemotherapy.  Boosted by the successes of FDA-approved Adcetris and Kadcyla, this drug class has been rapidly growing along with about 60 ADCs currently in clin. trials.  In this article, we briefly review mol. aspects of each component (the antibody, payload, and linker) of ADCs, and then mainly discuss traditional and new technologies of the conjugation and linker chemistries for successful construction of clin. effective ADCs.  Current efforts in the conjugation and linker chemistries will provide greater insights into mol. design and strategies for clin. effective ADCs from medicinal chem. and pharmacol. standpoints.  The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an esp. promising path to improving ADC design, which will open the way for novel cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQM6rnMshPgrVg90H21EOLACvtfcHk0li8AilzTA03DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslSlsrjJ&md5=774905d4270dfdbf53456f7ef6e2b7b6</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1007%2Fs13238-016-0323-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13238-016-0323-0%26sid%3Dliteratum%253Aachs%26aulast%3DTsuchikama%26aufirst%3DK.%26aulast%3DAn%26aufirst%3DZ.%26atitle%3DAntibody-Drug%2520Conjugates%253A%2520Recent%2520Advances%2520in%2520Conjugation%2520and%2520Linker%2520Chemistries%26jtitle%3DProtein%2520Cell%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D33%26epage%3D46%26doi%3D10.1007%2Fs13238-016-0323-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasarao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galliford, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, P. S.</span></span> <span> </span><span class="NLM_article-title">Principles in the Design of Ligand-Targeted Cancer Therapeutics and Imaging Agents</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1038/nrd4519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnrd4519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=25698644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtVylsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=203-219&issue=3&author=M.+Srinivasaraoauthor=C.+V.+Gallifordauthor=P.+S.+Low&title=Principles+in+the+Design+of+Ligand-Targeted+Cancer+Therapeutics+and+Imaging+Agents&doi=10.1038%2Fnrd4519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Principles in the design of ligand-targeted cancer therapeutics and imaging agents</span></div><div class="casAuthors">Srinivasarao, Madduri; Galliford, Chris V.; Low, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-219</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most cancer drugs are designed to interfere with one or more events in cell proliferation or survival.  As healthy cells may also need to proliferate and avoid apoptosis, anticancer agents can be toxic to such cells.  To minimize these toxicities, strategies have been developed wherein the therapeutic agent is targeted to tumor cells through conjugation to a tumor-cell-specific small-mol. ligand, thereby reducing delivery to normal cells and the assocd. collateral toxicity.  This Review describes the major principles in the design of ligand-targeted drugs and provides an overview of ligand-drug conjugates and ligand-imaging-agent conjugates that are currently in development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSVpXZcVlh_bVg90H21EOLACvtfcHk0liUSwkp39oG0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtVylsb4%253D&md5=71e2e7ad51f7f55415ccddb9ed1ea3db</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1038%2Fnrd4519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4519%26sid%3Dliteratum%253Aachs%26aulast%3DSrinivasarao%26aufirst%3DM.%26aulast%3DGalliford%26aufirst%3DC.%2BV.%26aulast%3DLow%26aufirst%3DP.%2BS.%26atitle%3DPrinciples%2520in%2520the%2520Design%2520of%2520Ligand-Targeted%2520Cancer%2520Therapeutics%2520and%2520Imaging%2520Agents%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26issue%3D3%26spage%3D203%26epage%3D219%26doi%3D10.1038%2Fnrd4519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walles, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hainzl, D.</span></span> <span> </span><span class="NLM_article-title">ADME and Safety Aspects of Non-Cleavable Linkers in Drug Discovery and Development</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">32</span>),  <span class="NLM_fpage">3463</span>– <span class="NLM_lpage">3475</span>, <span class="refDoi"> DOI: 10.2174/1568026618666180118153502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F1568026618666180118153502" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=3463-3475&issue=32&author=M.+Wallesauthor=A.+Connorauthor=D.+Hainzl&title=ADME+and+Safety+Aspects+of+Non-Cleavable+Linkers+in+Drug+Discovery+and+Development&doi=10.2174%2F1568026618666180118153502"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.2174%2F1568026618666180118153502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026618666180118153502%26sid%3Dliteratum%253Aachs%26aulast%3DWalles%26aufirst%3DM.%26aulast%3DConnor%26aufirst%3DA.%26aulast%3DHainzl%26aufirst%3DD.%26atitle%3DADME%2520and%2520Safety%2520Aspects%2520of%2520Non-Cleavable%2520Linkers%2520in%2520Drug%2520Discovery%2520and%2520Development%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2018%26volume%3D17%26issue%3D32%26spage%3D3463%26epage%3D3475%26doi%3D10.2174%2F1568026618666180118153502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seidi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenjob, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespy, D.</span></span> <span> </span><span class="NLM_article-title">Designing Smart Polymer Conjugates for Controlled Release of Payloads</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>118</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3965</span>– <span class="NLM_lpage">4036</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.8b00006</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.8b00006" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkt1Kru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2018&pages=3965-4036&issue=7&author=F.+Seidiauthor=R.+Jenjobauthor=D.+Crespy&title=Designing+Smart+Polymer+Conjugates+for+Controlled+Release+of+Payloads&doi=10.1021%2Facs.chemrev.8b00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Designing Smart Polymer Conjugates for Controlled Release of Payloads</span></div><div class="casAuthors">Seidi, Farzad; Jenjob, Ratchapol; Crespy, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3965-4036</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Incorporating labile bonds inside polymer backbone and side chains yields interesting polymer materials that are responsive to change of environmental stimuli.  Drugs can be conjugated to various polymers through different conjugation linkages and spacers.  One of the key factors influencing the release profile of conjugated drugs is the hydrolytic stability of the conjugated linkage.  Generally, the hydrolysis of acid-labile linkages, including acetal, imine, hydrazone, and to some extent β-thiopropionate, are relatively fast and the conjugated drug can be completely released in the range of several hours to a few days.  The cleavage of ester linkages are usually slow, which is beneficial for continuous and prolonged release.  Another key structural factor is the water soly. of polymer-drug conjugates.  Generally, the release rate from highly water-sol. prodrugs is fast.  In prodrugs with large hydrophobic segments, the hydrophobic drugs are usually located in the hydrophobic core of micelles and nanoparticles, which limits the access to the water, hence lowering significantly the hydrolysis rate.  Finally, self-immolative polymers are also an intriguing new class of materials.  New synthetic pathways are needed to overcome the fact that much of the small mols. produced upon degrdn. are not active mols. useful for biomedical applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoncOdguQX5UrVg90H21EOLACvtfcHk0liUSwkp39oG0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkt1Kru74%253D&md5=969466bfe9567e44f0e703910fa8fb0f</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.8b00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.8b00006%26sid%3Dliteratum%253Aachs%26aulast%3DSeidi%26aufirst%3DF.%26aulast%3DJenjob%26aufirst%3DR.%26aulast%3DCrespy%26aufirst%3DD.%26atitle%3DDesigning%2520Smart%2520Polymer%2520Conjugates%2520for%2520Controlled%2520Release%2520of%2520Payloads%26jtitle%3DChem.%2520Rev.%26date%3D2018%26volume%3D118%26issue%3D7%26spage%3D3965%26epage%3D4036%26doi%3D10.1021%2Facs.chemrev.8b00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frigerio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyle, A. F.</span></span> <span> </span><span class="NLM_article-title">The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">32</span>),  <span class="NLM_fpage">3393</span>– <span class="NLM_lpage">3424</span>, <span class="refDoi"> DOI: 10.2174/1568026618666180118155847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F1568026618666180118155847" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=3393-3424&issue=32&author=M.+Frigerioauthor=A.+F.+Kyle&title=The+Chemical+Design+and+Synthesis+of+Linkers+Used+in+Antibody+Drug+Conjugates&doi=10.2174%2F1568026618666180118155847"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.2174%2F1568026618666180118155847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026618666180118155847%26sid%3Dliteratum%253Aachs%26aulast%3DFrigerio%26aufirst%3DM.%26aulast%3DKyle%26aufirst%3DA.%2BF.%26atitle%3DThe%2520Chemical%2520Design%2520and%2520Synthesis%2520of%2520Linkers%2520Used%2520in%2520Antibody%2520Drug%2520Conjugates%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2018%26volume%3D17%26issue%3D32%26spage%3D3393%26epage%3D3424%26doi%3D10.2174%2F1568026618666180118155847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castañeda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chudasama, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chester, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caddick, S.</span></span> <span> </span><span class="NLM_article-title">Acid-Cleavable Thiomaleamic Acid Linker for Homogeneous Antibody–drug Conjugation</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">74</span>),  <span class="NLM_fpage">8187</span>, <span class="refDoi"> DOI: 10.1039/c3cc45220d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1039%2Fc3cc45220d" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=8187&issue=74&author=L.+Casta%C3%B1edaauthor=A.+Maruaniauthor=F.+F.+Schumacherauthor=E.+Mirandaauthor=V.+Chudasamaauthor=K.+A.+Chesterauthor=J.+R.+Bakerauthor=M.+E.+B.+Smithauthor=S.+Caddick&title=Acid-Cleavable+Thiomaleamic+Acid+Linker+for+Homogeneous+Antibody%E2%80%93drug+Conjugation&doi=10.1039%2Fc3cc45220d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1039%2Fc3cc45220d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3cc45220d%26sid%3Dliteratum%253Aachs%26aulast%3DCasta%25C3%25B1eda%26aufirst%3DL.%26aulast%3DMaruani%26aufirst%3DA.%26aulast%3DSchumacher%26aufirst%3DF.%2BF.%26aulast%3DMiranda%26aufirst%3DE.%26aulast%3DChudasama%26aufirst%3DV.%26aulast%3DChester%26aufirst%3DK.%2BA.%26aulast%3DBaker%26aufirst%3DJ.%2BR.%26aulast%3DSmith%26aufirst%3DM.%2BE.%2BB.%26aulast%3DCaddick%26aufirst%3DS.%26atitle%3DAcid-Cleavable%2520Thiomaleamic%2520Acid%2520Linker%2520for%2520Homogeneous%2520Antibody%25E2%2580%2593drug%2520Conjugation%26jtitle%3DChem.%2520Commun.%26date%3D2013%26volume%3D49%26issue%3D74%26spage%3D8187%26doi%3D10.1039%2Fc3cc45220d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubowchik, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofstead, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosure, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knipe, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasch, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trail, P. A.</span></span> <span> </span><span class="NLM_article-title">Cathepsin B-Labile Dipeptide Linkers for Lysosomal Release of Doxorubicin from Internalizing Immunoconjugates: Model Studies of Enzymatic Drug Release and Antigen-Specific in Vitro Anticancer Activity</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">869</span>, <span class="refDoi"> DOI: 10.1021/bc025536j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc025536j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD38XksFentr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=855-869&issue=4&author=G.+M.+Dubowchikauthor=R.+A.+Firestoneauthor=L.+Padillaauthor=D.+Willnerauthor=S.+J.+Hofsteadauthor=K.+Mosureauthor=J.+O.+Knipeauthor=S.+J.+Laschauthor=P.+A.+Trail&title=Cathepsin+B-Labile+Dipeptide+Linkers+for+Lysosomal+Release+of+Doxorubicin+from+Internalizing+Immunoconjugates%3A+Model+Studies+of+Enzymatic+Drug+Release+and+Antigen-Specific+in+Vitro+Anticancer+Activity&doi=10.1021%2Fbc025536j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin B-Labile Dipeptide Linkers for Lysosomal Release of Doxorubicin from Internalizing Immunoconjugates: Model Studies of Enzymatic Drug Release and Antigen-Specific In Vitro Anticancer Activity</span></div><div class="casAuthors">Dubowchik, Gene M.; Firestone, Raymond A.; Padilla, Linda; Willner, David; Hofstead, Sandra J.; Mosure, Kathleen; Knipe, Jay O.; Lasch, Shirley J.; Trail, Pamela A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">855-869</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The anticancer drug doxorubicin (DOX) was linked to chimeric BR96, an internalizing monoclonal antibody that binds to a Lewisy-related, tumor-assocd. antigen, through 2 lysosomally cleavable dipeptides, Phe-Lys and Val-Cit, giving immunoconjugates (I and II).  A self-immolative p-aminobenzyloxycarbonyl (PABC) spacer between the dipeptides and the DOX was required for rapid and quant. generation of free drug. DOX release from the model substrate Z-Phe-Lys-PABC-DOX was 30-fold faster than from Z-Val-Cit-PABC-DOX with the cysteine protease cathepsin B alone, but rates were identical in a rat liver lysosomal prepn. suggesting the participation of more than one enzyme.  Conjugates I and II showed rapid and near quant. drug release with cathepsin B and in a lysosomal prepn., while demonstrating excellent stability in human plasma.  Against tumor cell lines with varying levels of BR96 expression, both conjugates showed potent, antigen-specific cytotoxic activity, suggesting that they will be effective in delivering DOX selectively to antigen-expressing carcinomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqolCImqg5WKbVg90H21EOLACvtfcHk0lh5oDNt9d3nmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksFentr8%253D&md5=09fb70d94d8997033b109fa3b5e79621</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Fbc025536j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc025536j%26sid%3Dliteratum%253Aachs%26aulast%3DDubowchik%26aufirst%3DG.%2BM.%26aulast%3DFirestone%26aufirst%3DR.%2BA.%26aulast%3DPadilla%26aufirst%3DL.%26aulast%3DWillner%26aufirst%3DD.%26aulast%3DHofstead%26aufirst%3DS.%2BJ.%26aulast%3DMosure%26aufirst%3DK.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DLasch%26aufirst%3DS.%2BJ.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26atitle%3DCathepsin%2520B-Labile%2520Dipeptide%2520Linkers%2520for%2520Lysosomal%2520Release%2520of%2520Doxorubicin%2520from%2520Internalizing%2520Immunoconjugates%253A%2520Model%2520Studies%2520of%2520Enzymatic%2520Drug%2520Release%2520and%2520Antigen-Specific%2520in%2520Vitro%2520Anticancer%2520Activity%26jtitle%3DBioconjugate%2520Chem.%26date%3D2002%26volume%3D13%26issue%3D4%26spage%3D855%26epage%3D869%26doi%3D10.1021%2Fbc025536j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mhidia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bézière, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanpain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommery, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnyk, O.</span></span> <span> </span><span class="NLM_article-title">Assembly/disassembly of Drug Conjugates Using Imide Ligation</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">3982</span>– <span class="NLM_lpage">3985</span>, <span class="refDoi"> DOI: 10.1021/ol101049g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol101049g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=3982-3985&issue=18&author=R.+Mhidiaauthor=N.+B%C3%A9zi%C3%A8reauthor=A.+Blanpainauthor=N.+Pommeryauthor=O.+Melnyk&title=Assembly%2Fdisassembly+of+Drug+Conjugates+Using+Imide+Ligation&doi=10.1021%2Fol101049g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1021%2Fol101049g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol101049g%26sid%3Dliteratum%253Aachs%26aulast%3DMhidia%26aufirst%3DR.%26aulast%3DB%25C3%25A9zi%25C3%25A8re%26aufirst%3DN.%26aulast%3DBlanpain%26aufirst%3DA.%26aulast%3DPommery%26aufirst%3DN.%26aulast%3DMelnyk%26aufirst%3DO.%26atitle%3DAssembly%252Fdisassembly%2520of%2520Drug%2520Conjugates%2520Using%2520Imide%2520Ligation%26jtitle%3DOrg.%2520Lett.%26date%3D2010%26volume%3D12%26issue%3D18%26spage%3D3982%26epage%3D3985%26doi%3D10.1021%2Fol101049g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, S.
C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreyka, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardt, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kissler, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kline, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenox, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moser, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okeley, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span> <span> </span><span class="NLM_article-title">Development and Properties of β-Glucuronide Linkers for Monoclonal Antibody-Drug Conjugates</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">840</span>, <span class="refDoi"> DOI: 10.1021/bc0600214</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc0600214" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD28XktVert78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=831-840&issue=3&author=S.%0AC.+Jeffreyauthor=J.+B.+Andreykaauthor=S.+X.+Bernhardtauthor=K.+M.+Kisslerauthor=T.+Klineauthor=J.+S.+Lenoxauthor=R.+F.+Moserauthor=M.+T.+Nguyenauthor=N.+M.+Okeleyauthor=I.+J.+Stoneauthor=X.+Zhangauthor=P.+D.+Senter&title=Development+and+Properties+of+%CE%B2-Glucuronide+Linkers+for+Monoclonal+Antibody-Drug+Conjugates&doi=10.1021%2Fbc0600214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Development and Properties of β-Glucuronide Linkers for Monoclonal Antibody-Drug Conjugates</span></div><div class="casAuthors">Jeffrey, Scott C.; Andreyka, Jamie B.; Bernhardt, Starr X.; Kissler, Kim M.; Kline, Toni; Lenox, Joel S.; Moser, Ruth F.; Nguyen, Minh T.; Okeley, Nicole M.; Stone, Ivan J.; Zhang, Xinqun; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">831-840</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A β-glucuronide-based linker for attaching cytotoxic agents to monoclonal antibodies (mAbs) was designed and evaluated.  We employed the cytotoxic Monomethyl auristatin E (MMAE) and Monomethyl auristatin F (MMAF)and doxorubicin propyloxazoline (DPO) to give the β-glucuronide MMAE, Β-glucuronide MMAF, and (I), resp.  Cysteine-quenched derivs. of Β-glucuronide MMAF and I were detd. to be substrates for E. Coli β-glucuronidase, resulting in facile drug release.  The β-glucuronide MMAF was highly stable in rat plasma with an extrapolated half-life of 81 days.  Each drug-linker when conjugated to mAbs c1F6 (anti-CD70) and cAC10 (anti-CD30) gave monomeric antibody-drug conjugates (ADCs) with as many as eight drugs per mAb and had high levels of immunol. specific cytotoxic activity on cancer cell lines.  CAC10-β-glucuronide MMAE displayed pronounced antitumor activity in a s.c. Karpas 299 lymphoma tumor model.  A single dose treatment led to cures in all animals at the 0.5 mg/kg dose level and above, and the conjugate was well tolerated at 100 mg/kg.  In mice with s.c. renal cell carcinoma xenografts, the MMAF conjugate c1F6-Β-glucuronide MMAF was tolerated at 25 mg/kg and efficacious at 0.75 mg/kg.  These results demonstrate that the β-glucuronide linker system is an effective strategy for targeting cytotoxic agents providing ADCs with high degrees of efficacy at well-tolerated doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoubdLz5MUdl7Vg90H21EOLACvtfcHk0lh5oDNt9d3nmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktVert78%253D&md5=eebae444d27717c44b521eeb8d6c7ed7</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Fbc0600214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc0600214%26sid%3Dliteratum%253Aachs%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26aulast%3DAndreyka%26aufirst%3DJ.%2BB.%26aulast%3DBernhardt%26aufirst%3DS.%2BX.%26aulast%3DKissler%26aufirst%3DK.%2BM.%26aulast%3DKline%26aufirst%3DT.%26aulast%3DLenox%26aufirst%3DJ.%2BS.%26aulast%3DMoser%26aufirst%3DR.%2BF.%26aulast%3DNguyen%26aufirst%3DM.%2BT.%26aulast%3DOkeley%26aufirst%3DN.%2BM.%26aulast%3DStone%26aufirst%3DI.%2BJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DDevelopment%2520and%2520Properties%2520of%2520%25CE%25B2-Glucuronide%2520Linkers%2520for%2520Monoclonal%2520Antibody-Drug%2520Conjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D2006%26volume%3D17%26issue%3D3%26spage%3D831%26epage%3D840%26doi%3D10.1021%2Fbc0600214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span>; <span class="NLM_string-name">Bauer, U.</span>; <span class="NLM_string-name">Engkvist, O.</span></span> <span> </span><span class="NLM_article-title">Merged Multiple Ligands</span>. In  <i>Drug Selectivity</i>; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>, <span class="NLM_year">2017</span>; pp  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">274</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2F9783527674381.ch9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=247-274&author=H.+Chen&author=U.+Bauer&author=O.+Engkvist&title=Drug+Selectivity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1002%2F9783527674381.ch9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527674381.ch9%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26atitle%3DMerged%2520Multiple%2520Ligands%26btitle%3DDrug%2520Selectivity%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2017%26spage%3D247%26epage%3D274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalinowsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">5235</span>– <span class="NLM_lpage">5266</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01287</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01287" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1elsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5235-5266&issue=13&author=E.+Proschakauthor=P.+Heitelauthor=L.+Kalinowskyauthor=D.+Merk&title=Opportunities+and+Challenges+for+Fatty+Acid+Mimetics+in+Drug+Discovery&doi=10.1021%2Facs.jmedchem.6b01287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery</span></div><div class="casAuthors">Proschak, Ewgenij; Heitel, Pascal; Kalinowsky, Lena; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5235-5266</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fatty acids beyond their role as an endogenous energy source and storage are increasingly considered as signaling mols. regulating various physiol. effects in metab. and inflammation.  Accordingly, the mol. targets involved in formation and physiol. activities of fatty acids hold significant therapeutic potential.  A no. of these fatty acid targets are addressed by some of the oldest and most widely used drugs such as cyclooxygenase inhibiting NSAIDs, whereas others remain unexploited.  Compds. orthosterically binding to proteins that endogenously bind fatty acids are considered as fatty acid mimetics.  On the basis of their structural resemblance, fatty acid mimetics constitute a family of bioactive compds. showing specific binding thermodn. and following similar pharmacokinetic mechanisms.  This perspective systematically evaluates targets for fatty acid mimetics, investigates their common structural characteristics, and highlights demands in their discovery and design.  In summary, fatty acid mimetics share particularly favorable characteristics justifying the conclusion that their therapeutic potential vastly outweighs the challenges in their design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjMjaOmukt7bVg90H21EOLACvtfcHk0lh5oDNt9d3nmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1elsrw%253D&md5=78a3a6be0a9d9bfd672c5e851abffc3e</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01287%26sid%3Dliteratum%253Aachs%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DHeitel%26aufirst%3DP.%26aulast%3DKalinowsky%26aufirst%3DL.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DOpportunities%2520and%2520Challenges%2520for%2520Fatty%2520Acid%2520Mimetics%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D13%26spage%3D5235%26epage%3D5266%26doi%3D10.1021%2Facs.jmedchem.6b01287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahon, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V. L.</span></span> <span> </span><span class="NLM_article-title">Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1423</span>– <span class="NLM_lpage">1438</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201100145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fcmdc.201100145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=21608133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptFKrtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=1423-1438&issue=8&author=P.+M.+Woodauthor=L.+W.+L.+Wooauthor=M.+P.+Thomasauthor=M.+F.+Mahonauthor=A.+Purohitauthor=B.+V.+L.+Potter&title=Aromatase+and+Dual+Aromatase-Steroid+Sulfatase+Inhibitors+from+the+Letrozole+and+Vorozole+Templates&doi=10.1002%2Fcmdc.201100145"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates</span></div><div class="casAuthors">Wood, Paul M.; Woo, L. W. Lawrence; Thomas, Mark P.; Mahon, Mary F.; Purohit, Atul; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1423-1438</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Concurrent inhibition of aromatase and steroid sulfatase (STS) may provide a more effective treatment for hormone-dependent breast cancer than monotherapy against individual enzymes, and several dual aromatase-sulfatase inhibitors (DASIs) have been reported.  Three aromatase inhibitors with sub-nanomolar potency, better than the benchmark agent letrozole, were designed.  To further explore the DASI concept, a new series of letrozole-derived sulfamates and a vorozole-based sulfamate were designed and biol. evaluated in JEG-3 cells to reveal structure-activity relationships.  Amongst achiral and racemic compds., 2-bromo-4-(2-(4-cyanophenyl)-2-(1H-1,2,4-triazol-1-yl)ethyl)phenyl sulfamate is the most potent DASI (aromatase: IC50=0.87 nM; STS: IC50=593 nM).  The enantiomers of the phenolic precursor to this compd. were sepd. by chiral HPLC and their abs. configuration detd. by X-ray crystallog.  Following conversion to their corresponding sulfamates, the S-(+)-enantiomer was found to inhibit aromatase and sulfatase most potently (aromatase: IC50=0.52 nM; STS: IC50=280 nM).  The docking of each enantiomer and other ligands into the aromatase and sulfatase active sites was also investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq91XsDqvKlHrVg90H21EOLACvtfcHk0ljI-gbciEE1tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptFKrtrw%253D&md5=94dae7013fdf874ffe1540b8d31122c5</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100145%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DP.%2BM.%26aulast%3DWoo%26aufirst%3DL.%2BW.%2BL.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DMahon%26aufirst%3DM.%2BF.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL.%26atitle%3DAromatase%2520and%2520Dual%2520Aromatase-Steroid%2520Sulfatase%2520Inhibitors%2520from%2520the%2520Letrozole%2520and%2520Vorozole%2520Templates%26jtitle%3DChemMedChem%26date%3D2011%26volume%3D6%26issue%3D8%26spage%3D1423%26epage%3D1438%26doi%3D10.1002%2Fcmdc.201100145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V. L.</span></span> <span> </span><span class="NLM_article-title">Hybrid Dual Aromatase-Steroid Sulfatase Inhibitors with Exquisite Picomolar Inhibitory Activity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1021/ml100273k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100273k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1ags7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=243-247&issue=3&author=L.+W.+L.+Wooauthor=C.+Bubertauthor=A.+Purohitauthor=B.+V.+L.+Potter&title=Hybrid+Dual+Aromatase-Steroid+Sulfatase+Inhibitors+with+Exquisite+Picomolar+Inhibitory+Activity&doi=10.1021%2Fml100273k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrid Dual Aromatase-Steroid Sulfatase Inhibitors with Exquisite Picomolar Inhibitory Activity</span></div><div class="casAuthors">Woo, L. W. Lawrence; Bubert, Christian; Purohit, Atul; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">243-247</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Single agents against multiple drug targets are highly topical.  Hormone-dependent breast cancer (HDBC) may be more effectively treated by dual inhibition of aromatase and steroid sulfatase (STS), and several dual aromatase-sulfatase inhibitors (DASIs) have been recently reported.  The best compds. from two leading classes of DASI, 3 and 9, are low nanomolar inhibitors.  In search of a novel class of DASI, core motifs of two leading classes were combined to give a series of hybrid structures, with several compds. showing markedly improved dual inhibitory activities in the picomolar range in JEG-3 cells.  Thus, DASIs 14 (I, IC50: aromatase, 15 pM; STS, 830 pM) and 15 (IC50: aromatase, 18 pM; STS, 130 pM) are the first examples of an exceptional new class of highly potent dual inhibitor that should encourage further development toward multitargeted therapeutic intervention in HDBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_WoO0V3JbF7Vg90H21EOLACvtfcHk0ljI-gbciEE1tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1ags7zK&md5=2805cabcf0c8210afec7bf65825b24c7</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1021%2Fml100273k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100273k%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DL.%2BW.%2BL.%26aulast%3DBubert%26aufirst%3DC.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL.%26atitle%3DHybrid%2520Dual%2520Aromatase-Steroid%2520Sulfatase%2520Inhibitors%2520with%2520Exquisite%2520Picomolar%2520Inhibitory%2520Activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26issue%3D3%26spage%3D243%26epage%3D247%26doi%3D10.1021%2Fml100273k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W.
L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-Triazol-4-Yl)amino]methyl}phenyl Sulfamate</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">799</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201300015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fcmdc.201300015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=23495205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVentLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=779-799&issue=5&author=L.+W.%0AL.+Wooauthor=P.+M.+Woodauthor=C.+Bubertauthor=M.+P.+Thomasauthor=A.+Purohitauthor=B.+V.+L.+Potter&title=Synthesis+and+Structure-Activity+Relationship+Studies+of+Derivatives+of+the+Dual+Aromatase-Sulfatase+Inhibitor+4-%7B%5B%284-Cyanophenyl%29%284H-1%2C2%2C4-Triazol-4-Yl%29amino%5Dmethyl%7Dphenyl+Sulfamate&doi=10.1002%2Fcmdc.201300015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationship studies of derivatives of the dual aromatase-sulfatase inhibitor 4-{[(4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate</span></div><div class="casAuthors">Woo, L. W. Lawrence; Wood, Paul M.; Bubert, Christian; Thomas, Mark P.; Purohit, Atul; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">779-799</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivs. are first-generation dual aromatase and sulfatase inhibitors (DASIs).  Structure-activity relationship studies were performed on these compds., and various modifications were made to their structures involving relocation of the halogen atom, introduction of more halogen atoms, replacement of the halogen with another group, replacement of the methylene linker with a difluoromethylene linker, replacement of the para-cyanophenyl ring with other ring structures, and replacement of the triazolyl group with an imidazolyl group.  The most potent in vitro DASI discovered is an imidazole deriv. with IC50 values against aromatase and steroid sulfatase in a JEG-3 cell prepn. of 0.2 and 2.5 nM, resp.  The parent phenol of this compd. inhibits aromatase with an IC50 value of 0.028 nM in the same assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDg_Fo94VkELVg90H21EOLACvtfcHk0ljI-gbciEE1tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVentLo%253D&md5=2d34b5f5c7e29c46c959dabd15c441e5</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300015%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DL.%2BW.%2BL.%26aulast%3DWood%26aufirst%3DP.%2BM.%26aulast%3DBubert%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL.%26atitle%3DSynthesis%2520and%2520Structure-Activity%2520Relationship%2520Studies%2520of%2520Derivatives%2520of%2520the%2520Dual%2520Aromatase-Sulfatase%2520Inhibitor%25204-%257B%255B%25284-Cyanophenyl%2529%25284H-1%252C2%252C4-Triazol-4-Yl%2529amino%255Dmethyl%257Dphenyl%2520Sulfamate%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26issue%3D5%26spage%3D779%26epage%3D799%26doi%3D10.1002%2Fcmdc.201300015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutcliffe, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chander, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahon, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V. L.</span></span> <span> </span><span class="NLM_article-title">Dual Aromatase-Steroid Sulfatase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">3540</span>– <span class="NLM_lpage">3560</span>, <span class="refDoi"> DOI: 10.1021/jm061462b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061462b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1CjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=3540-3560&issue=15&author=L.+W.+L.+Wooauthor=C.+Bubertauthor=O.+B.+Sutcliffeauthor=A.+Smithauthor=S.+K.+Chanderauthor=M.+F.+Mahonauthor=A.+Purohitauthor=M.+J.+Reedauthor=B.+V.+L.+Potter&title=Dual+Aromatase-Steroid+Sulfatase+Inhibitors&doi=10.1021%2Fjm061462b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Aromatase-Steroid Sulfatase Inhibitors</span></div><div class="casAuthors">Woo, L. W. Lawrence; Bubert, Christian; Sutcliffe, Oliver B.; Smith, Andrew; Chander, Surinder K.; Mahon, Mary F.; Purohit, Atul; Reed, Michael J.; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3540-3560</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By introducing the steroid sulfatase inhibitory pharmacophore into aromatase inhibitor 1 (YM511), two series of single agent dual aromatase-sulfatase inhibitors (DASIs) were generated.  Two best DASIs (I and II) in vitro (JEG-3 cells) had IC50(aromatase) = 0.82 nM; IC50(sulfatase) = 39 nM, and IC50(aromatase) = 0.77 nM; IC50(sulfatase) = 590 nM, resp.  X-ray crystallog. of I, and docking studies of selected compds. into an aromatase homol. model and the steroid sulfatase crystal structure are presented.  Both I and II inhibit aromatase and sulfatase in PMSG pretreated adult female Wistar rats potently 3 h after a single oral 10 mg/kg dose.  Almost complete dual inhibition is obsd. for I but the levels were reduced to 85% (aromatase) and 72% (sulfatase) after 24 h.  DASI I did not inhibit aldosterone synthesis.  The development of a potent and selective DASI should allow the therapeutic potential of dual aromatase-sulfatase inhibition in hormone-dependent breast cancer to be assessed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPvCTamzS0qbVg90H21EOLACvtfcHk0lig2Jsu02wrVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1CjtLs%253D&md5=69641aaecd430daad1c2f8074be4b436</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1021%2Fjm061462b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061462b%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DL.%2BW.%2BL.%26aulast%3DBubert%26aufirst%3DC.%26aulast%3DSutcliffe%26aufirst%3DO.%2BB.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DChander%26aufirst%3DS.%2BK.%26aulast%3DMahon%26aufirst%3DM.%2BF.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DReed%26aufirst%3DM.%2BJ.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL.%26atitle%3DDual%2520Aromatase-Steroid%2520Sulfatase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D15%26spage%3D3540%26epage%3D3560%26doi%3D10.1021%2Fjm061462b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenney, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titeler, M.</span></span> <span> </span><span class="NLM_article-title">5-HT1 and 5-HT2 Binding Characteristics of Some Quipazine Analogues</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2375</span>– <span class="NLM_lpage">2380</span>, <span class="refDoi"> DOI: 10.1021/jm00161a038</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00161a038" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADyaL2sXltVWmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1986&pages=2375-2380&issue=11&author=R.+A.+Glennonauthor=R.+M.+Slusherauthor=J.+D.+McKenneyauthor=R.+A.+Lyonauthor=M.+Titeler&title=5-HT1+and+5-HT2+Binding+Characteristics+of+Some+Quipazine+Analogues&doi=10.1021%2Fjm00161a038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT1 and 5-HT2:  binding characteristics of some quipazine analogs</span></div><div class="casAuthors">Glennon, Richard A.; Slusher, R. M.; Lyon, Robert A.; Titeler, Milt; McKenney, J. D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2375-80</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Quipazine analogs, e.g., I (R = H, Me; R1 = MeO), II (R2 = piperidino, Pr2N, NH2), and 1-(2-naphthyl)piperazine were prepd.  Thus, 2-chloro-8-methoxyquinoline was treated with N-methylpiperazine to give I (R = Me, R1 = MeO).  The compds. were tested for 5-HT1 and 5-HT2 agonist activity.  The unsubstituted benzene ring of quipazine (I, R = R1 = H) and 1-(2-naphthyl)piperazine make a significant contribution to the binding of these agents to 5-HT2 sites and may account for their 5-HT2 agonist properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR_O2JFtM667Vg90H21EOLACvtfcHk0lig2Jsu02wrVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXltVWmuw%253D%253D&md5=dffa4f48a420e86d8d4f0496d747dc91</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1021%2Fjm00161a038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00161a038%26sid%3Dliteratum%253Aachs%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26aulast%3DSlusher%26aufirst%3DR.%2BM.%26aulast%3DMcKenney%26aufirst%3DJ.%2BD.%26aulast%3DLyon%26aufirst%3DR.%2BA.%26aulast%3DTiteler%26aufirst%3DM.%26atitle%3D5-HT1%2520and%25205-HT2%2520Binding%2520Characteristics%2520of%2520Some%2520Quipazine%2520Analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1986%26volume%3D29%26issue%3D11%26spage%3D2375%26epage%3D2380%26doi%3D10.1021%2Fjm00161a038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagel, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heym, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinick, F. J.</span></span> <span> </span><span class="NLM_article-title">1-Naphthylpiperazine Derivatives as Potential Atypical Antipsychotic Agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1860</span>– <span class="NLM_lpage">1866</span>, <span class="refDoi"> DOI: 10.1021/jm00110a016</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00110a016" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1991&pages=1860-1866&author=J.+A.+Loweauthor=T.+F.+Seegerauthor=A.+A.+Nagelauthor=H.+R.+Howardauthor=P.+A.+Seymourauthor=J.+H.+Heymauthor=F.+E.+Ewingauthor=M.+E.+Newmanauthor=A.+W.+Schmidtauthor=J.+S.+Furmanauthor=L.+A.+Vincentauthor=P.+R.+Maloneyauthor=G.+L.+Robinsonauthor=L.+S.+Reynoldsauthor=F.+J.+Vinick&title=1-Naphthylpiperazine+Derivatives+as+Potential+Atypical+Antipsychotic+Agents&doi=10.1021%2Fjm00110a016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Fjm00110a016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00110a016%26sid%3Dliteratum%253Aachs%26aulast%3DLowe%26aufirst%3DJ.%2BA.%26aulast%3DSeeger%26aufirst%3DT.%2BF.%26aulast%3DNagel%26aufirst%3DA.%2BA.%26aulast%3DHoward%26aufirst%3DH.%2BR.%26aulast%3DSeymour%26aufirst%3DP.%2BA.%26aulast%3DHeym%26aufirst%3DJ.%2BH.%26aulast%3DEwing%26aufirst%3DF.%2BE.%26aulast%3DNewman%26aufirst%3DM.%2BE.%26aulast%3DSchmidt%26aufirst%3DA.%2BW.%26aulast%3DFurman%26aufirst%3DJ.%2BS.%26aulast%3DVincent%26aufirst%3DL.%2BA.%26aulast%3DMaloney%26aufirst%3DP.%2BR.%26aulast%3DRobinson%26aufirst%3DG.%2BL.%26aulast%3DReynolds%26aufirst%3DL.%2BS.%26aulast%3DVinick%26aufirst%3DF.%2BJ.%26atitle%3D1-Naphthylpiperazine%2520Derivatives%2520as%2520Potential%2520Atypical%2520Antipsychotic%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1991%26volume%3D34%26spage%3D1860%26epage%3D1866%26doi%3D10.1021%2Fjm00110a016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howard, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorn, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrone, J.</span></span> <span> </span><span class="NLM_article-title">3-Benzisothiazolylpiperazine Derivatives as Potential Atypical Antipsychotic Agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.1021/jm950625l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm950625l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=143-148&issue=1&author=H.+R.+Howardauthor=J.+A.+Loweauthor=T.+F.+Seegerauthor=P.+A.+Seymourauthor=S.+H.+Zornauthor=P.+R.+Maloneyauthor=F.+E.+Ewingauthor=M.+E.+Newmanauthor=A.+W.+Schmidtauthor=J.+S.+Furmanauthor=G.+L.+Robinsonauthor=E.+Jacksonauthor=C.+Johnsonauthor=J.+Morrone&title=3-Benzisothiazolylpiperazine+Derivatives+as+Potential+Atypical+Antipsychotic+Agents&doi=10.1021%2Fjm950625l"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1021%2Fjm950625l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm950625l%26sid%3Dliteratum%253Aachs%26aulast%3DHoward%26aufirst%3DH.%2BR.%26aulast%3DLowe%26aufirst%3DJ.%2BA.%26aulast%3DSeeger%26aufirst%3DT.%2BF.%26aulast%3DSeymour%26aufirst%3DP.%2BA.%26aulast%3DZorn%26aufirst%3DS.%2BH.%26aulast%3DMaloney%26aufirst%3DP.%2BR.%26aulast%3DEwing%26aufirst%3DF.%2BE.%26aulast%3DNewman%26aufirst%3DM.%2BE.%26aulast%3DSchmidt%26aufirst%3DA.%2BW.%26aulast%3DFurman%26aufirst%3DJ.%2BS.%26aulast%3DRobinson%26aufirst%3DG.%2BL.%26aulast%3DJackson%26aufirst%3DE.%26aulast%3DJohnson%26aufirst%3DC.%26aulast%3DMorrone%26aufirst%3DJ.%26atitle%3D3-Benzisothiazolylpiperazine%2520Derivatives%2520as%2520Potential%2520Atypical%2520Antipsychotic%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26issue%3D1%26spage%3D143%26epage%3D148%26doi%3D10.1021%2Fjm950625l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bautista-Aguilera, Ó. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagenow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palomino-Antolin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farré-Alins, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismaili, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joffrin, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soukup, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janočková, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalinowsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iriepa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraleda, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwed, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero Martínez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López-Muñoz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chioua, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egea, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H3R Antagonism for Neurodegenerative Diseases</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">41</span>),  <span class="NLM_fpage">12765</span>– <span class="NLM_lpage">12769</span>, <span class="refDoi"> DOI: 10.1002/anie.201706072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fanie.201706072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVekt73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=12765-12769&issue=41&author=%C3%93.+M.+Bautista-Aguileraauthor=S.+Hagenowauthor=A.+Palomino-Antolinauthor=V.+Farr%C3%A9-Alinsauthor=L.+Ismailiauthor=P.+L.+Joffrinauthor=M.+L.+Jimenoauthor=O.+Soukupauthor=J.+Jano%C4%8Dkov%C3%A1author=L.+Kalinowskyauthor=E.+Proschakauthor=I.+Iriepaauthor=I.+Moraledaauthor=J.+S.+Schwedauthor=A.+Romero+Mart%C3%ADnezauthor=F.+L%C3%B3pez-Mu%C3%B1ozauthor=M.+Chiouaauthor=J.+Egeaauthor=R.+R.+Ramsayauthor=J.+Marco-Contellesauthor=H.+Stark&title=Multitarget-Directed+Ligands+Combining+Cholinesterase+and+Monoamine+Oxidase+Inhibition+with+Histamine+H3R+Antagonism+for+Neurodegenerative+Diseases&doi=10.1002%2Fanie.201706072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H3R Antagonism for Neurodegenerative Diseases</span></div><div class="casAuthors">Bautista-Aguilera, Oscar M.; Hagenow, Stefanie; Palomino-Antolin, Alejandra; Farre-Alins, Victor; Ismaili, Lhassane; Joffrin, Pierre-Louis; Jimeno, Maria L.; Soukup, Ondrej; Janockova, Jana; Kalinowsky, Lena; Proschak, Ewgenij; Iriepa, Isabel; Moraleda, Ignacio; Schwed, Johannes S.; Romero Martinez, Alejandro; Lopez-Munoz, Francisco; Chioua, Mourad; Egea, Javier; Ramsay, Rona R.; Marco-Contelles, Jose; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">12765-12769</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The therapy of complex neurodegenerative diseases requires the development of multitarget-directed drugs (MTDs).  Novel indole derivs. with inhibitory activity towards acetyl/butyrylcholinesterases and monoamine oxidases A/B as well as the histamine H3 receptor (H3R) were obtained by optimization of the neuroprotectant ASS234 by incorporating generally accepted H3R pharmacophore motifs.  These small-mol. hits demonstrated balanced activities at the targets, mostly in the nanomolar concn. range.  Addnl. in vitro studies showed antioxidative neuroprotective effects as well as the ability to penetrate the blood-brain barrier.  With this promising in vitro profile, contilisant (at 1 mg kg-1 i.p.) also significantly improved lipopolysaccharide-induced cognitive deficits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2wNLAClUFULVg90H21EOLACvtfcHk0lgLPlpiAw_Xmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVekt73L&md5=4a962ad1ada3f5b8e8102add09cd4e60</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1002%2Fanie.201706072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201706072%26sid%3Dliteratum%253Aachs%26aulast%3DBautista-Aguilera%26aufirst%3D%25C3%2593.%2BM.%26aulast%3DHagenow%26aufirst%3DS.%26aulast%3DPalomino-Antolin%26aufirst%3DA.%26aulast%3DFarr%25C3%25A9-Alins%26aufirst%3DV.%26aulast%3DIsmaili%26aufirst%3DL.%26aulast%3DJoffrin%26aufirst%3DP.%2BL.%26aulast%3DJimeno%26aufirst%3DM.%2BL.%26aulast%3DSoukup%26aufirst%3DO.%26aulast%3DJano%25C4%258Dkov%25C3%25A1%26aufirst%3DJ.%26aulast%3DKalinowsky%26aufirst%3DL.%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DIriepa%26aufirst%3DI.%26aulast%3DMoraleda%26aufirst%3DI.%26aulast%3DSchwed%26aufirst%3DJ.%2BS.%26aulast%3DRomero%2BMart%25C3%25ADnez%26aufirst%3DA.%26aulast%3DL%25C3%25B3pez-Mu%25C3%25B1oz%26aufirst%3DF.%26aulast%3DChioua%26aufirst%3DM.%26aulast%3DEgea%26aufirst%3DJ.%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DMultitarget-Directed%2520Ligands%2520Combining%2520Cholinesterase%2520and%2520Monoamine%2520Oxidase%2520Inhibition%2520with%2520Histamine%2520H3R%2520Antagonism%2520for%2520Neurodegenerative%2520Diseases%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26issue%3D41%26spage%3D12765%26epage%3D12769%26doi%3D10.1002%2Fanie.201706072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bento, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaulton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellis, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krüger, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Light, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGlinchey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowotka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadatos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span> <span> </span><span class="NLM_article-title">The ChEMBL Bioactivity Database: An Update</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">D1083</span>– <span class="NLM_lpage">D1090</span>, <span class="refDoi"> DOI: 10.1093/nar/gkt1031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1093%2Fnar%2Fgkt1031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=24214965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXoslWl" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=D1083-D1090&author=A.+P.+Bentoauthor=A.+Gaultonauthor=A.+Herseyauthor=L.+J.+Bellisauthor=J.+Chambersauthor=M.+Daviesauthor=F.+A.+Kr%C3%BCgerauthor=Y.+Lightauthor=L.+Makauthor=S.+McGlincheyauthor=M.+Nowotkaauthor=G.+Papadatosauthor=R.+Santosauthor=J.+P.+Overington&title=The+ChEMBL+Bioactivity+Database%3A+An+Update&doi=10.1093%2Fnar%2Fgkt1031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">The ChEMBL bioactivity database: an update</span></div><div class="casAuthors">Bento, A. Patricia; Gaulton, Anna; Hersey, Anne; Bellis, Louisa J.; Chambers, Jon; Davies, Mark; Krueger, Felix A.; Light, Yvonne; Mak, Lora; McGlinchey, Shaun; Nowotka, Michal; Papadatos, George; Santos, Rita; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D1083-D1090</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">ChEMBL is an open large-scale bioactivity database (https://www.ebi.ac.uk/chembl), previously described in the 2012 Nucleic Acids Research Database Issue.  Since then, a variety of new data sources and improvements in functionality have contributed to the growth and utility of the resource.  In particular, more comprehensive tracking of compds. from research stages through clin. development to market is provided through the inclusion of data from United States Adopted Name applications; a new richer data model for representing drug targets has been developed; and a no. of methods have been put in place to allow users to more easily identify reliable data.  Finally, access to ChEMBL is now available via a new Resource Description Framework format, in addn. to the web-based interface, data downloads and web services.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXb5k1IvJNaLVg90H21EOLACvtfcHk0lgLPlpiAw_Xmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXoslWl&md5=31b832d03d56ea3065d7aa29618362bc</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkt1031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkt1031%26sid%3Dliteratum%253Aachs%26aulast%3DBento%26aufirst%3DA.%2BP.%26aulast%3DGaulton%26aufirst%3DA.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DBellis%26aufirst%3DL.%2BJ.%26aulast%3DChambers%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DM.%26aulast%3DKr%25C3%25BCger%26aufirst%3DF.%2BA.%26aulast%3DLight%26aufirst%3DY.%26aulast%3DMak%26aufirst%3DL.%26aulast%3DMcGlinchey%26aufirst%3DS.%26aulast%3DNowotka%26aufirst%3DM.%26aulast%3DPapadatos%26aufirst%3DG.%26aulast%3DSantos%26aufirst%3DR.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520ChEMBL%2520Bioactivity%2520Database%253A%2520An%2520Update%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2014%26volume%3D42%26spage%3DD1083%26epage%3DD1090%26doi%3D10.1093%2Fnar%2Fgkt1031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gindulyte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiessen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">PubChem BioAssay: 2017 Update</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">D1</span>),  <span class="NLM_fpage">D955</span>– <span class="NLM_lpage">D963</span>, <span class="refDoi"> DOI: 10.1093/nar/gkw1118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1093%2Fnar%2Fgkw1118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27899599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslWhsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=D955-D963&issue=D1&author=Y.+Wangauthor=S.+H.+Bryantauthor=T.+Chengauthor=J.+Wangauthor=A.+Gindulyteauthor=B.+A.+Shoemakerauthor=P.+A.+Thiessenauthor=S.+Heauthor=J.+Zhang&title=PubChem+BioAssay%3A+2017+Update&doi=10.1093%2Fnar%2Fgkw1118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">PubChem BioAssay: 2017 update</span></div><div class="casAuthors">Wang, Yanli; Bryant, Stephen H.; Cheng, Tiejun; Wang, Jiyao; Gindulyte, Asta; Shoemaker, Benjamin A.; Thiessen, Paul A.; He, Siqian; Zhang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D955-D963</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">PubChem's BioAssay database (https://pubchem.ncbi.nlm.nih.gov) has served as a public repository for small-mol. and RNAi screening data since 2004 providing open access of its data content to the community.  PubChem accepts data submission from worldwide researchers at academia, industry and government agencies.  PubChem also collaborates with other chem. biol. database stakeholders with data exchange.  With over a decade's development effort, it becomes an important information resource supporting drug discovery and chem. biol. research.  To facilitate data discovery, PubChem is integrated with all other databases at NCBI.  In this work, we provide an update for the Pub- Chem BioAssay database describing several recent development including added sources of research data, redesigned BioAssay record page, new BioAssay classification browser and new features in the Upload system facilitating data sharing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptFOpprG7GhLVg90H21EOLACvtfcHk0lgLPlpiAw_Xmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslWhsbw%253D&md5=4043316b6be487277f360fb4cc2beabb</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkw1118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkw1118%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DBryant%26aufirst%3DS.%2BH.%26aulast%3DCheng%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGindulyte%26aufirst%3DA.%26aulast%3DShoemaker%26aufirst%3DB.%2BA.%26aulast%3DThiessen%26aufirst%3DP.%2BA.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DPubChem%2520BioAssay%253A%25202017%2520Update%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2017%26volume%3D45%26issue%3DD1%26spage%3DD955%26epage%3DD963%26doi%3D10.1093%2Fnar%2Fgkw1118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, M.</span></span> <span> </span><span class="NLM_article-title">Extended-Connectivity Fingerprints</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">754</span>, <span class="refDoi"> DOI: 10.1021/ci100050t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci100050t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlt1Onsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=742-754&issue=5&author=D.+Rogersauthor=M.+Hahn&title=Extended-Connectivity+Fingerprints&doi=10.1021%2Fci100050t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Extended-Connectivity Fingerprints</span></div><div class="casAuthors">Rogers, David; Hahn, Mathew</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">742-754</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Extended-connectivity fingerprints (ECFPs) are a novel class of topol. fingerprints for mol. characterization.  Historically, topol. fingerprints were developed for substructure and similarity searching.  ECFPs were developed specifically for structure-activity modeling.  ECFPs are circular fingerprints with a no. of useful qualities: they can be very rapidly calcd.; they are not predefined and can represent an essentially infinite no. of different mol. features (including stereochem. information); their features represent the presence of particular substructures, allowing easier interpretation of anal. results; and the ECFP algorithm can be tailored to generate different types of circular fingerprints, optimized for different uses.  While the use of ECFPs has been widely adopted and validated, a description of their implementation has not previously been presented in the literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra43orI-Y7lbVg90H21EOLACvtfcHk0lhpSjYS9KtBCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlt1Onsbg%253D&md5=cd6c736cd7a3d280b67f5316acce8006</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1021%2Fci100050t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci100050t%26sid%3Dliteratum%253Aachs%26aulast%3DRogers%26aufirst%3DD.%26aulast%3DHahn%26aufirst%3DM.%26atitle%3DExtended-Connectivity%2520Fingerprints%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2010%26volume%3D50%26issue%3D5%26spage%3D742%26epage%3D754%26doi%3D10.1021%2Fci100050t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnby, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span> <span> </span><span class="NLM_article-title">Circular Fingerprints: Flexible Molecular Descriptors with Applications from Physical Chemistry to ADME</span>. <i>IDrugs</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">204</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=16523386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD28Xjt12jtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2006&pages=199-204&issue=3&author=R.+C.+Glenauthor=A.+Benderauthor=C.+H.+Arnbyauthor=L.+Carlssonauthor=S.+Boyerauthor=J.+Smith&title=Circular+Fingerprints%3A+Flexible+Molecular+Descriptors+with+Applications+from+Physical+Chemistry+to+ADME"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Circular fingerprints: flexible molecular descriptors with applications from physical chemistry to ADME</span></div><div class="casAuthors">Glen, Robert C.; Bender, Andreas; Arnby, Catrin H.; Carlsson, Lars; Boyer, Scott; Smith, James</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">199-204</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">1369-7056</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  Circular fingerprints - the representation of mol. structures by atom neighborhoods - have been applied to a wide range of applications, such as similarity searching and the prediction of absorption, distribution, metab., excretion and toxicity properties.  In recent years there has been a surge in applications resulting from the superior performance of circular fingerprints in comparative studies.  This feature examines the nature of circular fingerprints as well as their applications, including virtual screening, metab. prediction and the estn. of pKa consts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXLQM7euMKYrVg90H21EOLACvtfcHk0lhpSjYS9KtBCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xjt12jtbk%253D&md5=40c48ee2893434e833a843aa793dcdad</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DArnby%26aufirst%3DC.%2BH.%26aulast%3DCarlsson%26aufirst%3DL.%26aulast%3DBoyer%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DJ.%26atitle%3DCircular%2520Fingerprints%253A%2520Flexible%2520Molecular%2520Descriptors%2520with%2520Applications%2520from%2520Physical%2520Chemistry%2520to%2520ADME%26jtitle%3DIDrugs%26date%3D2006%26volume%3D9%26issue%3D3%26spage%3D199%26epage%3D204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jasper, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbeck, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkjost, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, O.</span></span> <span> </span><span class="NLM_article-title">A Novel Interaction Fingerprint Derived from per Atom Score Contributions: Exhaustive Evaluation of Interaction Fingerprint Performance in Docking Based Virtual Screening</span>. <i>J. Cheminf.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">15</span>, <span class="refDoi"> DOI: 10.1186/s13321-018-0264-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1186%2Fs13321-018-0264-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtFWhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=15&author=J.+B.+Jasperauthor=L.+Humbeckauthor=T.+Brinkjostauthor=O.+Koch&title=A+Novel+Interaction+Fingerprint+Derived+from+per+Atom+Score+Contributions%3A+Exhaustive+Evaluation+of+Interaction+Fingerprint+Performance+in+Docking+Based+Virtual+Screening&doi=10.1186%2Fs13321-018-0264-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">A novel interaction fingerprint derived from per atom score contributions: exhaustive evaluation of interaction fingerprint performance in docking based virtual screening</span></div><div class="casAuthors">Jasper, Julia B.; Humbeck, Lina; Brinkjost, Tobias; Koch, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cheminformatics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15/1-15/13</span>CODEN:
                <span class="NLM_cas:coden">JCOHB3</span>;
        ISSN:<span class="NLM_cas:issn">1758-2946</span>.
    
            (<span class="NLM_cas:orgname">Chemistry Central Ltd.</span>)
        </div><div class="casAbstract">Protein ligand interaction fingerprints are a powerful approach for the anal. and assessment of docking poses to improve docking performance in virtual screening.  In this study, a novel interaction fingerprint approach (PADIF, protein per atom score contributions derived interaction fingerprint) is presented which was specifically designed for utilizing the GOLD scoring functions' atom contributions together with a specific scoring scheme.  This allows the incorporation of known protein-ligand complex structures for a target-specific scoring.  Unlike many other methods, this approach uses weighting factors reflecting the relative frequency of a specific interaction in the refs. and penalizes destabilizing interactions.  In addn., and for the first time, an exhaustive validation study was performed that assesses the performance of PADIF and two other interaction fingerprints in virtual screening.  Here, PADIF shows superior results, and some rules of thumb for a successful use of interaction fingerprints could be identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqafuamkpf1x7Vg90H21EOLACvtfcHk0lhpSjYS9KtBCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtFWhs7s%253D&md5=ffee53311343c44c37879e0d105daad0</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1186%2Fs13321-018-0264-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13321-018-0264-0%26sid%3Dliteratum%253Aachs%26aulast%3DJasper%26aufirst%3DJ.%2BB.%26aulast%3DHumbeck%26aufirst%3DL.%26aulast%3DBrinkjost%26aufirst%3DT.%26aulast%3DKoch%26aufirst%3DO.%26atitle%3DA%2520Novel%2520Interaction%2520Fingerprint%2520Derived%2520from%2520per%2520Atom%2520Score%2520Contributions%253A%2520Exhaustive%2520Evaluation%2520of%2520Interaction%2520Fingerprint%2520Performance%2520in%2520Docking%2520Based%2520Virtual%2520Screening%26jtitle%3DJ.%2520Cheminf.%26date%3D2018%26volume%3D10%26spage%3D15%26doi%3D10.1186%2Fs13321-018-0264-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Méndez-Lucio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kooistra, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graaf, C. de</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina-Franco, J. L.</span></span> <span> </span><span class="NLM_article-title">Analyzing Multitarget Activity Landscapes Using Protein-Ligand Interaction Fingerprints: Interaction Cliffs</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1021/ci500721x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci500721x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtl2js7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2015&pages=251-262&issue=2&author=O.+M%C3%A9ndez-Lucioauthor=A.+J.+Kooistraauthor=C.+de+Graafauthor=A.+Benderauthor=J.+L.+Medina-Franco&title=Analyzing+Multitarget+Activity+Landscapes+Using+Protein-Ligand+Interaction+Fingerprints%3A+Interaction+Cliffs&doi=10.1021%2Fci500721x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Analyzing Multitarget Activity Landscapes Using Protein-Ligand Interaction Fingerprints: Interaction Cliffs</span></div><div class="casAuthors">Mendez-Lucio, Oscar; Kooistra, Albert J.; Graaf, Chris de; Bender, Andreas; Medina-Franco, Jose L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">251-262</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Activity landscape modeling is mostly a descriptive technique that allows rationalizing continuous and discontinuous SARs.  Nevertheless, the interpretation of some landscape features, esp. of activity cliffs, is not straightforward.  As the nature of activity cliffs depends on the ligand and the target, information regarding both should be included in the anal.  A specific way to include this information is using protein-ligand interaction fingerprints (IFPs).  In this paper we report the activity landscape modeling of 507 ligand-kinase complexes (from the KLIFS database) including IFP, which facilitates the anal. and interpretation of activity cliffs.  Here we introduce the structure-activity-interaction similarity (SAIS) maps that incorporate information on ligand-target contact similarity.  We also introduce the concept of interaction cliffs defined as ligand-target complexes with high structural and interaction similarity but have a large potency difference of the ligands.  Moreover, the information retrieved regarding the specific interaction allowed the identification of activity cliff hot spots, which help to rationalize activity cliffs from the target point of view.  In general, the information provided by IFPs provides a structure-based understanding of some activity landscape features.  This paper shows examples of analyses that can be carried out when IFPs are added to the activity landscape model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWirYbPsbpybVg90H21EOLACvtfcHk0lhpSjYS9KtBCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtl2js7s%253D&md5=49e68e735c4ef76024a2f6ffaaebb883</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1021%2Fci500721x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci500721x%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A9ndez-Lucio%26aufirst%3DO.%26aulast%3DKooistra%26aufirst%3DA.%2BJ.%26aulast%3DGraaf%26aufirst%3DC.%2Bde%26aulast%3DBender%26aufirst%3DA.%26aulast%3DMedina-Franco%26aufirst%3DJ.%2BL.%26atitle%3DAnalyzing%2520Multitarget%2520Activity%2520Landscapes%2520Using%2520Protein-Ligand%2520Interaction%2520Fingerprints%253A%2520Interaction%2520Cliffs%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2015%26volume%3D55%26issue%3D2%26spage%3D251%26epage%3D262%26doi%3D10.1021%2Fci500721x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Da, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kireev, D.</span></span> <span> </span><span class="NLM_article-title">Structural Protein-Ligand Interaction Fingerprints (SPLIF) for Structure-Based Virtual Screening: Method and Benchmark Study</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2555</span>– <span class="NLM_lpage">2561</span>, <span class="refDoi"> DOI: 10.1021/ci500319f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci500319f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtleqt7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2014&pages=2555-2561&issue=9&author=C.+Daauthor=D.+Kireev&title=Structural+Protein-Ligand+Interaction+Fingerprints+%28SPLIF%29+for+Structure-Based+Virtual+Screening%3A+Method+and+Benchmark+Study&doi=10.1021%2Fci500319f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Protein-Ligand Interaction Fingerprints (SPLIF) for Structure-Based Virtual Screening: Method and Benchmark Study</span></div><div class="casAuthors">Da, C.; Kireev, D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2555-2561</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Accurate and affordable assessment of ligand-protein affinity for structure-based virtual screening (SB-VS) is a standing challenge.  Hence, empirical postdocking filters making use of various types of structure-activity information may prove useful.  Here, the authors introduce one such filter based upon three-dimensional structural protein-ligand interaction fingerprints (SPLIF).  SPLIF permits quant. assessment of whether a docking pose interacts with the protein target similarly to a known ligand and rescues active compds. penalized by poor initial docking scores.  An extensive benchmark study on 10 diverse data sets selected from the DUD-E database has been performed to evaluate the abs. and relative efficiency of this method.  SPLIF demonstrated an overall better performance than relevant std. methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBHPcDLkZEQrVg90H21EOLACvtfcHk0liuFBfHT16jpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtleqt7fP&md5=cef74887e6a233a638c79d44cdd44023</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1021%2Fci500319f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci500319f%26sid%3Dliteratum%253Aachs%26aulast%3DDa%26aufirst%3DC.%26aulast%3DKireev%26aufirst%3DD.%26atitle%3DStructural%2520Protein-Ligand%2520Interaction%2520Fingerprints%2520%2528SPLIF%2529%2520for%2520Structure-Based%2520Virtual%2520Screening%253A%2520Method%2520and%2520Benchmark%2520Study%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2014%26volume%3D54%26issue%3D9%26spage%3D2555%26epage%3D2561%26doi%3D10.1021%2Fci500319f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reutlinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todoroff, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span> <span> </span><span class="NLM_article-title">Chemically Advanced Template Search (CATS) for Scaffold-Hopping and Prospective Target Prediction for “Orphan” Molecules</span>. <i>Mol. Inf.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1002/minf.201200141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fminf.201200141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=23956801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitFeisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=133-138&issue=2&author=M.+Reutlingerauthor=C.+P.+Kochauthor=D.+Rekerauthor=N.+Todoroffauthor=P.+Schneiderauthor=T.+Rodriguesauthor=G.+Schneider&title=Chemically+Advanced+Template+Search+%28CATS%29+for+Scaffold-Hopping+and+Prospective+Target+Prediction+for+%E2%80%9COrphan%E2%80%9D+Molecules&doi=10.1002%2Fminf.201200141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically Advanced Template Search (CATS) for Scaffold-Hopping and Prospective Target Prediction for Orphan' Molecules</span></div><div class="casAuthors">Reutlinger, Michael; Koch, Christian P.; Reker, Daniel; Todoroff, Nickolay; Schneider, Petra; Rodrigues, Tiago; Schneider, Gisbert</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Informatics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-138</span>CODEN:
                <span class="NLM_cas:coden">MIONBS</span>;
        ISSN:<span class="NLM_cas:issn">1868-1743</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">In this study, the authors compared several popular two-dimensional mol. representations for their ability to retrieve actives (enrichment potential) and chemotypes (scaffold-hopping potential) from a collection of drug-like bioactive substances.  Subsequently the applied chem. advanced template search (CATS) was applied to predicting potential drug targets for a virtually assembled combinatorial compd. library, from which we synthesized and successfully tested candidate compds.  The results demonstrate that CATS is not only suited for its intended purpose of NCE retrieval by scaffold-hopping, but also for reliable target profiling of 'orphan' virtual mols.  This study's results corroborate CATS + SOM as a useful similarity-based approach for identifying pairs of mols. with similar bioactivity but different mol. scaffolds.  Inclusion of the arom. feature type in the CATS2 implementation increased enrichment in a retrospective anal.  Results of a preliminary prospective target-profiling study demonstrate that (i) the CATS2 descriptor may be employed to predict targets of virtually generated compds. with potential applications in de novo design and drug re-purposing, (ii) relying only on a single prediction algorithm bears the danger of missing relevant drug targets or focusing on false-pos. predictions, and (iii) different mol. descriptors (here: CATS2; SEA with ECFP4 fingerprints) in combination with its assocd. knowledge base (here: COBRA or ChEMBL) complement each other in their domains of applicability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjMpux8IBXebVg90H21EOLACvtfcHk0liuFBfHT16jpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitFeisLY%253D&md5=77426afd74fd95c09723429280cc0ffc</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1002%2Fminf.201200141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fminf.201200141%26sid%3Dliteratum%253Aachs%26aulast%3DReutlinger%26aufirst%3DM.%26aulast%3DKoch%26aufirst%3DC.%2BP.%26aulast%3DReker%26aufirst%3DD.%26aulast%3DTodoroff%26aufirst%3DN.%26aulast%3DSchneider%26aufirst%3DP.%26aulast%3DRodrigues%26aufirst%3DT.%26aulast%3DSchneider%26aufirst%3DG.%26atitle%3DChemically%2520Advanced%2520Template%2520Search%2520%2528CATS%2529%2520for%2520Scaffold-Hopping%2520and%2520Prospective%2520Target%2520Prediction%2520for%2520%25E2%2580%259COrphan%25E2%2580%259D%2520Molecules%26jtitle%3DMol.%2520Inf.%26date%3D2013%26volume%3D32%26issue%3D2%26spage%3D133%26epage%3D138%26doi%3D10.1002%2Fminf.201200141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nikolic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavridis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bautista-Aguilera, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">do Carmo Carreiras, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massarelli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agbaba, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, J. B. O.</span></span> <span> </span><span class="NLM_article-title">Predicting Targets of Compounds against Neurological Diseases Using Cheminformatic Methodology</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1007/s10822-014-9816-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1007%2Fs10822-014-9816-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=183-198&issue=2&author=K.+Nikolicauthor=L.+Mavridisauthor=O.+M.+Bautista-Aguileraauthor=J.+Marco-Contellesauthor=H.+Starkauthor=M.+do+Carmo+Carreirasauthor=I.+Rossiauthor=P.+Massarelliauthor=D.+Agbabaauthor=R.+R.+Ramsayauthor=J.+B.+O.+Mitchell&title=Predicting+Targets+of+Compounds+against+Neurological+Diseases+Using+Cheminformatic+Methodology&doi=10.1007%2Fs10822-014-9816-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1007%2Fs10822-014-9816-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-014-9816-1%26sid%3Dliteratum%253Aachs%26aulast%3DNikolic%26aufirst%3DK.%26aulast%3DMavridis%26aufirst%3DL.%26aulast%3DBautista-Aguilera%26aufirst%3DO.%2BM.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DStark%26aufirst%3DH.%26aulast%3Ddo%2BCarmo%2BCarreiras%26aufirst%3DM.%26aulast%3DRossi%26aufirst%3DI.%26aulast%3DMassarelli%26aufirst%3DP.%26aulast%3DAgbaba%26aufirst%3DD.%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DMitchell%26aufirst%3DJ.%2BB.%2BO.%26atitle%3DPredicting%2520Targets%2520of%2520Compounds%2520against%2520Neurological%2520Diseases%2520Using%2520Cheminformatic%2520Methodology%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2015%26volume%3D29%26issue%3D2%26spage%3D183%26epage%3D198%26doi%3D10.1007%2Fs10822-014-9816-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wale, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karypis, G.</span></span> <span> </span><span class="NLM_article-title">Target Fishing for Chemical Compounds Using Target-Ligand Activity Data and Ranking Based Methods</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2190</span>– <span class="NLM_lpage">2201</span>, <span class="refDoi"> DOI: 10.1021/ci9000376</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci9000376" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFGiurfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=2190-2201&issue=10&author=N.+Waleauthor=G.+Karypis&title=Target+Fishing+for+Chemical+Compounds+Using+Target-Ligand+Activity+Data+and+Ranking+Based+Methods&doi=10.1021%2Fci9000376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Target fishing for chemical compounds using target-ligand activity data and ranking based methods</span></div><div class="casAuthors">Wale, Nikil; Karypis, George</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2190-2201</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In recent years, the development of computational techniques that identify all the likely targets for a given chem. compd., also termed as the problem of Target Fishing, has been an active area of research.  Identification of likely targets of a chem. compd. in the early stages of drug discovery helps to understand issues such as selectivity, off-target pharmacol., and toxicity.  In this paper, we present a set of techniques whose goal is to rank or prioritize targets in the context of a given chem. compd. so that most targets against which this compd. may show activity appear higher in the ranked list.  These methods are based on our extensions to the SVM and ranking perception algorithms for this problem.  Our extensive exptl. study shows that the methods developed in this work outperform previous approaches 2% to 60% under different evaluation criterions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8s3kPZTP7w7Vg90H21EOLACvtfcHk0ljeFoxAi-Zjow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFGiurfF&md5=ebe62bd736132eae1966247529013b45</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1021%2Fci9000376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci9000376%26sid%3Dliteratum%253Aachs%26aulast%3DWale%26aufirst%3DN.%26aulast%3DKarypis%26aufirst%3DG.%26atitle%3DTarget%2520Fishing%2520for%2520Chemical%2520Compounds%2520Using%2520Target-Ligand%2520Activity%2520Data%2520and%2520Ranking%2520Based%2520Methods%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26issue%3D10%26spage%3D2190%26epage%3D2201%26doi%3D10.1021%2Fci9000376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raevsky, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhametov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigorev, V. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ustyugov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsay, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jih-Ru
Hwu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarla, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barreto, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliev, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachurin, S. O.</span></span> <span> </span><span class="NLM_article-title">Applications of Multi-Target Computer-Aided Methodologies in Molecular Design of CNS Drugs</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>, <span class="refDoi"> DOI: 10.2174/0929867324666170920154111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F0929867324666170920154111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28933295" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=O.+A.+Raevskyauthor=A.+Mukhametovauthor=V.+Y.+Grigorevauthor=A.+Ustyugovauthor=S.-C.+Tsayauthor=R.+Jih-Ru%0AHwuauthor=N.+S.+Yarlaauthor=G.+E.+Barretoauthor=G.+Alievauthor=S.+O.+Bachurin&title=Applications+of+Multi-Target+Computer-Aided+Methodologies+in+Molecular+Design+of+CNS+Drugs&doi=10.2174%2F0929867324666170920154111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.2174%2F0929867324666170920154111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867324666170920154111%26sid%3Dliteratum%253Aachs%26aulast%3DRaevsky%26aufirst%3DO.%2BA.%26aulast%3DMukhametov%26aufirst%3DA.%26aulast%3DGrigorev%26aufirst%3DV.%2BY.%26aulast%3DUstyugov%26aufirst%3DA.%26aulast%3DTsay%26aufirst%3DS.-C.%26aulast%3DJih-Ru%2BHwu%26aufirst%3DR.%26aulast%3DYarla%26aufirst%3DN.%2BS.%26aulast%3DBarreto%26aufirst%3DG.%2BE.%26aulast%3DAliev%26aufirst%3DG.%26aulast%3DBachurin%26aufirst%3DS.%2BO.%26atitle%3DApplications%2520of%2520Multi-Target%2520Computer-Aided%2520Methodologies%2520in%2520Molecular%2520Design%2520of%2520CNS%2520Drugs%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2017%26doi%3D10.2174%2F0929867324666170920154111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalash, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Val, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azuaje, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loza, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoufir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mervin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladds, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brea, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotelo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span> <span> </span><span class="NLM_article-title">Computer-Aided Design of Multi-Target Ligands at A1R, A2AR and PDE10A, Key Proteins in Neurodegenerative Diseases</span>. <i>J. Cheminf.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">67</span>, <span class="refDoi"> DOI: 10.1186/s13321-017-0249-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1186%2Fs13321-017-0249-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=67&author=L.+Kalashauthor=C.+Valauthor=J.+Azuajeauthor=M.+I.+Lozaauthor=F.+Svenssonauthor=A.+Zoufirauthor=L.+Mervinauthor=G.+Laddsauthor=J.+Breaauthor=R.+Glenauthor=E.+Soteloauthor=A.+Bender&title=Computer-Aided+Design+of+Multi-Target+Ligands+at+A1R%2C+A2AR+and+PDE10A%2C+Key+Proteins+in+Neurodegenerative+Diseases&doi=10.1186%2Fs13321-017-0249-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1186%2Fs13321-017-0249-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13321-017-0249-4%26sid%3Dliteratum%253Aachs%26aulast%3DKalash%26aufirst%3DL.%26aulast%3DVal%26aufirst%3DC.%26aulast%3DAzuaje%26aufirst%3DJ.%26aulast%3DLoza%26aufirst%3DM.%2BI.%26aulast%3DSvensson%26aufirst%3DF.%26aulast%3DZoufir%26aufirst%3DA.%26aulast%3DMervin%26aufirst%3DL.%26aulast%3DLadds%26aufirst%3DG.%26aulast%3DBrea%26aufirst%3DJ.%26aulast%3DGlen%26aufirst%3DR.%26aulast%3DSotelo%26aufirst%3DE.%26aulast%3DBender%26aufirst%3DA.%26atitle%3DComputer-Aided%2520Design%2520of%2520Multi-Target%2520Ligands%2520at%2520A1R%252C%2520A2AR%2520and%2520PDE10A%252C%2520Key%2520Proteins%2520in%2520Neurodegenerative%2520Diseases%26jtitle%3DJ.%2520Cheminf.%26date%3D2017%26volume%3D9%26spage%3D67%26doi%3D10.1186%2Fs13321-017-0249-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klabunde, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giegerich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, A.</span></span> <span> </span><span class="NLM_article-title">MARS: Computing Three-Dimensional Alignments for Multiple Ligands Using Pairwise Similarities</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2022</span>– <span class="NLM_lpage">2030</span>, <span class="refDoi"> DOI: 10.1021/ci3000369</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci3000369" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVaktrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=2022-2030&issue=8&author=T.+Klabundeauthor=C.+Giegerichauthor=A.+Evers&title=MARS%3A+Computing+Three-Dimensional+Alignments+for+Multiple+Ligands+Using+Pairwise+Similarities&doi=10.1021%2Fci3000369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">MARS: Computing Three-Dimensional Alignments for Multiple Ligands Using Pairwise Similarities</span></div><div class="casAuthors">Klabunde, Thomas; Giegerich, Clemens; Evers, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2022-2030</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The three-dimensional (3D) superimposition of mols. of one biol. target reflecting their relative bioactive orientation is key for several ligand-based drug design studies (e.g., QSAR studies, pharmacophore modeling).  However, with the lack of sufficient ligand-protein complex structures, an exptl. alignment is difficult or often impossible to obtain.  Several computational 3D alignment tools have been developed by academic or com. groups to address this challenge.  Here, we present a new approach, MARS (Multiple Alignments by ROCS-based Similarity), that is based on the pairwise alignment of all mols. within the data set using the tool ROCS (Rapid Overlay of Chem. Structures).  Each pairwise alignment is scored, and the results are captured in a score matrix.  The ideal superimposition of the compds. in the set is then identified by the anal. of the score matrix building stepwise a superimposition of all mols.  The algorithm exploits similarities among all mols. in the data set to compute an optimal 3D alignment.  This alignment tool presented here can be used for several applications, including pharmacophore model generation, 3D QSAR modeling, 3D clustering, identification of structural outliers, and addn. of compds. to an already existing alignment.  Case studies are shown, validating the 3D alignments for six different data sets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBgAGzrLYIwrVg90H21EOLACvtfcHk0ljeFoxAi-Zjow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVaktrrO&md5=a5c741f942d8c7e5a091b02043308b34</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1021%2Fci3000369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci3000369%26sid%3Dliteratum%253Aachs%26aulast%3DKlabunde%26aufirst%3DT.%26aulast%3DGiegerich%26aufirst%3DC.%26aulast%3DEvers%26aufirst%3DA.%26atitle%3DMARS%253A%2520Computing%2520Three-Dimensional%2520Alignments%2520for%2520Multiple%2520Ligands%2520Using%2520Pairwise%2520Similarities%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26issue%3D8%26spage%3D2022%26epage%3D2030%26doi%3D10.1021%2Fci3000369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedrich, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grisoni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span> <span> </span><span class="NLM_article-title">De Novo Design of Bioactive Small Molecules by Artificial Intelligence</span>. <i>Mol. Inf.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1700153</span>, <span class="refDoi"> DOI: 10.1002/minf.201700153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fminf.201700153" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=1700153&issue=1&author=D.+Merkauthor=L.+Friedrichauthor=F.+Grisoniauthor=G.+Schneider&title=De+Novo+Design+of+Bioactive+Small+Molecules+by+Artificial+Intelligence&doi=10.1002%2Fminf.201700153"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1002%2Fminf.201700153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fminf.201700153%26sid%3Dliteratum%253Aachs%26aulast%3DMerk%26aufirst%3DD.%26aulast%3DFriedrich%26aufirst%3DL.%26aulast%3DGrisoni%26aufirst%3DF.%26aulast%3DSchneider%26aufirst%3DG.%26atitle%3DDe%2520Novo%2520Design%2520of%2520Bioactive%2520Small%2520Molecules%2520by%2520Artificial%2520Intelligence%26jtitle%3DMol.%2520Inf.%26date%3D2018%26volume%3D37%26issue%3D1%26spage%3D1700153%26doi%3D10.1002%2Fminf.201700153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Handler, N.</span></span> <span> </span><span class="NLM_article-title">Pharmacophore Generation for Multiple Ligands</span>. In  <i>Drug Selectivity</i>; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>, <span class="NLM_year">2017</span>; pp  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">312</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2F9783527674381.ch10" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=275-312&author=N.+Handler&title=Drug+Selectivity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1002%2F9783527674381.ch10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527674381.ch10%26sid%3Dliteratum%253Aachs%26aulast%3DHandler%26aufirst%3DN.%26atitle%3DPharmacophore%2520Generation%2520for%2520Multiple%2520Ligands%26btitle%3DDrug%2520Selectivity%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2017%26spage%3D275%26epage%3D312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolber, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendix, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, T.</span></span> <span> </span><span class="NLM_article-title">Molecule-Pharmacophore Superpositioning and Pattern Matching in Computational Drug Design</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2007.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.drudis.2007.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=18190860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsVWhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=23-29&author=G.+Wolberauthor=T.+Seidelauthor=F.+Bendixauthor=T.+Langer&title=Molecule-Pharmacophore+Superpositioning+and+Pattern+Matching+in+Computational+Drug+Design&doi=10.1016%2Fj.drudis.2007.09.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Molecule-pharmacophore superpositioning and pattern matching in computational drug design</span></div><div class="casAuthors">Wolber, Gerhard; Seidel, Thomas; Bendix, Fabian; Langer, Thierry</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">23-29</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Three-dimensional (3D) pharmacophore modeling is a technique for describing the interaction of a small mol. ligand with a macromol. target.  Since chem. features in a pharmacophore model are well known and highly transparent for medicinal chemists, these models are intuitively understandable and have been increasingly successful in computational drug discovery in the past few years.  The performance and applicability of pharmacophore modeling depends on two main factors: the definition and placement of pharmacophoric features and the alignment techniques used to overlay 3D pharmacophore models and small mols.  An overview of key technologies and latest developments in the area of 3D pharmacophores is given and provides insight into different approaches as implemented by the 3D pharmacophore modeling packages like Catalyst, MOE, Phase and LigandScout.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf1WZmfDtNXLVg90H21EOLACvtfcHk0ljOyjE77ZtfGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsVWhtA%253D%253D&md5=ce232a83e23dac545e35b600de6aeb33</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2007.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2007.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DWolber%26aufirst%3DG.%26aulast%3DSeidel%26aufirst%3DT.%26aulast%3DBendix%26aufirst%3DF.%26aulast%3DLanger%26aufirst%3DT.%26atitle%3DMolecule-Pharmacophore%2520Superpositioning%2520and%2520Pattern%2520Matching%2520in%2520Computational%2520Drug%2520Design%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2008%26volume%3D13%26spage%3D23%26epage%3D29%26doi%3D10.1016%2Fj.drudis.2007.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. Y.</span></span> <span> </span><span class="NLM_article-title">Pharmacophore Modeling and Applications in Drug Discovery: Challenges and Recent Advances</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">11–12</span>),  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2010.03.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.drudis.2010.03.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=20362693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntVSltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=444-450&issue=11%E2%80%9312&author=S.+Y.+Yang&title=Pharmacophore+Modeling+and+Applications+in+Drug+Discovery%3A+Challenges+and+Recent+Advances&doi=10.1016%2Fj.drudis.2010.03.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacophore modeling and applications in drug discovery: challenges and recent advances</span></div><div class="casAuthors">Yang, Sheng-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11/12</span>),
    <span class="NLM_cas:pages">444-450</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Pharmacophore approaches have become one of the major tools in drug discovery after the past century's development.  Various ligand-based and structure-based methods have been developed for improved pharmacophore modeling and have been successfully and extensively applied in virtual screening, de novo design and lead optimization.  Despite these successes, pharmacophore approaches have not reached their expected full capacity, particularly in facing the demand for reducing the current expensive overall cost assocd. with drug discovery and development.  Here, the challenges of pharmacophore modeling and applications in drug discovery are discussed and recent advances and latest developments are described, which provide useful clues to the further development and application of pharmacophore approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqpfM_Jzed17Vg90H21EOLACvtfcHk0ljOyjE77ZtfGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntVSltbg%253D&md5=ff2899e0a75c87a9ec202ace7c3acb6a</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.03.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.03.013%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DPharmacophore%2520Modeling%2520and%2520Applications%2520in%2520Drug%2520Discovery%253A%2520Challenges%2520and%2520Recent%2520Advances%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2010%26volume%3D15%26issue%3D11%25E2%2580%259312%26spage%3D444%26epage%3D450%26doi%3D10.1016%2Fj.drudis.2010.03.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koutsoukas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simms, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchmair, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitmore, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span> <span> </span><span class="NLM_article-title">From in Silico Target Prediction to Multi-Target Drug Design: Current Databases, Methods and Applications</span>. <i>J. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2554</span>– <span class="NLM_lpage">2574</span>, <span class="refDoi"> DOI: 10.1016/j.jprot.2011.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.jprot.2011.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=21621023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOjtrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2011&pages=2554-2574&issue=12&author=A.+Koutsoukasauthor=B.+Simmsauthor=J.+Kirchmairauthor=P.+J.+Bondauthor=A.+V.+Whitmoreauthor=S.+Zimmerauthor=M.+P.+Youngauthor=J.+L.+Jenkinsauthor=M.+Glickauthor=R.+C.+Glenauthor=A.+Bender&title=From+in+Silico+Target+Prediction+to+Multi-Target+Drug+Design%3A+Current+Databases%2C+Methods+and+Applications&doi=10.1016%2Fj.jprot.2011.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">From in silico target prediction to multi-target drug design: Current databases, methods and applications</span></div><div class="casAuthors">Koutsoukas, Alexios; Simms, Benjamin; Kirchmair, Johannes; Bond, Peter J.; Whitmore, Alan V.; Zimmer, Steven; Young, Malcolm P.; Jenkins, Jeremy L.; Glick, Meir; Glen, Robert C.; Bender, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteomics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2554-2574</span>CODEN:
                <span class="NLM_cas:coden">JPORFQ</span>;
        ISSN:<span class="NLM_cas:issn">1874-3919</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Given the tremendous growth of bioactivity databases, the use of computational tools to predict protein targets of small mols. has been gaining importance in recent years.  Applications span a wide range, from the designed polypharmacol.' of compds. to mode-of-action anal.  In this review, we firstly survey databases that can be used for ligand-based target prediction and which have grown tremendously in size in the past.  We furthermore outline methods for target prediction that exist, both based on the knowledge of bioactivities from the ligand side and methods that can be applied in situations when a protein structure is known.  Applications of successful in silico target identification attempts are discussed in detail, which were based partly or in whole on computational target predictions in the first instance.  This includes the authors' own experience using target prediction tools, in this case considering phenotypic antibacterial screens and the anal. of high-throughput screening data.  Finally, we will conclude with the prospective application of databases to not only predict, retrospectively, the protein targets of a small mol., but also how to design ligands with desired polypharmacol. in a prospective manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQAhthzL8wiLVg90H21EOLACvtfcHk0ljOyjE77ZtfGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOjtrfE&md5=3fd699639ef3faf347537ef400030dd9</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1016%2Fj.jprot.2011.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jprot.2011.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DKoutsoukas%26aufirst%3DA.%26aulast%3DSimms%26aufirst%3DB.%26aulast%3DKirchmair%26aufirst%3DJ.%26aulast%3DBond%26aufirst%3DP.%2BJ.%26aulast%3DWhitmore%26aufirst%3DA.%2BV.%26aulast%3DZimmer%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DM.%2BP.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DBender%26aufirst%3DA.%26atitle%3DFrom%2520in%2520Silico%2520Target%2520Prediction%2520to%2520Multi-Target%2520Drug%2520Design%253A%2520Current%2520Databases%252C%2520Methods%2520and%2520Applications%26jtitle%3DJ.%2520Proteomics%26date%3D2011%26volume%3D74%26issue%3D12%26spage%3D2554%26epage%3D2574%26doi%3D10.1016%2Fj.jprot.2011.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rollinger, J. M.</span></span> <span> </span><span class="NLM_article-title">Accessing Target Information by Virtual Parallel Screening-The Impact on Natural Product Research</span>. <i>Phytochem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1016/j.phytol.2008.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.phytol.2008.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvFahs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=53-58&issue=2&author=J.+M.+Rollinger&title=Accessing+Target+Information+by+Virtual+Parallel+Screening-The+Impact+on+Natural+Product+Research&doi=10.1016%2Fj.phytol.2008.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Accessing target information by virtual parallel screening-the impact on natural product research</span></div><div class="casAuthors">Rollinger, Judith M.</div><div class="citationInfo"><span class="NLM_cas:title">Phytochemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">53-58</span>CODEN:
                <span class="NLM_cas:coden">PLHEBK</span>;
        ISSN:<span class="NLM_cas:issn">1874-3900</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Secondary metabolites exhibit an astonishing multitude of functionalities and enormous chem. diversity and these qualities are responsible for their favored selection as drug leads.  The complex process of finding natural products' bioactivities is largely based on trial and error, and is therefore risky, time- and cost-intensive.  In recent decades, computer-assisted techniques have emerged as promising tools to manage the huge amt. of available structural data of macromol. targets and compds. annotated to specific functions, and to ext. knowledge from these data for the prediction of new events.  The novel concept of virtual parallel screening aims to access a pharmacol. profile for each compd. screened using an array of macromol. targets.  Providing putative ligand-target interactions, this in silico multitarget application meets the requirements for natural product research in a complementary way.  It enables (i) a fast identification of potential targets (target fishing), (ii) insight into a putative mol. mechanism, and (iii) an estn. of the bioactivity profile which allows for prioritizing exptl. investigations.  The first application examples in natural product research are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyrrYT3SqUHLVg90H21EOLACvtfcHk0ljOyjE77ZtfGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvFahs7w%253D&md5=c7749d7d2566615cbaacb36131f89786</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1016%2Fj.phytol.2008.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phytol.2008.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DRollinger%26aufirst%3DJ.%2BM.%26atitle%3DAccessing%2520Target%2520Information%2520by%2520Virtual%2520Parallel%2520Screening-The%2520Impact%2520on%2520Natural%2520Product%2520Research%26jtitle%3DPhytochem.%2520Lett.%26date%3D2009%26volume%3D2%26issue%3D2%26spage%3D53%26epage%3D58%26doi%3D10.1016%2Fj.phytol.2008.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Pharmacophore-Based Virtual Screening</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1018</span>– <span class="NLM_lpage">1024</span>, <span class="refDoi"> DOI: 10.2174/092986708784049630</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.2174%2F092986708784049630" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=18393859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVyiur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=1018-1024&issue=10&author=H.+Sun&title=Pharmacophore-Based+Virtual+Screening&doi=10.2174%2F092986708784049630"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacophore-based virtual screening</span></div><div class="casAuthors">Sun, Hongmao</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1018-1024</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Virtual screening (VS) is an important component of cheminformatics and mol. modeling.  An abundance of structural information, indicated by both the ever-increasing availability of 3-dimensional (3D) protein structures and the readiness of free conformational databases of com. available compds., such as ZINC, supplies a broad platform for VS.  At the same time, new technol. enables the implementation of more accurate and sophisticated pharmacophore models and the screening of millions of compds. within a manageable period.  Therefore, VS is expected to play a more important role in future drug discovery efforts.  This paper will examine and compare the advantages and disadvantages of VS against exptl. high-throughput screening (HTS).  It will also evaluate pharmacophore-based VS against docking-based VS.  The strategies leading to successful pharmacophore-based VS are outlined, including how to enumerate a conformational database efficiently, how to select chem. features for a specific pharmacophore model, how to incorporate excluded vols. to enhance the geog. restrictions, and how to optimize a pharmacophore model.  Successful examples of pharmacophore-based VS will be presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2Kf1nFO8hd7Vg90H21EOLACvtfcHk0lhvO0X4YlOj9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVyiur0%253D&md5=32cb02879bb83e4e07f061c991386f83</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.2174%2F092986708784049630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708784049630%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26atitle%3DPharmacophore-Based%2520Virtual%2520Screening%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26issue%3D10%26spage%3D1018%26epage%3D1024%26doi%3D10.2174%2F092986708784049630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolber, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, T.</span></span> <span> </span><span class="NLM_article-title">LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">160</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1021/ci049885e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci049885e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BD2M%252FktVKrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=160-169&issue=1&author=G.+Wolberauthor=T.+Langer&title=LigandScout%3A+3-D+Pharmacophores+Derived+from+Protein-Bound+Ligands+and+Their+Use+as+Virtual+Screening+Filters&doi=10.1021%2Fci049885e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters</span></div><div class="casAuthors">Wolber Gerhard; Langer Thierry</div><div class="citationInfo"><span class="NLM_cas:title">Journal of chemical information and modeling</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">160-9</span>
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    </div><div class="casAbstract">From the historically grown archive of protein-ligand complexes in the Protein Data Bank small organic ligands are extracted and interpreted in terms of their chemical characteristics and features.  Subsequently, pharmacophores representing ligand-receptor interaction are derived from each of these small molecules and its surrounding amino acids.  Based on a defined set of only six types of chemical features and volume constraints, three-dimensional pharmacophore models are constructed, which are sufficiently selective to identify the described binding mode and are thus a useful tool for in-silico screening of large compound databases.  The algorithms for ligand extraction and interpretation as well as the pharmacophore creation technique from the automatically interpreted data are presented and applied to a rhinovirus capsid complex as application example.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQVi_-excgTX2BAiYWy6n3SfW6udTcc2eaZ4711dK7bYbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M%252FktVKrtg%253D%253D&md5=31f8ff7a2fa4c9411d54b001b7e1da50</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1021%2Fci049885e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci049885e%26sid%3Dliteratum%253Aachs%26aulast%3DWolber%26aufirst%3DG.%26aulast%3DLanger%26aufirst%3DT.%26atitle%3DLigandScout%253A%25203-D%2520Pharmacophores%2520Derived%2520from%2520Protein-Bound%2520Ligands%2520and%2520Their%2520Use%2520as%2520Virtual%2520Screening%2520Filters%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2005%26volume%3D45%26issue%3D1%26spage%3D160%26epage%3D169%26doi%3D10.1021%2Fci049885e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barillari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rognan, D.</span></span> <span> </span><span class="NLM_article-title">Hot-Spots-Guided Receptor-Based Pharmacophores (HS-Pharm): A Knowledge-Based Approach to Identify Ligand-Anchoring Atoms in Protein Cavities and Prioritize Structure-Based Pharmacophores</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1396</span>– <span class="NLM_lpage">1410</span>, <span class="refDoi"> DOI: 10.1021/ci800064z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci800064z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFGktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=1396-1410&issue=7&author=C.+Barillariauthor=G.+Marcouauthor=D.+Rognan&title=Hot-Spots-Guided+Receptor-Based+Pharmacophores+%28HS-Pharm%29%3A+A+Knowledge-Based+Approach+to+Identify+Ligand-Anchoring+Atoms+in+Protein+Cavities+and+Prioritize+Structure-Based+Pharmacophores&doi=10.1021%2Fci800064z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Hot-Spots-Guided Receptor-Based Pharmacophores (HS-Pharm): A Knowledge-Based Approach to Identify Ligand-Anchoring Atoms in Protein Cavities and Prioritize Structure-Based Pharmacophores</span></div><div class="casAuthors">Barillari, Caterina; Marcou, Gilles; Rognan, Didier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1396-1410</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design of biol. active compds. from ligand-free protein structures using a structure-based approach is still a major challenge.  In this paper, we present a fast knowledge-based approach (HS-Pharm) that allows the prioritization of cavity atoms that should be targeted for ligand binding, by training machine learning algorithms with atom-based fingerprints of known ligand-binding pockets.  The knowledge of hot spots for ligand binding is here used for focusing structure-based pharmacophore models.  Three targets of pharmacol. interest (neuraminidase, β2 adrenergic receptor, and cyclooxygenase-2) were used to test the evaluated methodol., and the derived structure-based pharmacophores were used in retrospective virtual screening studies.  The current study shows that structure-based pharmacophore screening is a powerful technique for the fast identification of potential hits in a chem. library, and that it is a valid alternative to virtual screening by mol. docking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1wuGUqc3VZbVg90H21EOLACvtfcHk0lhvO0X4YlOj9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFGktrg%253D&md5=75c0bc3d0e89f62f8382d3ff7e85fecc</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1021%2Fci800064z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci800064z%26sid%3Dliteratum%253Aachs%26aulast%3DBarillari%26aufirst%3DC.%26aulast%3DMarcou%26aufirst%3DG.%26aulast%3DRognan%26aufirst%3DD.%26atitle%3DHot-Spots-Guided%2520Receptor-Based%2520Pharmacophores%2520%2528HS-Pharm%2529%253A%2520A%2520Knowledge-Based%2520Approach%2520to%2520Identify%2520Ligand-Anchoring%2520Atoms%2520in%2520Protein%2520Cavities%2520and%2520Prioritize%2520Structure-Based%2520Pharmacophores%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2008%26volume%3D48%26issue%3D7%26spage%3D1396%26epage%3D1410%26doi%3D10.1021%2Fci800064z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tintori, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corradi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botta, M.</span></span> <span> </span><span class="NLM_article-title">Targets Looking for Drugs: A Multistep Computational Protocol for the Development of Structure-Based Pharmacophores and Their Applications for Hit Discovery</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2166</span>– <span class="NLM_lpage">2179</span>, <span class="refDoi"> DOI: 10.1021/ci800105p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci800105p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1OlsbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=2166-2179&issue=11&author=C.+Tintoriauthor=V.+Corradiauthor=M.+Magnaniauthor=F.+Manettiauthor=M.+Botta&title=Targets+Looking+for+Drugs%3A+A+Multistep+Computational+Protocol+for+the+Development+of+Structure-Based+Pharmacophores+and+Their+Applications+for+Hit+Discovery&doi=10.1021%2Fci800105p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Targets Looking for Drugs: A Multistep Computational Protocol for the Development of Structure-Based Pharmacophores and Their Applications for Hit Discovery</span></div><div class="casAuthors">Tintori, Cristina; Corradi, Valentina; Magnani, Matteo; Manetti, Fabrizio; Botta, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2166-2179</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pharmacophores, three-dimensional (3D) arrangements of essential features enabling a mol. to exert a particular biol. effect, constitute a very useful tool in drug design both in hit discovery and hit-to-lead optimization process.  Two basic approaches for pharmacophoric model generation can be used by chemists, depending on the availability or not of the target 3D structure.  In view of the rapidly growing no. of protein structures that are now available, receptor-based pharmacophore generation methods are becoming more and more used.  Since most of them require the knowledge of the 3D structure of the ligand-target complex, they cannot be applied when no compds. targeting the binding site of interest are known.  Here, a GRID-based procedure for the generation of receptor-based pharmacophores starting from knowledge solely of the protein structure is described and successfully applied to address three different tasks in the field of medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoptMpdGcbXALVg90H21EOLACvtfcHk0lhko1YPSlN0Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1OlsbzO&md5=b61f3550c41ed8007f160bb537526d0d</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1021%2Fci800105p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci800105p%26sid%3Dliteratum%253Aachs%26aulast%3DTintori%26aufirst%3DC.%26aulast%3DCorradi%26aufirst%3DV.%26aulast%3DMagnani%26aufirst%3DM.%26aulast%3DManetti%26aufirst%3DF.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DTargets%2520Looking%2520for%2520Drugs%253A%2520A%2520Multistep%2520Computational%2520Protocol%2520for%2520the%2520Development%2520of%2520Structure-Based%2520Pharmacophores%2520and%2520Their%2520Applications%2520for%2520Hit%2520Discovery%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2008%26volume%3D48%26issue%3D11%26spage%3D2166%26epage%3D2179%26doi%3D10.1021%2Fci800105p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, M.
P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, A. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarzycka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolaes, G. A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klomp, J. P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De
Vlieg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Rio, A.</span></span> <span> </span><span class="NLM_article-title">Comparative Analysis of Pharmacophore Screening Tools</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1607</span>– <span class="NLM_lpage">1620</span>, <span class="refDoi"> DOI: 10.1021/ci2005274</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci2005274" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnslahsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=1607-1620&issue=6&author=M.%0AP.+A.+Sandersauthor=A.+J.+M.+Barbosaauthor=B.+Zarzyckaauthor=G.+A.+F.+Nicolaesauthor=J.+P.+G.+Klompauthor=J.+De%0AVliegauthor=A.+Del+Rio&title=Comparative+Analysis+of+Pharmacophore+Screening+Tools&doi=10.1021%2Fci2005274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Analysis of Pharmacophore Screening Tools</span></div><div class="casAuthors">Sanders, Marijn P. A.; Barbosa, Armenio J. M.; Zarzycka, Barbara; Nicolaes, Gerry A. F.; Klomp, Jan P. G.; de Vlieg, Jacob; Del Rio, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1607-1620</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pharmacophore concept is of central importance in computer-aided drug design (CADD) mainly because of its successful application in medicinal chem. and, in particular, high-throughput virtual screening (HTVS).  The simplicity of the pharmacophore definition enables the complexity of mol. interactions between ligand and receptor to be reduced to a handful set of features.  With many pharmacophore screening softwares available, it is of the utmost interest to explore the behavior of these tools when applied to different biol. systems.  In this work, we present a comparative anal. of eight pharmacophore screening algorithms (Catalyst, Unity, LigandScout, Phase, Pharao, MOE, Pharmer, and POT) for their use in typical HTVS campaigns against four different biol. targets by using default settings.  The results herein presented show how the performance of each pharmacophore screening tool might be specifically related to factors such as the characteristics of the binding pocket, the use of specific pharmacophore features, and the use of these techniques in specific steps/contexts of the drug discovery pipeline.  Algorithms with rmsd-based scoring functions are able to predict more compd. poses correctly as overlay-based scoring functions.  However, the ratio of correctly predicted compd. poses vs. incorrectly predicted poses is better for overlay-based scoring functions that also ensure better performances in compd. library enrichments.  While the ensemble of these observations can be used to choose the most appropriate class of algorithm for specific virtual screening projects, we remarked that pharmacophore algorithms are often equally good, and in this respect, we also analyzed how pharmacophore algorithms can be combined together in order to increase the success of hit compd. identification.  This study provides a valuable benchmark set for further developments in the field of pharmacophore search algorithms, e.g., by using pose predictions and compd. library enrichment criteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqC2VxEmjeKbVg90H21EOLACvtfcHk0lhko1YPSlN0Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnslahsr4%253D&md5=2aef6c2e53097c2a25283f5a08ee900a</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1021%2Fci2005274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci2005274%26sid%3Dliteratum%253Aachs%26aulast%3DSanders%26aufirst%3DM.%2BP.%2BA.%26aulast%3DBarbosa%26aufirst%3DA.%2BJ.%2BM.%26aulast%3DZarzycka%26aufirst%3DB.%26aulast%3DNicolaes%26aufirst%3DG.%2BA.%2BF.%26aulast%3DKlomp%26aufirst%3DJ.%2BP.%2BG.%26aulast%3DDe%2BVlieg%26aufirst%3DJ.%26aulast%3DDel%2BRio%26aufirst%3DA.%26atitle%3DComparative%2520Analysis%2520of%2520Pharmacophore%2520Screening%2520Tools%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26issue%3D6%26spage%3D1607%26epage%3D1620%26doi%3D10.1021%2Fci2005274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Triballeau, N.</span>; <span class="NLM_string-name">Bertrand, H. O.</span>; <span class="NLM_string-name">Acher, F.</span></span> <span> </span><span class="NLM_article-title">Are You Sure You Have a Good Model?</span> In  <i>Pharmacophores and Pharmacophore Searches</i>; <span class="NLM_publisher-name">Wiley-Blackwell</span>, <span class="NLM_year">2006</span>; pp  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">364</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2F3527609164.ch15" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=325-364&author=N.+Triballeau&author=H.+O.+Bertrand&author=F.+Acher&title=Pharmacophores+and+Pharmacophore+Searches"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1002%2F3527609164.ch15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F3527609164.ch15%26sid%3Dliteratum%253Aachs%26aulast%3DTriballeau%26aufirst%3DN.%26atitle%3DAre%2520You%2520Sure%2520You%2520Have%2520a%2520Good%2520Model%253F%26btitle%3DPharmacophores%2520and%2520Pharmacophore%2520Searches%26pub%3DWiley-Blackwell%26date%3D2006%26spage%3D325%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of Multitarget Inhibitors by Combining Molecular Docking with Common Pharmacophore Matching</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">7882</span>– <span class="NLM_lpage">7888</span>, <span class="refDoi"> DOI: 10.1021/jm8010096</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8010096" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKlu7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7882-7888&issue=24&author=D.+Weiauthor=X.+Jiangauthor=L.+Zhouauthor=J.+Chenauthor=Z.+Chenauthor=C.+Heauthor=K.+Yangauthor=Y.+Liuauthor=J.+Peiauthor=L.+Lai&title=Discovery+of+Multitarget+Inhibitors+by+Combining+Molecular+Docking+with+Common+Pharmacophore+Matching&doi=10.1021%2Fjm8010096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Multitarget Inhibitors by Combining Molecular Docking with Common Pharmacophore Matching</span></div><div class="casAuthors">Wei, Dengguo; Jiang, Xiaolu; Zhou, Lu; Chen, Jing; Chen, Zheng; He, Chong; Yang, Kun; Liu, Ying; Pei, Jianfeng; Lai, Luhua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7882-7888</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multitarget drugs have been to be found effective in controlling complex diseases.  However, how to design multitarget drugs presents a great challenge. We have developed a computer-assisted strategy to screen for multitarget inhibitors using a combination of mol. docking and common pharmacophore matching.  This strategy was successfully applied to screen for dual-target inhibitors against both the human leukotriene A4 hydrolase (LTA4H-h) and the human nonpancreatic secretory phospholipase A2 (hnps-PLA2).  Three compds. screened from the chem. database MDL Available Chem. Directory were found to inhibit these two enzymes at the 10 μM level.  Moreover, one synthetic compd. matching the common pharmacophores inhibits LTA4H-h and hnps-PLA2 with IC50 values of 35 nM and 7.3 μM, resp.  The common pharmacophore model can also be used to search small mol. databases or collections of existing inhibitors, as well as to guide combinatorial library design to search for ideal multitarget inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJgzU8gGUcMrVg90H21EOLACvtfcHk0lhko1YPSlN0Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKlu7nK&md5=0039b1caccc0518b554a20ed1e2e42c9</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1021%2Fjm8010096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010096%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPei%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520Multitarget%2520Inhibitors%2520by%2520Combining%2520Molecular%2520Docking%2520with%2520Common%2520Pharmacophore%2520Matching%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D24%26spage%3D7882%26epage%3D7888%26doi%3D10.1021%2Fjm8010096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arooj, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakkiah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. W.</span></span> <span> </span><span class="NLM_article-title">An Innovative Strategy for Dual Inhibitor Design and Its Application in Dual Inhibition of Human Thymidylate Synthase and Dihydrofolate Reductase Enzymes</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e60470</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0060470</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1371%2Fjournal.pone.0060470" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e60470&author=M.+Aroojauthor=S.+Sakkiahauthor=G.+P.+Caoauthor=K.+W.+Lee&title=An+Innovative+Strategy+for+Dual+Inhibitor+Design+and+Its+Application+in+Dual+Inhibition+of+Human+Thymidylate+Synthase+and+Dihydrofolate+Reductase+Enzymes&doi=10.1371%2Fjournal.pone.0060470"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0060470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0060470%26sid%3Dliteratum%253Aachs%26aulast%3DArooj%26aufirst%3DM.%26aulast%3DSakkiah%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DG.%2BP.%26aulast%3DLee%26aufirst%3DK.%2BW.%26atitle%3DAn%2520Innovative%2520Strategy%2520for%2520Dual%2520Inhibitor%2520Design%2520and%2520Its%2520Application%2520in%2520Dual%2520Inhibition%2520of%2520Human%2520Thymidylate%2520Synthase%2520and%2520Dihydrofolate%2520Reductase%2520Enzymes%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De60470%26doi%3D10.1371%2Fjournal.pone.0060470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morissette, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouthillier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marceau, F.</span></span> <span> </span><span class="NLM_article-title">Dual Antagonists of the Bradykinin B1 and B2 Receptors Based on a Postulated Common Pharmacophore from Existing Non-Peptide Antagonists</span>. <i>Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>387</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">194</span>, <span class="refDoi"> DOI: 10.1515/BC.2006.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1515%2FBC.2006.025" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2006&pages=189-194&author=G.+Morissetteauthor=J.+Bouthillierauthor=F.+Marceau&title=Dual+Antagonists+of+the+Bradykinin+B1+and+B2+Receptors+Based+on+a+Postulated+Common+Pharmacophore+from+Existing+Non-Peptide+Antagonists&doi=10.1515%2FBC.2006.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1515%2FBC.2006.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252FBC.2006.025%26sid%3Dliteratum%253Aachs%26aulast%3DMorissette%26aufirst%3DG.%26aulast%3DBouthillier%26aufirst%3DJ.%26aulast%3DMarceau%26aufirst%3DF.%26atitle%3DDual%2520Antagonists%2520of%2520the%2520Bradykinin%2520B1%2520and%2520B2%2520Receptors%2520Based%2520on%2520a%2520Postulated%2520Common%2520Pharmacophore%2520from%2520Existing%2520Non-Peptide%2520Antagonists%26jtitle%3DBiol.%2520Chem.%26date%3D2006%26volume%3D387%26spage%3D189%26epage%3D194%26doi%3D10.1515%2FBC.2006.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sindhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, P.</span></span> <span> </span><span class="NLM_article-title">Identification of Potential Dual Agonists of FXR and TGR5 Using E-Pharmacophore Based Virtual Screening</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1305</span>– <span class="NLM_lpage">1318</span>, <span class="refDoi"> DOI: 10.1039/C5MB00137D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1039%2FC5MB00137D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=25787676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFegsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=1305-1318&issue=5&author=T.+Sindhuauthor=P.+Srinivasan&title=Identification+of+Potential+Dual+Agonists+of+FXR+and+TGR5+Using+E-Pharmacophore+Based+Virtual+Screening&doi=10.1039%2FC5MB00137D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of potential dual agonists of FXR and TGR5 using e-pharmacophore based virtual screening</span></div><div class="casAuthors">Sindhu, Thangaraj; Srinivasan, Pappu</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1305-1318</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-2051</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Farnesoid X receptor and Takeda G-protein-coupled receptor-5 are well known bile acid receptors and act as promising targets for the drug development and treatment of diabetes.  Agonists of both the bile acid receptors increase insulin sensitivity and control glucose, lipids and bile acid homeostasis.  The current study deals with the identification of novel dual agonists using ligand and structure-based virtual screening.  Initially, an exptl. proven well-known dual agonist of FXR and TGR5, namely INT-767, was docked into the binding sites of FXR and TGR5 to det. the protein residues important for ligand binding.  The docked complexes FXRINT-767 and TGR5INT-767 were used to generate e-pharmacophore hypotheses.  Ligand-based virtual screening was carried out using the hypothetical e-pharmacophore model against the ChemBridge database.  Further, structure-based virtual screening was performed with screened hits to find potential agonists of FXR and TGR5.  A total of four best agonists were identified based on their affinity and mode of interactions with the receptors.  The binding mode of these compds. with both receptors was analyzed in detail.  Furthermore, mol. dynamics, ADME toxicity prediction, d. functional theory and binding free energy calcns. were carried out to rank the compds.  Based on the above analyses, the most potent compd., ChemBridge_9149693, was selected for further in vitro studies.  The results of in vitro assays suggested that ChemBridge_9149693 is a potent and promising drug for the treatment of type II diabetes.  Thus, the compd. could be used for further drug design and development of dual agonists of FXR and TGR5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBxCMs-xT3KLVg90H21EOLACvtfcHk0ljQaj8pNrb0sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFegsbw%253D&md5=9da5dd11001aabfb51b227b2cc960a7e</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1039%2FC5MB00137D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MB00137D%26sid%3Dliteratum%253Aachs%26aulast%3DSindhu%26aufirst%3DT.%26aulast%3DSrinivasan%26aufirst%3DP.%26atitle%3DIdentification%2520of%2520Potential%2520Dual%2520Agonists%2520of%2520FXR%2520and%2520TGR5%2520Using%2520E-Pharmacophore%2520Based%2520Virtual%2520Screening%26jtitle%3DMol.%2520BioSyst.%26date%3D2015%26volume%3D11%26issue%3D5%26spage%3D1305%26epage%3D1318%26doi%3D10.1039%2FC5MB00137D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewska, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achenbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buscató, E. la</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klingler, F.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhilber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span> <span> </span><span class="NLM_article-title">Dual-Target Virtual Screening by Pharmacophore Elucidation and Molecular Shape Filtering</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1021/ml200286e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200286e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=155-158&issue=2&author=D.+Moserauthor=J.+M.+Wisniewskaauthor=S.+Hahnauthor=J.+Achenbachauthor=E.+la+Buscat%C3%B3author=F.-M.+Klinglerauthor=B.+Hofmannauthor=D.+Steinhilberauthor=E.+Proschak&title=Dual-Target+Virtual+Screening+by+Pharmacophore+Elucidation+and+Molecular+Shape+Filtering&doi=10.1021%2Fml200286e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1021%2Fml200286e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200286e%26sid%3Dliteratum%253Aachs%26aulast%3DMoser%26aufirst%3DD.%26aulast%3DWisniewska%26aufirst%3DJ.%2BM.%26aulast%3DHahn%26aufirst%3DS.%26aulast%3DAchenbach%26aufirst%3DJ.%26aulast%3DBuscat%25C3%25B3%26aufirst%3DE.%2Bla%26aulast%3DKlingler%26aufirst%3DF.-M.%26aulast%3DHofmann%26aufirst%3DB.%26aulast%3DSteinhilber%26aufirst%3DD.%26aulast%3DProschak%26aufirst%3DE.%26atitle%3DDual-Target%2520Virtual%2520Screening%2520by%2520Pharmacophore%2520Elucidation%2520and%2520Molecular%2520Shape%2520Filtering%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26issue%3D2%26spage%3D155%26epage%3D158%26doi%3D10.1021%2Fml200286e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartenfeller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zettl, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reisen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weggen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span> <span> </span><span class="NLM_article-title">DOGS: Reaction-Driven de Novo Design of Bioactive Compounds</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">e1002380</span>, <span class="refDoi"> DOI: 10.1371/journal.pcbi.1002380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1371%2Fjournal.pcbi.1002380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=22359493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Sjtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=e1002380&issue=2&author=M.+Hartenfellerauthor=H.+Zettlauthor=M.+Walterauthor=M.+Ruppauthor=F.+Reisenauthor=E.+Proschakauthor=S.+Weggenauthor=H.+Starkauthor=G.+Schneider&title=DOGS%3A+Reaction-Driven+de+Novo+Design+of+Bioactive+Compounds&doi=10.1371%2Fjournal.pcbi.1002380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">DOGS: reaction-driven de novo design of bioactive compounds</span></div><div class="casAuthors">Hartenfeller, Markus; Zettl, Heiko; Walter, Miriam; Rupp, Matthias; Reisen, Felix; Proschak, Ewgenij; Weggen, Sascha; Stark, Holger; Schneider, Gisbert</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e1002380</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">We present a computational method for the reaction-based de novo design of drug-like mols.  The software DOGS (Design of Genuine Structures) features a ligand-based strategy for automated 'in silico' assembly of potentially novel bioactive compds.  The quality of the designed compds. is assessed by a graph kernel method measuring their similarity to known bioactive ref. ligands in terms of structural and pharmacophoric features.  We implemented a deterministic compd. construction procedure that explicitly considers compd. synthesizability, based on a compilation of 25'144 readily available synthetic building blocks and 58 established reaction principles.  This enables the software to suggest a synthesis route for each designed compd.  Two prospective case studies are presented together with details on the algorithm and its implementation.  De novo designed ligand candidates for the human histamine H4 receptor and γ-secretase were synthesized as suggested by the software.  The computational approach proved to be suitable for scaffold-hopping from known ligands to novel chemotypes and for generating bioactive mols. with drug-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBGMIXUGjYJrVg90H21EOLACvtfcHk0ljQaj8pNrb0sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Sjtr0%253D&md5=cdcf6905d52761614c33ab068b608ac5</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1002380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1002380%26sid%3Dliteratum%253Aachs%26aulast%3DHartenfeller%26aufirst%3DM.%26aulast%3DZettl%26aufirst%3DH.%26aulast%3DWalter%26aufirst%3DM.%26aulast%3DRupp%26aufirst%3DM.%26aulast%3DReisen%26aufirst%3DF.%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DWeggen%26aufirst%3DS.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DSchneider%26aufirst%3DG.%26atitle%3DDOGS%253A%2520Reaction-Driven%2520de%2520Novo%2520Design%2520of%2520Bioactive%2520Compounds%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2012%26volume%3D8%26issue%3D2%26spage%3De1002380%26doi%3D10.1371%2Fjournal.pcbi.1002380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tschinke, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, N. C.</span></span> <span> </span><span class="NLM_article-title">The NEWLEAD Program: A New Method for the Design of Candidate Structures from Pharmacophoric Hypotheses</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">3863</span>– <span class="NLM_lpage">3870</span>, <span class="refDoi"> DOI: 10.1021/jm00076a016</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00076a016" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=3863-3870&issue=24&author=V.+Tschinkeauthor=N.+C.+Cohen&title=The+NEWLEAD+Program%3A+A+New+Method+for+the+Design+of+Candidate+Structures+from+Pharmacophoric+Hypotheses&doi=10.1021%2Fjm00076a016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1021%2Fjm00076a016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00076a016%26sid%3Dliteratum%253Aachs%26aulast%3DTschinke%26aufirst%3DV.%26aulast%3DCohen%26aufirst%3DN.%2BC.%26atitle%3DThe%2520NEWLEAD%2520Program%253A%2520A%2520New%2520Method%2520for%2520the%2520Design%2520of%2520Candidate%2520Structures%2520from%2520Pharmacophoric%2520Hypotheses%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26issue%3D24%26spage%3D3863%26epage%3D3870%26doi%3D10.1021%2Fjm00076a016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartenfeller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span> <span> </span><span class="NLM_article-title">De Novo Drug Design</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>672</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">323</span>, <span class="refDoi"> DOI: 10.1007/978-1-60761-839-3_12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1007%2F978-1-60761-839-3_12" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=672&publication_year=2010&pages=299-323&author=M.+Hartenfellerauthor=G.+Schneider&title=De+Novo+Drug+Design&doi=10.1007%2F978-1-60761-839-3_12"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1007%2F978-1-60761-839-3_12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-60761-839-3_12%26sid%3Dliteratum%253Aachs%26aulast%3DHartenfeller%26aufirst%3DM.%26aulast%3DSchneider%26aufirst%3DG.%26atitle%3DDe%2520Novo%2520Drug%2520Design%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2010%26volume%3D672%26spage%3D299%26epage%3D323%26doi%3D10.1007%2F978-1-60761-839-3_12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span> <span> </span><span class="NLM_article-title">De Novo Design at the Edge of Chaos</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">4077</span>– <span class="NLM_lpage">4086</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01849</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01849" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFahsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4077-4086&issue=9&author=P.+Schneiderauthor=G.+Schneider&title=De+Novo+Design+at+the+Edge+of+Chaos&doi=10.1021%2Facs.jmedchem.5b01849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">De Novo Design at the Edge of Chaos</span></div><div class="casAuthors">Schneider, Petra; Schneider, Gisbert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4077-4086</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Computational medicinal chem. offers viable strategies for finding, characterizing, and optimizing innovative pharmacol. active compds.  Technol. advances in both computer hardware and software as well as biol. chem. have enabled a renaissance of computer-assisted "de novo" design of mols. with desired pharmacol. properties.  Here, we present our current perspective on the concept of automated mol. generation by highlighting chemocentric methods that may capture druglike chem. space, consider ligand promiscuity for hit and lead finding, and provide fresh ideas for the rational design of customized screening of compd. libraries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvGnpbXPAgt7Vg90H21EOLACvtfcHk0lhs9RBPZfxS_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFahsLs%253D&md5=db6cc1e505e43d4721b2f89ce2cbe91a</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01849%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DP.%26aulast%3DSchneider%26aufirst%3DG.%26atitle%3DDe%2520Novo%2520Design%2520at%2520the%2520Edge%2520of%2520Chaos%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D9%26spage%3D4077%26epage%3D4086%26doi%3D10.1021%2Facs.jmedchem.5b01849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Network Analysis of Drug-Target Interactions: A Study on FDA-Approved New Molecular Entities Between 2000 to 2015</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">12230</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-12061-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fs41598-017-12061-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28947756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252Fit1yksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=12230&issue=1&author=H.-H.+Linauthor=L.-L.+Zhangauthor=R.+Yanauthor=J.-J.+Luauthor=Y.+Hu&title=Network+Analysis+of+Drug-Target+Interactions%3A+A+Study+on+FDA-Approved+New+Molecular+Entities+Between+2000+to+2015&doi=10.1038%2Fs41598-017-12061-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Network Analysis of Drug-target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015</span></div><div class="casAuthors">Lin Hui-Heng; Zhang Le-Le; Yan Ru; Lu Jin-Jian; Hu Yuanjia</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12230</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The U.S.  Food and Drug Administration (FDA) approves new drugs every year.  Drug targets are some of the most important interactive molecules for drugs, as they have a significant impact on the therapeutic effects of drugs.  In this work, we thoroughly analyzed the data of small molecule drugs approved by the U.S.  FDA between 2000 and 2015.  Specifically, we focused on seven classes of new molecular entity (NME) classified by the anatomic therapeutic chemical (ATC) classification system.  They were NMEs and their corresponding targets for the cardiovascular system, respiratory system, nerve system, general anti-infective systemic, genito-urinary system and sex hormones, alimentary tract and metabolisms, and antineoplastic and immunomodulating agents.  To study the drug-target interaction on the systems level, we employed network topological analysis and multipartite network projections.  As a result, the drug-target relations of different kinds of drugs were comprehensively characterized and global pictures of drug-target, drug-drug, and target-target interactions were visualized and analyzed from the perspective of network models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbYvmqnyNWSv3jf77P2BG3fW6udTcc2eaq6OqL6nnAO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252Fit1yksA%253D%253D&md5=2317e913a77fbb6fda31a06742c84c29</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-12061-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-12061-8%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.-H.%26aulast%3DZhang%26aufirst%3DL.-L.%26aulast%3DYan%26aufirst%3DR.%26aulast%3DLu%26aufirst%3DJ.-J.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DNetwork%2520Analysis%2520of%2520Drug-Target%2520Interactions%253A%2520A%2520Study%2520on%2520FDA-Approved%2520New%2520Molecular%2520Entities%2520Between%25202000%2520to%25202015%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26issue%3D1%26spage%3D12230%26doi%3D10.1038%2Fs41598-017-12061-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-T.</span></span> <span> </span><span class="NLM_article-title">Multi-Target Drugs: The Trend of Drug Research and Development</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">e40262</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0040262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1371%2Fjournal.pone.0040262" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e40262&issue=6&author=J.-J.+Luauthor=W.+Panauthor=Y.-J.+Huauthor=Y.-T.+Wang&title=Multi-Target+Drugs%3A+The+Trend+of+Drug+Research+and+Development&doi=10.1371%2Fjournal.pone.0040262"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0040262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0040262%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DJ.-J.%26aulast%3DPan%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DY.-J.%26aulast%3DWang%26aufirst%3DY.-T.%26atitle%3DMulti-Target%2520Drugs%253A%2520The%2520Trend%2520of%2520Drug%2520Research%2520and%2520Development%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26issue%3D6%26spage%3De40262%26doi%3D10.1371%2Fjournal.pone.0040262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wermuth, C. G.</span></span> <span> </span><span class="NLM_article-title">Selective Optimization of Side Activities: Another Way for Drug Discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1303</span>– <span class="NLM_lpage">1314</span>, <span class="refDoi"> DOI: 10.1021/jm030480f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030480f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1303-1314&issue=6&author=C.+G.+Wermuth&title=Selective+Optimization+of+Side+Activities%3A+Another+Way+for+Drug+Discovery&doi=10.1021%2Fjm030480f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1021%2Fjm030480f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030480f%26sid%3Dliteratum%253Aachs%26aulast%3DWermuth%26aufirst%3DC.%2BG.%26atitle%3DSelective%2520Optimization%2520of%2520Side%2520Activities%253A%2520Another%2520Way%2520for%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26issue%3D6%26spage%3D1303%26epage%3D1314%26doi%3D10.1021%2Fjm030480f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langer, T.</span>; <span class="NLM_string-name">Wermuth, C.-G.</span></span> <span> </span><span class="NLM_article-title">Selective Optimization of Side Activities (SOSA): A Promising Way for Drug Discovery</span>. In  <i>Polypharmacology in Drug Discovery</i>; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">2012</span>; pp  <span class="NLM_fpage">227</span>– <span class="NLM_lpage">243</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2F9781118098141.ch11" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=227-243&author=T.+Langer&author=C.-G.+Wermuth&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1002%2F9781118098141.ch11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141.ch11%26sid%3Dliteratum%253Aachs%26aulast%3DLanger%26aufirst%3DT.%26atitle%3DSelective%2520Optimization%2520of%2520Side%2520Activities%2520%2528SOSA%2529%253A%2520A%2520Promising%2520Way%2520for%2520Drug%2520Discovery%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2012%26spage%3D227%26epage%3D243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vitale, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercuro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castiglioni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornoldi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volterrani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosano, G. M. C.</span></span> <span> </span><span class="NLM_article-title">Metabolic Effect of Telmisartan and Losartan in Hypertensive Patients with Metabolic Syndrome</span>. <i>Cardiovasc. Diabetol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">6</span>, <span class="refDoi"> DOI: 10.1186/1475-2840-4-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1186%2F1475-2840-4-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=15892894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BD2Mzlt1CktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=6&issue=1&author=C.+Vitaleauthor=G.+Mercuroauthor=C.+Castiglioniauthor=A.+Cornoldiauthor=A.+Tulliauthor=M.+Finiauthor=M.+Volterraniauthor=G.+M.+C.+Rosano&title=Metabolic+Effect+of+Telmisartan+and+Losartan+in+Hypertensive+Patients+with+Metabolic+Syndrome&doi=10.1186%2F1475-2840-4-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome</span></div><div class="casAuthors">Vitale Cristiana; Mercuro Giuseppe; Castiglioni Carlotta; Cornoldi Alessandra; Tulli Arianna; Fini Massimo; Volterrani Maurizio; Rosano Giuseppe M C</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular diabetology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Metabolic syndrome is a cluster of common cardiovascular risk factors that includes hypertension and insulin resistance.  Hypertension and diabetes mellitus are frequent comorbidities and, like metabolic syndrome, increase the risk of cardiovascular events.  Telmisartan, an antihypertensive agent with evidence of partial peroxisome proliferator-activated receptor activity-gamma (PPARgamma) activity, may improve insulin sensitivity and lipid profile in patients with metabolic syndrome.  METHODS:  In a double-blind, parallel-group, randomized study, patients with World Health Organization criteria for metabolic syndrome received once-daily doses of telmisartan (80 mg, n = 20) or losartan (50 mg, n = 20) for 3 months.  At baseline and end of treatment, fasting and postprandial plasma glucose, insulin sensitivity, glycosylated haemoglobin (HBA1c) and 24-hour mean systolic and diastolic blood pressures were determined.  RESULTS:  Telmisartan, but not losartan, significantly (p < 0.05) reduced free plasma glucose, free plasma insulin, homeostasis model assessment of insulin resistance and HbAic.  Following treatment, plasma glucose and insulin were reduced during the oral glucose tolerance test by telmisartan, but not by losartan.  Telmisartan also significantly reduced 24-hour mean systolic blood pressure (p < 0.05) and diastolic blood pressure (p < 0.05) compared with losartan.  CONCLUSION:  As well as providing superior 24-hour blood pressure control, telmisartan, unlike losartan, displayed insulin-sensitizing activity, which may be explained by its partial PPARgamma activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnNx7JI9Biv3WEEzDrymxmfW6udTcc2eaq6OqL6nnAO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mzlt1CktQ%253D%253D&md5=a964c88094a8a08133efddc102d23e0a</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1186%2F1475-2840-4-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1475-2840-4-6%26sid%3Dliteratum%253Aachs%26aulast%3DVitale%26aufirst%3DC.%26aulast%3DMercuro%26aufirst%3DG.%26aulast%3DCastiglioni%26aufirst%3DC.%26aulast%3DCornoldi%26aufirst%3DA.%26aulast%3DTulli%26aufirst%3DA.%26aulast%3DFini%26aufirst%3DM.%26aulast%3DVolterrani%26aufirst%3DM.%26aulast%3DRosano%26aufirst%3DG.%2BM.%2BC.%26atitle%3DMetabolic%2520Effect%2520of%2520Telmisartan%2520and%2520Losartan%2520in%2520Hypertensive%2520Patients%2520with%2520Metabolic%2520Syndrome%26jtitle%3DCardiovasc.%2520Diabetol.%26date%3D2005%26volume%3D4%26issue%3D1%26spage%3D6%26doi%3D10.1186%2F1475-2840-4-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, X.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Telmisartan Improves Insulin Resistance: A Meta-Analysis</span>. <i>Am. J. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_fpage">1</span>, <span class="refDoi"> DOI: 10.1097/MJT.0000000000000733</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1097%2FMJT.0000000000000733" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=1&author=Y.+Wangauthor=S.+Qiaoauthor=D.-W.+Hanauthor=X.-R.+Rongauthor=Y.-X.+Wangauthor=J.-J.+Xueauthor=J.+Yang&title=Telmisartan+Improves+Insulin+Resistance%3A+A+Meta-Analysis&doi=10.1097%2FMJT.0000000000000733"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1097%2FMJT.0000000000000733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMJT.0000000000000733%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DQiao%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DD.-W.%26aulast%3DRong%26aufirst%3DX.-R.%26aulast%3DWang%26aufirst%3DY.-X.%26aulast%3DXue%26aufirst%3DJ.-J.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DTelmisartan%2520Improves%2520Insulin%2520Resistance%253A%2520A%2520Meta-Analysis%26jtitle%3DAm.%2520J.%2520Ther.%26date%3D2018%26spage%3D1%26doi%3D10.1097%2FMJT.0000000000000733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goebel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staels, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kintscher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gust, R.</span></span> <span> </span><span class="NLM_article-title">Characterization of New PPARgamma Agonists: Benzimidazole Derivatives - the Importance of Position 2</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1142</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200900067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fcmdc.200900067" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=1136-1142&issue=7&author=M.+Goebelauthor=B.+Staelsauthor=T.+Ungerauthor=U.+Kintscherauthor=R.+Gust&title=Characterization+of+New+PPARgamma+Agonists%3A+Benzimidazole+Derivatives+-+the+Importance+of+Position+2&doi=10.1002%2Fcmdc.200900067"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900067%26sid%3Dliteratum%253Aachs%26aulast%3DGoebel%26aufirst%3DM.%26aulast%3DStaels%26aufirst%3DB.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DKintscher%26aufirst%3DU.%26aulast%3DGust%26aufirst%3DR.%26atitle%3DCharacterization%2520of%2520New%2520PPARgamma%2520Agonists%253A%2520Benzimidazole%2520Derivatives%2520-%2520the%2520Importance%2520of%2520Position%25202%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26issue%3D7%26spage%3D1136%26epage%3D1142%26doi%3D10.1002%2Fcmdc.200900067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goebel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemenz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staels, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kintscher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gust, R.</span></span> <span> </span><span class="NLM_article-title">Characterization of New PPARgamma Agonists: Analysis of Telmisartan’s Structural Components</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">445</span>– <span class="NLM_lpage">456</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200800285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fcmdc.200800285" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=445-456&issue=3&author=M.+Goebelauthor=M.+Clemenzauthor=B.+Staelsauthor=T.+Ungerauthor=U.+Kintscherauthor=R.+Gust&title=Characterization+of+New+PPARgamma+Agonists%3A+Analysis+of+Telmisartan%E2%80%99s+Structural+Components&doi=10.1002%2Fcmdc.200800285"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200800285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200800285%26sid%3Dliteratum%253Aachs%26aulast%3DGoebel%26aufirst%3DM.%26aulast%3DClemenz%26aufirst%3DM.%26aulast%3DStaels%26aufirst%3DB.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DKintscher%26aufirst%3DU.%26aulast%3DGust%26aufirst%3DR.%26atitle%3DCharacterization%2520of%2520New%2520PPARgamma%2520Agonists%253A%2520Analysis%2520of%2520Telmisartan%25E2%2580%2599s%2520Structural%2520Components%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26issue%3D3%26spage%3D445%26epage%3D456%26doi%3D10.1002%2Fcmdc.200800285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Besnard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruda, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abecassis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norval, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassano, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidah, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constam, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bickerton, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span> <span> </span><span class="NLM_article-title">Automated Design of Ligands to Polypharmacological Profiles</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>492</i></span> (<span class="NLM_issue">7428</span>),  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1038/nature11691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnature11691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=23235874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=492&publication_year=2012&pages=215-220&issue=7428&author=J.+Besnardauthor=G.+F.+Rudaauthor=V.+Setolaauthor=K.+Abecassisauthor=R.+M.+Rodriguizauthor=X.-P.+Huangauthor=S.+Norvalauthor=M.+F.+Sassanoauthor=A.+I.+Shinauthor=L.+A.+Websterauthor=F.+R.+C.+Simeonsauthor=L.+Stojanovskiauthor=A.+Pratauthor=N.+G.+Seidahauthor=D.+B.+Constamauthor=G.+R.+Bickertonauthor=K.+D.+Readauthor=W.+C.+Wetselauthor=I.+H.+Gilbertauthor=B.+L.+Rothauthor=A.+L.+Hopkins&title=Automated+Design+of+Ligands+to+Polypharmacological+Profiles&doi=10.1038%2Fnature11691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Automated design of ligands to polypharmacological profiles</span></div><div class="casAuthors">Besnard, Jeremy; Ruda, Gian Filippo; Setola, Vincent; Abecassis, Keren; Rodriguiz, Ramona M.; Huang, Xi-Ping; Norval, Suzanne; Sassano, Maria F.; Shin, Antony I.; Webster, Lauren A.; Simeons, Frederick R. C.; Stojanovski, Laste; Prat, Annik; Seidah, Nabil G.; Constam, Daniel B.; Bickerton, G. Richard; Read, Kevin D.; Wetsel, William C.; Gilbert, Ian H.; Roth, Bryan L.; Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">492</span>
        (<span class="NLM_cas:issue">7428</span>),
    <span class="NLM_cas:pages">215-220</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy and safety of a drug is detd. by its activity profile across many proteins in the proteome.  However, designing drugs with a specific multi-target profile is both complex and difficult.  Therefore methods to design drugs rationally a priori against profiles of several proteins would have immense value in drug discovery.  Here is described a new approach for the automated design of ligands against profiles of multiple drug targets.  The method is demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug donepezil (I) into brain-penetrable ligands with either specific polypharmacol. or exquisite selectivity profiles for G-protein-coupled receptors.  Overall, 800 ligand-target predictions of prospectively designed ligands were tested exptl., of which 75% were confirmed to be correct.  Target engagement in vivo is also demonstrated.  The approach can be a useful source of drug leads when multi-target profiles are required to achieve either selectivity over other drug targets or a desired polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNu5bwrBD3tbVg90H21EOLACvtfcHk0lhw46gYNNIw_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN&md5=ace6cced250cf968d327b482a5bf1798</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1038%2Fnature11691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11691%26sid%3Dliteratum%253Aachs%26aulast%3DBesnard%26aufirst%3DJ.%26aulast%3DRuda%26aufirst%3DG.%2BF.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DAbecassis%26aufirst%3DK.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DShin%26aufirst%3DA.%2BI.%26aulast%3DWebster%26aufirst%3DL.%2BA.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DSeidah%26aufirst%3DN.%2BG.%26aulast%3DConstam%26aufirst%3DD.%2BB.%26aulast%3DBickerton%26aufirst%3DG.%2BR.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DAutomated%2520Design%2520of%2520Ligands%2520to%2520Polypharmacological%2520Profiles%26jtitle%3DNature%26date%3D2012%26volume%3D492%26issue%3D7428%26spage%3D215%26epage%3D220%26doi%3D10.1038%2Fnature11691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schierle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flauaus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goebel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahnt, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhilber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurglics, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rovati, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidtko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Boosting Anti-Inflammatory Potency of Zafirlukast by Designed Polypharmacology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">5758</span>– <span class="NLM_lpage">5764</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00458</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00458" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5758-5764&issue=13&author=S.+Schierleauthor=C.+Flauausauthor=P.+Heitelauthor=S.+Willemsauthor=J.+Schmidtauthor=A.+Kaiserauthor=L.+Weizelauthor=T.+Goebelauthor=A.+S.+Kahntauthor=G.+Geisslingerauthor=D.+Steinhilberauthor=M.+Wurglicsauthor=G.+E.+Rovatiauthor=A.+Schmidtkoauthor=E.+Proschakauthor=D.+Merk&title=Boosting+Anti-Inflammatory+Potency+of+Zafirlukast+by+Designed+Polypharmacology&doi=10.1021%2Facs.jmedchem.8b00458"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00458%26sid%3Dliteratum%253Aachs%26aulast%3DSchierle%26aufirst%3DS.%26aulast%3DFlauaus%26aufirst%3DC.%26aulast%3DHeitel%26aufirst%3DP.%26aulast%3DWillems%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DJ.%26aulast%3DKaiser%26aufirst%3DA.%26aulast%3DWeizel%26aufirst%3DL.%26aulast%3DGoebel%26aufirst%3DT.%26aulast%3DKahnt%26aufirst%3DA.%2BS.%26aulast%3DGeisslinger%26aufirst%3DG.%26aulast%3DSteinhilber%26aufirst%3DD.%26aulast%3DWurglics%26aufirst%3DM.%26aulast%3DRovati%26aufirst%3DG.%2BE.%26aulast%3DSchmidtko%26aufirst%3DA.%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DBoosting%2520Anti-Inflammatory%2520Potency%2520of%2520Zafirlukast%2520by%2520Designed%2520Polypharmacology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D13%26spage%3D5758%26epage%3D5764%26doi%3D10.1021%2Facs.jmedchem.8b00458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hann, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, G.</span></span> <span> </span><span class="NLM_article-title">Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery</span>. <i>J. Chem. Inf. Comput. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">856</span>– <span class="NLM_lpage">864</span>, <span class="refDoi"> DOI: 10.1021/ci000403i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci000403i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFynt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2001&pages=856-864&issue=3&author=M.+M.+Hannauthor=A.+R.+Leachauthor=G.+Harper&title=Molecular+Complexity+and+Its+Impact+on+the+Probability+of+Finding+Leads+for+Drug+Discovery&doi=10.1021%2Fci000403i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery</span></div><div class="casAuthors">Hann, Michael M.; Leach, Andrew R.; Harper, Gavin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Computer Sciences</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">856-864</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">0095-2338</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Using a simple model of ligand-receptor interactions, the interactions between ligands and receptors of varying complexities are studied and the probabilities of binding calcd.  It is obsd. that as the systems become more complex the chance of observing a useful interaction for a randomly chosen ligand falls dramatically.  The implications of this for the design of combinatorial libraries is explored.  A large set of drug leads and optimized compds. is profiled using several different properties relevant to mol. recognition.  The changes obsd. for these properties during the drug optimization phase support the hypothesis that less complex mols. are more common starting points for the discovery of drugs.  An extreme example of the use of simple mols. for directed screening against thrombin is provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7ed40mt9qb7Vg90H21EOLACvtfcHk0li4AnuGmj4i2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFynt7w%253D&md5=e89e76c8fb83fc5012369ae30f20e6b7</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1021%2Fci000403i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci000403i%26sid%3Dliteratum%253Aachs%26aulast%3DHann%26aufirst%3DM.%2BM.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DHarper%26aufirst%3DG.%26atitle%3DMolecular%2520Complexity%2520and%2520Its%2520Impact%2520on%2520the%2520Probability%2520of%2520Finding%2520Leads%2520for%2520Drug%2520Discovery%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Comput.%2520Sci.%26date%3D2001%26volume%3D41%26issue%3D3%26spage%3D856%26epage%3D864%26doi%3D10.1021%2Fci000403i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Achenbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klingler, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blöcher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Häfner, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rödl, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kretschmer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krüger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löhr, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhilber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span> <span> </span><span class="NLM_article-title">Exploring the Chemical Space of Multitarget Ligands Using Aligned Self-Organizing Maps</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1169</span>– <span class="NLM_lpage">1172</span>, <span class="refDoi"> DOI: 10.1021/ml4002562</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml4002562" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Kkt7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1169-1172&issue=12&author=J.+Achenbachauthor=F.+M.+Klinglerauthor=R.+Bl%C3%B6cherauthor=D.+Moserauthor=A.+K.+H%C3%A4fnerauthor=C.+B.+R%C3%B6dlauthor=S.+Kretschmerauthor=B.+Kr%C3%BCgerauthor=F.+L%C3%B6hrauthor=H.+Starkauthor=B.+Hofmannauthor=D.+Steinhilberauthor=E.+Proschak&title=Exploring+the+Chemical+Space+of+Multitarget+Ligands+Using+Aligned+Self-Organizing+Maps&doi=10.1021%2Fml4002562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the Chemical Space of Multitarget Ligands Using Aligned Self-Organizing Maps</span></div><div class="casAuthors">Achenbach, Janosch; Klingler, Franca-Maria; Bloecher, Rene; Moser, Daniel; Haefner, Ann-Kathrin; Roedl, Carmen B.; Kretschmer, Simon; Krueger, Bjoern; Loehr, Frank; Stark, Holger; Hofmann, Bettina; Steinhilber, Dieter; Proschak, Ewgenij</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1169-1172</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Design of multitarget drugs and polypharmacol. compds. has become popular during the past decade.  However, the main approach to design such compds. is to link two selective ligands via a flexible linker.  Although such chimeric ligands often have reasonable potency in vitro, the in vivo efficacy is low due to high mol. wt., low ligand efficiency, and poor pharmacokinetic profile.  We developed an unprecedented in silico approach for fragment-based design of multitarget ligands.  It relies on superposition of the chem. spaces related to the affinity on single targets represented by self-organizing maps.  We used this approach for screening of mol. fragments, which bind to the enzymes 5-lipoxygenase (5-LO) and sol. epoxide hydrolase (sEH).  Using STD-NMR and activity-based assays, we were able to identify fragments binding to both targets.  Furthermore, we were able to expand one of the fragments to a potent dual inhibitor bearing a reasonable mol. wt. (MW = 446) and high affinity to both targets (IC50 of 0.03 μM toward 5-LO and 0.17 μM toward sEH).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp120TeMy83c7Vg90H21EOLACvtfcHk0li4AnuGmj4i2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Kkt7fL&md5=4231074e150dd7db7b92242d4c1664ff</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1021%2Fml4002562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4002562%26sid%3Dliteratum%253Aachs%26aulast%3DAchenbach%26aufirst%3DJ.%26aulast%3DKlingler%26aufirst%3DF.%2BM.%26aulast%3DBl%25C3%25B6cher%26aufirst%3DR.%26aulast%3DMoser%26aufirst%3DD.%26aulast%3DH%25C3%25A4fner%26aufirst%3DA.%2BK.%26aulast%3DR%25C3%25B6dl%26aufirst%3DC.%2BB.%26aulast%3DKretschmer%26aufirst%3DS.%26aulast%3DKr%25C3%25BCger%26aufirst%3DB.%26aulast%3DL%25C3%25B6hr%26aufirst%3DF.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DHofmann%26aufirst%3DB.%26aulast%3DSteinhilber%26aufirst%3DD.%26aulast%3DProschak%26aufirst%3DE.%26atitle%3DExploring%2520the%2520Chemical%2520Space%2520of%2520Multitarget%2520Ligands%2520Using%2520Aligned%2520Self-Organizing%2520Maps%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26issue%3D12%26spage%3D1169%26epage%3D1172%26doi%3D10.1021%2Fml4002562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bottegoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veronesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisignano, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kacker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favia, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span> <span> </span><span class="NLM_article-title">Development and Application of a Virtual Screening Protocol for the Identification of Multitarget Fragments</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1259</span>– <span class="NLM_lpage">1263</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500521</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fcmdc.201500521" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1259-1263&issue=12&author=G.+Bottegoniauthor=M.+Veronesiauthor=P.+Bisignanoauthor=P.+Kackerauthor=A.+D.+Faviaauthor=A.+Cavalli&title=Development+and+Application+of+a+Virtual+Screening+Protocol+for+the+Identification+of+Multitarget+Fragments&doi=10.1002%2Fcmdc.201500521"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500521%26sid%3Dliteratum%253Aachs%26aulast%3DBottegoni%26aufirst%3DG.%26aulast%3DVeronesi%26aufirst%3DM.%26aulast%3DBisignano%26aufirst%3DP.%26aulast%3DKacker%26aufirst%3DP.%26aulast%3DFavia%26aufirst%3DA.%2BD.%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DDevelopment%2520and%2520Application%2520of%2520a%2520Virtual%2520Screening%2520Protocol%2520for%2520the%2520Identification%2520of%2520Multitarget%2520Fragments%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26issue%3D12%26spage%3D1259%26epage%3D1263%26doi%3D10.1002%2Fcmdc.201500521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Simone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armirotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrisano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Castillo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massenzio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polito, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatino, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottegoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">3,4-Dihydro-1,3,5-Triazin-2(1H)-Ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer’s Disease</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1665</span>– <span class="NLM_lpage">1682</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00121</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00121" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFKkt73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1665-1682&issue=10&author=F.+Pratiauthor=A.+De+Simoneauthor=A.+Armirottiauthor=M.+Summaauthor=D.+Pizziraniauthor=R.+Scarpelliauthor=S.+M.+Bertozziauthor=D.+I.+Perezauthor=V.+Andrisanoauthor=A.+Perez-Castilloauthor=B.+Montiauthor=F.+Massenzioauthor=L.+Politoauthor=M.+Racchiauthor=P.+Sabatinoauthor=G.+Bottegoniauthor=A.+Martinezauthor=A.+Cavalliauthor=M.+L.+Bolognesi&title=3%2C4-Dihydro-1%2C3%2C5-Triazin-2%281H%29-Ones+as+the+First+Dual+BACE-1%2FGSK-3%CE%B2+Fragment+Hits+against+Alzheimer%E2%80%99s+Disease&doi=10.1021%2Facschemneuro.5b00121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer's Disease</span></div><div class="casAuthors">Prati, Federica; De Simone, Angela; Armirotti, Andrea; Summa, Maria; Pizzirani, Daniela; Scarpelli, Rita; Bertozzi, Sine Mandrup; Perez, Daniel I.; Andrisano, Vincenza; Perez-Castillo, Ana; Monti, Barbara; Massenzio, Francesca; Polito, Letizia; Racchi, Marco; Sabatino, Piera; Bottegoni, Giovanni; Martinez, Ana; Cavalli, Andrea; Bolognesi, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1665-1682</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">One of the main obstacles toward the discovery of effective anti-Alzheimer drugs is the multifactorial nature of its etiopathol.  Therefore, the use of multitarget-directed ligands has emerged as particularly suitable.  Such ligands, able to modulate different neurodegenerative pathways, for example, amyloid and tau cascades, as well as cognitive and neurogenic functions, are fostered to come.  In this respect, we report herein on the first class of BACE-1/GSK-3β dual inhibitors based on a 3,4-dihydro-1,3,5-triazin-2(1H)-one skeleton, whose hit compd. 1 showed interesting properties in a preliminary investigation.  Notably, compd. 2, endowed with well-balanced potencies against the two isolated enzymes (IC50 of 16 and 7 μM against BACE-1 and GSK-3β, resp.), displayed effective neuroprotective and neurogenic activities and no neurotoxicity in cell-based assays.  It also showed good brain permeability in a pharmacokinetic assessment in mice.  Overall, triazinone derivs., thanks to the simultaneous modulation of multiple points of the diseased network, might emerge as suitable candidates to be tested in in vivo Alzheimer's disease models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9gpkNszZOQ7Vg90H21EOLACvtfcHk0li4AnuGmj4i2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFKkt73O&md5=5d02342f3164a73e41eb17c4f87fb4fa</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00121%26sid%3Dliteratum%253Aachs%26aulast%3DPrati%26aufirst%3DF.%26aulast%3DDe%2BSimone%26aufirst%3DA.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DSumma%26aufirst%3DM.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DBertozzi%26aufirst%3DS.%2BM.%26aulast%3DPerez%26aufirst%3DD.%2BI.%26aulast%3DAndrisano%26aufirst%3DV.%26aulast%3DPerez-Castillo%26aufirst%3DA.%26aulast%3DMonti%26aufirst%3DB.%26aulast%3DMassenzio%26aufirst%3DF.%26aulast%3DPolito%26aufirst%3DL.%26aulast%3DRacchi%26aufirst%3DM.%26aulast%3DSabatino%26aufirst%3DP.%26aulast%3DBottegoni%26aufirst%3DG.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3D3%252C4-Dihydro-1%252C3%252C5-Triazin-2%25281H%2529-Ones%2520as%2520the%2520First%2520Dual%2520BACE-1%252FGSK-3%25CE%25B2%2520Fragment%2520Hits%2520against%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2015%26volume%3D6%26issue%3D10%26spage%3D1665%26epage%3D1682%26doi%3D10.1021%2Facschemneuro.5b00121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span> <span> </span><span class="NLM_article-title">De Novo Design of Multitarget Ligands with an Iterative Fragment-Growing Strategy</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1235</span>– <span class="NLM_lpage">1241</span>, <span class="refDoi"> DOI: 10.1021/ci500021v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci500021v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjvVOnsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2014&pages=1235-1241&issue=4&author=E.+Shangauthor=Y.+Yuanauthor=X.+Chenauthor=Y.+Liuauthor=J.+Peiauthor=L.+Lai&title=De+Novo+Design+of+Multitarget+Ligands+with+an+Iterative+Fragment-Growing+Strategy&doi=10.1021%2Fci500021v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">De Novo Design of Multitarget Ligands with an Iterative Fragment-Growing Strategy</span></div><div class="casAuthors">Shang, Erchang; Yuan, Yaxia; Chen, Xinyi; Liu, Ying; Pei, Jianfeng; Lai, Luhua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1235-1241</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of multitarget drugs has recently attracted much attention.  Most of the reported multitarget ligands have been serendipitous discoveries.  Although a few methods have been developed for rational multitarget drug discovery, there is a lack of elegant methods for de novo multitarget drug design and optimization, esp. for multiple targets with large differences in their binding sites.  In this paper, we report the first de novo multitarget ligand design method, with an iterative fragment-growing strategy.  Using this method, dual-target inhibitors for COX-2 and LTA4H were designed, with the most potent one inhibiting PGE2 and LTB4 prodn. in the human whole blood assay with IC50 values of 7.0 and 7.1 μM, resp.  Our strategy is generally applicable in rational and efficient multitarget drug design, esp. for the design of highly integrated inhibitors for proteins with dissimilar binding pockets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYeSpPS20iL7Vg90H21EOLACvtfcHk0ljEv2cM3UobPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjvVOnsbY%253D&md5=964c8053de5457730dc369cf8f8ca6a7</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1021%2Fci500021v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci500021v%26sid%3Dliteratum%253Aachs%26aulast%3DShang%26aufirst%3DE.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPei%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DDe%2520Novo%2520Design%2520of%2520Multitarget%2520Ligands%2520with%2520an%2520Iterative%2520Fragment-Growing%2520Strategy%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2014%26volume%3D54%26issue%3D4%26spage%3D1235%26epage%3D1241%26doi%3D10.1021%2Fci500021v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D.
R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehra, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perreault, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erbe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krupka, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">England, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plotnikov, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Signaevsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kral, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantwell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settachatgull, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Womack, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlasuk, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobin, J. F.</span></span> <span> </span><span class="NLM_article-title">Scaffold-Based Discovery of Indeglitazar, a PPAR Pan-Active Anti-Diabetic Agent</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">262</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1073/pnas.0811325106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1073%2Fpnas.0811325106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=19116277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltF2rtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=262-267&issue=1&author=D.%0AR.+Artisauthor=J.+J.+Linauthor=C.+Zhangauthor=W.+Wangauthor=U.+Mehraauthor=M.+Perreaultauthor=D.+Erbeauthor=H.+I.+Krupkaauthor=B.+P.+Englandauthor=J.+Arnoldauthor=A.+N.+Plotnikovauthor=A.+Marimuthuauthor=H.+Nguyenauthor=S.+Willauthor=M.+Signaevskyauthor=J.+Kralauthor=J.+Cantwellauthor=C.+Settachatgullauthor=D.+S.+Yanauthor=D.+Fongauthor=A.+Ohauthor=S.+Shiauthor=P.+Womackauthor=B.+Powellauthor=G.+Habetsauthor=B.+L.+Westauthor=K.+Y.+J.+Zhangauthor=M.+V.+Milburnauthor=G.+P.+Vlasukauthor=K.+P.+Hirthauthor=K.+Nolopauthor=G.+Bollagauthor=P.+N.+Ibrahimauthor=J.+F.+Tobin&title=Scaffold-Based+Discovery+of+Indeglitazar%2C+a+PPAR+Pan-Active+Anti-Diabetic+Agent&doi=10.1073%2Fpnas.0811325106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent</span></div><div class="casAuthors">Artis, Dean R.; Lin, Jack J.; Zhang, Chao; Wang, Weiru; Mehra, Upasana; Perreault, Mylene; Erbe, David; Krupka, Heike I.; England, Bruce P.; Arnold, James; Plotnikov, Alexander N.; Marimuthu, Adhirai; Nguyen, Hoa; Will, Sarah; Signaevsky, Maxime; Kral, John; Cantwell, John; Settachatgull, Alvin; Yan, Douglas S.; Fong, Daniel; Oh, Angela; Shi, Shenghua; Womack, Patrick; Powell, Benjamin; Habets, Gaston; West, Brian L.; Zhang, Kam Y. J.; Milburn, Michael V.; Vlasuk, George P.; Hirth, K. Peter; Nolop, Keith; Bollag, Gideon; Ibrahim, Prabha N.; Tobin, James F.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">262-267</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">In a search for more effective anti-diabetic treatment, we used a process coupling low-affinity biochem. screening with high-throughput co-crystallog. in the design of a series of compds. that selectively modulate the activities of all three peroxisome proliferator-activated receptors (PPARs), PPARα, PPARγ, and PPARδ.  Transcriptional transactivation assays were used to select compds. from this chem. series with a bias toward partial agonism toward PPARγ, to circumvent the clin. obsd. side effects of full PPARγ agonists.  Co-crystallog. characterization of the lead mol., indeglitazar, in complex with each of the 3 PPARs revealed the structural basis for its PPAR pan-activity and its partial agonistic response toward PPARγ.  Compared with full PPARγ-agonists, indeglitazar is less potent in promoting adipocyte differentiation and only partially effective in stimulating adiponectin gene expression.  Evaluation of the compd. in vivo confirmed the reduced adiponectin response in animal models of obesity and diabetes while revealing strong beneficial effects on glucose, triglycerides, cholesterol, body wt., and other metabolic parameters.  Indeglitazar has now progressed to Phase II clin. evaluations for Type 2 diabetes mellitus (T2DM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiPwFlRHVN2bVg90H21EOLACvtfcHk0ljEv2cM3UobPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltF2rtg%253D%253D&md5=29503488bc79c51644c81d83add9040a</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0811325106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0811325106%26sid%3Dliteratum%253Aachs%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DMehra%26aufirst%3DU.%26aulast%3DPerreault%26aufirst%3DM.%26aulast%3DErbe%26aufirst%3DD.%26aulast%3DKrupka%26aufirst%3DH.%2BI.%26aulast%3DEngland%26aufirst%3DB.%2BP.%26aulast%3DArnold%26aufirst%3DJ.%26aulast%3DPlotnikov%26aufirst%3DA.%2BN.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DWill%26aufirst%3DS.%26aulast%3DSignaevsky%26aufirst%3DM.%26aulast%3DKral%26aufirst%3DJ.%26aulast%3DCantwell%26aufirst%3DJ.%26aulast%3DSettachatgull%26aufirst%3DC.%26aulast%3DYan%26aufirst%3DD.%2BS.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DOh%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DWomack%26aufirst%3DP.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DVlasuk%26aufirst%3DG.%2BP.%26aulast%3DHirth%26aufirst%3DK.%2BP.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DTobin%26aufirst%3DJ.%2BF.%26atitle%3DScaffold-Based%2520Discovery%2520of%2520Indeglitazar%252C%2520a%2520PPAR%2520Pan-Active%2520Anti-Diabetic%2520Agent%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26issue%3D1%26spage%3D262%26epage%3D267%26doi%3D10.1073%2Fpnas.0811325106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blundell, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhoti, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, C.</span></span> <span> </span><span class="NLM_article-title">High-Throughput Crystallography for Lead Discovery in Drug Design</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1038/nrd706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnrd706" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=45-54&issue=1&author=T.+L.+Blundellauthor=H.+Jhotiauthor=C.+Abell&title=High-Throughput+Crystallography+for+Lead+Discovery+in+Drug+Design&doi=10.1038%2Fnrd706"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1038%2Fnrd706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd706%26sid%3Dliteratum%253Aachs%26aulast%3DBlundell%26aufirst%3DT.%2BL.%26aulast%3DJhoti%26aufirst%3DH.%26aulast%3DAbell%26aufirst%3DC.%26atitle%3DHigh-Throughput%2520Crystallography%2520for%2520Lead%2520Discovery%2520in%2520Drug%2520Design%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26issue%3D1%26spage%3D45%26epage%3D54%26doi%3D10.1038%2Fnrd706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span> <span> </span><span class="NLM_article-title">Comparative Assessment of Scoring Functions on an Updated Benchmark: 1. Compilation of the Test Set</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1700</span>– <span class="NLM_lpage">1716</span>, <span class="refDoi"> DOI: 10.1021/ci500080q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci500080q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvFensbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2014&pages=1700-1716&issue=6&author=Y.+Liauthor=Z.+Liuauthor=J.+Liauthor=L.+Hanauthor=J.+Liuauthor=Z.+Zhaoauthor=R.+Wang&title=Comparative+Assessment+of+Scoring+Functions+on+an+Updated+Benchmark%3A+1.+Compilation+of+the+Test+Set&doi=10.1021%2Fci500080q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Assessment of Scoring Functions on an Updated Benchmark: 1. Compilation of the Test Set</span></div><div class="casAuthors">Li, Yan; Liu, Zhihai; Li, Jie; Han, Li; Liu, Jie; Zhao, Zhixiong; Wang, Renxiao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1700-1716</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Scoring functions are often applied in combination with mol. docking methods to predict ligand binding poses and ligand binding affinities or to identify active compds. through virtual screening.  An objective benchmark for assessing the performance of current scoring functions is expected to provide practical guidance for the users to make smart choices among available methods.  It can also elucidate the common weakness in current methods for future improvements.  The primary goal of our comparative assessment of scoring functions (CASF) project is to provide a high-std., publicly accessible benchmark of this type.  Our latest study, i.e., CASF-2013, evaluated 20 popular scoring functions on an updated set of protein-ligand complexes.  This data set was selected out of 8302 protein-ligand complexes recorded in the PDBbind database (version 2013) through a fairly complicated process.  Sample selection was made by considering the quality of complex structures as well as binding data.  Finally, qualified complexes were clustered by 90% similarity in protein sequences.  Three representative complexes were chosen from each cluster to control sample redundancy.  The final outcome, namely, the PDBbind core set (version 2013), consists of 195 protein-ligand complexes in 65 clusters with binding consts. spanning nearly 10 orders of magnitude.  In this data set, 82% of the ligand mols. are "druglike" and 78% of the protein mols. are validated or potential drug targets.  Correlation between binding consts. and several key properties of ligands are discussed.  Methods and results of the scoring function evaluation will be described in a companion work in this issue (doi: 10.1021/ci500081m).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO1hheW8ZvHrVg90H21EOLACvtfcHk0lhqz_aVp2NGPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvFensbk%253D&md5=c10b25fcdad140d69489c2f47dc9c511</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1021%2Fci500080q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci500080q%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DR.%26atitle%3DComparative%2520Assessment%2520of%2520Scoring%2520Functions%2520on%2520an%2520Updated%2520Benchmark%253A%25201.%2520Compilation%2520of%2520the%2520Test%2520Set%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2014%26volume%3D54%26issue%3D6%26spage%3D1700%26epage%3D1716%26doi%3D10.1021%2Fci500080q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schiebel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krimmer, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Röwer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knörlein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stieler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrmann, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radeva, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krug, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huschmann, F. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glöckner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heine, A.</span></span> <span> </span><span class="NLM_article-title">High-Throughput Crystallography: Reliable and Efficient Identification of Fragment Hits</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1398</span>– <span class="NLM_lpage">1409</span>, <span class="refDoi"> DOI: 10.1016/j.str.2016.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.str.2016.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=27452405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1eju7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1398-1409&issue=8&author=J.+Schiebelauthor=S.+G.+Krimmerauthor=K.+R%C3%B6werauthor=A.+Kn%C3%B6rleinauthor=X.+Wangauthor=A.+Y.+Parkauthor=M.+Stielerauthor=F.+R.+Ehrmannauthor=K.+Fuauthor=N.+Radevaauthor=M.+Krugauthor=F.+U.+Huschmannauthor=S.+Gl%C3%B6cknerauthor=M.+S.+Weissauthor=U.+Muellerauthor=G.+Klebeauthor=A.+Heine&title=High-Throughput+Crystallography%3A+Reliable+and+Efficient+Identification+of+Fragment+Hits&doi=10.1016%2Fj.str.2016.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">High-Throughput Crystallography: Reliable and Efficient Identification of Fragment Hits</span></div><div class="casAuthors">Schiebel, Johannes; Krimmer, Stefan G.; Roewer, Karine; Knoerlein, Anna; Wang, Xiaojie; Park, Ah Young; Stieler, Martin; Ehrmann, Frederik R.; Fu, Kan; Radeva, Nedyalka; Krug, Michael; Huschmann, Franziska U.; Gloeckner, Steffen; Weiss, Manfred S.; Mueller, Uwe; Klebe, Gerhard; Heine, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1398-1409</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Today the identification of lead structures for drug development often starts from small fragment-like mols. raising the chances to find compds. that successfully pass clin. trials.  At the heart of the screening for fragments binding to a specific target, crystallog. delivers structural information essential for subsequent drug design.  While it is common to search for bound ligands in electron densities calcd. directly after an initial refinement cycle, we raise the important question whether this strategy is viable for fragments characterized by low affinities.  Here, we describe and provide a collection of high-quality diffraction data obtained from 364 protein crystals treated with diverse fragments.  Subsequent data anal. showed that ∼25% of all hits would have been missed without further refining the resulting structures.  To enable fast and reliable hit identification, we have designed an automated refinement pipeline that will inspire the development of optimized tools facilitating the successful application of fragment-based methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZbbkxT06l9rVg90H21EOLACvtfcHk0lhqz_aVp2NGPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1eju7fN&md5=206c30aa2349a4ab285b6f51b746801d</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2016.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2016.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DSchiebel%26aufirst%3DJ.%26aulast%3DKrimmer%26aufirst%3DS.%2BG.%26aulast%3DR%25C3%25B6wer%26aufirst%3DK.%26aulast%3DKn%25C3%25B6rlein%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DPark%26aufirst%3DA.%2BY.%26aulast%3DStieler%26aufirst%3DM.%26aulast%3DEhrmann%26aufirst%3DF.%2BR.%26aulast%3DFu%26aufirst%3DK.%26aulast%3DRadeva%26aufirst%3DN.%26aulast%3DKrug%26aufirst%3DM.%26aulast%3DHuschmann%26aufirst%3DF.%2BU.%26aulast%3DGl%25C3%25B6ckner%26aufirst%3DS.%26aulast%3DWeiss%26aufirst%3DM.%2BS.%26aulast%3DMueller%26aufirst%3DU.%26aulast%3DKlebe%26aufirst%3DG.%26aulast%3DHeine%26aufirst%3DA.%26atitle%3DHigh-Throughput%2520Crystallography%253A%2520Reliable%2520and%2520Efficient%2520Identification%2520of%2520Fragment%2520Hits%26jtitle%3DStructure%26date%3D2016%26volume%3D24%26issue%3D8%26spage%3D1398%26epage%3D1409%26doi%3D10.1016%2Fj.str.2016.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Targeting the Cancer Kinome through Polypharmacology</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1038/nrc2787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnrc2787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=20094047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=130-137&issue=2&author=Z.+A.+Knightauthor=H.+Linauthor=K.+M.+Shokat&title=Targeting+the+Cancer+Kinome+through+Polypharmacology&doi=10.1038%2Fnrc2787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer kinome through polypharmacology</span></div><div class="casAuthors">Knight, Zachary A.; Lin, Henry; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-137</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Kinase inhibitors are the largest class of new cancer drugs.  However, it is already apparent that most tumors can escape from the inhibition of any single kinase.  If it is necessary to inhibit multiple kinases, how do we choose which ones.  In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDv2FeeH58rVg90H21EOLACvtfcHk0lhqz_aVp2NGPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D&md5=9aaa314e54b43889e147a9f11ac77072</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1038%2Fnrc2787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2787%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DTargeting%2520the%2520Cancer%2520Kinome%2520through%2520Polypharmacology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26issue%3D2%26spage%3D130%26epage%3D137%26doi%3D10.1038%2Fnrc2787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aronov, A.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClain, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moody, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murcko, M. A.</span></span> <span> </span><span class="NLM_article-title">Kinase-Likeness and Kinase-Privileged Fragments: Toward Virtual Polypharmacology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1214</span>– <span class="NLM_lpage">1222</span>, <span class="refDoi"> DOI: 10.1021/jm701021b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701021b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1214-1222&issue=5&author=A.%0AM.+Aronovauthor=B.+McClainauthor=C.+S.+Moodyauthor=M.+A.+Murcko&title=Kinase-Likeness+and+Kinase-Privileged+Fragments%3A+Toward+Virtual+Polypharmacology&doi=10.1021%2Fjm701021b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1021%2Fjm701021b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701021b%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26aulast%3DMcClain%26aufirst%3DB.%26aulast%3DMoody%26aufirst%3DC.%2BS.%26aulast%3DMurcko%26aufirst%3DM.%2BA.%26atitle%3DKinase-Likeness%2520and%2520Kinase-Privileged%2520Fragments%253A%2520Toward%2520Virtual%2520Polypharmacology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D5%26spage%3D1214%26epage%3D1222%26doi%3D10.1021%2Fjm701021b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref226"><div class="reference"><strong class="refLabel"><a href="#ref226" class="rightTabRefNumLink">226</a></strong><div class="NLM_citation" id="rightTab-cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frett, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moccia, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brescia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federico, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Falco, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Admire, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Discovery of a Dual Pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">30</span>),  <span class="NLM_fpage">8717</span>– <span class="NLM_lpage">8721</span>, <span class="refDoi"> DOI: 10.1002/anie.201501104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fanie.201501104" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=8717-8721&issue=30&author=B.+Frettauthor=F.+Carlomagnoauthor=M.+L.+Mocciaauthor=A.+Bresciaauthor=G.+Federicoauthor=V.+De+Falcoauthor=B.+Admireauthor=Z.+Chenauthor=W.+Qiauthor=M.+Santoroauthor=H.+Li&title=Fragment-Based+Discovery+of+a+Dual+Pan-RET%2FVEGFR2+Kinase+Inhibitor+Optimized+for+Single-Agent+Polypharmacology&doi=10.1002%2Fanie.201501104"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1002%2Fanie.201501104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201501104%26sid%3Dliteratum%253Aachs%26aulast%3DFrett%26aufirst%3DB.%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DMoccia%26aufirst%3DM.%2BL.%26aulast%3DBrescia%26aufirst%3DA.%26aulast%3DFederico%26aufirst%3DG.%26aulast%3DDe%2BFalco%26aufirst%3DV.%26aulast%3DAdmire%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DFragment-Based%2520Discovery%2520of%2520a%2520Dual%2520Pan-RET%252FVEGFR2%2520Kinase%2520Inhibitor%2520Optimized%2520for%2520Single-Agent%2520Polypharmacology%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26issue%3D30%26spage%3D8717%26epage%3D8721%26doi%3D10.1002%2Fanie.201501104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref227"><div class="reference"><strong class="refLabel"><a href="#ref227" class="rightTabRefNumLink">227</a></strong><div class="NLM_citation" id="rightTab-cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dar, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cagan, R. L.</span></span> <span> </span><span class="NLM_article-title">Chemical Genetic Discovery of Targets and Anti-Targets for Cancer Polypharmacology</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>486</i></span> (<span class="NLM_issue">7401</span>),  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1038/nature11127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnature11127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=22678283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot1Cnu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=80-84&issue=7401&author=A.+C.+Darauthor=T.+K.+Dasauthor=K.+M.+Shokatauthor=R.+L.+Cagan&title=Chemical+Genetic+Discovery+of+Targets+and+Anti-Targets+for+Cancer+Polypharmacology&doi=10.1038%2Fnature11127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genetic discovery of targets and anti-targets for cancer polypharmacology</span></div><div class="casAuthors">Dar, Arvin C.; Das, Tirtha K.; Shokat, Kevan M.; Cagan, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">7401</span>),
    <span class="NLM_cas:pages">80-84</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The complexity of cancer has led to recent interest in polypharmacol. approaches for developing kinase-inhibitor drugs; however, optimal kinase-inhibition profiles remain difficult to predict.  Using a Ret-kinase-driven Drosophila model of multiple endocrine neoplasia type 2 and kinome-wide drug profiling, here the authors identify that AD57 rescues oncogenic Ret-induced lethality, whereas related Ret inhibitors imparted reduced efficacy and enhanced toxicity.  Drosophila genetics and compd. profiling defined three pathways accounting for the mechanistic basis of efficacy and dose-limiting toxicity.  Inhibition of Ret plus Raf, Src and S6K was required for optimal animal survival, whereas inhibition of the anti-target' Tor led to toxicity owing to release of neg. feedback.  Rational synthetic tailoring to eliminate Tor binding afforded AD80 and AD81, compds. featuring balanced pathway inhibition, improved efficacy and low toxicity in Drosophila and mammalian multiple endocrine neoplasia type 2 models.  Combining kinase-focused chem., kinome-wide profiling and Drosophila genetics provides a powerful systems pharmacol. approach towards developing compds. with a maximal therapeutic index.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3OjBELXO9TbVg90H21EOLACvtfcHk0ljMBEjoVj2s8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot1Cnu7w%253D&md5=4ed2f85f51453c1b38ee390a0a5f14db</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1038%2Fnature11127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11127%26sid%3Dliteratum%253Aachs%26aulast%3DDar%26aufirst%3DA.%2BC.%26aulast%3DDas%26aufirst%3DT.%2BK.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DCagan%26aufirst%3DR.%2BL.%26atitle%3DChemical%2520Genetic%2520Discovery%2520of%2520Targets%2520and%2520Anti-Targets%2520for%2520Cancer%2520Polypharmacology%26jtitle%3DNature%26date%3D2012%26volume%3D486%26issue%3D7401%26spage%3D80%26epage%3D84%26doi%3D10.1038%2Fnature11127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref228"><div class="reference"><strong class="refLabel"><a href="#ref228" class="rightTabRefNumLink">228</a></strong><div class="NLM_citation" id="rightTab-cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pries, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldmann, H.</span></span> <span> </span><span class="NLM_article-title">Target Identification for Small Bioactive Molecules: Finding the Needle in the Haystack</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2744</span>– <span class="NLM_lpage">2792</span>, <span class="refDoi"> DOI: 10.1002/anie.201208749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fanie.201208749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3sXislSksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=2744-2792&issue=10&author=S.+Zieglerauthor=V.+Priesauthor=C.+Hedbergauthor=H.+Waldmann&title=Target+Identification+for+Small+Bioactive+Molecules%3A+Finding+the+Needle+in+the+Haystack&doi=10.1002%2Fanie.201208749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Target Identification for Small Bioactive Molecules: Finding the Needle in the Haystack</span></div><div class="casAuthors">Ziegler, Slava; Pries, Verena; Hedberg, Christian; Waldmann, Herbert</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2744-2792</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Identification and confirmation of bioactive small-mol. targets is a crucial, often decisive step both in academic and pharmaceutical research.  Through the development and availability of several new exptl. techniques, target identification is, in principle, feasible, and the no. of successful examples steadily grows.  However, a generic methodol. that can successfully be applied in the majority of the cases has not yet been established.  Herein we summarize current methods for target identification of small mols., primarily for a chem. audience but also the biol. community, for example, the chemist or biologist attempting to identify the target of a given bioactive compd.  We describe the most frequently employed exptl. approaches for target identification and provide several representative examples illustrating the state-of-the-art.  Among the techniques currently available, protein affinity isolation using suitable small-mol. probes (pulldown) and subsequent mass spectrometric anal. of the isolated proteins appears to be most powerful and most frequently applied.  To provide guidance for rapid entry into the field and based on our own experience we propose a typical workflow for target identification, which centers on the application of chem. proteomics as the key step to generate hypotheses for potential target proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYC9-7L3abMrVg90H21EOLACvtfcHk0ljMBEjoVj2s8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXislSksLk%253D&md5=3a124205e3a57a53f479b889073bda76</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1002%2Fanie.201208749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201208749%26sid%3Dliteratum%253Aachs%26aulast%3DZiegler%26aufirst%3DS.%26aulast%3DPries%26aufirst%3DV.%26aulast%3DHedberg%26aufirst%3DC.%26aulast%3DWaldmann%26aufirst%3DH.%26atitle%3DTarget%2520Identification%2520for%2520Small%2520Bioactive%2520Molecules%253A%2520Finding%2520the%2520Needle%2520in%2520the%2520Haystack%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26issue%3D10%26spage%3D2744%26epage%3D2792%26doi%3D10.1002%2Fanie.201208749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref229"><div class="reference"><strong class="refLabel"><a href="#ref229" class="rightTabRefNumLink">229</a></strong><div class="NLM_citation" id="rightTab-cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, C.</span></span> <span> </span><span class="NLM_article-title">Identification of Protein Binding Partners of Small Molecules Using Label-Free Methods</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1017</span>– <span class="NLM_lpage">1025</span>, <span class="refDoi"> DOI: 10.1080/17460441.2016.1227316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1080%2F17460441.2016.1227316" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1017-1025&issue=10&author=C.+Saxena&title=Identification+of+Protein+Binding+Partners+of+Small+Molecules+Using+Label-Free+Methods&doi=10.1080%2F17460441.2016.1227316"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1080%2F17460441.2016.1227316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2016.1227316%26sid%3Dliteratum%253Aachs%26aulast%3DSaxena%26aufirst%3DC.%26atitle%3DIdentification%2520of%2520Protein%2520Binding%2520Partners%2520of%2520Small%2520Molecules%2520Using%2520Label-Free%2520Methods%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2016%26volume%3D11%26issue%3D10%26spage%3D1017%26epage%3D1025%26doi%3D10.1080%2F17460441.2016.1227316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref230"><div class="reference"><strong class="refLabel"><a href="#ref230" class="rightTabRefNumLink">230</a></strong><div class="NLM_citation" id="rightTab-cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lomenick, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aghajan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warburton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlschlegel, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vondriska, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herschman, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clardy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span> <span> </span><span class="NLM_article-title">Target Identification Using Drug Affinity Responsive Target Stability (DARTS)</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">51</span>),  <span class="NLM_fpage">21984</span>– <span class="NLM_lpage">21989</span>, <span class="refDoi"> DOI: 10.1073/pnas.0910040106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1073%2Fpnas.0910040106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=19995983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlt1aiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=21984-21989&issue=51&author=B.+Lomenickauthor=R.+Haoauthor=N.+Jonaiauthor=R.+M.+Chinauthor=M.+Aghajanauthor=S.+Warburtonauthor=J.+Wangauthor=R.+P.+Wuauthor=F.+Gomezauthor=J.+A.+Looauthor=J.+A.+Wohlschlegelauthor=T.+M.+Vondriskaauthor=J.+Pelletierauthor=H.+R.+Herschmanauthor=J.+Clardyauthor=C.+F.+Clarkeauthor=J.+Huang&title=Target+Identification+Using+Drug+Affinity+Responsive+Target+Stability+%28DARTS%29&doi=10.1073%2Fpnas.0910040106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Target identification using drug affinity responsive target stability (DARTS)</span></div><div class="casAuthors">Lomenick, Brett; Hao, Rui; Jonai, Nao; Chin, Randall M.; Aghajan, Mariam; Warburton, Sarah; Wang, Jianing; Wu, Raymond P.; Gomez, Fernando; Loo, Joseph A.; Wohlschlegel, James A.; Vondriska, Thomas M.; Pelletier, Jerry; Herschman, Harvey R.; Clardy, Jon; Clarke, Catherine F.; Huang, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">21984-21989, S21984/1-S21984/14</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Identifying the mol. targets for the beneficial or detrimental effects of small-mol. drugs is an important and currently unmet challenge.  We have developed a method, drug affinity responsive target stability (DARTS), which takes advantage of a redn. in the protease susceptibility of the target protein upon drug binding.  DARTS is universally applicable because it requires no modification of the drug and is independent of the mechanism of drug action.  We demonstrate use of DARTS to identify known small-mol.-protein interactions and to reveal the eukaryotic translation initiation machinery as a mol. target for the longevity-enhancing plant natural product resveratrol.  We envisage that DARTS will also be useful in global mapping of protein-metabolite interaction networks and in label-free screening of unlimited varieties of compds. for development as mol. imaging agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBFsvOPfmmaLVg90H21EOLACvtfcHk0ljMBEjoVj2s8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlt1aiug%253D%253D&md5=0f14bce633a1ce0af6d95ad13876e405</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0910040106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0910040106%26sid%3Dliteratum%253Aachs%26aulast%3DLomenick%26aufirst%3DB.%26aulast%3DHao%26aufirst%3DR.%26aulast%3DJonai%26aufirst%3DN.%26aulast%3DChin%26aufirst%3DR.%2BM.%26aulast%3DAghajan%26aufirst%3DM.%26aulast%3DWarburton%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DR.%2BP.%26aulast%3DGomez%26aufirst%3DF.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DWohlschlegel%26aufirst%3DJ.%2BA.%26aulast%3DVondriska%26aufirst%3DT.%2BM.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DHerschman%26aufirst%3DH.%2BR.%26aulast%3DClardy%26aufirst%3DJ.%26aulast%3DClarke%26aufirst%3DC.%2BF.%26aulast%3DHuang%26aufirst%3DJ.%26atitle%3DTarget%2520Identification%2520Using%2520Drug%2520Affinity%2520Responsive%2520Target%2520Stability%2520%2528DARTS%2529%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26issue%3D51%26spage%3D21984%26epage%3D21989%26doi%3D10.1073%2Fpnas.0910040106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref231"><div class="reference"><strong class="refLabel"><a href="#ref231" class="rightTabRefNumLink">231</a></strong><div class="NLM_citation" id="rightTab-cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez Molina, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jafari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ignatushchenko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreekumar, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordlund, P.</span></span> <span> </span><span class="NLM_article-title">Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1126/science.1233606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1126%2Fscience.1233606" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=23828940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC3sjotlOqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2013&pages=84-87&author=D.+Martinez+Molinaauthor=R.+Jafariauthor=M.+Ignatushchenkoauthor=T.+Sekiauthor=E.+A.+Larssonauthor=C.+Danauthor=L.+Sreekumarauthor=Y.+Caoauthor=P.+Nordlund&title=Monitoring+Drug+Target+Engagement+in+Cells+and+Tissues+Using+the+Cellular+Thermal+Shift+Assay&doi=10.1126%2Fscience.1233606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay</span></div><div class="casAuthors">Martinez Molina Daniel; Jafari Rozbeh; Ignatushchenko Marina; Seki Takahiro; Larsson E Andreas; Dan Chen; Sreekumar Lekshmy; Cao Yihai; Nordlund Par</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">6141</span>),
    <span class="NLM_cas:pages">84-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The efficacy of therapeutics is dependent on a drug binding to its cognate target.  Optimization of target engagement by drugs in cells is often challenging, because drug binding cannot be monitored inside cells.  We have developed a method for evaluating drug binding to target proteins in cells and tissue samples.  This cellular thermal shift assay (CETSA) is based on the biophysical principle of ligand-induced thermal stabilization of target proteins.  Using this assay, we validated drug binding for a set of important clinical targets and monitored processes of drug transport and activation, off-target effects and drug resistance in cancer cell lines, as well as drug distribution in tissues.  CETSA is likely to become a valuable tool for the validation and optimization of drug target engagement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRRn5K_mF1rcrHHuJhbyicZfW6udTcc2ebSkL48zm1k_bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjotlOqtA%253D%253D&md5=a73bb49adb0d4f445223ea6f74fe3c10</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1126%2Fscience.1233606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1233606%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%2BMolina%26aufirst%3DD.%26aulast%3DJafari%26aufirst%3DR.%26aulast%3DIgnatushchenko%26aufirst%3DM.%26aulast%3DSeki%26aufirst%3DT.%26aulast%3DLarsson%26aufirst%3DE.%2BA.%26aulast%3DDan%26aufirst%3DC.%26aulast%3DSreekumar%26aufirst%3DL.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DNordlund%26aufirst%3DP.%26atitle%3DMonitoring%2520Drug%2520Target%2520Engagement%2520in%2520Cells%2520and%2520Tissues%2520Using%2520the%2520Cellular%2520Thermal%2520Shift%2520Assay%26jtitle%3DScience%26date%3D2013%26volume%3D341%26spage%3D84%26epage%3D87%26doi%3D10.1126%2Fscience.1233606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref232"><div class="reference"><strong class="refLabel"><a href="#ref232" class="rightTabRefNumLink">232</a></strong><div class="NLM_citation" id="rightTab-cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schulz-Fincke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robaa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kürner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greve, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haydn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lübbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lüdeke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schüle, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Studies on N-Substituted Tranylcypromine Derivatives Lead to Selective Inhibitors of Lysine Specific Demethylase 1 (LSD1) and Potent Inducers of Leukemic Cell Differentiation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">52</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.ejmech.2017.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29247860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFyju7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2018&pages=52-67&author=J.+Schulz-Finckeauthor=M.+Hauauthor=J.+Barthauthor=D.+Robaaauthor=D.+Willmannauthor=A.+K%C3%BCrnerauthor=J.+Haasauthor=G.+Greveauthor=T.+Haydnauthor=S.+Fuldaauthor=M.+L%C3%BCbbertauthor=S.+L%C3%BCdekeauthor=T.+Bergauthor=W.+Sipplauthor=R.+Sch%C3%BCleauthor=M.+Jung&title=Structure-Activity+Studies+on+N-Substituted+Tranylcypromine+Derivatives+Lead+to+Selective+Inhibitors+of+Lysine+Specific+Demethylase+1+%28LSD1%29+and+Potent+Inducers+of+Leukemic+Cell+Differentiation&doi=10.1016%2Fj.ejmech.2017.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation</span></div><div class="casAuthors">Schulz-Fincke, Johannes; Hau, Mirjam; Barth, Jessica; Robaa, Dina; Willmann, Dominica; Kuerner, Andreas; Haas, Julian; Greve, Gabriele; Haydn, Tinka; Fulda, Simone; Luebbert, Michael; Luedeke, Steffen; Berg, Tobias; Sippl, Wolfgang; Schuele, Roland; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">52-67</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">FAD-dependent lysine-specific demethylase 1 (LSD1) is overexpressed or deregulated in many cancers such as AML and prostate cancer and hence is a promising anticancer target with first inhibitors in clin. trials.  Clin. candidates are N-substituted derivs. of the dual LSD1-/monoamine oxidase-inhibitor tranylcypromine (2-PCPA) with a basic amine function in the N-substituent.  These derivs. are selective over monoamine oxidases.  So far, only very limited information on structure-activity studies about this important class of LSD1 inhibitors is published in peer reviewed journals.  Here, we show that N-substituted 2-PCPA derivs. without a basic function or even a polar group are still potent inhibitors of LSD1 in vitro and effectively inhibit colony formation of leukemic cells in culture.  Yet, these lipophilic inhibitors also block the structurally related monoamine oxidases (MAO-A and MAO-B), which may be of interest for the treatment of neurodegenerative disorders, but this property is undesired for applications in cancer treatment.  The introduction of a polar, non-basic function led to optimized structures that retain potent LSD1 inhibitors but exhibit selectivity over MAOs and are highly potent in the suppression of colony formation of cultured leukemic cells.  Cellular target engagement is shown via a Cellular Thermal Shift Assay (CETSA) for LSD1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS7XCIKeZiVrVg90H21EOLACvtfcHk0lisWu78Fz2apw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFyju7zN&md5=f9460e47baf69fb33d4e314564591bd4</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DSchulz-Fincke%26aufirst%3DJ.%26aulast%3DHau%26aufirst%3DM.%26aulast%3DBarth%26aufirst%3DJ.%26aulast%3DRobaa%26aufirst%3DD.%26aulast%3DWillmann%26aufirst%3DD.%26aulast%3DK%25C3%25BCrner%26aufirst%3DA.%26aulast%3DHaas%26aufirst%3DJ.%26aulast%3DGreve%26aufirst%3DG.%26aulast%3DHaydn%26aufirst%3DT.%26aulast%3DFulda%26aufirst%3DS.%26aulast%3DL%25C3%25BCbbert%26aufirst%3DM.%26aulast%3DL%25C3%25BCdeke%26aufirst%3DS.%26aulast%3DBerg%26aufirst%3DT.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DSch%25C3%25BCle%26aufirst%3DR.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DStructure-Activity%2520Studies%2520on%2520N-Substituted%2520Tranylcypromine%2520Derivatives%2520Lead%2520to%2520Selective%2520Inhibitors%2520of%2520Lysine%2520Specific%2520Demethylase%25201%2520%2528LSD1%2529%2520and%2520Potent%2520Inducers%2520of%2520Leukemic%2520Cell%2520Differentiation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D144%26spage%3D52%26epage%3D67%26doi%3D10.1016%2Fj.ejmech.2017.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref233"><div class="reference"><strong class="refLabel"><a href="#ref233" class="rightTabRefNumLink">233</a></strong><div class="NLM_citation" id="rightTab-cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franken, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Childs, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweetman, G. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tögel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doce, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gade, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhard, F. B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savitski, M. M.</span></span> <span> </span><span class="NLM_article-title">Thermal Proteome Profiling for Unbiased Identification of Direct and Indirect Drug Targets Using Multiplexed Quantitative Mass Spectrometry</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1567</span>– <span class="NLM_lpage">1593</span>, <span class="refDoi"> DOI: 10.1038/nprot.2015.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnprot.2015.101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=26379230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVyrtbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1567-1593&issue=10&author=H.+Frankenauthor=T.+Mathiesonauthor=D.+Childsauthor=G.+M.+A.+Sweetmanauthor=T.+Wernerauthor=I.+T%C3%B6gelauthor=C.+Doceauthor=S.+Gadeauthor=M.+Bantscheffauthor=G.+Drewesauthor=F.+B.+M.+Reinhardauthor=W.+Huberauthor=M.+M.+Savitski&title=Thermal+Proteome+Profiling+for+Unbiased+Identification+of+Direct+and+Indirect+Drug+Targets+Using+Multiplexed+Quantitative+Mass+Spectrometry&doi=10.1038%2Fnprot.2015.101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry</span></div><div class="casAuthors">Franken, Holger; Mathieson, Toby; Childs, Dorothee; Sweetman, Gavain M. A.; Werner, Thilo; Toegel, Ina; Doce, Carola; Gade, Stephan; Bantscheff, Marcus; Drewes, Gerard; Reinhard, Friedrich B. M.; Huber, Wolfgang; Savitski, Mikhail M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1567-1593</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The direct detection of drug-protein interactions in living cells is a major challenge in drug discovery research.  Recently, the authors introduced an approach termed thermal proteome profiling (TPP), which enables the monitoring of changes in protein thermal stability across the proteome using quant. mass spectrometry.  The authors detd. the intracellular thermal profiles for up to 7000 proteins, and by comparing profiles derived from cultured mammalian cells in the presence or absence of a drug it was possible to identify direct and indirect targets of drugs in living cells in an unbiased manner.  Here the authors demonstrate the complete workflow using the histone deacetylase inhibitor panobinostat.  The key to this approach is the use of isobaric tandem mass tag 10-plex (TMT10) reagents to label digested protein samples corresponding to each temp. point in the melting curve so that the samples can be analyzed by multiplexed quant. mass spectrometry.  Important steps in the bioinformatic anal. include data normalization, melting curve fitting and statistical significance detn. of compd. concn.-dependent changes in protein stability.  All anal. tools are made freely available as R and Python packages.  The workflow can be completed in 2 wk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS4LU9YprZqLVg90H21EOLACvtfcHk0lieJbaj4v0YZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVyrtbzN&md5=d9c225616a35fc5dcc97db234452d7e1</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2015.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2015.101%26sid%3Dliteratum%253Aachs%26aulast%3DFranken%26aufirst%3DH.%26aulast%3DMathieson%26aufirst%3DT.%26aulast%3DChilds%26aufirst%3DD.%26aulast%3DSweetman%26aufirst%3DG.%2BM.%2BA.%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DT%25C3%25B6gel%26aufirst%3DI.%26aulast%3DDoce%26aufirst%3DC.%26aulast%3DGade%26aufirst%3DS.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DReinhard%26aufirst%3DF.%2BB.%2BM.%26aulast%3DHuber%26aufirst%3DW.%26aulast%3DSavitski%26aufirst%3DM.%2BM.%26atitle%3DThermal%2520Proteome%2520Profiling%2520for%2520Unbiased%2520Identification%2520of%2520Direct%2520and%2520Indirect%2520Drug%2520Targets%2520Using%2520Multiplexed%2520Quantitative%2520Mass%2520Spectrometry%26jtitle%3DNat.%2520Protoc.%26date%3D2015%26volume%3D10%26issue%3D10%26spage%3D1567%26epage%3D1593%26doi%3D10.1038%2Fnprot.2015.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref234"><div class="reference"><strong class="refLabel"><a href="#ref234" class="rightTabRefNumLink">234</a></strong><div class="NLM_citation" id="rightTab-cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reinhard, F. B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberhard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franken, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Childs, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doce, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savitski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savitski, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span> <span> </span><span class="NLM_article-title">Thermal Proteome Profiling Monitors Ligand Interactions with Cellular Membrane Proteins</span>. <i>Nat. Methods</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1129</span>– <span class="NLM_lpage">1131</span>, <span class="refDoi"> DOI: 10.1038/nmeth.3652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnmeth.3652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=26524241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKgt7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=1129-1131&issue=12&author=F.+B.+M.+Reinhardauthor=D.+Eberhardauthor=T.+Wernerauthor=H.+Frankenauthor=D.+Childsauthor=C.+Doceauthor=M.+F.+Savitskiauthor=W.+Huberauthor=M.+Bantscheffauthor=M.+M.+Savitskiauthor=G.+Drewes&title=Thermal+Proteome+Profiling+Monitors+Ligand+Interactions+with+Cellular+Membrane+Proteins&doi=10.1038%2Fnmeth.3652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">Thermal proteome profiling monitors ligand interactions with cellular membrane proteins</span></div><div class="casAuthors">Reinhard, Friedrich B. M.; Eberhard, Dirk; Werner, Thilo; Franken, Holger; Childs, Dorothee; Doce, Carola; Savitski, Maria Faelth; Huber, Wolfgang; Bantscheff, Marcus; Savitski, Mikhail M.; Drewes, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Methods</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1129-1131</span>CODEN:
                <span class="NLM_cas:coden">NMAEA3</span>;
        ISSN:<span class="NLM_cas:issn">1548-7091</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We extended thermal proteome profiling to detect transmembrane protein-small mol. interactions in cultured human cells.  When we assessed the effects of detergents on ATP-binding profiles, we obsd. shifts in denaturation temp. for ATP-binding transmembrane proteins.  We also obsd. cellular thermal shifts in pervanadate-induced T cell-receptor signaling, delineating the membrane target CD45 and components of the downstream pathway, and with drugs affecting the transmembrane transporters ATP1A1 and MDR1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo45i1e8jbFF7Vg90H21EOLACvtfcHk0lieJbaj4v0YZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKgt7fO&md5=ec4651a2753f7969b16811faa8affa23</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1038%2Fnmeth.3652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmeth.3652%26sid%3Dliteratum%253Aachs%26aulast%3DReinhard%26aufirst%3DF.%2BB.%2BM.%26aulast%3DEberhard%26aufirst%3DD.%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DFranken%26aufirst%3DH.%26aulast%3DChilds%26aufirst%3DD.%26aulast%3DDoce%26aufirst%3DC.%26aulast%3DSavitski%26aufirst%3DM.%2BF.%26aulast%3DHuber%26aufirst%3DW.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DSavitski%26aufirst%3DM.%2BM.%26aulast%3DDrewes%26aufirst%3DG.%26atitle%3DThermal%2520Proteome%2520Profiling%2520Monitors%2520Ligand%2520Interactions%2520with%2520Cellular%2520Membrane%2520Proteins%26jtitle%3DNat.%2520Methods%26date%3D2015%26volume%3D12%26issue%3D12%26spage%3D1129%26epage%3D1131%26doi%3D10.1038%2Fnmeth.3652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref235"><div class="reference"><strong class="refLabel"><a href="#ref235" class="rightTabRefNumLink">235</a></strong><div class="NLM_citation" id="rightTab-cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savitski, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhard, F. B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franken, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savitski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberhard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez
Molina, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jafari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dovega, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaeger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuster, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordlund, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span> <span> </span><span class="NLM_article-title">Tracking Cancer Drugs in Living Cells by Thermal Profiling of the Proteome</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>346</i></span> (<span class="NLM_issue">6205</span>),  <span class="NLM_fpage">1255784</span>, <span class="refDoi"> DOI: 10.1126/science.1255784</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1126%2Fscience.1255784" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=25278616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC2M7ntVKgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2014&pages=1255784&issue=6205&author=M.+M.+Savitskiauthor=F.+B.+M.+Reinhardauthor=H.+Frankenauthor=T.+Wernerauthor=M.+F.+Savitskiauthor=D.+Eberhardauthor=D.+Martinez%0AMolinaauthor=R.+Jafariauthor=R.+B.+Dovegaauthor=S.+Klaegerauthor=B.+Kusterauthor=P.+Nordlundauthor=M.+Bantscheffauthor=G.+Drewes&title=Tracking+Cancer+Drugs+in+Living+Cells+by+Thermal+Profiling+of+the+Proteome&doi=10.1126%2Fscience.1255784"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Tracking cancer drugs in living cells by thermal profiling of the proteome</span></div><div class="casAuthors">Savitski Mikhail M; Reinhard Friedrich B M; Franken Holger; Werner Thilo; Savitski Maria Falth; Eberhard Dirk; Bantscheff Marcus; Drewes Gerard; Martinez Molina Daniel; Jafari Rozbeh; Dovega Rebecca Bakszt; Klaeger Susan; Kuster Bernhard; Nordlund Par</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">6205</span>),
    <span class="NLM_cas:pages">1255784</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The thermal stability of proteins can be used to assess ligand binding in living cells.  We have generalized this concept by determining the thermal profiles of more than 7000 proteins in human cells by means of mass spectrometry.  Monitoring the effects of small-molecule ligands on the profiles delineated more than 50 targets for the kinase inhibitor staurosporine.  We identified the heme biosynthesis enzyme ferrochelatase as a target of kinase inhibitors and suggest that its inhibition causes the phototoxicity observed with vemurafenib and alectinib.  Thermal shifts were also observed for downstream effectors of drug treatment.  In live cells, dasatinib induced shifts in BCR-ABL pathway proteins, including CRK/CRKL.  Thermal proteome profiling provides an unbiased measure of drug-target engagement and facilitates identification of markers for drug efficacy and toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0ur3d8ba-Bu2mnZh2OgS0fW6udTcc2ea55jIqEYy0Rrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7ntVKgsg%253D%253D&md5=493a89ad107e656e0f0786ff5c8e5f63</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1126%2Fscience.1255784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1255784%26sid%3Dliteratum%253Aachs%26aulast%3DSavitski%26aufirst%3DM.%2BM.%26aulast%3DReinhard%26aufirst%3DF.%2BB.%2BM.%26aulast%3DFranken%26aufirst%3DH.%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DSavitski%26aufirst%3DM.%2BF.%26aulast%3DEberhard%26aufirst%3DD.%26aulast%3DMartinez%2BMolina%26aufirst%3DD.%26aulast%3DJafari%26aufirst%3DR.%26aulast%3DDovega%26aufirst%3DR.%2BB.%26aulast%3DKlaeger%26aufirst%3DS.%26aulast%3DKuster%26aufirst%3DB.%26aulast%3DNordlund%26aufirst%3DP.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DDrewes%26aufirst%3DG.%26atitle%3DTracking%2520Cancer%2520Drugs%2520in%2520Living%2520Cells%2520by%2520Thermal%2520Profiling%2520of%2520the%2520Proteome%26jtitle%3DScience%26date%3D2014%26volume%3D346%26issue%3D6205%26spage%3D1255784%26doi%3D10.1126%2Fscience.1255784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref236"><div class="reference"><strong class="refLabel"><a href="#ref236" class="rightTabRefNumLink">236</a></strong><div class="NLM_citation" id="rightTab-cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hengst, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geffert, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kester, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughran, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulson, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claxton, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J. K.</span></span> <span> </span><span class="NLM_article-title">SKI-178: A Multitargeted Inhibitor of Sphingosine Kinase and Microtubule Dynamics Demonstrating Therapeutic Efficacy in Acute Myeloid Leukemia Models</span>. <i>Cancer Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.4103/ctm.ctm_7_17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.4103%2Fctm.ctm_7_17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28890935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFOhtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=109-121&issue=4&author=J.+A.+Hengstauthor=T.+E.+Dickauthor=A.+Sharmaauthor=K.+Doiauthor=S.+Hegdeauthor=S.-F.+Tanauthor=L.+M.+Geffertauthor=T.+E.+Foxauthor=A.+K.+Sharmaauthor=D.+Desaiauthor=S.+Aminauthor=M.+Kesterauthor=T.+P.+Loughranauthor=R.+F.+Paulsonauthor=D.+F.+Claxtonauthor=H.-G.+Wangauthor=J.+K.+Yun&title=SKI-178%3A+A+Multitargeted+Inhibitor+of+Sphingosine+Kinase+and+Microtubule+Dynamics+Demonstrating+Therapeutic+Efficacy+in+Acute+Myeloid+Leukemia+Models&doi=10.4103%2Fctm.ctm_7_17"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">SKI-178: a multitargeted inhibitor of sphingosine kinase and microtubule dynamics demonstrating therapeutic efficacy in acute myeloid leukemia models</span></div><div class="casAuthors">Hengst, Jeremy A.; Dick, Taryn E.; Sharma, Arati; Doi, Kenichiro; Hegde, Shailaja; Tan, Su-Fern; Geffert, Laura M.; Fox, Todd E.; Sharma, Arun K.; Desai, Dhimant; Amin, Shantu; Kester, Mark; Loughran, Thomas P.; Paulson, Robert F.; Claxton, David F.; Wang, Hong-Gang; Yun, Jong K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Translational Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">109-121, S1</span>CODEN:
                <span class="NLM_cas:coden">CTMABE</span>;
        ISSN:<span class="NLM_cas:issn">2395-3012</span>.
    
            (<span class="NLM_cas:orgname">Medknow Publications</span>)
        </div><div class="casAbstract">Aim: To further characterize the selectivity, mechanism of action, and therapeutic efficacy of the novel small mol. inhibitor, SKI-178.  Methods: We used the state-of-the-art cellular thermal shift assay technique to detect "direct target engagement" of proteins in intact cells.  In vitro and in vivo assays, pharmacol. assays, and multiple mouse models of acute myeloid leukemia (AML) were also used.  Results: Herein, we demonstrate that SKI-178 directly target engages both sphingosine kinase 1 and 2 (SphK1 and 2).  We also present evidence that, in addn. to its actions as a sphingosine kinase inhibitor, SKI-178 functions as a microtubule network disrupting agent both in vitro and in intact cells.  Interestingly, we sep. demonstrate that simultaneous SphK inhibition and microtubule disruption synergistically induce apoptosis in AML cell lines.  Furthermore, we demonstrate that SKI-178 is well tolerated in normal healthy mice.  Most importantly, we demonstrate that SKI-178 has therapeutic efficacy in several mouse models of AML.  Conclusion: SKI-178 is a multitargeted agent that functions both as an inhibitor of the SphKs as well as a disruptor of the microtubule network.  SKI-178-induced apoptosis arises from a synergistic interaction of these two activities.  SKI-178 is safe and effective in mouse models of AML, supporting its further development as a multitargeted anticancer therapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4CVSGc0jL9LVg90H21EOLACvtfcHk0ljX2pUSVChEDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFOhtL7I&md5=ef8a162ad34dbdc947433d302cced3d7</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.4103%2Fctm.ctm_7_17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252Fctm.ctm_7_17%26sid%3Dliteratum%253Aachs%26aulast%3DHengst%26aufirst%3DJ.%2BA.%26aulast%3DDick%26aufirst%3DT.%2BE.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DDoi%26aufirst%3DK.%26aulast%3DHegde%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DS.-F.%26aulast%3DGeffert%26aufirst%3DL.%2BM.%26aulast%3DFox%26aufirst%3DT.%2BE.%26aulast%3DSharma%26aufirst%3DA.%2BK.%26aulast%3DDesai%26aufirst%3DD.%26aulast%3DAmin%26aufirst%3DS.%26aulast%3DKester%26aufirst%3DM.%26aulast%3DLoughran%26aufirst%3DT.%2BP.%26aulast%3DPaulson%26aufirst%3DR.%2BF.%26aulast%3DClaxton%26aufirst%3DD.%2BF.%26aulast%3DWang%26aufirst%3DH.-G.%26aulast%3DYun%26aufirst%3DJ.%2BK.%26atitle%3DSKI-178%253A%2520A%2520Multitargeted%2520Inhibitor%2520of%2520Sphingosine%2520Kinase%2520and%2520Microtubule%2520Dynamics%2520Demonstrating%2520Therapeutic%2520Efficacy%2520in%2520Acute%2520Myeloid%2520Leukemia%2520Models%26jtitle%3DCancer%2520Transl.%2520Med.%26date%3D2017%26volume%3D3%26issue%3D4%26spage%3D109%26epage%3D121%26doi%3D10.4103%2Fctm.ctm_7_17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref237"><div class="reference"><strong class="refLabel"><a href="#ref237" class="rightTabRefNumLink">237</a></strong><div class="NLM_citation" id="rightTab-cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberhard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastuck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boesche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reader, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweetman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouwmeester, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsden, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuster, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span> <span> </span><span class="NLM_article-title">Quantitative Chemical Proteomics Reveals Mechanisms of Action of Clinical ABL Kinase Inhibitors</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1035</span>– <span class="NLM_lpage">1044</span>, <span class="refDoi"> DOI: 10.1038/nbt1328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fnbt1328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=17721511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVWksLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=1035-1044&issue=9&author=M.+Bantscheffauthor=D.+Eberhardauthor=Y.+Abrahamauthor=S.+Bastuckauthor=M.+Boescheauthor=S.+Hobsonauthor=T.+Mathiesonauthor=J.+Perrinauthor=M.+Raidaauthor=C.+Rauauthor=V.+Readerauthor=G.+Sweetmanauthor=A.+Bauerauthor=T.+Bouwmeesterauthor=C.+Hopfauthor=U.+Kruseauthor=G.+Neubauerauthor=N.+Ramsdenauthor=J.+Rickauthor=B.+Kusterauthor=G.+Drewes&title=Quantitative+Chemical+Proteomics+Reveals+Mechanisms+of+Action+of+Clinical+ABL+Kinase+Inhibitors&doi=10.1038%2Fnbt1328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors</span></div><div class="casAuthors">Bantscheff, Marcus; Eberhard, Dirk; Abraham, Yann; Bastuck, Sonja; Boesche, Markus; Hobson, Scott; Mathieson, Toby; Perrin, Jessica; Raida, Manfred; Rau, Christina; Reader, Valerie; Sweetman, Gavain; Bauer, Andreas; Bouwmeester, Tewis; Hopf, Carsten; Kruse, Ulrich; Neubauer, Gitte; Ramsden, Nigel; Rick, Jens; Kuster, Bernhard; Drewes, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1035-1044</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors describe a chem. proteomics approach to profile the interaction of small mols. with hundreds of endogenously expressed protein kinases and purine-binding proteins.  This subproteome is captured by immobilized nonselective kinase inhibitors (kinobeads), and the bound proteins are quantified in parallel by mass spectrometry using isobaric tags for relative and abs. quantification (iTRAQ).  By measuring the competition with the affinity matrix, the authors assess the binding of drugs to their targets in cell lysates and in cells.  By mapping drug-induced changes in the phosphorylation state of the captured proteome, the authors also analyze signaling pathways downstream of target kinases.  Quant. profiling of the drugs imatinib (Gleevec), dasatinib (Sprycel) and bosutinib in K562 cells confirms known targets including ABL and SRC family kinases and identifies the receptor tyrosine kinase DDR1 and the oxidoreductase NQO2 as novel targets of imatinib.  The data suggest that the approach is a valuable tool for drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsC3OpIuhl8LVg90H21EOLACvtfcHk0ljX2pUSVChEDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVWksLvF&md5=ed20d4684a8a6733aba24ca64602bae8</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1038%2Fnbt1328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1328%26sid%3Dliteratum%253Aachs%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DEberhard%26aufirst%3DD.%26aulast%3DAbraham%26aufirst%3DY.%26aulast%3DBastuck%26aufirst%3DS.%26aulast%3DBoesche%26aufirst%3DM.%26aulast%3DHobson%26aufirst%3DS.%26aulast%3DMathieson%26aufirst%3DT.%26aulast%3DPerrin%26aufirst%3DJ.%26aulast%3DRaida%26aufirst%3DM.%26aulast%3DRau%26aufirst%3DC.%26aulast%3DReader%26aufirst%3DV.%26aulast%3DSweetman%26aufirst%3DG.%26aulast%3DBauer%26aufirst%3DA.%26aulast%3DBouwmeester%26aufirst%3DT.%26aulast%3DHopf%26aufirst%3DC.%26aulast%3DKruse%26aufirst%3DU.%26aulast%3DNeubauer%26aufirst%3DG.%26aulast%3DRamsden%26aufirst%3DN.%26aulast%3DRick%26aufirst%3DJ.%26aulast%3DKuster%26aufirst%3DB.%26aulast%3DDrewes%26aufirst%3DG.%26atitle%3DQuantitative%2520Chemical%2520Proteomics%2520Reveals%2520Mechanisms%2520of%2520Action%2520of%2520Clinical%2520ABL%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26issue%3D9%26spage%3D1035%26epage%3D1044%26doi%3D10.1038%2Fnbt1328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref238"><div class="reference"><strong class="refLabel"><a href="#ref238" class="rightTabRefNumLink">238</a></strong><div class="NLM_citation" id="rightTab-cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mazaleuskaya, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesaros, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricciotti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FitzGerald, G. A.</span></span> <span> </span><span class="NLM_article-title">A Broad-Spectrum Lipidomics Screen of Antiinflammatory Drug Combinations in Human Blood</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">e87031</span>, <span class="refDoi"> DOI: 10.1172/jci.insight.87031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1172%2Fjci.insight.87031" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=e87031&author=L.+L.+Mazaleuskayaauthor=J.+A.+Lawsonauthor=X.+Liauthor=G.+Grantauthor=C.+Mesarosauthor=T.+Grosserauthor=I.+A.+Blairauthor=E.+Ricciottiauthor=G.+A.+FitzGerald&title=A+Broad-Spectrum+Lipidomics+Screen+of+Antiinflammatory+Drug+Combinations+in+Human+Blood&doi=10.1172%2Fjci.insight.87031"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.87031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.87031%26sid%3Dliteratum%253Aachs%26aulast%3DMazaleuskaya%26aufirst%3DL.%2BL.%26aulast%3DLawson%26aufirst%3DJ.%2BA.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DGrant%26aufirst%3DG.%26aulast%3DMesaros%26aufirst%3DC.%26aulast%3DGrosser%26aufirst%3DT.%26aulast%3DBlair%26aufirst%3DI.%2BA.%26aulast%3DRicciotti%26aufirst%3DE.%26aulast%3DFitzGerald%26aufirst%3DG.%2BA.%26atitle%3DA%2520Broad-Spectrum%2520Lipidomics%2520Screen%2520of%2520Antiinflammatory%2520Drug%2520Combinations%2520in%2520Human%2520Blood%26jtitle%3DJCI%2520Insight%26date%3D2016%26volume%3D1%26spage%3De87031%26doi%3D10.1172%2Fjci.insight.87031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref239"><div class="reference"><strong class="refLabel"><a href="#ref239" class="rightTabRefNumLink">239</a></strong><div class="NLM_citation" id="rightTab-cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meirer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhilber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the Arachidonic Acid Cascade: Interfering with Multiple Pathways</span>. <i>Basic Clin. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1111/bcpt.12134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1111%2Fbcpt.12134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=24015667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFGktL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2014&pages=83-91&issue=1&author=K.+Meirerauthor=D.+Steinhilberauthor=E.+Proschak&title=Inhibitors+of+the+Arachidonic+Acid+Cascade%3A+Interfering+with+Multiple+Pathways&doi=10.1111%2Fbcpt.12134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of the Arachidonic Acid Cascade: Interfering with Multiple Pathways</span></div><div class="casAuthors">Meirer, Karin; Steinhilber, Dieter; Proschak, Ewgenij</div><div class="citationInfo"><span class="NLM_cas:title">Basic & Clinical Pharmacology & Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">83-91</span>CODEN:
                <span class="NLM_cas:coden">BCPTBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-7835</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Modulators of the arachidonic acid cascade have been in the focus of research for treatments of inflammation and pain for several decades.  Targeting this complex pathway experiences a paradigm change towards the design and development of multi-target inhibitors, exhibiting improved efficacy and less undesired side effects.  This minireview summarizes recent developments in the field of designed multi-target ligands of the arachidonic acid cascade.  In addn. to the well-known dual inhibitors of 5-lipoxygenase and cyclooxygenase-2 such as licofelone, very recent developments are discussed.  Esp., multi-target inhibitors interfering with the cytochrome P 450 pathway via inhibition of sol. epoxide hydrolase seem to offer a novel opportunity for development of novel anti-inflammatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxIto5Wb10iLVg90H21EOLACvtfcHk0ljX2pUSVChEDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFGktL%252FF&md5=1b7c01f7e30d699dc57b25c215e4da9e</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1111%2Fbcpt.12134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcpt.12134%26sid%3Dliteratum%253Aachs%26aulast%3DMeirer%26aufirst%3DK.%26aulast%3DSteinhilber%26aufirst%3DD.%26aulast%3DProschak%26aufirst%3DE.%26atitle%3DInhibitors%2520of%2520the%2520Arachidonic%2520Acid%2520Cascade%253A%2520Interfering%2520with%2520Multiple%2520Pathways%26jtitle%3DBasic%2520Clin.%2520Pharmacol.%2520Toxicol.%26date%3D2014%26volume%3D114%26issue%3D1%26spage%3D83%26epage%3D91%26doi%3D10.1111%2Fbcpt.12134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref240"><div class="reference"><strong class="refLabel"><a href="#ref240" class="rightTabRefNumLink">240</a></strong><div class="NLM_citation" id="rightTab-cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dijkman, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castell, O. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz-Garcia, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Graaf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, A.</span></span> <span> </span><span class="NLM_article-title">Dynamic Tuneable G Protein-Coupled Receptor Monomer-Dimer Populations</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1710</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-03727-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1038%2Fs41467-018-03727-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29703992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADC%252BC1MjnsFGgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1710&author=P.+M.+Dijkmanauthor=O.+K.+Castellauthor=A.+D.+Goddardauthor=J.+C.+Munoz-Garciaauthor=C.+de+Graafauthor=M.+I.+Wallaceauthor=A.+Watts&title=Dynamic+Tuneable+G+Protein-Coupled+Receptor+Monomer-Dimer+Populations&doi=10.1038%2Fs41467-018-03727-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">Dynamic tuneable G protein-coupled receptor monomer-dimer populations</span></div><div class="casAuthors">Dijkman Patricia M; Goddard Alan D; Munoz-Garcia Juan C; Watts Anthony; Dijkman Patricia M; Castell Oliver K; Wallace Mark I; Castell Oliver K; Goddard Alan D; Munoz-Garcia Juan C; de Graaf Chris; Wallace Mark I</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1710</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are the largest class of membrane receptors, playing a key role in the regulation of processes as varied as neurotransmission and immune response.  Evidence for GPCR oligomerisation has been accumulating that challenges the idea that GPCRs function solely as monomeric receptors; however, GPCR oligomerisation remains controversial primarily due to the difficulties in comparing evidence from very different types of structural and dynamic data.  Using a combination of single-molecule and ensemble FRET, double electron-electron resonance spectroscopy, and simulations, we show that dimerisation of the GPCR neurotensin receptor 1 is regulated by receptor density and is dynamically tuneable over the physiological range.  We propose a "rolling dimer" interface model in which multiple dimer conformations co-exist and interconvert.  These findings unite previous seemingly conflicting observations, provide a compelling mechanism for regulating receptor signalling, and act as a guide for future physiological studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLYxi4q-LtzEEgZCMqtRBifW6udTcc2eZzBGJkgLcC6rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjnsFGgsw%253D%253D&md5=6a47bd3d5eb25e32ee6a6ca229f98dcc</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-03727-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-03727-6%26sid%3Dliteratum%253Aachs%26aulast%3DDijkman%26aufirst%3DP.%2BM.%26aulast%3DCastell%26aufirst%3DO.%2BK.%26aulast%3DGoddard%26aufirst%3DA.%2BD.%26aulast%3DMunoz-Garcia%26aufirst%3DJ.%2BC.%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26aulast%3DWallace%26aufirst%3DM.%2BI.%26aulast%3DWatts%26aufirst%3DA.%26atitle%3DDynamic%2520Tuneable%2520G%2520Protein-Coupled%2520Receptor%2520Monomer-Dimer%2520Populations%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D1710%26doi%3D10.1038%2Fs41467-018-03727-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref241"><div class="reference"><strong class="refLabel"><a href="#ref241" class="rightTabRefNumLink">241</a></strong><div class="NLM_citation" id="rightTab-cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhilber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert-Zsilavecz, M.</span></span> <span> </span><span class="NLM_article-title">Small Molecules with Anti-Inflammatory Properties in Clinical Development</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2015.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.pharmthera.2015.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=26627986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFertbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2016&pages=163-187&author=T.+Hankeauthor=D.+Merkauthor=D.+Steinhilberauthor=G.+Geisslingerauthor=M.+Schubert-Zsilavecz&title=Small+Molecules+with+Anti-Inflammatory+Properties+in+Clinical+Development&doi=10.1016%2Fj.pharmthera.2015.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit241R"><div class="casContent"><span class="casTitleNuber">241</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecules with anti-inflammatory properties in clinical development</span></div><div class="casAuthors">Hanke, Thomas; Merk, Daniel; Steinhilber, Dieter; Geisslinger, Gerd; Schubert-Zsilavecz, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">163-187</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Inflammation is a crucial physiol. response of our body to any kind of noxa be it an infection or tissue injury.  However, this physiol. process can be detrimental if dysregulated, and when the acute inflammatory response fails to resolve the cause of inflammation, there can be a switch to chronification.  According to ICD 10 (WHO) over 3.000 diseases exist with the suffix "-itis" which terms an inflammatory disease.  For the treatment of inflammation, non-steroidal anti-inflammatory drugs (NSAIDs) are the most widespread drugs while glucocorticoids are among our strongest weapons against inflammation, making them emergency treatments for acute episodes of chronic inflammation.  For the treatment of many inflammatory disorders, both are not satisfying.  Consequently, industrial and academic research on anti-inflammatory drugs is very intensive.  In this review, we evaluate current treatments and unmet needs of chronic inflammatory diseases with high prevalence (rheumatoid arthritis, multiple sclerosis, chronic obstructive pulmonary disease, inflammatory bowel disease, and psoriasis), and systematically review small mols. with anti-inflammatory properties presently in clin. trials for the aforementioned diseases.  As the pathophysiol. knowledge of diseases increased over the last decades, a more specific intervention of inflammatory pathways becomes possible.  After one hundred years of NSAIDs and over fifty years of glucocorticoids, more specific drugs for anti-inflammatory therapy such as roflumilast or fingolimod are rising.  The aim of this article is to critically review the literature on small anti-inflammatory mols. in clin. trials to generate an idea of what we can expect in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOd16UM0wRSbVg90H21EOLACvtfcHk0ljiz9Ecnl1Kpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFertbfM&md5=a9f5e04d82aad54d600e21307ca4bfb2</span></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2015.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2015.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DHanke%26aufirst%3DT.%26aulast%3DMerk%26aufirst%3DD.%26aulast%3DSteinhilber%26aufirst%3DD.%26aulast%3DGeisslinger%26aufirst%3DG.%26aulast%3DSchubert-Zsilavecz%26aufirst%3DM.%26atitle%3DSmall%2520Molecules%2520with%2520Anti-Inflammatory%2520Properties%2520in%2520Clinical%2520Development%26jtitle%3DPharmacol.%2520Ther.%26date%3D2016%26volume%3D157%26spage%3D163%26epage%3D187%26doi%3D10.1016%2Fj.pharmthera.2015.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref242"><div class="reference"><strong class="refLabel"><a href="#ref242" class="rightTabRefNumLink">242</a></strong><div class="NLM_citation" id="rightTab-cit242"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dalli, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serhan, C. N.</span></span> <span> </span><span class="NLM_article-title">Identification and Structure Elucidation of the Proresolving Mediators Provides Novel Leads for Resolution Pharmacology</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>, <span class="refDoi"> DOI: 10.1111/bph.14336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1111%2Fbph.14336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29679485" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=J.+Dalliauthor=C.+N.+Serhan&title=Identification+and+Structure+Elucidation+of+the+Proresolving+Mediators+Provides+Novel+Leads+for+Resolution+Pharmacology&doi=10.1111%2Fbph.14336"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1111%2Fbph.14336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14336%26sid%3Dliteratum%253Aachs%26aulast%3DDalli%26aufirst%3DJ.%26aulast%3DSerhan%26aufirst%3DC.%2BN.%26atitle%3DIdentification%2520and%2520Structure%2520Elucidation%2520of%2520the%2520Proresolving%2520Mediators%2520Provides%2520Novel%2520Leads%2520for%2520Resolution%2520Pharmacology%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2018%26doi%3D10.1111%2Fbph.14336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref243"><div class="reference"><strong class="refLabel"><a href="#ref243" class="rightTabRefNumLink">243</a></strong><div class="NLM_citation" id="rightTab-cit243"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tronci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francardo, V.</span></span> <span> </span><span class="NLM_article-title">Animal Models of L-DOPA-Induced Dyskinesia: The 6-OHDA-Lesioned Rat and Mouse</span>. <i>J. Neural Transm.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">1137</span>– <span class="NLM_lpage">1144</span>, <span class="refDoi"> DOI: 10.1007/s00702-017-1825-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1007%2Fs00702-017-1825-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2018&pages=1137-1144&author=E.+Tronciauthor=V.+Francardo&title=Animal+Models+of+L-DOPA-Induced+Dyskinesia%3A+The+6-OHDA-Lesioned+Rat+and+Mouse&doi=10.1007%2Fs00702-017-1825-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1007%2Fs00702-017-1825-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00702-017-1825-5%26sid%3Dliteratum%253Aachs%26aulast%3DTronci%26aufirst%3DE.%26aulast%3DFrancardo%26aufirst%3DV.%26atitle%3DAnimal%2520Models%2520of%2520L-DOPA-Induced%2520Dyskinesia%253A%2520The%25206-OHDA-Lesioned%2520Rat%2520and%2520Mouse%26jtitle%3DJ.%2520Neural%2520Transm.%26date%3D2018%26volume%3D125%26spage%3D1137%26epage%3D1144%26doi%3D10.1007%2Fs00702-017-1825-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref244"><div class="reference"><strong class="refLabel"><a href="#ref244" class="rightTabRefNumLink">244</a></strong><div class="NLM_citation" id="rightTab-cit244"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porras, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezard, E.</span></span> <span> </span><span class="NLM_article-title">Modeling Parkinson’s Disease in Primates: The MPTP Model</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">a009308</span>– <span class="NLM_lpage">a009308</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a009308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1101%2Fcshperspect.a009308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=22393538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlenu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=a009308-a009308&issue=3&author=G.+Porrasauthor=Q.+Liauthor=E.+Bezard&title=Modeling+Parkinson%E2%80%99s+Disease+in+Primates%3A+The+MPTP+Model&doi=10.1101%2Fcshperspect.a009308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling Parkinson's disease in primates: the MPTP model</span></div><div class="casAuthors">Porras, Gregory; Li, Qin; Bezard, Erwan</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">a009308/1-a009308/10</span>CODEN:
                <span class="NLM_cas:coden">CSHPFV</span>;
        ISSN:<span class="NLM_cas:issn">2157-1422</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate models of Parkinson's disease (PD) reproduce most, although not all, of the clin. and pathol. hallmarks of PD.  The present, contribution presents the possibilities offered by the MPTP monkey models of PD to readers with minimal knowledge of PD, emphasizing the diversity of species, route and regimen of administration, symptoms and pathol. features.  Readers would eventually find out that there is not a single MPTP monkey model of PD but instead MPTP monkey models of PD, each addressing a specific exptl. need.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxcavMuixlTbVg90H21EOLACvtfcHk0ljiz9Ecnl1Kpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlenu7c%253D&md5=ebcddd49aae2ff04944e5d5766cd0d69</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a009308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a009308%26sid%3Dliteratum%253Aachs%26aulast%3DPorras%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DBezard%26aufirst%3DE.%26atitle%3DModeling%2520Parkinson%25E2%2580%2599s%2520Disease%2520in%2520Primates%253A%2520The%2520MPTP%2520Model%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2012%26volume%3D2%26issue%3D3%26spage%3Da009308%26epage%3Da009308%26doi%3D10.1101%2Fcshperspect.a009308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref245"><div class="reference"><strong class="refLabel"><a href="#ref245" class="rightTabRefNumLink">245</a></strong><div class="NLM_citation" id="rightTab-cit245"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ernsberger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koletsky, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kline, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedol, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, J. E.</span></span> <span> </span><span class="NLM_article-title">The SHROB Model of Syndrome X: Effects of Excess Dietary Sucrose</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>892</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.1999.tb07806.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1111%2Fj.1749-6632.1999.tb07806.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=892&publication_year=1999&pages=315-318&author=P.+Ernsbergerauthor=R.+J.+Koletskyauthor=D.+D.+Klineauthor=D.+M.+Bedolauthor=J.+E.+Friedman&title=The+SHROB+Model+of+Syndrome+X%3A+Effects+of+Excess+Dietary+Sucrose&doi=10.1111%2Fj.1749-6632.1999.tb07806.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.1999.tb07806.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.1999.tb07806.x%26sid%3Dliteratum%253Aachs%26aulast%3DErnsberger%26aufirst%3DP.%26aulast%3DKoletsky%26aufirst%3DR.%2BJ.%26aulast%3DKline%26aufirst%3DD.%2BD.%26aulast%3DBedol%26aufirst%3DD.%2BM.%26aulast%3DFriedman%26aufirst%3DJ.%2BE.%26atitle%3DThe%2520SHROB%2520Model%2520of%2520Syndrome%2520X%253A%2520Effects%2520of%2520Excess%2520Dietary%2520Sucrose%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D1999%26volume%3D892%26spage%3D315%26epage%3D318%26doi%3D10.1111%2Fj.1749-6632.1999.tb07806.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref246"><div class="reference"><strong class="refLabel"><a href="#ref246" class="rightTabRefNumLink">246</a></strong><div class="NLM_citation" id="rightTab-cit246"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casimiro-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filzen, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigge, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmunds, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esmaeil, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heemstra, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalaie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohren, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostroski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaum, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoner, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Series of Imidazo[4,5- B]pyridines with Dual Activity at Angiotensin II Type 1 Receptor and Peroxisome Proliferator-Activated Receptor-γ</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4219</span>– <span class="NLM_lpage">4233</span>, <span class="refDoi"> DOI: 10.1021/jm200409s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200409s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4219-4233&issue=12&author=A.+Casimiro-Garciaauthor=G.+F.+Filzenauthor=D.+Flynnauthor=C.+F.+Biggeauthor=J.+Chenauthor=J.+A.+Davisauthor=D.+A.+Dudleyauthor=J.+J.+Edmundsauthor=N.+Esmaeilauthor=A.+Geyerauthor=R.+J.+Heemstraauthor=M.+Jalaieauthor=J.+F.+Ohrenauthor=R.+Ostroskiauthor=T.+Ellisauthor=R.+P.+Schaumauthor=C.+Stoner&title=Discovery+of+a+Series+of+Imidazo%5B4%2C5-+B%5Dpyridines+with+Dual+Activity+at+Angiotensin+II+Type+1+Receptor+and+Peroxisome+Proliferator-Activated+Receptor-%CE%B3&doi=10.1021%2Fjm200409s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=10.1021%2Fjm200409s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200409s%26sid%3Dliteratum%253Aachs%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26aulast%3DFilzen%26aufirst%3DG.%2BF.%26aulast%3DFlynn%26aufirst%3DD.%26aulast%3DBigge%26aufirst%3DC.%2BF.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DJ.%2BA.%26aulast%3DDudley%26aufirst%3DD.%2BA.%26aulast%3DEdmunds%26aufirst%3DJ.%2BJ.%26aulast%3DEsmaeil%26aufirst%3DN.%26aulast%3DGeyer%26aufirst%3DA.%26aulast%3DHeemstra%26aufirst%3DR.%2BJ.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DOhren%26aufirst%3DJ.%2BF.%26aulast%3DOstroski%26aufirst%3DR.%26aulast%3DEllis%26aufirst%3DT.%26aulast%3DSchaum%26aufirst%3DR.%2BP.%26aulast%3DStoner%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520a%2520Series%2520of%2520Imidazo%255B4%252C5-%2520B%255Dpyridines%2520with%2520Dual%2520Activity%2520at%2520Angiotensin%2520II%2520Type%25201%2520Receptor%2520and%2520Peroxisome%2520Proliferator-Activated%2520Receptor-%25CE%25B3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D12%26spage%3D4219%26epage%3D4233%26doi%3D10.1021%2Fjm200409s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref300"><div class="reference"><strong class="refLabel"><a href="#ref300" class="rightTabRefNumLink">247</a></strong><div class="NLM_citation" id="rightTab-cit300"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imig, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hye Khan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B.</span></span> <span> </span><span class="NLM_article-title">Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats</span>. <i>Exp. Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>237</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1402</span>– <span class="NLM_lpage">1412</span>, <span class="refDoi"> DOI: 10.1258/ebm.2012.012225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref300/cit300&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1258%2Febm.2012.012225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref300/cit300&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFagtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=237&publication_year=2012&pages=1402-1412&issue=12&author=J.+Imigauthor=K.+Walshauthor=M.+A.+Hye+Khanauthor=T.+Nagasawaauthor=M.+C.+Shawauthor=S.+M.+Shawauthor=B.+Hammock&title=Soluble+epoxide+hydrolase+inhibition+and+peroxisome+proliferator+activated+receptor+%CE%B3+agonist+improve+vascular+function+and+decrease+renal+injury+in+hypertensive+obese+rats&doi=10.1258%2Febm.2012.012225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit300R"><div class="casContent"><span class="casTitleNuber">300</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats</span></div><div class="casAuthors">Imig, John D.; Walsh, Katie A.; Abdul Hye Khan, Md; Nagasawa, Tasuku; Cherian-Shaw, Mary; Shaw, Sean M.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Biology and Medicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">237</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1402-1412</span>CODEN:
                <span class="NLM_cas:coden">EBMMBE</span>;
        ISSN:<span class="NLM_cas:issn">1535-3702</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Cardiometabolic syndrome occurs with obesity and consists of pathophysiol. factors that increase the risk for cardiovascular events.  Sol. epoxide hydrolase inhibition (sEHi) is a novel therapeutic approach that exerts renal and cardiovascular protection.  Although sEHi as a therapeutic approach is promising, it could be more effective for the treatment of cardiometabolic syndrome when combined with peroxisome proliferator activated receptor γ (PPARγ) agonists.  We hypothesized that the PPARγ agonist, rosiglitazone in combination with a sEHi (tAUCB) will provide synergistic actions to decrease blood pressure, improve vascular function, decrease inflammation, and prevent renal damage in spontaneously hypertensive obese rats (SHROB).  SHROB were treated with rosiglitazone, tAUCB or the combination of tAUCB and rosiglitazone for four-weeks and compared with spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) rats.  Blood pressure increased in SHROB (164 ± 7 mmHg) and decreased 10 mmHg when treated with rosiglitazone, tAUCB, or tAUCB and rosiglitazone.  Mesenteric artery dilation to the KATP channel opener pinacidil was attenuated in SHROB (EMax = 77 ± 7%), compared with WKY (EMax = 115 ± 19) and SHR (EMax = 93 ± 12%).  Vasodilation to pinacidil was improved by rosiglitazone (EMax = 92 ± 14%) but not tAUCB.  Renal macrophage infiltration increased in SHROB and significantly decreased with rosiglitazone or tAUCB and rosiglitazone treatment.  Albuminuria was increased in SHROB (90 ± 20 mg/d) and was significantly decreased by the combination of tAUCB and rosiglitazone (37 ± 9 mg/d).  Glomerular injury in SHROB was also significantly decreased by tAUCB and rosiglitazone.  These results indicate that even though sEHi or PPARγ agonist have benefits when used individually, the combination is more beneficial for the multidisease features in cardiometabolic syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoq2SjZgeqAHrVg90H21EOLACvtfcHk0lhZQ2i8551KpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFagtbk%253D&md5=d22fb0c9e2e8acf30dd6ce7614ad403c</span></div><a href="/servlet/linkout?suffix=cit300&amp;dbid=16384&amp;doi=10.1258%2Febm.2012.012225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1258%252Febm.2012.012225%26sid%3Dliteratum%253Aachs%26aulast%3DImig%26aufirst%3DJ.%26aulast%3DWalsh%26aufirst%3DK.%26aulast%3DHye%2BKhan%26aufirst%3DM.%2BA.%26aulast%3DNagasawa%26aufirst%3DT.%26aulast%3DShaw%26aufirst%3DM.%2BC.%26aulast%3DShaw%26aufirst%3DS.%2BM.%26aulast%3DHammock%26aufirst%3DB.%26atitle%3DSoluble%2520epoxide%2520hydrolase%2520inhibition%2520and%2520peroxisome%2520proliferator%2520activated%2520receptor%2520%25CE%25B3%2520agonist%2520improve%2520vascular%2520function%2520and%2520decrease%2520renal%2520injury%2520in%2520hypertensive%2520obese%2520rats%26jtitle%3DExp.%2520Biol.%2520Med.%26date%3D2012%26volume%3D237%26issue%3D12%26spage%3D1402%26epage%3D1412%26doi%3D10.1258%2Febm.2012.012225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref301"><div class="reference"><strong class="refLabel"><a href="#ref301" class="rightTabRefNumLink">248</a></strong><div class="NLM_citation" id="rightTab-cit301"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hye Khan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skibba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blöcher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imig, J.</span></span> <span> </span><span class="NLM_article-title">A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>, <span class="refDoi"> DOI: 10.1007/s00125-018-4685-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref301/cit301&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1007%2Fs00125-018-4685-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=M.+A.+Hye+Khanauthor=L.+Kolbauthor=M.+Skibbaauthor=M.+Hartmannauthor=R.+Bl%C3%B6cherauthor=E.+Proschakauthor=J.+Imig&title=A+novel+dual+PPAR-%CE%B3+agonist%2FsEH+inhibitor+treats+diabetic+complications+in+a+rat+model+of+type+2+diabetes&doi=10.1007%2Fs00125-018-4685-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit301&amp;dbid=16384&amp;doi=10.1007%2Fs00125-018-4685-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-018-4685-0%26sid%3Dliteratum%253Aachs%26aulast%3DHye%2BKhan%26aufirst%3DM.%2BA.%26aulast%3DKolb%26aufirst%3DL.%26aulast%3DSkibba%26aufirst%3DM.%26aulast%3DHartmann%26aufirst%3DM.%26aulast%3DBl%25C3%25B6cher%26aufirst%3DR.%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DImig%26aufirst%3DJ.%26atitle%3DA%2520novel%2520dual%2520PPAR-%25CE%25B3%2520agonist%252FsEH%2520inhibitor%2520treats%2520diabetic%2520complications%2520in%2520a%2520rat%2520model%2520of%2520type%25202%2520diabetes%26jtitle%3DDiabetologia%26date%3D2018%26doi%3D10.1007%2Fs00125-018-4685-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref247"><div class="reference"><strong class="refLabel"><a href="#ref247" class="rightTabRefNumLink">249</a></strong><div class="NLM_citation" id="rightTab-cit247"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kotagal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnen, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppe, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albin, R. L.</span></span> <span> </span><span class="NLM_article-title">Serotonin, Beta-Amyloid, and Cognition in Parkinson Disease</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>83</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">994</span>– <span class="NLM_lpage">1002</span>, <span class="refDoi"> DOI: 10.1002/ana.25236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1002%2Fana.25236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=29665066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Wrur3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2018&pages=994-1002&issue=5&author=V.+Kotagalauthor=C.+Spinoauthor=N.+I.+Bohnenauthor=R.+A.+Koeppeauthor=R.+L.+Albin&title=Serotonin%2C+Beta-Amyloid%2C+and+Cognition+in+Parkinson+Disease&doi=10.1002%2Fana.25236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit247R"><div class="casContent"><span class="casTitleNuber">247</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin, β-amyloid, and cognition in Parkinson disease</span></div><div class="casAuthors">Kotagal, Vikas; Spino, Cathie; Bohnen, Nicolaas I.; Koeppe, Robert; Albin, Roger L.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">994-1002</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : Serotoninergic neurotransmission may modulate β-amyloid peptide (Aβ) metab. through upregulation of α-secretase.  Early Parkinson disease (PD) shows variable serotoninergic denervation, which may impact Aβ deposition.  Methods : We conducted 3 analyses to explore assocns. between serotoninergic neurotransmission and cerebral Aβ burden in PD.  The first was a cross-sectional imaging study of PD subjects (n = 23) using the serotoninergic transporter positron emission tomog. (PET) ligand [11C]3-amino-4-(2-dimethylaminomethyl-phenylsulfaryl)-benzonitrile (DASB) and amyloid PET Pittsburgh compd. B ([11C]PiB).  The second was a baseline study of Parkinson's Progression Markers Initiative (PPMI) subjects exploring the influence of serotoninergic medications on cerebrospinal fluid (CSF) Aβ-42 levels (n = 389), controlling for age, sex, Geriatric Depression Scale, disease duration, and education.  Third, we fit an interval censored proportional hazard model with longitudinal PPMI data (n = 367) to test whether serotoninergic medication use assocs. with reduced risk of PD cognitive decline, defined as time to reach a Montreal Cognitive Assessment score ≤ 20, adjusting for baseline caudate dopamine transporter [123I]ioflupane single photon emission computed tomog. and CSF Aβ-42 levels.  Results : Serotoninergic DASB distribution vol. ratio (DVR) inversely assocd. with PiB DVR in the cerebral cortex (Pearson r = -0.478, p = 0.021) but not the striatum (r = -0.264, p = 0.224).  In the baseline PPMI anal., serotoninergic medication use for ≥6 mo assocd. with a lower level of CSF Aβ-42 (t = -2.20, p = 0.029).  In the longitudinal PPMI model, baseline serotoninergic medication use assocd. with a reduced risk of cognitive decline (t = -2.03, p = 0.043) after controlling for covariates.  Interpretation : Cortical Aβ burden in PD assocs. inversely with serotoninergic innervation.  Serotoninergic medications may alter Aβ metab. and reduce the risk of PD cognitive decline.  Ann Neurol 2018;83:994-1002.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSfO7_QmYx_LVg90H21EOLACvtfcHk0lhZQ2i8551KpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Wrur3F&md5=ae40a9f624232a1282f95bf439e0676f</span></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=10.1002%2Fana.25236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.25236%26sid%3Dliteratum%253Aachs%26aulast%3DKotagal%26aufirst%3DV.%26aulast%3DSpino%26aufirst%3DC.%26aulast%3DBohnen%26aufirst%3DN.%2BI.%26aulast%3DKoeppe%26aufirst%3DR.%2BA.%26aulast%3DAlbin%26aufirst%3DR.%2BL.%26atitle%3DSerotonin%252C%2520Beta-Amyloid%252C%2520and%2520Cognition%2520in%2520Parkinson%2520Disease%26jtitle%3DAnn.%2520Neurol.%26date%3D2018%26volume%3D83%26issue%3D5%26spage%3D994%26epage%3D1002%26doi%3D10.1002%2Fana.25236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref248"><div class="reference"><strong class="refLabel"><a href="#ref248" class="rightTabRefNumLink">250</a></strong><div class="NLM_citation" id="rightTab-cit248"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huot, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sgambato-Faure, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCreary, A. C.</span></span> <span> </span><span class="NLM_article-title">Serotonergic Approaches in Parkinson’s Disease: Translational Perspectives, an Update</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">973</span>– <span class="NLM_lpage">986</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.6b00440</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.6b00440" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvVems7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=973-986&issue=5&author=P.+Huotauthor=V.+Sgambato-Faureauthor=S.+H.+Foxauthor=A.+C.+McCreary&title=Serotonergic+Approaches+in+Parkinson%E2%80%99s+Disease%3A+Translational+Perspectives%2C+an+Update&doi=10.1021%2Facschemneuro.6b00440"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit248R"><div class="casContent"><span class="casTitleNuber">248</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an Update</span></div><div class="casAuthors">Huot, Philippe; Sgambato-Faure, Veronique; Fox, Susan H.; McCreary, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">973-986</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease (PD) has long been seen as a disorder caused by degeneration of the dopaminergic system, leading to the classic motor manifestations of the disease.  However, there is now overwhelming evidence that PD is more than a disease merely caused by dopamine depletion.  It is well known that a myriad of other neurotransmitters are affected by the disease process.  One such neurotransmitter is serotonin (5-HT). 5-HT has been shown to play a role in several motor and non-motor manifestations of PD, including tremor, cognition, depression and psychosis.  5-HT also seems to play a crit. role in L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia.  A breadth of pre-clin. studies and clin. trials have been conducted aimed at modulating the 5-HT system in order to alleviate depression, cognitive deficits, psychosis and dyskinesia.  In this review article, we summarize recent advances in the 5-HT field in PD, but with a translational emphasis.  We start by presenting a novel non-human primate model of PD that presents with dual dopamine and 5-HT lesions.  We then present pre-clin. and clin. data that introduce new concepts, such as the use of biased and partial agonists, as well as mols. recently introduced to the field of PD, such as eltoprazine, pimavanserin, nelotanserin and SYN-120, to enhance therapeutic benefit while minimizing adverse events, notably on parkinsonian disability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq42fCs4QfDtrVg90H21EOLACvtfcHk0ljritRMIvk3Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvVems7Y%253D&md5=13809198c78bc8053440fb976207b972</span></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.6b00440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.6b00440%26sid%3Dliteratum%253Aachs%26aulast%3DHuot%26aufirst%3DP.%26aulast%3DSgambato-Faure%26aufirst%3DV.%26aulast%3DFox%26aufirst%3DS.%2BH.%26aulast%3DMcCreary%26aufirst%3DA.%2BC.%26atitle%3DSerotonergic%2520Approaches%2520in%2520Parkinson%25E2%2580%2599s%2520Disease%253A%2520Translational%2520Perspectives%252C%2520an%2520Update%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D8%26issue%3D5%26spage%3D973%26epage%3D986%26doi%3D10.1021%2Facschemneuro.6b00440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref249"><div class="reference"><strong class="refLabel"><a href="#ref249" class="rightTabRefNumLink">251</a></strong><div class="NLM_citation" id="rightTab-cit249"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bezard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imbert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, C. E.</span></span> <span> </span><span class="NLM_article-title">Experimental Models of Parkinson’s Disease: From the Static to the Dynamic</span>. <i>Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1515/REVNEURO.1998.9.2.71</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1515%2FREVNEURO.1998.9.2.71" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=9711900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A280%3ADyaK1cznsFOiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1998&pages=71-90&author=E.+Bezardauthor=C.+Imbertauthor=C.+E.+Gross&title=Experimental+Models+of+Parkinson%E2%80%99s+Disease%3A+From+the+Static+to+the+Dynamic&doi=10.1515%2FREVNEURO.1998.9.2.71"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit249R"><div class="casContent"><span class="casTitleNuber">249</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental models of Parkinson's disease: from the static to the dynamic</span></div><div class="casAuthors">Bezard E; Imbert C; Gross C E</div><div class="citationInfo"><span class="NLM_cas:title">Reviews in the neurosciences</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">71-90</span>
        ISSN:<span class="NLM_cas:issn">0334-1763</span>.
    </div><div class="casAbstract">The experimental models of Parkinson's disease (PD) available today can be divided into two categories according to the mode of action of the compound used: transient pharmacological impairment of dopaminergic transmission along the nigrostriatal pathway or selective destruction by a neurotoxic agent of the dopaminergic neurons of the substantia nigra pars compacta.  The present article looks at the relative merits of each model, the clinical symptoms and neuronal impairment it induces, and the contribution it could make to the development of a truly dynamic model.  It is becoming more and more clear that there is an urgent need for a chronic model integrating all the clinical features of PD including resting tremor, and reproducing the gradual but continuous nigral degeneration observed in the human pathology.  Discrepancies have been reported several times between results obtained in classic animal models and those described in PD, and it would seem probable that such contradictions can be ascribed to the fact that animal models do not, as yet, reproduce the continuous evolution of the human disease.  Dynamic experimental models which come closer to the progressive neurodegeneration and gradual intensification of motor disability so characteristic of human PD will enable us to investigate crucial aspects of the disease, such as compensatory mechanisms and dyskinesia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQd6n-IVQ0JJUwlCcfExbvbfW6udTcc2eZTnhM0CeAverntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1cznsFOiug%253D%253D&md5=848c4fbf975277adc0937c5245991964</span></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=10.1515%2FREVNEURO.1998.9.2.71&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252FREVNEURO.1998.9.2.71%26sid%3Dliteratum%253Aachs%26aulast%3DBezard%26aufirst%3DE.%26aulast%3DImbert%26aufirst%3DC.%26aulast%3DGross%26aufirst%3DC.%2BE.%26atitle%3DExperimental%2520Models%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%253A%2520From%2520the%2520Static%2520to%2520the%2520Dynamic%26jtitle%3DRev.%2520Neurosci.%26date%3D1998%26volume%3D9%26spage%3D71%26epage%3D90%26doi%3D10.1515%2FREVNEURO.1998.9.2.71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref250"><div class="reference"><strong class="refLabel"><a href="#ref250" class="rightTabRefNumLink">252</a></strong><div class="NLM_citation" id="rightTab-cit250"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ko, W. K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezard, E.</span></span> <span> </span><span class="NLM_article-title">Experimental Animal Models of Parkinson’s Disease: A Transition from Assessing Symptomatology to α-Synuclein Targeted Disease Modification</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>298</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1016/j.expneurol.2017.07.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=10.1016%2Fj.expneurol.2017.07.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=28764902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Oku7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2017&pages=172-179&author=W.+K.+D.+Koauthor=E.+Bezard&title=Experimental+Animal+Models+of+Parkinson%E2%80%99s+Disease%3A+A+Transition+from+Assessing+Symptomatology+to+%CE%B1-Synuclein+Targeted+Disease+Modification&doi=10.1016%2Fj.expneurol.2017.07.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to α-synuclein targeted disease modification</span></div><div class="casAuthors">Ko, Wai Kin D.; Bezard, Erwan</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">Part_B</span>),
    <span class="NLM_cas:pages">172-179</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">With the understanding that α-synuclein plays a major role in the pathogenesis of Parkinson's disease (PD), novel animal models have been developed for conducting preclin. research in screening novel disease modifying therapies.  Advancements in research techniques in α-synuclein targeted disease modification have utilized methods such as viral mediated expression of human α-synuclein, as well as the inoculation of pathogenic α-synuclein species from Lewy Bodies of PD patients, for accurately modeling progressive self-propagating neurodegeneration.  In applying these cutting-edge research tools with sophisticated trial designs in preclin. drug trials, a useful platform has emerged for developing candidate agents with disease modifying actions, promising a greater chance of success for clin. translation.  In this article, we describe the transition of well-established animal models of PD symptomatol. to newly developed models of PD pathogenesis, with specific focus on methods of viral-mediated and inoculation of pathogenic α-synuclein, that aim to aid scientific translation of neuroprotective strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1K3iVMQhVULVg90H21EOLACvtfcHk0ljritRMIvk3Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Oku7jM&md5=c388159e19f8a705f68370c6e7092216</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1016%2Fj.expneurol.2017.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.expneurol.2017.07.020%26sid%3Dliteratum%253Aachs%26aulast%3DKo%26aufirst%3DW.%2BK.%2BD.%26aulast%3DBezard%26aufirst%3DE.%26atitle%3DExperimental%2520Animal%2520Models%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%253A%2520A%2520Transition%2520from%2520Assessing%2520Symptomatology%2520to%2520%25CE%25B1-Synuclein%2520Targeted%2520Disease%2520Modification%26jtitle%3DExp.%2520Neurol.%26date%3D2017%26volume%3D298%26spage%3D172%26epage%3D179%26doi%3D10.1016%2Fj.expneurol.2017.07.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-2%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00760" class="show-recommended-placeholder"></div>




        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00760" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799b78c3ac4d1ef","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
